Oncogene and Cancer by unknown
Oncogene and Cancer 
From Bench to Clinic
Edited by Yahwardiah Siregar
Edited by Yahwardiah Siregar
This book describes a course of cancer growth starting from normal cells to cancerous 
form and the genomic instability, the cancer treatment as well as its prevention in 
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through its molecular mechanism is needed to reduce the cancer incidence. How to 
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used to treat the cancer patients in the very near future. The book was divided into six 
main sections: 1. HER2 Carcinogenesis: Etiology, Treatment and Prevention; 2. DNA 
Repair Mechanism and Cancer; 3. New Approach to Cancer Mechanism; 4. New Role 
of Oncogenes and Tumor Suppressor Genes; 5. Non Coding RNA and Micro RNA in 
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It took a long journey to really understand what cancer is, although many researcher 
are still working of finding a definite answer on how to treat cancer, and, what is more 
important, how to detect cancer very early, when some cells start going abnormal and 
transform into cancer cells. 
The immune system might be the best weapon against cancer, since immune defense is 
programmed to recognize and destroy abnormal cells, but cancer cells may develop 
many defenses against immune attacks. Advances in biological processes, including 
apoptosis and cell proliferation, that are known to be dysregulated in tumors need to 
be understood in molecular mechanisms. During the last decade, scientists have 
shown an interest to create cancer vaccines as well as DNA vaccines using 
development of new biotechnological tools to elucidate an immune attack against 
cancer. 
Recently, a new players in cancer biology have appeared: microRNAs (miRs or 
miRNAs), a class of small non-coding RNAs that play important roles in cell 
differentiation, cell growth and cell death. miRNAs can act either as oncogenes or 
tumor suppressors and regulate the interaction between cancer cells and the 
microenvironment. Understanding the function of ncRNAs by focusing on the 
potential involvement of specific RNA species, such as microRNAs, small nucleolar 
RNAs, Piwi-interacting RNA, long non-coding RNAs, in the development and 
progression of cancer is described in this book. 
The book was written not only for medical students, but it can also be widely used  by 
clinical and biomedical scientists, as well as by doctors studying for their postgraduate 
research.   
My thanks are specifically aimed at Intech Open staff (Ms. Reinic, Ms. Blecic, Mr. 
Greblo and Ms Zgela) who helped finish this book. I would also like to express my 
thankfulness to all  authors who contributed a chapter to this publication. Finally, I 
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1. Introduction 
Breast cancer is the most common malignancy and the leading cause of cancer death in 
women globally. There has been a sharp increase in its incidence especially in the developed 
world due to a combination of better detection and lifestyle changes. Breast cancer is a 
disorder influenced by genetic, environmental, behavioral, and reproductive factors. The 
most significant risk factors are gender and age. Hereditary forms of breast cancer are often 
related to mutations in two high-penetrance susceptibility genes namely BRCA-1 and 
BRCA-2 (1), and account for around 5% of all breast cancer cases. Women who are born with 
these mutations have 10–30-fold increased risk of developing breast cancer compared to the 
general population and a cumulative lifetime risk of 60–80%. Sporadic forms of breast 
cancer account for around 95% of cases and are a consequence of somatic mutations 
acquired over the lifetime; they appear to be in part related to polymorphisms in low-
penetrance genes that encode proteins involved in DNA repair, cell signaling pathways, 
estrogen metabolism, etc. (2, 3). In the last few decades, the survival rate of breast cancer has 
improved due to advances in mammography and adjuvant therapy.  
Histopathologically identical tumours may exhibit different biological behaviors in terms of 
severity, course, and response to therapy, reflecting disease heterogeneity; in addition, 
variability of the host immune response further contributes to differences in treatment 
outcomes, underscoring the need for better understanding of this disease and its relation to 
the host (4). At the biological level, breast cancer is a complex disease caused by multiple 
genetic and epigenetic alterations that ultimately lead to changes in cell processes, including 
cell proliferation, apoptosis, and angiogenesis, with subsequent acquisition of a malignant 
phenotype (5). The main genetic abnormalities that are observed include increased proto-
oncogene expression, inactivation of tumour suppressor genes, chromosomal instability, 
 The Author(s). Li  I ech. This chapter is distributed under the terms of th  Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
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alterations in DNA repair genes, telomerase reactivation, and epigenetic changes, resulting 
in dysregulation of cell proliferation, clonal selection, and tumour formation (6). As such 
one can expect breast cancer to be a heterogeneous disease and better prognostic and 
predictive biomarkers are clearly needed to better manage this disease. 
The treatment of breast cancer continues to be challenging because of the heterogeneity of 
the disease. Breast cancer is staged by the TNM classification that assigns tumours to 
different stages based on depth of tumour invasion and presence of nodal and distant 
metastases. However, considering the heterogeneity in outcome of patients diagnosed with 
equivalent TNM stage, this classification system is suboptimal in tumour characterization or 
prognostication. In early-stage breast cancer, several clinicopathological factors are used to 
refine prognostication over and above TNM staging. These factors include histological 
grade, lymphovascular invasion and estrogen receptor (ER)/ progesterone (PR) status. Some 
of these factors have been incorporated into algorithms such as Adjuvant! Online to estimate 
the individual risk of cancer relapse (7-9). More recently, amplification and/or 
overexpression of the human epidermal growth factor receptor 2 (Her2), a therapeutic 
target, has been associated with worse prognosis, although its clinical utility as a prognostic 
marker remains uncertain (10-12). The variation in clinical outcome despite similar clinical 
and pathological prognostic scores seriously compromises the ability to advise women in 
making fully informed decisions about adjuvant systemic treatment after definitive surgery. 
Over the past few decades, substantial effort has been invested in the identification and 
validation of prognostic markers over and above ER, PR and Her2, in an attempt to improve 
risk stratification for breast cancer. As the evaluation of candidate prognostic markers is 
often limited by inadequate study design and analyses, formal recommendations for 
reporting tumour marker prognostic studies have been suggested, including guidelines on 
assay methods, study design and data analysis (13).  
In recent years, gene expression microarray-based technology has resulted in the 
identification of breast cancer molecular subtypes and gene-expression prognostic 
signatures (14-16). These classification and prognostic expression signatures hold great 
promise, but there are concerns regarding their significance independent of ER/ PR status 
(17, 18). The process of validating the clinical utility of two such prognostic gene expression 
signatures, Oncotype DX and Mammaprint, is ongoing through the TAILORx and 
MINDACT trials respectively. Until these are validated prospectively, the increasing usage 
of these two profiling tests is unfortunately based on mainly retrospective data. 
A fair proportion of breast cancers cannot be adequately resected upfront. In these 
situations, neoadjuvant chemotherapy is often given first. In recent times, even those 
tumours that are borderline resectable are often treated with neoadjuvant chemotherapy in 
an attempt to improve cosmetic results. Neoadjuvant chemotherapy provides prognostic 
information as the achievement of pathologic complete response (pCR) is associated with 
prolonged survival. The increasing use of neoadjuvant chemotherapy in patients with 
primary breast cancer makes it important to develop predictive markers of pCR, which is a 
surrogate marker of improved survival (19, 20). In addition, neoadjuvant chemotherapy 
allows the biological effect of the therapy to be evaluated as the surgically resected tumour 
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after treatment can be examined and compared with the pre-treatment biopsy sample, 
providing an opportunity to study tumour biology in vivo. Neoadjuvant trials thus offer an 
excellent opportunity to study tumour DNA, RNA and protein changes and to evaluate new 
prognostic and predictive biomarkers of treatment response. In addition, it has the potential 
to reveal post-treatment biomarkers that could be complementary or even superior to the 
routine baseline biomarkers currently in use. 
This chapter will review protein biomarkers in breast cancer. It will focus on established 
biomarkers, the timepoints of obtaining biomarkers, and the type of specimens on which to 
analyze these biomarkers. The different methods of measuring such biomarkers will also be 
described. In addition, several candidate protein biomarkers (e.g., Topo2, serum Her2, 

























   
Table 1. Biomarkers in breast cancer (*includes serum. #predictive of response.) 
A. Biomarkers in breast cancer 
 Prognostic versus predictive biomarkers 1.
A prognostic biomarker provides information about the patient’s overall cancer outcome, 
regardless of therapy, whilst a predictive biomarker gives information about the effect of a 
therapeutic intervention. A predictive biomarker can also be a target for therapy. Among the 
genes and proteins that have proven to be of relevance in cancer are well known predictive 
markers such as ER, PR and Her2/neu in breast cancer, c-KIT mutations in gastrointestinal 
stromal tumours, EGFR mutations in non-small cell lung cancer, and BCR-ABL fusion 
protein in chronic myeloid leukaemia. 
 Criteria of candidate biomarkers 2.
Several factors are important in selection and validation of candidate biomarkers. The 
analysis platform must be sufficiently robust to detect subtle changes between tumours. 
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Sample sets must be robust enough to reduce pre-analytical data biases and must reflect the 
intended use of the marker or marker set. Independent sample sets must be used to validate 
the prognostic and predictive power of biomarkers particularly when many biomarkers are 
assessed on small sample sets. Lastly, bioinformatics support is essential at all steps in any 
project. In addition, these markers would need to be validated, usually retrospectively first 
in existing large clinical datasets and ultimately in prospective randomized trials. 
 Gene expression biomarkers in breast cancer 3.
The complementary DNA (cDNA) -microarray technology has made it possible to analyze 
the mRNA expression of numerous genes simultaneously to better characterize breast 
cancers, including classification and prognostication. Several studies using transcriptional 
profiling have classified breast cancer into different subtypes with implications in patient 
prognosis (21-23), frequency of genomic alterations (24, 25), and therapy response (26, 27). In 
breast cancer classification, the first tier of separation is between ER-negative and ER-
positive tumours. Five breast cancer molecular subtypes have been identified using this 
technology, of which the luminal (A and B) type is ER-positive and accounts for 60% of 
breast tumours; the Her2 overexpressing type accounts for 15–20%; the ER and Her2 
negative basal-like type accounts for 20% of the cases and has a guarded prognosis; and 
lastly the normal-like type, which has no definitive clinical value (28, 29). ER-positive 
tumours respond to endocrine therapy (e.g., tamoxifen, aromatase inhibitors), and Her2 
positive tumours are eligible for targeted therapy with trastuzumab or lapatinib, whereas 
the basal-like type has a more aggressive phenotype and while generally responsive to 
various chemotherapy regimens tends to acquire resistance quickly and has short survival 
(28-31). Currently, the advocates of this classification have suggested that the normal-like 
subtype might actually be an artefact of sample representation, that is, contamination of the 
mammary tissue by normal cells (32, 33). More recently, three other ER-negative subtypes 
have been described, the molecular apocrine tumour, the interferon, and lastly the claudin-
low, which expresses breast epithelial stem cell markers. However, a definition of their 
clinical significance is still needed (34). Despite its significant contribution, the ‘gene 
signature’ described above is not a definitive classification method, but rather a developing 
work model that needs to be refined, considering that more subtypes have been described 
(5). Prognostic gene expression signatures in the form of Oncotype DX and Mammaprint 
have been tested in various large clinical datasets retrospectively to show prognostic value 
as well as value in predicting benefit from adjuvant chemotherapy, and are already in 
clinical use. On the other hand, predictive gene expression signatures for response to 
specific drug or drug regimens are still largely investigational although there have been 
many studies. This is because of small sample size in most studies, lack of independent 
validation sets in some studies, heterogeneity of the study population, a great variety of 
chemotherapy regimens that were evaluated in different studies, and variation in definition 
of response endpoint, making it difficult to pool the study results (35).  
 Protein biomarkers in breast cancer 4.
Cancer arises from successive genetic changes, by which several cellular processes, 
including growth control, senescence, apoptosis, angiogenesis, and metastasis, are altered 
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(36). Consequently, researchers initially searched for markers by employing genomic and 
transcriptomic approaches, providing new biomarkers (14, 37) and expanding our insight 
into the genetic basis of cancer. It is however currently understood that genetic analysis 
alone is insufficient. Alternative splicing of mRNA combined with numerous unique post-
translational protein modifications can give rise to multiple protein species (38). Hence, 
compared to the genome, the proteome can provide a more dynamic and accurate reflection 
of both the intrinsic genetic programme of the cell and the impact of its immediate 
environment (39).  
Since proteins are the effectors of cellular behavior, interrogation of the functional proteome 
is likely to complement data derived from transcriptional profiling. Thus, the integrated 
study of the expression and activation of multiple proteins and signaling pathways has the 
potential to provide powerful classifiers and predictors in breast cancer (40, 41). Currently, 
gene-profiling technology generally requires fresh or frozen tumor tissue (other than 
Oncotype DX), and is cumbersome and logistically demanding, which may limit its 
suitability for routine use in clinical practice for some time. As such, reliable protein markers 
that may be readily tested on routinely available biological specimens may be more widely 
applicable in the clinic. 
 Established protein biomarkers in breast cancer 5.
i. Estrogen Receptor (ER)/ Progesterone Receptor (PR) 
Assays for tumour expression of ER and PR have established utility in the clinical 
management of patients with both early stage and advanced breast cancer. They are 
routinely obtained on all tumour specimens and immunohistochemistry (IHC) is the 
predominant method for measuring ER and PR in clinical practice. Receptor positivity 
(staining of cell nuclei is considered positive) is an important indicator of hormone 
responsiveness and identifies tumours for which endocrine therapy is a valuable 
therapeutic option in both the adjuvant and advanced disease setting. Expression of ER 
and/or PR within tumours correlates well with low histologic grade especially in 
postmenopausal women. Reports have highlighted the extent of variability in ER and 
PR IHC assay caused by a variety of factors including differences in specimen handling, 
tissue fixation, antigen retrieval, and antibody type. In addition, variability in 
interpretation of assay results is caused by different laboratory threshold values for 
positive and negative. These variations have resulted in serious issues with ER 
reliability. In view of the controversy over what constitutes a positive test, most 
laboratories will report the actual percentage of positive cells. While many agree that 
≥5% is considered positive, tumours with a lower percentage (1-4%), or even no 
staining, may show a borderline response to endocrine therapy. The American Society 
of Clinical Oncology (ASCO) Tumour Marker Panel in 1995 concluded that: (1) ER and 
PR should be measured on every primary breast cancer and metastatic lesion if it would 
influence treatment planning, (2) ER and PR positivity supports use of endocrine 
therapy regardless of menopausal status in both adjuvant and metastatic disease, and 
(3) ER and PR receptors are weak prognostic indicators and should not be used to 
determine whether to treat a patient with adjuvant therapy. Newer guidelines from a 
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Sample sets must be robust enough to reduce pre-analytical data biases and must reflect the 
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the mRNA expression of numerous genes simultaneously to better characterize breast 
cancers, including classification and prognostication. Several studies using transcriptional 
profiling have classified breast cancer into different subtypes with implications in patient 
prognosis (21-23), frequency of genomic alterations (24, 25), and therapy response (26, 27). In 
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positive tumours. Five breast cancer molecular subtypes have been identified using this 
technology, of which the luminal (A and B) type is ER-positive and accounts for 60% of 
breast tumours; the Her2 overexpressing type accounts for 15–20%; the ER and Her2 
negative basal-like type accounts for 20% of the cases and has a guarded prognosis; and 
lastly the normal-like type, which has no definitive clinical value (28, 29). ER-positive 
tumours respond to endocrine therapy (e.g., tamoxifen, aromatase inhibitors), and Her2 
positive tumours are eligible for targeted therapy with trastuzumab or lapatinib, whereas 
the basal-like type has a more aggressive phenotype and while generally responsive to 
various chemotherapy regimens tends to acquire resistance quickly and has short survival 
(28-31). Currently, the advocates of this classification have suggested that the normal-like 
subtype might actually be an artefact of sample representation, that is, contamination of the 
mammary tissue by normal cells (32, 33). More recently, three other ER-negative subtypes 
have been described, the molecular apocrine tumour, the interferon, and lastly the claudin-
low, which expresses breast epithelial stem cell markers. However, a definition of their 
clinical significance is still needed (34). Despite its significant contribution, the ‘gene 
signature’ described above is not a definitive classification method, but rather a developing 
work model that needs to be refined, considering that more subtypes have been described 
(5). Prognostic gene expression signatures in the form of Oncotype DX and Mammaprint 
have been tested in various large clinical datasets retrospectively to show prognostic value 
as well as value in predicting benefit from adjuvant chemotherapy, and are already in 
clinical use. On the other hand, predictive gene expression signatures for response to 
specific drug or drug regimens are still largely investigational although there have been 
many studies. This is because of small sample size in most studies, lack of independent 
validation sets in some studies, heterogeneity of the study population, a great variety of 
chemotherapy regimens that were evaluated in different studies, and variation in definition 
of response endpoint, making it difficult to pool the study results (35).  
 Protein biomarkers in breast cancer 4.
Cancer arises from successive genetic changes, by which several cellular processes, 
including growth control, senescence, apoptosis, angiogenesis, and metastasis, are altered 
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(36). Consequently, researchers initially searched for markers by employing genomic and 
transcriptomic approaches, providing new biomarkers (14, 37) and expanding our insight 
into the genetic basis of cancer. It is however currently understood that genetic analysis 
alone is insufficient. Alternative splicing of mRNA combined with numerous unique post-
translational protein modifications can give rise to multiple protein species (38). Hence, 
compared to the genome, the proteome can provide a more dynamic and accurate reflection 
of both the intrinsic genetic programme of the cell and the impact of its immediate 
environment (39).  
Since proteins are the effectors of cellular behavior, interrogation of the functional proteome 
is likely to complement data derived from transcriptional profiling. Thus, the integrated 
study of the expression and activation of multiple proteins and signaling pathways has the 
potential to provide powerful classifiers and predictors in breast cancer (40, 41). Currently, 
gene-profiling technology generally requires fresh or frozen tumor tissue (other than 
Oncotype DX), and is cumbersome and logistically demanding, which may limit its 
suitability for routine use in clinical practice for some time. As such, reliable protein markers 
that may be readily tested on routinely available biological specimens may be more widely 
applicable in the clinic. 
 Established protein biomarkers in breast cancer 5.
i. Estrogen Receptor (ER)/ Progesterone Receptor (PR) 
Assays for tumour expression of ER and PR have established utility in the clinical 
management of patients with both early stage and advanced breast cancer. They are 
routinely obtained on all tumour specimens and immunohistochemistry (IHC) is the 
predominant method for measuring ER and PR in clinical practice. Receptor positivity 
(staining of cell nuclei is considered positive) is an important indicator of hormone 
responsiveness and identifies tumours for which endocrine therapy is a valuable 
therapeutic option in both the adjuvant and advanced disease setting. Expression of ER 
and/or PR within tumours correlates well with low histologic grade especially in 
postmenopausal women. Reports have highlighted the extent of variability in ER and 
PR IHC assay caused by a variety of factors including differences in specimen handling, 
tissue fixation, antigen retrieval, and antibody type. In addition, variability in 
interpretation of assay results is caused by different laboratory threshold values for 
positive and negative. These variations have resulted in serious issues with ER 
reliability. In view of the controversy over what constitutes a positive test, most 
laboratories will report the actual percentage of positive cells. While many agree that 
≥5% is considered positive, tumours with a lower percentage (1-4%), or even no 
staining, may show a borderline response to endocrine therapy. The American Society 
of Clinical Oncology (ASCO) Tumour Marker Panel in 1995 concluded that: (1) ER and 
PR should be measured on every primary breast cancer and metastatic lesion if it would 
influence treatment planning, (2) ER and PR positivity supports use of endocrine 
therapy regardless of menopausal status in both adjuvant and metastatic disease, and 
(3) ER and PR receptors are weak prognostic indicators and should not be used to 
determine whether to treat a patient with adjuvant therapy. Newer guidelines from a 
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joint panel of the ASCO and the College of American Pathologists (CAP) provide 
recommendations to improve test accuracy and reporting of results (42). Of note, the 
panel now recommends that ER and PR assays be considered positive if there are at 
least 1% positive tumour nuclei in the sample on testing in the presence of expected 
reactivity of internal (normal epithelial elements) and external controls. 
ii. Human epidermal growth factor receptor 2 (Her2)  
Her2 is a proto-oncogene that encodes the production of Her2, a cell surface protein 
important in cell regulation. Abnormalities of Her2 occur in 25-30% of breast 
carcinomas, especially those that are poorly differentiated, lymph node positive, 
hormone receptor negative, flow aneuploid and/or show high proliferation rates. Her2 
amplification and protein overexpression can be detected with Fluorescent In-situ 
hybridization (FISH) and IHC, respectively, both of which can be performed on 
paraffin-embedded tissue. Maximum sensitivity can be achieved by using both 
methods. The presence of Her2 overexpression predicts for response to anti-Her2 
therapy such as trastuzumab and lapatinib. In addition, many studies have shown a 
positive response effect with anthracyclines in Her2 positive breast cancer, although 
there have been some studies recently to dispute this (43). Assay for this molecular 
marker is warranted as a routine part of the diagnostic work-up on all breast cancers, 
since Her2 overexpression is of major value in selection of anti-Her2 therapy in these 
patients. The bulk of available evidence supports the view that Her2 overexpression is 
associated with a poor prognosis. However, the value of this information in clinical 
practice is questionable, and guidelines from an expert panel on tumour markers in 
breast cancer convened by ASCO recommended against the use of Her2 in assessing 
prognosis (44). Given the substantial benefit of adjuvant trastuzumab in patients with 
Her2-overexpressing tumours, it is difficult to separate out the prognostic versus 
predictive utility of Her2.  
Whilst the detection of tumour Her2 overexpression or amplification by IHC or FISH is 
standard clinical practice, the detection of serum (soluble) Her2 is a more controversial 
issue. In order to understand the relevance of serum Her2 we have to look at the 
structure of the Her2 protein. The Her2 protein is a 185-kDA transmembrane tyrosine 
kinase receptor with three defined domains: the intracellular tyrosine kinase portion, a 
short transmembrane portion, and the extracellular domain (ECD). The 105-kDa ECD 
(serum Her2) can be cleaved from the surface by metalloproteases and detected in the 
peripheral blood (45). It has been reported that trastuzumab inhibits Her2 extracellular 
domain cleavage; this is important considering that the remaining cleaved HER2 
receptor is constitutively activated (46, 47), suggesting that the detection of sHer2 also 
reflects a biologic process leading to a more aggressive tumour behavior (48). Elevated 
levels of sHer2 have been observed in patients with primary (49) or metastatic breast 
cancer (50, 51). As detailed below in the specific biomarker section (E.3), there are some 
studies to suggest that elevated serum Her2 levels are a negative prognostic and 
predictive factor. 
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iii. Ca15-3 
Ca15-3 detects circulating MUC-1 antigens in the blood. There are several studies that 
support the prognostic utility (52-55) of MUC-1 in early stage breast cancer. The trials 
showed as common finding that Ca15-3 was prognostic of disease free survival either 
on uni-variate or multi-variate analysis. We however do not use Ca15-3 to monitor 
patients with early stage breast cancer because there is no impact on the decision of 
chemotherapy regimen as established in a prospective clinical trial. In fact the sole 
approved use of this test (as per ASCO guidelines) is to monitor response to therapy in 
the metastatic breast cancer setting. 
 Candidate Protein Biomarkers with possible clinical application in breast cancer 6.
i. Topo2-alpha (Topo2) 
DNA topoisomerase 2-alpha is an enzyme that in humans is encoded by the Topo2 
gene. This gene encodes a DNA topoisomerase, an enzyme that controls and alters 
the topologic states of DNA during transcription. This nuclear enzyme is involved in 
processes such as chromosome condensation, chromatid separation, and the relief of 
torsional stress that occurs during DNA transcription and replication. It catalyzes the 
transient breaking and rejoining of two strands of duplex DNA which allows the 
strands to pass through one another, thus altering the topology of DNA. There is 
increasing interest on Topo2 and anthracycline sensitivity, although the results in 
the past have been somewhat mixed. The BCIRG006 investigators (56) have 
appropriately looked for markers of benefit from anthracyclines and have suggested 
in a large subset analysis that Topo2 co-amplification along with Her2 amplification 
could indicate a subset of patients who definitely benefit from anthracyclines, and, 
conversely, that the majority of patients who lack Topo2 co-amplification might 
possibly be just as well treated with trastuzumab without anthracyclines. However, 
because there is no widely available and validated Topo2 test and these data have 
not yet been corroborated independently, Topo2 testing is currently still not 
routinely performed in the clinic. 
 Protein biomarkers in breast cancer under evaluation 7.
i. Epidermal Growth Factor Receptor (EGFR) 
The epidermal growth factor receptor (EGFR; ErbB-1; Her1 in humans) is the cell-
surface receptor for members of the epidermal growth factor family (EGF-family) of 
extracellular protein ligands. The epidermal growth factor receptor is a member of the 
ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: 
EGFR (ErbB-1), Her2/neu (ErbB-2), Her3 (ErbB-3) and Her4 (ErbB-4). EGFR 
overexpression can be detected with IHC or FISH. In preclinical models of breast 
cancer, overexpression of EGFR leads to malignant transformation of mouse cells. It is 
associated with increased proliferation and resistance to apoptosis (57). One study 
analyzed 130 breast carcinomas using IHC analyses for the levels of nuclear and non-
nuclear EGFR, and found that 37.7% of the cohort immunostained positively for nuclear 
EGFR and 6.9% had high levels of expression. More importantly, survival analysis 
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joint panel of the ASCO and the College of American Pathologists (CAP) provide 
recommendations to improve test accuracy and reporting of results (42). Of note, the 
panel now recommends that ER and PR assays be considered positive if there are at 
least 1% positive tumour nuclei in the sample on testing in the presence of expected 
reactivity of internal (normal epithelial elements) and external controls. 
ii. Human epidermal growth factor receptor 2 (Her2)  
Her2 is a proto-oncogene that encodes the production of Her2, a cell surface protein 
important in cell regulation. Abnormalities of Her2 occur in 25-30% of breast 
carcinomas, especially those that are poorly differentiated, lymph node positive, 
hormone receptor negative, flow aneuploid and/or show high proliferation rates. Her2 
amplification and protein overexpression can be detected with Fluorescent In-situ 
hybridization (FISH) and IHC, respectively, both of which can be performed on 
paraffin-embedded tissue. Maximum sensitivity can be achieved by using both 
methods. The presence of Her2 overexpression predicts for response to anti-Her2 
therapy such as trastuzumab and lapatinib. In addition, many studies have shown a 
positive response effect with anthracyclines in Her2 positive breast cancer, although 
there have been some studies recently to dispute this (43). Assay for this molecular 
marker is warranted as a routine part of the diagnostic work-up on all breast cancers, 
since Her2 overexpression is of major value in selection of anti-Her2 therapy in these 
patients. The bulk of available evidence supports the view that Her2 overexpression is 
associated with a poor prognosis. However, the value of this information in clinical 
practice is questionable, and guidelines from an expert panel on tumour markers in 
breast cancer convened by ASCO recommended against the use of Her2 in assessing 
prognosis (44). Given the substantial benefit of adjuvant trastuzumab in patients with 
Her2-overexpressing tumours, it is difficult to separate out the prognostic versus 
predictive utility of Her2.  
Whilst the detection of tumour Her2 overexpression or amplification by IHC or FISH is 
standard clinical practice, the detection of serum (soluble) Her2 is a more controversial 
issue. In order to understand the relevance of serum Her2 we have to look at the 
structure of the Her2 protein. The Her2 protein is a 185-kDA transmembrane tyrosine 
kinase receptor with three defined domains: the intracellular tyrosine kinase portion, a 
short transmembrane portion, and the extracellular domain (ECD). The 105-kDa ECD 
(serum Her2) can be cleaved from the surface by metalloproteases and detected in the 
peripheral blood (45). It has been reported that trastuzumab inhibits Her2 extracellular 
domain cleavage; this is important considering that the remaining cleaved HER2 
receptor is constitutively activated (46, 47), suggesting that the detection of sHer2 also 
reflects a biologic process leading to a more aggressive tumour behavior (48). Elevated 
levels of sHer2 have been observed in patients with primary (49) or metastatic breast 
cancer (50, 51). As detailed below in the specific biomarker section (E.3), there are some 
studies to suggest that elevated serum Her2 levels are a negative prognostic and 
predictive factor. 
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iii. Ca15-3 
Ca15-3 detects circulating MUC-1 antigens in the blood. There are several studies that 
support the prognostic utility (52-55) of MUC-1 in early stage breast cancer. The trials 
showed as common finding that Ca15-3 was prognostic of disease free survival either 
on uni-variate or multi-variate analysis. We however do not use Ca15-3 to monitor 
patients with early stage breast cancer because there is no impact on the decision of 
chemotherapy regimen as established in a prospective clinical trial. In fact the sole 
approved use of this test (as per ASCO guidelines) is to monitor response to therapy in 
the metastatic breast cancer setting. 
 Candidate Protein Biomarkers with possible clinical application in breast cancer 6.
i. Topo2-alpha (Topo2) 
DNA topoisomerase 2-alpha is an enzyme that in humans is encoded by the Topo2 
gene. This gene encodes a DNA topoisomerase, an enzyme that controls and alters 
the topologic states of DNA during transcription. This nuclear enzyme is involved in 
processes such as chromosome condensation, chromatid separation, and the relief of 
torsional stress that occurs during DNA transcription and replication. It catalyzes the 
transient breaking and rejoining of two strands of duplex DNA which allows the 
strands to pass through one another, thus altering the topology of DNA. There is 
increasing interest on Topo2 and anthracycline sensitivity, although the results in 
the past have been somewhat mixed. The BCIRG006 investigators (56) have 
appropriately looked for markers of benefit from anthracyclines and have suggested 
in a large subset analysis that Topo2 co-amplification along with Her2 amplification 
could indicate a subset of patients who definitely benefit from anthracyclines, and, 
conversely, that the majority of patients who lack Topo2 co-amplification might 
possibly be just as well treated with trastuzumab without anthracyclines. However, 
because there is no widely available and validated Topo2 test and these data have 
not yet been corroborated independently, Topo2 testing is currently still not 
routinely performed in the clinic. 
 Protein biomarkers in breast cancer under evaluation 7.
i. Epidermal Growth Factor Receptor (EGFR) 
The epidermal growth factor receptor (EGFR; ErbB-1; Her1 in humans) is the cell-
surface receptor for members of the epidermal growth factor family (EGF-family) of 
extracellular protein ligands. The epidermal growth factor receptor is a member of the 
ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: 
EGFR (ErbB-1), Her2/neu (ErbB-2), Her3 (ErbB-3) and Her4 (ErbB-4). EGFR 
overexpression can be detected with IHC or FISH. In preclinical models of breast 
cancer, overexpression of EGFR leads to malignant transformation of mouse cells. It is 
associated with increased proliferation and resistance to apoptosis (57). One study 
analyzed 130 breast carcinomas using IHC analyses for the levels of nuclear and non-
nuclear EGFR, and found that 37.7% of the cohort immunostained positively for nuclear 
EGFR and 6.9% had high levels of expression. More importantly, survival analysis 
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revealed a significant inverse correlation between high nuclear EGFR expression and 
overall survival. Furthermore, expression of nuclear EGFR correlated positively with 
increased levels of cyclin D1 and Ki-67, both of which are indicators for cell 
proliferation (58). The expression of EGFR and its association with shorter survival 
observed in this study has also been reported in other studies (59), although its routine 
use in breast cancer at this time is still controversial.  
ii. p53 
p53 (also known as protein 53 or tumour protein 53), is a tumour suppressor protein 
that in humans is encoded by the TP53 gene. p53 is crucial in multicellular organisms, 
where it regulates the cell cycle and, thus, functions as a tumour suppressor that is 
involved in preventing cancer. As such, p53 has been described as "the guardian of the 
genome” because of its role in conserving stability by preventing genome mutation. 
Mutations of the p53 gene cause variant p53 proteins to have an increased half-life. 
These variant p53 proteins accumulate in the cell and can be detected with IHC in about 
90% of cases by increased nuclear staining. One study examined a chemoresistant 
subgroup of breast cancers (triple negative breast cancer) and showed that p53 was 
possibly prognostic (60). However, although over-accumulation of p53 protein has been 
associated with worse survival in breast cancer patients, it also correlates with cell 
proliferation and thus may not be an independent prognostic factor (61). In addition, 
the results of its prognostic significance in breast cancer have been inconsistent, and it is 
therefore not routinely used in breast cancer management. 
iii. Bcl2 
Expression of Bcl2, an anti-apoptotic protein, has been associated with low-grade, 
slowly proliferating, ER positive breast tumours (62, 63). In a report (64) which pooled 
five studies of 11,212 women with early-stage breast cancer together for analysis, 
individual patient data including tumour size, grade, lymph node status, use of 
adjuvant endocrine therapy and/or chemotherapy, and mortality were analyzed. Bcl2, 
ER, PR and Her2 levels were ascertained in all tumours. A Cox model was used to 
explore the prognostic significance of Bcl2. The study found that in univariate analysis, 
ER, PR and Bcl2 positivity was associated with improved survival and Her2 positivity 
with worse survival. Intriguingly, in multivariate analysis, Bcl2 positivity retained 
independent prognostic significance (hazard ratio 0.76). Bcl2 was a powerful prognostic 
marker in both ER negative (HR 0.63) and ER positive disease (HR 0.56), and in both 
Her2 negative (HR 0.55) and Her2 positive disease (HR 0.70), regardless of the type of 
adjuvant therapy received. The study also looked at the addition of Bcl2 to the 
Adjuvant! Online prognostic model, for a subset of cases with 10-year follow-up data 
and showed that Bcl2 improved the survival prediction. 
 Biomarkers elucidated by high throughput methods 8.
Serum and plasma protein profiling studies by mass spectrometry (MALDI-TOF or SELDI-
TOF) have yielded numerous protein peaks that are potentially diagnostic, prognostic, or 
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predictive in breast cancer. However, thus far, only a small percentage of reported peaks 
have been structurally identified. Moreover, since most studies did not investigate other 
cancer types or patients with benign breast disease, the specificity of reported markers for 
breast cancer still has to be addressed. 
i. Diagnostic markers 
The potential of proteomic pattern analysis was initially demonstrated in the diagnosis 
of ovarian cancer (65). In this study, exceptional results were seen using 5-20 specific 
key proteins identified, with a sensitivity and specificity of >95%, which is far superior 
to the sensitivities and specificities obtained with current serological cancer biomarkers. 
Subsequently, proteomic pattern analysis has been evaluated in a number of other 
cancer types, including breast, liver, and pancreatic cancers (66-68). 
Two studies in breast cancer have investigated the correlation between SELDI-TOF 
mass spectrometry (MS) protein profiles of 105 tumour tissue lysates (69) and 27 breast 
cancer cell lines (26, 70). In both studies, patient subgroups identified by hierarchical 
clustering of SELDI-TOF MS protein profiles were analogous to the molecular breast 
cancer subtypes (69, 70). Of the several differentially expressed protein peaks detected, 
heat shock protein (Hsp) 27 and annexin V were identified as over-expressed in the 
luminal A type tumour tissue lysates (69), while S100-A9 (higher in basal) and a C-
terminal truncated form of ubiquitin (higher in luminal) were found differentially 
expressed between the luminal-like and basal-like cell lines (70). Notably, subsequent 
IHC analysis of S100-A9 in tumour specimens of 547 early breast cancer patients 
confirmed its association with basal subtypes, as well as its value as an indicator of poor 
prognosis (70).  
ii. Prognostic markers 
In contrast to diagnostic studies, protein profiling studies aimed at discovering novel 
protein markers to prognosticate breast cancer are much more limited. One study (71) 
investigated the post-operative sera of 83 high-risk (mainly lymph node positive) breast 
cancer patients by SELDI-TOF MS and constructed a 40-protein signature that 
accurately predicted outcome in 83% of patients. The major components of this 
signature included haptoglobin alpha-1, complement component C3a, transferrin, and 
apolipoprotein A-I and C-I. These results should however be interpreted cautiously, as 
the number of proteins used for prognostication was rather high in comparison with the 
limited study population, indicating possible over-fitting of the data. 
In another SELDI-TOF MS study performed in 60 breast cancer tissues, high levels of 
ubiquitin and/or low levels of ferritin light chain were found associated with a good 
prognosis (72). Although the results have not been confirmed by analysis of 
independent sample sets, ubiquitin has also been found differentially expressed in 
breast cancer subtypes by three other studies investigating tissue specimens (73) and 
cell lines (70, 74).  
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possibly prognostic (60). However, although over-accumulation of p53 protein has been 
associated with worse survival in breast cancer patients, it also correlates with cell 
proliferation and thus may not be an independent prognostic factor (61). In addition, 
the results of its prognostic significance in breast cancer have been inconsistent, and it is 
therefore not routinely used in breast cancer management. 
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individual patient data including tumour size, grade, lymph node status, use of 
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ER, PR and Her2 levels were ascertained in all tumours. A Cox model was used to 
explore the prognostic significance of Bcl2. The study found that in univariate analysis, 
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with worse survival. Intriguingly, in multivariate analysis, Bcl2 positivity retained 
independent prognostic significance (hazard ratio 0.76). Bcl2 was a powerful prognostic 
marker in both ER negative (HR 0.63) and ER positive disease (HR 0.56), and in both 
Her2 negative (HR 0.55) and Her2 positive disease (HR 0.70), regardless of the type of 
adjuvant therapy received. The study also looked at the addition of Bcl2 to the 
Adjuvant! Online prognostic model, for a subset of cases with 10-year follow-up data 
and showed that Bcl2 improved the survival prediction. 
 Biomarkers elucidated by high throughput methods 8.
Serum and plasma protein profiling studies by mass spectrometry (MALDI-TOF or SELDI-
TOF) have yielded numerous protein peaks that are potentially diagnostic, prognostic, or 
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predictive in breast cancer. However, thus far, only a small percentage of reported peaks 
have been structurally identified. Moreover, since most studies did not investigate other 
cancer types or patients with benign breast disease, the specificity of reported markers for 
breast cancer still has to be addressed. 
i. Diagnostic markers 
The potential of proteomic pattern analysis was initially demonstrated in the diagnosis 
of ovarian cancer (65). In this study, exceptional results were seen using 5-20 specific 
key proteins identified, with a sensitivity and specificity of >95%, which is far superior 
to the sensitivities and specificities obtained with current serological cancer biomarkers. 
Subsequently, proteomic pattern analysis has been evaluated in a number of other 
cancer types, including breast, liver, and pancreatic cancers (66-68). 
Two studies in breast cancer have investigated the correlation between SELDI-TOF 
mass spectrometry (MS) protein profiles of 105 tumour tissue lysates (69) and 27 breast 
cancer cell lines (26, 70). In both studies, patient subgroups identified by hierarchical 
clustering of SELDI-TOF MS protein profiles were analogous to the molecular breast 
cancer subtypes (69, 70). Of the several differentially expressed protein peaks detected, 
heat shock protein (Hsp) 27 and annexin V were identified as over-expressed in the 
luminal A type tumour tissue lysates (69), while S100-A9 (higher in basal) and a C-
terminal truncated form of ubiquitin (higher in luminal) were found differentially 
expressed between the luminal-like and basal-like cell lines (70). Notably, subsequent 
IHC analysis of S100-A9 in tumour specimens of 547 early breast cancer patients 
confirmed its association with basal subtypes, as well as its value as an indicator of poor 
prognosis (70).  
ii. Prognostic markers 
In contrast to diagnostic studies, protein profiling studies aimed at discovering novel 
protein markers to prognosticate breast cancer are much more limited. One study (71) 
investigated the post-operative sera of 83 high-risk (mainly lymph node positive) breast 
cancer patients by SELDI-TOF MS and constructed a 40-protein signature that 
accurately predicted outcome in 83% of patients. The major components of this 
signature included haptoglobin alpha-1, complement component C3a, transferrin, and 
apolipoprotein A-I and C-I. These results should however be interpreted cautiously, as 
the number of proteins used for prognostication was rather high in comparison with the 
limited study population, indicating possible over-fitting of the data. 
In another SELDI-TOF MS study performed in 60 breast cancer tissues, high levels of 
ubiquitin and/or low levels of ferritin light chain were found associated with a good 
prognosis (72). Although the results have not been confirmed by analysis of 
independent sample sets, ubiquitin has also been found differentially expressed in 
breast cancer subtypes by three other studies investigating tissue specimens (73) and 
cell lines (70, 74).  
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iii. Predictive markers 
Several SELDI-TOF MS peaks (not structurally identified) were found indicative of 
treatment response in breast cancer cell lines to doxorubicin or paclitaxel (75). In 
addition, one study (76) found an increase of a 7.6kDa bovine transferrin fragment in 
serum-free conditioned medium of paclitaxel-resistant human breast cancer cell lines, 
corresponding to the increased expression of the transferrin receptor they observed in 
whole cell lysates. Although these results were not translated to the human in vivo 
setting, other studies have indeed reported an association between increased serum and 
cerebrospinal fluid transferrin levels and poor clinical outcome (71, 77). In one study, 
ubiquitin and S100-A6 were found to decrease in lysates of human breast cancer cell 
lines following chemotherapy-induced apoptosis (74); this coupled with the fact that 
aberrant expression of both proteins has also been reported in breast cancer tissue could 
make these two markers useful in predicting chemoresistant breast cancers (72, 73). In 
addition to these in vitro studies, in vivo studies have been performed as well (78, 79). In 
serum, both high molecular weight kininogen and apolipoprotein A-II were found to be 
significantly decreased in expression following docetaxel infusion in one particular 
patient with severe docetaxel side effects as compared to the other patients who 
tolerated the docetaxel infusion well. (79). The findings of this provocative study, if 
confirmed, suggest the potential of measuring protein biomarkers to predict adverse 
reaction to a drug. 
B. Neoadjuvant chemotherapy and post-chemotherapy time point of biomarker analysis 
in breast cancer 
Whilst the baseline pre-treatment time point is the commonest time point used in obtaining 
biomarkers to provide prognostic and/or predictive information, there are merits to using a 
post-chemotherapy time point biomarker, which may provide insights into biological effects 
of drugs and mechanisms of drug resistance. This however can only realistically occur in the 
setting of neoadjuvant or primary chemotherapy and in tumours from which serial tissue 
sampling can be safely obtained, such as in primary breast cancer. Neoadjuvant or primary 
chemotherapy in large primary breast cancers has been used with the purpose of reducing 
tumour volume and permitting less aggressive surgery (80). However, about 10-20% of 
patients do not benefit from this clinical approach (81, 82), and early identification of these 
patients could help avoid side effects from non-effective chemotherapy and unnecessary 
delay of definitive surgery.  
 Feasibility and significance of evaluating serial changes in protein expression post 1.
(neoadjuvant) chemotherapy in breast cancer 
Almost a decade ago, one of the earlier studies (83) assessed the feasibility of obtaining 
serial core breast biopsies, and correlated rates of apoptosis, proliferation, and 
expression of related proteins at baseline, during, and after neoadjuvant single agent 
chemotherapy for locally advanced breast cancer with treatment response. The study 
recruited women with a histologically confirmed unresected T3 or T4 infiltrating 
carcinoma of the breast. The first 20 patients received three cycles of doxorubicin 
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90mg/m2 followed by three cycles of paclitaxel 250mg/m2, or the reverse. Nine women 
received four cycles of each (doxorubicin 60mg/m2 and paclitaxel 175mg/m2). The end 
points studied included: clinical and pathological response, serial apoptotic [terminal 
deoxynucleotidyl transferase (Tdt)-mediated nick end labeling] and proliferation rates, 
and expression of ER, HER2, Bcl2, and p53 by IHC. Twelve patients (42%) had a clinical 
complete response (cCR), and 16 (55%) had a clinical partial response. Five women 
(17%) had pCR, 7 (24%) had microscopic residual disease, and 17 (58%) had 
macroscopic residual disease. Higher baseline apoptosis and proliferation were 
associated with a statistically significant improved pCR rate. In addition, among 14 
evaluable patients, apoptosis increased in women who had a cCR to the first agent but 
not in women without a cCR. The study however did not show any serial changes in 
ER, Her2, Bcl2 or p53. The authors concluded that it was feasible to obtain serial core 
biopsies that are informative for studies of apoptosis and IHC in patients undergoing 
neoadjuvant chemotherapy. 
 Limitations of post-chemotherapy biomarker analysis 2.
While feasible, for the most part, post-chemotherapy biomarker analysis is likely to be 
less well accepted by patients. This is because of all the accompanied logistical and 
patient discomfort issues with repeated biopsies. There would also be the issue of 
sampling error: biopsy and analysis of a chemotherapy-induced necrotic part of the 
tumour versus a still viable part or even chemo-resistant part of the tumour may reveal 
completely different profiles. It is also unclear at this point in time if any predictive 
biomarker for response obtained after treatment would be superior to standard clinical 
or radiological measurement of response. Having said that, many of the above issues 
also plague baseline biomarker analysis; a good example would be that of the recently 
recognized issue of Her2 heterogeneity in breast cancer (84). 
C. Specimen sources for measuring changes in protein expression 
 Blood/ plasma/ serum 1.
Since whole blood is considered to provide a dynamic reflection of physiological and 
pathological status, human plasma and serum represent the most extensively studied 
biological matrices in the quest for (breast) cancer biomarkers (85). Besides the usual 
circulatory proteins, it also contains specific tumour-secreted proteins, normal tissue- 
and plasma-proteins digested by tumour-secreted proteases, and proteins produced by 
local and distant responses to the tumour (86, 87). Several proteomic studies on plasma 
or serum utilizing MALDI-TOF MS and SELDI-TOF MS peaks have been reported to 
differentiate patients with breast cancer from those with benign breast disease and/or 
healthy controls (78, 88, 89) 
Blood plasma is the liquid component of blood in which the blood cells in whole blood 
are normally suspended. It makes up about 55% of the total blood volume, and is the 
intravascular fluid part of extracellular fluid, comprising mostly water (93% by volume) 
and contains dissolved proteins, glucose, clotting factors, mineral ions, hormones and 
carbon dioxide. Blood plasma is prepared by centrifuging a tube of fresh blood 
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iii. Predictive markers 
Several SELDI-TOF MS peaks (not structurally identified) were found indicative of 
treatment response in breast cancer cell lines to doxorubicin or paclitaxel (75). In 
addition, one study (76) found an increase of a 7.6kDa bovine transferrin fragment in 
serum-free conditioned medium of paclitaxel-resistant human breast cancer cell lines, 
corresponding to the increased expression of the transferrin receptor they observed in 
whole cell lysates. Although these results were not translated to the human in vivo 
setting, other studies have indeed reported an association between increased serum and 
cerebrospinal fluid transferrin levels and poor clinical outcome (71, 77). In one study, 
ubiquitin and S100-A6 were found to decrease in lysates of human breast cancer cell 
lines following chemotherapy-induced apoptosis (74); this coupled with the fact that 
aberrant expression of both proteins has also been reported in breast cancer tissue could 
make these two markers useful in predicting chemoresistant breast cancers (72, 73). In 
addition to these in vitro studies, in vivo studies have been performed as well (78, 79). In 
serum, both high molecular weight kininogen and apolipoprotein A-II were found to be 
significantly decreased in expression following docetaxel infusion in one particular 
patient with severe docetaxel side effects as compared to the other patients who 
tolerated the docetaxel infusion well. (79). The findings of this provocative study, if 
confirmed, suggest the potential of measuring protein biomarkers to predict adverse 
reaction to a drug. 
B. Neoadjuvant chemotherapy and post-chemotherapy time point of biomarker analysis 
in breast cancer 
Whilst the baseline pre-treatment time point is the commonest time point used in obtaining 
biomarkers to provide prognostic and/or predictive information, there are merits to using a 
post-chemotherapy time point biomarker, which may provide insights into biological effects 
of drugs and mechanisms of drug resistance. This however can only realistically occur in the 
setting of neoadjuvant or primary chemotherapy and in tumours from which serial tissue 
sampling can be safely obtained, such as in primary breast cancer. Neoadjuvant or primary 
chemotherapy in large primary breast cancers has been used with the purpose of reducing 
tumour volume and permitting less aggressive surgery (80). However, about 10-20% of 
patients do not benefit from this clinical approach (81, 82), and early identification of these 
patients could help avoid side effects from non-effective chemotherapy and unnecessary 
delay of definitive surgery.  
 Feasibility and significance of evaluating serial changes in protein expression post 1.
(neoadjuvant) chemotherapy in breast cancer 
Almost a decade ago, one of the earlier studies (83) assessed the feasibility of obtaining 
serial core breast biopsies, and correlated rates of apoptosis, proliferation, and 
expression of related proteins at baseline, during, and after neoadjuvant single agent 
chemotherapy for locally advanced breast cancer with treatment response. The study 
recruited women with a histologically confirmed unresected T3 or T4 infiltrating 
carcinoma of the breast. The first 20 patients received three cycles of doxorubicin 
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90mg/m2 followed by three cycles of paclitaxel 250mg/m2, or the reverse. Nine women 
received four cycles of each (doxorubicin 60mg/m2 and paclitaxel 175mg/m2). The end 
points studied included: clinical and pathological response, serial apoptotic [terminal 
deoxynucleotidyl transferase (Tdt)-mediated nick end labeling] and proliferation rates, 
and expression of ER, HER2, Bcl2, and p53 by IHC. Twelve patients (42%) had a clinical 
complete response (cCR), and 16 (55%) had a clinical partial response. Five women 
(17%) had pCR, 7 (24%) had microscopic residual disease, and 17 (58%) had 
macroscopic residual disease. Higher baseline apoptosis and proliferation were 
associated with a statistically significant improved pCR rate. In addition, among 14 
evaluable patients, apoptosis increased in women who had a cCR to the first agent but 
not in women without a cCR. The study however did not show any serial changes in 
ER, Her2, Bcl2 or p53. The authors concluded that it was feasible to obtain serial core 
biopsies that are informative for studies of apoptosis and IHC in patients undergoing 
neoadjuvant chemotherapy. 
 Limitations of post-chemotherapy biomarker analysis 2.
While feasible, for the most part, post-chemotherapy biomarker analysis is likely to be 
less well accepted by patients. This is because of all the accompanied logistical and 
patient discomfort issues with repeated biopsies. There would also be the issue of 
sampling error: biopsy and analysis of a chemotherapy-induced necrotic part of the 
tumour versus a still viable part or even chemo-resistant part of the tumour may reveal 
completely different profiles. It is also unclear at this point in time if any predictive 
biomarker for response obtained after treatment would be superior to standard clinical 
or radiological measurement of response. Having said that, many of the above issues 
also plague baseline biomarker analysis; a good example would be that of the recently 
recognized issue of Her2 heterogeneity in breast cancer (84). 
C. Specimen sources for measuring changes in protein expression 
 Blood/ plasma/ serum 1.
Since whole blood is considered to provide a dynamic reflection of physiological and 
pathological status, human plasma and serum represent the most extensively studied 
biological matrices in the quest for (breast) cancer biomarkers (85). Besides the usual 
circulatory proteins, it also contains specific tumour-secreted proteins, normal tissue- 
and plasma-proteins digested by tumour-secreted proteases, and proteins produced by 
local and distant responses to the tumour (86, 87). Several proteomic studies on plasma 
or serum utilizing MALDI-TOF MS and SELDI-TOF MS peaks have been reported to 
differentiate patients with breast cancer from those with benign breast disease and/or 
healthy controls (78, 88, 89) 
Blood plasma is the liquid component of blood in which the blood cells in whole blood 
are normally suspended. It makes up about 55% of the total blood volume, and is the 
intravascular fluid part of extracellular fluid, comprising mostly water (93% by volume) 
and contains dissolved proteins, glucose, clotting factors, mineral ions, hormones and 
carbon dioxide. Blood plasma is prepared by centrifuging a tube of fresh blood 
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containing an anti-coagulant until the blood cells fall to the bottom of the tube. The 
blood plasma is then drawn off. In contradistinction, blood serum is blood plasma with 
the clotting factors removed by letting a collected tube of blood clot and the ensuing 
liquid portion aliquoted off. This would thus require less equipment than collecting 
blood plasma. Serum contains all proteins not used in blood clotting (coagulation) and 
all the electrolytes, antibodies, antigens, hormones and any exogenous substances. 
Plasma specimens may thus be analyzed for biomarkers related to the coagulation 
cascade, unlike serum specimens where the coagulation factors would have been 
consumed in the clotting process. 
The commonest clinical use of blood instead of tissue biopsy to assess a tumour’s status 
serially in breast cancer would be the use of Ca15-3 (Section A5) as a surrogate for 
tumour response in metastatic breast cancer. The serial decrease in Ca15-3 in response 
to treatment is often congruent with the imaging findings of a response to 
chemotherapy even though it is based on expert panel (ASCO) recommendations rather 
than rigorous prospective data. 
The most promising use of blood instead of tissue biopsy for measuring serial changes 
in protein expression would be in the area of Her2 oncoprotein. Other blood markers 
(e.g. osteopontin) showing serial changes of possible prognostic significance are 
discussed below. (Section E) 
 Tumour tissue 2.
Tumour tissue can be collected fresh, ‘snap’ frozen in liquid nitrogen, or in formalin and 
then fixed in paraffin. The former is much more labour and logistics intensive while the 
latter has the potential problems of protein degradation from the fixation process. As it 
stands now most protein biomarker analysis are done on paraffin-fixed tissue due to the low 
cost and ease of transport. Fresh or fresh frozen tissue can be subject to MALDI/SELDI-TOF 
analysis but paraffin-fixed tissue can essentially only be used for IHC assessment.  
 Cerebrospinal fluid (CSF) 3.
Besides blood, CSF has also been explored for cancer biomarkers (77, 90). CSF contains less 
total protein than serum and provides a low fluid-volume-to-organ ratio, thereby 
augmenting biomarker discovery (91). As collection of CSF by invasive lumbar puncture is 
not applicable to healthy controls, the studies thus far only have been for diagnosis of 
metastatic disease in the leptomeninges or for prognosis rather than for primary diagnostic 
purposes in breast cancer. In one study which aimed to search for markers indicative of 
leptomeningeal metastases, CSF samples of 106 breast cancer patients were digested with 
trypsin (77); the resulting peptides were then analysed by MALDI-TOF MS and a 164 peak 
classifier with 77% accuracy in determining leptomeningeal disease was constructed. The 
discriminative tryptic peptides were derived of several proteins (90), three of which (i.e. 
apolipoprotein A-I, haptoglobin and transferrin) have also been found to be associated with 
clinical outcome in serum (71). 
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 Urine 4.
Urine has also been looked at as a source of biomarkers for breast cancer due to its ease of 
collection. One study looked at matrix metalloproteinase-9 (MMP-9) and a disintegrin and 
metalloprotease 12 (ADAM12) and found that they could predict women who were at 
increased risk of developing breast cancer (92). 
 Nipple aspirate 5.
Nipple aspirate and nipple ductal lavage have been investigated as a source of biomarkers; 
the rationale being that tumour cells could secrete proteins into the ducts. One study looked 
at nipple aspirate and ductal lavage specimens in patients with and without breast cancer, 
and found that elevated human neutrophil peptide in high risk cancer-free women, defined 
as those with estimated 5-year Gail risk of >1.6% or history of lobular carcinoma in situ, 
could predict early onset breast cancer better than current detection methods (93). 
 Tumour lysates 6.
Tumour lysates are harvested from fresh or fresh frozen tumour samples. They are 
homogenized in a lysis buffer with protease inhibitors to prevent protein degradation. The 
sample is then centrifuged and the supernatant decanted to obtain the tumour lysate, which 
can be used for MALDI-TOF or SELDI-TOF, reverse phase protein array (RRPA; see below), 
and other high throughput proteomic analyses. 
 Circulating tumour cells (CTCs) 7.
It has been appreciated in the past several years that tumour cells are shed from the primary 
tumour/ metastases and circulate in the blood stream. Intense research is ongoing to 
determine the utility of the detection of these cells in prognostication and prediction of 
therapy. One study showed that captured CTCs are amenable to biomarker analyses such as 
Her2 status, quantitative RT-PCR for breast cancer subtype markers, KRAS mutation 
detection and EGFR staining by immunofluorescence. The study was able to determine 
Her2 status by immunofluorescence and FISH in CTCs from metastatic breast cancer 
patients, although concordance with tumor Her2 status was only 89% (94).  
D. Methods of measuring protein expression and its changes 
 Enzyme-Linked ImmunoSorbent Assay (ELISA)/ antibody microarray 1.
In ELISA, an unknown amount of antigen is affixed to a surface, and then a specific 
antibody is applied over the surface so that it can bind to the antigen. This antibody is 
linked to an enzyme, and, in the final step, a substance containing the enzyme's substrate is 
added. The subsequent reaction produces a detectable signal, most commonly a color 
change in the substrate. 
Performing an ELISA involves at least one antibody with specificity for a particular antigen. 
The sample with an unknown amount of antigen is immobilized on a solid support either 
non-specifically (via adsorption to the surface) or specifically (via capture by another 
antibody specific to the same antigen, in a "sandwich" ELISA). After the antigen is 
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containing an anti-coagulant until the blood cells fall to the bottom of the tube. The 
blood plasma is then drawn off. In contradistinction, blood serum is blood plasma with 
the clotting factors removed by letting a collected tube of blood clot and the ensuing 
liquid portion aliquoted off. This would thus require less equipment than collecting 
blood plasma. Serum contains all proteins not used in blood clotting (coagulation) and 
all the electrolytes, antibodies, antigens, hormones and any exogenous substances. 
Plasma specimens may thus be analyzed for biomarkers related to the coagulation 
cascade, unlike serum specimens where the coagulation factors would have been 
consumed in the clotting process. 
The commonest clinical use of blood instead of tissue biopsy to assess a tumour’s status 
serially in breast cancer would be the use of Ca15-3 (Section A5) as a surrogate for 
tumour response in metastatic breast cancer. The serial decrease in Ca15-3 in response 
to treatment is often congruent with the imaging findings of a response to 
chemotherapy even though it is based on expert panel (ASCO) recommendations rather 
than rigorous prospective data. 
The most promising use of blood instead of tissue biopsy for measuring serial changes 
in protein expression would be in the area of Her2 oncoprotein. Other blood markers 
(e.g. osteopontin) showing serial changes of possible prognostic significance are 
discussed below. (Section E) 
 Tumour tissue 2.
Tumour tissue can be collected fresh, ‘snap’ frozen in liquid nitrogen, or in formalin and 
then fixed in paraffin. The former is much more labour and logistics intensive while the 
latter has the potential problems of protein degradation from the fixation process. As it 
stands now most protein biomarker analysis are done on paraffin-fixed tissue due to the low 
cost and ease of transport. Fresh or fresh frozen tissue can be subject to MALDI/SELDI-TOF 
analysis but paraffin-fixed tissue can essentially only be used for IHC assessment.  
 Cerebrospinal fluid (CSF) 3.
Besides blood, CSF has also been explored for cancer biomarkers (77, 90). CSF contains less 
total protein than serum and provides a low fluid-volume-to-organ ratio, thereby 
augmenting biomarker discovery (91). As collection of CSF by invasive lumbar puncture is 
not applicable to healthy controls, the studies thus far only have been for diagnosis of 
metastatic disease in the leptomeninges or for prognosis rather than for primary diagnostic 
purposes in breast cancer. In one study which aimed to search for markers indicative of 
leptomeningeal metastases, CSF samples of 106 breast cancer patients were digested with 
trypsin (77); the resulting peptides were then analysed by MALDI-TOF MS and a 164 peak 
classifier with 77% accuracy in determining leptomeningeal disease was constructed. The 
discriminative tryptic peptides were derived of several proteins (90), three of which (i.e. 
apolipoprotein A-I, haptoglobin and transferrin) have also been found to be associated with 
clinical outcome in serum (71). 
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 Urine 4.
Urine has also been looked at as a source of biomarkers for breast cancer due to its ease of 
collection. One study looked at matrix metalloproteinase-9 (MMP-9) and a disintegrin and 
metalloprotease 12 (ADAM12) and found that they could predict women who were at 
increased risk of developing breast cancer (92). 
 Nipple aspirate 5.
Nipple aspirate and nipple ductal lavage have been investigated as a source of biomarkers; 
the rationale being that tumour cells could secrete proteins into the ducts. One study looked 
at nipple aspirate and ductal lavage specimens in patients with and without breast cancer, 
and found that elevated human neutrophil peptide in high risk cancer-free women, defined 
as those with estimated 5-year Gail risk of >1.6% or history of lobular carcinoma in situ, 
could predict early onset breast cancer better than current detection methods (93). 
 Tumour lysates 6.
Tumour lysates are harvested from fresh or fresh frozen tumour samples. They are 
homogenized in a lysis buffer with protease inhibitors to prevent protein degradation. The 
sample is then centrifuged and the supernatant decanted to obtain the tumour lysate, which 
can be used for MALDI-TOF or SELDI-TOF, reverse phase protein array (RRPA; see below), 
and other high throughput proteomic analyses. 
 Circulating tumour cells (CTCs) 7.
It has been appreciated in the past several years that tumour cells are shed from the primary 
tumour/ metastases and circulate in the blood stream. Intense research is ongoing to 
determine the utility of the detection of these cells in prognostication and prediction of 
therapy. One study showed that captured CTCs are amenable to biomarker analyses such as 
Her2 status, quantitative RT-PCR for breast cancer subtype markers, KRAS mutation 
detection and EGFR staining by immunofluorescence. The study was able to determine 
Her2 status by immunofluorescence and FISH in CTCs from metastatic breast cancer 
patients, although concordance with tumor Her2 status was only 89% (94).  
D. Methods of measuring protein expression and its changes 
 Enzyme-Linked ImmunoSorbent Assay (ELISA)/ antibody microarray 1.
In ELISA, an unknown amount of antigen is affixed to a surface, and then a specific 
antibody is applied over the surface so that it can bind to the antigen. This antibody is 
linked to an enzyme, and, in the final step, a substance containing the enzyme's substrate is 
added. The subsequent reaction produces a detectable signal, most commonly a color 
change in the substrate. 
Performing an ELISA involves at least one antibody with specificity for a particular antigen. 
The sample with an unknown amount of antigen is immobilized on a solid support either 
non-specifically (via adsorption to the surface) or specifically (via capture by another 
antibody specific to the same antigen, in a "sandwich" ELISA). After the antigen is 
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immobilized, the detection antibody is added, forming a complex with the antigen. The 
detection antibody can be covalently linked to an enzyme, or can itself be detected by a 
secondary antibody that is linked to an enzyme through bioconjugation. Between each step, 
the plate is typically washed with a mild detergent solution to remove any proteins or 
antibodies that are not specifically bound. After the final wash step, the plate is developed 
by adding an enzymatic substrate to produce a visible signal, which indicates the quantity 
of antigen in the sample. The commonest medical use of ELISA is for assaying antigens/ 
substances that can be found in the serum component of blood or bodily fluids (e.g., human 
immunodeficiency virus). 
An antibody microarray is a specific form of ELISA-based protein microarray; a collection of 
antibodies are fixed on a solid surface such as glass, plastic or silicon chip, for the purpose of 
detecting antigens. The antibody microarray is often used for detecting protein expression 
from cell lysates and special biomarkers from serum or urine for diagnostic applications. 
 Tumour Immunohistochemistry (IHC) 2.
Immunohistochemistry, which is the most practical method for assessing protein expression 
changes, not only provides a semi-quantitative assessment of protein abundance but also 
reveals cellular localization. Because no special processing of tissue samples is needed and 
labour intensive and expensive diagnostic techniques are avoided, IHC is perhaps the most 
readily adaptable technique to clinical practice. Inter-observer reproducibility of 
immunohistochemical scoring is sometimes problematic, although this can generally be 
resolved by re-evaluation and discussion to reach consensus. Analysis of protein expression 
using IHC has identified molecular subtypes in breast cancer that are similar to those 
derived from gene expression arrays (95). The most powerful use of IHC is that of a tissue 
microarray (TMA), which analyzes simultaneously a new protein marker or a group of 
‘protein signature’ markers in hundreds to thousands of cylindrical fragments of clustered 
tumour samples collected from original paraffin blocks (96). 
 Proteomics: MALDI-TOF/ SELDI-TOF 3.
Proteomic-pattern profiling is a recent approach to protein biomarker discovery. Given that 
mRNA information does not always accurately reflect the function of proteins which are the 
functional components within organisms, the use of proteomic patterns to enable tumour 
diagnosis or sub-classification seems more promising. The rationale is that proteins 
produced by cancer cells or their microenvironment may eventually enter the circulation 
and that the patterns of expression of these proteins could be assessed by mass spectrometry 
(MS) in combination with mathematical algorithms for diagnostic purposes. The search for 
novel protein biomarkers has for the longest time been dominated by two-dimensional gel 
electrophoresis (97), a significant disadvantage of which is its lack of real high-throughput 
capability. However, recent advances in analytical technologies, such as protein microarrays 
and mass spectrometry, have enabled large-scale proteomic analyses (98). 
Technologies such as differential in-gel electrophoresis, two-dimensional polyacrylamide 
gel electrophoresis and multidimensional protein identification technology, can be used for 
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high-throughput protein profiling. Due to their relative ease of sample preparation, high 
analytical sensitivity and speed of data acquisition, two MS-based technologies in particular, 
matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) MS (99) and its 
variant surface-enhanced laser desorption/ionisation (SELDI-) TOF MS (100) have been 
widely deployed for cancer biomarker discovery (101). In both platforms, biological samples 
(e.g., serum, tissue lysate) are co-crystallised with an energy absorbing matrix on a sample 
probe surface. Subsequent irradiation with brief laser pulses sublimates and ionises the 
proteins out of their crystalline matrix, after which an electric field migrates the charged 
proteins to the time-of-flight mass analyser. The proteins are then separated based on their 
mass, as the time to detector impact (TOF) is proportional to the protein mass per charge. 
The two platforms differ in their sample probe surfaces. In MALDI, the probe surface 
merely presents the sample to the mass spectrometer, warranting off-line sample 
fractionation and clean-up to produce usable MS signals. In contrast, the probe surfaces 
utilised by SELDI are comprised of various chromatographic surfaces, enabling their active 
role in sample fractionation. 
The technology that has received considerable attention involves the use of a minute 
amount of biological sample added to a ‘protein-chip’, which is subsequently analyzed by 
MALDI or SELDI-TOF-MS to generate a proteomic signature (102). These patterns reflect 
part of the tissue or body fluid proteome, but without knowledge of the actual identity of 
the proteins. In addition to the issue of protein identification, there are also problems related 
to the other aspects of this technology. Validation and the consistency of bioinformatics 
analysis is of great importance to ascertain reproducibility and prevent systematic bias and 
overfitting of data. This is highlighted by a study (103), in which the potential markers for 
breast cancer and lymph node status reported by two studies (104, 105) could not be 
confirmed following analysis of an independent sample set. The shortcomings also include 
bias from artefacts related to the clinical sample collection and storage, the inherent 
qualitative control issues of mass spectrometric analysis, failure to identify well-established 
cancer biomarkers, bias when identifying high-abundance molecules within the serum, and 
disagreement between peaks generated by different laboratories (106, 107). Another 
limitation concerns possible bioinformatic artifacts; one study (108) showed that even 
signals that are detected that are actually a result of ‘noise’ can also achieve a high level of 
discrimination between patients with cancer and those without, further highlighting the lack 
of specificity of some of the signals detected. As such, despite a significant period since the 
first report of this technology, no independent validation studies have been published, and 
no product has yet reached the clinic. 
 Isobaric Tags for Relative and Absolute Quantification (iTRAQ) 4.
iTRAQ is based on the labeling of the N-terminus and side chain amines of peptides from 
digested proteins with tags of varying mass. One such method commercialized by Applied 
Biosystems is called iTRAQ and uses four amine specific (4-plex) isobaric reagents to label 
the primary amines of peptides from four different biological samples. In recent times, an 
eight amine specific set of reagents (8-plex) has also been available. These samples are then 
 
Oncogene and Cancer – From Bench to Clinic 16 
immobilized, the detection antibody is added, forming a complex with the antigen. The 
detection antibody can be covalently linked to an enzyme, or can itself be detected by a 
secondary antibody that is linked to an enzyme through bioconjugation. Between each step, 
the plate is typically washed with a mild detergent solution to remove any proteins or 
antibodies that are not specifically bound. After the final wash step, the plate is developed 
by adding an enzymatic substrate to produce a visible signal, which indicates the quantity 
of antigen in the sample. The commonest medical use of ELISA is for assaying antigens/ 
substances that can be found in the serum component of blood or bodily fluids (e.g., human 
immunodeficiency virus). 
An antibody microarray is a specific form of ELISA-based protein microarray; a collection of 
antibodies are fixed on a solid surface such as glass, plastic or silicon chip, for the purpose of 
detecting antigens. The antibody microarray is often used for detecting protein expression 
from cell lysates and special biomarkers from serum or urine for diagnostic applications. 
 Tumour Immunohistochemistry (IHC) 2.
Immunohistochemistry, which is the most practical method for assessing protein expression 
changes, not only provides a semi-quantitative assessment of protein abundance but also 
reveals cellular localization. Because no special processing of tissue samples is needed and 
labour intensive and expensive diagnostic techniques are avoided, IHC is perhaps the most 
readily adaptable technique to clinical practice. Inter-observer reproducibility of 
immunohistochemical scoring is sometimes problematic, although this can generally be 
resolved by re-evaluation and discussion to reach consensus. Analysis of protein expression 
using IHC has identified molecular subtypes in breast cancer that are similar to those 
derived from gene expression arrays (95). The most powerful use of IHC is that of a tissue 
microarray (TMA), which analyzes simultaneously a new protein marker or a group of 
‘protein signature’ markers in hundreds to thousands of cylindrical fragments of clustered 
tumour samples collected from original paraffin blocks (96). 
 Proteomics: MALDI-TOF/ SELDI-TOF 3.
Proteomic-pattern profiling is a recent approach to protein biomarker discovery. Given that 
mRNA information does not always accurately reflect the function of proteins which are the 
functional components within organisms, the use of proteomic patterns to enable tumour 
diagnosis or sub-classification seems more promising. The rationale is that proteins 
produced by cancer cells or their microenvironment may eventually enter the circulation 
and that the patterns of expression of these proteins could be assessed by mass spectrometry 
(MS) in combination with mathematical algorithms for diagnostic purposes. The search for 
novel protein biomarkers has for the longest time been dominated by two-dimensional gel 
electrophoresis (97), a significant disadvantage of which is its lack of real high-throughput 
capability. However, recent advances in analytical technologies, such as protein microarrays 
and mass spectrometry, have enabled large-scale proteomic analyses (98). 
Technologies such as differential in-gel electrophoresis, two-dimensional polyacrylamide 
gel electrophoresis and multidimensional protein identification technology, can be used for 
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high-throughput protein profiling. Due to their relative ease of sample preparation, high 
analytical sensitivity and speed of data acquisition, two MS-based technologies in particular, 
matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) MS (99) and its 
variant surface-enhanced laser desorption/ionisation (SELDI-) TOF MS (100) have been 
widely deployed for cancer biomarker discovery (101). In both platforms, biological samples 
(e.g., serum, tissue lysate) are co-crystallised with an energy absorbing matrix on a sample 
probe surface. Subsequent irradiation with brief laser pulses sublimates and ionises the 
proteins out of their crystalline matrix, after which an electric field migrates the charged 
proteins to the time-of-flight mass analyser. The proteins are then separated based on their 
mass, as the time to detector impact (TOF) is proportional to the protein mass per charge. 
The two platforms differ in their sample probe surfaces. In MALDI, the probe surface 
merely presents the sample to the mass spectrometer, warranting off-line sample 
fractionation and clean-up to produce usable MS signals. In contrast, the probe surfaces 
utilised by SELDI are comprised of various chromatographic surfaces, enabling their active 
role in sample fractionation. 
The technology that has received considerable attention involves the use of a minute 
amount of biological sample added to a ‘protein-chip’, which is subsequently analyzed by 
MALDI or SELDI-TOF-MS to generate a proteomic signature (102). These patterns reflect 
part of the tissue or body fluid proteome, but without knowledge of the actual identity of 
the proteins. In addition to the issue of protein identification, there are also problems related 
to the other aspects of this technology. Validation and the consistency of bioinformatics 
analysis is of great importance to ascertain reproducibility and prevent systematic bias and 
overfitting of data. This is highlighted by a study (103), in which the potential markers for 
breast cancer and lymph node status reported by two studies (104, 105) could not be 
confirmed following analysis of an independent sample set. The shortcomings also include 
bias from artefacts related to the clinical sample collection and storage, the inherent 
qualitative control issues of mass spectrometric analysis, failure to identify well-established 
cancer biomarkers, bias when identifying high-abundance molecules within the serum, and 
disagreement between peaks generated by different laboratories (106, 107). Another 
limitation concerns possible bioinformatic artifacts; one study (108) showed that even 
signals that are detected that are actually a result of ‘noise’ can also achieve a high level of 
discrimination between patients with cancer and those without, further highlighting the lack 
of specificity of some of the signals detected. As such, despite a significant period since the 
first report of this technology, no independent validation studies have been published, and 
no product has yet reached the clinic. 
 Isobaric Tags for Relative and Absolute Quantification (iTRAQ) 4.
iTRAQ is based on the labeling of the N-terminus and side chain amines of peptides from 
digested proteins with tags of varying mass. One such method commercialized by Applied 
Biosystems is called iTRAQ and uses four amine specific (4-plex) isobaric reagents to label 
the primary amines of peptides from four different biological samples. In recent times, an 
eight amine specific set of reagents (8-plex) has also been available. These samples are then 
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pooled and usually fractionated by nano liquid chromatography and analyzed by tandem 
mass spectrometry. A database search is then performed using the fragmentation data to 
identify the labeled peptides and hence the corresponding proteins. The fragmentation of 
the attached tag generates a low molecular mass reporter ion that can be used to relatively 
quantify the peptides and the proteins from which they originated. iTRAQ reagents 
therefore allow simultaneous identification and quantification of proteins in four or eight 
different samples using tandem mass spectrometry. 
 Reverse Phase Protein Array (RPPA) 5.
The principle of RPPA involves the spotting of patient samples in an array format onto a 
nitrocellulose support. Hundreds of patient specimens can be spotted onto the same array, 
allowing a large number of samples to be compared simultaneously under identical 
conditions. Each array is incubated with one particular antibody, and signal intensity 
proportional to the amount of analyte in the sample spot is generated. Signal detection is 
commonly performed by fluorescence, chemiluminescence or colorimetric methods, and the 
results are quantified by scanning and analyzed by software such as P-SCAN and 
ProteinScan. 
RPPA is possibly a useful tool to identify and validate proteins and phospho-proteins in 
cancer (109, 110). The aim of one such study was to determine whether functional 
proteomics using RPPA improves breast cancer classification and prognostication and also 
whether it can predict pCR in patients receiving neoadjuvant taxane and anthracycline-
taxane-based chemotherapy. Six breast cancer subgroups were identified by a 10-protein 
biomarker panel in the 712 tumour training set, that were associated with different 
recurrence-free survival. A prognosis score constructed using the 10 protein-signature (ER, 
PR, Bcl2, GATA3, CCNB1, CCNE1, EGFR, Her2, Her2p1248 and EIG121) in the training set 
was associated with relapse free survival in both the training and test sets. In addition, there 
was a significant association between the prognostic score and likelihood of pCR to 
neoadjuvant chemotherapy in yet another independent sample set. 
E. Serial changes in expression of various established protein biomarkers in response to 
neoadjuvant chemotherapy 
 ER/PR 1.
The most obvious candidate biomarker for which one would expect extensive data on with 
regards to serial changes post chemotherapy would be ER and PR. Much as it would have 
been hoped that the data on this would be consistent, the fact is that various trials showed a 
spectrum of findings. In a relatively recent meta-analysis (111), it was found that 
discordance in ER and PR between core needle biopsy and subsequent resection material 
was more evident in the patients treated with neoadjuvant chemotherapy (around 15%) 
than the reported discordance in patients not treated with neoadjuvant chemotherapy 
(around 2%). Although the studies reviewed were quite heterogeneous with respect to study 
methodology, design and outcome measures, the discordances could only partly be 
explained by the study design confounders and are instead more likely due to the direct 
effect of the chemotherapy. A change of hormone receptor status in up to a third of patients 
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after neoadjuvant chemotherapy was reported in several studies (112-114). In general, 
studies that reported a good concordance of hormone receptor status before and after 
neoadjuvant chemotherapy had a relatively smaller number of patients compared to the 
studies that found significant changes. The small sample size might have prevented these 
trials from showing statistical significance. Intriguingly, PR was found to be more 
discordant compared to ER. 
Various postulations regarding the mechanisms resulting in a change in the receptor status 
caused by chemotherapy have been put forth. The targeting of chemosensitive tumour cells 
leaves resistant tumour cells behind, which may have different ER status (positive or 
negative) from the sensitive tumour cells that were eradicated. Lower circulating levels of 
estrogens caused by ovarian insufficiency during or after chemotherapy in premenopausal 
women (115) might cause downregulation of the estrogen and/or progesterone receptor of 
the tumour leading to estrogen-independent growth.  
In spite of the likely true observed phenomenon of serial changes in ER/PR status post 
chemotherapy, however, little is known about the predictive or prognostic value of a 
changed receptor status. A few investigators tried to correlate changes to treatment 
response, but discordant conclusions were drawn (116, 117). A positive switch of the 
hormone receptor status could be an indicator for a better outcome and indeed was 
significantly correlated with better disease-free and overall survival in patients who were 
treated with adjuvant endocrine therapy compared to those with a positive switch who 
were not (118). In clinical practice, the likely utility of repeating the ER/PR status post 
chemotherapy is to evaluate if there is any hormone receptor positivity necessitating 
endocrine therapy. 
 Tumor Her2 2.
In one study (119), the authors evaluated the correlation among patients' characteristics, 
immunohistochemical expression of hormonal receptors (ER and PR), p53, p21 and Her2 
protein expression and the clinical and pathological response to a neoadjuvant combination 
of docetaxel and epirubicin chemotherapy. There was a reduction in p53 protein expression, 
as well as in p21 protein expression after neoadjuvant chemotherapy. However, 
neoadjuvant taxane and anthracycline did not change Her2 expression in patients with 
locally advanced breast carcinoma. The tissue Her2 stable phenotype observed in this study 
during neoadjuvant chemotherapy has also been reported by other groups (112, 117, 120). 
Recent studies have focused on the role of tumour Her2 as a predictive factor of response to 
neoadjuvant chemotherapy (112) but have failed to observe a correlation between tumour 
baseline Her2 positivity and the clinical or pathological response to neoadjuvant 
chemotherapy. This is in contradistinction to serum Her2 which will be detailed below. 
 Serum Her2 3.
There have been several studies showing serial changes in serum Her2 (sHer2) following 
neoadjuvant chemotherapy. One study within a large clinical trial (121) sought to use serum 
markers to optimize treatment strategies in breast cancer. The authors investigated serum 
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pooled and usually fractionated by nano liquid chromatography and analyzed by tandem 
mass spectrometry. A database search is then performed using the fragmentation data to 
identify the labeled peptides and hence the corresponding proteins. The fragmentation of 
the attached tag generates a low molecular mass reporter ion that can be used to relatively 
quantify the peptides and the proteins from which they originated. iTRAQ reagents 
therefore allow simultaneous identification and quantification of proteins in four or eight 
different samples using tandem mass spectrometry. 
 Reverse Phase Protein Array (RPPA) 5.
The principle of RPPA involves the spotting of patient samples in an array format onto a 
nitrocellulose support. Hundreds of patient specimens can be spotted onto the same array, 
allowing a large number of samples to be compared simultaneously under identical 
conditions. Each array is incubated with one particular antibody, and signal intensity 
proportional to the amount of analyte in the sample spot is generated. Signal detection is 
commonly performed by fluorescence, chemiluminescence or colorimetric methods, and the 
results are quantified by scanning and analyzed by software such as P-SCAN and 
ProteinScan. 
RPPA is possibly a useful tool to identify and validate proteins and phospho-proteins in 
cancer (109, 110). The aim of one such study was to determine whether functional 
proteomics using RPPA improves breast cancer classification and prognostication and also 
whether it can predict pCR in patients receiving neoadjuvant taxane and anthracycline-
taxane-based chemotherapy. Six breast cancer subgroups were identified by a 10-protein 
biomarker panel in the 712 tumour training set, that were associated with different 
recurrence-free survival. A prognosis score constructed using the 10 protein-signature (ER, 
PR, Bcl2, GATA3, CCNB1, CCNE1, EGFR, Her2, Her2p1248 and EIG121) in the training set 
was associated with relapse free survival in both the training and test sets. In addition, there 
was a significant association between the prognostic score and likelihood of pCR to 
neoadjuvant chemotherapy in yet another independent sample set. 
E. Serial changes in expression of various established protein biomarkers in response to 
neoadjuvant chemotherapy 
 ER/PR 1.
The most obvious candidate biomarker for which one would expect extensive data on with 
regards to serial changes post chemotherapy would be ER and PR. Much as it would have 
been hoped that the data on this would be consistent, the fact is that various trials showed a 
spectrum of findings. In a relatively recent meta-analysis (111), it was found that 
discordance in ER and PR between core needle biopsy and subsequent resection material 
was more evident in the patients treated with neoadjuvant chemotherapy (around 15%) 
than the reported discordance in patients not treated with neoadjuvant chemotherapy 
(around 2%). Although the studies reviewed were quite heterogeneous with respect to study 
methodology, design and outcome measures, the discordances could only partly be 
explained by the study design confounders and are instead more likely due to the direct 
effect of the chemotherapy. A change of hormone receptor status in up to a third of patients 
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after neoadjuvant chemotherapy was reported in several studies (112-114). In general, 
studies that reported a good concordance of hormone receptor status before and after 
neoadjuvant chemotherapy had a relatively smaller number of patients compared to the 
studies that found significant changes. The small sample size might have prevented these 
trials from showing statistical significance. Intriguingly, PR was found to be more 
discordant compared to ER. 
Various postulations regarding the mechanisms resulting in a change in the receptor status 
caused by chemotherapy have been put forth. The targeting of chemosensitive tumour cells 
leaves resistant tumour cells behind, which may have different ER status (positive or 
negative) from the sensitive tumour cells that were eradicated. Lower circulating levels of 
estrogens caused by ovarian insufficiency during or after chemotherapy in premenopausal 
women (115) might cause downregulation of the estrogen and/or progesterone receptor of 
the tumour leading to estrogen-independent growth.  
In spite of the likely true observed phenomenon of serial changes in ER/PR status post 
chemotherapy, however, little is known about the predictive or prognostic value of a 
changed receptor status. A few investigators tried to correlate changes to treatment 
response, but discordant conclusions were drawn (116, 117). A positive switch of the 
hormone receptor status could be an indicator for a better outcome and indeed was 
significantly correlated with better disease-free and overall survival in patients who were 
treated with adjuvant endocrine therapy compared to those with a positive switch who 
were not (118). In clinical practice, the likely utility of repeating the ER/PR status post 
chemotherapy is to evaluate if there is any hormone receptor positivity necessitating 
endocrine therapy. 
 Tumor Her2 2.
In one study (119), the authors evaluated the correlation among patients' characteristics, 
immunohistochemical expression of hormonal receptors (ER and PR), p53, p21 and Her2 
protein expression and the clinical and pathological response to a neoadjuvant combination 
of docetaxel and epirubicin chemotherapy. There was a reduction in p53 protein expression, 
as well as in p21 protein expression after neoadjuvant chemotherapy. However, 
neoadjuvant taxane and anthracycline did not change Her2 expression in patients with 
locally advanced breast carcinoma. The tissue Her2 stable phenotype observed in this study 
during neoadjuvant chemotherapy has also been reported by other groups (112, 117, 120). 
Recent studies have focused on the role of tumour Her2 as a predictive factor of response to 
neoadjuvant chemotherapy (112) but have failed to observe a correlation between tumour 
baseline Her2 positivity and the clinical or pathological response to neoadjuvant 
chemotherapy. This is in contradistinction to serum Her2 which will be detailed below. 
 Serum Her2 3.
There have been several studies showing serial changes in serum Her2 (sHer2) following 
neoadjuvant chemotherapy. One study within a large clinical trial (121) sought to use serum 
markers to optimize treatment strategies in breast cancer. The authors investigated serum 
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Her2 levels (sHer2) in 175 breast cancer patients participating in the GeparQuattro trial. This 
study incorporated neoadjuvant chemotherapy approaches in Her2-positive and negative 
patients (epirubicin/cyclophosphamide prior to randomization to either docetaxel alone, 
docetaxel in combination with capecitabine or docetaxel followed by capecitabine) and the 
addition of trastuzumab treatment for patients with Her2-positive tumours. sHer2 levels 
were measured by ELISA before and after initiation of neoadjuvant chemotherapy in 90 
Her2 positive and 85 Her2 negative patients. Median pre-chemotherapy sHer2 levels were 
higher in patients with positive Her2 status of the primary tumour than in patients with 
negative tumor Her2 status (14.9ng/ml versus 7.7ng/ml). A pre-chemotherapy sHer2 cut-off 
level of 10ng/ml had the best sensitivity and specificity in differentiating between Her2 
positive and Her2 negative tumours. In Her2 positive patients, the authors found a 
significant positive association between pCR and elevated baseline sHer2 levels (above 
15ng/ml) and a more than 20% decrease of sHer2 levels during neoadjuvant chemotherapy, 
which was of borderline significance in multivariate analysis (odds ratio=3.29). In Her2 
negative patients, the authors observed no association between sHer2 levels and pCR. The 
authors thus hypothesized that monitoring sHer2 levels in the presence of anti-Her2 
treatment might be an adjunct to clinical evaluation during neoadjuvant chemotherapy in 
Her2 positive disease. 
Two smaller published reports investigated the correlation between treatment-induced 
changes in sHer2 and pathologic complete response from neoadjuvant chemotherapy plus 
trastuzumab. One study evaluated sHer2 levels in a trastuzumab-based neoadjuvant setting 
in 16 patients. In this small group of patients, the authors could show that a decrease of 
sHer2 levels was associated with response to therapy (122). In the other study which 
monitored sHer levels serially over 6 months, 39 patients were treated with neoadjuvant 
chemotherapy including 29 patients who received a trastuzumab combination. A 9% 
decrease in sHer2 levels from week 3 to week 6 after initiation of therapy (but not earlier or 
later) was predictive of pCR (123). This study also illustrated that time dependency of post 
chemotherapy biomarkers could be an important issue. In this study, the mean sHer2 
baseline values were not different between the pCR group and the group with residual 
disease suggesting that post-chemotherapy evaluation could be superior to baseline 
evaluation. 
In contrast, Quaranta et al. could not find a correlation between serum positivity for Her2 
(using a cutoff of 10ng/ml as per the GeparQuattro trial) and tissue positivity for Her2 levels 
in an unselected patient group of 108 patients (124). In addition, no clear relationship was 
found between baseline sHer2 levels and tumour response to trastuzumab-based treatment 
in a recently published meta-analysis (125). In an abstract of a small study presented at 
ASCO 2011, Lee et al investigated the correlation between the response of advanced breast 
cancers to neoadjuvant chemotherapy and the change of serum Her2 and short-term disease 
free survival. Twenty-two locally advanced Her2 IHC 3+ or FISH amplified breast cancer 
patients were treated with neoadjuvant doxorubicin or trastuzumab. Serum Her2 levels 
were measured by chemiluminescence immunoassay before and after neoadjuvant 
chemotherapy. The cutoff value was 10.2mg/ml which is similar to that of the GeparQuattro 
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trial. Mean serum Her2 before chemotherapy was 15.8± 1.6ng/ml, and that after 
chemotherapy was 10.6 ± 0.38ng/ml. The change of serum Her2 in the CR group was higher 
than that in the PR group (13.26 ± 14.1ng/ml and 2.74±3.2ng/ml respectively). However, at a 
mean follow-up of 41 months, the change of serum Her2 before and after chemotherapy was 
not correlated with disease recurrence or with disease free interval. 
Several groups have postulated that monitoring changes in sHer2 levels after a specific time-
period after trastuzumab treatment might be valuable for identifying a patient population 
that might benefit from additional treatment regimens with other Her2 targeted therapies 
and certainly merits confirmation in further large prospective trials (126). 
F. Serial changes in expression of various candidate protein biomarkers in response to 
neoadjuvant chemotherapy 
 COX-2 1.
Cyclooxygenases (COX-1 and COX-2) are rate-limiting enzymes in the formation of 
prostaglandins from arachidonic acid. COX-1 is considered to be constitutively expressed 
while COX-2 is highly inducible by various factors and is associated with tumourigenesis 
(127-129). Several studies have shown the unfavourable prognostic significance of COX-2 
expression in breast cancer (130, 131). A few retrospective breast cancer studies have also 
suggested that tumour expression of COX-2 may be associated with more aggressive breast 
cancer phenotypes, poorer response to chemotherapy and inferior survival (130, 132). One 
study compared serial tumour samples from individual breast cancer patients before and 
after exposure to sequential cycles of doxorubicin and docetaxel and examined changes in 
tumour expression of COX-2 by IHC. The study also correlated any significant changes in 
biomarker expression with tumour clinical response and progression-free survival. There 
was a statistically significant progressive downward trend in COX-2 expression with 
increasing cycles of chemotherapy for the entire cohort. Subgroup analysis found that this 
decrease in COX-2 expression to be predominant in clinical responders but not in non-
responders. COX-2-positive tumours at baseline showed a statistically significant reduction 
in COX-2 expression with chemotherapy. This downward trend was most marked between 
the third and sixth cycle of chemotherapy rather than after one cycle of chemotherapy 
suggesting that this change did not occur early during chemotherapy. Tumours that were 
COX-2 positive both at baseline and after treatment had the worst outcome, while those that 
were COX-2 negative both at baseline and after treatment had the best outcome with a 
median progression free survival (PFS) of 25 versus 47 months. Another significant finding 
is related to ER status and COX-2 overexpression. For ER-positive and COX-2-positive 
tumours at baseline, a change to COX-2 negativity resulted in a statistically significant 
improvement in PFS compared with tumours that remained COX-2 positive (52 versus 27 
months). As for ER-negative and COX-2-positive tumours at baseline, the PFS is generally 
poor regardless of whether the tumour remained COX-2 positive or became negative after 
chemotherapy. The study also showed that COX-2-positive tumours at baseline correlated 
with more advanced tumour size, presence of metastases and inferior PFS as compared with 
COX-2-negative tumours. That neoadjuvant chemotherapy resulted in a reduction in COX-2 
expression in breast tumours is consistent with findings previously observed in breast 
 
Oncogene and Cancer – From Bench to Clinic 20 
Her2 levels (sHer2) in 175 breast cancer patients participating in the GeparQuattro trial. This 
study incorporated neoadjuvant chemotherapy approaches in Her2-positive and negative 
patients (epirubicin/cyclophosphamide prior to randomization to either docetaxel alone, 
docetaxel in combination with capecitabine or docetaxel followed by capecitabine) and the 
addition of trastuzumab treatment for patients with Her2-positive tumours. sHer2 levels 
were measured by ELISA before and after initiation of neoadjuvant chemotherapy in 90 
Her2 positive and 85 Her2 negative patients. Median pre-chemotherapy sHer2 levels were 
higher in patients with positive Her2 status of the primary tumour than in patients with 
negative tumor Her2 status (14.9ng/ml versus 7.7ng/ml). A pre-chemotherapy sHer2 cut-off 
level of 10ng/ml had the best sensitivity and specificity in differentiating between Her2 
positive and Her2 negative tumours. In Her2 positive patients, the authors found a 
significant positive association between pCR and elevated baseline sHer2 levels (above 
15ng/ml) and a more than 20% decrease of sHer2 levels during neoadjuvant chemotherapy, 
which was of borderline significance in multivariate analysis (odds ratio=3.29). In Her2 
negative patients, the authors observed no association between sHer2 levels and pCR. The 
authors thus hypothesized that monitoring sHer2 levels in the presence of anti-Her2 
treatment might be an adjunct to clinical evaluation during neoadjuvant chemotherapy in 
Her2 positive disease. 
Two smaller published reports investigated the correlation between treatment-induced 
changes in sHer2 and pathologic complete response from neoadjuvant chemotherapy plus 
trastuzumab. One study evaluated sHer2 levels in a trastuzumab-based neoadjuvant setting 
in 16 patients. In this small group of patients, the authors could show that a decrease of 
sHer2 levels was associated with response to therapy (122). In the other study which 
monitored sHer levels serially over 6 months, 39 patients were treated with neoadjuvant 
chemotherapy including 29 patients who received a trastuzumab combination. A 9% 
decrease in sHer2 levels from week 3 to week 6 after initiation of therapy (but not earlier or 
later) was predictive of pCR (123). This study also illustrated that time dependency of post 
chemotherapy biomarkers could be an important issue. In this study, the mean sHer2 
baseline values were not different between the pCR group and the group with residual 
disease suggesting that post-chemotherapy evaluation could be superior to baseline 
evaluation. 
In contrast, Quaranta et al. could not find a correlation between serum positivity for Her2 
(using a cutoff of 10ng/ml as per the GeparQuattro trial) and tissue positivity for Her2 levels 
in an unselected patient group of 108 patients (124). In addition, no clear relationship was 
found between baseline sHer2 levels and tumour response to trastuzumab-based treatment 
in a recently published meta-analysis (125). In an abstract of a small study presented at 
ASCO 2011, Lee et al investigated the correlation between the response of advanced breast 
cancers to neoadjuvant chemotherapy and the change of serum Her2 and short-term disease 
free survival. Twenty-two locally advanced Her2 IHC 3+ or FISH amplified breast cancer 
patients were treated with neoadjuvant doxorubicin or trastuzumab. Serum Her2 levels 
were measured by chemiluminescence immunoassay before and after neoadjuvant 
chemotherapy. The cutoff value was 10.2mg/ml which is similar to that of the GeparQuattro 
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trial. Mean serum Her2 before chemotherapy was 15.8± 1.6ng/ml, and that after 
chemotherapy was 10.6 ± 0.38ng/ml. The change of serum Her2 in the CR group was higher 
than that in the PR group (13.26 ± 14.1ng/ml and 2.74±3.2ng/ml respectively). However, at a 
mean follow-up of 41 months, the change of serum Her2 before and after chemotherapy was 
not correlated with disease recurrence or with disease free interval. 
Several groups have postulated that monitoring changes in sHer2 levels after a specific time-
period after trastuzumab treatment might be valuable for identifying a patient population 
that might benefit from additional treatment regimens with other Her2 targeted therapies 
and certainly merits confirmation in further large prospective trials (126). 
F. Serial changes in expression of various candidate protein biomarkers in response to 
neoadjuvant chemotherapy 
 COX-2 1.
Cyclooxygenases (COX-1 and COX-2) are rate-limiting enzymes in the formation of 
prostaglandins from arachidonic acid. COX-1 is considered to be constitutively expressed 
while COX-2 is highly inducible by various factors and is associated with tumourigenesis 
(127-129). Several studies have shown the unfavourable prognostic significance of COX-2 
expression in breast cancer (130, 131). A few retrospective breast cancer studies have also 
suggested that tumour expression of COX-2 may be associated with more aggressive breast 
cancer phenotypes, poorer response to chemotherapy and inferior survival (130, 132). One 
study compared serial tumour samples from individual breast cancer patients before and 
after exposure to sequential cycles of doxorubicin and docetaxel and examined changes in 
tumour expression of COX-2 by IHC. The study also correlated any significant changes in 
biomarker expression with tumour clinical response and progression-free survival. There 
was a statistically significant progressive downward trend in COX-2 expression with 
increasing cycles of chemotherapy for the entire cohort. Subgroup analysis found that this 
decrease in COX-2 expression to be predominant in clinical responders but not in non-
responders. COX-2-positive tumours at baseline showed a statistically significant reduction 
in COX-2 expression with chemotherapy. This downward trend was most marked between 
the third and sixth cycle of chemotherapy rather than after one cycle of chemotherapy 
suggesting that this change did not occur early during chemotherapy. Tumours that were 
COX-2 positive both at baseline and after treatment had the worst outcome, while those that 
were COX-2 negative both at baseline and after treatment had the best outcome with a 
median progression free survival (PFS) of 25 versus 47 months. Another significant finding 
is related to ER status and COX-2 overexpression. For ER-positive and COX-2-positive 
tumours at baseline, a change to COX-2 negativity resulted in a statistically significant 
improvement in PFS compared with tumours that remained COX-2 positive (52 versus 27 
months). As for ER-negative and COX-2-positive tumours at baseline, the PFS is generally 
poor regardless of whether the tumour remained COX-2 positive or became negative after 
chemotherapy. The study also showed that COX-2-positive tumours at baseline correlated 
with more advanced tumour size, presence of metastases and inferior PFS as compared with 
COX-2-negative tumours. That neoadjuvant chemotherapy resulted in a reduction in COX-2 
expression in breast tumours is consistent with findings previously observed in breast 
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cancer cell lines after chemotherapy (133). Furthermore, this reduction in COX-2 expression 
was seen mainly in clinical responders, a phenomenon that is also documented in other 
cancers (134). Another interesting finding in this study was that in patients with ER-positive 
and COX-2-positive tumours at baseline, post-chemotherapy COX-2 positivity had a 
significant negative influence on PFS, suggesting that COX-2 could play an important role in 
hormone-dependent breast cancers.  
The interest in COX-2 expression in cancer arises from the fact that this over-expression 
occurs in many human malignancies including colon and lung cancer (131, 135, 136), and the 
possibility of using widely available COX-2 inhibitors, e.g., nonsteroidal anti-inflammatory 
drugs, together with conventional anticancer therapy to enhance treatment efficacy. This is 
based on the premise that many of the COX-2-regulated genes that contribute to tumour 
progression may also be determinants of tumour sensitivity to treatment (137). Although the 
potential chemopreventive properties of selective COX-2 inhibitors are being actively 
investigated, little is known about the utility of these agents in the treatment of cancer. 
However, there is emerging data from breast, pancreatic and lung cancer studies showing 
potential benefit of combining COX-2 inhibitors with chemotherapy (137-139). In particular, 
a recent study involving patients with heavily pretreated breast cancer showed that the 
combination of chemotherapy and a selective COX-2 inhibitor resulted in a statistically 
significant doubling of time to progression for COX-2-positive tumours compared with 
COX-2 negative ones. At this point in time, there have not been confirmatory studies on 
COX2 serial changes post chemotherapy in breast cancer but this appears to be an area 
worth exploring. In particular, post-chemotherapy COX-2 expression may serve as a 
biomarker for COX-2 inhibition as a therapeutic strategy that warrants evaluation.  
 Topo2 2.
A seminal study (140) analyzed the value of Topo2α in predicting clinical response to 
anthracycline-based neoadjuvant chemotherapy in breast cancers and its potential changes 
after chemotherapy. The study also looked at p53 and Her2 the latter being commonly 
coexpressed with Topo2. Forty-one patients with primary breast cancer and treated with 
neoadjuvant anthracycline-based chemotherapy were included in the study. Topo2, Her2 
and p53 expression were measured by IHC in pre- and post-chemotherapy tumour 
specimens and the results were correlated with clinical response. Topo2 was 
overexpressed in 16 of 41 (31%) tumours before treatment, and this baseline overexpression 
was significantly associated with clinical response. Of note, Topo2 overexpression, but not 
Her2 or p53, was lost in specimens after chemotherapy, although this change did not 
correlate with clinical response. The observed link between baseline Topo2 expression and 
clinical response to neoadjuvant anthracycline-based chemotherapy, together with its loss 
after chemotherapy, suggests that Topo2 deserves further testing in a prospective setting 
as a predictive marker for chemotherapy response.  
 MGMT 3.
O6-Methylguanine-DNA methyltransferase (MGMT) rapidly reverses alkylation (including 
methylation) at the O6 position of guanine by transferring the alkyl-group to the active site 
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of the enzyme, constituted by a cysteine. An inactivated MGMT gene allows accumulation 
of O6-alkylguanine that is the most cytotoxic lesion of alkylating agents, which subsequent 
to incorrect pairing with thymidine triggers mismatch repair, thereby inducing DNA 
damage and eventually cell death. There has been one recent trial published by a Japanese 
group showing the possible utility of MGMT in breast cancer (141). The study evaluated 
thirty-two basal like breast cancer patients receiving neoadjuvant chemotherapy with an 
anthracycline and taxane-based regimen. The immunoreactivities of MGMT, MLH1, MSH2 
and BRCA1 before and after neoadjuvant chemotherapy were evaluated. pCR was achieved 
in 10 of 32 cases (31%), and cancer-related and disease-free survival rates were significantly 
higher in the pCR group than in the non-pCR group. In biopsy samples before neoadjuvant 
chemotherapy, attenuated expression of MGMT, MLH1, MSH2 and BRCA1 was observed in 
12/32 (38%), 0/32 (0%), 5/32 (16%) and 28/32 (88%) cases, respectively. On evaluation of 
predictors of pCR, including patient characteristics (age, menopausal status, clinical and 
pathological stages) and immunohistochemical patterns, pre-chemotherapy reduced 
expression of MGMT was found to be the only factor significantly predictive of pCR. Paired 
biopsy samples before neoadjuvant chemotherapy and surgical tumour material after 
neoadjuvant chemotherapy were available for 19 cases of non-pCR. In these 19 cases, 
decrease in expression of MGMT during neoadjuvant chemotherapy was more frequently 
observed in those with tumour shrinkage (i.e. > 60%) as compared to those with no decrease, 
although the difference was not statistically significant possibly due to the small sample 
size. If these results can be validated, baseline MGMT expression may be used as a predictor 
of pCR to neoadjuvant chemotherapy, while decrease in MGMT expression with 
chemotherapy may have additional predictive value for treatment response.  
 Heat shock protein 70 4.
Recently one group has shown using proteomic analysis (2-dimensional gel electrophoresis 
and mass spectrometry) of fourteen matched pairs of ER positive tumour tissues before and 
after neoadjuvant treatment with an aromatase inhibitor (AI) that ten proteins were 
differentially expressed before and after AI treatment. Among the identified proteins, 
treatment-induced reduction in heat shock protein 70 (Hsp-70) expression was the most 
significantly correlated with both clinical and pathological responses (142). This 
downregulation of Hsp-70 with chemotherapy was subsequently confirmed by IHC. These 
findings suggest that Hsp-70 may represent a potential novel predictive marker to endocrine 
therapy response (143). 
 Osteopontin 5.
Osteopontin has been reported to be a malignancy-associated protein measurable in tumour 
tissue and blood. In a prospective clinical study that measured serial plasma osteopontin 
levels in women with metastatic breast cancer throughout the course of their disease, serial 
elevation of osteopontin was found to be prognostic (144). 
One hundred fifty-eight women with newly diagnosed metastatic breast cancer were 
enrolled in the study. Plasma osteopontin was measured using an ELISA assay, at baseline 
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overexpressed in 16 of 41 (31%) tumours before treatment, and this baseline overexpression 
was significantly associated with clinical response. Of note, Topo2 overexpression, but not 
Her2 or p53, was lost in specimens after chemotherapy, although this change did not 
correlate with clinical response. The observed link between baseline Topo2 expression and 
clinical response to neoadjuvant anthracycline-based chemotherapy, together with its loss 
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group showing the possible utility of MGMT in breast cancer (141). The study evaluated 
thirty-two basal like breast cancer patients receiving neoadjuvant chemotherapy with an 
anthracycline and taxane-based regimen. The immunoreactivities of MGMT, MLH1, MSH2 
and BRCA1 before and after neoadjuvant chemotherapy were evaluated. pCR was achieved 
in 10 of 32 cases (31%), and cancer-related and disease-free survival rates were significantly 
higher in the pCR group than in the non-pCR group. In biopsy samples before neoadjuvant 
chemotherapy, attenuated expression of MGMT, MLH1, MSH2 and BRCA1 was observed in 
12/32 (38%), 0/32 (0%), 5/32 (16%) and 28/32 (88%) cases, respectively. On evaluation of 
predictors of pCR, including patient characteristics (age, menopausal status, clinical and 
pathological stages) and immunohistochemical patterns, pre-chemotherapy reduced 
expression of MGMT was found to be the only factor significantly predictive of pCR. Paired 
biopsy samples before neoadjuvant chemotherapy and surgical tumour material after 
neoadjuvant chemotherapy were available for 19 cases of non-pCR. In these 19 cases, 
decrease in expression of MGMT during neoadjuvant chemotherapy was more frequently 
observed in those with tumour shrinkage (i.e. > 60%) as compared to those with no decrease, 
although the difference was not statistically significant possibly due to the small sample 
size. If these results can be validated, baseline MGMT expression may be used as a predictor 
of pCR to neoadjuvant chemotherapy, while decrease in MGMT expression with 
chemotherapy may have additional predictive value for treatment response.  
 Heat shock protein 70 4.
Recently one group has shown using proteomic analysis (2-dimensional gel electrophoresis 
and mass spectrometry) of fourteen matched pairs of ER positive tumour tissues before and 
after neoadjuvant treatment with an aromatase inhibitor (AI) that ten proteins were 
differentially expressed before and after AI treatment. Among the identified proteins, 
treatment-induced reduction in heat shock protein 70 (Hsp-70) expression was the most 
significantly correlated with both clinical and pathological responses (142). This 
downregulation of Hsp-70 with chemotherapy was subsequently confirmed by IHC. These 
findings suggest that Hsp-70 may represent a potential novel predictive marker to endocrine 
therapy response (143). 
 Osteopontin 5.
Osteopontin has been reported to be a malignancy-associated protein measurable in tumour 
tissue and blood. In a prospective clinical study that measured serial plasma osteopontin 
levels in women with metastatic breast cancer throughout the course of their disease, serial 
elevation of osteopontin was found to be prognostic (144). 
One hundred fifty-eight women with newly diagnosed metastatic breast cancer were 
enrolled in the study. Plasma osteopontin was measured using an ELISA assay, at baseline 
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and every 3 to 12 weeks during and after therapy until death. Multivariate time-dependent 
survival analyses were conducted using models that right censored patient outcomes 3, 6, 
and 12 months after the last known osteopontin measurement. Osteopontin was measured 
in 1,378 samples (median, 9 per patient). Ninety-nine patients had elevated baseline 
osteopontin (median, 177 ng/ml; range, 1-2,648 ng/ml). In univariate analysis, elevated 
baseline osteopontin was associated with shorter survival (p = 0.02). In a multivariate model 
incorporating standard prognostic factors, baseline osteopontin was only marginally 
significantly associated with survival duration (relative risk, 1.001; p = 0.038). However, in a 
multivariate model incorporating standard prognostic factors and changes in sequential 
osteopontin levels, an osteopontin increase of >250 ng/mL at any time was the variable with 
the most prognostic value for poor survival (relative risk, 3.26; p=0.0003).  
This study is a further proof of concept that serial changes (and not just a baseline value) in 
a blood biomarker (and not just a tumour biomarker) can be prognostic in breast cancer. 
 Serial changes in protein profiles identified by high-throughput assays 6.
The study of serial changes in protein profiles in tumour and/or serum induced by 
chemotherapy has been assessed in a high throughput fashion. In a proteomics study, 
comparison of protein profiles using MALDI-TOF analysis of sera acquired before and after 
preoperative chemotherapy for breast cancer was performed (145). The study analyzed pre- 
and post-chemotherapy protein profiles of sera from 39 Her2-postive breast cancer patients 
who received 6 months of preoperative chemotherapy using liquid chromatography-
MALDI-TOF/MS technology, and detected qualitative and quantitative differences in pair-
wise comparison of pre- and post chemotherapy samples that were different in the 21 
patients who achieved pathological complete response compared with the 18 patients with 
residual disease. 2329 and 3152 peaks were identified as differentially expressed in the pre-
chemotherapy samples of the responders and non-responders respectively. Comparison of 
paired pre- and post-chemotherapy samples identified 34 (32 decreased, 2 increased) and 
304 peaks (157 decreased, 147 increased) that significantly changed after treatment in 
responders and non-responders, respectively. The top 11 most significantly altered peptide 
peaks with the greatest change in intensity were also identified. These peaks matched eight 
different known proteins in an NCBInr database search by MASCOT software, including 
-2-macroglobulin, complement 3, hemopexin, and serum amyloid P in the responder 
group and chains C and A of apolipoprotein A-I, hemopexin precursor, complement C, and 
amyloid P component in the non-responding group. All proteins decreased after therapy, 
except chain C apolipoprotein A and hemopexin precursor that increased. These results 
suggest that changes in serum protein levels occur in response to chemotherapy and these 
changes to a certain extent appear different in patients who are highly sensitive to 
chemotherapy compared with those who are more resistant. 
 Negative studies of post chemotherapy changes in biomarkers 7.
Publication bias would tend to result in under-reporting of negative findings of changes in 
biomarkers post-chemotherapy. In the few negative trials published, some of them conflict 
with the findings of the other trials mentioned above. For example, in a study of 97 patients 
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who received neoadjuvant anthracycline-based chemotherapy (146), the authors failed to 
find any post-chemotherapy change in ER, Her2, p53, Ki67 or Bcl2 as assessed by IHC. This 
is in contradistinction to the study by Dawson et al (64) who found changes in Bcl2. One 
possible reason for the failure to find a change in the biomarkers post-chemotherapy is the 
small sample size in this trial. 
G. The future of protein biomarkers in breast cancer 
Studies of protein biomarkers in breast cancer still rely heavily on IHC and with a possible 
emerging role of ELISA. Newer technologies on the horizon could facilitate the discovery of 
novel biomarkers in a high throughput fashion, and there are a few interesting 
developments attempting to push the frontier in proteomics. 
 SILAC 1.
SILAC (stable isotope labeling by/with amino acids in cell culture) is a MS-based 
methodology (used for quantitative proteomics) that detects differences in protein 
abundance using non-radioactive labeling. SILAC has emerged as a very powerful method 
to study cell signaling, post translation modifications, protein-protein interaction and 
regulation of gene expression. 
 Peptidomics 2.
The low-molecular-weight plasma (serum proteome) has been the focus of recent attempts 
to find new biomarkers (147). Peptides are critical for many physiological processes, such as 
blood glucose (insulin) regulation. It has been suggested that “the low molecular-weight 
region of the blood proteome contains precious diagnostic information (148). The low-
molecular-weight serum proteome has been characterized by ultrafiltration, enzymatic 
digestion, and liquid chromatography coupled to tandem mass spectrometry (149, 150), or 
via a top-down proteomics approach (whereby the intact peptide is distinguished directly 
by its fragment ions) (151) or by means of pattern profiling (152). Informative diagnostic 
peptides that are generated after proteolysis of high-abundance proteins by the coagulation 
and complement enzymatic cascades can be identified by mass spectrometry. These 
proteomic patterns were claimed to distinguish not only healthy controls from patients with 
cancer (153) but also between various types of cancer (152). However, one major concern is 
that these peptides present in the serum are derived from a small number of highly 
abundant proteins. One study showed that peptides in serum are affected by collection 
conditions. Improper collection could give rise to artefacts and serum is not ideal for 
proteomic experiments as it contains substantial endoproteolytic and exoproteolytic 
enzymatic activity (154). These findings raise concerns regarding peptidomics data 
generated by profiling technologies, with some investigators suggesting that peptidomic 
profiling might represent nothing more than peptides cleaved during coagulation or 
functions inherent to plasma or serum, including immune modulation, inflammatory 
response and protease inhibition (155). In addition, many of the issues associated with mass-
spectrometry- based protein profiling technologies also apply to peptidomics. Thus, while 
this technology looks promising, more confirmatory data is required and awaited.  
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chemotherapy compared with those who are more resistant. 
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Publication bias would tend to result in under-reporting of negative findings of changes in 
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who received neoadjuvant anthracycline-based chemotherapy (146), the authors failed to 
find any post-chemotherapy change in ER, Her2, p53, Ki67 or Bcl2 as assessed by IHC. This 
is in contradistinction to the study by Dawson et al (64) who found changes in Bcl2. One 
possible reason for the failure to find a change in the biomarkers post-chemotherapy is the 
small sample size in this trial. 
G. The future of protein biomarkers in breast cancer 
Studies of protein biomarkers in breast cancer still rely heavily on IHC and with a possible 
emerging role of ELISA. Newer technologies on the horizon could facilitate the discovery of 
novel biomarkers in a high throughput fashion, and there are a few interesting 
developments attempting to push the frontier in proteomics. 
 SILAC 1.
SILAC (stable isotope labeling by/with amino acids in cell culture) is a MS-based 
methodology (used for quantitative proteomics) that detects differences in protein 
abundance using non-radioactive labeling. SILAC has emerged as a very powerful method 
to study cell signaling, post translation modifications, protein-protein interaction and 
regulation of gene expression. 
 Peptidomics 2.
The low-molecular-weight plasma (serum proteome) has been the focus of recent attempts 
to find new biomarkers (147). Peptides are critical for many physiological processes, such as 
blood glucose (insulin) regulation. It has been suggested that “the low molecular-weight 
region of the blood proteome contains precious diagnostic information (148). The low-
molecular-weight serum proteome has been characterized by ultrafiltration, enzymatic 
digestion, and liquid chromatography coupled to tandem mass spectrometry (149, 150), or 
via a top-down proteomics approach (whereby the intact peptide is distinguished directly 
by its fragment ions) (151) or by means of pattern profiling (152). Informative diagnostic 
peptides that are generated after proteolysis of high-abundance proteins by the coagulation 
and complement enzymatic cascades can be identified by mass spectrometry. These 
proteomic patterns were claimed to distinguish not only healthy controls from patients with 
cancer (153) but also between various types of cancer (152). However, one major concern is 
that these peptides present in the serum are derived from a small number of highly 
abundant proteins. One study showed that peptides in serum are affected by collection 
conditions. Improper collection could give rise to artefacts and serum is not ideal for 
proteomic experiments as it contains substantial endoproteolytic and exoproteolytic 
enzymatic activity (154). These findings raise concerns regarding peptidomics data 
generated by profiling technologies, with some investigators suggesting that peptidomic 
profiling might represent nothing more than peptides cleaved during coagulation or 
functions inherent to plasma or serum, including immune modulation, inflammatory 
response and protease inhibition (155). In addition, many of the issues associated with mass-
spectrometry- based protein profiling technologies also apply to peptidomics. Thus, while 
this technology looks promising, more confirmatory data is required and awaited.  
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 Cancer-biomarker-family approach 3.
The basis for the ‘cancer biomarker family’ approach is that if a member of a protein family 
is already an established biomarker, then other members of that family might also be 
candidate cancer biomarkers. As an example, Prostate Specific Antigen (PSA) is a member of 
the human tissue kallikrein family. Kallikreins are secreted enzymes with trypsin-like or 
chymotrypsin-like serine protease activity. This enzyme family consists of 15 genes 
clustered in tandem on chromosome 19q13.4.63. PSA (KLK3) and KLK2 currently have 
important clinical applications as prostate cancer biomarkers (156). Other members of the 
human kallikrein family have been implicated in the process of carcinogenesis and are being 
investigated as biomarkers for diagnosis and prognosis. For example, KLK6 has been 
studied as a novel biomarker for ovarian cancer (157), and it was found that elevated serum 
levels of KLK6 was associated with late-stage tumour, high grade and serous histology and 
chemo-resistance. Similarly, KLK3, KLK5 and KLK14 have been shown to be increased in 
the serum of patients with breast cancer, thereby potentially serving as diagnostic markers. 
The fact that these proteins are serine proteases could implicate them in tumour progression 
through extracellular matrix degradation. 
 Secreted protein approach 4.
Examination of tissues or biological fluids near to the tumour site of origin could facilitate 
identification of candidate biomarker molecules. The mounting evidence that tumour 
growth is dependent on the malignant potential of the tumour cells as well as on the 
microenvironment surrounding the tumour (e.g., stroma, inflammatory cells, etc) further 
supports this approach (158). A number of technologies can be employed for analysis of 
these samples, but for systematic characterization of proteins in complex mixtures, mass 
spectrometry is the preferred technology. In the case of breast cancer, breast tissue, nipple 
aspirate fluid, breast cyst fluid and tumour interstitial fluid can all be explored. The tumour 
interstitial fluid that perfuses the tumour microenvironment in invasive ductal carcinomas 
of the breast has been examined by proteomic approaches (159). Over 250 proteins were 
identified, many of which were relevant to processes such as cell proliferation and invasion. 
The identification of secreted proteins in tissues or other biological fluids does not 
necessarily imply that the proteins will be detectable in the sera of cancer patients though, as 
this will depend on the stability of the protein, its clearance, its association with other serum 
proteins and the extent of post-translational modifications. 
20–25% of all proteins are secreted and/ or undergo aberrant secretion of membrane-bound 
proteins that have a secretable/ cleavable extracellular domain. Alterations in the signal 
peptide of proteins as a result of single nucleotide polymorphisms can result in unusual 
secretion patterns (160). Moreover, elevation of molecules in biological fluids can result from 
a change in the polarity of cancer cells, which can lead to the release of cancer-associated 
glycoproteins into the circulation. Increased expression of proteases that cleave the 
extracellular domain portion of membrane proteins can also cause increased circulating 
levels. One currently used secreted marker in breast cancer is that of CA15-3; it being a 
soluble form of MUC1, which is an antigenic focus on breast cancer. It is hoped that in the 
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years to come, more of such secreted proteins can be discovered so as to facilitate breast 
cancer monitoring. 
2. Conclusion 
Biomarkers guide physicians in counseling patients with regard to their prognosis and also 
provide information to physicians with respect to the optimal treatment for a particular 
patient/ patient group. The latter scenario (predictive biomarkers) is an area in which the 
natural history of the patient can be affected positively and thus are deemed to be more 
important. 
The baseline status of the predictive protein biomarkers ER, PR and Her2 are the most 
important in current breast cancer management. While post chemotherapy protein 
biomarkers in breast cancer is not currently used in routine clinical practice, evaluation of 
serial changes in expression of proteins in response to neoadjuvant chemotherapy has been 
shown to be feasible and in some studies shown to be a better biomarker than the baseline 
biomarker. It is achievable using an ELISA or IHC platform, which are technologies that are 
readily available in almost all clinical practices. However, the logistical challenges of 
obtaining serial tumour samples, reproducibility of the expression profile and patients’ 
compliance could be major factors that may limit widespread application of studying serial 
changes of protein expression in tumor routinely. There is also the issue of intra and inter-
individual variability when examining for the presence of prognostic and/or predictive 
serial changes in any putative biomarkers. In fact such an issue already exists with regard to 
Her2 testing by FISH; the clinical significance of genetic heterogeneity (i.e. in certain 
tumours, only a fraction of the cells are positive for the oncoprotein) of Her2 is still being 
investigated (84, 161). 
Although newer technologies (e.g., MALDI-TOF, etc.) are promising, the inability to identify 
all ‘peaks’ and the reproducibility issues at this point in time are major limitations. 
However, development of methods that allows rapid characterization of identified protein 
peaks holds promise for more widespread use of these technologies in the near future. 
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proteins that have a secretable/ cleavable extracellular domain. Alterations in the signal 
peptide of proteins as a result of single nucleotide polymorphisms can result in unusual 
secretion patterns (160). Moreover, elevation of molecules in biological fluids can result from 
a change in the polarity of cancer cells, which can lead to the release of cancer-associated 
glycoproteins into the circulation. Increased expression of proteases that cleave the 
extracellular domain portion of membrane proteins can also cause increased circulating 
levels. One currently used secreted marker in breast cancer is that of CA15-3; it being a 
soluble form of MUC1, which is an antigenic focus on breast cancer. It is hoped that in the 
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years to come, more of such secreted proteins can be discovered so as to facilitate breast 
cancer monitoring. 
2. Conclusion 
Biomarkers guide physicians in counseling patients with regard to their prognosis and also 
provide information to physicians with respect to the optimal treatment for a particular 
patient/ patient group. The latter scenario (predictive biomarkers) is an area in which the 
natural history of the patient can be affected positively and thus are deemed to be more 
important. 
The baseline status of the predictive protein biomarkers ER, PR and Her2 are the most 
important in current breast cancer management. While post chemotherapy protein 
biomarkers in breast cancer is not currently used in routine clinical practice, evaluation of 
serial changes in expression of proteins in response to neoadjuvant chemotherapy has been 
shown to be feasible and in some studies shown to be a better biomarker than the baseline 
biomarker. It is achievable using an ELISA or IHC platform, which are technologies that are 
readily available in almost all clinical practices. However, the logistical challenges of 
obtaining serial tumour samples, reproducibility of the expression profile and patients’ 
compliance could be major factors that may limit widespread application of studying serial 
changes of protein expression in tumor routinely. There is also the issue of intra and inter-
individual variability when examining for the presence of prognostic and/or predictive 
serial changes in any putative biomarkers. In fact such an issue already exists with regard to 
Her2 testing by FISH; the clinical significance of genetic heterogeneity (i.e. in certain 
tumours, only a fraction of the cells are positive for the oncoprotein) of Her2 is still being 
investigated (84, 161). 
Although newer technologies (e.g., MALDI-TOF, etc.) are promising, the inability to identify 
all ‘peaks’ and the reproducibility issues at this point in time are major limitations. 
However, development of methods that allows rapid characterization of identified protein 
peaks holds promise for more widespread use of these technologies in the near future. 
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1. Introduction 
The immune system might well be the best weapon against cancer, since immune defense is 
programmed to recognize and destroy abnormal cells infected by viruses or affected by 
transforming genetic or epigenetic alterations. If properly activated, a specific immune 
attack can be amplified and maintained long-term. These powerful mechanisms must be 
harnessed to fight against invading microorganisms and against cancer cells, which subvert 
the circuits that normally control cell proliferation and survival by displaying an anarchic 
behavior.  
Even at the start of the 20th century, the physician Paul Ehrlich proposed the potential 
ability of the immune system to continually survey and destroy newly arising cancer cells 
[1]. This hypothesis represented the first version of the immune surveillance theory, 
formulated in 1957 by Burnet [2, 3]. However, this theory was long-discredited by evidence 
that while the immune system can fight tumors, it is often unable to eradicate them. In the 
last decade, many cancer immunologists have shown renewed interest in immune 
surveillance theory, with the goal of generating novel immunotherapies against cancer, such 
as cancer vaccines. Advances in cancer biology, increased knowledge of immune 
mechanisms, and the availability of new animal models that recapitulate several human 
cancers have all helped to elucidate the critical issues that influence the efficacy of an 
immune attack against cancer [4]. This information is crucial for the rational design of cancer 
vaccines.  
Cancer cells elaborate many defenses against immune attack. For example, they try to 
evade recognition by T cells and, in turn, T cell-mediated cytotoxicity, one of the major 
mechanisms to control tumor growth, by decreasing the expression of glycoproteins of the 
 The Author(s). License  InTech. This chapter is distributed und the terms of the Creative Commons 
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major histocompatibility complex (MHC) on the cell membrane [5]. In fact, the T-cell 
receptor (TCR) recognizes antigen only when it is displayed on the surface of the target 
cell as peptide fragments by the class I and class II molecules of the MHC. Moreover, the 
increasing instability of the genome of transformed cells favors the emergence of clones 
with low immunogenicity no longer expressing tumor antigens. Thus, tumors can evade 
immune recognition, an ability that appears to increase as a tumor grows. Finally, cancer 
cells suppress immune reactivity through direct release of transforming growth factor 
(TGF)-beta, interleukin (IL)-10, and indoleamine 2,3-dioxygenase (IDO), or through the 
activation of myeloid-derived suppressor cells, tumor-associated macrophages and 
dendritic cells to secrete these molecules. As a consequence, a tumor favors the activation 
and the expansion of adaptive regulatory T (Treg) cells, leading to the generation of a 
tolerogenic environment [6]. 
In these conditions, the choice of antigen is a crucial factor in deriving a cancer vaccine. 
Recently, Lollini et al. [7] defined the “oncoantigens” as ideal targets since these antigens are 
indispensible for tumor progression and thus cannot be lost, and since, depending on their 
localization, they can be targeted by both cytotoxic cells and antibodies. Among 
oncoantigens, HER2 represents a very attractive target in light of its direct association with 
the malignant transformation of epithelial cells and its shared presence in several human 
carcinomas. Indeed, vaccines targeting HER2, designed as whole cells, peptides, as well as 
DNA expression plasmids, are able to hamper cancer progression when used at early stages 
of the disease [8]. However, the promising results obtained in preclinical models are difficult 
to reproduce in advanced cancers, when the immune system is already severely weakened. 
New molecular strategies are required to generate effective cancer vaccines able to awaken 
the immune responses against established tumors. 
1.1. HER2 protein structure and function 
HER2, also known as ErbB2 or neu in rat, is a 185-kd transmembrane receptor with tyrosine 
kinase activity and initially identified in a rat glioblastoma model. HER2 belongs to the 
epidermal growth factor receptor (EGFR) family, which also includes HER1 (EGFR, ErbB1), 
HER3 (ErbB3) and HER4 (ErbB4). Each of these receptors consists of an extracellular binding 
domain (ECD), a single transmembrane-spanning domain, and a long cytoplasmic tyrosine 
kinase domain. The ECD is about 630 amino acids long and contains four subdomains 
arranged as a tandem repeat of a two-domain unit. The first and third subdomains (I/L1 and 
III/L2) have a -barrel conformation, and the second and fourth subdomains (II/CR1 and 
IV/CR2) are cysteine-rich [9] (Figure 1). 
Generally, binding of ligand to the extracellular region induces receptor dimerization and 
activation of the cytoplasmic kinase, which in turn lead to autophosphorylation and 
initiation of downstream signaling events. Among the EGFR family members, HER2 and 
HER3 are exceptional since HER3 is kinase-inactive and HER2 has no identified ligand. 
Although HER2 is the only receptor without a known ligand, it is the preferred partner in 
heterodimer formation with other HER members. 
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Figure 1. The structure of HER2. Ribbon diagram of HER2 ECD: Subdomains I (dark red), II (green), III 
(yellow) and IV (red), are indicated. Adapted from Cho H.S. et al., 2003 [9]. 
Crystallographic studies have helped to elucidate the structural basis for the differences in 
HER receptor function. There are two conformations of the ECD, the closed configuration 
and the open configuration. In the closed configuration, a dimerization arm located on 
domain II makes an intramolecular contact with a pocket on domain IV, preventing its 
association with the dimerization arms of other HER receptors and maintaining the receptor 
in an auto-inhibited form. Binding of its native ligand to the receptor brings domains I and 
III close together, switching the receptor’s conformation to the open configuration (active 
state), in which the dimerization arm is free to participate in receptor dimerization. Unlike 
the three other HER receptors, HER2 can adopt a fixed conformation resembling a ligand-
activated state but permitting it to dimerize in the absence of a ligand (Figure 2). The 
constitutive open structure of HER2 helps to explain its readiness to interact with the ligand-
activated HER receptors [10].  
Receptor homo- and heterodimerization leads to the activation of downstream signaling 
pathways associated with cell proliferation, differentiation, survival and angiogenesis. 
Activation of the kinase domains by receptor dimerization and the subsequent 
transphosphorylation of tyrosine residues in the carboxy-terminal tails creates binding sites 
for several key proteins. These specific proteins activate intracellular signaling pathways, 
including the mitogen-activated protein kinases (Ras/Raf/MEK/MAPK) pathway, which 
mainly regulates cell proliferation, and the phosphoinositide 3-kinase (PI3K)–activated Akt 
(PI3K/Akt) pathway, which is important for cell survival [10].  
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Figure 2. Schematic overview of the structural basis for HER receptor dimerization and activation. In 
the ligand-free state, HER1, HER3, and HER4 have a closed conformation. Binding of ligand, involving 
subdomains I and III, creates an extended conformation, allowing for receptor homo- and 
heterodimerization. Receptor dimerization leads to C-terminal tyrosine phosphorylation, creating 
phosphotyrosine binding sites for binding of adaptors, signaling molecules and regulatory proteins. 
HER2 is unique in that it is fixed in the active conformation ready to interact with other HER receptors. 
Adapted from Wieduwilt M. J. and Moasser M. M., 2008 [10]. 
The HER signaling network normally governs cellular programs during development and 
post-natal life, but its deregulation is directly involved in the pathogenesis of several human 
tumors. Overexpression of HER2, enhancing and prolonging signals that trigger cell 
transformation, has a causal role in the promotion of carcinogenesis. The absence of the 
auto-inhibited conformation explains, at least in part, this HER2 transforming potential. 
Amplification and/or overexpression of HER2 have been reported in malignancies, such as 
breast, ovarian, prostate, colorectal, pancreatic and gastric cancers [11]. 
1.2. Role of HER2 oncogene in breast carcinoma 
Breast cancer, one of the most common malignancies worldwide, is a heterogeneous disease 
that can be classified according to the expression of the estrogen receptor, progesterone 
receptor, and HER2. The resulting subgroups differ not only in clinical behavior and 
prognosis, but also in the predicted response to targeted therapies against these receptors 
and the pathways they activate. Amplification of the HER2 gene and overexpression at the 
messenger RNA or protein level occurs in about 20-30% of patients with early stage breast 
cancer and predicts a poor prognosis [12]. Further support for the involvement of HER2 in 
the initiation and progression of breast cancer comes from studies on transgenic mice, 
although careful analysis of these transgenic mouse models suggests that overexpression of 
HER2, primarily due to gene amplification, is necessary but not sufficient to induce 
transformation. The expression of the oncoprotein induces tumors only when accompanied 
by genetic alterations, which include point mutations, deletions, and insertions. These 
alterations are invariably located in the juxtamembrane region of HER2 and lead to an 
unbalanced number of cysteines, potentially affecting cysteine-mediated dimerization [13].  
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Evidence for the insufficiency of wild-type HER2 expression, alone and without additional 
mutations, to induce full malignant transformation was reported by Finkle et al. [14], who 
found that transgenic mice overexpressing human HER2 under the murine mammary 
tumor virus (MMTV) promoter developed mammary tumors in a stochastic manner and 
after a long latency. Interestingly, those authors found sequence anomalies, including in-
frame small deletions, in the juxtamembrane region of wild-type HER2 in more than half of 
the analyzed mammary tumors. The majority of these mutations affected the conserved 
cysteine residues and could function as a second hit in the transformation process, implying 
that additional genetic changes beyond HER2 overexpression are required for mammary 
tissue transformation and tumor formation. Accordingly, somatic mutations confined to the 
juxtamembranous region of neu have been associated with the induction of mammary 
tumors in neu protooncogene transgenic mice described by Siegel et al. [15]. The relatively 
long latency period for the progression of these tumors seems to reflect the acquisition of 
activating mutations in the transgene. 
Interestingly, an alternative splice form of the human HER2 gene, 16HER2, containing an 
in-frame deletion in the same region mutated in rat neu or human HER2 protooncogene 
transgenic mice, has been described [16]. This oncogenic isoform is clinically important and 
commonly coexpressed with HER2 in human breast tumors, as reported by Castiglioni et al. 
[17] and Mitra et al. [18], who detected Δ16HER2 transcripts in human breast carcinomas in 
about 10% of total HER2 transcripts. This deletion removes the relevant cysteine residues in 
HER2, disrupting the disulfide bond structure of the protein and leaving the remaining 
unpaired cysteine residues available for intermolecular bonding. Consequently, Δ16HER2, 
which can be defined as a normal byproduct of HER2, forms stable homodimers maintained 
by intermolecular disulfide bonds (Figure 3). 
Δ16HER2 has increased transforming potency as compared with the wild-type HER2, as 
first demonstrated in vitro [17, 18]. Ectopic expression of Δ16HER2, but not wild-type HER2, 
promoted receptor dimerization and significantly enhanced the proliferation of murine 
NIH3T3 fibroblasts and human MCF-7 breast tumor cells. In addition, Δ16HER2 expression 
potentiated MCF-7 cell migration and invasion, whereas HER2 did not. In analysis of 
anchorage-independent growth as an in vitro test for tumorigenesis, both HER2 wild-type- 
and ∆16HER2-transfected MCF-7 cells showed enhanced colony formation in soft agar 
medium, but the Δ16HER2-expressing cells formed significantly larger colonies [18]. We 
obtained similar results with human embryonic kidney HEK293 cells stably transfected with 
wild-type HER2 or Δ16HER2 (Figure 4). In vivo analyses showed that the Δ16HER2 variant 
is tumorigenic per se since athymic mice injected with Δ16HER2-expressing HEK293 
transfectants developed tumors, whereas mice injected with HEK293 control cells 
ectopically overexpressing only wild-type HER2 did not [17]. The predicted enhanced 
oncogenic potential of Δ16HER2-expressing cells in vivo is supported by analysis of our new 
mouse model transgenically expressing the human Δ16HER2 under the transcriptional 
control of the MMTV promoter; all of the transgenic females developed multifocal 
mammary tumors with a rapid onset, suggesting that the Δ16HER2 splice variant represents 
the transforming form of the HER2 oncoprotein [19]. 
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Figure 3. Δ16HER2 splice variant. a. Schematic representation of the small region of the human HER2 
genomic locus indicating the exon-intron boundaries and the alternative splicing that eliminates exon 
16. The values indicated above the schematic represent nucleotide numbers corresponding to the 
cDNA. b. Alignment of the wild-type and alternatively spliced Δ16HER2 mRNAs; the grey box 
indicates sequences removed by the splicing event.  
 
Figure 4. Anchorage-independent growth of stable transfected HEK293 cells. Cells expressing 
∆16HER2 (b) form larger colonies than cells expressing wild-type HER2 (a). 
The key role of the cysteine residues in the HER2 juxtamembrane region has been also 
demonstrated by Pedersen et al. [20], who described a subtype of HER2-positive tumors 
expressing a series of carboxy-terminal fragments collectively known as p95HER2. These 
fragments arise through at least two different mechanisms: proteolytic shedding of the ECD 
of the full-length receptor; and translation of the mRNA encoding HER2 from internal 
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initiation codons [21]. One of these fragments, 611-CTF, which contains a transmembrane 
domain and a short extracellular region including the sequence deleted in Δ16HER2, is 
hyperactive because of its ability to form homodimers maintained by intermolecular 
disulfide bonds. Despite lacking the majority of the ECD, this HER2 fragment drives breast 
cancer progression in vivo, as shown by the development of aggressive mammary tumors in 
mice transgenically expressing 611-CTF and suggesting a causal role for p95HER2 fragments 
in tumorigenesis based on their ability to constitutively homodimerize [20]. 
Together, these findings demonstrate that the overexpression of full-length HER2 alone is 
not sufficient to drive malignant transformation of mammary glands. 
1.3. Mouse models for HER2-positive breast cancer 
The first direct evidence for the involvement of HER2 in the initiation and progression of 
breast cancer came from analysis of transgenic mice with MMTV promoter-targeted 
overexpression of activated neu (the rat homolog of HER2) in the mammary gland. Activated 
neu (neu-NT) is a mutated form with valine instead of glutamic acid at residue 664 in the 
transmembrane domain of the protein. Although the endogenous mouse HER2 promoter has 
recently been used to control mammary-specific expression of activated neu-NT [22], MMTV-
based mouse models have greatly increased our knowledge of the mechanisms that control 
HER2-mediated mammary tumor progression (Figure 5). In 1988, Leder and co-workers [23] 
generated the first transgenic mice that developed mammary tumors due to MMTV-driven 
expression of neu-NT. The short latency (11-13 weeks) and the high multiplicity of mammary 
tumors arising in those MMTV-neu-NT mice suggested that overexpression of the activated 
neu variant could drive mammary carcinogenesis in a single step. 
 
Figure 5. Timeline. Several mouse models transgenic for the rat or human HER2 been generated over 
the past 24 years, increasing our knowledge of the mechanisms that control HER2-mediated mammary 
tumour progression. Adapted from Ursini-Siegel et al., 2007 [33]. 
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However only 1 year later, Jolicoeur’s laboratory developed a second MMTV-neu-NT 
transgenic mouse model in which mammary tumor development was stochastic and with a 
significantly longer latency, suggesting that mammary epithelial cells require many genetic 
events in concert with neu-NT overexpression to undergo transformation [24]. The 
differences between these two transgenic mouse models probably reflect the ability of the 
transgene to integrate randomly into the mouse genome, which, in turn, influences 
transgene expression levels. In fact, transgenic animals generated even with the same 
construct may exhibit different tumor multiplicity and latency depending on the site of 
integration and on the transgene copy number. Nonetheless, subsequent studies of 
additional MMTV-neu-NT transgenic mice clearly demonstrated that overexpression of 
activated neu is sufficient to efficiently transform mammary epithelial cells [25]. To assess 
the dependence of cancer cells in advanced tumors or metastases on an initiating oncogenic 
event for maintenance of the transformed state, an inducible transgenic model for neu was 
obtained, using the tetracycline regulatory system to conditionally express activated neu in 
the mammary epithelium [26]. In these MMTV-rtTA/TetO-neu-NT mice, neu-initiated 
tumorigenesis is reversible: upon induction with doxycycline, multiple invasive mammary 
carcinomas developed that regressed to a clinically undetectable state following transgene 
deinduction. Interestingly, most animals eventually developed neu-independent recurrent 
tumors long after the apparently complete regression of their tumors, indicating that neu-
induced mammary tumors typically progress to a neu-independent state [26]. 
Although rapid onset of multifocal mammary tumors has been observed in the majority of 
activated neu transgenic mice, this mutation has never been observed in human cancers, 
which present only amplification of the HER2 gene copy number and consequent 
overexpression of HER2 protein on the cell membrane. In wild-type neu-expressing mice 
under the MMTV promoter, focal mammary tumors arise next to hyperplastic mammary 
tissue after a long latency period (17-48 weeks) [27], suggesting that genetic alterations in 
addition to those inducing HER2 overexpression are required for mammary transformation. 
Notably, tumors in these transgenic mice arose only when the oncoprotein carried 
mutations in the ECD involving small deletions that promote neu transforming activity 
through formation of intermolecular covalent cysteine bonds [15, 28]. Accordingly, 
mammary epithelium-specific expression of two activated neu receptors harboring distinct 
in-frame neu deletions (NDL) (MMTV-neu-NDL mice) led to rapid induction of mammary 
tumors [29]. Other transgenic animals with mutated forms of neu that couple specifically 
with Grb2 (neu-NDL-YB) or Shc (neu-NDL-YD) adaptor proteins have been generated to 
address the significance of HER2-coupled unique downstream signaling pathways in 
induction of mammary cancers [30].  
More recently, after initial failed attempts [31], transgenic mice with wild-type human HER2 
have been generated. A transgenic mouse expressing human HER2 under the whey acidic 
protein promoter was obtained, but no mammary neoplastic transformation was ever detected 
in any animal [32]. While another human wild-type HER2 transgenic model under the MMTV 
promoter did develop HER2-overexpressing breast tumors, but with a long latency of about 
28.6 weeks [14]. Sequencing of the human HER2 transcripts from primary mammary tumors 
developed in these transgenic mice identified an in-frame 15-bp deletion in the wild-type 
HER2 juxtamembrane region, potentially affecting cysteine-mediated dimerization [14].  
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Overall, these results point to the role of HER2-activating mutations that change the number 
of cysteines in mammary tumorigenesis. In this context, expression of the alternatively 
spliced 16HER2 isoform, which is constitutively active by virtue of its ability to form 
disulfide-bridged homodimers, might be required to obtain an oncogenic phenotype. HER2 
gene amplification in primary human breast cancer might increase the levels of this 
oncogenic variant above a critical threshold, allowing it to contribute to breast cancer 
progression. 
1.4. Δ16HER2 mice 
The value of Δ16HER2 transgenic mouse models in addressing the biological importance of 
this oncogenic variant in breast cancer progression and in response to targeted therapies 
was suggested in 2007 by Ursini-Siegal et al. [33]. Indeed, we recently generated a mouse 
line transgenically expressing human 16HER2, established using a bicistronic vector 
containing an IRES sequence between the human 16HER2 and the firefly luciferase gene to 
ensure their coordinated expression driven by the same MMTV promoter (Figure 6) [19]. 
Luciferase was chosen as a reporter gene since it is rapidly detectable by optical imaging in 
live organisms and simultaneously allows accurate quantitation in tissue extracts and 
immunohistochemical detection using specific antibodies. In addition, a restriction enzyme 
PCR-based technique [34, 35] confirmed integration of the transgene at a single site on 
murine chromosome 5, inside an intergenic region containing neither genes nor regulatory 
sequences such that the insertion itself does not affect tumorigenesis. Quantitative PCR 
analysis revealed a transgene copy number of 5 [36] (Figure 6). 
In steps to characterize 16HER2 mice, we found that the founder female developed 8 
spontaneous mammary tumors starting at 18 weeks of age and, as expected, readily 
visualized by bioluminescence analysis even one month before tumors became palpable, 
suggesting that luciferase expression might be predictive of tumor onset. Whole-mount and 
histological analysis of the mammary glands confirmed the presence of small neoplastic 
masses (Figure 7a). Immunohistochemical analysis of these non-palpable tumors revealed 
HER2 protein expression (Figure 7c), with larger tumors displaying heterogeneous 
membrane staining for the human transgene, while small tumors showed homogeneous 
distribution of HER2 in the tumor parenchyma. In all cases, HER2 expression was detected 
only in the mammary gland and in strict correlation with tumor development. HER2 
expression also correlated with that of PCNA, a marker for mitotic activity in transformed 
epithelial cells (Figure 7d). 
Because the MMTV promoter is hormonally regulated and tumor development in founder 
females might be enhanced by increased transgene expression in the mammary gland 
during pregnancy and lactation, we monitored spontaneous mammary tumor development 
by palpation in virgin female F2 transgenic mice; all of these mice developed multiple 
asynchronous mammary tumors (4-5 tumors/mouse) at 12 to 19 weeks of age (Figure 8c), 
each reaching 1-1.5 cm3 within a short time-frame (Figure 8d). Histologically, these fast-
growing tumors were classified as invasive HER2-positive adenocarcinomas. Indeed, 
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Figure 6. Bicistronic vector for 16HER2 mice generation. Schematic representation of the MMTV-
driven human 16HER2-LUC transgene, with the MMTV LTR promoter (pMMTV, red), the human 
16HER2 cDNA (green), the internal ribosome entry site (IRES, yellow), the luciferase cDNA (LUC, 
orange), and the termination signal from the SV40 (Poly A). Relevant restriction sites are indicated. The 
MMTV-16HER2-IRES-LUC expression cassette (8381 bp) was isolated from the plasmid backbone by 
NheI and SalI digestions, purified, and microinjected into fertilized eggs from FVB females. The 
transgene randomly integrated at a single site (at 85.72 Mb) on murine chromosome 5 region E-1 
(NT109320.4) inside an intergenic region (NCBI Build m37.1). The insertion occurred exactly 1.17 Mb 
downstream of the non-histone chromosomal protein HMG-17-like gene and 718 Kb upstream of the 
centromere protein C1 gene. Quantitative PCR analysis revealed a transgene copy number of 5. 
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Figure 7. Analysis of non-palpable tumors in 16HER2 transgenic mice. a. Whole-mount analysis of 
an inguinal mammary gland of a 14 week old mouse reveals non-palpable tumors (red arrows); blue 
arrow indicates a limph node. Hematoxylin-eosin (b) and immunohistochemical staining for HER2 (c) 
and PCNA (d) of non-palpable mammary tumors at 14 weeks. Magnification: a, X6; b-d, X400. 
immunohistochemical analysis confirmed the concurrent expression of the human 16HER2 
oncogene and the luciferase gene, and revealed the specific staining of epithelial cells but 
not of stromal cells or adipocytes, while non-neoplastic mammary ducts were negative. 
Tumors consisted of cells with round nuclei and eosinophilic cytoplasm growing in solid 
sheets and packets traversed by delicate fibrovascular septa. Growth of these 
unencapsulated tumors compressed the surrounding tissues (Figure 8b). Subsequent 
monitoring of all generations following F2 revealed similar results, indicating that formation 
of 16HER2-overexpressing mammary tumors is a reproducible phenotype in these 
transgenic mice. Furthermore, transgenic 16HER2 females bearing primary mammary 
tumors developed lung metastases starting at 25 weeks of age and present in 100% of mice 
at 36 weeks, suggesting particularly aggressive tumor behavior upon expression of the 
16HER2 splice variant. The histological features of these pulmonary metastatic lesions 
were consistent with a primary breast tumor origin, with robust staining for HER2 
demonstrating high-level transgene expression (Figure 9). 
Western analysis using lysates of cells isolated ex vivo from 16HER2 mice revealed a 
protein expression profile consistent with the immunohistochemical data, but also the 
presence of some phosphorylated 16HER2 dimers with a higher activation status in the 
 
Oncogene and Cancer – From Bench to Clinic 48 
 
Figure 6. Bicistronic vector for 16HER2 mice generation. Schematic representation of the MMTV-
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NheI and SalI digestions, purified, and microinjected into fertilized eggs from FVB females. The 
transgene randomly integrated at a single site (at 85.72 Mb) on murine chromosome 5 region E-1 
(NT109320.4) inside an intergenic region (NCBI Build m37.1). The insertion occurred exactly 1.17 Mb 
downstream of the non-histone chromosomal protein HMG-17-like gene and 718 Kb upstream of the 
centromere protein C1 gene. Quantitative PCR analysis revealed a transgene copy number of 5. 
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Figure 7. Analysis of non-palpable tumors in 16HER2 transgenic mice. a. Whole-mount analysis of 
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and PCNA (d) of non-palpable mammary tumors at 14 weeks. Magnification: a, X6; b-d, X400. 
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unencapsulated tumors compressed the surrounding tissues (Figure 8b). Subsequent 
monitoring of all generations following F2 revealed similar results, indicating that formation 
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transgenic mice. Furthermore, transgenic 16HER2 females bearing primary mammary 
tumors developed lung metastases starting at 25 weeks of age and present in 100% of mice 
at 36 weeks, suggesting particularly aggressive tumor behavior upon expression of the 
16HER2 splice variant. The histological features of these pulmonary metastatic lesions 
were consistent with a primary breast tumor origin, with robust staining for HER2 
demonstrating high-level transgene expression (Figure 9). 
Western analysis using lysates of cells isolated ex vivo from 16HER2 mice revealed a 
protein expression profile consistent with the immunohistochemical data, but also the 
presence of some phosphorylated 16HER2 dimers with a higher activation status in the 
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Figure 8. Characterization of tumorigenesis in Δ16HER2 mice. a. Primary breast tumors just before 
their removal from a Δ16HER2 transgenic female mouse. b. Immunohistochemical detection of HER2, 
revealing strong and uniform expression of HER2 protein in the mammary tumor, while the normal 
duct (right) is negative. Magnification: X400. c. Kaplan-Meier disease-free survival plot for F2 
generation Δ16HER2-LUC transgenic mice. Mammary tumor incidence is 100% and tumor onset is from 
11 to the 19 weeks (n=20). d. Tumor growth curves of five different tumors. Tumor volume was 
calculated as 0.5xd12xd2, where d1 and d2 are the smaller and larger diameters, respectively. 
 
Figure 9. Pulmonary metastases. Hematoxylin-eosin (left) and immunohistochemical staining for 
HER2 (middle) and luciferase (right) in intravascular lung metastases in ∆16HER2 transgenic mice. 
Tumor cell aggregates are strongly positive for both human HER2 and luciferase staining. 
Magnification: X400. 
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dimeric than the monomeric form. These findings suggest a mechanism through which the 
disulfide-bonded 16HER2 homodimer amplifies HER2 transforming potential. The same 
analysis showed that Src kinase and several other protein mediators involved in the 
signaling cascade were consistently activated (phosphorylated), implicating this pathway in 
neoplastic transformation and tumor progression dynamics.  
In vitro analyses to elucidate the oncogenic mechanisms involving the 16HER2 splice 
variant will benefit from the availability of 16HER2-positive cell lines derived from 
surgically excised primary breast tumors and lung metastases from 16HER2 transgenic 
mice. Preliminary data from our ongoing efforts to establish such lines show that these cells 
maintain transgene expression even after repeated passages. 
Overall, the higher tumor incidence as well as the shorter latency period in16HER2 
transgenic mice as compared with that in the MMTV-wild-type HER2 transgenic mice 
described by Finkle et al. [14], together with the higher metastatic potential of the splice 
variant, strongly supports the candidacy of 16HER2 as the transforming form of the HER2 
oncoprotein. Indeed, despite some similarities between the two different experimental 
models, i.e., use of the same mouse strain (FVB) to derive the transgenic lines, use of the 
same MMTV promoter, and the development of rapidly growing adenocarcinomas, these 
transgenic experimental systems appear to differ greatly in some features that determine 
tumor aggressiveness. Not only do 16HER2 females develop asynchronous mammary 
adenocarcinomas with a higher tumor incidence and a significantly shorter average latency 
compared to wild-type HER2 transgenic females (15.1 vs 28.6 weeks), but transgene 
expression in the model described by Finkle et al was detected in tumor tissue as well as in 
normal mammary gland and several other epithelial tissues, whereas our transgenic mice 
revealed strong staining for the 16HER2 human transgene exclusively in tumor mammary 
tissue, suggesting that overexpression of 16HER2 in the mammary gland is sufficient to 
induce malignant transformation in a single step. It is also noteworthy that only 5 transgene 
copies can drive neoplastic transformation of mammary epithelial cells compared to a 
relatively high number of wild-type HER2 transgene copies (30-50) necessary to induce 
mammary adenocarcinomas in about 80% of MMTV-wild-type HER2 transgenic mice. Since 
the16HER2 splice variant represents about 10% of total HER2 transcript in human breast 
carcinoma, it is plausible that malignant transformation ensues when 16HER2 reaches a 
critical threshold in mammary cells presenting HER2 gene amplification. 
1.5. HER2 as target of immunotherapies 
The crucial role of HER2 in epithelial transformation as well as its selective overexpression 
in cancer tissues makes it an ideal target for cancer immunotherapy. Notwithstanding the 
clinically approved use of the anti-HER2 monoclonal antibody Trastuzumab, a number of 
concerns, including resistance, considerable costs associated with repeated treatments, and 
side effects, make active immunotherapies that generate polyclonal and long-lasting 
immune responses desirable alternative approaches. 
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dimeric than the monomeric form. These findings suggest a mechanism through which the 
disulfide-bonded 16HER2 homodimer amplifies HER2 transforming potential. The same 
analysis showed that Src kinase and several other protein mediators involved in the 
signaling cascade were consistently activated (phosphorylated), implicating this pathway in 
neoplastic transformation and tumor progression dynamics.  
In vitro analyses to elucidate the oncogenic mechanisms involving the 16HER2 splice 
variant will benefit from the availability of 16HER2-positive cell lines derived from 
surgically excised primary breast tumors and lung metastases from 16HER2 transgenic 
mice. Preliminary data from our ongoing efforts to establish such lines show that these cells 
maintain transgene expression even after repeated passages. 
Overall, the higher tumor incidence as well as the shorter latency period in16HER2 
transgenic mice as compared with that in the MMTV-wild-type HER2 transgenic mice 
described by Finkle et al. [14], together with the higher metastatic potential of the splice 
variant, strongly supports the candidacy of 16HER2 as the transforming form of the HER2 
oncoprotein. Indeed, despite some similarities between the two different experimental 
models, i.e., use of the same mouse strain (FVB) to derive the transgenic lines, use of the 
same MMTV promoter, and the development of rapidly growing adenocarcinomas, these 
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revealed strong staining for the 16HER2 human transgene exclusively in tumor mammary 
tissue, suggesting that overexpression of 16HER2 in the mammary gland is sufficient to 
induce malignant transformation in a single step. It is also noteworthy that only 5 transgene 
copies can drive neoplastic transformation of mammary epithelial cells compared to a 
relatively high number of wild-type HER2 transgene copies (30-50) necessary to induce 
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the16HER2 splice variant represents about 10% of total HER2 transcript in human breast 
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The crucial role of HER2 in epithelial transformation as well as its selective overexpression 
in cancer tissues makes it an ideal target for cancer immunotherapy. Notwithstanding the 
clinically approved use of the anti-HER2 monoclonal antibody Trastuzumab, a number of 
concerns, including resistance, considerable costs associated with repeated treatments, and 
side effects, make active immunotherapies that generate polyclonal and long-lasting 
immune responses desirable alternative approaches. 
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1.5.1. Involvement of Δ16HER2 in Trastuzumab resistance 
Trastuzumab, a humanized monoclonal antibody against the ectodomain of HER2, was the 
first rationally designed anti-HER2 therapy approved by the US Food and Drug 
Administration for the clinical treatment of HER2-overexpressing breast cancer. 
Trastuzumab uses multiple mechanisms to interfere with HER2 downstream signaling and 
inhibit tumor growth, including HER2 receptor downregulation and blocking cleavage of 
the HER2 ECD, which otherwise leads to activation of the HER2 receptor [37]. In particular, 
the cytostatic effect of Trastuzumab is associated with the reduction of the signaling by the 
PI3K/Akt pathway and the upregulation of the cyclin-dependent kinase inhibitor p27kip1, 
as demonstrated by Western analysis of breast tumor cell lines treated with Trastuzumab in 
vitro [38]. The consequences of these Trastuzumab actions are G1 arrest, reduction in cell 
proliferation, and apoptosis. Trastuzumab also has cytotoxic properties, such as antibody-
dependent cell-mediated cytotoxicity (ADCC) against HER2-overexpressing tumor cells. 
ADCC is mainly due to natural killer (NK) cells which express the Fcγ receptor that binds 
the Fc domain of the IgG1 Trastuzumab [38]. 
Overall, Trastuzumab is clinically effective, but a significant proportion of HER2-
overexpressing breast cancer patients either do not respond to initial Trastuzumab 
treatment (de novo resistance) or eventually become resistant after continuous treatment 
(acquired resistance). In fact, an objective response (complete + partial) when Trastuzumab 
is used alone is observed in only about 26% of patients with HER2-positive tumors, and 
many of the initial responders develop resistance in less than 6 months [39]. While higher 
response rates (50–80%) have been reported when Trastuzumab is used in combination with 
standard chemotherapy for metastatic disease, primary and acquired resistance to this 
reagent remains a significant clinical problem.  
Understanding the molecular mechanisms of Trastuzumab resistance is crucial for the 
development of new therapeutic strategies and for improved survival of HER2-positive 
breast cancer patients. Several mechanisms have been proposed in Trastuzumab resistance 
[38], including steric hindrance of HER2-antibody interaction by membrane-associated 
glycoproteins [40], PTEN deficiency (phosphatase and tensin homolog deleted on 
chromosome 10) [41], increased PI3K/Akt pathway activation [42], and HER2 crosstalk with 
other HER members or with insulin-like growth factor-I receptor (IGF-IR) [43]. In the latter 
context, Huang et al. [43] showed that a heterotrimeric complex of IGF-IR, HER2 and HER3 
forming exclusively in Trastuzumab-resistant cells plays a key role in resistance, since 
knockdown of HER3 or IGF-IR by short hairpin RNA–mediated strategies upregulates 
p27kip1, inactivates downstream receptor signaling, and resensitizes resistant cells.  
While these mechanisms may explain Trastuzumab resistance in tumors expressing only the 
full-length HER2 receptor, there is increasing recognition that HER2 altered forms, 
including p95HER2 fragments and the 16HER2 splice variant commonly coexpressed with 
wild-type protein in human tumors, play a significant role in Trastuzumab resistance. In a 
series of patients with HER2–positive advanced breast cancer and treated with 
Trastuzumab, Scaltriti et al. [44] reported that the presence of p95HER2 fragments, which 
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lack the Trastuzumab binding domain but retain kinase activity, was associated with clinical 
resistance to Trastuzumab, whereas tumors expressing only the full-length receptor 
exhibited a high response rate to Trastuzumab. Analysis of cell lines expressing either full-
length HER2 or p95HER2 confirmed the ineffectiveness of Trastuzumab on cells expressing 
p95HER2 fragments [44]. Using a similar experimental approach, Mitra and coworkers [18] 
found that ectopic expression of 16HER2, but not wild-type HER2, promotes Trastuzumab 
resistance in NIH3T3 fibroblasts and MCF-7 breast tumor cells; both 16HER2-expressing 
cell types were refractory to Trastuzumab treatment, as shown in both cell proliferation and 
invasion assays, and displayed sustained oncogenic signaling. It seems likely that 16HER2 
expression above a critical threshold in wild-type HER2-overexpressing human breast 
cancer contributes to Trastuzumab resistance, consistent with clinical evidence of an inverse 
correlation between increased HER2 FISH ratios (>8) and Trastuzumab responsiveness [45]. 
Although the Trastuzumab binding site is amino-terminal to the exon 16 deletion of 
16HER2, Trastuzumab resistance might reflect the inefficient targeting of the splice variant 
receptor by the antibody because of the stable disulfide-bonded HER2 homodimers or the 
activation of alternative compensatory signaling pathways. In fact, 16HER2 harbors an in-
frame deletion which promotes constitutive dimerization of the receptor and the coupling of 
16HER2 to unique oncogenic signaling pathways mediated by Src kinase. Indeed, Mitra 
and coworkers [18] proposed Src kinase as the “master regulator” of Δ16HER2 protein 
signal transduction, based on the cooperation between 16HER2 and Src kinase as 
demonstrated by the ability of the Src family inhibitor dasatinib to induce Src inactivation, 
destabilization of 16HER2, and suppression of tumorigenicity. Consistent with this 
proposal, a recent study by Zhang et al [46] identified Src activation as a key convergence 
point of several Trastuzumab resistance mechanisms, since targeting Src in combination 
with Trastuzumab resensitized multiple resistant cell lines and eliminated Trastuzumab-
resistant tumors in vivo. The association between Src-mediated transduction pathways and 
the transforming ability of HER16 in our transgenic model [19] points to the value of this 
model in preclinical studies to elucidate the in vivo mechanisms underlying Trastuzumab 
resistance as well as the role of this variant in HER2-targeted drug responsiveness. 
Moreover, 16HER2 transgenic mice may recapitulate the clinical spectrum of Trastuzumab 
resistance associated with HER2-positive tumors and thus serve in testing innovative 
immunotherapies. 
1.5.2. DNA vaccines 
The idea of generating DNA vaccines comes from the pioneer work of Wolff and colleagues 
[47], who first showed that direct injection of naked DNA into the muscles of mice led to 
expression of the encoded reporter proteins. DNA vaccines are simple circles of DNA 
derived primarily from bacterial plasmids and contain a cDNA encoding the full-length or 
truncated target antigen, a strong viral promoter to drive antigen expression in mammalian 
cells, and a polyadenylation signal (usually from bovine growth hormone or from SV40) to 
terminate transcription. In addition, DNA vaccines contain sequences necessary for the 
cloning procedures (a multiple cloning site) and for plasmid production in bacteria,  
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lack the Trastuzumab binding domain but retain kinase activity, was associated with clinical 
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exhibited a high response rate to Trastuzumab. Analysis of cell lines expressing either full-
length HER2 or p95HER2 confirmed the ineffectiveness of Trastuzumab on cells expressing 
p95HER2 fragments [44]. Using a similar experimental approach, Mitra and coworkers [18] 
found that ectopic expression of 16HER2, but not wild-type HER2, promotes Trastuzumab 
resistance in NIH3T3 fibroblasts and MCF-7 breast tumor cells; both 16HER2-expressing 
cell types were refractory to Trastuzumab treatment, as shown in both cell proliferation and 
invasion assays, and displayed sustained oncogenic signaling. It seems likely that 16HER2 
expression above a critical threshold in wild-type HER2-overexpressing human breast 
cancer contributes to Trastuzumab resistance, consistent with clinical evidence of an inverse 
correlation between increased HER2 FISH ratios (>8) and Trastuzumab responsiveness [45]. 
Although the Trastuzumab binding site is amino-terminal to the exon 16 deletion of 
16HER2, Trastuzumab resistance might reflect the inefficient targeting of the splice variant 
receptor by the antibody because of the stable disulfide-bonded HER2 homodimers or the 
activation of alternative compensatory signaling pathways. In fact, 16HER2 harbors an in-
frame deletion which promotes constitutive dimerization of the receptor and the coupling of 
16HER2 to unique oncogenic signaling pathways mediated by Src kinase. Indeed, Mitra 
and coworkers [18] proposed Src kinase as the “master regulator” of Δ16HER2 protein 
signal transduction, based on the cooperation between 16HER2 and Src kinase as 
demonstrated by the ability of the Src family inhibitor dasatinib to induce Src inactivation, 
destabilization of 16HER2, and suppression of tumorigenicity. Consistent with this 
proposal, a recent study by Zhang et al [46] identified Src activation as a key convergence 
point of several Trastuzumab resistance mechanisms, since targeting Src in combination 
with Trastuzumab resensitized multiple resistant cell lines and eliminated Trastuzumab-
resistant tumors in vivo. The association between Src-mediated transduction pathways and 
the transforming ability of HER16 in our transgenic model [19] points to the value of this 
model in preclinical studies to elucidate the in vivo mechanisms underlying Trastuzumab 
resistance as well as the role of this variant in HER2-targeted drug responsiveness. 
Moreover, 16HER2 transgenic mice may recapitulate the clinical spectrum of Trastuzumab 
resistance associated with HER2-positive tumors and thus serve in testing innovative 
immunotherapies. 
1.5.2. DNA vaccines 
The idea of generating DNA vaccines comes from the pioneer work of Wolff and colleagues 
[47], who first showed that direct injection of naked DNA into the muscles of mice led to 
expression of the encoded reporter proteins. DNA vaccines are simple circles of DNA 
derived primarily from bacterial plasmids and contain a cDNA encoding the full-length or 
truncated target antigen, a strong viral promoter to drive antigen expression in mammalian 
cells, and a polyadenylation signal (usually from bovine growth hormone or from SV40) to 
terminate transcription. In addition, DNA vaccines contain sequences necessary for the 
cloning procedures (a multiple cloning site) and for plasmid production in bacteria,  
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Figure 10. DNA vaccine backbone. pVAX1 (Invitrogen) is a 3.0 kb plasmid vector designed for use in 
the development of DNA vaccines and approved for such use by the US Food and Drug 
Administration. Features of the vector allow high-copy number replication in E. coli and high-level 
transient expression of the protein of interest in most mammalian cells. The vector contains the 
following elements: human cytomegalovirus immediate-early (CMV) promoter for high-level 
expression in a wide range of mammalian cells; bovine growth hormone (BGH) polyadenylation signal 
for efficient transcription termination and polyadenylation of mRNA; kanamycin resistance gene for 
selection in E. coli; and origin of bacterial replication (pUC ori) 
(http://products.invitrogen.com:80/ivgn/product/V26020). 
consisting of the origin of replication (usually from E. coli) and an antibiotic-resistance gene 
to permit selective amplification of the vaccine [48] (Figure 10). 
After purification (Figure 11), the DNA vaccine is commonly delivered into the skin or 
muscle using the biolistic system, in which compressed helium propels DNA-coated 
microparticles through a gene gun [49], or by simple intradermal or i.m. injection. While 
both delivery methods permit the introduction of DNA vaccines, the efficacy of DNA 
vaccination is strongly increased if it is followed by an in vivo short electric pulse, i.e., 
electroporation [50], which enhances DNA transfection into normal tissues by inducing 
transient permeability of biological membranes through the opening of microscopic pores. 
Once DNA vaccines enter mammalian cells, antigen synthesis and presentation occur [48], 
with professional antigen-presenting cells (APCs), such as dendritic cells, presenting the 
transcribed and translated antigen in the context of major histocompatibility complex 
(MHC) and costimulatory molecules. If DNA vaccine-coded antigens are processed as 
endogenous intracytoplasmic proteins, the peptide fragments are presented on cell surface 
MHC I molecules to cytolytic T lymphocytes (CD8+ T cells). If the antigens are secreted from 
the cells, they can be taken up by APCs, processed through the exogenous pathway, and 
presented by MHC II molecules for the activation of specific helper T cells (CD4+ T cells) 
which produce ‘helpful’ cytokines. For antibody responses, B cells recognize and respond to 
extracellularly exposed antigens, both secreted and transmembrane proteins [48]. Through 
these mechanisms, DNA vaccines can elicit both cellular and humoral responses, and this 
combined immunity may be more effective than either arm alone.  
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Figure 11. DNA vaccines production in bacteria. Once the antigen of interest is cloned into the 
plasmid, the vaccine is introduced into bacterial cells, where it replicates as the bacterium multiplies. 
The presence of a “relaxed origin of replication” and an antibiotic-resistance gene allows efficient 
plasmid replication in bacterial cells and their selection, two key aspects for high-scale plasmid 
production. Finally, the vaccine, i.e., RHuT, can be purified using commercial kits. 
The ability to induce cytotoxic responses is a distinctive property of DNA vaccines, 
representing the only approach other than the use of live viruses for the activation of CD8+ 
T cells. In addition, unlike mammalian DNA, bacterial plasmids are rich in unmethylated 
CpG dinucleotides, which act as a “danger signal” that warns of bacterial infection and 
activates the innate immune response through recognition of CpG motifs by Toll-like 
receptor 9 expressed on B cells and APCs. Thus, DNA vaccines are effective even when 
administrated without adjuvants [51]. 
DNA vaccines also have further distinct advantages over other vaccine prototypes, such as 
stability and ease of manipulation. Since the subcellular localization of the recombinant 
antigen dictates the type and the intensity of the immune response, it is possible to change 
the intracellular fate of a protein to induce selective immune responses [52, 53]. For example, 
signal (leader) sequences can be added or deleted from an antigen to modulate its 
immunogenic performance. Signal peptides, consisting of amino-terminal extensions that 
direct the insertion of proteins into the membrane of the endoplasmic reticulum, can be 
removed from secreted or membrane proteins to target them into the cytoplasm to improve 
antigen presentation by the MHC class I pathway and thereby enhance cytotoxic T cell 
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Figure 11. DNA vaccines production in bacteria. Once the antigen of interest is cloned into the 
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antigen dictates the type and the intensity of the immune response, it is possible to change 
the intracellular fate of a protein to induce selective immune responses [52, 53]. For example, 
signal (leader) sequences can be added or deleted from an antigen to modulate its 
immunogenic performance. Signal peptides, consisting of amino-terminal extensions that 
direct the insertion of proteins into the membrane of the endoplasmic reticulum, can be 
removed from secreted or membrane proteins to target them into the cytoplasm to improve 
antigen presentation by the MHC class I pathway and thereby enhance cytotoxic T cell 
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induction. To optimize cytotoxic responses, an antigen can also be ubiquitinated; when 
expressed in fusion with a target protein, ubiquitin can promote rapid proteasomal 
degradation of the protein, leading to MHC I peptide presentation [54]. Alternatively, CD4+ 
T-cell responses can be enhanced by a DNA vaccine designed to direct endogenously 
synthesized proteins to the lysosomal compartment of APCs, where the proteins are 
degraded into peptides that can be eventually loaded into the pockets of MHC class II 
molecules. For this purpose, a fusion construct of the full-length protein and the 20-amino 
acid C-terminal tail of lysosomal integral membrane protein-II (LIMP-II) has been used [55]. 
To favor the antibody response, signal sequences, usually of 16 to 30 amino acid residues 
comprising a central hydrophobic core and a C-terminal region with the cleavage site for 
signal peptidase, can be cloned in-frame with the sequence encoding a cytoplasmic protein, 
driving it toward the plasma membrane. 
Recently, we have conceived a new kind of DNA vaccine that combines antigen expression 
with the silencing of molecules involved in the immunosuppression exerted by growing 
cancers. This double action is associated with two distinct modules: one is the conventional 
antigen expression cassette, while the other generates short hairpin (sh)RNA under the 
control of a polymerase III promoter [56, 57]. The RNA interference with synthesis of 
negative immune regulators, such as IDO or IL-10, is expected to ensure optimal 
presentation of the encoded antigen by APCs. 
1.5.3. DNA vaccination targeting HER2 
While the success of vaccination in preventing infectious diseases is uncontested, the 
derivation of efficient vaccines against cancer represents a more difficult challenge. 
Although cancer cells express antigens in a way that distinguishes them immunologically 
from normal cells, most tumors are only weakly immunogenic because most tumor antigens 
are "self" proteins and generally tolerated by the host. Thus, an effective cancer vaccine must 
activate the immune system to react against tumor–associated molecules and, in some cases, 
overcome immunological tolerance to such molecules. This implies a vaccine-stimulated 
immune reaction in patients showing no or only a weak pre-existing immune response 
against the tumor antigen [58]. 
The HER2 oncoantigen is considered an ideal target for DNA vaccination because it is 
directly involved in cancer progression and because it plays a causal role in the transformed 
phenotype, restricting the emergence of antigen-loss variants. HER2 overexpression in 
several carcinomas with an aggressive course, unlike its expression in normal tissues, 
ensures a specific anti-cancer response and minimal risk of an autoimmune attack on 
healthy tissues. Finally, HER2 is exposed on the cell membrane and can thus be readily 
targeted by antibodies and cell-mediated immunity [5]. On the other hand, HER2 is a “self” 
molecule, such that triggering a response to it must circumvent tolerance mechanisms. 
An abundance of experiments in preclinical models demonstrates the promise of DNA 
vaccination as an effective approach to prevent the development of HER2-positive tumors, 
eliciting immune protection against spontaneous mammary carcinomas in mice transgenic 
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for the rat HER2 oncogene as well as in transplantable rat and human HER2-expressing 
tumors [59-65]. As we specifically documented [63], anti-HER2 antibody production after 
vaccination represents the main mechanism responsible for the anti-tumor response. In fact, 
anti-HER2 antibodies are able to downmodulate the expression of this growth factor 
receptor causally implicated in carcinogenesis. Indirect reactions, such as ADCC and 
complement-mediated cytotoxicity, are also crucial in preventing the onset of a tumor and 
controlling its progression. 
As mentioned above, DNA vaccines are easily manipulated to optimize immune activation 
using recombinant DNA technologies. In one of the first studies of HER2-targeted DNA 
vaccination, the plasmid encoding the extracellular and transmembrane (EC-TM) domains 
of this molecule proved to be far superior to plasmids encoding only the extracellular 
domain (secreted form) or the full-length protein [59]. Most subsequent studies, performed 
in both wild-type BALB/c mice and cancer-prone BALB-neuT transgenic mice, confirmed 
the unique ability of this vaccine to trigger protective immunity toward rat HER2-positive 
tumors [60-63]. BALB-neuT mice transgenically expressing the rat activated neu oncogene 
under the control of the MMTV promoter are genetically predestined to develop lethal 
invasive carcinomas in the mammary glands at high multiplicity (all mammary glands are 
affected) and with relatively short latency [66]. About 50% of BALB-neuT mice 
electroporated with EC-TM plasmid when the mammary glands display atypical 
hyperplasia, at 10 and 12 weeks of age, remained free of autochthonous mammary tumors 
up to at least 1 year of age, whereas all unvaccinated mice succumbed to mammary cancer 
within 22–27 weeks [62].  
In efforts to define the minimal antigen portion still able to elicit protective immunity, we 
carried out molecular dissection of the HER2 molecule through sequential deletions of 
multiples of 240 bp, corresponding to 80 amino acids, starting from the amino-terminal of 
the extracellular sequence [63]. The resulting seven cut-down fragments were cloned into a 
recipient expression vector downstream of the leader sequence, which drives the proteins 
through the endoplasmic reticulum toward the plasma membrane (Figure 12).  
A first series of DNA vaccination experiments with these seven cut-down plasmids was 
performed in wild-type BALB/c mice transplanted with syngeneic rat HER2-positive 
adenocarcinoma cells, established from a mammary tumor of BALB-neuT mice (TUBO 
cells). Significant protection was obtained in mice immunized with the first four cut-down 
plasmids, while protection declined in mice immunized with shorter fragments. In 
particular, EC4-TM, which lacks almost half of the EC domain and exposes only 344 amino 
acids, protected all vaccinated mice through the induction of anti-rat HER2 antibodies at 
levels comparable to those in mice vaccinated with the whole EC-TM [63]. However, in 
wild-type BALB/c mice, vaccination triggered a strong immune response because the rat 
HER2 protein target is a foreign, xenogeneic antigen. It is much more difficult to induce 
immunoprotection in cancer-prone BALB-neuT mice, which are tolerant to rat HER2 protein 
because they express the transgene in the thymus early in life [67]. In those mice, only 
electroporation with EC-TM or EC4-TM led to a significant delay in the progression of 
mammary lesions, whereas the other cut-down plasmids were completely ineffective. 
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for the rat HER2 oncogene as well as in transplantable rat and human HER2-expressing 
tumors [59-65]. As we specifically documented [63], anti-HER2 antibody production after 
vaccination represents the main mechanism responsible for the anti-tumor response. In fact, 
anti-HER2 antibodies are able to downmodulate the expression of this growth factor 
receptor causally implicated in carcinogenesis. Indirect reactions, such as ADCC and 
complement-mediated cytotoxicity, are also crucial in preventing the onset of a tumor and 
controlling its progression. 
As mentioned above, DNA vaccines are easily manipulated to optimize immune activation 
using recombinant DNA technologies. In one of the first studies of HER2-targeted DNA 
vaccination, the plasmid encoding the extracellular and transmembrane (EC-TM) domains 
of this molecule proved to be far superior to plasmids encoding only the extracellular 
domain (secreted form) or the full-length protein [59]. Most subsequent studies, performed 
in both wild-type BALB/c mice and cancer-prone BALB-neuT transgenic mice, confirmed 
the unique ability of this vaccine to trigger protective immunity toward rat HER2-positive 
tumors [60-63]. BALB-neuT mice transgenically expressing the rat activated neu oncogene 
under the control of the MMTV promoter are genetically predestined to develop lethal 
invasive carcinomas in the mammary glands at high multiplicity (all mammary glands are 
affected) and with relatively short latency [66]. About 50% of BALB-neuT mice 
electroporated with EC-TM plasmid when the mammary glands display atypical 
hyperplasia, at 10 and 12 weeks of age, remained free of autochthonous mammary tumors 
up to at least 1 year of age, whereas all unvaccinated mice succumbed to mammary cancer 
within 22–27 weeks [62].  
In efforts to define the minimal antigen portion still able to elicit protective immunity, we 
carried out molecular dissection of the HER2 molecule through sequential deletions of 
multiples of 240 bp, corresponding to 80 amino acids, starting from the amino-terminal of 
the extracellular sequence [63]. The resulting seven cut-down fragments were cloned into a 
recipient expression vector downstream of the leader sequence, which drives the proteins 
through the endoplasmic reticulum toward the plasma membrane (Figure 12).  
A first series of DNA vaccination experiments with these seven cut-down plasmids was 
performed in wild-type BALB/c mice transplanted with syngeneic rat HER2-positive 
adenocarcinoma cells, established from a mammary tumor of BALB-neuT mice (TUBO 
cells). Significant protection was obtained in mice immunized with the first four cut-down 
plasmids, while protection declined in mice immunized with shorter fragments. In 
particular, EC4-TM, which lacks almost half of the EC domain and exposes only 344 amino 
acids, protected all vaccinated mice through the induction of anti-rat HER2 antibodies at 
levels comparable to those in mice vaccinated with the whole EC-TM [63]. However, in 
wild-type BALB/c mice, vaccination triggered a strong immune response because the rat 
HER2 protein target is a foreign, xenogeneic antigen. It is much more difficult to induce 
immunoprotection in cancer-prone BALB-neuT mice, which are tolerant to rat HER2 protein 
because they express the transgene in the thymus early in life [67]. In those mice, only 
electroporation with EC-TM or EC4-TM led to a significant delay in the progression of 
mammary lesions, whereas the other cut-down plasmids were completely ineffective. 
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Interestingly, EC4-TM induced a stronger ADCC response than did the whole EC-TM, 
suggesting that EC4-TM provides accessible critical determinants that may be partially 
masked in the whole EC-TM [63]. Together, the results of these experiments suggest that the 
first 390 amino acids of HER2 are those responsible for triggering the protective immunity 
induced by EC-TM vaccination. 
 
Figure 12. HER2 cut-down vaccines. The seven cut-down HER2 DNA fragments were inserted 
downstream of the leader sequence using EcoRI and XbaI restriction enzymes. The truncated protein 
encoded by the first cut-down plasmid (EC1-TM) displays an EC domain lacking the first 70 NH2-
terminal residues. All the other truncated proteins, encoded respectively by the EC2-TM, EC3-TM, EC4-
TM, EC5-TM, EC6-TM, and EC7-TM cut-down plasmids, display EC domains progressively shortened 
by 80 NH2-terminal residues. All of these truncated proteins have an identical TM domain. 
In a strategy aimed at breaking the tolerance to HER2 and further improving the elicited 
protection in BALB-neuT mice, we constructed two new DNA vaccines, RHuT and HuRT, 
encoding rat and human HER2 chimeric proteins. Containing both syngeneic and 
xenogeneic portions of the protein antigen, they ensure specificity as well as a tolerance 
break [64, 65]. In particular, HuRT was derived by cloning the human cDNA fragment 
encoding the first 390 amino-terminal residues into the rat EC5-TM cut-down plasmid to 
regenerate the whole EC domain. Almost symmetrically, RHuT encodes a protein in which 
the 410 amino-terminal residues are from the rat HER2 and the remaining residues from 
human HER2 (Figure 13 and Figure 14). 
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Figure 13. RHuT electroporation. RHuT encodes for a chimeric protein in which the 410 NH2-terminal 
residues are from the rat HER2 extracellular domain and the remaining residues from the human 
protein. After i.m. injection of 50 g of DNA plasmid, two low voltage pulses of 150V of 25 ms with a 
300 s interval were applied through the insertion of Cliniporator needles (Igea, Carpi, Italy) into the 
mouse quadriceps muscles. 
 
Figure 14. Presentation of xenogeneic peptides by dendritic cells (DC) contributes to an antibody 
response to both the tolerated and non-tolerated moieties of the antigen. Following DNA 
electroporation (a) with RHuT plasmid encoding for a rat (orange) and human (blue) chimeric HER2 
protein, T cells (T) recognizing the xenogeneic peptides proliferate. The expanded T cells interact and 
provide helper signals to B cells, leading to the production of antibodies (Y) to both the xenogeneic and 
tolerated moieties by plasmacells (PC). Adapted from Iezzi M. et al, 2012 [68]. 
Chimeric vaccines displayed superior performance in tolerant BALB neu-T mice [64, 65]. 
While control mice vaccinated with empty pVAX plasmid developed HER2-positive 
mammary tumors within 27 weeks of age, all mice electroporated at 10 weeks and at 12 
weeks of age with RHuT or fully rat EC-TM (RRT) remained tumor-free at 40 weeks. 
However, 10 weeks later, the protection of mice vaccinated with RRT decreased to about 
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50%, while 80% of RHuT vaccinated mice remained tumor-free (Figure 15a). In both cases, 
the tumor rejection pattern correlated with higher titers of anti-rat HER2 antibodies (Figure 
15b). In addition, RHuT protection could be further extended by repeated boosting to 
maintain immunological memory [64]. 
Preclinical data obtained with RHuT provided the rationale for its use in an ongoing phase I 
clinical trial (EudraCT 2011-001104-34) approved by Italian Ministry of Health in HER2-
positive head-and-neck cancers (protocol code: IOV-HN-1-2011). Moreover, preliminary 
data have shown that chimeric vaccines used in 16HER2 transgenic mice are also able to 
counteract the aggressive breast carcinogenesis driven by the 16HER2 splice variant. 
 
Figure 15. Vaccination with RHuT effectively protects Balb-neuT mice from HER2-driven mammary 
carcinogenesis. a. Mammary tumor incidence of BALB-neuT vaccinated mice with RHuT (dotted red line, 
n = 7 mice), RRT (continuous red line, n = 8 mice), and empty control pVAX (dotted black line, n = 6 
mice). Differences in tumor incidence were analyzed by the log-rank (Mantel-Cox) test. b. Mouse sera 
collected 2 weeks after the second vaccination were analyzed for anti-rat HER2 antibody titer by flow 
cytometry (b). Data are mean MFI ± SEM (* p = 0.02, Student’s t test). 
2. Conclusions 
Breast cancer remains one of the major causes of morbidity and mortality in Western 
Countries, despite progress in both knowledge and treatment. A deeper understanding of 
the underlying biology of breast cancer is necessary for the identification of new molecular 
targets and development of novel targeted therapeutics. 
In the last three decades, a large number of transgenic mice have been generated that 
demonstrate the direct involvement of the HER2 receptor in mammary carcinogenesis. In 
these cancer-prone mice transgenically expressing the rat or human HER2 molecule, the 
development of autochthonous tumors recapitulates several of the molecular and genetic 
features of human cancer progression. Some of these animal models support the hypothesis 
that overexpression of HER2 alone is not sufficient to generate mammary tumors and 
requires activating mutations.  
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Emerging evidence indicates that the 16HER2 splice variant plays a key role in tumor 
progression and refractoriness to Trastuzumab treatment. Currentlya new mouse model 
transgenic for the human 16HER2 isoform is available. While no single genetically 
engineered mouse can offer a complete model of the wide assortment of human neoplasms 
found in human breast cancer, the 16HER2 mouse represents a novel tool to test the ability 
of drugs and vaccines to inhibit the progression of HER2-driven cancer and to investigate 
Trastuzumab resistance. 
Among targeted therapies being developed for breast cancer, anti-HER2 cancer vaccines 
seem particularly promising. 
However, the generation of an effective vaccine able to trigger a long-lasting immunity that 
prevents tumor recurrence in cancer patients implies the understanding of how tolerance, 
immunity and immunosuppression regulate antitumor immune responses. Equally 
important for the rational design of cancer vaccines is the development of new 
biotechnological tools for the identification of the most immunogenic portions of a molecule 
and for the selection of the key epitopes within a protein.  
In Steven Spielberg’s “War of the Worlds”, mankind prevailed over extraterrestrial invaders 
thanks to immunity, because “For neither do men live nor die in vain." The challenge is to 
redirect the powerful mechanisms of the immune response, so effective against outside 
invaders such as microorganisms, against an inside enemy, i.e., cancer. 
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1. Introduction 
EGFR and HER2 family with signal pathway and carcinogenesis: The human epidermal 
growth factor receptors (HER-2) gene is localized to chromosome 17q and encodes a 
transmembrane tyrosine kinase receptor protein.  Numerous studies were done from basic 
mechanism of HER family for cell proliferation and oncogenesis, HER2 overexpression or 
amplification in various solid tumors to clinical treatment of breast cancer, gastro-
esophageal cancer by trastuzumab in many recent reviews [1-8]. 
HER2 belongs to a family including epidermal growth factor receptor (EGFR), HER2, HER3 
and HER4, which are a group of transmembrane glycoproteins, collectively named receptor 
tyrosine kinases (RTKs), whose cytoplasmic domains harbor an enzymatic activity, namely 
tyrosine-specific phosphorylation [9]. The family of epidermal growth factor molecules, 
which comprises different ligands sharing a 50–60 amino acid receptor-binding domain, 
bind with subtype RTKs. Each receptor consists of an extracellular ligand-binding domain, a 
transmembrane domain, and a tyrosine kinase portion [10]. Upon ligand binding, the 
otherwise inactive monomeric receptors form active homodimers or heterodimers, thereby 
leading to receptor phosphorylation and signaling via various biochemical pathways (Fig.1), 
such as the mitogen-activated protein kinase (MAPK), the phosphatidylinositol 3-kinase 
(PI3K), phospholipase C-γ, and transcription factors like the signal transducers and activators 
of transcription (STATs) or SMAD proteins [1]. These modules of cellular activation and the 
respective growth factors (GFs)s are co-opted in several phases of tumor progression. 
HER-2 gene amplification in breast cancer has been associated with increased cell 
proliferation, cell motility, tumor invasiveness, progressive regional and distant metastases, 
accelerated angiogenesis, and reduced apoptosis [11]. Overexpression of HER2 in human  
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growth factor receptors (HER-2) gene is localized to chromosome 17q and encodes a 
transmembrane tyrosine kinase receptor protein.  Numerous studies were done from basic 
mechanism of HER family for cell proliferation and oncogenesis, HER2 overexpression or 
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leading to receptor phosphorylation and signaling via various biochemical pathways (Fig.1), 
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of transcription (STATs) or SMAD proteins [1]. These modules of cellular activation and the 
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Figure 1. Signal transduction pathways instigated by HER2, co-receptors and EGF-like growth factors. 
Heterodimers of HER2/ErbB-2 and either EGFR/ErbB-1 or the kinase-defective ErbB-3/HER3 (note the 
letter X that symbolizes a defective cytoplasm-facing kinase domain) are shown, along with the growth 
factor ligands they bind. All ligands share an epidermal growth factor (EGF) motif of 50–60 amino 
acids. They include, in addition to EGF, epiregulin (EPG), transforming growth factor alpha (TGF-
alpha), heparin-binding epidermal growth factor-like factor (HB-EGF), amphiregulin (AR), epiregulin 
(EPR) and betacellulin. Another group includes four classes of neuregulins (NRGs). Note that HER2 is 
unable to bind a ligand. Nevertheless, HER2 takes part in signaling via its own constitutive 
phosphorylation, as well as by trans-activation of its heterodimerization partners. Tyrosine 
phsphorylated receptors are coupled to several biochemical cascades, including the phosphoinositide-3-
kinase (PI3K) pathway and the extracellular signal-regulated kinase (ERK), which belongs to the MAPK 
family. Activation of ERK/MAPK is mediated via the RAS-RAF-MEK pathway and leads to cellular 
proliferation via the activation of a number of nuclear targets, including the AP1 (FOS and JUN) 
complex, MYC, which regulates cell cycle progression, and ELK1, a member of the ETS family of 
transcription factors. SHC and GRB2 are adaptor proteins sharing the ability to bind each other, as well 
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as tyrosine phosphorylated receptors. The EGFR/HER2 heterodimer also couples to phospholipase C 
(PLC) and the downstream protein kinase C. On the other hand, ErbB-3/HER3-containing heterodimers 
strongly activate another kinase, AKT, via a lipid kinase, PI3K, leading to activation of mTOR 
(mechanistic target of rapamycin). Activation of AKT blocks signaling via BAD, a BH3-only protein, 
which contributes to tissue homeostasis by regulating initiation of apoptosis. Activation of AKT inhibits 
FKHR and the cyclin-dependent kinase inhibitor p27KIP. The forkhead box O1 (FKHR, FOXO1) 
transcription factor is a member of the FOXO family of transcription factors, involved in tumor 
suppression and cell death. (From Emde A, et al. Crit Rev Oncol/Hematol (2010), 
http://dx.doi.org/10.1016/j.critrevonc.2010.09.002, Permitted by Elsevier Limited). 
mammary epithelial cells induces proliferative advantage, transformed characteristics, 
tumorigenic growth, and induces proliferative and anti-apoptotic changes that mimic early 
stages of epithelial cell transformation [12]. HER2 amplification is also seen in early in situ 
ductal carcinomas without any evidence of invasive disease [13, 14]. HER2 status is 
maintained during progression to invasive disease, nodal metastasis and distant metastasis 
[14, 15]. HER2 overexpression has been shown to activate multiple signaling complexes, 
which results in a striking dysregulation of the global transcriptome [1].  
Clinical treatment targeting on HER2 receptor:  It took a long journey to develop 
monoantibody to target HER2. Murine origin of mAb to HER2 limits their clinical 
application since immunoglobulin molecules are immunogenic. When injected into humans, 
it shortens their half-lives in circulation. Winter and colleagues (1988) generated a mouse–
human chimeric antibody [16]. Later transgenic mice whose immunoglobulin loc have been 
genetically inactive, was used to produce the first fully human antibody, Panitumumab, an 
antibody to EGFR. Then, trastuzumab which carry all human immunoglobulin genes, a 
monoclonal antibody to HER2, was approved for clinical use in lymphoma and in breast 
cancer [17]. So far, only two drugs that target HER2, Trastuzumab and a kinase inhibitor 
called Lapatinib/Tykerb, are approved for clinical application in breast cancer, but several 
novel drugs are in development (see figure 2). 
Trastuzumab, monoclone antibody on HER2: Trastuzumab, a monoclonal antibody that 
targets HER2, induces antibody-dependent cellular cytotoxicity, inhibits HER2-mediated 
signaling and prevents cleavage of the extracellular domain of HER2 [12]. Based on multi-
centers and countries clinical trial for HER2 positive breast cancer, [18,19,20] trastuzumab 
was significantly improve the prognosis of breast cancer. Therefore, it was initially 
approved for treatment of patients with HER2 overexpressing metastatic breast cancer. 
Because Trastuzumab also enhances the efficacy of adjuvant chemotherapy in operable or 
locally advanced HER2-positive tumors [21], the antibody currently represents the standard 
of care for patients with early or advanced stages of HER2-overexpressing breast cancer.  
Since breast cancer showed better prognosis with trastuzumab treatment for HER2 positive 
breast cancer patients and similar HER2 positive cancers were identified in gastric and 
gastro-esophageal cancer, clinical trial ToGA was performed in gastric carcinoma. ToGA 
(Trastuzumab for Gastric Cancer) was an open-label, international, phase 3, randomized 
controlled trial undertaken in 122 centers in 24 countries [22]. Clinical trial ToGA used 
trastuzumab combined with standard chemotherapy for HER2 positive gastric cancer and 
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gastro-esophageal junction cancer which demonstrated a significant improvement of gastric 
cancer survival. Now, trastuzumab is approved for treatment of gastric cancer in European, 
United States, Japan and other multiple countries.  
 
Figure 2. Clinically approved and experimental therapeutic strategies targeting ErbB-2/HER2 in 
carcinomas. Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain 
of HER2, is approved for the treatment of HER2-overexpressing breast cancer. The antibody recruits 
immune effector mechanisms and can induce apoptosis, block angiogenesis and inhibit tumor cell 
proliferation. Similarly, Pertuzumab is able to prevent heterodimerization of HER2 with other family 
members. Unlike the ultimate specificity of Trastuzumab and Pertuzumab to HER2, tyrosine kinase 
inhibitors like the reversible inhibitor Lapatinib (approved for treatment of breast cancer) and the 
irreversible inhibitor Neratinib variably inhibit a broad range of tyrosine kinases. The drug has 
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completed phase II clinical trials. HSP90 is a molecular chaperone required for proper folding of protein 
kinases like HER2. Hence, HSP90 inhibitors, such as 17-AAG, which block the ATP/ADP binding 
pocket of HSP90 and target HER2 for proteasomal degradation are in clinical trials. A naturally 
occurring truncated form of HER2, p95-HER2, has been implicated as a mechanism conferring 
resistance to Trastuzumab. Its formation is mediated by processing of the membrane bound HER2 by 
matrix metalloproteinases (MMPs) of the ADAM (a disintegrin and metalloproteinase) family. INCB3619 
and INCB7839 are potent inhibitors of ADAM10 and ADAM17. ADAM10 is the principle sheddase for 
different molecules associated with tumor cell proliferation, whereas ADAM17 is the main sheddase for 
the EGFR ligands TGF-alpha, AR, NRGs, and HB-EGF. These similar inhibitors may effectively block 
truncation of HER2 and onset of patient resistance to Trastuzumab, but clinical testing has not been 
completed. (From Emde A, et al. Crit Rev Oncol/Hematol (2010), 
http://dx.doi.org/10.1016/j.critrevonc.2010.09.002, Permitted by Elsevier Limited). 
The clinical efficacy of Trastuzumab likely entails a combination of immunological and non-
immunological mechanisms [1]. The ability of Trastuzumab to elicit antibody-dependent 
cellular cytotoxicity critically influences the efficacy of Trastuzumab-based therapies. Non-
immunological mechanisms of Trastuzumab action include the inhibition of HER2 
activation and downstream signaling. Alternatively, Trastuzumab may act by removing 
HER2 from the cell surface. Because it binds to an epitope near the cleavage site of HER2's 
extracellular domain, Trastuzumab inhibits HER2 activation by metalloproteinase-mediated 
shedding of the extracellular domain. The resulting interference with HER2-mediated 
downstream signaling processes shuts down cell proliferation, angiogenesis, invasive 
growth, resistance to apoptosis, and DNA repair, thus sensitizing tumor cells to 
conventional therapeutic modalities such as chemotherapy, endocrine treatment and 
radiotherapy. 
Lapatinib, small molecule kinase inhibitor: Lapatinib, binding either reversibly or 
irreversibly to the nucleotide-binding cleft of their target kinases, is a highly specific, 
reversible inhibitor that blocks the catalytic action of both HER2 and EGFR23. Experiments in 
vitro and xenograft models, established the ability of Lapatinib to inhibit both the intact 
form of HER2 and the truncated intracellular form (p95-HER2), which is not recognized by 
Trastuzumab. 
Similar to Trastuzumab, Lapatinib combined with chemotherapy was found to be better 
effect than capecitabine alone in HER2-positive women with advanced breast cancer that 
progressed after treatment with regimens that included Trastuzumab, an anthracycline and 
a taxane [24]. In addition, Lapatinib demonstrated clinical activity and was well tolerated as 
first-line monotherapy in HER2-amplified, locally advanced or metastatic breast cancer [25, 
26]. Recently, laptinib showed a synergistic effect with trastuzumab in vitro and in vivo to 
inhibit HER2 amplified human gastric cancer cells and animal model [23]. Clinical phase II 
trial of lapatinib as first line therapy in patients with advanced or metastatic cancer showed 
well tolerated, which will be another potential drug to target HER2 receptors. 
Lapatinib response correlated with EGFR and HER2 expression levels in patients’ tumors, 
and associated with increased pre-treatment expression of phosphorylated-HER2 (p-
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gastro-esophageal junction cancer which demonstrated a significant improvement of gastric 
cancer survival. Now, trastuzumab is approved for treatment of gastric cancer in European, 
United States, Japan and other multiple countries.  
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the EGFR ligands TGF-alpha, AR, NRGs, and HB-EGF. These similar inhibitors may effectively block 
truncation of HER2 and onset of patient resistance to Trastuzumab, but clinical testing has not been 
completed. (From Emde A, et al. Crit Rev Oncol/Hematol (2010), 
http://dx.doi.org/10.1016/j.critrevonc.2010.09.002, Permitted by Elsevier Limited). 
The clinical efficacy of Trastuzumab likely entails a combination of immunological and non-
immunological mechanisms [1]. The ability of Trastuzumab to elicit antibody-dependent 
cellular cytotoxicity critically influences the efficacy of Trastuzumab-based therapies. Non-
immunological mechanisms of Trastuzumab action include the inhibition of HER2 
activation and downstream signaling. Alternatively, Trastuzumab may act by removing 
HER2 from the cell surface. Because it binds to an epitope near the cleavage site of HER2's 
extracellular domain, Trastuzumab inhibits HER2 activation by metalloproteinase-mediated 
shedding of the extracellular domain. The resulting interference with HER2-mediated 
downstream signaling processes shuts down cell proliferation, angiogenesis, invasive 
growth, resistance to apoptosis, and DNA repair, thus sensitizing tumor cells to 
conventional therapeutic modalities such as chemotherapy, endocrine treatment and 
radiotherapy. 
Lapatinib, small molecule kinase inhibitor: Lapatinib, binding either reversibly or 
irreversibly to the nucleotide-binding cleft of their target kinases, is a highly specific, 
reversible inhibitor that blocks the catalytic action of both HER2 and EGFR23. Experiments in 
vitro and xenograft models, established the ability of Lapatinib to inhibit both the intact 
form of HER2 and the truncated intracellular form (p95-HER2), which is not recognized by 
Trastuzumab. 
Similar to Trastuzumab, Lapatinib combined with chemotherapy was found to be better 
effect than capecitabine alone in HER2-positive women with advanced breast cancer that 
progressed after treatment with regimens that included Trastuzumab, an anthracycline and 
a taxane [24]. In addition, Lapatinib demonstrated clinical activity and was well tolerated as 
first-line monotherapy in HER2-amplified, locally advanced or metastatic breast cancer [25, 
26]. Recently, laptinib showed a synergistic effect with trastuzumab in vitro and in vivo to 
inhibit HER2 amplified human gastric cancer cells and animal model [23]. Clinical phase II 
trial of lapatinib as first line therapy in patients with advanced or metastatic cancer showed 
well tolerated, which will be another potential drug to target HER2 receptors. 
Lapatinib response correlated with EGFR and HER2 expression levels in patients’ tumors, 
and associated with increased pre-treatment expression of phosphorylated-HER2 (p-
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HER2)[27]. Lapatinib is able to induce apoptosis of Trastuzumab-resistant breast cancer cells 
via alteration of IGF-1 signaling, [28, 29] and also block NRG-induced p95-HER2/HER3 
heterodimers formation [30]. 
2. HER2 in gastric adenocarcinoma 
Gastric cancer is the fourth most common cancer worldwide and the second most common 
cause of cancer-related death in the world [31, 32]. The incidence of gastric cancer varies 
substantially worldwide, with the highest rates (>20 per 100,000) occurring in Japan, China, 
Eastern Europe, and South America, but the lowest rates (<10 per 100,000) finding in North 
America, southern Asia, North and East Africa, Australia, and New Zealand. In addition, it 
is more common in men than in women (10.9 vas 5.5 per 100,000). Although the survival of 
gastric cancer is improved in recently years in Western countries the 5 year survival is still 
around 5-20%. The multimodality treatments including surgery and neoadjuvent 
chemotherapy have a limited effect on the overall survival. In breast cancer, HER2 
overexpression and amplification were reported around 25% and associate with poorer 
prognosis [2]. Trastuzumab treatment of HER2 positive breast cancer patient improved 
survival. HER2 overexpression and amplification were reported in gastric and gastro-
esophageal junction (GEJ) tumors from 6-43%. In addition, trastuzumab were found to 
inhibit tumor growth in gastric carcinoma cell lines, animal model and xenograft models 
[33-35]. Recently international large scale phase III clinical trial called ToGA showed that 
trastuzumab added to standard chemotherapy significantly improved the response rate, 
median progression-free survival, and overall survival of gastric adenocarcinoma[22]. 
Trastuzumab combined with standard chemical therapy (such as capecitabine or 5-
fluorouracil and cisplatin) now is approved by European Medicines Agency, United States 
and Japan etc. for the treatment of patients with HER2 overexpression or amplification. 
Thus clinical tests for HER2 overexpression and amplification in gastric adenocarcinoma 
patients become a key to recruit eligible patients for clinical treatment and evaluation of 
treatment effect. 
IHC studies on HER2 overexpression: HER 2 overexpression was reported from 7-34% by 
many studies [3]. For clinical trial and treatment, it is very important to develop a standard 
HER2 test to recruit eligible patients for trastuzumab treatment. Before clinical trial ToGA, 
Hofmann and colleagues (2008)[36] first set up an IHC criteria based on HER2 IHC test on 
168 gastric and GEJ resection patients (see Table 2).  Based on the standard HER2 test on the 
breast cancer, they further proposed that strong incompletely membranous stain with 
basolateral “U” shape in gastric cancer was positive for HER2 overexpression. In addition, 
the HER2 expression showed higher heterogeneity about 4.8% in gastric samples than about 
1.4% in breast cancer. They modified breast criteria in several points including incomplete 
membranous stain pattern and percentage of cells (≥ 10% cut off), which improved the 
concordance level between IHC and FISH tests to 93.5%. For ToGA clinical trial, Bang et al 
[22] reported that HER2 positive rate was a 22.1%. In addition, they found that HER2- 
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Gastric Cancer  Breast Cancer Score/classification 
IHC score criteria
No reactivity or membranous 
reactivity in <10% of cells; 
Biopsy specimens < 5 Cells 
No reactivity or membranous 
reactivity in <10% of cells 
0/negative 
Faint/barely perceptible 
membranous reactivity in ≥10% 
of cells;  biopsy specimens≥5 
Cells 
Faint membranous reactivity in 
>10% of cells; 
1+/negative 
Weak to moderate complete or 
basolateral membranous activity 
in ≥10% of tumor cells; biopsy 
specimens≥5 Cells 
Weak to moderate complete 
membrane staining in >10% of 
tumor cells  
 
2+/equivocal 
Moderate to strong complete or 
basal/lateral membranous 
activity  in ≥10% of resection 
tumor cells; biopsy specimens≥5 
Cells 
Strong complete membrane 
staining in >10% of tumor cells 
3+/positive 
FISH HER2/CEP 17  
≥ 2 At least 20 evaluable, non-
overlapping cells in the invasive 
component 
> 2.2 At least 20 evaluable, non-
overlapping cells in the invasive 
component
Amplification 
 1.8-2.2 Equivocal 
<2 At least 20 evaluable, non-
overlapping cells in the invasive 
component 
<1.8 At least 20 evaluable, non-
overlapping cells in the invasive 
component
negative 
Table 1. Consensus panel recommendations on HER2 scoring for gastric cancer 
positive rate were higher in GEJ cancer than in gastric cancer (33% vs 21%) and in intestinal 
than diffuse or mixed cancer (32.2% vs 6.1% vs 20.4%). The concordance between IHC and 
FISH was 87.5%. Ruschoff and colleaguesl37, 38(2010, 2012) further validate the HER2 test 
procedure to determine whether pathologists from different sits  were able to reproduce the 
method of gastric cancer HER2 status evaluation as it was used by Ruschoff within the 
ToGA study. They validated the HER2 status testing procedure in terms of inter-laboratory 
and inter-observe consensus for IHC scoring a series of 547 gastric cancer tissue samples on 
a tissue microarray.  They published a practical approach of HER2 test in gastric carcinoma. 
Based on multiple laboratories and 8 pathologists HER2 test results, they further confirmed 
the HER2 positive rate of 22.8% which is close to 22.1% from Hoffman’s score system. In 
addition, they compared Daco (HecepTest) and Ventana (Pathway HER2 antibody, 4B5).  
They found that HercepTest had a higher inter-laboratory discordance than 4B5.  
Furthermore, Ruschoff and a group of international pathologist reviewed previous HER2 
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[33-35]. Recently international large scale phase III clinical trial called ToGA showed that 
trastuzumab added to standard chemotherapy significantly improved the response rate, 
median progression-free survival, and overall survival of gastric adenocarcinoma[22]. 
Trastuzumab combined with standard chemical therapy (such as capecitabine or 5-
fluorouracil and cisplatin) now is approved by European Medicines Agency, United States 
and Japan etc. for the treatment of patients with HER2 overexpression or amplification. 
Thus clinical tests for HER2 overexpression and amplification in gastric adenocarcinoma 
patients become a key to recruit eligible patients for clinical treatment and evaluation of 
treatment effect. 
IHC studies on HER2 overexpression: HER 2 overexpression was reported from 7-34% by 
many studies [3]. For clinical trial and treatment, it is very important to develop a standard 
HER2 test to recruit eligible patients for trastuzumab treatment. Before clinical trial ToGA, 
Hofmann and colleagues (2008)[36] first set up an IHC criteria based on HER2 IHC test on 
168 gastric and GEJ resection patients (see Table 2).  Based on the standard HER2 test on the 
breast cancer, they further proposed that strong incompletely membranous stain with 
basolateral “U” shape in gastric cancer was positive for HER2 overexpression. In addition, 
the HER2 expression showed higher heterogeneity about 4.8% in gastric samples than about 
1.4% in breast cancer. They modified breast criteria in several points including incomplete 
membranous stain pattern and percentage of cells (≥ 10% cut off), which improved the 
concordance level between IHC and FISH tests to 93.5%. For ToGA clinical trial, Bang et al 
[22] reported that HER2 positive rate was a 22.1%. In addition, they found that HER2- 
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reactivity in <10% of cells; 
Biopsy specimens < 5 Cells 
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0/negative 
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1+/negative 
Weak to moderate complete or 
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<1.8 At least 20 evaluable, non-
overlapping cells in the invasive 
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negative 
Table 1. Consensus panel recommendations on HER2 scoring for gastric cancer 
positive rate were higher in GEJ cancer than in gastric cancer (33% vs 21%) and in intestinal 
than diffuse or mixed cancer (32.2% vs 6.1% vs 20.4%). The concordance between IHC and 
FISH was 87.5%. Ruschoff and colleaguesl37, 38(2010, 2012) further validate the HER2 test 
procedure to determine whether pathologists from different sits  were able to reproduce the 
method of gastric cancer HER2 status evaluation as it was used by Ruschoff within the 
ToGA study. They validated the HER2 status testing procedure in terms of inter-laboratory 
and inter-observe consensus for IHC scoring a series of 547 gastric cancer tissue samples on 
a tissue microarray.  They published a practical approach of HER2 test in gastric carcinoma. 
Based on multiple laboratories and 8 pathologists HER2 test results, they further confirmed 
the HER2 positive rate of 22.8% which is close to 22.1% from Hoffman’s score system. In 
addition, they compared Daco (HecepTest) and Ventana (Pathway HER2 antibody, 4B5).  
They found that HercepTest had a higher inter-laboratory discordance than 4B5.  
Furthermore, Ruschoff and a group of international pathologist reviewed previous HER2 
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studies; they built up new detailed criteria for gastric and gastro-esophageal HER2 tests (see 
Table 3; Ruschoff 2012). In their practical procedure for gastric cancer HER2 test, the surgical 
specimen cutoff is complete, basolateral, or lateral membranous reactivity in ≥10% of cells; 
the biopsy specimen cutoff is complete, basolateral, or lateral membranous reactivity in ≥5 
clustered cells; the borderline cutoff is immunohistochemistry 1+/immunohistochemistry 2+ 
or focal staining in <10% cells which recommend for FISH or SISH tests. This new score 
system further improved Hoffmann’s score system, but it still need further proved in future 
HER2 tests, especially the results mostly based on European laboratories. The large scale 
HER2 studies in Asia are need to build up an optimal HER2 test system in gastric cancer 




 Representative surgical samples or an adequate number of viable biopsy specimens (ideally 
six to eight) are required 
 If few biopsies are available, all viable specimens should be tested 
 Immunohistochemistry should be the initial HER2 testing methodology for gastric cancer 
and bright-field methodologies are preferred wherever possible 
HER2-positive per European Medicines Agency license: immunohistochemistry 3+ or 
immunohistochemistry 2+/fluorescence in situ hybridization-positive or 
immunohistochemistry 2+/silver in situ hybridization-positive 
Borderline immunohistochemistry 1+/immunohistochemistry 2+ cases and samples with 
focal and intense membranous reactivity in <10% cells may also be retested with 
fluorescence in situ hybridization or silver in situ hybridization (scores for both assays 
should be indicated separately on the report) 
 Validated immunohistochemistry HER2 assays should be used 
Scoring recommendations 
 Due to the tumor heterogeneity (focal areas of positivity) and incomplete membrane staining 
commonly seen in gastric cancer, the gastric cancer-specific scoring criteria should be 
adhered to: 
 Surgical specimen cutoff: complete, basolateral, or lateral membranous reactivity in 
≥10% of cells 
 Biopsy specimen cutoff: complete, basolateral, or lateral membranous reactivity in 
≥5 clustered cells 
 The ‘magnification rule’ should be used in conjunction with the scoring criteria 
 Borderline cases (immunohistochemistry 1+/immunohistochemistry 2+ or focal staining in 
<10% cells) that score fluorescence in situ hybridization-positive or silver in situ 
hybridization-positive may be considered HER2-positive (scores for both assays should be 
indicated separately on the report) 
b. In situ hybridization 
Testing recommendations 
  Tumor samples classified as immunohistochemistry 2+ should be retested by fluorescence 
in situ hybridization or silver in situ hybridization to assess HER2 status 
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  Silver in situ hybridization is a more suitable methodology than fluorescence in situ 
hybridization for assessing HER2 status in gastric tumor samples as it is a bright-field 
methodology and thus allows for rapid identification of HER2-positive tumor foci within a 
heterogeneous sample 
Validated in situ hybridization HER2 assays should be used 
Scoring recommendations 
 The definition of fluorescence in situ hybridization or silver in situ hybridization positivity in 
gastric or gastro–esophageal junction cancer is a HER2:chromosome 17 ratio of ≥2.0 
 The entire case should be screened for amplified regions (particularly important for 
fluorescence in situ hybridization samples where a bright-field image is not available) 
 At least 20 evaluable, non-overlapping cells in the invasive component should be counted 
initially 
 In borderline amplification cases, ~20 additional cells should be recounted or scoring should 
be performed in an alternative area of tissue 
The overall HER2 gene count is important: 
 >6 HER2 gene copies using single probe: considered positive 
 Four to six HER2 gene copies: dual probe test advised and the ratio should be 
recalculated by counting an additional 20 cells 
Ensuring quality and timely HER2 testing results 
 The use of validated immunohistochemistry and in situ hybridization tests is strongly 
recommended and appropriate controls should be included in each run 
 Turnaround time from initial diagnosis to reporting of results should ideally not exceed 5 
working days and a multidisciplinary approach is required 
 Centralized testing is recommended wherever possible and all laboratories should 
participate in validated quality assurance programs 
Table 2. Human epidermal growth factor receptor 2 (HER2) testing recommendations in gastric cancer, 
(a) immunohistochemistry and (b) in situ hybridization (From Ruschoff J, Hanna W, Bilous M, et al. 
HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012) 
 
HER2 immunohistochemistry features Score 
No reactivity or very faint membranous stain in <10% of cells; 
biopsy specimens<5 Cells 
0 
Faint membranous stain in >10% of cells; biopsy specimens≥5 Cells 1+ 
Weak to moderate complete or baso/lateral membranous stain in >10% of tumor 
cells; biopsy specimens≥5 Cells 
2+/positive 
Strong complete or basal/lateral membranous stain in >10% of tumor cells; 
biopsy specimens≥5 Cells 
3+/positive 
HER2 FISH/chromogenic in situ hybridization test  
Ratio of average HER2/CEP17 ≥2.0 Positive 
Ratio of average HER2/CEP17 <2.0 Negative 
Table 3. Modified score criteria of HER2 immunohistochemical stain and FISH/chromogenic in situ 
hybridization for esophageal adenocarcinoma  
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studies; they built up new detailed criteria for gastric and gastro-esophageal HER2 tests (see 
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the biopsy specimen cutoff is complete, basolateral, or lateral membranous reactivity in ≥5 
clustered cells; the borderline cutoff is immunohistochemistry 1+/immunohistochemistry 2+ 
or focal staining in <10% cells which recommend for FISH or SISH tests. This new score 
system further improved Hoffmann’s score system, but it still need further proved in future 
HER2 tests, especially the results mostly based on European laboratories. The large scale 
HER2 studies in Asia are need to build up an optimal HER2 test system in gastric cancer 
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 Validated immunohistochemistry HER2 assays should be used 
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 Due to the tumor heterogeneity (focal areas of positivity) and incomplete membrane staining 
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adhered to: 
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≥10% of cells 
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<10% cells) that score fluorescence in situ hybridization-positive or silver in situ 
hybridization-positive may be considered HER2-positive (scores for both assays should be 
indicated separately on the report) 
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  Tumor samples classified as immunohistochemistry 2+ should be retested by fluorescence 
in situ hybridization or silver in situ hybridization to assess HER2 status 
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fluorescence in situ hybridization samples where a bright-field image is not available) 
 At least 20 evaluable, non-overlapping cells in the invasive component should be counted 
initially 
 In borderline amplification cases, ~20 additional cells should be recounted or scoring should 
be performed in an alternative area of tissue 
The overall HER2 gene count is important: 
 >6 HER2 gene copies using single probe: considered positive 
 Four to six HER2 gene copies: dual probe test advised and the ratio should be 
recalculated by counting an additional 20 cells 
Ensuring quality and timely HER2 testing results 
 The use of validated immunohistochemistry and in situ hybridization tests is strongly 
recommended and appropriate controls should be included in each run 
 Turnaround time from initial diagnosis to reporting of results should ideally not exceed 5 
working days and a multidisciplinary approach is required 
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participate in validated quality assurance programs 
Table 2. Human epidermal growth factor receptor 2 (HER2) testing recommendations in gastric cancer, 
(a) immunohistochemistry and (b) in situ hybridization (From Ruschoff J, Hanna W, Bilous M, et al. 
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HER2 immunohistochemistry features Score 
No reactivity or very faint membranous stain in <10% of cells; 
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Weak to moderate complete or baso/lateral membranous stain in >10% of tumor 
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Table 3. Modified score criteria of HER2 immunohistochemical stain and FISH/chromogenic in situ 
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Recently, in Asia, several IHC HER2 tests focused on comparing the HER2 antibodies from 
various companies. Cho and colleagues [39] used four different HER2 antibodies compared 
to standard FISH test. They found the various positive rates with HercepTest (14%), A0485 
(16%), 4B5 (14%), and CB11 (9%). The sensitivity and specificity of IHC compared to FISH 
was 78.9%/96% for HercepTest, 86.5%/94.4% for A0485, 76.3%/95.6% for 4B5 and 
60.5%/98.4% for CB11. Compare to FISH, there was no significantly differences in the 
sensitivity and specificity among the four IHC tests. However, CB11 had a highest 
specificity (98%), but a lowest sensitivity (61%). Park et al [39] (2012) compared HercepTest 
with 4B5, only 41 cases showed discrepancies, yielding a 96.1% concordance rate. However, 
HER2 positive rate with both methods are very low: HecepTEST, 5.9% and 4B5, 6.4%.   
In addition, the standard breast HER2 test was compared with modified gastric carcinoma 
HER2 test (Table2). Sever studies used breast cancer score rule [40-42]. Barros-Silva et al. [40] 
found 3.9% as IHC2+ and 5.4% as IHC3+ from resection 463 gastric adenocarcinomas using 
the breast cancer scoring rules. Using breast cancer scoring, Park et al. (2012)[41] found that 
HER2 positive rate are very low with two antibodies: HecepTEST, 5.9% and 4B5, 6.4%. The 
similar result also was presented in TMA data which were classified as IHC2+ (1.6%) or 
IHC3+ (3.2%) if breast cancer scoring was applied[42]. As the same group also tested gastric 
cancer TMAs using gastric cancer specific scoring [36]the corresponding rates were 4% 
IHC2+ and 13% for IHC3+, demonstrating an about fourfold increase of HER2 positivity 
rate[42]. Therefore, Rushcoff concluded that it is supposed that application of breast cancer 
scoring to gastric cancer may produce an up to 50% false-negative rate if IHC is used as the 
primary test platform as favored by EMEA[37]. 
FISH, CISH and SISH studies on HER2 amplification: HER2 amplification was first 
reported  in gastric cancer in 198643. Since then, HER2 amplification in gastric cancer was 
extensively studied (see Table 3). Kimura  et al. 44 first set criteria of FISH test as 
HER2/CEP17 ≥ 2.0 which is modified from breast standard HER2 FISH test with 83% of 
concordance between IHC 2+ and 3+ samples. Hoffman et al.36 proved that these FISH 
criteria for gastric cancer showed a higher concordance (93%) between HER2 amplification 
and overexpression in gastric cancer. Ruschoff  et al. 38, 45  (2010, 2012) further validate the 
HER2 test procedure to determine whether pathologists from different sits  were able to 
reproduce the method of gastric cancer HER2 status evaluation as it was used by Ruschoff 
within the ToGA study. HER2 amplification was determined by FISH assays, using either 
HER2 FISH pharmDX™ (Dako Denmark A/S) or PathVysion® (Abbott Laboratories, Des 
Plaines, IL, USA). Automated brightfield dual-color silver in situ hybridization (SISH) assay 
(BDISH; Inform™, Ventana Medical Systems SA) was used to determine gene amplification 
at three of the participating sites. Based on their experience and previous studies, a new 
practical procedure for HER2 FISH, CISH or SISH tests were established. The positivity of 
HER2 FISH, CISH or SISH tests in gastric or gastro-esophageal junction cancer is a 
HER2/Chromosome 17 ratio ≥ 2.0 and > 6 HER2 gene copies using single probe.  At least 20 
evaluable, non-overlapping cells in the invasive component should be counted initially. If 
the results are borderline (four to six HER2 gene copies or HER2/Chromosome 17 ratio 1.8-
2.2), [20] additional cells should be recounted or scoring should be performed in an 
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alternative area of tissue. However, they also concluded that silver in situ hybridization is a 
more suitable methodology than fluorescence in situ hybridization for assessing HER2 status 
in gastric tumor samples as it is a bright-field methodology and thus allows for rapid 
identification of HER2-positive tumor foci within a heterogeneous sample.  
Comparing FISH and SISH methods for HER2 test in gastric cancer was also reported by 
several studies. Park et al [41] (2012) compared both SISH and FISH HER2 tests in Korea 
gastric adenocarcinoma 588 cases. They found only 9 cases with discrepancy, yielding a 
98.3% concordance rate. Garcia-Garcia et al [46] (2011) compared both SISH and FISH HER2 
tests in Spanish gastric adenocarcinoma in 166 cases. They found 96% concordance rate. 
Long et al [47] (2011) compared both SISH and FISH HER2 tests in China gastric 
adenocarcinoma 80 cases. They found only one case with discrepancy, yielding a 99% 
concordance rate. From above studies, FISH and SISH showed similar positive rates. The 
only difference between two methods is that SISH is much easier to count the HER2 signals.  
HER2 amplification or overexpression in primary tumor vs metastatic tumor was also 
reported. Bozzetti  et al [48] (2011) tested HER2 status with both FISH and IHC. The found 
that concordance of HER2 status between primary and metastatic tumor is 98.2% by FISH 
and 94.9% by IHC. They concluded that HER2 status is maintained in most cases unchanged 
during the metastatic process.  
HER2 amplification or overexpression correlating with patient survival and 
clinicopathological features: In breast cancer, HER2 amplification or overexpression is 
clearly associated with poorer prognosis and aggressive disease. However, the prognosis of 
HER2 amplification or overexpression in gastric cancer is controversial. In addition, the 
association of HER2 positive gastric cancer with clinicopathological features are also not 
consistent. 
Yonemura  et al [49] (1991) first reported HER2 overexpression in 260 primary gastric 
cancer. Patients with erbB-2 protein-positive tumors had 5-fold greater relative risk of death, 
as compared with those with erbB-2 protein-negative tumors. erbB-2 protein expression was 
associated with serosal invasion, lymph node metastasis, and lymphatic invasion.  Later, 
their results were confirmed by Nakajima et al (1999). Nakajima et al. [50](1999) also 
reported HER2 overexpression in 16.4% of gastric cancer, which was associated with 
significantly poorer survival. However, Kim et al. [51] (1994) studied the HER2 
overexpression in 152 Korea gastric carcinoma patients. They reported that the survival 
analysis of 104 patients with stage III gastric carcinoma revealed no significant association 
between c-erbB-2 staining status and survival duration. The 5-year survival rates of the c-
erbB-2 positive group and its negative group were 21% and 28%, respectively. In addition, 
there was little association between staining of c-erbB-2 protein and clinicopathological 
findings such as age, sex, location, histology, gross type, lymph node status, depth of 
invasion, and stage. However, other Korea studies found HER2 positive gastric cancer had a 
poor prognosis [41,52]. Park et al [41] reported that HER-2/neu overexpression and 
amplification in 182 gastric cancer Korea patients was examined with IHC. Twenty-nine  of 
182 patients expressed the HER-2/neu protein by IHC. Tumors with HER-2/neu 
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Recently, in Asia, several IHC HER2 tests focused on comparing the HER2 antibodies from 
various companies. Cho and colleagues [39] used four different HER2 antibodies compared 
to standard FISH test. They found the various positive rates with HercepTest (14%), A0485 
(16%), 4B5 (14%), and CB11 (9%). The sensitivity and specificity of IHC compared to FISH 
was 78.9%/96% for HercepTest, 86.5%/94.4% for A0485, 76.3%/95.6% for 4B5 and 
60.5%/98.4% for CB11. Compare to FISH, there was no significantly differences in the 
sensitivity and specificity among the four IHC tests. However, CB11 had a highest 
specificity (98%), but a lowest sensitivity (61%). Park et al [39] (2012) compared HercepTest 
with 4B5, only 41 cases showed discrepancies, yielding a 96.1% concordance rate. However, 
HER2 positive rate with both methods are very low: HecepTEST, 5.9% and 4B5, 6.4%.   
In addition, the standard breast HER2 test was compared with modified gastric carcinoma 
HER2 test (Table2). Sever studies used breast cancer score rule [40-42]. Barros-Silva et al. [40] 
found 3.9% as IHC2+ and 5.4% as IHC3+ from resection 463 gastric adenocarcinomas using 
the breast cancer scoring rules. Using breast cancer scoring, Park et al. (2012)[41] found that 
HER2 positive rate are very low with two antibodies: HecepTEST, 5.9% and 4B5, 6.4%. The 
similar result also was presented in TMA data which were classified as IHC2+ (1.6%) or 
IHC3+ (3.2%) if breast cancer scoring was applied[42]. As the same group also tested gastric 
cancer TMAs using gastric cancer specific scoring [36]the corresponding rates were 4% 
IHC2+ and 13% for IHC3+, demonstrating an about fourfold increase of HER2 positivity 
rate[42]. Therefore, Rushcoff concluded that it is supposed that application of breast cancer 
scoring to gastric cancer may produce an up to 50% false-negative rate if IHC is used as the 
primary test platform as favored by EMEA[37]. 
FISH, CISH and SISH studies on HER2 amplification: HER2 amplification was first 
reported  in gastric cancer in 198643. Since then, HER2 amplification in gastric cancer was 
extensively studied (see Table 3). Kimura  et al. 44 first set criteria of FISH test as 
HER2/CEP17 ≥ 2.0 which is modified from breast standard HER2 FISH test with 83% of 
concordance between IHC 2+ and 3+ samples. Hoffman et al.36 proved that these FISH 
criteria for gastric cancer showed a higher concordance (93%) between HER2 amplification 
and overexpression in gastric cancer. Ruschoff  et al. 38, 45  (2010, 2012) further validate the 
HER2 test procedure to determine whether pathologists from different sits  were able to 
reproduce the method of gastric cancer HER2 status evaluation as it was used by Ruschoff 
within the ToGA study. HER2 amplification was determined by FISH assays, using either 
HER2 FISH pharmDX™ (Dako Denmark A/S) or PathVysion® (Abbott Laboratories, Des 
Plaines, IL, USA). Automated brightfield dual-color silver in situ hybridization (SISH) assay 
(BDISH; Inform™, Ventana Medical Systems SA) was used to determine gene amplification 
at three of the participating sites. Based on their experience and previous studies, a new 
practical procedure for HER2 FISH, CISH or SISH tests were established. The positivity of 
HER2 FISH, CISH or SISH tests in gastric or gastro-esophageal junction cancer is a 
HER2/Chromosome 17 ratio ≥ 2.0 and > 6 HER2 gene copies using single probe.  At least 20 
evaluable, non-overlapping cells in the invasive component should be counted initially. If 
the results are borderline (four to six HER2 gene copies or HER2/Chromosome 17 ratio 1.8-
2.2), [20] additional cells should be recounted or scoring should be performed in an 
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alternative area of tissue. However, they also concluded that silver in situ hybridization is a 
more suitable methodology than fluorescence in situ hybridization for assessing HER2 status 
in gastric tumor samples as it is a bright-field methodology and thus allows for rapid 
identification of HER2-positive tumor foci within a heterogeneous sample.  
Comparing FISH and SISH methods for HER2 test in gastric cancer was also reported by 
several studies. Park et al [41] (2012) compared both SISH and FISH HER2 tests in Korea 
gastric adenocarcinoma 588 cases. They found only 9 cases with discrepancy, yielding a 
98.3% concordance rate. Garcia-Garcia et al [46] (2011) compared both SISH and FISH HER2 
tests in Spanish gastric adenocarcinoma in 166 cases. They found 96% concordance rate. 
Long et al [47] (2011) compared both SISH and FISH HER2 tests in China gastric 
adenocarcinoma 80 cases. They found only one case with discrepancy, yielding a 99% 
concordance rate. From above studies, FISH and SISH showed similar positive rates. The 
only difference between two methods is that SISH is much easier to count the HER2 signals.  
HER2 amplification or overexpression in primary tumor vs metastatic tumor was also 
reported. Bozzetti  et al [48] (2011) tested HER2 status with both FISH and IHC. The found 
that concordance of HER2 status between primary and metastatic tumor is 98.2% by FISH 
and 94.9% by IHC. They concluded that HER2 status is maintained in most cases unchanged 
during the metastatic process.  
HER2 amplification or overexpression correlating with patient survival and 
clinicopathological features: In breast cancer, HER2 amplification or overexpression is 
clearly associated with poorer prognosis and aggressive disease. However, the prognosis of 
HER2 amplification or overexpression in gastric cancer is controversial. In addition, the 
association of HER2 positive gastric cancer with clinicopathological features are also not 
consistent. 
Yonemura  et al [49] (1991) first reported HER2 overexpression in 260 primary gastric 
cancer. Patients with erbB-2 protein-positive tumors had 5-fold greater relative risk of death, 
as compared with those with erbB-2 protein-negative tumors. erbB-2 protein expression was 
associated with serosal invasion, lymph node metastasis, and lymphatic invasion.  Later, 
their results were confirmed by Nakajima et al (1999). Nakajima et al. [50](1999) also 
reported HER2 overexpression in 16.4% of gastric cancer, which was associated with 
significantly poorer survival. However, Kim et al. [51] (1994) studied the HER2 
overexpression in 152 Korea gastric carcinoma patients. They reported that the survival 
analysis of 104 patients with stage III gastric carcinoma revealed no significant association 
between c-erbB-2 staining status and survival duration. The 5-year survival rates of the c-
erbB-2 positive group and its negative group were 21% and 28%, respectively. In addition, 
there was little association between staining of c-erbB-2 protein and clinicopathological 
findings such as age, sex, location, histology, gross type, lymph node status, depth of 
invasion, and stage. However, other Korea studies found HER2 positive gastric cancer had a 
poor prognosis [41,52]. Park et al [41] reported that HER-2/neu overexpression and 
amplification in 182 gastric cancer Korea patients was examined with IHC. Twenty-nine  of 
182 patients expressed the HER-2/neu protein by IHC. Tumors with HER-2/neu 
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amplification were associated with poor mean survival rates (922 vs 3243 days) and 5-year 
survival rates (21.4% vs 63.0%; P < 0.05). Age, TNM stage, and amplification of HER-2/neu 
were found to be independently related to survival by multivariate analysis. In another 
Korea study with 1,414 cases and 595 tissue microarray cases, HER2-positivity was detected 
in 12.3% of whole-tissue sections and 17% of TMAs [53]. They found that HER2-positivity 
was correlated with age, histological type, lymphovascular invasion, and lymph node 
metastasis. Multivariate analyses of the differentiated gastric carcinoma subgroup revealed 
that HER2-positivity was an independent poor prognostic.  
Zhang et al (2009) studied the HER2 and HER3 overexpression in Chinese gastric cancer 
with 102 cases.  Overexpression of HER2 and HER3 was detected around 18.6% and 13.7%. 
HER2 and HER3 overexpression was correlated with a significantly worse survival (p = 
0.046 and 0.024, respectively). The overexpression rates of HER2 and HER3 in phase III-IV 
(TNM stage) disease were significantly higher than that in phase I-II disease (24.0% vs. 7.7%, 
p < 0.05 and 22.0% vs. 5.8%, p < 0.05, respectively). They proposed that HER3 may become 
another molecular target.  
In European and United States, Tanner  et al [54] (2005) found that HER2 amplification was 
present in 12.2% of the 131 gastric cancer and 24% of the 100 GEJ adenocarcinomas in 
Finland which was associated with poor carcinoma-specific survival.  In contrast, Kunz 
[55](2012) reported that twelve of 99 (12%) gastric carcinomas were positive for HER2 and 
seven of 70 (10%) gastroesophageal junction carcinomas were positive for HER2. HER2 
status or primary tumor site did not correlate with patient survival. 
Recently, Jorgensen and Hersom [56]  (2012) reviewed previous studies with more than 100 
patients and analysis of association between the HER2 status and survival or relevant 
clinicopathological characteristics. Forty-two publications with a total of 12,749 patients 
fulfilled the two criteria and were reviewed in detail. The majority of the publications (71%) 
showed that a HER2-postive status measured either by IHC or ISH was associated with 
poor survival and/or clinicopathological characteristics, such as serosal invasion, lymph 
node metastases, disease stage, or distant metastases. Based on the current analysis a clear 
trend towards a potential role for HER2 as a negative prognostics factor in gastric cancer 
was shown, suggesting that HER2 overexpression and/or amplification is a molecular 
abnormality that might be linked to the development of gastric cancer  
Trastuzumab or other HER2 related medication on treatment of HER2 amplification 
gastric adenocarcinoma: Trastuzumab, a monoclonal antibody that targets HER2, induces 
antibody-dependent cellular cytotoxicity, inhibits HER2-mediated signaling, and prevents 
cleavage of the extracellular domain of HER2[12]. Trastuzumab were found to inhibit tumor 
growth in gastric carcinoma cell lines, animal model and xenograft models[23, 33, 57, 58]. 
Fujimoto-Ouchi (2007) used trastuzumab as a single agent inhibited the tumor growth in 
both of the HER2-overexpressing models but not in the HER2-negative models, GXF97 and 
MKN-45. In any combination with capecitabine, cisplatin, irinotecan, docetaxel, or 
paclitaxel, trastuzumab showed more potent antitumor activity than the anticancer agents 
alone. A three-drug combination of capecitabine, cisplatin, and trastuzumab showed 
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remarkable tumor growth inhibition. Since breast cancer showed better prognosis with 
trastuzumab treatment for HER2 positive breast cancer patients, clinical trial was also 
performed in gastric carcinoma. ToGA (Trastuzumab for Gastric Cancer) was an open-label, 
international, phase 3, randomised controlled trial undertaken in 122 centers in 24 
countries[22]. Patients with gastric or gastro-esophageal junction cancer were eligible for 
inclusion if their tumors showed overexpression of HER2 protein by immunohistochemistry 
or gene amplification by fluorescence in-situ hybridization. Participants were randomly 
assigned in a 1:1 ratio to receive a chemotherapy regimen consisting of capecitabine plus 
cisplatin or fluorouracil plus cisplatin given every 3 weeks for six cycles or chemotherapy in 
combination with intravenous trastuzumab. 594 patients were randomly assigned to study 
treatment (trastuzumab plus chemotherapy, n=298; chemotherapy alone, n=296). Median 
follow-up was 18·6 months in the trastuzumab plus chemotherapy group and 17·1 months 
in the chemotherapy alone group. Median overall survival was 13·8 months in those 
assigned to trastuzumab plus chemotherapy compared with 11·1 months in those assigned 
to chemotherapy alone (hazard ratio 0·74). 
Although the survival improvement about 3 months, it is a great breakthrough for gastric 
carcinoma treatment since the survival of these cancer has not change for a decade. After 
ToGA clinical trial, trastuzumab combined with standard chemical therapy (such as 
capecitabine or 5-fluorouracil and cisplatin) now is approved by European Medicines 
Agency, United States and Japan etc. for the treatment of patients with HER2 
overexpression or amplification. In addition, laptinib showed a synergistic effect with 
trastuzumab in vitro and in vivo to inhibit HER2 amplified human gastric cancer cells and 
animal model [23]. Clinical phase II trial of lapatinib as first line therapy in patients with 
advanced or metastatic cancer showed well tolerated, which will be another potential drug 
to target HER2 receptors[59]. 
3. HER2 in esophageal adenocarcinoma 
EAC incidence has increased 6 folds in United States and Western countries in the last three 
decades and the prognosis is usually very poor with 5-year survival rates ranging from 14-
22%[60-63]. While surgical treatment of EAC can offer cure, many patients first present as a 
disseminated disease and require systemic therapy. Current chemotherapy regimens 
provide only minimal survival benefit, predominantly when used in combination with 
surgery or radiation. Recently clinical trial (ToGA) in Asian and European countries showed 
that anti-HER2 monoclonal antibody trastuzumab treatment significantly improved the 
survival of patients with gastric adenocarcinoma and HER2 overexpression and 
amplification. The clinical trial of trastuzumab to treat esophageal adenocarcinoma patients 
are approved in United States and European countries. Here is a comprehensive review of 
HER2 overexpression and amplification in esophageal adenocarcinoma.  
IHC studies on HER2 overexpression: In esophageal adenocarcinoma, HER2 
overexpression and amplification recently has been reported at frequencies similar to those 
observed in breast cancer. Based on most reports from English literature, the frequency of 
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amplification were associated with poor mean survival rates (922 vs 3243 days) and 5-year 
survival rates (21.4% vs 63.0%; P < 0.05). Age, TNM stage, and amplification of HER-2/neu 
were found to be independently related to survival by multivariate analysis. In another 
Korea study with 1,414 cases and 595 tissue microarray cases, HER2-positivity was detected 
in 12.3% of whole-tissue sections and 17% of TMAs [53]. They found that HER2-positivity 
was correlated with age, histological type, lymphovascular invasion, and lymph node 
metastasis. Multivariate analyses of the differentiated gastric carcinoma subgroup revealed 
that HER2-positivity was an independent poor prognostic.  
Zhang et al (2009) studied the HER2 and HER3 overexpression in Chinese gastric cancer 
with 102 cases.  Overexpression of HER2 and HER3 was detected around 18.6% and 13.7%. 
HER2 and HER3 overexpression was correlated with a significantly worse survival (p = 
0.046 and 0.024, respectively). The overexpression rates of HER2 and HER3 in phase III-IV 
(TNM stage) disease were significantly higher than that in phase I-II disease (24.0% vs. 7.7%, 
p < 0.05 and 22.0% vs. 5.8%, p < 0.05, respectively). They proposed that HER3 may become 
another molecular target.  
In European and United States, Tanner  et al [54] (2005) found that HER2 amplification was 
present in 12.2% of the 131 gastric cancer and 24% of the 100 GEJ adenocarcinomas in 
Finland which was associated with poor carcinoma-specific survival.  In contrast, Kunz 
[55](2012) reported that twelve of 99 (12%) gastric carcinomas were positive for HER2 and 
seven of 70 (10%) gastroesophageal junction carcinomas were positive for HER2. HER2 
status or primary tumor site did not correlate with patient survival. 
Recently, Jorgensen and Hersom [56]  (2012) reviewed previous studies with more than 100 
patients and analysis of association between the HER2 status and survival or relevant 
clinicopathological characteristics. Forty-two publications with a total of 12,749 patients 
fulfilled the two criteria and were reviewed in detail. The majority of the publications (71%) 
showed that a HER2-postive status measured either by IHC or ISH was associated with 
poor survival and/or clinicopathological characteristics, such as serosal invasion, lymph 
node metastases, disease stage, or distant metastases. Based on the current analysis a clear 
trend towards a potential role for HER2 as a negative prognostics factor in gastric cancer 
was shown, suggesting that HER2 overexpression and/or amplification is a molecular 
abnormality that might be linked to the development of gastric cancer  
Trastuzumab or other HER2 related medication on treatment of HER2 amplification 
gastric adenocarcinoma: Trastuzumab, a monoclonal antibody that targets HER2, induces 
antibody-dependent cellular cytotoxicity, inhibits HER2-mediated signaling, and prevents 
cleavage of the extracellular domain of HER2[12]. Trastuzumab were found to inhibit tumor 
growth in gastric carcinoma cell lines, animal model and xenograft models[23, 33, 57, 58]. 
Fujimoto-Ouchi (2007) used trastuzumab as a single agent inhibited the tumor growth in 
both of the HER2-overexpressing models but not in the HER2-negative models, GXF97 and 
MKN-45. In any combination with capecitabine, cisplatin, irinotecan, docetaxel, or 
paclitaxel, trastuzumab showed more potent antitumor activity than the anticancer agents 
alone. A three-drug combination of capecitabine, cisplatin, and trastuzumab showed 
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remarkable tumor growth inhibition. Since breast cancer showed better prognosis with 
trastuzumab treatment for HER2 positive breast cancer patients, clinical trial was also 
performed in gastric carcinoma. ToGA (Trastuzumab for Gastric Cancer) was an open-label, 
international, phase 3, randomised controlled trial undertaken in 122 centers in 24 
countries[22]. Patients with gastric or gastro-esophageal junction cancer were eligible for 
inclusion if their tumors showed overexpression of HER2 protein by immunohistochemistry 
or gene amplification by fluorescence in-situ hybridization. Participants were randomly 
assigned in a 1:1 ratio to receive a chemotherapy regimen consisting of capecitabine plus 
cisplatin or fluorouracil plus cisplatin given every 3 weeks for six cycles or chemotherapy in 
combination with intravenous trastuzumab. 594 patients were randomly assigned to study 
treatment (trastuzumab plus chemotherapy, n=298; chemotherapy alone, n=296). Median 
follow-up was 18·6 months in the trastuzumab plus chemotherapy group and 17·1 months 
in the chemotherapy alone group. Median overall survival was 13·8 months in those 
assigned to trastuzumab plus chemotherapy compared with 11·1 months in those assigned 
to chemotherapy alone (hazard ratio 0·74). 
Although the survival improvement about 3 months, it is a great breakthrough for gastric 
carcinoma treatment since the survival of these cancer has not change for a decade. After 
ToGA clinical trial, trastuzumab combined with standard chemical therapy (such as 
capecitabine or 5-fluorouracil and cisplatin) now is approved by European Medicines 
Agency, United States and Japan etc. for the treatment of patients with HER2 
overexpression or amplification. In addition, laptinib showed a synergistic effect with 
trastuzumab in vitro and in vivo to inhibit HER2 amplified human gastric cancer cells and 
animal model [23]. Clinical phase II trial of lapatinib as first line therapy in patients with 
advanced or metastatic cancer showed well tolerated, which will be another potential drug 
to target HER2 receptors[59]. 
3. HER2 in esophageal adenocarcinoma 
EAC incidence has increased 6 folds in United States and Western countries in the last three 
decades and the prognosis is usually very poor with 5-year survival rates ranging from 14-
22%[60-63]. While surgical treatment of EAC can offer cure, many patients first present as a 
disseminated disease and require systemic therapy. Current chemotherapy regimens 
provide only minimal survival benefit, predominantly when used in combination with 
surgery or radiation. Recently clinical trial (ToGA) in Asian and European countries showed 
that anti-HER2 monoclonal antibody trastuzumab treatment significantly improved the 
survival of patients with gastric adenocarcinoma and HER2 overexpression and 
amplification. The clinical trial of trastuzumab to treat esophageal adenocarcinoma patients 
are approved in United States and European countries. Here is a comprehensive review of 
HER2 overexpression and amplification in esophageal adenocarcinoma.  
IHC studies on HER2 overexpression: In esophageal adenocarcinoma, HER2 
overexpression and amplification recently has been reported at frequencies similar to those 
observed in breast cancer. Based on most reports from English literature, the frequency of 
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HER-2 immunohistochemistry shows an average of 12%. The current problems for IHC test 
for HER2 overexpression is the standard score criteria of the intensity of IHC stain. Recently, 
Zhou and his colleagues (2011) set up a new score criteria which is modified from 
Hoffman’s gastric adenocarcinoma score system (Table 3). In our modified score criteria, 
IHC 2+ will be counted as positive HER2 overexpression since all IHC 2+ case had HER2 
amplification with CISH test. However, the recent Mayo Clinic study reported that only 15% 
of IHC2+ cases showed HER2 amplification with FISH tests with breast HER2 criteria. It is 
difficult to compare their criteria since there are no pictures in their reports.            
FISH and CISH studies on HER2 amplification: In esophageal adenocarcinoma, HER2 
amplification recently has been extensively studies. Reichelt et al. found that 15% (16/110) of 
tumors had HER2 gene amplification with FISH. Similarly, Brien et al. showed that 19% 
(12/63) of esophageal adenocarcinomas had HER2 gene amplification. In addition, with 3-
dimentional FISH method in thick slides (16 µm, n=124), Rauser et al. [64] found that HER2 
amplification was 10.5% in high-level amplification (≥ 6.0 signals) and 60% in low-level copy 
number change ( ≥ 2.5-4.0 signals). However, in thin slides (4 µm, n=123), HER2 
amplification was found in 9 % in high-level amplification (≥ 6.0 signals) and 6 % in low-
level copy number change ( ≥ 2.5-4.0 signals). However, there is a huge difference between 
traditional FISH in thin section (6%) and three-dimensional FISH in thick section (60%) to 
detect the low-level HER2 amplification. They considered that the tumor cell nuclei were 
truncated due to standardized thin tissue sectioning. Therefore, three dimension FISH need 
to be further evaluated to help better understand any prognostic significance. In our study, 
we found that HER2 amplification was 18% (21/116) detected by CISH and 16.4% (19/116) by 
high definition microarray in cases of esophageal adenocarcinoma. In addition we found no 
evidence of HER2 amplification in low grad dysplasia, Barrett’s esophagus, columnar cell 
metaplasia or normal esophageal squamous epithelium. Thus, the frequency of HER2 
amplification in esophageal adenocarcinoma appears to be consistent between studies with 
a range of 15-19% and this event appears not to occur prior to the development of high 
grade dysplasia.  Radu et al65 (2012) compared HER2 antibodies with FISH tests. They used 
CAP definition of HER2 amplification to evaluate the FISH results. They found that the very 
high HER2 amplification rate (30/103, 29%) with HER2/CEP17 ≥ 2.2 and (32/102, 31%) with 
HER2/CEP17 ≥ 2.0. From their slides, they used 5 µm instead of 3-4 µm routine section. 
Actually the similar phenomenon was reported in esophageal adenocarcinoma cases 64. 
Using 16 µm vs 4 µm sections for HER2 FISH tests, they found that 16 µm sections showed 
higher HER2 amplification than 4 µm. Higher HER2 amplification from Radu may be 
caused by thicker section. 
HER2 amplification or overexpression correlating with patient survival and 
clinicopathological factors: In esophageal adenocarcinoma, the relationship between HER2 
amplification and prognosis is limited and controversial [66, 67]. Brien et al. [66] found that 
patients with HER2 amplification (n=11) had shorter survival durations than did patients 
without amplification (n=43). In contrast, Reichelt et al.67 found no survival difference 
between the HER2 amplification (n=16) and no HER2 amplification groups (n=90)(p=0.953). 
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In addition,  Rauser et al.28 found that HER2 gene amplification was associated with 
increased disease-specific mortality on 3-dimensional fluorescence in situ hybridization 
(FISH) analysis in thick slides (16 µm), but not on FISH and immunohistochemical analyses 
in thin (4 µm) sections. Our results 68 indicate no association of HER2 amplification with 
patient survival in a large cohort studies (total 232 patients) by both CISH and high density 
DNA microarrays methods although HER2 amplification group shows better prognosis (23 
months vs 25 months). However, Yoon et al69 (2012) found that HER2 amplification 
significantly associated with improved overall survival (n=713) with 35% of HER2 positive 
patients alive at 5 years as compared with 26% of HER2 negative patients. It is interesting 
that they divided the HER2 positive EAC into two groups: EAC with and without adjacent 
BE. They found that HER2 positive EAC with BE significantly associated with disease 
specific survival and overall survival, but HER2 positive EAC without BE was not 
significantly associated with disease-specific-survival and overall survival. The prognosis of 
HER2 positive EAC patients still cannot be concluded. At present, we can say HER2 positive 
EAC patients do not show worse prognosis.  
The association between HER2 amplification and these clinicopathological factors were 
controversial. First, Brien [66] 2000 reported that HER2 amplification was not significantly 
associated with any clinicopathological features such as depth of tumor invasion, lymph 
node metastasis, differentiation and pathological stage. Reichelt et al [67]  (2007) found that 
HER2 amplification was not associated with pathological staging (TNM) and grade. In our 
study [68], 21 of 116 EAC patients had HER2 amplification. Nineteen were male, and 2 
female (M:F ratio, 10:1), with a mean age of 63 years (range, 51 to 74 years). The remaining 
patients (85 males and 10 females [M:F ratio, 9:1]; mean age, 65 years [34 to 85 years]) had no 
amplification. A Fisher’s exact test shows that there is no significant association between 
HER2 and gender (p=1.0), age (p =0.188,), the stage (p =0.325), and the number of metastatic 
lymph nodes (p =0.234). However, the frequency of HER2 amplification was found to be 
significantly higher (p=0.004) in moderately differentiated tumors (13/22) compared with 
poor or well differentiated tumors (1/6 and 7/61 respectively). Yoon [69](2012) study 
supported our finding that HER2 amplification cases were significantly associated with 
better differentiation, but HER2 amplification cases were not associated with age and 
gender. However, they also showed that HER2 amplification was associated with lower 
depth of tumor invasion (T stage), fewer malignant nodes, and absence of signet ring cells.  
In summary, the association of HER2 amplification with survival and clinicopathological 
features is not very clear. At least HER2 amplification was not associated with worse 
prognosis in most large cohort studies. In addition, the HER2 amplification may be 
associated better differentiation, but not associated with age and sex. The large, multi-
institute study is needed to confirm current studies.  
Trastuzumab or other HER2 related medication on treatment of HER2 amplification 
esophageal adenocarcinoma: Safran et al [70, 71] (2004, 2007) first reported clinical trial with 
trastuzumab, paclitaxel, cisplatin and radiation for locally advanced esophageal 
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HER-2 immunohistochemistry shows an average of 12%. The current problems for IHC test 
for HER2 overexpression is the standard score criteria of the intensity of IHC stain. Recently, 
Zhou and his colleagues (2011) set up a new score criteria which is modified from 
Hoffman’s gastric adenocarcinoma score system (Table 3). In our modified score criteria, 
IHC 2+ will be counted as positive HER2 overexpression since all IHC 2+ case had HER2 
amplification with CISH test. However, the recent Mayo Clinic study reported that only 15% 
of IHC2+ cases showed HER2 amplification with FISH tests with breast HER2 criteria. It is 
difficult to compare their criteria since there are no pictures in their reports.            
FISH and CISH studies on HER2 amplification: In esophageal adenocarcinoma, HER2 
amplification recently has been extensively studies. Reichelt et al. found that 15% (16/110) of 
tumors had HER2 gene amplification with FISH. Similarly, Brien et al. showed that 19% 
(12/63) of esophageal adenocarcinomas had HER2 gene amplification. In addition, with 3-
dimentional FISH method in thick slides (16 µm, n=124), Rauser et al. [64] found that HER2 
amplification was 10.5% in high-level amplification (≥ 6.0 signals) and 60% in low-level copy 
number change ( ≥ 2.5-4.0 signals). However, in thin slides (4 µm, n=123), HER2 
amplification was found in 9 % in high-level amplification (≥ 6.0 signals) and 6 % in low-
level copy number change ( ≥ 2.5-4.0 signals). However, there is a huge difference between 
traditional FISH in thin section (6%) and three-dimensional FISH in thick section (60%) to 
detect the low-level HER2 amplification. They considered that the tumor cell nuclei were 
truncated due to standardized thin tissue sectioning. Therefore, three dimension FISH need 
to be further evaluated to help better understand any prognostic significance. In our study, 
we found that HER2 amplification was 18% (21/116) detected by CISH and 16.4% (19/116) by 
high definition microarray in cases of esophageal adenocarcinoma. In addition we found no 
evidence of HER2 amplification in low grad dysplasia, Barrett’s esophagus, columnar cell 
metaplasia or normal esophageal squamous epithelium. Thus, the frequency of HER2 
amplification in esophageal adenocarcinoma appears to be consistent between studies with 
a range of 15-19% and this event appears not to occur prior to the development of high 
grade dysplasia.  Radu et al65 (2012) compared HER2 antibodies with FISH tests. They used 
CAP definition of HER2 amplification to evaluate the FISH results. They found that the very 
high HER2 amplification rate (30/103, 29%) with HER2/CEP17 ≥ 2.2 and (32/102, 31%) with 
HER2/CEP17 ≥ 2.0. From their slides, they used 5 µm instead of 3-4 µm routine section. 
Actually the similar phenomenon was reported in esophageal adenocarcinoma cases 64. 
Using 16 µm vs 4 µm sections for HER2 FISH tests, they found that 16 µm sections showed 
higher HER2 amplification than 4 µm. Higher HER2 amplification from Radu may be 
caused by thicker section. 
HER2 amplification or overexpression correlating with patient survival and 
clinicopathological factors: In esophageal adenocarcinoma, the relationship between HER2 
amplification and prognosis is limited and controversial [66, 67]. Brien et al. [66] found that 
patients with HER2 amplification (n=11) had shorter survival durations than did patients 
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In addition,  Rauser et al.28 found that HER2 gene amplification was associated with 
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significantly higher (p=0.004) in moderately differentiated tumors (13/22) compared with 
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In summary, the association of HER2 amplification with survival and clinicopathological 
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Trastuzumab or other HER2 related medication on treatment of HER2 amplification 
esophageal adenocarcinoma: Safran et al [70, 71] (2004, 2007) first reported clinical trial with 
trastuzumab, paclitaxel, cisplatin and radiation for locally advanced esophageal 
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adenocarcinoma patients with HER2 overexpression. They took patients with histologically 
documented EAC with T3, T4 or lymph nodal disease. They used IHC 2+ and 3+ with more 
than 10% cells as HER2 positive overexpression and set FISH ratio greater than 2 as HER2 
amplification. The median survival for all 19 patients is 24 months, which is similar to prior 
studies. Esophagitis, nausea, dehydration, and neutropenia were the most common toxicity. 
However, toxicity was modest with only 2 patients (10%) having grade 3-4 esophagitis. 
Therefore, trastuzumab does not increase toxicities when added to chemoradiation for 
patients with esophageal cancer.  
ToGA clinical trials in patients with gastric adenocarcinoma (trial vs control: 236 vs 243 
patients) and gastroesophageal junction adenocarcinoma (trial vs control: 58 vs 48 patients) 
have shown a significant survival benefit for patients treated with a combination of 
trastuzumab and standard chemotherapy.[22,72] Now Safran and colleagues started Phase 
III clinical trial to study Radiotherapy, Paclitaxel, and Carboplatin with versus without 
Trastuzumab in patients with HER2-overexpressing esophageal adenocarcinoma (RTOG-
1010, and NCI web site: http://www.cancer.gov/ncicancerbulletin/062811/page6). Their 
primary goal is to determine whether trastuzumab increases disease-free survival when 
combined with radiotherapy, paclitaxel, and carboplatin followed by surgery in patients 
with HER2-overexpressing esophageal adenocarcinoma. It is interesting to follow up their 
results. 
4. HER2 in breast cancers 
Among new breast cancer patients, 15% to 20% will develop tumors that harbor a genomic 
alteration involving the HER2 gene locus. This alteration results in amplification of an 
amplicon on chromosome 17 that contains the HER2 proto-oncogene[73, 74]. Gene 
amplification is the primary mechanism that drives HER2 receptor protein over-expression 
in this important subset of breast cancers. HER2 over-expression resulting from gene 
amplification dramatically increases the likelihood of receptor activation and signaling, 
contributing to a more aggressive tumor biology and is associated with worse clinical 
outcome including higher rates of early, predominantly visceral and central nervous system 
recurrence and mortality. [75, 76]  In addition to the prognostic impact, HER2 over-
expression in breast cancer is highly correlated with a younger age at presentation, higher 
tumor grade as well as a higher tumor burden compared with HER2 negative disease [77]. 
HER2 over-expression in breast cancer was recognized early on as being an ideal target for 
therapy, given the location of the receptor on the surface of tumor cells and its role in 
driving the clinical course of disease for the subset of patients with the HER2 alteration [78], 
[79]. The drug Trastuzumab was developed as a targeted biologic therapeutic against the 
HER2 receptor protein. Trastuzumab is a humanized monoclonal antibody that combines 
the mouse recognition sequence of a monoclonal antibody (clone 4D5) against an 
extracellular epitope of the receptors with a human IgG1[74]. Trastuzumab demonstrates a 
high affinity and specificity for the HER2 receptor and in preclinical studies was shown to 
be effective at inhibiting the growth of HER2 over-expressing breast cancer cells.[80] 
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In numerous clinical trials, targeting HER2 has been shown to be remarkably effective 
against HER2 positive breast cancer in both the metastatic and the adjuvant settings, 
particularly in combination with cytotoxic chemotherapy. Treatment with the drug 
Trastuzumab has been shown to improve response rates, time to progression, and even 
survival when used alone[18] or added to chemotherapy in metastatic setting .[78] The 
success of therapeutically targeting HER2 in the metastatic setting led to several 
international, prospective randomized trials that have demonstrated that adjuvant 
trastuzumab reduces the relative risk of recurrence by half and mortality by one third in 
early-stage breast cancer.[81-84] The data from these clinical trials highlights the importance 
of accurate HER2 testing for every newly diagnosed breast cancer patient in order to help 
select those patients who will be the most suitable candidates for HER2 targeted therapy. 
[85] 
Clinical assays to assess the HER2 status include IHC, which detects protein over-
expression, or FISH, which detects gene amplification. [85-87] Both assays have been 
clinically validated in the above mentioned prospective randomized clinical trials and have 
received FDA approval for predicting a clinical response and patient benefit from HER2-
targeted treatment. Published data from these clinical trials suggest that only those patients 
whose breast cancer demonstrates protein over-expression and/or gene amplification by the 
above assays are likely to benefit from therapy with Trastuzumab. [88] Since the results of 
HER2 assays stand alone in determining which breast cancer patients will be the most 
appropriate for HER2-targeted therapy, accurate, reliable and reproducible results are a 
high priority for ensuring optimal patient treatment. 
The ASCO/CAP task force, has published recommendations for HER2 testing, in which the 
panel has concluded that both tests were equally efficient in identifying patients who are 
candidates for HER2-targeted therapy, as long as the assays have been properly validated 
and all aspects of the testing is performed in a highly standardized fashion with a rigorous 
quality assurance program. [89] This task force also recognized the importance of 
standardizing pre-analytical variables including tissue handling and fixation to improve the 
quality of clinical samples for predictive factor analysis. [90] The IHC and FISH 
methodologies for evaluating the HER2 status in breast cancer are complementary in nature. 
[91] These tests examine different aspects of the biology that underlies HER2 driven breast 
tumors. FISH evaluates the status of the HER2 gene in the nucleus and is a surrogate for 
protein expression, while IHC directly evaluates over-expression of the receptor protein at 
the surface of the cell. In the majority of HER2-positive cancers, HER2 protein over-
expression is the result of gene amplification, thus HER2 gene/protein status should be 
highly correlated in most cases. Consequently, HER2 gene/protein discordant results in the 
majority of cases are related to technical issues. However, unusual HER2 genotypes such as 
polysomy for chromosome 17 and genomic heterogeneity can lead to discrepant non-
correlating cases that may be clinically important. [92, 93] For such cases, the assessment of 
both the gene and the protein may be necessary in order to sort out the most appropriate 
HER2 status for the purpose of determining therapy.  
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Despite the remarkable clinical efficacy of HER2 targeted therapy, not all patients respond 
and de novo as well as acquired resistance remains an important clinical issue.  Currently 
there are no clinically validated factors that can be used to predict resistance to HER2 
targeted therapy in breast cancer.  Preclinical data and more recent clinical studies have 
suggested a number of potential mechanisms of resistance including reduction of antibody 
affinity and binding due to steric hindrance from MUC4 over-expression, constitutively 
active downstream signaling involving p27 Kip1, PTEN, PI3K, mTOR, and Akt as well as 
cross-talk with other signaling pathways including EGFR and IGFR-1, that can by-pass 
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 moderate 13  22   
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Table 4. Association of HER2 amplified group and non-HER2 amplified group with multiple clinical 
factors (From Hu Y, Bandla S, Godfrey TE, et al. HER2 amplification, overexpression and score criteria 
in esophageal adenocarcinoma. Mod Pathol 2011;24:899-907) 
Author details 
Zhongren Zhou and David G. Hick 
University of Rochester Medical Center, USA 
HER2 Amplification or Overexpression in  
Upper GI Tract and Breast Cancer with Clinical Diagnosis and Treatment 85 
5. References 
[1] Emde A, Kostler WJ, Yarden Y. Therapeutic strategies and mechanisms of 
tumorigenesis of HER2-overexpressing breast cancer. Crit Rev Oncol Hematol 2010 
http://dx.doi.org/10.1016/j.critrevonc.2010.09.002. 
[2] Ross JS. Update on HER2 testing for breast and upper gastrointestinal tract cancers. 
Biomark Med 2011; 5(3):307-18. 
[3] Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 
2011; 18(1):53-9. 
[4] Fornaro L, Lucchesi M, Caparello C, et al. Anti-HER agents in gastric cancer: from bench 
o bedside. Nat Rev Gastroenterol Hepatol 2011; 8(7):369-83. 
[5] Hicks DG, Whitney-Miller C. HER2 testing in gastric and gastroesophageal junction 
cancers: a new therapeutic target and diagnostic challenge. Appl Immunohistochem Mol 
Morphol 2011; 19(6):506-8. 
[6] Tsang RY, Finn RS. Beyond trastuzumab: novel therapeutic strategies in HER2-positive 
metastatic breast cancer. Br J Cancer 2012; 106(1):6-13. 
[7] Rexer BN, Arteaga CL. Intrinsic and Acquired Resistance to HER2-Targeted Therapies n 
HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications. Crit Rev 
Oncog 2012; 17(1):1-16. 
[8] Petrelli F, Barni S. Role of HER2-neu as a prognostic factor for survival and relapse in 
pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis. 
Med Oncol 2012. 
[9] Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology 
Bethesda) 2010; 25(2):85-101. 
[10] Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor 
heterodimerization in development and cancer. EMBO J 2000; 19(13):3159-67. 
[11] Moasser MM. The oncogene HER2: its signaling and transforming functions and its role 
in human cancer pathogenesis. Oncogene 2007; 26(45):6469-87. 
[12] Moulder SL, Yakes FM, Muthuswamy SK, et al. Epidermal growth factor receptor 
(HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-
overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61(24):8887-95. 
[13] Liu E, Thor A, He M, et al. The HER2 (c-erbB-2) oncogene is frequently amplified in in 
situ carcinomas of the breast. Oncogene 1992; 7(5):1027-32. 
[14] Park K, Han S, Kim HJ, Kim J, Shin E. HER2 status in pure ductal carcinoma in situ and 
in the intraductal and invasive components of invasive ductal carcinoma determined by 
fluorescence in situ hybridization and immunohistochemistry. Histopathology 2006; 
48(6):702-7. 
[15] Carlsson J, Nordgren H, Sjostrom J, et al. HER2 expression in breast cancer primary 
tumours and corresponding metastases. Original data and literature review. Br J Cancer 
2004; 90(12):2344-8. 
[16] Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for 
therapy. Nature 1988; 332(6162):323-7. 
[17] Ben-Kasus T, Schechter B, Sela M, Yarden Y. Cancer therapeutic antibodies come of age: 
targeting minimal residual disease. Mol Oncol 2007; 1(1):42-54. 
 
Oncogene and Cancer – From Bench to Clinic 84 
Despite the remarkable clinical efficacy of HER2 targeted therapy, not all patients respond 
and de novo as well as acquired resistance remains an important clinical issue.  Currently 
there are no clinically validated factors that can be used to predict resistance to HER2 
targeted therapy in breast cancer.  Preclinical data and more recent clinical studies have 
suggested a number of potential mechanisms of resistance including reduction of antibody 
affinity and binding due to steric hindrance from MUC4 over-expression, constitutively 
active downstream signaling involving p27 Kip1, PTEN, PI3K, mTOR, and Akt as well as 
cross-talk with other signaling pathways including EGFR and IGFR-1, that can by-pass 







Age  63 (51-74)  65 (34-85)  0.188 
       
Gender  MALE FEMALE MALE FEMALE 1.0 
  19 2 85 10  
       
  POS NEG POS NEG  
Lymph node 
METASTASIS 
 13 8 69 26 0.234 
       
pStaging      0.325 
 I 3  10   
 II 8  25   
 III 10  60   
       
Median survival
(months) 
 25 (7-71)  23 (0.03-108)  0.19 
Differentiation      0.004 
 poor 7  61   
 moderate 13  22   
 well 1  6   
Table 4. Association of HER2 amplified group and non-HER2 amplified group with multiple clinical 
factors (From Hu Y, Bandla S, Godfrey TE, et al. HER2 amplification, overexpression and score criteria 
in esophageal adenocarcinoma. Mod Pathol 2011;24:899-907) 
Author details 
Zhongren Zhou and David G. Hick 
University of Rochester Medical Center, USA 
HER2 Amplification or Overexpression in  
Upper GI Tract and Breast Cancer with Clinical Diagnosis and Treatment 85 
5. References 
[1] Emde A, Kostler WJ, Yarden Y. Therapeutic strategies and mechanisms of 
tumorigenesis of HER2-overexpressing breast cancer. Crit Rev Oncol Hematol 2010 
http://dx.doi.org/10.1016/j.critrevonc.2010.09.002. 
[2] Ross JS. Update on HER2 testing for breast and upper gastrointestinal tract cancers. 
Biomark Med 2011; 5(3):307-18. 
[3] Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 
2011; 18(1):53-9. 
[4] Fornaro L, Lucchesi M, Caparello C, et al. Anti-HER agents in gastric cancer: from bench 
o bedside. Nat Rev Gastroenterol Hepatol 2011; 8(7):369-83. 
[5] Hicks DG, Whitney-Miller C. HER2 testing in gastric and gastroesophageal junction 
cancers: a new therapeutic target and diagnostic challenge. Appl Immunohistochem Mol 
Morphol 2011; 19(6):506-8. 
[6] Tsang RY, Finn RS. Beyond trastuzumab: novel therapeutic strategies in HER2-positive 
metastatic breast cancer. Br J Cancer 2012; 106(1):6-13. 
[7] Rexer BN, Arteaga CL. Intrinsic and Acquired Resistance to HER2-Targeted Therapies n 
HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications. Crit Rev 
Oncog 2012; 17(1):1-16. 
[8] Petrelli F, Barni S. Role of HER2-neu as a prognostic factor for survival and relapse in 
pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis. 
Med Oncol 2012. 
[9] Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology 
Bethesda) 2010; 25(2):85-101. 
[10] Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor 
heterodimerization in development and cancer. EMBO J 2000; 19(13):3159-67. 
[11] Moasser MM. The oncogene HER2: its signaling and transforming functions and its role 
in human cancer pathogenesis. Oncogene 2007; 26(45):6469-87. 
[12] Moulder SL, Yakes FM, Muthuswamy SK, et al. Epidermal growth factor receptor 
(HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-
overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61(24):8887-95. 
[13] Liu E, Thor A, He M, et al. The HER2 (c-erbB-2) oncogene is frequently amplified in in 
situ carcinomas of the breast. Oncogene 1992; 7(5):1027-32. 
[14] Park K, Han S, Kim HJ, Kim J, Shin E. HER2 status in pure ductal carcinoma in situ and 
in the intraductal and invasive components of invasive ductal carcinoma determined by 
fluorescence in situ hybridization and immunohistochemistry. Histopathology 2006; 
48(6):702-7. 
[15] Carlsson J, Nordgren H, Sjostrom J, et al. HER2 expression in breast cancer primary 
tumours and corresponding metastases. Original data and literature review. Br J Cancer 
2004; 90(12):2344-8. 
[16] Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for 
therapy. Nature 1988; 332(6162):323-7. 
[17] Ben-Kasus T, Schechter B, Sela M, Yarden Y. Cancer therapeutic antibodies come of age: 
targeting minimal residual disease. Mol Oncol 2007; 1(1):42-54. 
 
Oncogene and Cancer – From Bench to Clinic 86 
[18] Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety 
of humanized anti-HER2 monoclonal antibody in women who have HER2-
overexpressing metastatic breast cancer that has progressed after chemotherapy for 
metastatic disease. J Clin Oncol 1999; 17(9):2639-48. 
[19] Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single 
agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin 
Oncol 2002; 20(3):719-26. 
[20] Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer 
trials. Semin Oncol 2001; 28(1 Suppl 3):13-9. 
[21] Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-
positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 
28(12):2024-31. 
[22] Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with 
chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced 
gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, 
randomised controlled trial. Lancet 2010; 376(9742):687-97. 
[23] Wainberg ZA, Anghel A, Desai AJ, et al. Lapatinib, a dual EGFR and HER2 kinase 
inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is 
synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010; 16(5):1509-19. 
[24] Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive 
advanced breast cancer. N Engl J Med 2006; 355(26):2733-43. 
[25] Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive 
early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. 
Lancet 2012; 379(9816):633-40. 
[26] Gravalos C, Gomez-Martin C, Rivera F, et al. Phase II study of trastuzumab and 
cisplatin as first-line therapy in patients with HER2-positive advanced gastric or 
gastroesophageal junction cancer. Clin Transl Oncol 2011; 13(3):179-84. 
[27] Spector NL, Xia W, Burris H, 3rd, et al. Study of the biologic effects of lapatinib, a 
reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival 
pathways in patients with advanced malignancies. J Clin Oncol 2005; 23(11):2502-12. 
[28] Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-
resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer 
Ther 2007; 6(2):667-74. 
[29] Nahta R, Shabaya S, Ozbay T, Rowe DL. Personalizing HER2-targeted therapy in 
metastatic breast cancer beyond HER2 status: what we have learned from clinical 
specimens. Curr Pharmacogenomics Person Med 2009; 7(4):263-74. 
[30] Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by 
heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual 
EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004; 23(3):646-53. 
[31] Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and 
prevalence across five continents: defining priorities to reduce cancer disparities in 
different geographic regions of the world. J Clin Oncol 2006; 24(14):2137-50. 
[32] Patel SH, Kooby DA. Gastric adenocarcinoma surgery and adjuvant therapy. Surg Clin 
North Am 2011; 91(5):1039-77. 
HER2 Amplification or Overexpression in  
Upper GI Tract and Breast Cancer with Clinical Diagnosis and Treatment 87 
[33] Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: 
association with Topoisomerase IIalpha gene amplification, intestinal type, poor 
prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16(2):273-8. 
[34] Matsui Y, Inomata M, Tojigamori M, et al. Suppression of tumor growth in human 
gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. 
Int J Oncol 2005; 27(3):681-5. 
[35] Tanaka S, Mori M, Akiyoshi T, et al. Coexpression of Grb7 with epidermal growth factor 
receptor or Her2/erbB2 in human advanced esophageal carcinoma. Cancer Res 1997; 
57(1):28-31. 
[36] Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric 
cancer: results from a validation study. Histopathology 2008; 52(7):797-805. 
[37] Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline 
validation and development of standardized immunohistochemical testing. Virchows 
Arch 2010; 457(3):299-307. 
[38] Ruschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical 
approach. Mod Pathol 2012 25(5):637-50. 
[39] Cho EY, Srivastava A, Park K, et al. Comparison of four immunohistochemical tests and 
FISH for measuring Her2 expression in gastric carcinomas. Pathology 2012; 44(3):216-20. 
[40] Barros-Silva JD, Leitao D, Afonso L, et al. Association of ERBB2 gene status with 
histopathological parameters and disease-specific survival in gastric carcinoma 
patients. Br J Cancer 2009; 100(3):487-93. 
[41] Park YS, Hwang HS, Park HJ, et al. Comprehensive analysis of HER2 expression and 
gene amplification in gastric cancers using immunohistochemistry and in situ 
hybridization: which scoring system should we use? Hum Pathol 2012; 43(3):413-22. 
[42] Tapia C, Glatz K, Novotny H, et al. Close association between HER-2 amplification and 
overexpression in human tumors of non-breast origin. Mod Pathol 2007; 20(2):192-8. 
[43] Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-
erb-B-2 gene to epidermal growth factor receptor. Nature 1986; 319(6050):230-4. 
[44] Kimura M, Tsuda H, Morita D, et al. Usefulness and limitation of multiple endoscopic 
biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients 
with gastric adenocarcinoma. Jpn J Clin Oncol 2005; 35(6):324-31. 
[45] Ruschoff J, Nagelmeier I, Baretton G, et al. [Her2 testing in gastric cancer. What is 
different in comparison to breast cancer?]. Pathologe 2010; 31(3):208-17. 
[46] Garcia-Garcia E, Gomez-Martin C, Angulo B, et al. Hybridization for human epidermal 
growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-
situ hybridization with a novel fully automated dual-colour silver in-situ hybridization 
method. Histopathology 2011; 59(1):8-17. 
[47] Long XY, Bu H, Wei B, et al. [Dual-color silver-enhanced in-situ hybridization and 
fluorescence in-situ hybridization for determination of HER2 gene status in gastric 
carcinoma]. Zhonghua Bing Li Xue Za Zhi 2011; 40(5):300-3. 
[48] Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and 
paired metastatic sites of gastric carcinoma. Br J Cancer 2011; 104(9):1372-6. 
 
Oncogene and Cancer – From Bench to Clinic 86 
[18] Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety 
of humanized anti-HER2 monoclonal antibody in women who have HER2-
overexpressing metastatic breast cancer that has progressed after chemotherapy for 
metastatic disease. J Clin Oncol 1999; 17(9):2639-48. 
[19] Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single 
agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin 
Oncol 2002; 20(3):719-26. 
[20] Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer 
trials. Semin Oncol 2001; 28(1 Suppl 3):13-9. 
[21] Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-
positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 
28(12):2024-31. 
[22] Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with 
chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced 
gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, 
randomised controlled trial. Lancet 2010; 376(9742):687-97. 
[23] Wainberg ZA, Anghel A, Desai AJ, et al. Lapatinib, a dual EGFR and HER2 kinase 
inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is 
synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010; 16(5):1509-19. 
[24] Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive 
advanced breast cancer. N Engl J Med 2006; 355(26):2733-43. 
[25] Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive 
early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. 
Lancet 2012; 379(9816):633-40. 
[26] Gravalos C, Gomez-Martin C, Rivera F, et al. Phase II study of trastuzumab and 
cisplatin as first-line therapy in patients with HER2-positive advanced gastric or 
gastroesophageal junction cancer. Clin Transl Oncol 2011; 13(3):179-84. 
[27] Spector NL, Xia W, Burris H, 3rd, et al. Study of the biologic effects of lapatinib, a 
reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival 
pathways in patients with advanced malignancies. J Clin Oncol 2005; 23(11):2502-12. 
[28] Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-
resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer 
Ther 2007; 6(2):667-74. 
[29] Nahta R, Shabaya S, Ozbay T, Rowe DL. Personalizing HER2-targeted therapy in 
metastatic breast cancer beyond HER2 status: what we have learned from clinical 
specimens. Curr Pharmacogenomics Person Med 2009; 7(4):263-74. 
[30] Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by 
heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual 
EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004; 23(3):646-53. 
[31] Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and 
prevalence across five continents: defining priorities to reduce cancer disparities in 
different geographic regions of the world. J Clin Oncol 2006; 24(14):2137-50. 
[32] Patel SH, Kooby DA. Gastric adenocarcinoma surgery and adjuvant therapy. Surg Clin 
North Am 2011; 91(5):1039-77. 
HER2 Amplification or Overexpression in  
Upper GI Tract and Breast Cancer with Clinical Diagnosis and Treatment 87 
[33] Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: 
association with Topoisomerase IIalpha gene amplification, intestinal type, poor 
prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16(2):273-8. 
[34] Matsui Y, Inomata M, Tojigamori M, et al. Suppression of tumor growth in human 
gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. 
Int J Oncol 2005; 27(3):681-5. 
[35] Tanaka S, Mori M, Akiyoshi T, et al. Coexpression of Grb7 with epidermal growth factor 
receptor or Her2/erbB2 in human advanced esophageal carcinoma. Cancer Res 1997; 
57(1):28-31. 
[36] Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric 
cancer: results from a validation study. Histopathology 2008; 52(7):797-805. 
[37] Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline 
validation and development of standardized immunohistochemical testing. Virchows 
Arch 2010; 457(3):299-307. 
[38] Ruschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical 
approach. Mod Pathol 2012 25(5):637-50. 
[39] Cho EY, Srivastava A, Park K, et al. Comparison of four immunohistochemical tests and 
FISH for measuring Her2 expression in gastric carcinomas. Pathology 2012; 44(3):216-20. 
[40] Barros-Silva JD, Leitao D, Afonso L, et al. Association of ERBB2 gene status with 
histopathological parameters and disease-specific survival in gastric carcinoma 
patients. Br J Cancer 2009; 100(3):487-93. 
[41] Park YS, Hwang HS, Park HJ, et al. Comprehensive analysis of HER2 expression and 
gene amplification in gastric cancers using immunohistochemistry and in situ 
hybridization: which scoring system should we use? Hum Pathol 2012; 43(3):413-22. 
[42] Tapia C, Glatz K, Novotny H, et al. Close association between HER-2 amplification and 
overexpression in human tumors of non-breast origin. Mod Pathol 2007; 20(2):192-8. 
[43] Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-
erb-B-2 gene to epidermal growth factor receptor. Nature 1986; 319(6050):230-4. 
[44] Kimura M, Tsuda H, Morita D, et al. Usefulness and limitation of multiple endoscopic 
biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients 
with gastric adenocarcinoma. Jpn J Clin Oncol 2005; 35(6):324-31. 
[45] Ruschoff J, Nagelmeier I, Baretton G, et al. [Her2 testing in gastric cancer. What is 
different in comparison to breast cancer?]. Pathologe 2010; 31(3):208-17. 
[46] Garcia-Garcia E, Gomez-Martin C, Angulo B, et al. Hybridization for human epidermal 
growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-
situ hybridization with a novel fully automated dual-colour silver in-situ hybridization 
method. Histopathology 2011; 59(1):8-17. 
[47] Long XY, Bu H, Wei B, et al. [Dual-color silver-enhanced in-situ hybridization and 
fluorescence in-situ hybridization for determination of HER2 gene status in gastric 
carcinoma]. Zhonghua Bing Li Xue Za Zhi 2011; 40(5):300-3. 
[48] Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and 
paired metastatic sites of gastric carcinoma. Br J Cancer 2011; 104(9):1372-6. 
 
Oncogene and Cancer – From Bench to Clinic 88 
[49] Yonemura Y, Ninomiya I, Ohoyama S, et al. Expression of c-erbB-2 oncoprotein in 
gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of 
poor short-term prognosis in patients with gastric carcinoma. Cancer 1991; 67(11):2914-8. 
[50] Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification 
and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 
85(9):1894-902. 
[51] Kim JP, Oh ST, Hwang TS, Chi JG. The prognostic significance of c-erbB-2 and p53 
protein expressions in gastric carcinoma--a multivariate analysis of prognostic factors. J 
Korean Med Sci 1994; 9(3):248-53. 
[52] Kim JW, Im SA, Kim M, et al. The Prognostic Significance of HER2 Positivity for 
Advanced Gastric Cancer Patients Undergoing First-line Modified FOLFOX-6 Regimen. 
Anticancer Res 2012; 32(4):1547-53. 
[53] Kim KC, Koh YW, Chang HM, et al. Evaluation of HER2 protein expression in gastric 
carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases 
of tissue microarrays. Ann Surg Oncol 2011; 18(10):2833-40. 
[54] Tanner SM, Li Z, Perko JD, et al. Hereditary juvenile cobalamin deficiency caused by 
mutations in the intrinsic factor gene. Proc Natl Acad Sci U S A 2005; 102(11):4130-3. 
[55] Kunz PL, Mojtahed A, Fisher GA, et al. HER2 expression in gastric and 
gastroesophageal junction adenocarcinoma in a US population: clinicopathologic 
analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol 
Morphol 2012; 20(1):13-24. 
[56] Jorgensen JT, Hersom M. HER2 as a Prognostic Marker in Gastric Cancer - A Systematic 
Analysis of Data from the Literature. J Cancer 2012; 3:137-44. 
[57] Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, et al. Antitumor activity of trastuzumab in 
combination with chemotherapy in human gastric cancer xenograft models. Cancer 
Chemother Pharmacol 2007; 59(6):795-805. 
[58] Yamashita-Kashima Y, Iijima S, Yorozu K, et al. Pertuzumab in combination with 
trastuzumab shows significantly enhanced antitumor activity in HER2-positive human 
gastric cancer xenograft models. Clin Cancer Res 2011; 17(15):5060-70. 
[59] Wainberg ZA, Lin LS, DiCarlo B, et al. Phase II trial of modified FOLFOX6 and erlotinib 
in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-
oesophageal junction. Br J Cancer 2011; 105(6):760-5. 
[60] Gamliel Z, Krasna MJ. Multimodality treatment of esophageal cancer. Surg Clin North 
Am 2005; 85(3):621-30. 
[61] Luketich JD, Alvelo-Rivera M, Buenaventura PO, et al. Minimally invasive 
esophagectomy: outcomes in 222 patients. Annals of surgery 2003; 238(4):486-94; 
discussion 94-5. 
[62] Swanson SJ, Batirel HF, Bueno R, et al. Transthoracic esophagectomy with radical 
mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy 
for esophageal carcinoma. Ann Thorac Surg 2001; 72(6):1918-24; discussion 24-5. 
[63] Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked 
increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97(2):142-6. 
HER2 Amplification or Overexpression in  
Upper GI Tract and Breast Cancer with Clinical Diagnosis and Treatment 89 
[64] Rauser S, Weis R, Braselmann H, et al. Significance of HER2 low-level copy gain in 
Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues. 
Clin Cancer Res 2007; 13(17):5115-23. 
[65] Radu OM, Foxwell T, Cieply K, et al. HER2 Amplification in Gastroesophageal 
Adenocarcinoma: Correlation of Two Antibodies Using Gastric Cancer Scoring Criteria, 
H Score, and Digital Image Analysis With Fluorescence In Situ Hybridization. Am J Clin 
Pathol 2012; 137(4):583-94. 
[66] Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS. HER-2/neu gene amplification 
by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. 
Human pathology 2000; 31(1):35-9. 
[67] Reichelt U, Duesedau P, Tsourlakis M, et al. Frequent homogeneous HER-2 
amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 
2007; 20(1):120-9. 
[68] Hu Y, Bandla S, Godfrey TE, et al. HER2 amplification, overexpression and score criteria 
in esophageal adenocarcinoma. Mod Pathol 2011; 24(7):899-907. 
[69] Yoon HH, Shi Q, Sukov WR, et al. Association of HER2/ErbB2 expression and gene 
amplification with pathologic features and prognosis in esophageal adenocarcinomas. 
Clin Cancer Res 2012; 18(2):546-54. 
[70] Safran H, Dipetrillo T, Akerman P, et al. Phase I/II study of trastuzumab, paclitaxel, 
cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal 
adenocarcinoma. Int J Radiat Oncol Biol Phys 2007; 67(2):405-9. 
[71] Safran H, DiPetrillo T, Nadeem A, et al. Trastuzumab, paclitaxel, cisplatin, and radiation 
for adenocarcinoma of the esophagus: a phase I study. Cancer Invest 2004; 22(5):670-7. 
[72] Jorgensen JT. Target HER2 treatment in advanced gastric cancer Oncology 2010; 78(1):26-33. 
[73] Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ 
hybridization: a technical review with interpretive guidelines. Hum Pathol 2005; 36(3):250-61. 
[74] Ross JS. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. 
Drug News Perspect 2009; 22(2):93-106. 
[75] Winstanley J, Cooke T, Murray GD, et al. The long term prognostic significance of c-
erbB-2 in primary breast cancer. Br J Cancer 1991; 63(3):447-50. 
[76] Hicks DG, Yoder BJ, Short S, et al. Loss of breast cancer metastasis suppressor 1 protein 
expression predicts reduced disease-free survival in subsets of breast cancer patients. 
Clin Cancer Res 2006; 12(22):6702-8. 
[77] Crowe JP, Patrick RJ, Rybicki LA, et al. A data model to predict HER2 status in breast 
cancer based on the clinical and pathologic profiles of a large patient population at a 
single institution. Breast 2006; 15(6):728-35. 
[78] Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal 
antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J 
Med 2001; 344(11):783-92. 
[79] Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and 
survival with amplification of the HER-2/neu oncogene. Science 1987; 235(4785):177-82. 
[80] Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61 Suppl 
2:1-13. 
 
Oncogene and Cancer – From Bench to Clinic 88 
[49] Yonemura Y, Ninomiya I, Ohoyama S, et al. Expression of c-erbB-2 oncoprotein in 
gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of 
poor short-term prognosis in patients with gastric carcinoma. Cancer 1991; 67(11):2914-8. 
[50] Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification 
and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 
85(9):1894-902. 
[51] Kim JP, Oh ST, Hwang TS, Chi JG. The prognostic significance of c-erbB-2 and p53 
protein expressions in gastric carcinoma--a multivariate analysis of prognostic factors. J 
Korean Med Sci 1994; 9(3):248-53. 
[52] Kim JW, Im SA, Kim M, et al. The Prognostic Significance of HER2 Positivity for 
Advanced Gastric Cancer Patients Undergoing First-line Modified FOLFOX-6 Regimen. 
Anticancer Res 2012; 32(4):1547-53. 
[53] Kim KC, Koh YW, Chang HM, et al. Evaluation of HER2 protein expression in gastric 
carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases 
of tissue microarrays. Ann Surg Oncol 2011; 18(10):2833-40. 
[54] Tanner SM, Li Z, Perko JD, et al. Hereditary juvenile cobalamin deficiency caused by 
mutations in the intrinsic factor gene. Proc Natl Acad Sci U S A 2005; 102(11):4130-3. 
[55] Kunz PL, Mojtahed A, Fisher GA, et al. HER2 expression in gastric and 
gastroesophageal junction adenocarcinoma in a US population: clinicopathologic 
analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol 
Morphol 2012; 20(1):13-24. 
[56] Jorgensen JT, Hersom M. HER2 as a Prognostic Marker in Gastric Cancer - A Systematic 
Analysis of Data from the Literature. J Cancer 2012; 3:137-44. 
[57] Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, et al. Antitumor activity of trastuzumab in 
combination with chemotherapy in human gastric cancer xenograft models. Cancer 
Chemother Pharmacol 2007; 59(6):795-805. 
[58] Yamashita-Kashima Y, Iijima S, Yorozu K, et al. Pertuzumab in combination with 
trastuzumab shows significantly enhanced antitumor activity in HER2-positive human 
gastric cancer xenograft models. Clin Cancer Res 2011; 17(15):5060-70. 
[59] Wainberg ZA, Lin LS, DiCarlo B, et al. Phase II trial of modified FOLFOX6 and erlotinib 
in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-
oesophageal junction. Br J Cancer 2011; 105(6):760-5. 
[60] Gamliel Z, Krasna MJ. Multimodality treatment of esophageal cancer. Surg Clin North 
Am 2005; 85(3):621-30. 
[61] Luketich JD, Alvelo-Rivera M, Buenaventura PO, et al. Minimally invasive 
esophagectomy: outcomes in 222 patients. Annals of surgery 2003; 238(4):486-94; 
discussion 94-5. 
[62] Swanson SJ, Batirel HF, Bueno R, et al. Transthoracic esophagectomy with radical 
mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy 
for esophageal carcinoma. Ann Thorac Surg 2001; 72(6):1918-24; discussion 24-5. 
[63] Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked 
increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97(2):142-6. 
HER2 Amplification or Overexpression in  
Upper GI Tract and Breast Cancer with Clinical Diagnosis and Treatment 89 
[64] Rauser S, Weis R, Braselmann H, et al. Significance of HER2 low-level copy gain in 
Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues. 
Clin Cancer Res 2007; 13(17):5115-23. 
[65] Radu OM, Foxwell T, Cieply K, et al. HER2 Amplification in Gastroesophageal 
Adenocarcinoma: Correlation of Two Antibodies Using Gastric Cancer Scoring Criteria, 
H Score, and Digital Image Analysis With Fluorescence In Situ Hybridization. Am J Clin 
Pathol 2012; 137(4):583-94. 
[66] Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS. HER-2/neu gene amplification 
by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. 
Human pathology 2000; 31(1):35-9. 
[67] Reichelt U, Duesedau P, Tsourlakis M, et al. Frequent homogeneous HER-2 
amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 
2007; 20(1):120-9. 
[68] Hu Y, Bandla S, Godfrey TE, et al. HER2 amplification, overexpression and score criteria 
in esophageal adenocarcinoma. Mod Pathol 2011; 24(7):899-907. 
[69] Yoon HH, Shi Q, Sukov WR, et al. Association of HER2/ErbB2 expression and gene 
amplification with pathologic features and prognosis in esophageal adenocarcinomas. 
Clin Cancer Res 2012; 18(2):546-54. 
[70] Safran H, Dipetrillo T, Akerman P, et al. Phase I/II study of trastuzumab, paclitaxel, 
cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal 
adenocarcinoma. Int J Radiat Oncol Biol Phys 2007; 67(2):405-9. 
[71] Safran H, DiPetrillo T, Nadeem A, et al. Trastuzumab, paclitaxel, cisplatin, and radiation 
for adenocarcinoma of the esophagus: a phase I study. Cancer Invest 2004; 22(5):670-7. 
[72] Jorgensen JT. Target HER2 treatment in advanced gastric cancer Oncology 2010; 78(1):26-33. 
[73] Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ 
hybridization: a technical review with interpretive guidelines. Hum Pathol 2005; 36(3):250-61. 
[74] Ross JS. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. 
Drug News Perspect 2009; 22(2):93-106. 
[75] Winstanley J, Cooke T, Murray GD, et al. The long term prognostic significance of c-
erbB-2 in primary breast cancer. Br J Cancer 1991; 63(3):447-50. 
[76] Hicks DG, Yoder BJ, Short S, et al. Loss of breast cancer metastasis suppressor 1 protein 
expression predicts reduced disease-free survival in subsets of breast cancer patients. 
Clin Cancer Res 2006; 12(22):6702-8. 
[77] Crowe JP, Patrick RJ, Rybicki LA, et al. A data model to predict HER2 status in breast 
cancer based on the clinical and pathologic profiles of a large patient population at a 
single institution. Breast 2006; 15(6):728-35. 
[78] Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal 
antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J 
Med 2001; 344(11):783-92. 
[79] Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and 
survival with amplification of the HER-2/neu oncogene. Science 1987; 235(4785):177-82. 
[80] Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61 Suppl 
2:1-13. 
 
Oncogene and Cancer – From Bench to Clinic 90 
[81] Slamon DJ, Romond EH, Perez EA. Advances in adjuvant therapy for breast cancer. 
Clin Adv Hematol Oncol 2006; 4(3 Suppl 7):suppl 1, 4-9; discussion suppl 10; quiz 2 p 
following suppl  
[82] Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine 
with or without trastuzumab for breast cancer. N Engl J Med 2006; 354(8):809-20. 
[83] Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for 
operable HER2-positive breast cancer. N Engl J Med 2005; 353(16):1673-84. 
[84] Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant 
chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353(16):1659-72. 
[85] Hicks DG, Kulkarni S. Trastuzumab as adjuvant therapy for early breast cancer: the 
importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol 
Lab Med 2008; 132(6):1008-15. 
[86] Tubbs RR, Hicks DG, Cook J, et al. Fluorescence in situ hybridization (FISH) as primary 
methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a 
single institution experience. Diagn Mol Pathol 2007; 16(4):207-10. 
[87] Powell WC, Hicks DG, Prescott N, et al. A new rabbit monoclonal antibody (4B5) for the 
immunohistochemical (IHC) determination of the HER2 status in breast cancer: 
comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory 
reproducibility. Appl Immunohistochem Mol Morphol 2007; 15(1):94-102. 
[88] Yoder BJ, Tso E, Skacel M, et al. The expression of fascin, an actin-bundling motility 
protein, correlates with hormone receptor-negative breast cancer and a more aggressive 
clinical course. Clin Cancer Res 2005; 11(1):186-92. 
[89] Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical 
Oncology/College of American Pathologists guideline recommendations for human 
epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 
131(1):18-43. 
[90] Hicks DG, Kushner L, McCarthy K. Breast cancer predictive factor testing: the 
challenges and importance of standardizing tissue handling. J Natl Cancer Inst Monogr 
2011; 2011(42):43-5. 
[91] Hicks DG, Kulkarni S. HER2+ breast cancer: review of biologic relevance and optimal 
use of diagnostic tools. Am J Clin Pathol 2008; 129(2):263-73. 
[92] Downs-Kelly E, Yoder BJ, Stoler M, et al. The influence of polysomy 17 on HER2 gene 
and protein expression in adenocarcinoma of the breast: a fluorescent in situ 
hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. 
Am J Surg Pathol 2005; 29(9):1221-7. 
[93] Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast 
cancer: panel summary and guidelines. Arch Pathol Lab Med 2009; 133(4):611-2. 
[94] Khoury T, Mojica W, Hicks D, et al. ERBB2 juxtamembrane domain (trastuzumab 
binding site) gene mutation is a rare event in invasive breast cancers overexpressing the 
ERBB2 gene. Mod Pathol 2011; 24(8):1055-9. 
[95] Gallardo A, Lerma E, Escuin D, et al. Increased signalling of EGFR and IGF1R, and 
deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in 










Oncogene and Cancer – From Bench to Clinic 90 
[81] Slamon DJ, Romond EH, Perez EA. Advances in adjuvant therapy for breast cancer. 
Clin Adv Hematol Oncol 2006; 4(3 Suppl 7):suppl 1, 4-9; discussion suppl 10; quiz 2 p 
following suppl  
[82] Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine 
with or without trastuzumab for breast cancer. N Engl J Med 2006; 354(8):809-20. 
[83] Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for 
operable HER2-positive breast cancer. N Engl J Med 2005; 353(16):1673-84. 
[84] Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant 
chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353(16):1659-72. 
[85] Hicks DG, Kulkarni S. Trastuzumab as adjuvant therapy for early breast cancer: the 
importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol 
Lab Med 2008; 132(6):1008-15. 
[86] Tubbs RR, Hicks DG, Cook J, et al. Fluorescence in situ hybridization (FISH) as primary 
methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a 
single institution experience. Diagn Mol Pathol 2007; 16(4):207-10. 
[87] Powell WC, Hicks DG, Prescott N, et al. A new rabbit monoclonal antibody (4B5) for the 
immunohistochemical (IHC) determination of the HER2 status in breast cancer: 
comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory 
reproducibility. Appl Immunohistochem Mol Morphol 2007; 15(1):94-102. 
[88] Yoder BJ, Tso E, Skacel M, et al. The expression of fascin, an actin-bundling motility 
protein, correlates with hormone receptor-negative breast cancer and a more aggressive 
clinical course. Clin Cancer Res 2005; 11(1):186-92. 
[89] Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical 
Oncology/College of American Pathologists guideline recommendations for human 
epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 
131(1):18-43. 
[90] Hicks DG, Kushner L, McCarthy K. Breast cancer predictive factor testing: the 
challenges and importance of standardizing tissue handling. J Natl Cancer Inst Monogr 
2011; 2011(42):43-5. 
[91] Hicks DG, Kulkarni S. HER2+ breast cancer: review of biologic relevance and optimal 
use of diagnostic tools. Am J Clin Pathol 2008; 129(2):263-73. 
[92] Downs-Kelly E, Yoder BJ, Stoler M, et al. The influence of polysomy 17 on HER2 gene 
and protein expression in adenocarcinoma of the breast: a fluorescent in situ 
hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. 
Am J Surg Pathol 2005; 29(9):1221-7. 
[93] Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast 
cancer: panel summary and guidelines. Arch Pathol Lab Med 2009; 133(4):611-2. 
[94] Khoury T, Mojica W, Hicks D, et al. ERBB2 juxtamembrane domain (trastuzumab 
binding site) gene mutation is a rare event in invasive breast cancers overexpressing the 
ERBB2 gene. Mod Pathol 2011; 24(8):1055-9. 
[95] Gallardo A, Lerma E, Escuin D, et al. Increased signalling of EGFR and IGF1R, and 
deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in 















© 2013 Cain and Beeser, licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Emerging Roles of Atypical Dual Specificity 
Phosphatases in Cancer 
Erica L. Cain and Alexander Beeser 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/54485 
1. Introduction 
The dual specificity phosphatases (DUSPs) are a subfamily within the protein tyrosine 
phosphatase (PTP) family, with the unique property of being able to hydrolyze phospho-
serine or phospho-threonine residues and phospho-tyrosine residues [1]. All DUSPs share 
the characteristic Class I PTP consensus sequence, D…HC(X)5RS/T, with C representing the 
essential catalytic cysteine [1]. Unlike other PTPs, DUSPs lack the phospho-tyrosine 
recognition domain, resulting in a shallower catalytic cleft, most likely enabling DUSPs to 
dephosphorylate all three residues (S/T/Y) [1]. In addition to protein substrates, the DUSP 
subfamily contains members that dephosphorylate additional substrates including lipids, 
nucleic acids, and sugars [2].  
DUSPs are regulators of multiple signaling pathways driving fundamental cell processes 
such as growth, proliferation, apoptosis, and migration, and as such they are often 
deregulated in a variety of diseases [2]. DUSPs can be further classified on substrate 
specificity and sequence homology, but all DUSPs share a highly conserved prototypical 
DUSP domain initially characterized in the Vaccinia virus’s VH1 gene [3]. The best-
characterized DUSPs include the MAP kinase phosphatases (MKP's), which directly 
antagonize the activating dual phosphorylation of mitogen activated protein kinases, and 
PTEN that functions to dephosphorylate phosphatidyl-inositol 3,4,5 triphosphate (PIP3), the 
product of PI3 kinase (PI3K) [2]. As these signaling pathways are intimately implicated in 
cancer initiation and progression, it is not surprising that their cognate phosphatases also 
functionally contribute to disease progression [2,4].  
In addition to DUSPs described above, the DUSP subfamily contains a distinct subgroup 
described as the atypical DUSPs [2,5]. In humans there are at least 16 DUSPs classified as 
atypical (Table 1) based on the lack of sequence similarity to better-characterized DUSPs 
and/or due to their substrate specificity [2,5]. Physiological substrates for several atypical  
 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 







© 2013 Cain and Beeser, licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Emerging Roles of Atypical Dual Specificity 
Phosphatases in Cancer 
Erica L. Cain and Alexander Beeser 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/54485 
1. Introduction 
The dual specificity phosphatases (DUSPs) are a subfamily within the protein tyrosine 
phosphatase (PTP) family, with the unique property of being able to hydrolyze phospho-
serine or phospho-threonine residues and phospho-tyrosine residues [1]. All DUSPs share 
the characteristic Class I PTP consensus sequence, D…HC(X)5RS/T, with C representing the 
essential catalytic cysteine [1]. Unlike other PTPs, DUSPs lack the phospho-tyrosine 
recognition domain, resulting in a shallower catalytic cleft, most likely enabling DUSPs to 
dephosphorylate all three residues (S/T/Y) [1]. In addition to protein substrates, the DUSP 
subfamily contains members that dephosphorylate additional substrates including lipids, 
nucleic acids, and sugars [2].  
DUSPs are regulators of multiple signaling pathways driving fundamental cell processes 
such as growth, proliferation, apoptosis, and migration, and as such they are often 
deregulated in a variety of diseases [2]. DUSPs can be further classified on substrate 
specificity and sequence homology, but all DUSPs share a highly conserved prototypical 
DUSP domain initially characterized in the Vaccinia virus’s VH1 gene [3]. The best-
characterized DUSPs include the MAP kinase phosphatases (MKP's), which directly 
antagonize the activating dual phosphorylation of mitogen activated protein kinases, and 
PTEN that functions to dephosphorylate phosphatidyl-inositol 3,4,5 triphosphate (PIP3), the 
product of PI3 kinase (PI3K) [2]. As these signaling pathways are intimately implicated in 
cancer initiation and progression, it is not surprising that their cognate phosphatases also 
functionally contribute to disease progression [2,4].  
In addition to DUSPs described above, the DUSP subfamily contains a distinct subgroup 
described as the atypical DUSPs [2,5]. In humans there are at least 16 DUSPs classified as 
atypical (Table 1) based on the lack of sequence similarity to better-characterized DUSPs 
and/or due to their substrate specificity [2,5]. Physiological substrates for several atypical  
 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
 
Oncogene and Cancer – From Bench to Clinic 94 
Table 1. The atypical DUSPs and their various aliases. 
DUSPs include proteins (MAPKs), nucleic aids (RNA), and phosphorylated carbohydrates 
(amylopectin and glycogen), but for many atypical DUSPs physiological substrates are 
unknown [2,5]. However, even for cases where phosphatase-substrate relationships are 
known, they are somewhat complicated by the fact that several DUSPs appear to function 
independently of their phosphatase activity and instead function as scaffolds in signal 
transduction pathways [6-8]. 
Several atypical DUSPs have been implicated in apoptosis and proliferation [2,5], but how 
the DUSPs contribute to these processes is largely also unknown. Emerging roles for 
atypical DUSPs in malignancy are beginning to be inferred from high throughput 
sequencing/ genomic approaches, which have demonstrated that, like MKP's and lipid 
phosphatases, the atypical DUSP genes are differentially expressed in a variety of cancers 
and may contribute to cancer initiation and/or progression [2,4,5]. The following sections 
present a current synthesis of what is known about how the atypical DUSPs function, and 
will focus specifically on how these proteins may contribute to cancer initiation and 
progression. Current gaps in knowledge on the function of these proteins in both normal 
and cancer cell biology is highlighted to hopefully inspire new research on these poorly 
understood proteins.  
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2. Atypical DUSPs currently implicated in cancer 
2.1. Laforin 
Due to alternative splicing of mRNA encoded by the epm2a gene, at least two isoforms of 
Laforin have been described that differ in their subcellular localization and phosphatase 
activity [9]. The major isoform encodes for a 331 amino acid protein containing a 
catalytically active DUSP domain and a N-terminal carbohydrate-binding module (CBM). 
Loss of function mutations of the major isoform are causative for Lafora’s disease, a fatal 
form of progressive myoclonus epilepsy that is thought to occur as a result of deregulated 
glycogen metabolism [10-13] with the accumulation of insoluble complex carbohydrates 
[14]. Laforin regulates glycogen metabolism, in part, by its ability to directly 
dephosphorylate phosphorylated carbohydrates including glycogen [14]. Loss of epm2a or 
mutations in epm2a that prevent glycogen binding or alter its phosphatase activity, 
contribute to Lafora’s disease [14,15]. Laforin also regulates glycogen metabolism in a 
phosphatase independent manner by functioning as an adapter protein to promote the 
ubiquitination of proteins involved in glycogen metabolism by recruiting Malin, an E3 
ubiquitin ligase [16]. Proteins regulating glycogen metabolism are often complexed with 
glycogen, as Laforin can bind glycogen and independently recruit Malin this provides an 
additional regulatory mechanism [16]. As a result, mutations in epm2a that disrupt the 
ability to bind Malin also contribute to Lafora’s disease [16]. Over the last several years, 
studies have revealed additional potential role(s) for Laforin in cancer development and/or 
progression where it most likely functions as a tumor suppressor, but may also contribute to 
cancer by promoting cell survival [17,18]. Here, we focus on potential roles of the major 
isoform in cancer, as it is the most studied. 
A role for Laforin as a tumor suppressor was demonstrated by the observation that 
immunocompromised mice lacking Laforin produce spontaneous lymphomas [19]. 
Additionally, Laforin mRNA and protein levels were reduced in murine and human 
primary lymphomas [19]. In addition to the roles of Laforin in glycogen metabolism and 
Lafora’s disease, Laforin regulates glycogen synthase kinase 3 (GSK3β) activity, a key 
signaling protein in the β-catenin/WNT signaling pathway [20] by removal of the inhibitory 
phosphate at Ser9 [21]. Cells lacking Laforin display decreased GSK3β activity resulting in 
increased cyclin D1 stability, and increased WNT signaling [21,22]. As both cyclin D1 
expression and WNT signaling have been implicated in a variety of cancers [20], the ability 
of Laforin to regulate GSK3β to inhibit cyclin D1 and WNT signaling is a possible 
mechanism by which Laforin may function as a tumor suppressor. In addition to a GSK3β-
dependent role in promoting cell cycle progression [21,22], Laforin additionally possesses 
pro-survival attributes and may be a potential therapeutic target in lymphomas where low 
Laforin expression promotes apoptosis induced by energy deprivation, while lymphomas 
with high Laforin expression are resistant [18]. Laforin's ability to promote cell survival 
could be related to glycogen metabolism, or alternatively due to its indirect regulation of the 
WNT signaling pathway via activation of GSK3β [18,19].  
Laforin additionally has a role in stress induced proteostasis [23-26].  Knock down of Laforin 
in human embryonic kidney (HEK293) cells and the neuroblastoma cell line, SH-SY5Y, 
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resulted in increased apoptosis induced by endoplasmic reticulum (ER) stress [24]. Laforin 
also promotes autophagy by inhibiting the mammalian target of rapamycin (mTOR) 
pathway by a currently unknown mechanism to further protect cells from ER stress [25]. In 
addition to targeting genes involved in glycogen metabolism, recruitment of Malin further 
promotes ubiquitination of misfolded and aggregated proteins, thereby facilitating their 
proteosomal degradation [27]. Laforin also interacts with heat shock factor 1 (HSF1), an 
essential transcription factor in the heat shock response [26] and is necessary for up-
regulation of HSF1-dependent gene expression and for protection from thermal stress in 
COS7 cells [26]. Accordingly, increased Laforin expression may allow cancer cells to survive 
in conditions where proteostasis has been perturbed.  
2.2. DUSP3/VHR 
Despite the ability of DUSP3 (alternatively named VHR for VH-1 related) to 
dephosphorylate the ERK1/2 and JNK MAPKs, it is generally not considered a MKP as it 
lacks the MAPK binding domain characteristic of MKPs [2,28,29].  Nevertheless, as a 
functional MAPK phosphatase, it is not surprising that DUSP3 is implicated in cancer, 
where it has been alternatively described as having both oncogenic [30-32] and tumor 
suppressive [33,34] properties.  
dusp3 is up-regulated in cervical cancer cell lines and primary cervical cancers [30], and in 
HeLa cells, knock-down of dusp3 inhibited proliferation by increasing the phosphorylation 
levels of ERK1/2 and JNK [31,35]. dusp3 is also over-expressed in primary prostate tumors 
where it may function as a pro-survival phosphatase [32]. In prostate cancer cells (LNCaP), 
DUSP3 functions as an inhibitor of apoptosis, where dusp3 knock-down resulted in 
increased JNK phosphorylation and increased apoptosis when treated with thapsigargin, an 
inducer of ER stress, or 12-0-tetradecanoylophorbol-13-acetate (TPA) [31]. 
DUSP3 may also inhibit tumor growth by regulating proliferation, particularly in the 
context of breast cancer cells expressing the oncogene, brca1-iris. brca1-iris is a splice variant 
of the breast cancer type 1 susceptibility (brca1) locus that promotes cell proliferation, cell 
migration, and invasion [34,36]. Over-expression of brca1-iris in breast cancer cell lines 
MCF7 and SKBR3 promoted proliferation through up-regulation of cyclin D1, and over-
expression of dusp3 was sufficient to suppress cyclin D1 expression [34]. dusp3 expression is 
also down-regulated in primary  non-small cell lung cancer (NSCLC) tumors [34]. A tumor 
suppressive function for DUSP3 in NSCLC is supported experimentally, as in both the 
NSCLC H1299 cell line and mouse xenographs, over-expression of dusp3 suppressed growth 
of cells and tumors respectively [32]. Further supporting a tumor suppressor function for 
DUSP3, its expression suppressed phospholipase C (PLC) - protein kinase C (PKC) signaling 
[36]. The ErbB tyrosine kinase receptor, known to act upstream of PLC-gamma was 
subsequently identified as a direct DUSP3 substrate [37]. Increased ErbB tyrosine kinase 
activity drives several cancer-relevant properties including proliferation, cell motility, and 
invasion [36]. dusp3 over-expression removed the activating phosphate from Y992 of ErbB, 
preventing ErbB kinase activity [33]. As the ErbB family of proto-oncogenes is strongly 
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associated with cancers in a kinase dependent manner [37], the ability of DUSP3 to inhibit 
its activity may have important implications for cancer therapies. 
If DUSP3 functions as a tumor suppressor or oncogene, modulators of DUSP3 function(s) 
could be attractive anti-cancer drug targets. The ZAP70 cytoplasmic tyrosine kinase, a key 
component in signaling machinery downstream of the T-cell antigen receptor, directly 
phosphorylates DUSP3  on  tyrosine 138 (Y138) and increases it's ability to temper Erk1/2 
and JNK signaling and reduce expression of a NFAT-AP1 dependent luciferase reporter, as 
VHRY138F functions as a dominant negative [38].  This observation is consistent with Y138 
increasing the catalytic activity VHR, but this hypothesis is technically difficult to confirm 
due to VHR's ability to auto-dephosphorylate [38].  ZAP70 has been implicated in cancer as 
it is a prognostic marker for chronic lymphocytic leukemia (CLL) and B-cell acute 
lymphoblastic leukemia (B-ALL) where increased ZAP70 expression correlates with poor 
clinical outcome [39,40]. Besides being a prognostic marker, ZAP70 contributes to cancer by 
promoting survival and migration in both CLL and B-ALL [41,42] but whether ZAP70's 
modulation of DUSP3 has importance in B-ALL and CLL remains unknown. ZAP70 is not 
the only tyrosine kinase to target DUSP3 at tyrosine 138. TYK2, the non receptor tyrosine 
kinase of the Janus kinase family that regulates the expression of type 1 interferons and 
interleukin 12 [43] also targets this site [44]. Phosphorylation of DUSP3 by TYK2 was 
required for DUSP3 to dephosphorylate and inhibit signal transducer and activator of 
transcription 5 (STAT5) [44]. The ability of DUSP3 to inhibit STAT5 transcriptional activity 
may have consequences in cancer cell biology, since STAT5 activity is known to promote 
cancer by transcriptionally regulating genes involved in proliferation and survival [45], 
therefore loss of DUSP3 activity could possibly result in increased STAT5 activity thereby 
promoting cancer development. Furthermore, TYK2 has a suggested role in breast cancer 
metastasis, as analysis of 140 tissue samples from 70 breast cancer patients revealed that 
TYK2 protein levels are reduced in tumors that have metastasized to the regional lymph 
nodes [46]. Additionally, knock-down of tyk2 in the MCF10A breast epithelial cell line 
decreased cell migration and invasion [46]. Whether loss of TYK2 promotes metastasis, 
migration, and invasion due to reduced DUSP3 activity remains to be determined 
DUSP3’s activity is additionally activated by the pseudokinase, Vaccinia-related kinase 3 
(VRK3) [47], whose expression is down-regulated in colorectal cancer [48]. VRK3 inhibits 
ERK1/2 signaling by the formation of a VRK3-DUSP3-ERK1/2 complex where VRK3 is able 
to enhance the activity of DUSP3 towards ERK1/2 in a kinase independent manner [47]. It 
would be interesting to examine whether tumors with decreased vrk3 expression also have 
decreased DUSP3 activity. Since VRK3 promotes DUSP3’s activity towards ERK1/2, one 
would expect tumors with decreased VRK3 to have increased ERK1/2 signaling, and these 
investigations could further indicate a potential tumor suppressor for DUSP3. 
2.3. DUSP11 
Due to interactions with ribonucleoprotein (RNP) complexes and RNA splicing factors and 
its ability to dephosphorylate RNA trinucleotides, DUSP11 is thought to have a role in RNA 
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nodes [46]. Additionally, knock-down of tyk2 in the MCF10A breast epithelial cell line 
decreased cell migration and invasion [46]. Whether loss of TYK2 promotes metastasis, 
migration, and invasion due to reduced DUSP3 activity remains to be determined 
DUSP3’s activity is additionally activated by the pseudokinase, Vaccinia-related kinase 3 
(VRK3) [47], whose expression is down-regulated in colorectal cancer [48]. VRK3 inhibits 
ERK1/2 signaling by the formation of a VRK3-DUSP3-ERK1/2 complex where VRK3 is able 
to enhance the activity of DUSP3 towards ERK1/2 in a kinase independent manner [47]. It 
would be interesting to examine whether tumors with decreased vrk3 expression also have 
decreased DUSP3 activity. Since VRK3 promotes DUSP3’s activity towards ERK1/2, one 
would expect tumors with decreased VRK3 to have increased ERK1/2 signaling, and these 
investigations could further indicate a potential tumor suppressor for DUSP3. 
2.3. DUSP11 
Due to interactions with ribonucleoprotein (RNP) complexes and RNA splicing factors and 
its ability to dephosphorylate RNA trinucleotides, DUSP11 is thought to have a role in RNA 
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splicing [49]. DUSP11 also associates with SAM68 (SRC-associated protein in mitotic cells), 
an ERK1/2 phosphorylated splicing factor that promotes the alternative splicing of cluster of 
differentiation 44 (CD44) mRNA encoding a glycoprotein involved in cell-cell interactions, 
cell adhesion, and migration [50,51].   Alternatively spliced isoforms of CD44 include up to 
10 variant exon sequences (V1 to V10) that are though to contribute to human organismal 
complexity from a relatively restricted number of genes [50].   The v5 exon splice variant of 
CD44 is suggested to promote metastatic cancers [50,51] and this alternative splicing event is 
thought to be under the control of Ras singaling pathway through recruitement of SAM68.  
As forced overexpression of Sam68 leads to increased inclusion of the V5-exon sequence in 
CD44 and Dusp11 associated with SAM68, and variants of SAM68 that cannot be 
phosphrylated by ERK abrogate the inclusion of the V5-exon variant, it suggests that SAM68 
function is under control of Ras signaling pathways in response to extracellular cues, but 
whether DUSP11 can counteract the ERK1/2 dependent phosphorylation of SAM68 similar 
to Sam68 varaints lacking all candidate ERK1/2 phosphorylation sites remains to be 
determined experimentally. As alternative splicing affects the activities of many oncogenes 
and tumor suppressors, DUSP11’s role in splicing may extend beyond CD44, which could 
have important implications for cancer [52].  
dusp11 is also a transcriptional target of the p53 tumor suppressor [53]. p53 is a potent tumor 
suppressor that induces cell cycle arrest, senescence, and apoptosis in response to DNA 
damage and oncogene activation, and is one of the most commonly mutated genes in cancer 
[54]. The ability of p53 to up-regulate dusp11 may provide a link between p53 function and 
to the splicing machinery [53]. 
DUSP11 regulates proliferation as over-expression of dusp11 in U20S and mouse embryonic 
fibroblasts resulted in inhibition of proliferation in a manner dependent on DUSP11’s 
phosphatase activity [53]. Additionally, knock-down of dusp11 increased proliferation in 
both untreated and UV or Doxorubicin DNA damaged U20S cells where DUSP11 most 
likely inhibits proliferation in response to genotoxic stress in a p53 dependent manner [53]. 
Loss of growth arrest in response to DNA damage in cells lacking dusp11 could result in 
genomic instability, which can promote cancer development and/or progression [55]. 
2.4. DUSP12 
dusp12 is up-regulated or amplified in a variety of cancers including neuroblastoma, 
retinoblastoma, intracranial ependymoma, and chronic myelogenous leukemia [56-59]. 
Additionally, dusp12 is one of only two candidate genes for the target of a 1q21-1q23 
amplification found in invasive liposarcomas [60] leading to the hypothesis that dusp12 is an 
oncogene. Within the atypical DUSPs, DUSP12 is unique in that it contains an evolutionarily 
conserved cysteine-rich domain (CRD) at the C-terminus that binds zinc [61], but whose 
biological function remains obscure. 
DUSP12 was initially identified as a pro-survival phosphatase from a high throughput 
siRNA screen in HeLa cells [62] as knock-down of dusp12 induced spontaneous apoptosis 
[62]. Later, it was demonstrated that transient over-expression of dusp12 in HeLa rendered 
 
Emerging Roles of Atypical Dual Specificity Phosphatases in Cancer 99 
cells resistant to apoptotic stimuli including heat shock, oxidative stress, and FAS death 
receptor activation, but not against the DNA damage inducing agent, cisplatin [63]. In HeLa 
cells, the ability of DUSP12 to protect cells from apoptosis was dependent on phosphatase 
activity [63]. 
DUSP12 interacts with the heat shock protein 70 (HSP70) and the requirement of the 
enzymatic activity to protect cells from apoptosis activity raises the possibility that HSP70 
may be a direct  substrate for DUSP12.  However, if DUSP12 does regulate HSP70, it does 
not appear to regulate HSP70’s chaperone function as demonstrated by in vitro folding 
assays [63]. Conversely, HSP70 was able to promote DUSP12’s phosphatase activity against 
the phospho-tyrosine analog, 6,8-di-fluoro-4-methylumbeliferyl phosphate (DiFMUP), in a 
manner that is most likely not a chaperone:substrate interaction as DUSP12 binds the 
ATPase domain of HSP70 [63]. The C-terminal CRD was also required for DUSP12 to 
protect from apoptosis [63]. As oxidation of catalytic cysteines is a common mechanism to 
post-translationally regulate DUSP's [64], it was later demonstrated that the zinc binding 
ability of the C-terminus protected DUSP12’s phosphatase activity during oxidizing 
conditions in vitro [65].  
DUSP12 also has a role in cell cycle regulation. Transient over-expression of dusp12 in 
HEK293 cells resulted in an increase in the percentage of cells in the G2/M phase and 
polyploidy and knock-down resulted in cell cycle arrest and senescence [66]. Since, dusp12 is 
amplified in several cancers [56,57,60], it is possible that DUSP12 may promote cancer by 
increasing genomic instability. Unlike the pro-survival properties described above, 
DUSP12's effect on the cell cycle was independent of its phosphatase activity and required 
the CRD domain [66]. The CRD function is also likely regulated post-translationally: 
replacement of serine 335 with alanine (S335A) elicited cell cycle profiles similar to wild type 
DUSP12, whereas the phosphomimetic S335E variant led to a significant increase in the 
percentage of G2/M cells (29.8 % for S335A vs. 36.6 % for S335E) [66]. This alteration also 
affects subcellular localization from the cytoplasm (WT and S335E) to the nuclear 
compartment (S335A), but does not affect DUSP12’s phosphatase activity in vitro [66]. To the 
best of our knowledge this is the only study demonstrating phosphorylation dependent 
regulation of DUSP12  and the kinases and/or  phosphatases responsible remain unknown. 
Additionally, The S335 kinases may be restricted to mammals, as the S335 site is not well 
conserved in other organisms [66].  
To determine whether DUSP12 has oncogenic properties, we examined the oncogenic 
potential of DUSP12 in a cell culture model [67]. Unlike the cell cycle effects in HEK293 cells 
transiently over-expressing dusp12 described above, we observed no difference in 
proliferation in HEK293 cells stably over-expressing gfp-dusp12 (hereafter referred to as 
dusp12 over-expression) [67]. Despite the lack of effect on proliferation, we did find that 
dusp12 over-expression protected cells from apoptosis induced by both staurosporine and 
thapsigargin [67]. We additionally observed, that dusp12 over-expression increased cell 
motility in scratch wound and transmigration assays [67]. dusp12 over-expression also up-
regulated the expression of two validated oncogenes; integrin alpha 1 (itga1) and the 
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splicing [49]. DUSP11 also associates with SAM68 (SRC-associated protein in mitotic cells), 
an ERK1/2 phosphorylated splicing factor that promotes the alternative splicing of cluster of 
differentiation 44 (CD44) mRNA encoding a glycoprotein involved in cell-cell interactions, 
cell adhesion, and migration [50,51].   Alternatively spliced isoforms of CD44 include up to 
10 variant exon sequences (V1 to V10) that are though to contribute to human organismal 
complexity from a relatively restricted number of genes [50].   The v5 exon splice variant of 
CD44 is suggested to promote metastatic cancers [50,51] and this alternative splicing event is 
thought to be under the control of Ras singaling pathway through recruitement of SAM68.  
As forced overexpression of Sam68 leads to increased inclusion of the V5-exon sequence in 
CD44 and Dusp11 associated with SAM68, and variants of SAM68 that cannot be 
phosphrylated by ERK abrogate the inclusion of the V5-exon variant, it suggests that SAM68 
function is under control of Ras signaling pathways in response to extracellular cues, but 
whether DUSP11 can counteract the ERK1/2 dependent phosphorylation of SAM68 similar 
to Sam68 varaints lacking all candidate ERK1/2 phosphorylation sites remains to be 
determined experimentally. As alternative splicing affects the activities of many oncogenes 
and tumor suppressors, DUSP11’s role in splicing may extend beyond CD44, which could 
have important implications for cancer [52].  
dusp11 is also a transcriptional target of the p53 tumor suppressor [53]. p53 is a potent tumor 
suppressor that induces cell cycle arrest, senescence, and apoptosis in response to DNA 
damage and oncogene activation, and is one of the most commonly mutated genes in cancer 
[54]. The ability of p53 to up-regulate dusp11 may provide a link between p53 function and 
to the splicing machinery [53]. 
DUSP11 regulates proliferation as over-expression of dusp11 in U20S and mouse embryonic 
fibroblasts resulted in inhibition of proliferation in a manner dependent on DUSP11’s 
phosphatase activity [53]. Additionally, knock-down of dusp11 increased proliferation in 
both untreated and UV or Doxorubicin DNA damaged U20S cells where DUSP11 most 
likely inhibits proliferation in response to genotoxic stress in a p53 dependent manner [53]. 
Loss of growth arrest in response to DNA damage in cells lacking dusp11 could result in 
genomic instability, which can promote cancer development and/or progression [55]. 
2.4. DUSP12 
dusp12 is up-regulated or amplified in a variety of cancers including neuroblastoma, 
retinoblastoma, intracranial ependymoma, and chronic myelogenous leukemia [56-59]. 
Additionally, dusp12 is one of only two candidate genes for the target of a 1q21-1q23 
amplification found in invasive liposarcomas [60] leading to the hypothesis that dusp12 is an 
oncogene. Within the atypical DUSPs, DUSP12 is unique in that it contains an evolutionarily 
conserved cysteine-rich domain (CRD) at the C-terminus that binds zinc [61], but whose 
biological function remains obscure. 
DUSP12 was initially identified as a pro-survival phosphatase from a high throughput 
siRNA screen in HeLa cells [62] as knock-down of dusp12 induced spontaneous apoptosis 
[62]. Later, it was demonstrated that transient over-expression of dusp12 in HeLa rendered 
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cells resistant to apoptotic stimuli including heat shock, oxidative stress, and FAS death 
receptor activation, but not against the DNA damage inducing agent, cisplatin [63]. In HeLa 
cells, the ability of DUSP12 to protect cells from apoptosis was dependent on phosphatase 
activity [63]. 
DUSP12 interacts with the heat shock protein 70 (HSP70) and the requirement of the 
enzymatic activity to protect cells from apoptosis activity raises the possibility that HSP70 
may be a direct  substrate for DUSP12.  However, if DUSP12 does regulate HSP70, it does 
not appear to regulate HSP70’s chaperone function as demonstrated by in vitro folding 
assays [63]. Conversely, HSP70 was able to promote DUSP12’s phosphatase activity against 
the phospho-tyrosine analog, 6,8-di-fluoro-4-methylumbeliferyl phosphate (DiFMUP), in a 
manner that is most likely not a chaperone:substrate interaction as DUSP12 binds the 
ATPase domain of HSP70 [63]. The C-terminal CRD was also required for DUSP12 to 
protect from apoptosis [63]. As oxidation of catalytic cysteines is a common mechanism to 
post-translationally regulate DUSP's [64], it was later demonstrated that the zinc binding 
ability of the C-terminus protected DUSP12’s phosphatase activity during oxidizing 
conditions in vitro [65].  
DUSP12 also has a role in cell cycle regulation. Transient over-expression of dusp12 in 
HEK293 cells resulted in an increase in the percentage of cells in the G2/M phase and 
polyploidy and knock-down resulted in cell cycle arrest and senescence [66]. Since, dusp12 is 
amplified in several cancers [56,57,60], it is possible that DUSP12 may promote cancer by 
increasing genomic instability. Unlike the pro-survival properties described above, 
DUSP12's effect on the cell cycle was independent of its phosphatase activity and required 
the CRD domain [66]. The CRD function is also likely regulated post-translationally: 
replacement of serine 335 with alanine (S335A) elicited cell cycle profiles similar to wild type 
DUSP12, whereas the phosphomimetic S335E variant led to a significant increase in the 
percentage of G2/M cells (29.8 % for S335A vs. 36.6 % for S335E) [66]. This alteration also 
affects subcellular localization from the cytoplasm (WT and S335E) to the nuclear 
compartment (S335A), but does not affect DUSP12’s phosphatase activity in vitro [66]. To the 
best of our knowledge this is the only study demonstrating phosphorylation dependent 
regulation of DUSP12  and the kinases and/or  phosphatases responsible remain unknown. 
Additionally, The S335 kinases may be restricted to mammals, as the S335 site is not well 
conserved in other organisms [66].  
To determine whether DUSP12 has oncogenic properties, we examined the oncogenic 
potential of DUSP12 in a cell culture model [67]. Unlike the cell cycle effects in HEK293 cells 
transiently over-expressing dusp12 described above, we observed no difference in 
proliferation in HEK293 cells stably over-expressing gfp-dusp12 (hereafter referred to as 
dusp12 over-expression) [67]. Despite the lack of effect on proliferation, we did find that 
dusp12 over-expression protected cells from apoptosis induced by both staurosporine and 
thapsigargin [67]. We additionally observed, that dusp12 over-expression increased cell 
motility in scratch wound and transmigration assays [67]. dusp12 over-expression also up-
regulated the expression of two validated oncogenes; integrin alpha 1 (itga1) and the 
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hepatocyte growth factor receptor, c-met [67]. ITGA1, a component of the cellular receptor 
for collagen, promotes proliferation, invasion, and angiogenesis of cancer cells [68-70], but 
whether it is responsible for the DUSP12 dependent motility remains to be determined. The 
c-MET proto-oncogene is a well established regulator of growth, survival, and migratory 
signaling [71], but it seems unlikely that c-MET is responsible for the pro-survival and 
migratory function of DUSP12 overexpression, since we failed to observed increased c-MET 
activation in cells over-expressing dusp12 [67]. This was not wholly unexpected as c-MET 
frequently requires its ligand, HGF, to be supplied in an autocrine or paracrine manner in 
order to function [72]. The ability of elevated DUSP12 to promote c-MET and ITGA1 
expression has potential implications in cancer where, in the right tumor microenvironment, 
DUSP12-dependent up-regulation could co-opt the oncogenic potential of these validated 
oncogenes [73]. 
Although it is clear that DUSP12 regulates several important cancer-relevant processes, how 
DUSP12 accomplishes this is largely unknown. Insights into DUSP12’s cellular function(s) 
can be obtained by investigating the budding yeast DUSP12 ortholog, Yvh1p. YVH1 
transcription is up-regulated by nitrogen starvation and low temperatures and yvh1Δ yeast 
strains exhibit a severe growth phenotype, display defects in sporulation, glycogen 
accumulation, and ribosome biogenesis [74-78]. Expression of the Yvh1p CRD domain in 
isolation was able to suppress all the mutant phenotypes of yvh1Δ strains, suggesting that 
neither phosphatase activity nor the N-terminal phosphatase domain is required for its 
cellular function in yeast [76]. The DUSP12 CRD has been alternatively described as a LIM-
domain, a zinc-finger and a RING-variant domain due to its ability to coordinate zinc, but 
how it contributes to biological function is not clear [61]. However, either full-length human 
DUSP12 or a variant rendered catalytically inactive (C115S) were able to suppress the yvh1Δ 
phenotypes, suggesting that these proteins are functional orthologs [61]. It is important to 
note that to date, unlike human DUSP12, phosphatase-dependent function(s) of Yvh1p have 
yet to be characterized, suggesting that, DUSP12 has acquired additional cellular functions 
than those described in yeast.  
Recent independent genetic screens in yeast have revealed that Yvh1p is a critical factor in 
ribosome biogenesis [77,78]. Ribosome biogenesis is an extremely complex process that is 
regulated both spatially and temporally [79]. Ribosomal RNA is transcribed and processed 
in the nucleolus and the pre-40S and pre-60S subunits, are assembled in the nucleus [79]. 
The pre-40S and pre-60S subunits are exported into the cytoplasm where additional 
maturation occurs including the binding of multiple translation initiation factors to the 
small ribosomal subunit to form a 48S complex [79]. Upon recognition of the Met initiation 
anticodon, the translation initiation factors are expelled to facilitate the joining of the large 
60S ribosomal subunit to form a translationally competent 80S ribosome [79]. Defects within 
specific steps or association of proteins with defined complexes within this multistep 
process can be inferred from polysome analyses as each complex in endowed with a unique 
sedimentation coefficient within sucrose gradients [80]. Polysome analysis in yeast 
demonstrated that Yvh1p associates with pre-60S ribosomes and loss of YVH1 results in an 
increase in half-mers (consisting of a 48S small subunit that fails to join to a large 60S 
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ribosomal subunit) [81]. The production of translationally incompetent half-mers likely 
results from defects in cytoplasmic 60S maturation [80,81]. In addition to specific temporal 
associations of initiation factors with the 40S subunit, the nuclear pre-60S subunits associate 
with Mrt4p, which is subsequently displaced by the P0/P1/P2 ribosomal stalk proteins upon 
export of the complex into the cytoplasm [78, 82]. The addition of the ribosomal stalk to the 
cytoplasmic 60S ribosomal subunits is one of the last essential steps prior to large subunit 
joining [82]. In yvh1 null yeast strains Mrt4p remained associated with the cytoplasmic 60S 
subunits preventing the assemblage of the P0/P1/P2 proteins that form the ribosomal stalk 
[78]. Further supporting a genetic interaction between YVH1 and MRT4, specific mutations 
of mtr4 suppressed all yvh1Δ phenotypes, suggesting that the pleiotropic phenotypes 
associated with yvh1Δ strains may be an indirect consequence of aberrant ribosome 
maturation [83]. 
A similar role for DUSP12 regulating ribosome biogenesis in humans is borne from 
observations that knock-down of human dusp12 in HeLa cells promoted the mislocalization 
of the ribosome factors MRTO4 and eIF6, a translation initiation factor that also binds to the 
60S subunit preventing its association with the 40S subunit [84]. In addition, siRNA knock-
down of the ribosome factor P0 in HeLa cells resulted in exclusion of DUSP12 from the 
nucleus [84], its initially characterized sub-cellular localization [61]. As was described in 
yeast, the reported pleiotropic roles for human DUSP12 may also be an indirect consequence 
of defects in the production of translationally competent ribosomes, as several proteins 
affecting ribosome biogenesis are known oncogenes [85] and many other oncogenes are 
selectively regulated at the translational level [86].  
2.5. DUSP18 
dusp18 mRNA is expressed in a variety of primary tumors and cancer cell lines [87]. The 
crystal structure of DUSP18 demonstrates that the phosphatase domain adopts a structure 
similar to the phosphatase domain of DUSP3/VHR with some minor modifications, 
including alterations in charge distribution within the active site pocket, suggesting the 
possibility that it may have distinct substrate specificity profile [88]. Additionally, DUSP18 
contains a C-terminal motif (CT) that specifically interacts with the catalytic domain, which 
may be responsible for Dusp18's elevated thermostability, with a temperature optimum of 
55°C [89]. DUSP18 localizes to the nuclear and cytoplasmic compartments as well as the 
intermembrane space of the mitochondria [90,91] although it appears that the 
mitrochondrial localization is native as reports of DUSP18 localizing to the cytoplasm and 
nucleus was due to over-expression of dusp18 with an N-terminal tag that disrupted the 
mitochondrial localization [91]. Like components of the intrinsic pathway of apoptosis, 
mitochondrial DUSP18 can be released into the cytoplasm in response to apoptotic signals 
[91]. DUSP18 selectively dephosphorylates the JNK stress activated MAPK in vitro and in 
vivo [87,90,91], but since JNK is not thought to be mitochondrially resident, it seems unlikely 
that DUSP18 interacts with JNK under normal conditions [91]. However, due to the ability 
of intrinsic apoptosis to release DUSP18 from mitochondria, it is possible that DUSP18 may 
be able to interact with and dephosphorylate JNK under apoptotic conditions. The JNK 
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hepatocyte growth factor receptor, c-met [67]. ITGA1, a component of the cellular receptor 
for collagen, promotes proliferation, invasion, and angiogenesis of cancer cells [68-70], but 
whether it is responsible for the DUSP12 dependent motility remains to be determined. The 
c-MET proto-oncogene is a well established regulator of growth, survival, and migratory 
signaling [71], but it seems unlikely that c-MET is responsible for the pro-survival and 
migratory function of DUSP12 overexpression, since we failed to observed increased c-MET 
activation in cells over-expressing dusp12 [67]. This was not wholly unexpected as c-MET 
frequently requires its ligand, HGF, to be supplied in an autocrine or paracrine manner in 
order to function [72]. The ability of elevated DUSP12 to promote c-MET and ITGA1 
expression has potential implications in cancer where, in the right tumor microenvironment, 
DUSP12-dependent up-regulation could co-opt the oncogenic potential of these validated 
oncogenes [73]. 
Although it is clear that DUSP12 regulates several important cancer-relevant processes, how 
DUSP12 accomplishes this is largely unknown. Insights into DUSP12’s cellular function(s) 
can be obtained by investigating the budding yeast DUSP12 ortholog, Yvh1p. YVH1 
transcription is up-regulated by nitrogen starvation and low temperatures and yvh1Δ yeast 
strains exhibit a severe growth phenotype, display defects in sporulation, glycogen 
accumulation, and ribosome biogenesis [74-78]. Expression of the Yvh1p CRD domain in 
isolation was able to suppress all the mutant phenotypes of yvh1Δ strains, suggesting that 
neither phosphatase activity nor the N-terminal phosphatase domain is required for its 
cellular function in yeast [76]. The DUSP12 CRD has been alternatively described as a LIM-
domain, a zinc-finger and a RING-variant domain due to its ability to coordinate zinc, but 
how it contributes to biological function is not clear [61]. However, either full-length human 
DUSP12 or a variant rendered catalytically inactive (C115S) were able to suppress the yvh1Δ 
phenotypes, suggesting that these proteins are functional orthologs [61]. It is important to 
note that to date, unlike human DUSP12, phosphatase-dependent function(s) of Yvh1p have 
yet to be characterized, suggesting that, DUSP12 has acquired additional cellular functions 
than those described in yeast.  
Recent independent genetic screens in yeast have revealed that Yvh1p is a critical factor in 
ribosome biogenesis [77,78]. Ribosome biogenesis is an extremely complex process that is 
regulated both spatially and temporally [79]. Ribosomal RNA is transcribed and processed 
in the nucleolus and the pre-40S and pre-60S subunits, are assembled in the nucleus [79]. 
The pre-40S and pre-60S subunits are exported into the cytoplasm where additional 
maturation occurs including the binding of multiple translation initiation factors to the 
small ribosomal subunit to form a 48S complex [79]. Upon recognition of the Met initiation 
anticodon, the translation initiation factors are expelled to facilitate the joining of the large 
60S ribosomal subunit to form a translationally competent 80S ribosome [79]. Defects within 
specific steps or association of proteins with defined complexes within this multistep 
process can be inferred from polysome analyses as each complex in endowed with a unique 
sedimentation coefficient within sucrose gradients [80]. Polysome analysis in yeast 
demonstrated that Yvh1p associates with pre-60S ribosomes and loss of YVH1 results in an 
increase in half-mers (consisting of a 48S small subunit that fails to join to a large 60S 
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ribosomal subunit) [81]. The production of translationally incompetent half-mers likely 
results from defects in cytoplasmic 60S maturation [80,81]. In addition to specific temporal 
associations of initiation factors with the 40S subunit, the nuclear pre-60S subunits associate 
with Mrt4p, which is subsequently displaced by the P0/P1/P2 ribosomal stalk proteins upon 
export of the complex into the cytoplasm [78, 82]. The addition of the ribosomal stalk to the 
cytoplasmic 60S ribosomal subunits is one of the last essential steps prior to large subunit 
joining [82]. In yvh1 null yeast strains Mrt4p remained associated with the cytoplasmic 60S 
subunits preventing the assemblage of the P0/P1/P2 proteins that form the ribosomal stalk 
[78]. Further supporting a genetic interaction between YVH1 and MRT4, specific mutations 
of mtr4 suppressed all yvh1Δ phenotypes, suggesting that the pleiotropic phenotypes 
associated with yvh1Δ strains may be an indirect consequence of aberrant ribosome 
maturation [83]. 
A similar role for DUSP12 regulating ribosome biogenesis in humans is borne from 
observations that knock-down of human dusp12 in HeLa cells promoted the mislocalization 
of the ribosome factors MRTO4 and eIF6, a translation initiation factor that also binds to the 
60S subunit preventing its association with the 40S subunit [84]. In addition, siRNA knock-
down of the ribosome factor P0 in HeLa cells resulted in exclusion of DUSP12 from the 
nucleus [84], its initially characterized sub-cellular localization [61]. As was described in 
yeast, the reported pleiotropic roles for human DUSP12 may also be an indirect consequence 
of defects in the production of translationally competent ribosomes, as several proteins 
affecting ribosome biogenesis are known oncogenes [85] and many other oncogenes are 
selectively regulated at the translational level [86].  
2.5. DUSP18 
dusp18 mRNA is expressed in a variety of primary tumors and cancer cell lines [87]. The 
crystal structure of DUSP18 demonstrates that the phosphatase domain adopts a structure 
similar to the phosphatase domain of DUSP3/VHR with some minor modifications, 
including alterations in charge distribution within the active site pocket, suggesting the 
possibility that it may have distinct substrate specificity profile [88]. Additionally, DUSP18 
contains a C-terminal motif (CT) that specifically interacts with the catalytic domain, which 
may be responsible for Dusp18's elevated thermostability, with a temperature optimum of 
55°C [89]. DUSP18 localizes to the nuclear and cytoplasmic compartments as well as the 
intermembrane space of the mitochondria [90,91] although it appears that the 
mitrochondrial localization is native as reports of DUSP18 localizing to the cytoplasm and 
nucleus was due to over-expression of dusp18 with an N-terminal tag that disrupted the 
mitochondrial localization [91]. Like components of the intrinsic pathway of apoptosis, 
mitochondrial DUSP18 can be released into the cytoplasm in response to apoptotic signals 
[91]. DUSP18 selectively dephosphorylates the JNK stress activated MAPK in vitro and in 
vivo [87,90,91], but since JNK is not thought to be mitochondrially resident, it seems unlikely 
that DUSP18 interacts with JNK under normal conditions [91]. However, due to the ability 
of intrinsic apoptosis to release DUSP18 from mitochondria, it is possible that DUSP18 may 
be able to interact with and dephosphorylate JNK under apoptotic conditions. The JNK 
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MAPK is a well-established regulator of tumorigenesis, and regulates processes such as cell 
proliferation [92], apoptosis [93], and inflammation [94]. 
2.6. DUSP22 
DUSP22 expression is down-regulated in breast cancer and lymphomas [95, 96], and is used 
as a prognostic marker for B cell chronic lymphocytic leukemia patients [97]. In anaplastic 
lymphoma kinase (ALK)-negative anaplastic large cell lymphomas, the commonly found 
t(6;7)(p25.3;q32.3) translocation disrupts the dusp22 gene [96]. Down-regulation of dusp22 in 
cancer suggests a possible tumor suppressive role for DUSP22, but exactly how DUSP22 
may function in cancer and normal cell biology awaits further characterization. 
There are conflicting reports concerning the ability of DUSP22 to dephosphorylate MAPKs 
[97-100], but most studies indicate DUSP22 as a regulator of JNK [99-101]. Over-expression 
of both JNK and DUSP22 in COS7 suppressed JNK phosphorylation [99]. However, other 
reports have identified a phosphatase-dependent role for DUSP22 in promoting JNK activity 
[100,101]. Glutathione S-transferase (GST) pull downs and immunoprecipitations revealed 
that DUSP22 can bind the JNK activating kinase, MKK7, but not JNK itself, and the 
association with MKK7 activates MKK7's phosphorylation of JNK [99]. Exactly how DUSP22 
activates MKK7 and JNK activity is unclear but the requirement is biologically significant as 
mouse embryonic stem cells lacking DUSP22 were unable to activate JNK in response to 
cytokines [100].  
Another reported substrate of DUSP22 is the estrogen receptor (ERα) an important 
prognostic marker for breast cancer regulating proliferation and apoptosis [102,103]. 
DUSP22 most likely functions within a negative feedback loop to regulate ERα, as activation 
of ERα induces dusp22 mRNA expression and DUSP22 dephosphorylates and inhibits ERα’s 
transcriptional activity in breast cancer cells [102]. Additionally, dusp22 expression is down-
regulated in breast cancers, specifically those containing the 8p11-12 amplicon [95]. This 
amplicon contains the potential oncogene, ppapdc1b, which is thought to be responsible for 
DUSP22 down-regulation as siRNA knock-down of ppapdc1b increases dusp22 expression 
[95]. The oncogenic ability of ppapdc1b, in part, may be due to its ability to down-regulate 
dusp22 expression to allow for increased estrogen receptor activity, as it was reported that all 
11 tumor samples analyzed that contain the 8p11-12 amplicon, had ER-positive statuses [95]. 
DUSP22 may also regulate metastasis as it dephosphorylates tyrosines 576/577 and 397 of 
focal adhesion kinase (FAK) [104]. FAK is a key regulator of integrin-mediated attachment 
and FAK inhibition results in detachment and apoptosis in some cell lines [105]. dusp22 
over-expression inhibited cell migration and reduced FAK phosphorylation while dusp22 
knock-down promoted cell migration and FAK phosphorylation in H1299 cells [104]. 
DUSP22 is myristoylated [106], which may allow for its co-localization with FAK at actin 
filament enriched regions of lamelapodia [104]. The subcellular localization of DUSP22 
likely contributes to its biological function as myristoylation-deficient variants of DUSP22 
do not display altered enzymatic activity in vitro, but unlike wild-type DUSP22, induced cell 
detachment and apoptosis when over-expressed [106].  
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2.7. DUSP23 
DUSP23 dephosphorylates ERK1/2 in vitro, but DUSP23 is an activator of JNK and p38 in 
COS7 cells [6]. In addition, the regulation of JNK and p38 is phosphatase independent, and 
the MAPKKs for JNK and p38, MKK4 and MKK6, also have increased phosphorylation 
when dusp23 is over-expressed and the cells are treated with sorbitol,  suggesting that 
DUSP23 may act as a scaffold to promote MKK binding to JNK and p38 [6]. 
The dusp23 gene is highly methylated and decreased dusp23 mRNA expression is observed 
in neuroblastoma [107]. Interestingly, dusp23 mRNA levels were lower in tumors from 
deceased patients than patients exhibiting no clinical symptoms, suggesting that DUSP23 
levels could be a prognostic marker for neuroblastomas [107]. The generality of dusp23 
functioning as a tumor suppressor is called into question by observations that it is amplified 
in many other cancers, including breast, colon, lung, squamous carcinoma, pancreatic, brain, 
esophageal, stomach, bladder, kidney, skin, ovary, prostate, and testicular cancers [108], and 
selective over-expression of dusp23 in MCF7 cells increased proliferation while knock-down 
of dusp23 decreased proliferation [108]. 
2.8. DUSP26 
A role for dusp26 in cancer is borne by observations that it is located on an 8p12 amplicon 
found in anaplastic thyroid carcinoma tissue [109] and differential expression of dusp26 has 
additionally been observed in glioblastoma tissues, neuroblastoma, brain, and ovarian 
cancer cell lines, where dusp26 is down-regulated [110,111]. Additionally, knock-down of 
dusp26 in immortalized ovarian epithelia HOSE17.1 cells increased both colony formation 
and proliferation [111]. Over-expression of dusp26 in immortalized breast epithelial 
MCF10A, cells suppressed colony formation and acinar growth in 3D culture [111]. 
Alternatively, in anaplastic thyroid carcinoma primary tumors and cell lines, over-
expression of dusp26 promoted colony formation, while knock-down of dusp26 expression 
reduced proliferation [109]. Defining a more precise role for DUSP26 is further complicated 
by the fact that different groups have come to opposing conclusions regarding dusp26 
expression in neuroblastoma cell lines [111,112]. 
The cellular function of DUSP26 is also unclear as the substrates for DUSP26 are debated. 
DUSP26 can dephosphorylate the tumor suppressor p53 at Ser20 and Ser37, inhibiting p53-
mediated apoptosis induced by genotoxic stress [112], suggesting a pro-survival role. In 
addition to p53, several other in vitro DUSP26 substrates have been described, including p38 
[109]. In HEK293T cells, over-expression of dusp26 resulted in reduction of p38 activity and 
p38-mediated apoptosis [113]. The small molecule inhibitor NSC-87877 functions as an in 
vitro DUSP26 inhibitor with an IC50 of 16.7 uM that additionally prevented the DUSP26-
dependent dephosphorylation of p38 in HEK293 cells [114]. However, in COS7 cells, over-
expression of dusp26 increased both JNK and p38 activities [6], and in the rat neuronal cell 
line, PC12, and epithelial cells DUSP26 had no affect on MAPKs [17,112] questioning the 
generality of DUSP26 functioning as a p38 phosphatase. 
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MAPK is a well-established regulator of tumorigenesis, and regulates processes such as cell 
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DUSP26 is also implicated in regulating the kinesin superfamily 3 (KIF3) microtubule-
directed protein motor complex by dephosphorylating the kinesin-associated protein 3 
(KAP3) [111]. The KIF3 motor complex has been implicated in cancer due to its ability to 
traffic cancer relevant proteins including, adenamaous polyposis coli (APC), β-catenin, 
cadherins, and the polarity complex, PAR3 [115,116]. Consistent with DUSP26 functioning 
as a positive regulator of KIF3, over-expression of dusp26 in the mouse fibroblast cell line, 
NIH3T3, increased cell-to-cell adhesion and intracellular transport of N-cadherin and β-
catenin to the cell surface [111].  
3. Less well-characterized atypical DUSPs. 
The previous sections discussed the atypical DUSPs that have been described in the 
literature as having a relationship, however tenuous or controversial, to tumor suppressive 
and/or oncogenic properties and are often supported by genetic/genomic analyses of 
primary tumors samples. Although the previous sections should reaffirm that the 
function(s) of many of the atypical DUSPs are likely both cell type and context dependent, 
we nevertheless undertook a comparison of the expression profiles of all the atypical DUSPs 
in tumors of the prostate to normal prostate tissue using the cBio Cancer Genomics Portal 
(http://www.cbioportal.org/) and microarray data deposited by the Memorial Sloan-
Kettering Cancer (MSKCC) Center’s Prostate Oncogenome Project [117]. Comparison of the 
transcriptome of 85 tumors to normal prostate tissue revealed that many atypical DUSPs 
have aberrant expression in prostate cancer (Table 2). In at least two cases this difference  
 
Gene Down Up Total 
EPM2A 13% 0% 13% 
STYX 2% 7% 9% 
DUSP3 40% 0% 40% 
DUSP11 4% 5% 8% 
DUSP12 1% 15% 16% 
DUSP13 0% 5% 5% 
DUSP14 6% 11% 16% 
DUSP15 4% 0% 4% 
DUSP18 40% 4% 44% 
DUSP19 1% 1% 2% 
DUSP21 0% 7% 7% 
DUSP22 15% 2% 18% 
DUSP23 11% 8% 19% 
DUSP26 1% 2% 4% 
DUSP27 2% 5% 7% 
Androgen Receptor (AR) 2% 7% 9% 
Table 2. Using the cBio Cancer Genomics protal (http://www.cbioportal.org/), and microarray data 
deposited by MSKCC Prostate Oncogenome Project [117]. we compared the expression of atypical 
DUSPs in tumors to normal prostate tissue using a Z score threshold of +/- 2.  The androgen receptor 
(AR) is included for comparison as a gene already implicated in cancer progression [117] 
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was reflected clinically as patients harboring tumors with aberrant dusp22 or dusp23 
expression had faster disease relapse than those harboring tumors with normal dusp22 or 
dusp23 expression (Figure 1). Although differential expression of any particular gene in 
prostate cancer may not functionally contribute to the initiation or progression of the 
disease, this analysis serves as an example of one way to potentially identify cancer-relevant 
markers. The following sections describe what is currently known about the remaining 
atypical DUSPs that, to date, have not been specifically associated with cancer. 
 
Figure 1. Kaplan-Meyer analysis of disease free survival for patients with altered expression of the 
androgen receptor or atypical DUSPs. This graph was generated by the cBio Cancer Genomics Portal 
(http://www.cbioportal.org/) using data deposited by the MSKCC Prostate Oncogenome Project [117]. 
Microarray expression data from tumors compared to normal prostate was used in this analysis with a 
Z-score threshold of +/- 2. 
3.1. STYX 
The prototypical pseudophosphatase, STYX, contains a substitution of the catalytic cysteine 
for glycine, rendering it catalytically inactive [118]. As this mutation abrogates catalysis, but 
not substrate binding, pseudophosphatases are though to function as substrate traps 
preventing dephosphorylation of the target protein(s) [119]. In mice, styx expression is 
restricted to the testis, and is essential for spermatogenesis, as STYX knock-out male mice 
are infertile [118]. 
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3.2. DUSP13A/B 
The dusp13 gene encodes for two similar protein products via alternative reading frames 
[120,121]. Designated DUSP13A and DUSP13B, the proteins are expressed in the muscle and 
testis respectively [121,122]. Both proteins have phosphatase activity in vitro, with DUSP13B 
exhibiting higher activity than DUSP13A [122]. Interestingly, both DUSP13A and B regulate 
apoptosis, but by different mechanisms. Knock-down of DUSP13A in mouse embryonic 
fibroblasts reduced apoptosis signal regulating kinase 1 (ASK1) kinase activity and intrinsic 
apoptosis induced by ask1 over-expression [7]. Furthermore, autophosphorylation assays of 
ASK1 with increasing amounts of DUSP13A demonstrated that DUSP13A increases ASK1 
autophosphorylation in a phosphatase independent manner [7]. In contrast to DUSP13A, 
DUSP13B appears to be pro-survival [123]. Over-expression of DUSP13B in COS7 cells 
resulted in reduced phosphorylation of the stress activated MAPKs, JNK and p38 [123]. 
Over-expression of DUSP13B resulted in reduced activity of the down-stream JNK effector 
AP-1 in a phosphatase dependent manner [123]. AP-1 activity is associated with a large 
number of cellular processes including transformation, proliferation, differentiation, and is 
specifically implicated in apoptosis [124]. 
3.3. DUSP14 
dusp14 is located on a chromosomal region that is amplified in gastric cancer,  but it may not 
be the target for the genetic amplification, as dusp14 expression is not increased [125]. In 
vitro, DUSP14 dephosphorylates all three MAPK isoforms, leading to its alternate 
designations of  MKP-L (MKP1-Like) and MKP-6 [126]. However, DUSP14 is classified as an 
atypical DUSP as it lacks the characteristic MAPK binding domain found in the MKP DUSP 
subfamily [2]. In T-cells, expression of the catalytically inactive DUSP14 C111S variant 
enhanced ERK1/2 and JNK phosphorylation, suggesting that in vivo, p38 is not a DUSP14 
substrate [126]. Additionally, in β pancreatic cells, knock-down of dusp14 expression or the 
expression of a dominant negative DUSP14 variant resulted in increased ERK1/2 
phosphorylation and cell proliferation [127].  Elucidating a role for DUSP14 may be aided by 
the discovery of the PTP inhibitor IV, an inhibitor of DUSP14 in vitro that increases 
hydrogen peroxide induced JNK activation in a concentration dependent manner [128]. 
3.4. DUSP15 
The DUSP15 crystal structure reveals it lacks the MAPK substrate recognition domain and it 
has a unique additional alpha helix located at the back end of the active site suggesting that 
DUSP15 has unique substrate recognition mechanisms [129]. DUSP15 displays phosphatase 
activity against the artificial substrate pNPP in vitro [130], but physiological substrates for 
DUSP15 have yet to be reported. DUSP15 contains an N-terminal myristoylation signal, 
resulting in targeting of the protein to plasma membrane [90] and in mice DUSP15 has been 
identified as a candidate gene in a quantitative trait locus (QTL) thought to harbor genes 
that control for the predisposition to growth and fatness in mice [131].  
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3.5. DUSP19 
Like DUSP13A, DUSP19 is thought to facilitate ASK1 activation leading to MKK7 activation 
and in turn activating JNK as DUSP19 directly binds MKK7, but not JNK in vitro, and co-
immunoprecipitates with ASK1 and MKK7 [8,132]. The proposed model for how DUSP19 
differentially regulates JNK activation is that at high levels of DUSP19 ASK1 is sequestered 
by DUSP19 thereby inhibiting MKK7 and JNK activation, while at low levels DUSP19 
functions as a scaffold to promote the activation of MKK7 by ASK1 [8,132]. 
3.6. DUSP21 
Similar to DUSP18, DUSP21 contains a highly conserved mitochondrial localization signal, 
however DUSP21 localizes to the peripheral membrane of the inner membrane of the 
mitochondria, which is the opposing side to which DUSP18 is found [91]. DUSP21 exhibits 
activity against synthetic MAPK peptides in vitro, but cell based assays fail to demonstrate 
that DUSP21 has activity against any cellular MAPKs [90]. 
3.7. DUSP27 
Substrates for the newest atypical DUSP, DUSP27, are unknown but solution of the DUSP27 
3D structure suggests that it may have substrates other than the MAPKs [133]. The catalytic 
site can accommodate dually-phosphorylated residues separated by two amino acids, which 
differs from the catalytic site of DUSPs that can dephosphorylate the characteristic MAPK 
activation loop (T-X-Y) [133].  
4. Conclusion 
Although many atypical DUSPs display differential expression in tumor samples, significant 
amounts of work will be required to determine whether and how these differences 
contribute to malignancy, especially with the common discrepancy between in vitro and in 
vivo results. Due to the central localization of the MAPK signaling cascade and the role of 
MKPs in malignancy, much of the initial work has been to evaluate if and how atypical 
DUSPs affect MAPK signaling. The MAPK pathway however represents a doubled edged 
sword, although it is strongly associated with disease, it is difficult to modulate 
pharmacologically due to complex crosstalk and feedback loops. We envision that specific 
inhibitors for atypical DUSPs, particularly those that do not target MAPK isoforms but other 
cancer-relevant substrates, could have important therapeutic value. Even in the event that 
these inhibitors fail to function as therapeutics, we think that selective inhibitors will be 
instrumental in advancing the elucidation of the cellular functions, substrates, and 
expression of the atypical DUSPs. Even in instances where the mechanism of oncogenesis 
remains unknown, we anticipate that continued large-scale expression profiling of the 
atypical DUSPs may be increasingly used to for clinical benefit to patients through the 
identification of potential novel biomarkers. 
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1. Introduction 
Cells are equipped with the multiple DNA repair mechanisms to deal with DNA damage 
and transduce the signal downward, which provokes a process to inhibit cell cycle 
progression and to induce DNA repair [1, 2]. The main DNA damage recognition molecule 
is ataxia telangiectasia-mutated (ATM), which is a checkpoint kinase that phosphorylates a 
number of proteins including p53 and BRCA1 in response to DNA damage (Figure 1), and 
thus induce the response to it [3, 4]. Mutations in the ATM have been associated with 
increased risk of developing a cancer. In addition, it is well known that mutations in the p53 
and BRCA1 tumor suppressor genes account for a certain amount of cancers. The p53 
protein is a key transcription factor that regulates several signaling pathways involved in 
the cellular response to genome stress and DNA damage. Through the stress-induced 
activation, p53 triggers the expression of target genes that protect the genetic integrity of 
cells [5, 6]. Normal cells show an exquisite balance among these various mechanisms of 
DNA repair. 
Genomic instability is often linked to DNA repair deficiencies. Standard DNA repair 
pathways available in mammalian cells include homologous repair, nonhomologous end 
joining, single strand annealing and so on. Those are different pathways that repair DNA 
double strand breaks (DSBs) [7]. The DNA repair is essential for the survival of both normal 
and cancer cells. An elaborate set of signaling pathways detect the DSBs and mediate either 
survival on the DNA repair or apoptotic cell death [8, 9]. The DNA damaging agents for 
cancer therapies are potent inducers of cell death triggered by the apoptosis. Recent 
advances in basic science have led to a better understanding of the molecular events 
important in the pathogenesis of cancer. In the present review, we summarize the function 
of prominent DNA repair molecules and the tumor suppressor gene products, p53 and 
 The Author(s). License  InTech. This chapter is distributed und the terms of the Creativ  Commons 
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Figure 1. Schematic representation of the DNA repair and Growth arrest signaling pathways. Examples 
of the molecule known to act on the regulatory pathways are shown. 
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Figure 2. Schematic diagram indicating the domain structures of the p53 and BRCA1 proteins. The 
functionally important sites including the sites of protein phosphorylation are also shown. 
2. Function and involvement of p53 in DNA repair pathway 
The p53 is a transcription factor that regulates a number of genes and protects against 
genomic instability. It is inactive under normal physiological conditions and activated in 
response to various types of cellular stresses including DNA damage. Under the stress 
conditions, p53 functions to block cell cycle progression [10], and failure of the DNA repair 
mechanisms leads to p53 mediated induction of apoptotic cell death programs. The p53 
protein is also induced and activated in the nucleus by a stress such as hypoxia and 
oxidative stress. In addition, p53 undergoes post-translational modifications such as 
acetylation of lysines, nitration of tyrosines, phosphorylation of serine/threonine residues in 
response to those stresses [11]. Activated p53 protein regulates its downstream genes and 
subsequently inhibits malignant transformation of normal cells. Because p53 plays an 
important role in the transcriptional regulation of genes encoding proteins involved in DNA 
repair and programmed cell death, the modification of p53 protein appears to be a pivotal 
determinant of cells fate in some conditions. 
The p53 protein is involved in a lot of signaling pathways of cell growth regulation, and 
multiple mechanisms have been revealed to accomplish the regulation of p53 activity, which 
determines the selectivity of p53 for specific transcriptional targets, resulting in control of 
the p53 activity. A large number of molecules capable of activating p53 have been 
developed. Studies have documented the importance of Mdm2 in the control of the p53 
activity [12]. MdmX is also recognized as the p53 negative regulators [13]. A p14 ARF 
controls the level of p53 by inhibiting the p53-specific ubiquitin ligase MDM2 [14]. The 
MdmX has been identified as a highly homologous gene that is closely related to Mdm2. 
Although MdmX possesses a p53 binding domain at its N-terminus, the MdmX does not 
have ubiquitin ligase activity like Mdm2. The 53BP1 protein also has a role in the cellular 
response to DNA damage. Convincing evidence exists for the 53BP1 affecting the outcome 
of DNA double strand break repair [15, 16]. Among a number of transcriptional targets of 
the p53, the p21WAF1 has been shown to play an important role in both p53-dependent and 
independent pathways [17]. The p21 WAF1 inhibits cell cycle progression through 
interaction with the cyclin and CDK complexes. CLCA2 has been reported as a p53 target 
gene that regulates the p53 induced apoptotic pathways. In addition, CLCA2 has been 
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gene that regulates the p53 induced apoptotic pathways. In addition, CLCA2 has been 
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shown to be down-regulated in breast cancer tissues [18]. ABL1 includes nuclear localization 
signals and a DNA binding domain through which it mediates DNA damage repair 
functions. Several ABL targets including the p53 are primary regulators for the DNA 
damage induced apoptosis [19, 20]. Ciz1 is an estrogen-responsive gene (ER), whose 
product co-regulates ER by enhancing its transactivation activity. The Ciz1 protein induces 
hypersensitivity of breast cancer cells to estrogen and induces the expression of ER target 
gene such as cyclin D1 [21]. Moreover, Ciz1 promotes the proliferation, anchorage 
independent growth of breast cancer cells. The Ciz1 protein also interacts with a novel 
protein named PDRG1, which is regulated by the p53 and DNA damage [22]. 
The gene of the p53 is frequently mutated in multiple cancer tissues, suggesting that p53 
plays a critical role in preventing cancers. Studies have shown that p53 is mutated or deleted 
in nearly half of all human cancers. During neoplastic progression, the p53 is often mutated 
and fails to perform its normal functions. Mutant p53 can be classified as a loss of function 
or a gain of function proteins depending on the type of mutation. The p53 activation by 
something cellular regulator including a gain of function-mutation may lead to regression of 
an early neoplastic lesion, and therefore may be important in developing cancer chemo-
prevention.  
3. Function and involvement of BRCA1 in DNA repair pathway 
Mutations in the tumor suppressor gene BRCA1 confer an increased risk for the 
development of breast and ovarian cancers [23]. BRCA1 hereditary breast cancer is a type of 
cancer with defects in a DNA repair pathway. Actually, mutation of a single allele of the 
cancer susceptibility gene BRCA1 is associated with increased genomic instability in human 
breast epithelial cells [24], which accelerates the mutation rate of other critical genes. Several 
functions of BRCA1 may contribute to its tumor suppressor activity including roles in the 
DNA repair. Although BRCA1 gene mutations are rare in sporadic breast and/or ovarian 
cancers, BRCA1 protein expression is frequently reduced in the sporadic cases.  
The BRCA1 has the important role in concert with BRCA2, Rad50 and Rad51 [25], in order 
to activate the checkpoints. For example, BRCA1 is colocalized with Rad51, a DNA 
recombinase related to the bacterial RecA protein. The BRCA1 protein becomes hyper-
phosphorylated after exposure to the DNA damaging agents, and the function of BRCA1 
seems to be regulated by the phosphorylation in response to DNA damage. Pharmacological 
inhibition of poly-ADP-ribose polymerase induces cell death in tumors with mutations in 
certain DNA repair pathways, when combined with DNA damaging chemotherapies. Then, 
poly-ADP-ribose polymerase inhibitors have been investigated for the treatment of patients 
with BRCA 1 mutation, as a strategy to potentiate the DNA damaging effects of 
chemotherapy and irradiation [26, 27].  
The BRCA1 plays an important role in maintaining genomic integrity by protecting cells 
from double-strand breaks that arise after DNA damage. The BRCA1 cDNA encodes for 
1863 amino acids protein with an amino terminal zinc ring finger motif and two putative 
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nuclear localization signals (Figure 2). The amino-terminal domain possesses E3 ubiquitin 
ligase activity [28] and the carboxyl-terminal domain is involved in binding to specific 
phospho-proteins. The role of BRCA1 in cell cycle control has been understood by its ability 
to interact with various cyclins and cyclin-dependent kinases. The BRCA1 activates the CDK 
inhibitor p21 and the p53 tumor suppressor protein, which regulates several genes that 
control cell cycle checkpoints. BRCA1 also has binding domains for Rb, Rad50 and Rad51 
[29, 30]. They may also be involved in DNA double strand break repair. Previous studies 
have suggested that the BRCA1 pathway dysfunction may also provide an opportunity for 
therapeutic intervention. 
4. DNA repair and cancer therapy 
DNA damaging strategies are frequently used as nonsurgical therapies against cancers. 
Among them, methylating agents such as cisplatin and ionizing radiation are important. 
DNA double strand breaks are induced following the exposure to the methylating agents 
[31]. Those also activate the DNA damage checkpoints, which induce cell cycle arrest in 
order to repair the DNA damage. However, down-regulation of DNA repair mechanism 
promotes genetic instability, which can lead to carcinogenesis. When defects in certain DNA 
repair molecules are present in immune system, for example, lymphocyte development can 
be compromised and the patients can consequently develop primary immune-deficiencies. 
Those patients often have a predisposition for cancer development. An additional 
consequence of defective DNA repair is cellular hypersensitivity to DNA damaging agents 
[32]. In another words, DNA damaging agents work well in cells with DNA repair defects. 
Mutations in BRCA1, for example, make cancer cells highly susceptible to inhibitors of a 
DNA repair pathway such as poly-ADP-ribose polymerase [33]. Inhibition of DNA repair 
pathway also seems to block the mechanisms that are required for survival in the presence 
of oncogenic mutations. As the consequence, selective elimination of the mutation bearing 
cells occurs, which can upregulate the DNA repair system. Epigenetic mechanisms such as 
histone modifications and DNA methylation have been evaluated with a view for enhancing 
the cancer therapy via the regulation of the expression of genes involved in DNA repair [34].  
Treatment of cancers with DNA damaging therapy causes cytotoxicity through induction of 
high levels of the DNA damage. Cancer cells also respond to DNA damage by activation of 
the DNA repair and may counteract chemo and radiation efficacy. Actually, DNA repair 
have been shown to influence radiosensitivity, and the activation of DNA repair of cancer 
cells might be one of the most important factors in the therapeutical resistance. Inactivation 
of ATM give rise to cell cycle defects in response to irradiation and radiosensitise cancer 
cells [35]. In this way, Zebularine and 5-aza-2'-deoxycytidine are employed as 
radiosensitizing agents [36, 37]. Histone deacetylase inhibitors such as LBH589 and MS-275 
have been shown to enhance radiosensitivity through the similar mechanisms [38]. Several 
histone deacetylase inhibitors exert direct cytotoxic effects and sensitize cancer cells to 
radiotherapy. For example, trichostatin A, which is the potent histone deacetylase inhibitor 
enhances radiosensitivity in a variety of human cancers [39]. A previous study has 
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to interact with various cyclins and cyclin-dependent kinases. The BRCA1 activates the CDK 
inhibitor p21 and the p53 tumor suppressor protein, which regulates several genes that 
control cell cycle checkpoints. BRCA1 also has binding domains for Rb, Rad50 and Rad51 
[29, 30]. They may also be involved in DNA double strand break repair. Previous studies 
have suggested that the BRCA1 pathway dysfunction may also provide an opportunity for 
therapeutic intervention. 
4. DNA repair and cancer therapy 
DNA damaging strategies are frequently used as nonsurgical therapies against cancers. 
Among them, methylating agents such as cisplatin and ionizing radiation are important. 
DNA double strand breaks are induced following the exposure to the methylating agents 
[31]. Those also activate the DNA damage checkpoints, which induce cell cycle arrest in 
order to repair the DNA damage. However, down-regulation of DNA repair mechanism 
promotes genetic instability, which can lead to carcinogenesis. When defects in certain DNA 
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the cancer therapy via the regulation of the expression of genes involved in DNA repair [34].  
Treatment of cancers with DNA damaging therapy causes cytotoxicity through induction of 
high levels of the DNA damage. Cancer cells also respond to DNA damage by activation of 
the DNA repair and may counteract chemo and radiation efficacy. Actually, DNA repair 
have been shown to influence radiosensitivity, and the activation of DNA repair of cancer 
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radiotherapy. For example, trichostatin A, which is the potent histone deacetylase inhibitor 
enhances radiosensitivity in a variety of human cancers [39]. A previous study has 
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demonstrated that a histone deacetylase inhibitor downregulate the expression of Rad51, 
which participate in the DNA repair pathway. The marine product, psammaplin A, has 
been shown to have potent cytotoxicity against several cancer cells. As psammaplin A has 
been shown to exhibit histone deacetylase inhibitory activity, this may be a promising 
radiosensitizing agent [40]. Actually, the psammaplin A has the potential to increase 
radiosensitivity in lung cancer A549 and glioblastoma U373MG cells. Thus, it has been 
found that a variety of histone deacetylase inhibitors synergistically enhance the growth 
inhibition and apoptosis of DNA damaging drugs. As numerous parameters may influence 
cancer therapeutical sensitivity, the impairment of DNA repair may be one of the most 
crucial mechanisms underlying enhanced the therapeutical responses. So, detection of DNA 
damage and repair pathways is important component of the intrinsic therapy sensitivity 
(Figure 3). 
Platinum compounds such as cisplatin and carboplatin are one of the most widely used and 
effective chemotherapeutic agents for several cancers including cerebellar tumor and 
medulloblastoma [41]. However, cancer cells often develop resistance to those genotoxic 
drugs. Improvements of the effectiveness to cancers are urgently needed. Some cell lines 
develop acute resistance to cisplatin in the presence of estrogen receptor antagonist. In the 
presence of it, cisplatin treated medulloblastoma cells show recruitment of Rad51 to the sites 
of damaged DNA lesions, and increase DNA repair activity. BRCA1 is required for 
subnuclear assembly of the Rad51 and survival following treatment with the cisplatin [42]. 
DNA damage in MCF7 cells in which estrogen receptor is activated, lead to the inhibition of 
cell cycle checkpoint, which results in less effective DNA repair [43]. DNA damage in the 
cancer cells in which estrogen receptor is inhibited, result in better DNA repair and 
improved cell survival, which attenuated cytotoxic action of cisplatin. 
Proper intake of dietary nutrients including zinc has been considered crucial for preventing 
the initiation of events leading to the development of cancer. The zinc is an essential element 
that is integral to some transcription factors which regulate key cellular functions such as 
the response to oxidative stress and DNA damage repair. Zinc is involved in stabilization 
and activation of the p53 that appears to be an important component of the apoptotic 
process [44]. Thus, zinc provides an effective dietary chemopreventive approach to disease 
in a cancer, and zinc could be effective in the treatment of several cancers. However, it needs 
further exploration to investigate the genetic and epigenetic pathways of the effects by the 
zinc. There is interest in mechanisms of acquired resistance to epidermal growth factor 
receptor (EGFR) inhibitors that are being used in the treatment of a variety of cancers [45]. 
Acquired resistance to EGFR inhibitors is associated with the loss of p53 and cross resistance 
to irradiation. The p53 may enhance sensitivity to irradiation via induction of DNA damage 
repair at this point. The cytotoxic agents target stabilization of p53 through DNA damage. 
Thus, p53 represents an attractive target for therapeutic design and development of 
anticancer agents. Restoration of hypoxia induced p53-mediated signaling may well be 
effective in the targeting of hypoxic cells [46]. The DNA damage response is also induced in 
cells by the hypoxia. 
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Figure 3. Implication of DNA repair modulations in cancer. DNA repair downregulation can contribute 
to genomic instability, which promotes malignant transformation of cells, and leads to cellular 
sensitivity to DNA damaging therapy. DNA repair upregulation can contribute to genomic stability, 
which lead to acquired resistance to the DNA damaging therapy. 
5. Perspective 
It has been paid more attention to the DNA repair as a therapeutic target, because DNA 
repair enzymes regulation and specific cytotoxic cancer therapy may be possible via the 
mechanism based on the appropriate DNA damaging approaches (Figure 4). The cancer cell 
genome is aberrant as a consequence of incomplete DNA repair. As many anticancer drugs 
further reduce the integrity of DNA, they may be able to cause more mutations and another 
cancer, if the lesions are not repaired. However, cancer cells, in which its DNA repair is 
down-regulated, have been shown to exhibit increased sensitivity to DNA damaging 
chemotherapy. A new therapeutic approach will be possibly developed, in which radiation 
therapy or cytotoxic anticancer agents are employed in conjunction with the DNA repair 
modulators. For example, cells exposing to hypoxia are sensitive to inhibition of 
components of the DNA damage response. The DNA damage response induced by hypoxia 
is distinct from the classical pathways induced by the DNA damaging agents due to the 
coincident repression of DNA repair in hypoxic conditions. The principle aims of the 
hypoxia induced DNA damage response seem to be the induction of p53 dependent 
apoptosis. Such combinations can cause severe genomic instability in cancer cells resulting  
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Figure 4. Survival or Apoptosis, that’s the problem in cancer therapy and for individual health. The 
determination either survival or apoptosis is due to the balance between DNA damage and the DNA 
repair levels in cells. 
in apoptotic cancer cell death. Tumor recurrence frequently occurs after genome damaging 
therapy, but the characteristics and the behavior of resistant cancer cells remain unknown. 
Recently, it has been reported that the peri-necrotic tumor cells after radiation therapy 
acquire hypoxia-inducible factor 1 (HIF-1) activity after surviving radiation, which triggers 
their translocation towards tumor blood vessels. So, the HIF-1 inhibitors suppress the 
incidence of post-irradiation tumor recurrence [47]. 
Understanding of the cellular aberrations of cancer cells has allowed the development of 
therapies to target biological pathways. Active inhibition of DNA repair enzyme in a tumor 
can lead to genomic instability and cell death by exploiting the paradigm of synthetic 
lethality, which potentiates anti-neoplastic effects of DNA damaging therapy including 
radiation. Several studies have evaluated the role of DNA repair enzyme inhibitors for 
treatment of cancer [48, 49]. In conclusion, the combination of DNA damaging agent and 
DNA repair enzyme inhibitor results in beneficial improved anticancer efficacy. However, 
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side effects of the blocking of DNA repair system on the normal cell may overcome their 
benefit action. So it is important to precisely investigate the effects in both the target and 
normal cells. Optimizing treatment according to tumor status for DNA-repair biomarkers such 
as BRCA1 could predict response to DNA toxic cancer therapies and might improve the 
response of tumors to the therapies. Variation in DNA repair genes may also be informative. 
Further investigations will be required to identify other additional mechanisms associated 
with the therapeutic sensitivity and other epigenetic drugs such as the histone deacetylase 
inhibitors. Investigations are warranted to determine whether alterations in the methylation 
patterns of set of genes involved in DNA repair might be modulated by the inhibitors. Also, 
future studies should be conducted to determine whether the combination of DNA damaging 
agents and DNA repair modulator has potential for the treatment against cancer. 
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1. Introduction 
The genetic information stored in DNA can be transcribed and translated into functional 
proteins with various biological roles, and the control of gene expression and cell division is 
tightly controlled under normal physiological conditions. However, genetic mutations 
arising during DNA replication can trigger uncontrolled cell growth, leading to the 
development of various types of cancers (Croce 2008). The cellular transformational events 
associated with cancer have been linked with mutations in particular genes, termed proto-
oncogenes. These genes are necessary for the normal development and differentiation of 
cells, but when mutated into oncogenes they can lead to the overexpression of proteins 
involved in signal transduction and mitosis, ultimately resulting in cancer development. 
Blocking oncogenic translation using siRNAs has attracted intense attention in the literature 
(Heidenreich 2009; Ventura et al. 2009), but inhibiting oncogenic transcription through 
targeting DNA itself has been less explored. 
While DNA is a well-established biomolecular target for anti-cancer therapy, most DNA-
binding drugs such as cisplatin (Alderden et al. 2006) and its analogues interact with DNA 
non-selectively, resulting in adverse side effects (Jung et al. 2007). Consequently, this has 
driven interest in the targeting of unusual, non-canonical structures in DNA, in order to 
achieve selectivity for particular (onco)genes while potentially reducing adverse side effects. 
One such DNA structure that has attracted significant attention in the recent literature as an 
anti-cancer target is the G-quadruplex. While G-quadruplexes were initially regarded as 
somewhat of a structural curiosity when they were first discovered, accumulating evidence 
over the past decade have suggested that these non-canonical DNA structures may play 
important roles in modulating various biological processes (Lipps et al. 2009). 
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G-quadruplexes are four-stranded guanine-rich DNA structures that were first found at the 
ends of eukaryotic telomeres, and the role of telomeric G-quadruplexes for inhibiting 
telomerase activity has been intensely studied since the early 1990s (Blackburn 1991). 
Human telomeric DNA is usually 4–14 kilobases long, and is comprised of TTAGGG 
tandem repeats. Up-regulated telomerase activity in cancer cells maintains the length of 
telomeres after cell division, conferring immortality. Hurley and co-workers demonstrated 
that the activity of telomerase can be inhibited by small molecule-induced stabilization of 
telomeric G-quadruplex (Wheelhouse et al. 1998).  
A few years later, Hurley and co-workers reported the seminal discovery of a potential G-
quadruplex structure in the nuclease hypersensitive element III1 (NHEIII1) of the promoter 
region of the c-myc oncogene, and they further demonstrated that the transcriptional 
repression of c-myc can be achieved by induction of putative G-quadruplex formation by a 
small molecule (Siddiqui-Jain et al. 2002). Evidently, c-myc transcription was inhibited by 
the putative formation of the G-quadruplex structure in the promoter region, thus 
suppressing oncogenic expression. Later, other studies identified the presence of G-
quadruplex-forming sequences in the promoter regions of other oncogenes such as c-kit 
(Rankin et al. 2005), KRAS (Cogoi et al. 2006), bcl-2 (Dai et al. 2006) and VEGF (Jiang et al. 
1991). In 2007, Huppert and Balasubramanian conducted a large-scale bioinformatics 
analysis throughout the human genome, and found that G-quadruplex-forming sequences 
are enriched in the promoter regions of genes, and that >40% of annotated genes bears at 
least one potential G-quadruplex sequence within 1kb of the transcription start site 
(Huppert et al. 2007). Recent evidence has suggested that G-quadruplexes may exist in vivo 
and may play putative roles in various biological processes, such as the regulation of gene 
expression (Dexheimer et al. 2009; Gonzalez et al. 2009). Consequently, targeting the 
oncogenic G-quadruplexes using small molecules has emerged as an alternative strategy for 
the potential treatment of cancers (Balasubramanian et al. 2009).  
Since the discovery of the first c-myc G-quadruplex stabilizer TMPyP4 and inhibitor of c-myc 
oncogenic expression by Hurley and co-workers, many other c-myc interactive small 
molecule ligands have been identified. For example, cationic porphyrins (Grand et al. 2002), 
quindoline and berberine derivatives (Ou et al. 2007; Lu et al. 2008; Ma et al. 2008), and 
trisubstituted isoalloxazines (Bejugam et al. 2007) have been demonstrated to interfere with 
the oncogenic transcription in vitro. Quarfloxin, developed by Cylene Pharmaceuticals, 
entered clinical trials due to its ability to interact with G-quadruplexes in vivo (Duan et al. 
2001). Interestingly, quarfloxin concentrates in the nucleus and disrupts the G-quadruplex-
nucleolin interaction, leading to the redistribution of nucleolin in the nucleoplasm which 
ultimately triggers the apoptosis and inhibition of cancer cell growth. 
With advances in computer processing power and in the development of algorithms for 
molecular stimulation and docking, the use of high-throughput virtual screening for drug 
discovery has become increasingly popular (McInnes 2007). The rapid screening of a large 
chemical library using computational programs can efficiently weed out non-binding 
ligands in silico, thus dramatically reducing the number of compounds to be tested in vitro. 
While the use of computer-aided virtual screening for discovering enzyme antagonists has 
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been widely employed, the use of computational analysis for identifying G-quadruplex 
ligands has been comparatively less explored (Ma et al. 2012). In this chapter, we first 
describe the general structure of G-quadruplexes and their involvement in transcriptional 
events, particularly those relevant to oncogenic expression. We then discuss the use of in 
silico methods to identify small molecule ligands of oncogenic promoter G-quadruplexes, 
and identify features or limitations of each method. Finally, we highlight recent, 
representative, examples of promoter G-quadruplex targeting by small molecules 
discovered using in silico methods.  
2. General structure of the G-quadruplex and its involvement in 
transcriptional events  
G-quadruplexes are constructed from stacks of G-tetrads, which consist of four guanine 
bases aligned in a co-planar arrangement stabilized by Hoogsteen hydrogen-bonding and 
monovalent cations (e.g. K+ and Na+) in the central cavity (Figure 1) (Mergny et al. 1998; 
Parkinson et al. 2002; Huppert et al. 2007). G-quadruplexes exhibit a high degree of 
structural polymorphism, contributing to the wide variety of distinct G-quadruplex 
topologies that differ in strand orientation, loop size, surface and groove dimensions (Burge 
et al. 2006). Consequently, G-quadruplexes formed from different DNA sequences may 
exhibit unique structural features that can be specifically targeted by small molecule ligands 
(Monchaud et al. 2008). 
 
Figure 1. The structure of a G-tetrad stabilized by Hoogsteen hydrogen bonding and a monovalent 
cation resided in the central channel (left). Some possible topologies for an intramolecular G-
quadruplex (right). 
As previously mentioned, the occurrence of G-quadruplex-forming regions in the promoter 
region of oncogenes offers an alternative therapeutic avenue for the treatment of cancer. The 
induction of the G-quadruplex structure in the promoter region of the target gene could 
inhibit transcription of the oncogene, thus suppressing the production of the resultant 
oncoprotein. The potential to repress oncogenic expression by G-quadruplex formation can 
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be illuminated by considering the history of the efforts targeted against well-studied 
oncogene c-myc.   
 
Figure 2. Transcription regulation of oncogenes by promoter G-quadruplex formation mediated by 
small molecules (circle). 
MYC protein is a transcription factor that controls cell proliferation, differentiation and 
apoptosis (Marcu et al. 1992), and its cellular level is strictly regulated in normal cells. 
Mutation of c-myc and the overexpression of the MYC protein are observed in around 80% 
of solid tumors, including cervical carcinoma, myeloid leukemias and osteosarcomas (Lutz 
et al. 2002; Meyer et al. 2008; Wierstra et al. 2008). Accumulating evidence has revealed that 
the c-myc promoter region plays a pivotal role in the regulation of c-myc transcriptional 
activity. In particular, the nuclear hypersensitivity element III1 (NHE III1), a 27 bp guanine 
rich sequence located upstream of the c-myc protein, has been reported to control around 
90% of c-myc transcription (Davis et al. 1989). In vitro experiments suggested that this 
sequence is able to fold into an intramolecular parallel G-quadruplex with predominant 
1:2:1 and 2:1:1 loop topologies (Seenisamy et al. 2004). Hurley and co-workers showed the 
basal transcription activity of c-myc can be significantly enhanced by destabilizing the c-myc 
G-quadruplex through a guanine-to-thymine mutation in the quadruplex-forming sequence 
(Siddiqui-Jain et al. 2002). In the same report, they demonstrated the suppression of 
oncogenic c-myc transcription activity by a cationic porphyrin that can stabilize the G-
quadruplex structure (Siddiqui-Jain et al. 2002). These results demonstrated that the c-myc 
promoter G-quadruplex may act as a regulator of oncogenic transcription, and that small 
molecule stabilizers of the G-quadruplex could potentially down-regulate the expression of 
oncogenes (Figure 2).  
These promoter G-quadruplex-stabilizing ligands have potential advantages as alternative 
anti-cancer compounds compared to conventional protein or enzyme inhibitors 
(Balasubramanian et al. 2011). Firstly, since the availability of G-quadruplexes in cells is 
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generally limited, a lower concentration of inhibitor could theoretically be used to achieve 
the desired biological effect. Secondly, due to the unique structural diversity of G-
quadruplex motifs, superior selectivity towards a particular G-quadruplex may be 
potentially achieved by the rational design and modification of the lead compound. Thirdly, 
a number of oncogenes such as c-kit, BRAF and c-myc, which have been reported to contain 
G-quadruplex-forming motifs in their promoter regions, encode kinase or protein products 
that have been clinically validated as targets for the treatment of cancer. However,  a 
number of issues remain for the development of effective promoter G-quadruplex ligands 
for the treatment of human diseases. These include acquiring more detailed and 
comprehensive structural information on the relevant topologies of G-quadruplexes in 
living systems, as well as developing ligands with sufficient G-quadruplex selectivity and 
affinity for potential in vivo application. Leading experts Balasubramanian, Hurley and 
Neidle have recently reviewed the targeting of oncogenic promoter G-quadruplexes as a 
potential anti-cancer strategy (Balasubramanian et al. 2011).  
3. In silico methods in drug discovery 
Virtual screening techniques have recently emerged as a complementary technique to 
traditional high-throughput screening technologies employed in the pharmaceutical 
industry (Shoichet 2004; Ghosh et al. 2006; Cavasotto et al. 2007). Using computer-aided 
methodologies, large numbers of compounds can be rapidly screened in order to efficiently 
eliminate non-binding compounds in silico, thus dramatically reducing the costs associated 
with preliminary testing in a drug discovery project. However, while the application of in 
silico techniques for discovering enzyme inhibitors has been well-established, the targeting 
of DNA structures using virtual screening has been comparatively less explored. Broadly 
speaking, virtual screening can be sub-divided into pharmacophore modelling and 
molecular docking. A representative list of commercially available molecular docking 
softwares for both pharmacophore modelling and molecular docking (receptor-ligand 
modelling) is given in Table 1. 
Pharmacophore modelling can be further classified into structure-based and ligand-based 
methods. In structure-based pharmacophore modelling, the structure of receptor must be 
first determined using techniques such as X-ray crystallography and nuclear magnetic 
resonance (NMR). Alternatively, if the structure of particular target is not known, a model 
can be constructed by homology with closely-related structures. In general, a structure 
containing the biomolecular target complexed with its ligand is advantageous for virtual 
screening since the key features of the interaction between the ligand and the binding pocket 
can be directly examined. Some commercially available computational software programs 
such as LIGANDSCOUT (Wolber et al. 2004) and POCKET v.2 (Chen et al. 2006) are able to 
analyse the binding interaction and calculate the relevant contributions of each feature to the 
specificity and inhibitory potency of the ligand. Ligand–target interactions can include 
hydrogen bonding, ionic interactions and hydrophobic interactions, and this information 
can be harnessed to generate a three-dimensional (3D) pharmacophore model.  
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be illuminated by considering the history of the efforts targeted against well-studied 
oncogene c-myc.   
 
Figure 2. Transcription regulation of oncogenes by promoter G-quadruplex formation mediated by 
small molecules (circle). 
MYC protein is a transcription factor that controls cell proliferation, differentiation and 
apoptosis (Marcu et al. 1992), and its cellular level is strictly regulated in normal cells. 
Mutation of c-myc and the overexpression of the MYC protein are observed in around 80% 
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et al. 2002; Meyer et al. 2008; Wierstra et al. 2008). Accumulating evidence has revealed that 
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rich sequence located upstream of the c-myc protein, has been reported to control around 
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quadruplex structure (Siddiqui-Jain et al. 2002). These results demonstrated that the c-myc 
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molecule stabilizers of the G-quadruplex could potentially down-regulate the expression of 
oncogenes (Figure 2).  
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generally limited, a lower concentration of inhibitor could theoretically be used to achieve 
the desired biological effect. Secondly, due to the unique structural diversity of G-
quadruplex motifs, superior selectivity towards a particular G-quadruplex may be 
potentially achieved by the rational design and modification of the lead compound. Thirdly, 
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eliminate non-binding compounds in silico, thus dramatically reducing the costs associated 
with preliminary testing in a drug discovery project. However, while the application of in 
silico techniques for discovering enzyme inhibitors has been well-established, the targeting 
of DNA structures using virtual screening has been comparatively less explored. Broadly 
speaking, virtual screening can be sub-divided into pharmacophore modelling and 
molecular docking. A representative list of commercially available molecular docking 
softwares for both pharmacophore modelling and molecular docking (receptor-ligand 
modelling) is given in Table 1. 
Pharmacophore modelling can be further classified into structure-based and ligand-based 
methods. In structure-based pharmacophore modelling, the structure of receptor must be 
first determined using techniques such as X-ray crystallography and nuclear magnetic 
resonance (NMR). Alternatively, if the structure of particular target is not known, a model 
can be constructed by homology with closely-related structures. In general, a structure 
containing the biomolecular target complexed with its ligand is advantageous for virtual 
screening since the key features of the interaction between the ligand and the binding pocket 
can be directly examined. Some commercially available computational software programs 
such as LIGANDSCOUT (Wolber et al. 2004) and POCKET v.2 (Chen et al. 2006) are able to 
analyse the binding interaction and calculate the relevant contributions of each feature to the 
specificity and inhibitory potency of the ligand. Ligand–target interactions can include 
hydrogen bonding, ionic interactions and hydrophobic interactions, and this information 
can be harnessed to generate a three-dimensional (3D) pharmacophore model.  
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Company/Institution Software Uses
Accelrys Discovery Studio, 
Insight II 
Pharmacophore modelling, receptor-
ligand docking, de novo drug design, 
molecular stimulation 
MolSoft ICM-Pro Pharmacophore modelling, receptor-
ligand docking, 3D QSAR model 
constructions  
Tripos Sybyl Receptor-ligand docking, 




Autodock Receptor-ligand docking 
Schrodinger Phase Receptor-ligand docking, 
pharmacophore modelling 
Table 1. Examples of commercially available drug discovery softwares. 
In contrast, a prior knowledge of the biomolecular target is not needed in ligand based 
pharmacophore modelling, but instead a library of compounds with known potencies 
towards the biomolecular target is required for the construction of a training set. In silico 
techniques are then employed to generate a 3D pharmacophore that bears the representative 
electronic and steric features of the compounds from the training set. To obtain a reliable 3D 
pharmacophore, the training set should include structurally diverse compounds with in 
vitro potencies spanning a few orders of magnitude.  
To confirm the validity of the 3D pharmacophore generated from either structure-based or 
ligand-based pharmacophore modelling, cost analysis techniques can be carried out based 
on statistical calculations in order to generate the “best” hypothetical structure. The 
validated pharmacophore is then subjected to virtual screening from chemical libraries to 
identify molecules that possess similar steric and electronic features with the 
pharmacophore. However, a drawback of pharmacophore modelling is that since the 
affinity calculation only involves the matching of geometry and functional groups of the 
potential ligand with the 3D pharmacophore, the screening process will tend to reveal 
ligands that structurally and electronically resemble the training set of compounds, rather 
than uncovering novel hit scaffolds. 
On the other hand, molecular docking represents a totally different approach for virtual 
screening of bioactive compounds. Molecular docking involves stimulating the interactions 
between biomolecules and the ligands by computational algorithms. Molecular modelling 
has been gaining in popularity due to the increasing availability of biomolecular structures 
determined by either X-ray crystallography or NMR. In addition, advances in computational 
power and the continual development of more refined docking algorithms help to mitigate 
the relatively high computational strain demanded by molecular docking. In molecular 
docking, knowledge of the 3D biomolecular structure is essential, with or without the 
binding ligand. As previously described, the use of a biomolecular structure co-crystallized 
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with a ligand is preferred as the binding pocket of the ligand can be easily identified and the 
subsequent docking analysis can then be restricted to the areas around the binding pocket in 
order to avoid wastage of computational resources and to eliminate false positives that 
interact outside of the binding site. 
After completion of a virtual screening campaign, the resulting hit list of compounds can be 
subjected to experimental assays for hit validation (Figure 3). Alternatively, the hit 
structures can be used to construct analogues that can be screened in silico to potentially 
generate more potent ligands before chemical synthesis and biological testing.  
 
Figure 3. Pipeline of computer-aided drug discovery and lead optimization processes. 
4. Molecular docking to discover promoter G-quadruplex stabilizing 
ligands 
In order to drive the development of more potent and selective ligands targeting promoter 
G-quadruplexes, it is important to understand the detailed interactions between the G-
quadruplex and the ligand at the molecular scale. Molecular modelling can provide a tool 
for visualizing the three-dimensional interactions of the G-quadruplex-ligand complex in 
order to better understand the structural or functional features required for effective 
binding. Compared to pharmacophore-based methods, molecular docking can potentially 
make more effective use of the structural information of the receptor for the discovery of 
novel G-quadruplex-targeting compounds. In particular, high-quality structural data on the 
distinctive features of different promoter G-quadruplexes may aid the design and 
optimization of bioactive ligands that are able to discriminate between related G-
quadruplex topologies. In this section, we give a general overview for the in silico structure-
based discovery of oncogenic promoter G-quadruplex stabilizing ligands.  
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than uncovering novel hit scaffolds. 
On the other hand, molecular docking represents a totally different approach for virtual 
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In order to drive the development of more potent and selective ligands targeting promoter 
G-quadruplexes, it is important to understand the detailed interactions between the G-
quadruplex and the ligand at the molecular scale. Molecular modelling can provide a tool 
for visualizing the three-dimensional interactions of the G-quadruplex-ligand complex in 
order to better understand the structural or functional features required for effective 
binding. Compared to pharmacophore-based methods, molecular docking can potentially 
make more effective use of the structural information of the receptor for the discovery of 
novel G-quadruplex-targeting compounds. In particular, high-quality structural data on the 
distinctive features of different promoter G-quadruplexes may aid the design and 
optimization of bioactive ligands that are able to discriminate between related G-
quadruplex topologies. In this section, we give a general overview for the in silico structure-
based discovery of oncogenic promoter G-quadruplex stabilizing ligands.  
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Computer-aided high-throughput molecular docking and hit validation usually involves 
three stages (Tang et al. 2006). The first stage is the construction and preparation/selection of 
the chemical library, and the preparation of the biomolecular model for molecular docking. 
The second stage is the docking of the individual compounds of the chemical library against 
the biomolecule, followed by score calculation. In the third stage, the high-scoring 
compounds can be selected for in vitro biological assays to validate their activities towards 
the biomolecular target. 
4.1. Selection of chemical library  
A poorly-designed chemical library can result a high rate of false positives, or otherwise 
poor-quality hits. Therefore, the careful selection of a chemical library containing members 
possessing favourable pharmacokinetic properties (absorption, distribution, metabolism, 
excretion, and toxicity; ADMET) or structural diversity could improve the hit rate of a single 
docking campaign. Today, most chemical libraries are focused in some way by applying a 
manually selected pre-filter. For example, the Lipinski rule-of-five is a common filter that 
represents a collection of structural properties correlated with desirable solubility and 
bioavailability of small molecules (Lipinski et al. 2001). Screening compounds libraries with 
a pre-filter reduces the likelihood of identifying hit compounds with undesirable ADMET 
properties, therefore minimizing any loss of investment in chemical synthesis or biological 
assays. Two types of chemical libraries commonly chosen for virtual screening campaigns 
are drug/drug-like databases and natural product libraries. 
 
Name Company Size of library URL




ZINC Bioinfomatics and 
Chemical Informatics 
Research Center (BCIRC) 
>21 million http://zinc.docking.org/ 
IBS Database InterBioScreen Ltd >45000 http://www.ibscreen.com/na
tural.shtml 






DrugBank  University of Alberta 6711 http://www.drugbank.ca/ 
Table 2. Examples of commercially available chemical libraries used in computer-aided drug 
discovery. 
Approved drugs usually have favourable or validated pharmacokinetic properties and 
toxicological profiles, which can improve the hit rate of the screening campaign, and could 
allow promising hit compounds to potentially bypass early-stage testing, thus streamlining 
the hit-to-lead optimization process. However, the use of an existing drug library for virtual 
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screening cannot uncover novel bioactive compounds against the biological target. On the 
other hand, natural products represent the largest class of compounds in the chemical 
world. The interactions of natural products with biomolecules have been refined throughout 
evolutionary timescales, and these unique interactions can be harnessed by medicinal 
chemists to discover potential drugs. Since most natural products do not strictly adhere to 
Lipinski rule-of-fives, the virtual screening of natural product libraries can yield novel 
bioactive scaffolds that could not be obtained from drug-like or combinatorial libraries. 
Examples of commercially available drug databases and natural product libraries that can 
be used in high-throughput virtual screening are shown in Table 2. 
4.2. Receptor preparation 
To construct the receptor model for molecular docking, the atomic coordinates of G-
quadruplex solved by the X-ray crystallography and NMR studies with or without bound 
ligand can usually be retrieved from the Protein Data Bank (Berman et al. 2000) or Nucleic 
Acid Database (Berman et al. 1996). Generally, structural data obtained from X-ray 
crystallography is considered more advantageous compared to those from solution NMR 
studies, as more detailed structural information can be obtained at the atomic scale. For G-
quadruplexes lacking hard structural data, a model can be constructed by homology by 
modification of known, related G-quadruplex structures determined by X-ray 
crystallography. Commercially available software such as Discovery Studio (Accelrys Inc.) 
or ICM-Pro (Molsoft) can perform modification of the G-quadruplex conformation or 
topology through the addition or deletion of nucleobases, addition of monovalent cations in 
the central ion channel, or modification of the loop length and/or addition of nucleotides in 
the loop region (Lee et al. 2010).  
4.3. G-quadruplex flexibility 
The receptor model prepared can then be subjected to local energy minimization to generate 
the most suitable conformer for subsequent molecular docking analysis. While the small 
molecule ligands are usually assumed to be flexible so that the binding geometry of the 
ligand can be corrected predicted, the target is usually assumed to be mostly rigid, as the 
explicit treatment of receptor flexibility in the docking calculations would be too 
computationally expensive. Several approaches have been proposed to account for receptor 
flexibility in virtual screening campaigns. In the case of the G-quadruplex, the flexibility of 
the loop regions could be important especially for G-quadruplex groove-binding ligands.  
An early approach tackling the problem of receptor flexibility was the “soft-docking” 
method (Jiang et al. 1991). In this approach, the compounds need not fit perfectly to the 
binding pocket of receptor and a certain degree of steric crash is allowed. During the 
docking process, the ligand and the receptor adjust their conformations continuously in 
order to achieve the most suitable conformation with maximum interaction. However, this 
method only utilizes a single receptor conformation, and thus the choice of receptor model 
for docking is of the utmost importance.  
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Computer-aided high-throughput molecular docking and hit validation usually involves 
three stages (Tang et al. 2006). The first stage is the construction and preparation/selection of 
the chemical library, and the preparation of the biomolecular model for molecular docking. 
The second stage is the docking of the individual compounds of the chemical library against 
the biomolecule, followed by score calculation. In the third stage, the high-scoring 
compounds can be selected for in vitro biological assays to validate their activities towards 
the biomolecular target. 
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poor-quality hits. Therefore, the careful selection of a chemical library containing members 
possessing favourable pharmacokinetic properties (absorption, distribution, metabolism, 
excretion, and toxicity; ADMET) or structural diversity could improve the hit rate of a single 
docking campaign. Today, most chemical libraries are focused in some way by applying a 
manually selected pre-filter. For example, the Lipinski rule-of-five is a common filter that 
represents a collection of structural properties correlated with desirable solubility and 
bioavailability of small molecules (Lipinski et al. 2001). Screening compounds libraries with 
a pre-filter reduces the likelihood of identifying hit compounds with undesirable ADMET 
properties, therefore minimizing any loss of investment in chemical synthesis or biological 
assays. Two types of chemical libraries commonly chosen for virtual screening campaigns 
are drug/drug-like databases and natural product libraries. 
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the hit-to-lead optimization process. However, the use of an existing drug library for virtual 
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screening cannot uncover novel bioactive compounds against the biological target. On the 
other hand, natural products represent the largest class of compounds in the chemical 
world. The interactions of natural products with biomolecules have been refined throughout 
evolutionary timescales, and these unique interactions can be harnessed by medicinal 
chemists to discover potential drugs. Since most natural products do not strictly adhere to 
Lipinski rule-of-fives, the virtual screening of natural product libraries can yield novel 
bioactive scaffolds that could not be obtained from drug-like or combinatorial libraries. 
Examples of commercially available drug databases and natural product libraries that can 
be used in high-throughput virtual screening are shown in Table 2. 
4.2. Receptor preparation 
To construct the receptor model for molecular docking, the atomic coordinates of G-
quadruplex solved by the X-ray crystallography and NMR studies with or without bound 
ligand can usually be retrieved from the Protein Data Bank (Berman et al. 2000) or Nucleic 
Acid Database (Berman et al. 1996). Generally, structural data obtained from X-ray 
crystallography is considered more advantageous compared to those from solution NMR 
studies, as more detailed structural information can be obtained at the atomic scale. For G-
quadruplexes lacking hard structural data, a model can be constructed by homology by 
modification of known, related G-quadruplex structures determined by X-ray 
crystallography. Commercially available software such as Discovery Studio (Accelrys Inc.) 
or ICM-Pro (Molsoft) can perform modification of the G-quadruplex conformation or 
topology through the addition or deletion of nucleobases, addition of monovalent cations in 
the central ion channel, or modification of the loop length and/or addition of nucleotides in 
the loop region (Lee et al. 2010).  
4.3. G-quadruplex flexibility 
The receptor model prepared can then be subjected to local energy minimization to generate 
the most suitable conformer for subsequent molecular docking analysis. While the small 
molecule ligands are usually assumed to be flexible so that the binding geometry of the 
ligand can be corrected predicted, the target is usually assumed to be mostly rigid, as the 
explicit treatment of receptor flexibility in the docking calculations would be too 
computationally expensive. Several approaches have been proposed to account for receptor 
flexibility in virtual screening campaigns. In the case of the G-quadruplex, the flexibility of 
the loop regions could be important especially for G-quadruplex groove-binding ligands.  
An early approach tackling the problem of receptor flexibility was the “soft-docking” 
method (Jiang et al. 1991). In this approach, the compounds need not fit perfectly to the 
binding pocket of receptor and a certain degree of steric crash is allowed. During the 
docking process, the ligand and the receptor adjust their conformations continuously in 
order to achieve the most suitable conformation with maximum interaction. However, this 
method only utilizes a single receptor conformation, and thus the choice of receptor model 
for docking is of the utmost importance.  
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An alternative strategy that may be useful in G-quadruplex ligand discovery is the use of 
multiple receptor conformations (MRC) to probe the receptor flexibility (Totrov et al. 2008). 
This could involve a combination of multiple structures experimentally determined by X-ray 
crystallography or NMR, or could be generated by molecular stimulation (MD). By 
considering the different receptor features from multiple conformations, a more 
representative receptor conformation could be generated for virtual screening. Some 
modern docking algorithms are able to explicitly model receptor flexibility, but this is 
usually constrained to the ligand binding domain in order to conserve computing resources. 
A more thorough discussion of the common approaches used to model receptor flexibility 
can be found in review articles by Kavraki and co-worker (Teodoro et al. 2003), and Durrant 
and co-worker (Durrant et al. 2010). 
4.4. Global energy optimization 
The compounds from the chemical libraries are docked to the receptor structure 
individually. Generally, assigning the docking site across the entire G-quadruplex structure 
yields end-stacking compounds as the highest-scoring hits. For discovering groove-binders, 
which typically display weaker binding affinities, the search area for docking can be limited 
to the groove or loop regions of the G-quadruplex. Once the compound has been docked 
into the receptor, most computer algorithms will perform global energy optimization of the 
small molecule inside the binding pocket to find the most favourable orientation of the small 
molecule (Abagyan et al. 1994). For example, ICM-Pro (Molsoft) docking software (Abagyan 
et al. 1997) includes the following steps for global energy optimization: 
1. A random conformational change of free variables according to a predefined 
continuous probability distribution. 
2. A local energy minimization of analytical differentiable terms. 
3. A calculation of the complete energy including non-differentiable terms such us 
entropy and solvation energy. 
4. An acceptance or rejection of the total energy based on the Metropolis criterion and a 
return to the first step. 
4.5. Score assignment 
After the global energy optimization, score assignment is then performed to rank the 
compounds according to their predicted binding affinities. The score is a qualitative 
parameter that reflects the binding strength of the compound to the receptor and is 
composed a collection of factors such as hydrophobic interactions, van der Waal 
interactions, hydrogen bonding, and electrostatic interactions. However, the accuracy of the 
docking score will necessarily be limited by the assumptions and approximations of the 
scoring function. Other factors which may not be explicitly predicted by the computational 
algorithms, such as solvent environment and binding pocket availability, could also 
influence the actual binding affinity of the ligand.  
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Different docking programs may employ different scoring functions, which are generally 
classified into the following types: 1) force-field functions; 2) knowledge-based scoring 
functions; and 3) empirical scoring functions (Kitchen et al. 2004). These scoring functions 
perform calculations that involve different parameters such as statistical potential and 
weighted interaction terms to rank the apparent potency of the compounds. To improve the 
accuracy of the scoring assignment, the consensus scoring approach has been investigated. 
This strategy involves the combination of the weighted scores obtained for a single ligand 
from different score functions, to improve the hit rate of a docking campaign (Charifson et 
al. 1999; Clark et al. 2002; Baber et al. 2005; Yang et al. 2005). 
5. Structure-based lead optimization 
In the conventional drug discovery, validation of a screening hit by in vitro assays is usually 
followed by the synthesis of a range of structurally related analogues in order to optimize 
the binding and selectivity of the ligand towards the target. However, this approach 
necessarily entails a significant investment into manpower and materials, and can be very 
time-consuming. An alternative strategy utilizes the principles of computer-aided structure-
based design in order to achieve the more efficient allocation of resources towards 
analogues with higher predicted binding affinities. By analysis of the receptor-ligand 
complex determined using X-ray crystallography or molecular modelling, a library of 
derivatives can be generated in silico that retain the important features of hit ligand that 
contribute to high binding affinity. This focused library can then undergo a second round of 
molecular docking procedure to identify the most promising derivatives for synthesis and 
evaluation.. The application of in silico structure-based optimization has also been applied 
for the development of oncogenic promoter G-quadruplex stabilizing ligands.  
6. Discovery of oncogenic promoter G-quadruplex-stabilizing ligands 
using structure-based approaches 
The use of in silico virtual screening to discover promoter G-quadruplex-stabilizing ligands 
has only been recently reported. Tang and co-workers utilized ligand-based pharmacophore 
modelling techniques to identify two non-planar alkaloids as groove binders of the parallel 
G-quadruplex (Li et al. 2009). In their report, the representative pharmacophore was 
constructed using the CATALYST software package (version 4.11, Accelrys Inc.) (Nicklaus 
et al. 1997). A total of 38 1,4-disubstituted anthraquinone derivatives comprised the training 
set, with IC50 values against rat glioma C6 cells spanning three orders of magnitudes (from 
0.07 mM to 103 mM). Ten hypothetical models were constructed using the HypoGen 
hypothesis process, with the best pharmacophore containing one hydrogen bond receptor, 
one hydrogen bond donor, one positive ionizable group and two hydrophobic sites. The 
best pharmacophore model was selected for virtual screening and was mapped against a 
natural product database containing ca. 10,000 compounds derived from Chinese herbal 
medicines. A total of 176 hit compounds were identified with a diversity of scaffolds 
different to those of the training set, and 20 compounds were chosen for further evaluation 
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An alternative strategy that may be useful in G-quadruplex ligand discovery is the use of 
multiple receptor conformations (MRC) to probe the receptor flexibility (Totrov et al. 2008). 
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After the global energy optimization, score assignment is then performed to rank the 
compounds according to their predicted binding affinities. The score is a qualitative 
parameter that reflects the binding strength of the compound to the receptor and is 
composed a collection of factors such as hydrophobic interactions, van der Waal 
interactions, hydrogen bonding, and electrostatic interactions. However, the accuracy of the 
docking score will necessarily be limited by the assumptions and approximations of the 
scoring function. Other factors which may not be explicitly predicted by the computational 
algorithms, such as solvent environment and binding pocket availability, could also 
influence the actual binding affinity of the ligand.  
 
Structure-Based Approaches Targeting Oncogene Promoter G-Quadruplexes 141 
Different docking programs may employ different scoring functions, which are generally 
classified into the following types: 1) force-field functions; 2) knowledge-based scoring 
functions; and 3) empirical scoring functions (Kitchen et al. 2004). These scoring functions 
perform calculations that involve different parameters such as statistical potential and 
weighted interaction terms to rank the apparent potency of the compounds. To improve the 
accuracy of the scoring assignment, the consensus scoring approach has been investigated. 
This strategy involves the combination of the weighted scores obtained for a single ligand 
from different score functions, to improve the hit rate of a docking campaign (Charifson et 
al. 1999; Clark et al. 2002; Baber et al. 2005; Yang et al. 2005). 
5. Structure-based lead optimization 
In the conventional drug discovery, validation of a screening hit by in vitro assays is usually 
followed by the synthesis of a range of structurally related analogues in order to optimize 
the binding and selectivity of the ligand towards the target. However, this approach 
necessarily entails a significant investment into manpower and materials, and can be very 
time-consuming. An alternative strategy utilizes the principles of computer-aided structure-
based design in order to achieve the more efficient allocation of resources towards 
analogues with higher predicted binding affinities. By analysis of the receptor-ligand 
complex determined using X-ray crystallography or molecular modelling, a library of 
derivatives can be generated in silico that retain the important features of hit ligand that 
contribute to high binding affinity. This focused library can then undergo a second round of 
molecular docking procedure to identify the most promising derivatives for synthesis and 
evaluation.. The application of in silico structure-based optimization has also been applied 
for the development of oncogenic promoter G-quadruplex stabilizing ligands.  
6. Discovery of oncogenic promoter G-quadruplex-stabilizing ligands 
using structure-based approaches 
The use of in silico virtual screening to discover promoter G-quadruplex-stabilizing ligands 
has only been recently reported. Tang and co-workers utilized ligand-based pharmacophore 
modelling techniques to identify two non-planar alkaloids as groove binders of the parallel 
G-quadruplex (Li et al. 2009). In their report, the representative pharmacophore was 
constructed using the CATALYST software package (version 4.11, Accelrys Inc.) (Nicklaus 
et al. 1997). A total of 38 1,4-disubstituted anthraquinone derivatives comprised the training 
set, with IC50 values against rat glioma C6 cells spanning three orders of magnitudes (from 
0.07 mM to 103 mM). Ten hypothetical models were constructed using the HypoGen 
hypothesis process, with the best pharmacophore containing one hydrogen bond receptor, 
one hydrogen bond donor, one positive ionizable group and two hydrophobic sites. The 
best pharmacophore model was selected for virtual screening and was mapped against a 
natural product database containing ca. 10,000 compounds derived from Chinese herbal 
medicines. A total of 176 hit compounds were identified with a diversity of scaffolds 
different to those of the training set, and 20 compounds were chosen for further evaluation 
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based on compound availability. Intriguingly, the hit compounds included two neutral non-
planar compounds, peimine (1) and peimimine (2). In UV melting experiments, peimine (2) 
and peimimine (3) were found to stabilize the tetramolecular G-quadruplex motif with 
significant increases in Tm. Further experiments indicated that both compounds were 
selective for parallel G-quadruplexes, and did not stabilize other G-quadruplex topologies 
or duplex DNA. Circular dichroism (CD) experiments found that compound 1 was able to 
enhance the characteristic parallel G-quadruplex CD signal at 262 nm of all the parallel G-
quadruplexes examined, including c-kit oncogenic promoter G-quadruplex. The study from 
Tang and co-workers demonstrated the feasibility of employing ligand-based 
pharmacophore modelling to identity novel oncogenic promoter G-quadruplex-stabilizing 
compounds. However, further research would be required to fully characterize the possible 
biological effects of the compound in living cells.  
In 2010, our group has employed high-throughput virtual screening techniques to identify 
fonsecin B (3) as a c-myc G-quadruplex stabilizer (Lee et al. 2010). Since no X-ray structure of 
the c-myc G-quadruplex was available, a molecular model of the predominant 1:2:1 loop 
isomer of c-myc G-quadruplex was constructed using the X-ray crystal structure of the 
related intramolecular human telomeric G-quadruplex. The model was built by the insertion 
or deletion of nucleobases and modification of the loop size to correspond to the 1:2:1 loop 
isomer of the c-myc G-quadruplex (Ou et al. 2007) using ICM-Pro (Molsoft). After the 
preparation of the receptor model, over 20,000 compounds from a natural product library 
were docked against the molecular model using the Molsoft ICM-Pro (3.6.1 d) docking 
protocol. Since most G-quadruplex stabilizing ligands possess a large polyaromatic scaffold 
for end-stacking, the docking area to the termini of the G-quadruplex was restricted to avoid 
the wastage of computational time. From the results of the virtual screening campaign, four 
hits were identified and tested in a preliminary in vitro PCR stop assay to assess their 
abilities to stabilize the c-myc G-quadruplex, and fonsecin B (3) emerged as the top 
candidate.  
A variety of experiments were performed to analyze the interaction and selectivity of 
fonsecin B towards the c-myc G-quadruplex. UV-visible absorption spectroscopy revealed 
that compound 3 displayed 5.5-fold and 16.5-fold higher binding affinities for the c-myc G-
quadruplex over duplex and single-stranded DNA, respectively. We then performed a 
detailed molecular modelling experiment in order to investigate the binding mode of the 
compound to the c-myc G-quadruplex. The modelling results revealed that 3 was stacked 
against the 3ʹ-terminal of G-quadruplex with a binding energy of –48 kcal mol–1. The 
phenolic and carbonyl oxygen atoms were predicted to orientate towards the central ionic 
channel, where the two oxygen atoms could possibly be stabilized by electrostatic 
interactions with the potassium ion. By comparison, intercalation of 3 into the G-quadruplex 
was calculated to be extremely unfavourable, with a binding energy of ca. 25 kcal mol–1. PCR 
stop assays showed that 3 was able to stabilize the c-myc G-quadruplex with the similar 
potency to the well-known G-quadruplex ligand TmPyP4.  
Apart from the high-throughput virtual screening of chemical libraries, structure-based 
optimization by in silico approaches have also been employed to improve the potency of the 
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lead compounds to a particular oncogenic promoter G-quadruplex target. In 2009, Che and 
co-workers developed a series of Pt(II) complexes as c-myc G-quadruplex stabilizing ligands 
using an in silico structure-based optimization strategy (Wu et al. 2009). Among a series of 
Pt(II)-salphen complexes tested in preliminary in vitro assays, complex 4 was found to be 
most potent and was chosen for in silico structural modification. Over 60 derivatives of 
complex 4 were designed that contained side chains with various lengths and functional 
groups to interact with the grooves of the G-quadruplex, and these compounds were docked 
to the c-myc G-quadruplex using the ICM program. In the molecular docking analysis, the 
highest scoring compound 5 was found to bind more favorably to the c-myc G-quadruplex 
compared to the parent complex 4 due to the additional interactions between the side chains 
of 5 with the G-quadruplex grooves regions. Compound 5 was then synthesized for 
biological evaluation, and the PCR stop assay results showed 5 could stabilize the formation 
of the c-myc G-quadruplex with an IC50 value of 4.4 µM, which was an order lower than that 
of parent compound 4. In this report, Che and co-workers successfully demonstrate the use 
of structure-based optimization of a Pt(II)-salphen complex to devise a more promising 
scaffold for stabilization of the c-myc oncogenic promoter G-quadruplex.  
 
Figure 4. Structures of promoter G-quadruplex-targeting compounds discovered via high-throughput 
virtual screening. 
Later, the Che group reported another successful application of computer-based lead 
optimization of Pt(II) metal complexes to discover efficient c-myc G-quadruplex stabilizing 
ligands (Wang et al. 2010). Based on hit complex 6, over 550 derivatives were designed by 
attaching side chains of various lengths and functionality to the parent scaffold, the library 
of compounds were rapidly screened in silico. Three of the highest scoring complexes 7–9 
were then synthesized and subjected to comprehensive in vitro assays to evaluate their 
ability to stabilize the c-myc G-quadruplex. In the UV-Vis absorption experiments, all three 
complexes showed at least 10-fold higher binding affinities towards the c-myc G-quadruplex 
over duplex DNA. Furthermore, the complexes increased the Tm of the c-myc G-quadruplex 
by over 9 °C, and displayed improved potency at stabilizing the c-myc G-quadruplex in the 
PCR stop assay when compared to the parent compound. Subsequent reverse transcriptase 
PCR (RT-PCR) experiments showed that the mRNA level of the c-myc gene could be 
significantly diminished in the presence of complexes 7–9, suggesting that these compounds 
could be used as suppressors of oncogenic expressing in living cells. This report by Che and 
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based on compound availability. Intriguingly, the hit compounds included two neutral non-
planar compounds, peimine (1) and peimimine (2). In UV melting experiments, peimine (2) 
and peimimine (3) were found to stabilize the tetramolecular G-quadruplex motif with 
significant increases in Tm. Further experiments indicated that both compounds were 
selective for parallel G-quadruplexes, and did not stabilize other G-quadruplex topologies 
or duplex DNA. Circular dichroism (CD) experiments found that compound 1 was able to 
enhance the characteristic parallel G-quadruplex CD signal at 262 nm of all the parallel G-
quadruplexes examined, including c-kit oncogenic promoter G-quadruplex. The study from 
Tang and co-workers demonstrated the feasibility of employing ligand-based 
pharmacophore modelling to identity novel oncogenic promoter G-quadruplex-stabilizing 
compounds. However, further research would be required to fully characterize the possible 
biological effects of the compound in living cells.  
In 2010, our group has employed high-throughput virtual screening techniques to identify 
fonsecin B (3) as a c-myc G-quadruplex stabilizer (Lee et al. 2010). Since no X-ray structure of 
the c-myc G-quadruplex was available, a molecular model of the predominant 1:2:1 loop 
isomer of c-myc G-quadruplex was constructed using the X-ray crystal structure of the 
related intramolecular human telomeric G-quadruplex. The model was built by the insertion 
or deletion of nucleobases and modification of the loop size to correspond to the 1:2:1 loop 
isomer of the c-myc G-quadruplex (Ou et al. 2007) using ICM-Pro (Molsoft). After the 
preparation of the receptor model, over 20,000 compounds from a natural product library 
were docked against the molecular model using the Molsoft ICM-Pro (3.6.1 d) docking 
protocol. Since most G-quadruplex stabilizing ligands possess a large polyaromatic scaffold 
for end-stacking, the docking area to the termini of the G-quadruplex was restricted to avoid 
the wastage of computational time. From the results of the virtual screening campaign, four 
hits were identified and tested in a preliminary in vitro PCR stop assay to assess their 
abilities to stabilize the c-myc G-quadruplex, and fonsecin B (3) emerged as the top 
candidate.  
A variety of experiments were performed to analyze the interaction and selectivity of 
fonsecin B towards the c-myc G-quadruplex. UV-visible absorption spectroscopy revealed 
that compound 3 displayed 5.5-fold and 16.5-fold higher binding affinities for the c-myc G-
quadruplex over duplex and single-stranded DNA, respectively. We then performed a 
detailed molecular modelling experiment in order to investigate the binding mode of the 
compound to the c-myc G-quadruplex. The modelling results revealed that 3 was stacked 
against the 3ʹ-terminal of G-quadruplex with a binding energy of –48 kcal mol–1. The 
phenolic and carbonyl oxygen atoms were predicted to orientate towards the central ionic 
channel, where the two oxygen atoms could possibly be stabilized by electrostatic 
interactions with the potassium ion. By comparison, intercalation of 3 into the G-quadruplex 
was calculated to be extremely unfavourable, with a binding energy of ca. 25 kcal mol–1. PCR 
stop assays showed that 3 was able to stabilize the c-myc G-quadruplex with the similar 
potency to the well-known G-quadruplex ligand TmPyP4.  
Apart from the high-throughput virtual screening of chemical libraries, structure-based 
optimization by in silico approaches have also been employed to improve the potency of the 
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lead compounds to a particular oncogenic promoter G-quadruplex target. In 2009, Che and 
co-workers developed a series of Pt(II) complexes as c-myc G-quadruplex stabilizing ligands 
using an in silico structure-based optimization strategy (Wu et al. 2009). Among a series of 
Pt(II)-salphen complexes tested in preliminary in vitro assays, complex 4 was found to be 
most potent and was chosen for in silico structural modification. Over 60 derivatives of 
complex 4 were designed that contained side chains with various lengths and functional 
groups to interact with the grooves of the G-quadruplex, and these compounds were docked 
to the c-myc G-quadruplex using the ICM program. In the molecular docking analysis, the 
highest scoring compound 5 was found to bind more favorably to the c-myc G-quadruplex 
compared to the parent complex 4 due to the additional interactions between the side chains 
of 5 with the G-quadruplex grooves regions. Compound 5 was then synthesized for 
biological evaluation, and the PCR stop assay results showed 5 could stabilize the formation 
of the c-myc G-quadruplex with an IC50 value of 4.4 µM, which was an order lower than that 
of parent compound 4. In this report, Che and co-workers successfully demonstrate the use 
of structure-based optimization of a Pt(II)-salphen complex to devise a more promising 
scaffold for stabilization of the c-myc oncogenic promoter G-quadruplex.  
 
Figure 4. Structures of promoter G-quadruplex-targeting compounds discovered via high-throughput 
virtual screening. 
Later, the Che group reported another successful application of computer-based lead 
optimization of Pt(II) metal complexes to discover efficient c-myc G-quadruplex stabilizing 
ligands (Wang et al. 2010). Based on hit complex 6, over 550 derivatives were designed by 
attaching side chains of various lengths and functionality to the parent scaffold, the library 
of compounds were rapidly screened in silico. Three of the highest scoring complexes 7–9 
were then synthesized and subjected to comprehensive in vitro assays to evaluate their 
ability to stabilize the c-myc G-quadruplex. In the UV-Vis absorption experiments, all three 
complexes showed at least 10-fold higher binding affinities towards the c-myc G-quadruplex 
over duplex DNA. Furthermore, the complexes increased the Tm of the c-myc G-quadruplex 
by over 9 °C, and displayed improved potency at stabilizing the c-myc G-quadruplex in the 
PCR stop assay when compared to the parent compound. Subsequent reverse transcriptase 
PCR (RT-PCR) experiments showed that the mRNA level of the c-myc gene could be 
significantly diminished in the presence of complexes 7–9, suggesting that these compounds 
could be used as suppressors of oncogenic expressing in living cells. This report by Che and 
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co-workers again demonstrated the feasibility of in silico structure-based lead optimization 
of metal complexes, and suggested that the use of a larger chemical library of derivatives 
could generate a larger diversity of hits with potentially improved potencies. 
 
Figure 5. Chemical structures of the platinum(II) complexes discovered through in silico structure-
based optimization as c-myc oncogenic G-quadruplex stabilizing ligands. 
Our group has recently reported the structural-based optimization of FDA-approved drug 
methylene blue (MB) to generate more potent analogues as c-myc G-quadruplex stabilizers 
(Chan et al. 2011). Over 3,000 FDA-approved drugs were screened in silico against the 1:2:1 
loop isomer model of the c-myc G-quadruplex developed by our group, and MB emerged as 
the top candidate. Although the MB is a well-known DNA intercalator and has been 
previously reported to bind the G-quadruplex, its application as a c-myc oncogenic promoter 
G-quadruplex stabilizer was first discovered by our group. 50 MB derivatives were 
designed in silico and were docked against the c-myc G-quadruplex using ICM-Pro software. 
Compounds 10a–c bearing a bromophenyl pendant linked by an aliphatic side chain 
showed the greatest binding energy from the virtual screening, and they were synthesized 
for biological evaluation. In the fluorescence intercalator displacement (FID) assay, 
compound 10b was found to effectively displace thiazole orange (TO) from the c-myc G-
quadruplex with a DC50 value of 0.75 µM, while compounds 10a and 10c displayed higher 
DC50 values of ca. 6 and 2 µM, respectively. Furthermore, compound 10b could inhibit Taq 
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polymerase mediated-extension of the c-myc sequence through induction of the G-
quadruplex structure in the PCR stop assay with superior potency compared to the parent 
compound MB. Detailed molecular docking analysis revealed that compound 10b was 
predicted to form strong end-stacking interactions with the terminal of c-myc G-quadruplex 
with groove interactions, whereas the parent compound MB was predicted to interact with 
the G-quadruplex via a mostly intercalative mode. In living cells, compound 10b was shown 
to be effectively down-regulate the c-myc promoter activity with an IC50 value of ca. 1 µM as 
revealed by a luciferase assay. The increased activity of the 10b compared to MB against c-
myc promoter activity could be potentially attributed, at least in part, to the stabilization of 
c-myc G-quadruplex structure. This report demonstrated the structure-based lead 
optimization approach effectively generate novel analogues of existing drug as oncogenic G-
quadruplex stabilizing ligands. 
 
Figure 6. Chemical structures of the FDA-approved drug methylene blue and its analogues designed 
by a structural-based optimization strategy as c-myc oncogenic G-quadruplex stabilizing ligands. 
7. Conclusion 
The identification of oncogenes involved in the progression of various types of tumours has 
stimulated the development of various anti-cancer strategies targeting oncogenic 
expression. The discovery of G-quadruplex motifs in the promoter regions of oncogenes and 
the elucidation of their putative roles in the regulation of oncogenic transcription has 
opened a new potential therapeutic avenue for the treatment of cancer. However, it should 
be noted that the application of G-quadruplex-stabilizing ligands for the modulation of 
oncogenic activity in living systems is still in its infancy. Most promoter quadruplex ligands 
discovered thus far have not yet progressed past pre-clinical investigation. To advance 
further, several important criteria have to be addressed. These include the bioavailability of 
G-quadruplex-binding compounds as well their conformational rigidity and promiscuity for 
other physiological targets. In particular, the action of the lead candidates against the large 
number of other gene promoters and G‑quadruplex structures that are likely to be present 
in normal cells should be rigorously assessed. These factors would aid in the determination 
of the permissible dosage and therapeutic window of the G-quadruplex-targeting 
compounds for the potential treatment of cancer. With continual advances in computational 
technologies and modelling techniques, as well as the concurrent development of more 
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co-workers again demonstrated the feasibility of in silico structure-based lead optimization 
of metal complexes, and suggested that the use of a larger chemical library of derivatives 
could generate a larger diversity of hits with potentially improved potencies. 
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showed the greatest binding energy from the virtual screening, and they were synthesized 
for biological evaluation. In the fluorescence intercalator displacement (FID) assay, 
compound 10b was found to effectively displace thiazole orange (TO) from the c-myc G-
quadruplex with a DC50 value of 0.75 µM, while compounds 10a and 10c displayed higher 
DC50 values of ca. 6 and 2 µM, respectively. Furthermore, compound 10b could inhibit Taq 
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polymerase mediated-extension of the c-myc sequence through induction of the G-
quadruplex structure in the PCR stop assay with superior potency compared to the parent 
compound MB. Detailed molecular docking analysis revealed that compound 10b was 
predicted to form strong end-stacking interactions with the terminal of c-myc G-quadruplex 
with groove interactions, whereas the parent compound MB was predicted to interact with 
the G-quadruplex via a mostly intercalative mode. In living cells, compound 10b was shown 
to be effectively down-regulate the c-myc promoter activity with an IC50 value of ca. 1 µM as 
revealed by a luciferase assay. The increased activity of the 10b compared to MB against c-
myc promoter activity could be potentially attributed, at least in part, to the stabilization of 
c-myc G-quadruplex structure. This report demonstrated the structure-based lead 
optimization approach effectively generate novel analogues of existing drug as oncogenic G-
quadruplex stabilizing ligands. 
 
Figure 6. Chemical structures of the FDA-approved drug methylene blue and its analogues designed 
by a structural-based optimization strategy as c-myc oncogenic G-quadruplex stabilizing ligands. 
7. Conclusion 
The identification of oncogenes involved in the progression of various types of tumours has 
stimulated the development of various anti-cancer strategies targeting oncogenic 
expression. The discovery of G-quadruplex motifs in the promoter regions of oncogenes and 
the elucidation of their putative roles in the regulation of oncogenic transcription has 
opened a new potential therapeutic avenue for the treatment of cancer. However, it should 
be noted that the application of G-quadruplex-stabilizing ligands for the modulation of 
oncogenic activity in living systems is still in its infancy. Most promoter quadruplex ligands 
discovered thus far have not yet progressed past pre-clinical investigation. To advance 
further, several important criteria have to be addressed. These include the bioavailability of 
G-quadruplex-binding compounds as well their conformational rigidity and promiscuity for 
other physiological targets. In particular, the action of the lead candidates against the large 
number of other gene promoters and G‑quadruplex structures that are likely to be present 
in normal cells should be rigorously assessed. These factors would aid in the determination 
of the permissible dosage and therapeutic window of the G-quadruplex-targeting 
compounds for the potential treatment of cancer. With continual advances in computational 
technologies and modelling techniques, as well as the concurrent development of more 
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focused yet diverse chemical libraries, we envisage that the discovery and investigation of 
novel promoter G-quadruplex-stabilizing ligands would continue to thrive in the near 
future. Furthermore, in silico hit-to-lead optimization allows the chemical space around hit 
compounds to be explored without necessitating the actual synthesis of analogue molecules, 
thus significantly reducing expenses associated with materials and manpower. 
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focused yet diverse chemical libraries, we envisage that the discovery and investigation of 
novel promoter G-quadruplex-stabilizing ligands would continue to thrive in the near 
future. Furthermore, in silico hit-to-lead optimization allows the chemical space around hit 
compounds to be explored without necessitating the actual synthesis of analogue molecules, 
thus significantly reducing expenses associated with materials and manpower. 
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1. Introduction 
The census of cancer genes (http://www.sanger.ac.uk/genetics/CGP/Census/) includes 487 
mutated genes (data on September 2012) manually curated from the scientic literature, 
which are proved to induce or accelerate cancer development when appropriately changed 
(point mutations, deletions, translocations or amplifications) (see criteria for inclusion in the 
cancer gene census in [1]). Studies in mice have magnified the number of the potential 
cancer genes to more than 3000 [2] and the number of mutated genes revealed in tumor 
sequencing studies are gradually approaching this number (NCG 3.0, http://bio.ifom-ieo-
campus.it/ncg) [3, 4]. Nevertheless, despite the impressive data accumulated from studies of 
gene mutations and pathway alterations, an overwhelming amount of diverse molecular 
information has offered limited understanding of the general mechanisms of cancer [5, 6]. 
For decades tumor development from precancerous lesions to obvious malignancy and 
metastases has been considered as a result of deterministic sequential accumulation of 
mutations in the handful of “driver” cancer genes, occurring in a continuous linear pattern 
of cancer progression, while genome/karyotype changes were judged as a by-product of 
transformation (see ref. in [5-10]). However, only a few genes have been shown to be 
commonly mutated in cancer sequencing studies, and they are neither highly prevalent nor 
in multiple tumor types [11-14]. Furthermore, the whole exome sequencing of multiple 
spatially separated samples obtained from the same tumor followed by phylogenetic 
reconstruction of tumor progression has revealed significant intratumoral heterogeneity 
with “no dominant clones in the cancer tissue” [15], “punctuated clonal evolution… without 
observable intermediate branching” [16] or “branched evolutionary tumor growth” with 63 
to 69% of all somatic mutations not detectable across every tumor region and some genes 
undergoing multiple distinct and spatially separated inactivating mutations within a single 
tumor [17]. High-resolution SNP array of B-cell chronic lymphocytic leukemia (B-CLL) has 
demonsterated “clearly a nonlinear, branching sub-clonal hierarchy in B-CLL with multiple 
ancestral subclones” [18]. Similarly, it has been concluded that CLL progression can occur in 
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transformation (see ref. in [5-10]). However, only a few genes have been shown to be 
commonly mutated in cancer sequencing studies, and they are neither highly prevalent nor 
in multiple tumor types [11-14]. Furthermore, the whole exome sequencing of multiple 
spatially separated samples obtained from the same tumor followed by phylogenetic 
reconstruction of tumor progression has revealed significant intratumoral heterogeneity 
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to 69% of all somatic mutations not detectable across every tumor region and some genes 
undergoing multiple distinct and spatially separated inactivating mutations within a single 
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“either a linear or branching manner, with multiple genetic subclones evolving either in 
succession or in parallel” [19]. Evaluation of the clonal relationships among pancreatic 
cancer metastases and primary tumor has led to conclusion that the genetic heterogeneity of 
metastases reflects heterogeneity already existing within the primary carcinoma, and that 
the primary carcinoma is a mixture of numerous subclones [20]. Thus, as Cahill et al [21] 
point out, “The tumor is clonal only in the sense that all cells within a tumor are derived 
from the same cell precursor. Genetic instability makes the tumor itself a population under 
change – a huge collection of coexisting subclones, each with the potential for future 
changes in the face of selective pressures”. Altogether, these data seriously contradict to 
deterministic sequential accumulation of mutations in the handful of “driver” cancer genes 
occurring in a continuous linear pattern of cancer progression postulated by conventional 
gene mutation theory of cancer.  
In contrast, chromosome instability (CIN) and the resulting magnitude of intratumor 
clonal/non-clonal heterogeneity are recognized to be the main driving forces of tumor 
evolution (immortalization, transformation, metastasis, acquisition of drug resistance) 
(reviewed in [5-10]). CIN results from persistent defects in mitotic fidelity and implies both 
whole chromosome instability and segmental chromosome instability (translocations, 
deletions, and amplifications). Although defects in telomere maintenance, sister chromatid 
cohesion, kinetochore-microtubule attachments, assembly of amphitelic bipolar mitotic 
spindles, as well as translocations containing breakpoints within fragile sites, instability of 
satellite repeats in heterochromatin, cell-in-cell formation by entosis (as a result, cytokinesis 
frequently fails, generating binucleate cells that produce aneuploid cell lineages) and 
random fragmentation of the entire chromosome (chromothripsis) in which chromosomes 
are broken into many pieces and then randomly stitched back together can contribute to 
CIN during tumor evolution, in established cancer cell lines mechanism of centrosome 
amplification and clustering is proposed to be the major contributor to CIN (discussed 
below). It is documented that extreme CIN relative to tumors with intermediate CIN is 
associated with improved survival outcome in cancer and experimental models have 
evidenced that extreme CIN has a negative impact on cellular fitness, generating 
nonneoplastic and nonviable cells, and constrains tumorigenesis. However, CIN represents 
early and causative event in cancer progression and significantly correlates with 
tumorigenic potential of cells and such clinical variables as tumor progression from 
precancerous lesions to malignant tumors and then to metastases, survival, treatment 
sensitivity, and the risk of acquired therapy resistance (reviewed in [22]).  
In this review we provide evidence that tumorigenic action of cancer genes or mutagenic 
and non-mutagenic carcinogens is directly linked to centrosome deregulation and CIN. Any 
factors or stresses that contribute to CIN inevitably promote the evolution of cancer. CIN 
and clonal/non-clonal intratumor heterogeneity are the interconnected driving forces of 
immortalization and transformation and the reasons of oncogene addiction independence of 
tumors from any particular oncogene and general ineffectiveness of targeted therapy in 
clinic.  
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2. Immortalization and transformation: The central role of karyotype 
Comparing gene expression in glioblastoma, the most aggressive form of human brain 
tumors, to the normal brain cells we have found CHI3L1 among the genes with the highest 
expression level in glioblastomas [23, 24]. Addition of CHI3L1 to cell medium increased 
mitogenic and proliferative properties of 293 cells (human embryonic kidney 293 cells, also 
often referred to as HEK293) [25, 26]. 293 cells stably transfected with CHI3L1 have an 
accelerated growth rate relatively to the parental cells and can undergo anchorage-
independent growth in soft agar that is one of the consistent indicators of oncogenic 
transformation [25, 27]. Furthermore, 293_CHI3L1 cells implanted in the rat brain of adult 
immunocompetent animals have given rise to the large intracerebral tumors with the newly 
ingrown blood vessels [27, 28].  
Previously, similar data on transformation of immortalized 293 cells by one gene 
transfection was obtained for multiple diverse genes (see ref. in [29, 30]). However, 293 cells 
themselves (the same as many other cell lines) are already immortalized. In a given case, 
ectopic expression of CHI3L1 alone results in the tumorigenic conversion of previously 
immortalized 293 cells with shared adenovirus 5 DNA [31]. An immortalized cell (as well as 
a normal cell) must acquire a number of chromosome changes to become a fully malignant 
tumor cell. Karyotype analysis of 293_CHI3L1 clones have shown that these cells differ from 
wild type [31, 32] and control cells (293_pcDNA3.1) in modal chromosome number and 
structure of chromosomes (manuscript in preparation). Other authors have also shown that 
overexpression, for example, of tripeptidyl-peptidase II [33], EBNA1 binding protein 2 [34], 
GLI1 transcripton factor [35] or Cut homeobox 1 trancription factor [36] have triggered 
centrosome and chromosomal abnormalities in 293 cells.  
Transformation with one oncogene is not cell type-spesific. Analysis of literature has 
revealed that different oncogenes with diverse and nonoverlapping intracellular functions 
are characterized by the same ability: to trigger conversion of immortalized cells (e.g., 293, 
NIH3T3, HMEC, MCF10A, HCT116) or even primary cells into malignant tumor cells or 
aggravate tumorigenicity of tumor cells (reviewed in [30]). What is the basis for cell 
immortalization and how do different cancer genes trigger conversion of immortalized and 
even primary normal cells into malignant tumor cells in vitro and in vivo? Overcoming of 
senescence and acquisition of immortality is an essential rate-limiting step in the process of 
malignant transformation of mammalian somatic cells. In vitro immortalization of various 
cell types was successfully implemented by the introduction of viral genomes/oncogenes, 
ectopic expression of human telomerase reverse transcriptase (hTERT), some transcription 
factors (e.g. c-MYC, BMI1, ZNF217, or β-catenin), or carcinogen treatment, whereas 
spontaneously immortalized cells emerge at an extremely low frequency in vitro (about 10−7) 
[30]. Multiple investigations have revealed that irrespectively of the nature of 
“immortalizing/transforming agent” for immortalization/transformation in vitro cells must 
overcome cellular senescence by inactivating/dysregulating p16INK4A-pRB and/or ARF-p53 
pathways and maintaining their telomeres by activation of hTERT expression (a 
predominant way) or by an alternative mechanism for lengthening telomeres (ALT) [30].  
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frequently fails, generating binucleate cells that produce aneuploid cell lineages) and 
random fragmentation of the entire chromosome (chromothripsis) in which chromosomes 
are broken into many pieces and then randomly stitched back together can contribute to 
CIN during tumor evolution, in established cancer cell lines mechanism of centrosome 
amplification and clustering is proposed to be the major contributor to CIN (discussed 
below). It is documented that extreme CIN relative to tumors with intermediate CIN is 
associated with improved survival outcome in cancer and experimental models have 
evidenced that extreme CIN has a negative impact on cellular fitness, generating 
nonneoplastic and nonviable cells, and constrains tumorigenesis. However, CIN represents 
early and causative event in cancer progression and significantly correlates with 
tumorigenic potential of cells and such clinical variables as tumor progression from 
precancerous lesions to malignant tumors and then to metastases, survival, treatment 
sensitivity, and the risk of acquired therapy resistance (reviewed in [22]).  
In this review we provide evidence that tumorigenic action of cancer genes or mutagenic 
and non-mutagenic carcinogens is directly linked to centrosome deregulation and CIN. Any 
factors or stresses that contribute to CIN inevitably promote the evolution of cancer. CIN 
and clonal/non-clonal intratumor heterogeneity are the interconnected driving forces of 
immortalization and transformation and the reasons of oncogene addiction independence of 
tumors from any particular oncogene and general ineffectiveness of targeted therapy in 
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However, in vivo research has shown that telomerase-deficient primary mouse embryonic 
fibroblasts (MEFs) have generated tumors in nude mice following transformation [37]. 
Transformation of human primary fibroblasts and human primary mesodermal cells has 
resulted in cells capable to form colonies in soft agar and tumors in mice but they and the 
majority of the tumors derived from them have lacked telomerase activity, and telomere 
erosion has been observed [38]. To the point, human primary melanomas show telomere 
maintenance as a late event in tumor progression (metastatic melanoma); thus, telomere 
maintenance/immortalization is associated with progression rather than initiation of 
melanoma [39]. Moreover, approximately 40% of glioblastomas have no defined telomere 
maintenance mechanism (nither telomerase expression nor the alternative lengthening of 
telomeres mechanism) [40]. Numerous studies have proved that telomere dysfunction in the 
absence of telomerase activity drives chromosomal instability/karyotype evolution through 
telomere-telomere type rearrangements (breakage-fusion-bridge cycles) promoting the 
appearance of chromosomal rearrangements and numerical chromosome aberrations, 
contributing to genomic intratumor diversity and favoring cell immortalization, the 
acquisition of a tumor phenotype and increased metastasis [41-46] 
Studing karyotype evolution in both individual cells and cell populations during various 
stages of cellular immortalization process in in vitro cell culture model it has been revealed 
that the karyotype evolution with the complex interplay between clonal and non-clonal 
chromosome abberations serves as the driving force for immortalization. By repeating the 
same experiments or analyzing the parallel clones derived from the same initial cell 
population, it has been found out that the immortalized cells display unique distinctive 
karyotypes, demonstrating the stochastic nature of karyotype evolution during cellular 
immortalization (reviewed in [5, 10]). Additional follow-up experiments have demonstrated 
that genome-based evolution can be detected in most of the major transition steps in cancer 
including immortalization, transformation, metastasis, and drug resistance [5]. Similarly, 
analyzing the karyotypes of clonal tumorigenic cell lines arising from the mass cultures of 
human cells within months after transfection with the same set of articially activated 
oncogenes it has been found that different tumorigenic cell lines had individual clonal 
karyotypes and phenotypes and the phenotypes and karyotypes of different tumors 
induced by these lines in different mice have been karyotypic and phenotypic variants of the 
parental prototypes [47].  
Thus, the process of immortalization/transformation is not simply a number of well defined 
events like inactivation of cell cycle negative regulators (p16INK4A-pRB and/or ARF-p53) and 
activation of telomerase (hTERT) but, instead, is associated with karyotype/genome 
abnormalities (structural and numeral aneuploidy as well as abberant methylation and gene 
mutations) and, as a consequence, with global changes in gene expression and function. 
Analysis of 45 spontaneously transformed murine cell lines from normal epithelial cells has 
demonstrated that supernumerary centrosomes, aneuploidy and CIN precedes 
immortalization and transformation [48]. Also, CIN precedes chemical induced malignant 
transformation [7-9]. All immortalized and malignantly transformed cells have abnormal 
karyotypes irrespectively of “immortalizing/transforming agents”, and karyotype evolution 
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plays the central role in immortalization, transformation, metastasis, and drug resistance 
(reviewed in [5-10, 22, 30, 47, 49-52]). 
3. Tumor genome profile output 
In 2008 The International Cancer Genome Consortium (http://www.icgc.org/icgc) stated the 
primary goal to comprehensively characterize over 25,000 cancer genomes from 50 different 
cancer types and/or subtypes at the genomic, epigenomic, and transcriptomic levels to 
reveal the repertoire of oncogenic mutations and signaling networks, which can be exploited 
for the development of new cancer therapies [53]. Thus, “designed to identify the Achilles’ 
heel of cancer” [54] and “driver universal cancer genes” [55] whole exome and genome 
sequencing studies (see ref. in [3, 4]) instead have revealed a large number of stochastic gene 
mutations in solid tumors for each individual with the same cancer type [11-14]. Searching 
for the “universal” cancer genes among deleted, amplified and sequence mutated genes 
across breast, colon, pancreatic cancers and glioblastoma has shown that only one gene, 
TP53, is commonly mutated in all four major cancer types [55, 56] and no single gene is 
commonly deleted or amplified [55]. Similarly, from more than 1,000 mutated genes 
identified across whole exome or genome sequencing of 10 tumor types, only 46 genes have 
been found mutated in two types, 7 (TP53, CDKN2A, RB1, PIK3CA, KRAS, NF1, and 
KIAA0774) in three types and only 1 (TP53) in four types (in 6 types) [3]. Ongoing Cancer 
Cell Line Project (http://www.sanger.ac.uk/genetics/CGP/CellLines/), which target is to 
sequence all known cancer genes in ~800 cell lines, has confirmed that TP53, CDKN2A, RB1, 
PTEN, PIK3CA, KRAS, and BRAF are the most frequenly mutated genes. 
Interestingly, analysis of 70 tyrosine kinases with altered gene expression or located at a 
genomic site of copy number gain or loss in 95 chronic lymphocytic leukemias (CLLs) has 
revealed no somatic mutations [57]. Extension of this research, sequencing of 515 kinase 
genes in 23 CLLs, has revealed only six somatically acquired mutations (e.g., in RAS and 
RAF) across all kinase genes [58]. Further B-RAF sequencing in 250 CLLs has detected four 
B-RAF mutations, none involving B-RAF amino acid residue 600, which is the predominant 
B-RAF mutation found across human tumors. N-RAS mutations were found in 2 cases and 
none of K-RAS among 234 CLLs analyzed [58].  
High-resolution analysis of somatic copy-number alterations (SCNAs) from 3,131 cancer 
specimens, belonging largely to 26 histological types, revealed a total of 75,700 gains and 
55,101 losses across the cancers, for a mean of 24 gains and 18 losses per sample [59]. An 
average of 17% of the genome was amplified and 16% deleted in a typical cancer sample. 
From all SCNAs only 158 regions of focal SCNA were altered at significant frequency across 
several cancer types, of which 122 could not be explained by the presence of a known cancer 
target gene located within these regions [59]. High-resolution aCGH analysis of 598 human 
cancer cell lines derived from 29 different tissues revealed 2424 amplifications and 14010 
deletions across the entire cell line panel [60]. SNP array screening of 746 cancer cell lines 
identified 2428 somatic homozygous deletions, which overlie 11% of protein-coding genes 
[61]. These cell lines have also been sequenced for mutations in the coding exons of 46 
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[61]. These cell lines have also been sequenced for mutations in the coding exons of 46 
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known cancer genes. In total, 1753 putative oncogenic mutations were identified [61]. 
Another research group identified 2576 somatic mutations across 1507 coding genes from 
441 tumors comprising breast, lung, ovarian and prostate cancer types and subtypes [62].  
Thus, the list of “non-universal” cancer genes and mutations within them is growing 
proportionally to seqencing studies stuffing databases. The Network of Cancer Genes (NCG 
3.0, http://bio.ifom-ieo-campus.it/ncg) collects information on hundreds of cancer genes that 
have been found mutated in 16 different cancer types [4]. These genes were collected from 
the Cancer Gene Census as well as from 18 whole exome and 11 whole-genome screenings 
of cancer samples (see referenses in [3, 4]. COSMIC database (http://www.sanger. 
ac.uk/genetics/CGP/cosmic/) combines cancer mutation data manually curated from the 
scientic literature with the output from the Cancer Genome Project [63, 64]. COSMIC 
catalogues all somatic mutations in benign and malignant tumors as well as tumor cell lines 
[65]. Release v61 (September 2012) includes 22170 genes, 405271 mutations (224649 unique 
mutations), and 8931 gene fusions, described in 773098 tumor samples (2556 whole 
genomes).  
It is worth noting that the total number of mutations in tumor samples are significantly 
underestimated, as the current methods of DNA sequencing detect a single base change 
only if it presents in >10% of the molecules, that is, therefore predominately clonal 
mutations [14]. Methodologies for studing patterns of genomic changes (e.g., aCGH and 
SNP) also detect only dominant clonal aberrations [10]. Estimate of all mutations including 
sub-clonal and random suggests that each cancer cell within most tumors contains >10,000 
mutations and by the time a tumor is clinically detected (108–109 cells) it might harbour >1011 
different mutations [14].  
Importantly, genome profiling of a tumor bulk produces average profile of genetic changes 
in a tumor sample and does not mirror heterogeneity of genetic changes within tumor 
sample, i.e., changes restricted to the separate populations of tumor cells or single tumor 
cells [66]. However, there is a high level of genomic and (epi)genetic heterogeneity within 
individual lesions, as well as between primary tumors, metastatic cells, and relapses (see ref. 
in [22]). 
4. Cancer genes induce, promote and licence CIN 
CIN/random aneuploidy and intratumor heterogeneity drive tumor evolution. Which 
should surveillance mechanisms be disrupted to unleash CIN? As it follows from tumor 
sequencing studies, beyond the overwhelming “mutator phenotype”, the most altered 
signaling pathways within and across different cancer types are p14ARF-p53 pathway 
(CDKN2A/ARF and TP53 genes), p16INK4A-pRB pathway (CDKN2A/INK4A and RB1 genes), 
MAPK pathway (NF1, KRAS, and BRAF genes) and PI3K-AKT pathway (PTEN and PIK3CA 
genes).  
CIN results from persistent defects in mitotic fidelity and is strongly favored in cells with 
disrupted p14ARF-p53 and/or p16INK4A-pRB pathways explaining their highest deregulation 
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frequency in immortalized and tumor cells [29]. Patients with Li-Fraumeni syndrome 
characterized by germline mutations of TP53 develop a wide range of malignancies 
(reviewed in [67]). Mice expressing the TP53 mutants have increased incidence of sarcomas 
and carcinomas (reviewed in [68, 69]). In contrast, "super TP53" mice, carrying TP53 alleles 
in addition to the two endogenous alleles, exhibit an enhanced response to DNA damage 
and are significantly protected from cancer when compared with normal mice [70]. Cancer 
patients with missense mutations in TP53 often have a poorer prognosis than those lacking 
TP53 entirely, as the presence of dominantly mutated p53 not only confers loss of tumor 
suppressor activity but also provides a gain of oncogenic function [68, 71]. P53 gain of 
oncogenic function mutants have enhanced oncogenic potential and effectively induce CIN 
[68, 69, 72]. In vitro and in vivo data have established that loss of p53 activity and, to a greater 
degree, dominantly mutated p53 is the major event responsible for increased expression of 
cell-cycle and proliferation-associated genes (reviewed in [73]). The presence of disrupted 
TP53/dysregulated p53 pathway is significantly associated with intratumor genetic 
heterogeneity/clonal diversity [74], radio- and (multi)drug resistance [75-78]. Strikingly, 
high-grade serous ovarian cancer is characterized by TP53 mutations in 96% of tumours (303 
of 316 samples analysed) [79], and TP53 is the most frequently known altered gene in acute 
myeloid leukemias with complex karyotype (CK-AML) [80]. Multivariable analysis of 234 
CK-AMLs revealed that TP53 alteration (70% of samples) was the most important 
prognostic factor in CK-AML, outweighing all other variables [80]. Evaluation of CIN in 
Barrett's esophagus tissue has revealed that CIN is highly correlated with TP53 LOH [81]. In 
agreement, patients with LOH in TP53 are 16 times more likely to progress from 
premalignant Barrett’s esophagus to esophageal adenocarcinoma than patients without 
TP53 LOH, supporting the hypothesis that expansion of CIN clones drive malignancy [82, 
83]. Moreover, usage of integrated DNA sequence and copy number information to 
reconstruct the order of abnormalities in individual cutaneous squamous cell carcinomas 
and serous ovarian adenocarcinomas have allowed to reveal that loss of the second TP53 
allele appears to precede not only the development of CIN but also a vast expansion of 
simple mutations [84]. Mutation in TP53 is the most common genetic alteration reported 
during metastasis to the brain in breast cancer [85]. Analysis of breast cancer cell line MCF-7 
variant overexpressing a dominantly mutated TP53 have showed that impaired p53 
function drives breast cancer progression by CIN, which generates karyotypic variability, 
leading to transcriptome signatures that are responsible for cell proliferation, epithelial-to-
mesenchymal transition, chemoresistance, and invasion [86]. Indeed, correlation of 
expression profiles with karyotypic parameters of the NCI-60 cancer cell line panel has 
revealed that CIN is associated with higher expression of genes implicated in epithelial-to-
mesenchymal transition, cancer invasiveness, and metastasis and with lower expression of 
genes involved in cell cycle checkpoints, DNA repair, and chromatin maintenance [87]. P53-
dependent pathways (as well as pRB1 pathways) alterations promote epithelial-to-
mesenchymal transition in tumor cells through both CIN licencing and global aberrant 
transcription regulation (reviewed in [88, 89]). Furthermore, proliferation of aneuploid 
human cells is limited by p53 pathway [90]. In support, in genetically engineered mutant 
mice that are prone to aneuploidy TP53 is a limiting factor in aneuploidy-induced 
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known cancer genes. In total, 1753 putative oncogenic mutations were identified [61]. 
Another research group identified 2576 somatic mutations across 1507 coding genes from 
441 tumors comprising breast, lung, ovarian and prostate cancer types and subtypes [62].  
Thus, the list of “non-universal” cancer genes and mutations within them is growing 
proportionally to seqencing studies stuffing databases. The Network of Cancer Genes (NCG 
3.0, http://bio.ifom-ieo-campus.it/ncg) collects information on hundreds of cancer genes that 
have been found mutated in 16 different cancer types [4]. These genes were collected from 
the Cancer Gene Census as well as from 18 whole exome and 11 whole-genome screenings 
of cancer samples (see referenses in [3, 4]. COSMIC database (http://www.sanger. 
ac.uk/genetics/CGP/cosmic/) combines cancer mutation data manually curated from the 
scientic literature with the output from the Cancer Genome Project [63, 64]. COSMIC 
catalogues all somatic mutations in benign and malignant tumors as well as tumor cell lines 
[65]. Release v61 (September 2012) includes 22170 genes, 405271 mutations (224649 unique 
mutations), and 8931 gene fusions, described in 773098 tumor samples (2556 whole 
genomes).  
It is worth noting that the total number of mutations in tumor samples are significantly 
underestimated, as the current methods of DNA sequencing detect a single base change 
only if it presents in >10% of the molecules, that is, therefore predominately clonal 
mutations [14]. Methodologies for studing patterns of genomic changes (e.g., aCGH and 
SNP) also detect only dominant clonal aberrations [10]. Estimate of all mutations including 
sub-clonal and random suggests that each cancer cell within most tumors contains >10,000 
mutations and by the time a tumor is clinically detected (108–109 cells) it might harbour >1011 
different mutations [14].  
Importantly, genome profiling of a tumor bulk produces average profile of genetic changes 
in a tumor sample and does not mirror heterogeneity of genetic changes within tumor 
sample, i.e., changes restricted to the separate populations of tumor cells or single tumor 
cells [66]. However, there is a high level of genomic and (epi)genetic heterogeneity within 
individual lesions, as well as between primary tumors, metastatic cells, and relapses (see ref. 
in [22]). 
4. Cancer genes induce, promote and licence CIN 
CIN/random aneuploidy and intratumor heterogeneity drive tumor evolution. Which 
should surveillance mechanisms be disrupted to unleash CIN? As it follows from tumor 
sequencing studies, beyond the overwhelming “mutator phenotype”, the most altered 
signaling pathways within and across different cancer types are p14ARF-p53 pathway 
(CDKN2A/ARF and TP53 genes), p16INK4A-pRB pathway (CDKN2A/INK4A and RB1 genes), 
MAPK pathway (NF1, KRAS, and BRAF genes) and PI3K-AKT pathway (PTEN and PIK3CA 
genes).  
CIN results from persistent defects in mitotic fidelity and is strongly favored in cells with 
disrupted p14ARF-p53 and/or p16INK4A-pRB pathways explaining their highest deregulation 
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frequency in immortalized and tumor cells [29]. Patients with Li-Fraumeni syndrome 
characterized by germline mutations of TP53 develop a wide range of malignancies 
(reviewed in [67]). Mice expressing the TP53 mutants have increased incidence of sarcomas 
and carcinomas (reviewed in [68, 69]). In contrast, "super TP53" mice, carrying TP53 alleles 
in addition to the two endogenous alleles, exhibit an enhanced response to DNA damage 
and are significantly protected from cancer when compared with normal mice [70]. Cancer 
patients with missense mutations in TP53 often have a poorer prognosis than those lacking 
TP53 entirely, as the presence of dominantly mutated p53 not only confers loss of tumor 
suppressor activity but also provides a gain of oncogenic function [68, 71]. P53 gain of 
oncogenic function mutants have enhanced oncogenic potential and effectively induce CIN 
[68, 69, 72]. In vitro and in vivo data have established that loss of p53 activity and, to a greater 
degree, dominantly mutated p53 is the major event responsible for increased expression of 
cell-cycle and proliferation-associated genes (reviewed in [73]). The presence of disrupted 
TP53/dysregulated p53 pathway is significantly associated with intratumor genetic 
heterogeneity/clonal diversity [74], radio- and (multi)drug resistance [75-78]. Strikingly, 
high-grade serous ovarian cancer is characterized by TP53 mutations in 96% of tumours (303 
of 316 samples analysed) [79], and TP53 is the most frequently known altered gene in acute 
myeloid leukemias with complex karyotype (CK-AML) [80]. Multivariable analysis of 234 
CK-AMLs revealed that TP53 alteration (70% of samples) was the most important 
prognostic factor in CK-AML, outweighing all other variables [80]. Evaluation of CIN in 
Barrett's esophagus tissue has revealed that CIN is highly correlated with TP53 LOH [81]. In 
agreement, patients with LOH in TP53 are 16 times more likely to progress from 
premalignant Barrett’s esophagus to esophageal adenocarcinoma than patients without 
TP53 LOH, supporting the hypothesis that expansion of CIN clones drive malignancy [82, 
83]. Moreover, usage of integrated DNA sequence and copy number information to 
reconstruct the order of abnormalities in individual cutaneous squamous cell carcinomas 
and serous ovarian adenocarcinomas have allowed to reveal that loss of the second TP53 
allele appears to precede not only the development of CIN but also a vast expansion of 
simple mutations [84]. Mutation in TP53 is the most common genetic alteration reported 
during metastasis to the brain in breast cancer [85]. Analysis of breast cancer cell line MCF-7 
variant overexpressing a dominantly mutated TP53 have showed that impaired p53 
function drives breast cancer progression by CIN, which generates karyotypic variability, 
leading to transcriptome signatures that are responsible for cell proliferation, epithelial-to-
mesenchymal transition, chemoresistance, and invasion [86]. Indeed, correlation of 
expression profiles with karyotypic parameters of the NCI-60 cancer cell line panel has 
revealed that CIN is associated with higher expression of genes implicated in epithelial-to-
mesenchymal transition, cancer invasiveness, and metastasis and with lower expression of 
genes involved in cell cycle checkpoints, DNA repair, and chromatin maintenance [87]. P53-
dependent pathways (as well as pRB1 pathways) alterations promote epithelial-to-
mesenchymal transition in tumor cells through both CIN licencing and global aberrant 
transcription regulation (reviewed in [88, 89]). Furthermore, proliferation of aneuploid 
human cells is limited by p53 pathway [90]. In support, in genetically engineered mutant 
mice that are prone to aneuploidy TP53 is a limiting factor in aneuploidy-induced 
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tumorigenesis [91]. All together, these data justify reputation of mutant p53 as “the demon 
of the guardian of the genome” [92] and “a master regulator of human malignancies” [93].  
Survivors of hereditary retinoblastoma, a childhood cancer of the eye caused by germline 
mutations of the RB1 tumor suppressor gene, have an elevated risk of developing sarcomas, 
brain cancer, melanoma or some epithelial cancers [94, 95]. It was shown that inactivation of 
the pRB1 pathway in the developing mouse or human retina was accompanied by p19ARF-
p53 pathway activation and RB1-deficient retinoblasts underwent p53-mediated apoptosis 
and exited the cell cycle [96]. In contrast, RB1-deficient cell with inactivated p14ARF-p53 
pathway had growth advantage, clonally expanded, and formed retinoblastoma [96]. As it is 
expected, retinoblastoma is characterized by CIN, strengthening the view that the 
chromosomal changes contribute to the development and progression of malignancy [97, 
98]. Also, analysis of hundreds of chronic lymphocytic leukemias (CLLs) has revealed a 
strong association between RB1 deletion and aberrant p53 pathway with elevated genomic 
complexity, which is a strong independent predictor of rapid disease progression, disease 
aggressiveness, short remission duration, short survival, and therapy efficaciousness in CLL 
[99-101].  
PRB1 plays a critical role in proper chromosome condensation and cohesion, centromeric 
function, and chromosome stability in mammalian cells (reviewed in [102, 103]). Inactivation 
of pRB1 not only allows inappropriate proliferation but also undermines mitotic fidelity 
leading to CIN and ploidy changes [102, 103]. pRB1 pathways deregulation correlates with 
(multi)drug and radioresistance [104, 105]. Screening of more than 25,000 compounds in 
human fibroblasts in which pRB1 activity was compromised by viral oncoproteins revealed 
that the only compounds selective for RB1-deficient cell death were topoisomerase II 
inhibitors (e.g., doxorubicin) [106]. Moreover, RB1-deficient cells displayed increased 
proliferation in the presence of the PI3K (LY294002) and MEK1/2 (U0126) inhibitors [107].  
The CDKN2A locus comprises the INK4A and ARF genes encoding tumor suppressors 
p16INK4A and p14ARF (p19ARF in mice) that up-regulate the activities of pRB1 and p53 
transcription factors, respectively [108]. Inactivation of INK4A, ARF or both genes strongly 
predisposes mice to tumor development (reviewed in [69]). Loss of p16INK4A plays a causal 
role in centrosome dysfunction and the subsequent generation of CIN cells in multiple cell 
types [109]. Furthermore, both CDKN2A and TP53 are rate-limiting for reprogramming of 
somatic cells [110]. CDKN2A or TP53 inactivation has a profound positive effect on the 
efficiency of induced pluripotent stem (iPS) cell generation, increasing both the kinetics of 
reprogramming and the number of emerging iPS cell colonies [110, 111]. Reprogramming of 
somatic cells is accompanied by chromosome abnormalities, point mutations, epigenetic 
changes, and the drastic gene expression changes (reviewed in [112]). CDKN2A or TP53 
inactivation leads to CIN and tumorigenicity of iPS cells (reviewed in [113]). In contrast, iPS 
cells containing an extra copy of the TP53 or CDKN2A show reduced tumorigenic potential 
in various in vitro and in vivo assays and an improved response to anticancer drugs [114]. In 
addition to the reprogramming process itself the (epi)genomic stability of both iPS and 
human embrionic stem cells is affected by in vitro environmental conditions and the 
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techniques used for cell derivation. Also, there is no passage number threshold ensuring 
safety of iPS. However, the risk of abnormalities increases with the time in culture [113].  
PTEN can increase p53 stability and its DNA binding activity through physical association 
with p53 [115]. Germline mutations of PTEN have been found in cancer susceptibility 
Cowden and Bannayan–Riley–Ruvalcaba syndromes, which are now collectively referred to 
as the PTEN hamartoma tumor syndrome. Mice heterozygous for PTEN develop 
spontaneous tumors and conditional tissue-specific disruption of PTEN leads to different 
tumors in the affected tissues (reviewed in [116]). PTEN plays a fundamental role in the 
maintenance of chromosomal stability through the physical interaction with centromeres 
and control of DNA repair. PTEN null cells exhibit extensive centromere breakages and 
chromosomal translocations [117, 118]. Interestingly, comparison of spectra of PTEN and 
TP53 somatic mutations across tumors has revealed that they are usually independent and 
even mutually exclusive [116]. 
Neurofibromatosis type 1 (NF1), a tumor predisposition syndrome, is characterised by the 
growth of benign and malignant tumors involving the peripheral and central nervous 
system and results from inactivating germline mutations of the NF1 gene [119, 120]. NF1 
gene encodes a neurofibromin, which plays a role in MAPK, AKT-mTOR, adenylate cyclase, 
and PKC mediated pathways [121]. One of the main features of neurofibromatosis type 1 is 
benign neurofibromas, 10% of which become transformed into malignant peripheral nerve 
sheath tumors [119]. TP53, CDKN2A, and RB1 mutations or deletions are detected in 
malignant peripheral nerve sheath tumors but not in benign neurofibromas [119, 120, 122]. 
In consistence with it, but in contrast to benign neurofibromas, malignant peripheral nerve 
sheath tumors are caracterized by CIN [119, 122].  
Hyperactivation of the MAPK or PI3K-AKT pathway induces frequently cell cycle arrest 
and senescence in vitro and in vivo. Oncogene-induced senescence program, a state of stable 
cell-cycle arrest, together with oncogene induced apoptosis are recognized to represent an 
important barrier against tumor development in vivo [123]. Senescence cells are 
characterized by the inability to proliferate despite the presence of a steady supply of 
abundant nutrients, mitogens, ample room for expansion, and by maintenance of cell 
viability/resistance to apoptosis and metabolic activity for months. Expression of activated 
forms of RAS (N-RASG12D, H-RASV12, K-RASG12V), B-RAFE600 or MEK was shown to elicit cell 
cycle arrest and senescence in primary fibroblasts, Schwann cells, hepatocytes, T 
lymphocytes, keratinocytes, astrocytes, epithelial intestinal cells and other cell types; AKT 
overexpression induced senescence of primary and immortalized esophageal epithelial cells, 
primary MEFs, primary human aortic endothelial cells, human dermal microvascular 
endothelial cells, and human umbilical vein endothelial cells. Moreover, in vitro and/or in 
vivo inactivation of PTEN, VHL, RB1, NF1 or activation of RHEB, PKC, EGFR, TGFβ, INFβ, 
Cyclin E, Cyclin D, STAT5, c-MYC, β-Catenin, E2F, Rho small GTPases and many other 
proteins triggers senescence (reviewed in [30, 123-126]). Furthermore, mouse embrionic 
fibroblasts deficient in DNA damage response and DNA repair genes (ATM, NBS1, TopBP1, 
BRCA1, BRCA2, Ku86, XRCC4, WRN and ERCC1) undergo premature senescence (reviewed 
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tumorigenesis [91]. All together, these data justify reputation of mutant p53 as “the demon 
of the guardian of the genome” [92] and “a master regulator of human malignancies” [93].  
Survivors of hereditary retinoblastoma, a childhood cancer of the eye caused by germline 
mutations of the RB1 tumor suppressor gene, have an elevated risk of developing sarcomas, 
brain cancer, melanoma or some epithelial cancers [94, 95]. It was shown that inactivation of 
the pRB1 pathway in the developing mouse or human retina was accompanied by p19ARF-
p53 pathway activation and RB1-deficient retinoblasts underwent p53-mediated apoptosis 
and exited the cell cycle [96]. In contrast, RB1-deficient cell with inactivated p14ARF-p53 
pathway had growth advantage, clonally expanded, and formed retinoblastoma [96]. As it is 
expected, retinoblastoma is characterized by CIN, strengthening the view that the 
chromosomal changes contribute to the development and progression of malignancy [97, 
98]. Also, analysis of hundreds of chronic lymphocytic leukemias (CLLs) has revealed a 
strong association between RB1 deletion and aberrant p53 pathway with elevated genomic 
complexity, which is a strong independent predictor of rapid disease progression, disease 
aggressiveness, short remission duration, short survival, and therapy efficaciousness in CLL 
[99-101].  
PRB1 plays a critical role in proper chromosome condensation and cohesion, centromeric 
function, and chromosome stability in mammalian cells (reviewed in [102, 103]). Inactivation 
of pRB1 not only allows inappropriate proliferation but also undermines mitotic fidelity 
leading to CIN and ploidy changes [102, 103]. pRB1 pathways deregulation correlates with 
(multi)drug and radioresistance [104, 105]. Screening of more than 25,000 compounds in 
human fibroblasts in which pRB1 activity was compromised by viral oncoproteins revealed 
that the only compounds selective for RB1-deficient cell death were topoisomerase II 
inhibitors (e.g., doxorubicin) [106]. Moreover, RB1-deficient cells displayed increased 
proliferation in the presence of the PI3K (LY294002) and MEK1/2 (U0126) inhibitors [107].  
The CDKN2A locus comprises the INK4A and ARF genes encoding tumor suppressors 
p16INK4A and p14ARF (p19ARF in mice) that up-regulate the activities of pRB1 and p53 
transcription factors, respectively [108]. Inactivation of INK4A, ARF or both genes strongly 
predisposes mice to tumor development (reviewed in [69]). Loss of p16INK4A plays a causal 
role in centrosome dysfunction and the subsequent generation of CIN cells in multiple cell 
types [109]. Furthermore, both CDKN2A and TP53 are rate-limiting for reprogramming of 
somatic cells [110]. CDKN2A or TP53 inactivation has a profound positive effect on the 
efficiency of induced pluripotent stem (iPS) cell generation, increasing both the kinetics of 
reprogramming and the number of emerging iPS cell colonies [110, 111]. Reprogramming of 
somatic cells is accompanied by chromosome abnormalities, point mutations, epigenetic 
changes, and the drastic gene expression changes (reviewed in [112]). CDKN2A or TP53 
inactivation leads to CIN and tumorigenicity of iPS cells (reviewed in [113]). In contrast, iPS 
cells containing an extra copy of the TP53 or CDKN2A show reduced tumorigenic potential 
in various in vitro and in vivo assays and an improved response to anticancer drugs [114]. In 
addition to the reprogramming process itself the (epi)genomic stability of both iPS and 
human embrionic stem cells is affected by in vitro environmental conditions and the 
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techniques used for cell derivation. Also, there is no passage number threshold ensuring 
safety of iPS. However, the risk of abnormalities increases with the time in culture [113].  
PTEN can increase p53 stability and its DNA binding activity through physical association 
with p53 [115]. Germline mutations of PTEN have been found in cancer susceptibility 
Cowden and Bannayan–Riley–Ruvalcaba syndromes, which are now collectively referred to 
as the PTEN hamartoma tumor syndrome. Mice heterozygous for PTEN develop 
spontaneous tumors and conditional tissue-specific disruption of PTEN leads to different 
tumors in the affected tissues (reviewed in [116]). PTEN plays a fundamental role in the 
maintenance of chromosomal stability through the physical interaction with centromeres 
and control of DNA repair. PTEN null cells exhibit extensive centromere breakages and 
chromosomal translocations [117, 118]. Interestingly, comparison of spectra of PTEN and 
TP53 somatic mutations across tumors has revealed that they are usually independent and 
even mutually exclusive [116]. 
Neurofibromatosis type 1 (NF1), a tumor predisposition syndrome, is characterised by the 
growth of benign and malignant tumors involving the peripheral and central nervous 
system and results from inactivating germline mutations of the NF1 gene [119, 120]. NF1 
gene encodes a neurofibromin, which plays a role in MAPK, AKT-mTOR, adenylate cyclase, 
and PKC mediated pathways [121]. One of the main features of neurofibromatosis type 1 is 
benign neurofibromas, 10% of which become transformed into malignant peripheral nerve 
sheath tumors [119]. TP53, CDKN2A, and RB1 mutations or deletions are detected in 
malignant peripheral nerve sheath tumors but not in benign neurofibromas [119, 120, 122]. 
In consistence with it, but in contrast to benign neurofibromas, malignant peripheral nerve 
sheath tumors are caracterized by CIN [119, 122].  
Hyperactivation of the MAPK or PI3K-AKT pathway induces frequently cell cycle arrest 
and senescence in vitro and in vivo. Oncogene-induced senescence program, a state of stable 
cell-cycle arrest, together with oncogene induced apoptosis are recognized to represent an 
important barrier against tumor development in vivo [123]. Senescence cells are 
characterized by the inability to proliferate despite the presence of a steady supply of 
abundant nutrients, mitogens, ample room for expansion, and by maintenance of cell 
viability/resistance to apoptosis and metabolic activity for months. Expression of activated 
forms of RAS (N-RASG12D, H-RASV12, K-RASG12V), B-RAFE600 or MEK was shown to elicit cell 
cycle arrest and senescence in primary fibroblasts, Schwann cells, hepatocytes, T 
lymphocytes, keratinocytes, astrocytes, epithelial intestinal cells and other cell types; AKT 
overexpression induced senescence of primary and immortalized esophageal epithelial cells, 
primary MEFs, primary human aortic endothelial cells, human dermal microvascular 
endothelial cells, and human umbilical vein endothelial cells. Moreover, in vitro and/or in 
vivo inactivation of PTEN, VHL, RB1, NF1 or activation of RHEB, PKC, EGFR, TGFβ, INFβ, 
Cyclin E, Cyclin D, STAT5, c-MYC, β-Catenin, E2F, Rho small GTPases and many other 
proteins triggers senescence (reviewed in [30, 123-126]). Furthermore, mouse embrionic 
fibroblasts deficient in DNA damage response and DNA repair genes (ATM, NBS1, TopBP1, 
BRCA1, BRCA2, Ku86, XRCC4, WRN and ERCC1) undergo premature senescence (reviewed 
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in [125]. Importantly, oncogene-induced senescence is frequently observed in premalignant 
lesions both in animal tumor models and in human patients but is essentially absent in 
advanced cancers, suggesting that malignant tumor cells have found ways to bypass or 
escape senescence [125, 126]. In vitro and in vivo models have shown that senescence and/or 
apoptosis evasion requires p14ARF/p19ARF-p53 and/or p16INK4A-pRB pathway inactivation, 
which results in immortalization and malignant transformation in vitro and invasive tumor 
formation in vivo [30, 123-126].  
The ability to induce CIN after inactivation/hyperactivation is not restricted to cancer genes 
the most frequently mutated across cancer types. BCR-ABL oncogene is mainly associated 
with Philadelphia chromosome positive chronic myeloid leukemia (>90% of patients) but is 
also found in acute lymphoblastic leukemia and occasionally in acute myelogenous leukemia. It 
results from a reciprocal translocation between chromosome 9 and 22. BCR-ABL is engaged 
in multiple signaling pathways and its expression in cells induces CIN (reviewed in [127, 
128]). Heterozygous germline mutations in tumor supressors BRCA1 or BRCA2 are 
associated with hereditary cancers (e.g., breast and ovarian). BRCA1 and BRCA2 proteins 
have multiple functions including participating in a pathway that mediates repair of DNA 
double strand breaks by error-free methods. Inactivation of BRCA1 or BRCA2 results in 
centrosome amplification, cell-cycle checkpoint defects, DNA damage and CIN (reviewed in 
[129-131]). Von Hippel-Lindau disease is caused by germline mutations in the VHL tumour 
suppressor gene. VHL mutations predispose to the development of a variety of tumors 
(reviewed in [132]). Loss of VHL causes the mitotic spindle misorientation and CIN 
(reviewed in [133, 134]). Adenomatous polyposis coli (APC) was identified as a tumor 
suppressor gene mutated in familial colon cancer. Now it is well documented that loss of 
APC function plays an important role in CIN induction (reviewed in [135, 136]). Ataxia 
telangiectasia syndrome is characterized by extreme sensitivity to radiation, cell-cycle 
checkpoint defects, CIN, and predisposition to cancer. The disease is caused by germline 
mutations in the ATM gene involved in DNA double-strand break signaling and repair 
(reviewed in [137, 138]). Multiple endocrine neoplasia type 1 (MEN1) is an inherited cancer 
predisposition syndrome characterized by development of tumors in both endocrine and 
nonendocrine organs in patients and a mouse model of MEN1 [139]. MEN1 encodes a tumor 
suppressor menin participating in regulation of cell proliferation, apoptosis, and DNA 
damage response/genome stability in part localizing to the promoters of thousands of 
human genes and regulating transcription mediated by interactions with chromatin 
modifying enzymes (reviewed in [140, 141]). Aberrant MYC activity is associated with the 
appearance of DNA damage-associated markers and CIN (reviewed in [142, 143]).  
Furthermore, in vitro and in vivo research has proven that dozens of proteins involved in 
regulation of chromosome cohesion, centrosome amplification, spindle assembly 
checkpoint, kinetochore-microtubule attachment, cell cycle as well as homologous and non-
homologous recombination can trigger centrosome amplifiction and CIN in primary or 
chromosomaly stable immortalized cells and induce tumors in genetically engineered mice 
(reviewed in [144-148] “offering proof of principle that CIN alone can be the root cause of 
spontaneous tumors in mammals” [71]. Moreover, diverse growth factors, transmembrane 
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receptors, transcription factors when extopically overexpressed in cells also trigger 
centrosome amplification and CIN and are able to transform cells. Also, there is a significant 
association between global hypomethylation and CIN [149-153]. DNA methyltransferase 
deficient cells are chromosomally unstable [154, 155], and mice models have demonstrated 
that genomewide DNA hypomethylation can induce tumors [156-158]. Thus, a specific effect 
of oncoproteins is to cause aneuploidization [50] and the elevation of stochastic CIN [10].  
5. All roads lead to centrosome 
In cancer cells mechanism of centrosome amplification and clustering is proposed to be the 
major contributor to CIN [159, 160]. Centrosomes are microtubule-organizing structures that 
determine the organization of the mitotic spindle poles that segregate duplicated 
chromosomes between dividing cells. Mechanistically, CIN is driven by bipolar spindle 
formation through centrosomal clustering, which increases the formation of merotelic 
attachments (an error in which a single kinetochore is attached to microtubules emanating 
from both spindle poles [161]) producing chromosome missegregation [159, 160]. 
Chromosome missegregation was widely considered to occur due to anaphase lagging 
chromosomes. Nevertheless, recently it has been evidenced that most lagging chromosomes 
end up in the correct daughter cell, and the largest contribution to missegregation without 
obvious lagging in anaphase makes chromosomes with multimerotelic kinetochores, those 
with many microtubules oriented toward the wrong pole [162]. Centrosomal clustering 
allows successful completion of a cell division. In contrast, progeny of rarely and 
spontaneously arising multipolar cell divisions are often unviable undergoing mitotic cell 
death or cell-cycle arrest [159]. Whole-chromosome segregation errors frequently results in 
double-strand breaks, which can lead to unbalanced translocations in the daughter cells 
[163, 164] and chromosome pulverization/ chromothripsis defined by small-scale DNA copy 
number changes and extensive inter- and intrachromosomal rearrangements [165, 166]. 
Structural chromosomal aberrations lead to loss of heterozygosity for tumor suppressor 
genes [165, 167-170]. The transplantation of the generated Drosophila larval neural stem cells 
with extra centrosomes in normal hosts can induce the formation of metastatic tumors [171]. 
Centrosome abnormalities have been reported in most cancers. 
Centrosome is made up of and regulated by more than 350 proteins (reviewed in [172-174] 
and numerous additional centrosome component candidates were revealed [175]. Genome-
wide RNA interference screens have confirmed that about 200 genes contribute to spindle 
assembly [176], 32 genes are involved in centriole duplication and centrosome maturation 
[177], and 133 genes are engaged in centrosome clustering in drosophila cells [178]; silencing 
of 82 genes has resulted in the prevention of spindle multipolarity in human oral squamous 
cell carcinoma cells with supernumerary centrosomes [179]. Moreover, a system-wide two-
hybrid screen on 94 proteins implicated in spindle function in Saccharomyces cerevisiae has 
uncovered 604 protein-protein interactions [180], and a cell cycle phosphoproteome of 18 
yeast centrosome proteins has identified 297 phosphorylation sites [181]. Thus, accounting 
only these figures and that all these genes/proteins are regulated on multiple levels and 
changes of the abundance or activity of any one will affect the whole process, it is easy to 
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in [125]. Importantly, oncogene-induced senescence is frequently observed in premalignant 
lesions both in animal tumor models and in human patients but is essentially absent in 
advanced cancers, suggesting that malignant tumor cells have found ways to bypass or 
escape senescence [125, 126]. In vitro and in vivo models have shown that senescence and/or 
apoptosis evasion requires p14ARF/p19ARF-p53 and/or p16INK4A-pRB pathway inactivation, 
which results in immortalization and malignant transformation in vitro and invasive tumor 
formation in vivo [30, 123-126].  
The ability to induce CIN after inactivation/hyperactivation is not restricted to cancer genes 
the most frequently mutated across cancer types. BCR-ABL oncogene is mainly associated 
with Philadelphia chromosome positive chronic myeloid leukemia (>90% of patients) but is 
also found in acute lymphoblastic leukemia and occasionally in acute myelogenous leukemia. It 
results from a reciprocal translocation between chromosome 9 and 22. BCR-ABL is engaged 
in multiple signaling pathways and its expression in cells induces CIN (reviewed in [127, 
128]). Heterozygous germline mutations in tumor supressors BRCA1 or BRCA2 are 
associated with hereditary cancers (e.g., breast and ovarian). BRCA1 and BRCA2 proteins 
have multiple functions including participating in a pathway that mediates repair of DNA 
double strand breaks by error-free methods. Inactivation of BRCA1 or BRCA2 results in 
centrosome amplification, cell-cycle checkpoint defects, DNA damage and CIN (reviewed in 
[129-131]). Von Hippel-Lindau disease is caused by germline mutations in the VHL tumour 
suppressor gene. VHL mutations predispose to the development of a variety of tumors 
(reviewed in [132]). Loss of VHL causes the mitotic spindle misorientation and CIN 
(reviewed in [133, 134]). Adenomatous polyposis coli (APC) was identified as a tumor 
suppressor gene mutated in familial colon cancer. Now it is well documented that loss of 
APC function plays an important role in CIN induction (reviewed in [135, 136]). Ataxia 
telangiectasia syndrome is characterized by extreme sensitivity to radiation, cell-cycle 
checkpoint defects, CIN, and predisposition to cancer. The disease is caused by germline 
mutations in the ATM gene involved in DNA double-strand break signaling and repair 
(reviewed in [137, 138]). Multiple endocrine neoplasia type 1 (MEN1) is an inherited cancer 
predisposition syndrome characterized by development of tumors in both endocrine and 
nonendocrine organs in patients and a mouse model of MEN1 [139]. MEN1 encodes a tumor 
suppressor menin participating in regulation of cell proliferation, apoptosis, and DNA 
damage response/genome stability in part localizing to the promoters of thousands of 
human genes and regulating transcription mediated by interactions with chromatin 
modifying enzymes (reviewed in [140, 141]). Aberrant MYC activity is associated with the 
appearance of DNA damage-associated markers and CIN (reviewed in [142, 143]).  
Furthermore, in vitro and in vivo research has proven that dozens of proteins involved in 
regulation of chromosome cohesion, centrosome amplification, spindle assembly 
checkpoint, kinetochore-microtubule attachment, cell cycle as well as homologous and non-
homologous recombination can trigger centrosome amplifiction and CIN in primary or 
chromosomaly stable immortalized cells and induce tumors in genetically engineered mice 
(reviewed in [144-148] “offering proof of principle that CIN alone can be the root cause of 
spontaneous tumors in mammals” [71]. Moreover, diverse growth factors, transmembrane 
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receptors, transcription factors when extopically overexpressed in cells also trigger 
centrosome amplification and CIN and are able to transform cells. Also, there is a significant 
association between global hypomethylation and CIN [149-153]. DNA methyltransferase 
deficient cells are chromosomally unstable [154, 155], and mice models have demonstrated 
that genomewide DNA hypomethylation can induce tumors [156-158]. Thus, a specific effect 
of oncoproteins is to cause aneuploidization [50] and the elevation of stochastic CIN [10].  
5. All roads lead to centrosome 
In cancer cells mechanism of centrosome amplification and clustering is proposed to be the 
major contributor to CIN [159, 160]. Centrosomes are microtubule-organizing structures that 
determine the organization of the mitotic spindle poles that segregate duplicated 
chromosomes between dividing cells. Mechanistically, CIN is driven by bipolar spindle 
formation through centrosomal clustering, which increases the formation of merotelic 
attachments (an error in which a single kinetochore is attached to microtubules emanating 
from both spindle poles [161]) producing chromosome missegregation [159, 160]. 
Chromosome missegregation was widely considered to occur due to anaphase lagging 
chromosomes. Nevertheless, recently it has been evidenced that most lagging chromosomes 
end up in the correct daughter cell, and the largest contribution to missegregation without 
obvious lagging in anaphase makes chromosomes with multimerotelic kinetochores, those 
with many microtubules oriented toward the wrong pole [162]. Centrosomal clustering 
allows successful completion of a cell division. In contrast, progeny of rarely and 
spontaneously arising multipolar cell divisions are often unviable undergoing mitotic cell 
death or cell-cycle arrest [159]. Whole-chromosome segregation errors frequently results in 
double-strand breaks, which can lead to unbalanced translocations in the daughter cells 
[163, 164] and chromosome pulverization/ chromothripsis defined by small-scale DNA copy 
number changes and extensive inter- and intrachromosomal rearrangements [165, 166]. 
Structural chromosomal aberrations lead to loss of heterozygosity for tumor suppressor 
genes [165, 167-170]. The transplantation of the generated Drosophila larval neural stem cells 
with extra centrosomes in normal hosts can induce the formation of metastatic tumors [171]. 
Centrosome abnormalities have been reported in most cancers. 
Centrosome is made up of and regulated by more than 350 proteins (reviewed in [172-174] 
and numerous additional centrosome component candidates were revealed [175]. Genome-
wide RNA interference screens have confirmed that about 200 genes contribute to spindle 
assembly [176], 32 genes are involved in centriole duplication and centrosome maturation 
[177], and 133 genes are engaged in centrosome clustering in drosophila cells [178]; silencing 
of 82 genes has resulted in the prevention of spindle multipolarity in human oral squamous 
cell carcinoma cells with supernumerary centrosomes [179]. Moreover, a system-wide two-
hybrid screen on 94 proteins implicated in spindle function in Saccharomyces cerevisiae has 
uncovered 604 protein-protein interactions [180], and a cell cycle phosphoproteome of 18 
yeast centrosome proteins has identified 297 phosphorylation sites [181]. Thus, accounting 
only these figures and that all these genes/proteins are regulated on multiple levels and 
changes of the abundance or activity of any one will affect the whole process, it is easy to 
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understand why introduction of an oncogene into a cell directly or indirectly but inevitably 
will result in CIN. Indeed, monitoring phosphorylation of the histone variant H2AX, an 
early mark of DNA damage, it was identied hundreds of genes whose downregulation led 
to elevated levels of H2AX phosphorylation [182], and screening of 2,000 reduction-of-
function alleles (1038 genes) for 90% of essential genes in Saccharomyces cerevisiae has 
generated a catalogue of 692 CIN genes whose disruption may lead to CIN [183]. Enriched 
gene ontology together with sequence orthologs created a list of human CIN candidate 
genes, which, when was cross-referenced to published somatic mutation databases, revealed 
hundreds of mutated CIN candidate genes [183].  
Thus, irrespectively of their functions oncogenes and tumor suppressors directly or 
indirectly converge on centrosomes and mitotic checkpoints (reviewed in [144, 147, 148]). 
Deregulation of oncogenic and tumor suppressor pathways triggers and collaborates with 
CIN during tumorigenesis [184]. In contrast, supernumerary centrosome formation and CIN 
is reduced by overexpression of tumor suppressors in CIN cells [185-188]. Relationship 
between CIN and cancer genes explains well why such large number of cancer genes was 
identified (487 genes, data on September 2012) and why hundreds of oncogenes with 
diverse functions, when are ectopically overexpressed, are characterized by the same ability: 
to transform a cell or aggravate tumorigenicity.  
6. CIN induction: Beyond cancer genes 
CIN/aneuploidy induction is not restricted to cancer genes. Exposure of cells to drugs, 
chemical agents, and physical influences, as well as contacts with bacterial cells and 
infection with some viruses do induce centrosome amplification, CIN and can eventually 
result in transformation or aggravate transformed phenotype.  
Metals in general are considered to be weak mutagens, if mutagenic at all, still many metals 
are carcinogenic (reviewed in [9, 189]). All of the carcinogenic metals are able to induce CIN. 
It was systematically shown that carcinogenic metals cause centrosome amplification, 
centriolar defects, spindle assembly checkpoint bypass, suppression of the dynamic 
instability of microtubules (reviewed in [189, 190]). Non-mutagenic carcinogen asbestos 
causes centrosome amplification and CIN [191] by binding to a subset of proteins that 
include regulators of the cell cycle, cytoskeleton, and mitotic process [192]. Non-mutagenic 
carcinogens polycyclic aromatic hydrocarbons including dioxins or benzo[a]pyrene also 
provoke CIN [9]. One of the possible mechanisms is through activation of a cytoplasmic 
aryl hydrocarbon receptor (reviewed in [193]), which itself when is ectopically 
overexpressed can induce centrosome amplification [194]. Nanomaterials give rise to 
aneuploidy mainly by interfering with microtubules (reviewed in [195]). Both intestinal 
commensal Enterococcus faecalis and pathogen Helicobacter pylori are potential important 
contributors to the etiology of sporadic colorectal cancers and can contribute to cellular 
transformation and tumorigenesis triggering DNA double breaks and CIN [196, 197]. 
Human papillomavirus oncoproteins E6 and E7 induce centrosome abnormalities and 
CIN (reviewed in [198]).  
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Thus, any factor, genetic or non-genetic, internal or external, producing stress-induced 
genome system instability and its mediated increase in the cell population heterogeneity 
will contribute to cancer evolution [5, 6].  
7. Oncogene addiction concept 
The term “oncogene addiction” was first coined by B. Weinstein to describe the dependency 
of certain tumor cells on a single activated oncogenic protein or pathway to maintain their 
malignant properties, despite the likely accumulation of multiple gain and loss-of-function 
mutations that contribute to tumorigenicity. Decoding oncogene addiction in cancer is 
believed to provide a key for effective molecular targeted therapy [199-204]. The concept of 
oncogene addiction has been obtained from various human tumor-derived cell lines and 
conditional transgenic animal models in which acute inactivation of the overexpressed wild 
type (e.g., MYC and WNT1) or mutated oncogenes (e.g., EGFR, K-RAS, H-RAS, B-RAF, MET, 
FGFR3, ALK, AURK, and RET) via switching off an inducible oncogene, siRNA, or small-
molecule inhibitors typically has resulted in rapid apoptosis, or sometimes growth arrest 
and differentiation of tumor cells causing regression of the tumor [199-201, 206, 207]. 
However, many research groups monitoring long-term tumor response in diverse 
conditional mice models after oncoprotein withdrawal have repeatedly observed tumor 
relapses: H-RAS and p16INK4A-/- (melanoma model), HER2/NEU (mammary carcinoma 
model), BCR-ABL (acute B-cell lymphoma model) (reviewed in [206]), MYC (lymphoma and 
mammary carcinoma models) [206, 208, 209], WNT1 (mammary carcinoma model) [206, 208, 
210], MYC and K-RAS (mammary carcinoma model) [207], K-RAS and MAD2 (lung 
carcinoma model) [211], K-RAS (glioma model) [212] (see also [50] for additional examples), 
supporting the statement that “the nature of the initiating oncogene appears to be of little 
influence on the response of the resulting tumors to oncogene inactivation” [211]. In many 
cases tumor escape from oncogene dependence upon the primary oncogene inactivation 
was attributed to the acquired diverse novel genetic lesions [206, 211]. For example, MYC-
induced lung cancers after oncogene inactivation failed to regress completely because of 
secondary activating events in K-RAS associated pathways [212] and the loss of TP53 
resulted in the absence of tumor regression [213], whereas loss of one TP53 allele 
dramatically facilitated the progression of WNT1-induced mammary tumors to a oncogene 
independent state both by impairing the regression of primary tumors and by promoting 
the recurrence of fully regressed tumors following oncogene inactivation [214]. The 
acquisition of oncogene independence and tumor recurrence in K-RAS glioma model 
coincided with loss of CDKN2A [215]. Concurrent mutational inactivation of the PTEN and 
RB1 tumor suppressors was determined as a mechanism for loss of B-RAF/MEK 
dependence in melanomas harboring B-RAF mutations [216]. Loss-of-function mutations in 
PTEN genes rendered T cell acute lymphoblastic leukemia independent of the MYC 
oncogene in conditional zebrafish model [209]. It is worth recalling that TP53, RB1, 
CDKN2A, K-RAS, and PTEN are among the most frequently mutated genes in human 
tumors [3]. It follows that advanced tumors already harbour “escape mechanisms”!  
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understand why introduction of an oncogene into a cell directly or indirectly but inevitably 
will result in CIN. Indeed, monitoring phosphorylation of the histone variant H2AX, an 
early mark of DNA damage, it was identied hundreds of genes whose downregulation led 
to elevated levels of H2AX phosphorylation [182], and screening of 2,000 reduction-of-
function alleles (1038 genes) for 90% of essential genes in Saccharomyces cerevisiae has 
generated a catalogue of 692 CIN genes whose disruption may lead to CIN [183]. Enriched 
gene ontology together with sequence orthologs created a list of human CIN candidate 
genes, which, when was cross-referenced to published somatic mutation databases, revealed 
hundreds of mutated CIN candidate genes [183].  
Thus, irrespectively of their functions oncogenes and tumor suppressors directly or 
indirectly converge on centrosomes and mitotic checkpoints (reviewed in [144, 147, 148]). 
Deregulation of oncogenic and tumor suppressor pathways triggers and collaborates with 
CIN during tumorigenesis [184]. In contrast, supernumerary centrosome formation and CIN 
is reduced by overexpression of tumor suppressors in CIN cells [185-188]. Relationship 
between CIN and cancer genes explains well why such large number of cancer genes was 
identified (487 genes, data on September 2012) and why hundreds of oncogenes with 
diverse functions, when are ectopically overexpressed, are characterized by the same ability: 
to transform a cell or aggravate tumorigenicity.  
6. CIN induction: Beyond cancer genes 
CIN/aneuploidy induction is not restricted to cancer genes. Exposure of cells to drugs, 
chemical agents, and physical influences, as well as contacts with bacterial cells and 
infection with some viruses do induce centrosome amplification, CIN and can eventually 
result in transformation or aggravate transformed phenotype.  
Metals in general are considered to be weak mutagens, if mutagenic at all, still many metals 
are carcinogenic (reviewed in [9, 189]). All of the carcinogenic metals are able to induce CIN. 
It was systematically shown that carcinogenic metals cause centrosome amplification, 
centriolar defects, spindle assembly checkpoint bypass, suppression of the dynamic 
instability of microtubules (reviewed in [189, 190]). Non-mutagenic carcinogen asbestos 
causes centrosome amplification and CIN [191] by binding to a subset of proteins that 
include regulators of the cell cycle, cytoskeleton, and mitotic process [192]. Non-mutagenic 
carcinogens polycyclic aromatic hydrocarbons including dioxins or benzo[a]pyrene also 
provoke CIN [9]. One of the possible mechanisms is through activation of a cytoplasmic 
aryl hydrocarbon receptor (reviewed in [193]), which itself when is ectopically 
overexpressed can induce centrosome amplification [194]. Nanomaterials give rise to 
aneuploidy mainly by interfering with microtubules (reviewed in [195]). Both intestinal 
commensal Enterococcus faecalis and pathogen Helicobacter pylori are potential important 
contributors to the etiology of sporadic colorectal cancers and can contribute to cellular 
transformation and tumorigenesis triggering DNA double breaks and CIN [196, 197]. 
Human papillomavirus oncoproteins E6 and E7 induce centrosome abnormalities and 
CIN (reviewed in [198]).  
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Thus, any factor, genetic or non-genetic, internal or external, producing stress-induced 
genome system instability and its mediated increase in the cell population heterogeneity 
will contribute to cancer evolution [5, 6].  
7. Oncogene addiction concept 
The term “oncogene addiction” was first coined by B. Weinstein to describe the dependency 
of certain tumor cells on a single activated oncogenic protein or pathway to maintain their 
malignant properties, despite the likely accumulation of multiple gain and loss-of-function 
mutations that contribute to tumorigenicity. Decoding oncogene addiction in cancer is 
believed to provide a key for effective molecular targeted therapy [199-204]. The concept of 
oncogene addiction has been obtained from various human tumor-derived cell lines and 
conditional transgenic animal models in which acute inactivation of the overexpressed wild 
type (e.g., MYC and WNT1) or mutated oncogenes (e.g., EGFR, K-RAS, H-RAS, B-RAF, MET, 
FGFR3, ALK, AURK, and RET) via switching off an inducible oncogene, siRNA, or small-
molecule inhibitors typically has resulted in rapid apoptosis, or sometimes growth arrest 
and differentiation of tumor cells causing regression of the tumor [199-201, 206, 207]. 
However, many research groups monitoring long-term tumor response in diverse 
conditional mice models after oncoprotein withdrawal have repeatedly observed tumor 
relapses: H-RAS and p16INK4A-/- (melanoma model), HER2/NEU (mammary carcinoma 
model), BCR-ABL (acute B-cell lymphoma model) (reviewed in [206]), MYC (lymphoma and 
mammary carcinoma models) [206, 208, 209], WNT1 (mammary carcinoma model) [206, 208, 
210], MYC and K-RAS (mammary carcinoma model) [207], K-RAS and MAD2 (lung 
carcinoma model) [211], K-RAS (glioma model) [212] (see also [50] for additional examples), 
supporting the statement that “the nature of the initiating oncogene appears to be of little 
influence on the response of the resulting tumors to oncogene inactivation” [211]. In many 
cases tumor escape from oncogene dependence upon the primary oncogene inactivation 
was attributed to the acquired diverse novel genetic lesions [206, 211]. For example, MYC-
induced lung cancers after oncogene inactivation failed to regress completely because of 
secondary activating events in K-RAS associated pathways [212] and the loss of TP53 
resulted in the absence of tumor regression [213], whereas loss of one TP53 allele 
dramatically facilitated the progression of WNT1-induced mammary tumors to a oncogene 
independent state both by impairing the regression of primary tumors and by promoting 
the recurrence of fully regressed tumors following oncogene inactivation [214]. The 
acquisition of oncogene independence and tumor recurrence in K-RAS glioma model 
coincided with loss of CDKN2A [215]. Concurrent mutational inactivation of the PTEN and 
RB1 tumor suppressors was determined as a mechanism for loss of B-RAF/MEK 
dependence in melanomas harboring B-RAF mutations [216]. Loss-of-function mutations in 
PTEN genes rendered T cell acute lymphoblastic leukemia independent of the MYC 
oncogene in conditional zebrafish model [209]. It is worth recalling that TP53, RB1, 
CDKN2A, K-RAS, and PTEN are among the most frequently mutated genes in human 
tumors [3]. It follows that advanced tumors already harbour “escape mechanisms”!  
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Importantly, acquisition of novel genetic lesions as primary oncogene dependence escape 
mechanisms is accompanied by CIN in tumor models. Analysis of relapsed lymphomas 
after MYC de-induction in conditional mice model showed that every relapsed tumor 
exhibited additional chromosomal rearrangements, both numerical and structural, 
compared with the primary tumor of origin [217] and high levels of aneuploidy in the 
primary tumor and in remaining cells survived after K-RAS and MAD2 oncoproteins 
withdrawal correlated with lung tumor relapses [218].  
Observation of tumor relapses after oncogene inactivation and unsuccess of targeted 
therapies in multiple diverse clinical trials inclined many researchers to accept the pitfalls of 
oncogene addiction concept [6, 199, 200, 202, 211, 219-222]. Majority of tumors contain a 
heterogeneous cell population with a number of stochastic genome alterations, extensively 
rewired signaling networks and addicted to multiple oncogenes [6, 200, 220]. Furthermore, 
the addicted states can easily switch with each other during cancer progression and in 
particular during medical intervention [5, 202]. It is proposed that the concept of “network 
addiction”, rather than “oncogene addiction”, recapitulates more closely what is happening 
during tumor development and after exposure to therapeutic agents [219]. There is no 
particular pathway that would play a prominent role in maintaining cell viability [221]. For 
example, over 100 altered signaling pathways were identified in squamous cell lung 
carcinoma [222]. Illusion of oncogene dependence [199] and limited relevance of oncogene 
addiction concept for the majority of tumors [211] led to eradication of the hope of targeting 
the key addictive oncogene that maintains one’s cancer [220]. Really, the obvious success of 
targeted therapy based on oncogene addiction concept is mainly restricted only to chronic 
myelogenous leukaemia (CML) in clinic [22, 223], which possesses in chronic phase, a major 
phase of drug response, a homogeneous population of tumor cells arisen from a single 
driver mutation, although still with high frequency of resistance development (35% of 
patients in chronic phase treated with imatinib) [224, 225].  
Oncogene addiction concept and models, which it has been derived from, have obvious 
shortcomings and pitfalls. Cell lines display a genetic drift and low heterogeneity different 
from tumors in vivo as a consequence of selection and adaptation for cell culture conditions 
[226, 227]. Numerous tissue-specifc genetically engineered mouse cancer models have been 
developed that exhibit many biologic hallmarks of human cancer (reviewed in [69, 228]), 
however, they still poorly reproduce spontaneous tumors (reviewed in [229]). In transgenic 
mice models all the cells share the same genetic defects, which can not be the case in most 
sporadic cancers. Activated oncogenes form a dominant pathway through artificial selection 
favoring cancer progression and promoting cancer evolution much more strongly than what 
occurs in nature. It results in drastically reduced genome heterogeneity, which helps 
investigators illustrate the importance of favored genes [6]. Limited number of initiating 
genetic alterations, artificially activated oncogenes, benign levels of CIN, intratumor genetic 
homogeneity, and fostered evolution make mice tumors inappropriate models for the 
targeted treatment of cancers [6, 50, 218, 229]. Cancer therapy based on oncogene addiction 
concept is palliative rather than curative in clinic [22]. Also, the uniqueness and significance 
of oncogene addiction concept should be questioned by a growing list of non-oncogenes 
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that are not inherently oncogenic themselves (not mutated or altered in any way) but 
required for tumor initiation and maintenance in a variety of cancer models [230-234]. This 
has led to establishment of non-oncogene addiction concept (reviewed in [233]).  
Now it is supposed that insights into tumor evolution and the changes of tumor 
heterogeneity upon targeted therapy will allow identifying the non-responsive clones and 
targeting them [235-237]. However, underestimated intratumor heterogeneity can be a 
serious obstacle making this strategy hardly clinically implementable [15-20, 238].  
8. Conclusion 
Solid tumor evolution is cyclical and consists of two distinct phases: a punctuated phase 
(high CIN, frequent non-clonal chromosome aberrations) and a stepwise phase (low CIN, 
clonal evolution with dominant clonal chromosome aberrations). Shifts between phases are 
induced by stress and subsequent selection [5, 6, 10]. Thus, severity of CIN can be changed 
during tumour evolution and is affected by diverse genetic and non-genetic, internal and 
external stresses (modulation of expression of cancer genes, drugs, chemical 
agents/carcinogens, physical influences, and microenvironment changes). CIN results in 
genomic and (epi)genetic heterogeneity facilitating evolution of cancers and creating 
multiclonal tumour architecture, which increases the chance of pre-existance before or 
appearance during therapy of resistant sublones. There is a significant correlation in 
primary tumors between the degree of CIN and treatment sensitivity, the risk of acquired 
resistance and further tumor relapses. p14ARF-p53 and p16INK4A-pRB pathways are the main 
safeguards of mitotic fidelity. Once p14ARF-p53 or/and p16INK4A-pRB pathway is 
compromised, CIN is unleashed. Oncogene/stress induced senescence or apoptosis evasion 
requires p14ARF/p19ARF-p53 and/or p16INK4A-pRB pathway inactivation, which results in 
successful immortalization and malignant transformation in vitro and invasive tumor 
formation in vivo. Consequently, increasing both the kinetics of reprogramming and the 
number of emerging iPS cell colonies by disrupting CDKN2A or TP53 will inevitably result 
in transformation.  
CIN and the resulting clonal/non-clonal intratumor heterogeneity elucidate why large-scale 
tumor genome sequencing and high-resolution analysis of somatic copy-number alterations 
have failed to reveal “universal” cancer genes except well known for decades (TP53, 
CDKN2A, RB1, PIK3CA, KRAS, and NF1), and type- and stage-specific recurrent aberrations 
in solid tumors, whereas most recurrent chromosome abberations (deletions, amplifications, 
and translocations) ever ocurring genome-wide in tumors can be explained by 3D genome 
organization, spatial proximity among chromosome loci, and replication timing of sites 
producing rearrangements [239-241]. CIN explains how non-mutagenic chemical agents, 
physical influences, contacts with bacterial cells, and infection with some viruses induce or 
promote transformation of cells in vitro and tumor development in vivo, as well as 
spontaneous in vitro transformation of primary and immortalized cells and tumorigenicity 
of induced pluripotent stem (iPS) cells. CIN accounts for the acquisition of oncogene 
independence and tumor recurrence after inductor withdrawal in oncogene on/off 
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Importantly, acquisition of novel genetic lesions as primary oncogene dependence escape 
mechanisms is accompanied by CIN in tumor models. Analysis of relapsed lymphomas 
after MYC de-induction in conditional mice model showed that every relapsed tumor 
exhibited additional chromosomal rearrangements, both numerical and structural, 
compared with the primary tumor of origin [217] and high levels of aneuploidy in the 
primary tumor and in remaining cells survived after K-RAS and MAD2 oncoproteins 
withdrawal correlated with lung tumor relapses [218].  
Observation of tumor relapses after oncogene inactivation and unsuccess of targeted 
therapies in multiple diverse clinical trials inclined many researchers to accept the pitfalls of 
oncogene addiction concept [6, 199, 200, 202, 211, 219-222]. Majority of tumors contain a 
heterogeneous cell population with a number of stochastic genome alterations, extensively 
rewired signaling networks and addicted to multiple oncogenes [6, 200, 220]. Furthermore, 
the addicted states can easily switch with each other during cancer progression and in 
particular during medical intervention [5, 202]. It is proposed that the concept of “network 
addiction”, rather than “oncogene addiction”, recapitulates more closely what is happening 
during tumor development and after exposure to therapeutic agents [219]. There is no 
particular pathway that would play a prominent role in maintaining cell viability [221]. For 
example, over 100 altered signaling pathways were identified in squamous cell lung 
carcinoma [222]. Illusion of oncogene dependence [199] and limited relevance of oncogene 
addiction concept for the majority of tumors [211] led to eradication of the hope of targeting 
the key addictive oncogene that maintains one’s cancer [220]. Really, the obvious success of 
targeted therapy based on oncogene addiction concept is mainly restricted only to chronic 
myelogenous leukaemia (CML) in clinic [22, 223], which possesses in chronic phase, a major 
phase of drug response, a homogeneous population of tumor cells arisen from a single 
driver mutation, although still with high frequency of resistance development (35% of 
patients in chronic phase treated with imatinib) [224, 225].  
Oncogene addiction concept and models, which it has been derived from, have obvious 
shortcomings and pitfalls. Cell lines display a genetic drift and low heterogeneity different 
from tumors in vivo as a consequence of selection and adaptation for cell culture conditions 
[226, 227]. Numerous tissue-specifc genetically engineered mouse cancer models have been 
developed that exhibit many biologic hallmarks of human cancer (reviewed in [69, 228]), 
however, they still poorly reproduce spontaneous tumors (reviewed in [229]). In transgenic 
mice models all the cells share the same genetic defects, which can not be the case in most 
sporadic cancers. Activated oncogenes form a dominant pathway through artificial selection 
favoring cancer progression and promoting cancer evolution much more strongly than what 
occurs in nature. It results in drastically reduced genome heterogeneity, which helps 
investigators illustrate the importance of favored genes [6]. Limited number of initiating 
genetic alterations, artificially activated oncogenes, benign levels of CIN, intratumor genetic 
homogeneity, and fostered evolution make mice tumors inappropriate models for the 
targeted treatment of cancers [6, 50, 218, 229]. Cancer therapy based on oncogene addiction 
concept is palliative rather than curative in clinic [22]. Also, the uniqueness and significance 
of oncogene addiction concept should be questioned by a growing list of non-oncogenes 
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that are not inherently oncogenic themselves (not mutated or altered in any way) but 
required for tumor initiation and maintenance in a variety of cancer models [230-234]. This 
has led to establishment of non-oncogene addiction concept (reviewed in [233]).  
Now it is supposed that insights into tumor evolution and the changes of tumor 
heterogeneity upon targeted therapy will allow identifying the non-responsive clones and 
targeting them [235-237]. However, underestimated intratumor heterogeneity can be a 
serious obstacle making this strategy hardly clinically implementable [15-20, 238].  
8. Conclusion 
Solid tumor evolution is cyclical and consists of two distinct phases: a punctuated phase 
(high CIN, frequent non-clonal chromosome aberrations) and a stepwise phase (low CIN, 
clonal evolution with dominant clonal chromosome aberrations). Shifts between phases are 
induced by stress and subsequent selection [5, 6, 10]. Thus, severity of CIN can be changed 
during tumour evolution and is affected by diverse genetic and non-genetic, internal and 
external stresses (modulation of expression of cancer genes, drugs, chemical 
agents/carcinogens, physical influences, and microenvironment changes). CIN results in 
genomic and (epi)genetic heterogeneity facilitating evolution of cancers and creating 
multiclonal tumour architecture, which increases the chance of pre-existance before or 
appearance during therapy of resistant sublones. There is a significant correlation in 
primary tumors between the degree of CIN and treatment sensitivity, the risk of acquired 
resistance and further tumor relapses. p14ARF-p53 and p16INK4A-pRB pathways are the main 
safeguards of mitotic fidelity. Once p14ARF-p53 or/and p16INK4A-pRB pathway is 
compromised, CIN is unleashed. Oncogene/stress induced senescence or apoptosis evasion 
requires p14ARF/p19ARF-p53 and/or p16INK4A-pRB pathway inactivation, which results in 
successful immortalization and malignant transformation in vitro and invasive tumor 
formation in vivo. Consequently, increasing both the kinetics of reprogramming and the 
number of emerging iPS cell colonies by disrupting CDKN2A or TP53 will inevitably result 
in transformation.  
CIN and the resulting clonal/non-clonal intratumor heterogeneity elucidate why large-scale 
tumor genome sequencing and high-resolution analysis of somatic copy-number alterations 
have failed to reveal “universal” cancer genes except well known for decades (TP53, 
CDKN2A, RB1, PIK3CA, KRAS, and NF1), and type- and stage-specific recurrent aberrations 
in solid tumors, whereas most recurrent chromosome abberations (deletions, amplifications, 
and translocations) ever ocurring genome-wide in tumors can be explained by 3D genome 
organization, spatial proximity among chromosome loci, and replication timing of sites 
producing rearrangements [239-241]. CIN explains how non-mutagenic chemical agents, 
physical influences, contacts with bacterial cells, and infection with some viruses induce or 
promote transformation of cells in vitro and tumor development in vivo, as well as 
spontaneous in vitro transformation of primary and immortalized cells and tumorigenicity 
of induced pluripotent stem (iPS) cells. CIN accounts for the acquisition of oncogene 
independence and tumor recurrence after inductor withdrawal in oncogene on/off 
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conditional transgenic mice models. CIN and intratumor heterogeneity are the reasons of 
oncogene addiction independence of solid tumors from any particular oncogene and general 
ineffectiveness of targeted therapy in clinic. Any factors or stresses that contribute to CIN 
can potentially promote the evolution of cancer.  
Author details 
Alexey Stepanenko and Vadym Kavsan* 
State Key Laboratory on Molecular and Cellular Biology,  
Institute of Molecular Biology and Genetics, Kyiv, Ukraine 
Acknowledgement 
This work was supported in part by grant SFFR F46/457-2011 “State key laboratory of 
molecular and cellular biology” and by Informatization of Ukraine in frames of mutual 
Ukrainian-Russian program of fundamental research, project F40.4/018 “Search and 
characterization of oncogenes and tumor suppressor genes involved in the initiation and 
development of gliomas”. 
9. References 
[1] Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton 
MR (2004) A census of human cancer genes. Nat. rev. cancer. 4: 177-183. 
[2] Touw IP, Erkeland SJ (2007) Retroviral insertion mutagenesis in mice as a comparative 
oncogenomics tool to identify disease genes in human leukemia. Mol. ther. 15: 13-19.  
[3] Ciccarelli FD (2010) The (r)evolution of cancer genetics. BMC biol. doi:10.1186/1741-
7007-8-74. 
[4] D'Antonio M, Pendino V, Sinha S, Ciccarelli FD (2012) Network of Cancer Genes (NCG 
3.0): integration and analysis of genetic and network properties of cancer genes. Nucleic 
acids res. 40: 978-983. 
[5] Heng HH, Stevens JB, Bremer SW, Ye KJ, Liu G, Ye CJ (2010) The evolutionary 
mechanism of cancer. J. cell biochem. 109: 1072-1084. 
[6] Heng HH, Stevens JB, Bremer SW, Liu G, Abdallah BY, Ye CJ (2011) Evolutionary 
mechanisms and diversity in cancer. Adv. cancer res. 112: 217-53. 
[7] Duesberg P, Rasnick D (2000) Aneuploidy, the somatic mutation that makes cancer a 
species of its own. Cell motil. cytoskeleton. 47: 81-107. 
[8] Duesberg P, Fabarius A, Hehlmann R (2004) Aneuploidy, the primary cause of the 
multilateral genomic instability of neoplastic and preneoplastic cells. IUBMB life. 56: 65-
81. 
[9] Duesberg P, Li R, Fabarius A, Hehlmann R (2005) The chromosomal basis of cancer. 
Cell oncol. 27: 293-318.  
                                                                 
* Corresponding Author 
 
Cancer Genes and Chromosome Instability 167 
[10] Heng HH, Stevens JB, Liu G, Bremer SW, Ye KJ, Reddy PV, Wu GS, Wang YA, Tainsky 
MA, Ye CJ (2006) Stochastic cancer progression driven by non-clonal chromosome 
aberrations. J. cell physiol. 208: 461-472. 
[11] Fox EJ, Salk JJ, Loeb LA (2009) Cancer genome sequencing - an interim analysis. Cancer 
res. 69: 4948-4950. 
[12] Salk JJ, Fox EJ, Loeb LA (2010) Mutational heterogeneity in human cancers: origin and 
consequences. Annu. rev. pathol. 5: 51-75. 
[13] Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature. 458: 719-724. 
[14] Loeb LA (2011) Human cancers express mutator phenotypes: origin, consequences and 
targeting. Nat. rev. cancer. 11: 450-457. 
[15] Xu X, Hou Y, Yin X, Bao L, Tang A, Song L, Li F, Tsang S, Wu K, Wu H, He W, Zeng L, 
Xing M, Wu R, Jiang H, Liu X, Cao D, Guo G, Hu X, Gui Y, Li Z, Xie W, Sun X, Shi M, 
Cai Z, Wang B, Zhong M, Li J, Lu Z, Gu N, Zhang X, Goodman L, Bolund L, Wang J, 
Yang H, Kristiansen K, Dean M, Li Y, Wang J (2012) Single-cell exome sequencing 
reveals single-nucleotide mutation characteristics of a kidney tumor. Cell. 148: 886-895. 
[16] Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, 
Levy D, Esposito D, Muthuswamy L, Krasnitz A, McCombie WR, Hicks J, Wigler M 
(2011) Tumour evolution inferred by single-cell sequencing. Nature. 472: 90-94.  
[17] Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, 
Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, 
Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-
Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, 
Swanton C (2012) Intratumor heterogeneity and branched evolution revealed by 
multiregion sequencing. N. engl. j. med. 366: 883-892.  
[18] Knight SJ, Yau C, Clifford R, Timbs AT, Akha ES, Dréau HM, Burns A, Ciria C, Oscier 
DG, Pettitt AR, Dutton S, Holmes CC, Taylor J, Cazier JB, Schuh A (2012) Quantification 
of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and 
relapse samples from patients with B-cell chronic lymphocytic leukemia. Leukemia. 
doi:10.1038/leu.2012.13. 
[19] Braggio E, Kay NE, Vanwier S, Tschumper RC, Smoley S, Eckel-Passow JE, Sassoon T, 
Barrett M, Van Dyke DL, Byrd JC, Jelinek DF, Shanafelt TD, Fonseca R (2012) 
Longitudinal genome wide analysis of patients with chronic lymphocytic leukemia 
reveals complex evolution of clonal architecture at disease progression and at the time 
of relapse. Leukemia. doi: 10.1038/leu.2012.14. 
[20] Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman 
JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA 
(2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. 
Nature. 467: 1114-1117. 
[21] Cahill DP, Kinzler KW, Vogelstein B, Lengauer C (1999) Genetic instability and 
darwinian selection in tumours. Trends cell biol. 9: 57-60. 
[22] Stepanenko AA, Kavsan VM (2012) Evolutionary karyotypic cancer theory versus 
conventional cancer gene mutation theory. Biopol. cell. 28: in press. 
 
Oncogene and Cancer – From Bench to Clinic 166 
conditional transgenic mice models. CIN and intratumor heterogeneity are the reasons of 
oncogene addiction independence of solid tumors from any particular oncogene and general 
ineffectiveness of targeted therapy in clinic. Any factors or stresses that contribute to CIN 
can potentially promote the evolution of cancer.  
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1. Introduction 
One of the most common sexually transmitted diseases is human papillomavirus (HPV) 
infection that affects around 80% of sexually active women. Although most of the women 
clear HPV infection, individuals with inadequate immune responses develop persistent 
infections which lead to premalignant lesions such as high-grade cervical intraepithelial 
neoplasia (CIN-III), with high potential to progress to cervical carcinoma. Based on 
molecular and epidemiological data, high risk papillomaviruses (hrHPVs) are now 
recognized as etiologic agents of cervical carcinoma, although some additional events are 
required [1, 2].  
From 200 HPV genotypes identified so far, nearly 40 can infect cervix and at least 15 hrHPVs 
(16, 18, 45, 31, 52, 33, 58, 35, 59, 51, 56, 39, 68, 73, and 82) are usually associated with the 
development of carcinomas. Although HPVs 26, 53, and 66 are probably high-risk types 
limited data link them to cervix cancer [3]. HPV16 accounts for near 60% of the cervical 
cancer cases in most countries, followed by HPV-18, -31 and -45. 
HPVs are small non-enveloped double-stranded DNA viruses of about 8000-base pair long 
[4]. The viral genome codes for eight proteins and is divided in three functional regions: 
early (E1-E6), late (L1-L2) and long coding region (LCR). Early genes are synthesized in the 
infected basal cells and the late ones are expressed in differentiated cells [5], the replication 
of HPV cycle depending on complete squamous differentiation of the host epithelium. 
Except for E1 and E2 proteins (necessary for viral replication), papillomaviruses use the host 
cell machinery for viral DNA synthesis.  
New data confirmed that papillomavirus genomes are organized in the form of chromatin-
like structures composed by nucleoprotein complexes (nucleosomes) interconnected by a 
DNA filament. Treatment of CaSki human cervical carcinoma cell line with 
methidiumpropyl-EDTA-Fe (II) reveals nucleosomes in specific positions on the LCR and 
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1. Introduction 
One of the most common sexually transmitted diseases is human papillomavirus (HPV) 
infection that affects around 80% of sexually active women. Although most of the women 
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[4]. The viral genome codes for eight proteins and is divided in three functional regions: 
early (E1-E6), late (L1-L2) and long coding region (LCR). Early genes are synthesized in the 
infected basal cells and the late ones are expressed in differentiated cells [5], the replication 
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the E6 and E7 genes. First observed by electron microscopy for bovine papillomavirus (BPV) 
and HPV from human plantar warts, respectively [6], they were subsequently confirmed for 
CaSki cell line where the localization of nucleosomes was found at LCR, E6 and E7 genes 
level. The role of nucleosomes is to repress the activity of the E6 promoter. An open 
chromatin structure (transcriptionally active status) at early and late viral promoter regions 
was characterized by the presence of dimethylated forms of histone H3K4 as well as 
acetylated histones H3 and H4 [7]. These observations suggest the involvement of histone 
modification in HPV transcription regulation. 
2. HPV oncogenesis 
Most cervical cancers arise at the squamo-columnar junction, a site characterized by 
continuous metaplastic changes. The highest metaplastic activity occurs in young women 
who are reported to have the highest incidence of HPV infection. As cervical cancer is 
frequently detected in women over 35 years, it was suggested that the disease is a 
consequence of a slow progression of the viral infection acquired at younger age [8]. 
HPVs complete their life cycle only in fully differentiated squamous epithelium and the 
presence of viral genomes in the infected cells is essential both for papillomaviruses and 
their associated pathologies. HPV cervical infections result in three types of clinical 
manifestations: (a) productive infection which lead to virions production; viral genes 
expression is strictly associated with host cell differentiation; (b) latent (asymptomatic) 
infection (characterized by viral genome presence in basal layers) develops within the first 
three months or it can remain undetected for years [2]; (c) abortive infection, associated in 
particular with high risk HPV genotypes, arises especially in sites which are non-optimal for 
productive infection. Squamous and glandular carcinomas do not support the productive 
program.  
Both in vivo and in vitro studies associated cervical cancer with three viral oncogenes (E5, E6 
and E7) coded by hrHPVs [9]. HPV-induced carcinogenesis is a complex process 
characterized by alterations in tumour-suppressor genes. The aberrant function of these 
genes and the genomic instability determined by HPV viral genes, cumulated with the 
action of various cofactors, lead to progressive lesions and finally to cancer. Nevertheless, in 
the absence of persistent infection, the risk of cervical cancer is low [10].  
The switch from productive to abortive infection is determined by a deregulated expression 
of E6 and E7 viral oncogenes in proliferating cells, thus leading to an extended lifespan [11]. 
The oncoproteins E6 and E7 interfere with tumor suppressors p53 and pRb respectively, and 
favour cells to overcome senescence barrier. Moreover, these proteins target a growing 
number of other cellular proteins/ factors. Epidemiologic and experimental data showed 
that also the E6 and E7 genes of low-risk types interfere with p53 and pRb and under certain 
circumstances are able to induce cervical neoplasia.  
While in the normal viral life cycle, the genome replicates as episomal molecules, the up-
regulation of viral oncogenes expression is associated with the HPV genome integration into 
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the host cell chromosome [12]. As a result of integration, viral E1 and E2 genes are disrupted 
and their repressive action on E6 and E7 open reading frames is discontinued. Recent data 
point out that E2hrHPV proteins exhibit new oncogenic properties which rely on their 
ability to induce abnormal mitoses, leading to either loss or excess of DNA, together with 
DNA breaks during anaphase [13]. Although HPV integration plays an important role in the 
progression to cancer, the mechanisms are still unclear. Viral integration seems to confer 
selective advantage for oncogenes transcription and stability for transcripts encoding the E6 
and E7 proteins which affect the key tumor suppressors p53 and pRB [14]. Cytogenetic 
mapping of multiple integration sites suggests that HPV integration occurrs preferentially in 
chromosomal fragile sites (CFS) [15] although it is under debate whether these sites present 
a greater susceptibility or accessibility to integration [16]. Sometimes, hrHPVs integration 
occurs within or adjacent to cellular oncogenes like myc, APM1, TP63, hTERT [17, 18]. 
Generally, coding regions are rarely targeted by HPV but gene expression and mRNA 
structure can be altered by insertion of the strong HPV promoter [14, 19].  
Up-regulation of viral oncogenes expression together with loss of inhibitory effects of E2, 
result in cellular immortalization, deregulated proliferation and increased genomic 
instability [20]. The viral oncogenes are transcribed by a nucleoprotein complex 
(enhanceosome) that consists of transcriptional factors (JunB/Fra2) and a chromatin 
remodelling factor (HMG-I(Y) [21]. SMARCA2, a member of the SWI/SNF family of 
proteins, similar to the brahma (Brm) protein from Drosophila, is involved in transcriptional 
regulation of certain genes by altering the chromatin structure. When HPV is present as 
episome, SMARCA2 associates with E2 promoter and enhances E2 transcriptional activation 
[22]. SMARCA2 mRNA is a specific target for miR-199a-5p and miR-199a-3p in tumor cell 
lines, being often silenced in tumor cells at the post-transcriptional levels [23]. That might 
offer an alternative pathway for E2 gene silencing in HPV transforming infection. 
The expression of the HPV oncogenes is necessary and sufficient for the initiation of cervical 
carcinogenesis, but host genome mutations are needed for malignant progression. In 
cervical cancer, cells accumulate a wide range of numerical and structural chromosomal 
abnormalities [24] including lagging chromosomal material, anaphase bridges, and 
multipolar mitoses [25]. As mentioned, persistent infection with HPV could lead, under 
certain conditions, to the insertion of viral genes into the host genome. As a consequence 
host defense mechanisms, including methylation machinery are activated [26]. Some viruses 
can find ways to regulate their gene expression (e.g. by modulating DNA methylation) in 
order to facilitate persistent infection and circumvent immune system [27]. Viral 
oncoproteins have the ability to modulate the methylation machinery in order to silent 
tumor suppressor genes. Studies on biological samples revealed an inverse correlation 
between the hypomethylation status of LCR region, E6 gene expression and the severity of 
lesion suggesting that hypomethylation accompanies progression to cancer [28, 29]. The 
studies of Badal et al. [30] revealed a clonal heterogeneity of methylation status in various 
regions of the viral genome, thus indicating that methylation of the viral oncogenes in 
cervical lesions is not an event that causes neoplastic progression but the result of 
transcriptional activity levels.  
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the host cell chromosome [12]. As a result of integration, viral E1 and E2 genes are disrupted 
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ability to induce abnormal mitoses, leading to either loss or excess of DNA, together with 
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As mentioned, cellular transformation is a consequence of persistent infection by hrHPVs 
that leads to clonal progression of the persistently infected epithelium. Viral oncogenes are 
essential for carcinogenesis and their expression induces the tumorigenic state which 
ensures cell survival, essential for viral replication and the spread of progeny [31] Although 
the viral oncogenes were intensively studied, new data bring more information about their 
involvement in cervix carcinogenesis. 
3. E6 HPV 
High-risk E6 proteins are known for their ability to associate and degrade tumor suppressor 
p53. E6HPVs inactivate p53 in the infected cells, by inducing its degradation through the 
ubiquitin–proteasome pathway (Mdm2 E3, E6AP) [32]. This interaction prevents p53 from 
inducing growth arrest and apoptosis and promotes the perpetuation of damaged DNA 
during the host cell reproduction. Even both high and low risk E6HPV proteins interact 
with p53, only high risk oncogenes are capable of binding to the core region of p53. This 
step is mediated by recruitment of E6-AP (E3 ubiquitin ligase) which interacts with the 
viraloncogene and forms a complex with both E6 and target proteins [33].  
E6 may inhibit p53 signalling pathways independent of protein degradation through p53 
sequestration in the cytoplasm or by enhancing p53 nuclear export [34]. As a consequence, 
E6 oncoprotein precludes the growth-suppressive activities of p53 by transcriptional 
suppression of its target genes. It inhibits p53 activity by abrogation of the p53 
transactivation via interaction with CBP/p300 [35, 36] or hADA3 histone acetyl-transferases, 
proteins involved in the regulation of transcription and DNA replication [37][38]. E6hrHPV 
proteins display a PDZ (postsynaptic density protein, discs large tumor suppressor, and the 
epithelial tight junction protein, Z0-1) motif designated as S/TXV at their C-terminus end 
which mediates E6 binding to proteins with these specific domains [39]. There are many 
studies focused on these interactions with proteins involved in proliferation control such as 
hDlg1 [40], hScrib [41], MAGI, PTPN3, MUPP1 [42, 43]. hScrib functions as a tumor 
suppressor that negatively regulates proliferation. hDlg and hScrib are proteins associated 
with cell junctions mediating the adhesion of basal cells to the ECM. Both are targeted for 
ubiquitination by high risk E6–E6AP complex, thus affecting epithelial cell growth [41]. 
MAGI proteins (membrane-associated guanylate kinase homologues –MAGUKs) are found 
at the tight junctions in epithelial cells and are thought to act in signalling pathways. Their 
degradation by E6 disrupts regulation of epithelial proliferation [42, 43]. Experimental 
evidence indicates that the interaction of E6 with PDZ proteins is necessary for the 
development of epithelial hyperplasia [44].  
Several proteins involved in apoptosis and immune evasion (Bak, FADD,c-Myc, NFX1, 
procaspase 8, etc) [45, 46, 47, 48] are also targeted by E6 HPV. Bak, a member of the Bcl-2 
family, is a proapoptotic protein whose interaction with the viral oncogene leads to the 
inhibition of apoptosis. This strategy by which the virus circumvents apoptosis might 
contribute to its oncogenic potential.  
E6 oncoprotein is also able to modulate transcription from other cellular signaling pathways 
by interacton with three G-protein (E6TP, Gps2, Tuberin). E6 binds and degrades E6TP1 (E6-
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targeted protein 1) in an E6AP dependent manner [49]. E6TP1 has homology to GAPs (GTPase 
activating proteins) for Rap [50] and its interaction with E6 was observed only in cancer-
associated high-risk HPV but not in lesion-associated low-risk HPV. E6TP1 is involved in 
regulating cell proliferation and malignant cellular transformation, and its degradation by 
ubiquitination seems to be related to cellular immortalization suggesting a critical role of 
functional inactivation of E6TP1 in E6-induced cellular immortalization. 
Tuberin is another protein with GAP activity which is degraded by E6. Tuberin functions in 
the harmatin–tuberin complex, which exhibits GAP activity toward Rheb proten. This 
complex is a negative regulator of mTOR signaling [51]. E6 also binds and degrades Gps2, 
that is involved in suppressing G-protein signaling pathway and c-Jun N-terminal kinase 
(JNK) activity [52].  
E6 is involved in the blockage of apoptosis acting in both major apoptotic pathways:  
a. the extrinsic pathway, which triggers extracellular signals that induce the activation of 
“death receptors” on the cell surface: 1) E6 binds to the death receptor TNFR-1, inhibiting 
TNFR-1 association with the TRADD (TNFR1- associated death domain adapter molecule) and 
blocking TNFR-1 death domain mediated apoptosis [47]; 2) E6 inhibits apoptosis by binding 
and degrading both the FADD adapter protein and caspase-8 [53]. 
b. the intrinsic pathway, which triggers sensing apoptotic signals that arise within the cell 
(DNA damage, oxidative stress) [54]. The lr/hrE6 oncoproteins block intrinsic apoptotic 
signaling interacting with Bak, inducing its proteasomal-dependent degradation [55], or 
using a mechanism depending or not on E6AP and E3 ubiquitin ligases [56].  
Another biological activity of E6 oncoprotein consists in alteration of cell adhesion in order 
to allow proliferation of differentiated cells and inhibition of terminal differentiation: 
extracellular matrix adhesion, cell:cell contact and cytoskeletal organization. For example, 
Paxillin and zyxin are focal adhesion molecules involved in binding cellular cytoskeleton to 
the ECM and transmitting signals along the actin network from the ECM to nucleus. Focal 
adhesions form a structural link between the extracellular matrix and the actin cytoskeleton, 
and are important sites of signal transduction. Paxillin has been shown to bind to β-integrin, 
oncoproteins such as v-Src, v-Crk, p210BCR/ABL, p125FAK, vinculin, and talin, and is 
involved in changing the organization of the actin cytoskeleton. E6HPV interacts with 
paxillin [57], and the binding leads to the disruption of the actin cytoskeleton, a 
characteristic of many transformed cells.  
E6 interacts with proteins involved in chromosomal stability within the HPV infected cell. 
Viral protein mediates MCM7 (minichromosome maintenance 7) degradation via E6AP and 
leads to chromosomal abnormalities in HPV infected cells [58]. Moreover, its interactions 
with XRCC1 and O(6)-methylguanine-DNA methyltransferase (MGMT) (proteins involved 
in single strand DNA break repair) induce DNA damage [59] or sensitize HPV infected cells 
to alkylating DNA damage [60]. These interactions increase genomic instability and 
accelerate the progression to carcinogenesis. 
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As mentioned, cellular transformation is a consequence of persistent infection by hrHPVs 
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Paxillin and zyxin are focal adhesion molecules involved in binding cellular cytoskeleton to 
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Viral protein mediates MCM7 (minichromosome maintenance 7) degradation via E6AP and 
leads to chromosomal abnormalities in HPV infected cells [58]. Moreover, its interactions 
with XRCC1 and O(6)-methylguanine-DNA methyltransferase (MGMT) (proteins involved 
in single strand DNA break repair) induce DNA damage [59] or sensitize HPV infected cells 
to alkylating DNA damage [60]. These interactions increase genomic instability and 
accelerate the progression to carcinogenesis. 
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E6 hrHPV is also involved in immune evasion by interacting with IFR-3 (Interferon regulatory 
factor-3) [61], that is required for the expression of type I interferon. IFR-3 is activated by 
virus infection to form a complex with transcriptional regulators of the IFN-beta. Therefore 
IFR-3 inhibition affects its transactivation ability and results in the induction of IFN-β 
following viral infection [62]. Interferon induced growth arrest is dependent on p53 
acetylation, a modification which affects p53 stability and increases its transcriptional 
activity. As E6 targets p53 directly or through p300/CBP, the virus induces proliferation of 
HPV infected cells in the presence of interferon [63]. Moreover, E6 inhibits TLR9 
transcription, leading to a functional loss of TLR9 signaling pathways within the cell [61]. By 
activating telomerase, E6 promotes malignancy as the mutant cells continue to reproduce 
uncontrollably [64] 
It was noticed that oncogenic E6HPV is able to modulate the expression of many cellular 
miRNAs via p53. For example, miR-34a gene is a direct transcriptional target of p53 and its 
expression is transactivated by p53 binding to a consensus p53 binding site in the miR-34a 
promoter region [65, 66, 67]. As E6 is a regulator of p53, viral oncoprotein leads to the 
reduction of miR-34a, and this affects the expression of cell cycle regulators, including cyclin 
E2, cyclin D1, CDK4, CDK6, Bcl-2, SIRT1, and p18Ink4c [68, 69]. The hypothesis that p53 
modulates cellular miRNAs down-regulation mediated by E6HPV16 was sustained by the 
fact that the genes encoding miR-34a and miR-23b contain a promoter region with a p53 
binding site [70].  
4. E7HPV 
The HPV life cycle is associated with the differentiation process of the infected epithelial 
cell. Interaction between E7 and pRB determines degradation and phosphorylation of pRB 
with the release of E2F and activation of genes that promote cellular proliferation. The 
actions of E7 induce cells to enter in the S phase of cell cycle (including suprabasal epithelial 
cells) which ensures all cellular factors necessary for viral replication. On the other hand, E7 
can directly bind E2F1 and enhance E2F1-mediated transcription [71]. E2F transcription 
factors are critical regulators of G1 exit and S-phase progression. In addition, cellular 
differentiation, apoptosis and genomic instability are controlled by E2Fs [72]. E7 also 
interacts with pRb associated proteins (p107, p130) which are negative regulators of the cell 
cycle involved in G1/S and G2/M transition, via the LXCXE motif in CR2 [73].  
E7hrHPV can associate and alter the activities of multiple cellular factors that normally 
contribute to the regulation of the cell cycle. In addition to targeting pRB for proteasomal 
degradation [74] E7 inhibits p21 functions by direct binding, thus contributing to sustained 
activity of CDK [73, 75, 76]. Cyclin dependent kinases (cdks) are the most important in cell 
division cycle. Expression of cyclins E and A, the regulatory subunits of cdk2, which drives 
S-phase entry and progression, is under E2F control and they are both expressed at higher 
levels in E7 expressing cells [77].  
A cell infected by virus will usually respond by producing interferons (IFNs) that have an 
antiviral and antitumour effect. HPV16 E7 protein has been shown to block IFN-α activity 
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and inhibit IFN-β promoter [78]. Besides its role in cell proliferation E7 also regulates 
apoptosis. Some studies underlined that the actions of E7 appear to be anti-apoptotic. On the 
other hand, overexpression of E7 in genital keratinocytes induces spontaneous cell death. 
However, its effect on cellular apoptotic pathways is pleiomorphic. 
E7hrHPV increases genomic instability in primary human cells [79] and generates mitotic 
defects and aneuploidy as a consequence of gains or losses of entire chromosomes during 
mitosis, or by induction of supernumerary centrosomes and multipolar mitoses [25]. 
Supernumerary centrosomes and associated multipolar mitoses have been detected in cells 
that express low copy numbers of episomal E7HPV [80] and their incidence increases in cells 
with integrated HPV, presumably due to higher E7 expression. Induced aberrant centriole 
synthesis is dependent on cdk2 activity in E7 expressing cells [81, 82]. The ability of HPV16 
E7 to induce supernumerary centrosomes is at least in part independent from the ability to 
target pRB family members. A possible pRB/p107/p130 independent mechanism involves 
the association of E7 with the centrosomal regulator γ-tubulin [83]. E7HPV expression also 
causes other types of mitotic abnormalities including lagging chromosomal material and 
anaphase bridges that may represent chromosomal fusions caused by double stand DNA 
breaks [84]. The presence of DNA repair foci indicates that E7 may induce double strand 
DNA breaks or interfere with break repair. This may facilitate viral genome integration.  
High-risk E7 proteins are also able of direct the interaction with chromatin modifiers such as 
histone deacetylases HDACs 1, 2, 3 and 8, events independent of pRB inactivation. HDACs 
are involved in regulation of transcription of different genes, including those that present 
promoters activated by E2F transcriptional factor [84]. This interaction additionally affects 
the expression of S phase genes. Experimental studies showed that L67 mutation of HPV31 
E7 protein determines the impossibility to bind HDACs, and affects the virus ability to 
remain in an episomal status or to complete the later stages of the viral life cycle [85]. 
Currently, there is no study to prove the connection between the viral replication and the 
binding of E7 to HDACs. E7hrHPV also interacts with c-myc, augments c-myc 
transactivation, contributing to an efficient immortalization.  
As we mentioned before, HPV16 E7 oncoprotein interacts with complexes formed between 
E2F6 and polycomb transcriptional repressor (PRCs) [86]. PRCs associate with histone H3 
lysine 27 trimethyl (H3K27me3) [87] and inactivate p14ARF tumor suppressor [88]. Highly 
HPV16E7 expression correlates with high levels of H3K27me3 [89] and an increased 
expression of p16INK4A through KDM6B induction. This process is not dependent of pRB 
inactivation by E7 oncogene, but several genes (Hox) regulated by KDM6A or KDM6B are 
highly expressed, promoting cell proliferation and escape from senescence. Gathering these 
data, HPV16E7 expression may cause epigenetic reprogramming in host cells, inducing 
alterations in H3K27me3 levels and transcriptional changes. On the other hand, KDM5 has 
been linked to oncogenesis process [86]: E2 protein recruits KDM5 in order to repress the 
transcription of the E6 and E7 oncoproteins through the HPV LCR [90, 91]. The interplay 
between histone methyl-transferases and demethylases in the context of viral oncogenes 
activity is shown in figure 1.  
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Figure 1. The interplay between histone methyl-trasferases and demethylases in the context of viral 
oncogenes activity 
Expression of both early and late HPV genes seems to be subject to miRNA-mediated 
regulation at the post-transcriptional level in cervical cancer cell lines [68, 69].  
E7 increases the expression of miR-15/16 cluster through pRB degradation and release of E2, 
a factor which promotes miR-15a/16-1 cluster expression [68, 69]. On the other hand, 
E7hrHPV down-regulates the expression of miR-203 [92], a micromolecule involved in the 
control of the keratinocytes differentiation by shift from a proliferative to a nonproliferative 
status [93, 94]. Another cause of miR-203 down-regulation is due to methylation of CpG 
islands in the promoter region. Hypermethylation of miR203 as well as miR-34b and miR-
124 was correlated with CIN III and cervical cancer [95].  
Beside the E6 and E7 oncogenes, recent studies emphasize the role of two other viral 
proteins in HPV induced oncogenesis: E5 and E2.  
5. E5 HPV 
E5 HPV16 is a hydrophobic protein (83 amino acid long), localized in the intracellular 
membranes (plasma membrane, endoplasmic reticulum, nuclear envelope and Golgi 
apparatus) [96]. Based on its interactions with cellular proteins, E5 seems to be a weak 
transforming protein. These interactions lead to alterations in normal biological activity and 
evasion of the immune response. E5 gene encodes short hydrophobic peptides, which have 
mitogenic activity, synergic with EGF (epidermal growth factor) [97]. In hrHPV infections, (e.g. 
HPV 16) EGF receptor increases 2-5 times in the human keratinocytes expressing E5, leading 
to cell proliferation. This suggests that HPV16 E5 plays a major role in expanding 
populations of HPV16-infected basal keratinocytes in vivo by augmenting extracellular 
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growth signals in viral infected cells (enhancing ligand-dependent EGF-R activation). E5 
oncoprotein binds and inhibits the activity of the 16 kDa subunit of vacuolar ATP-ase (V-
ATPase), altering the endosomal acidification and degradation of EGF-R [98, 99]. The delay 
of EGF-R degradation can be reached by E5 interference with membrane trafficking and the 
fusion of early and late endosomes [100].  
E5 activates EGF-R signaling pathway through either EGF-dependent or EGF-independent 
processes, but it is also capable of interacting with, enhancing/ altering the signaling of other 
different classes of growth factor receptors like:  
- G protein-coupled endothelin receptor [96]; this interaction induces mitogenic activity 
of ET-1, leading to the chronic stimulation of keratinocyte proliferation;  
- keratinocyte growth factor receptor/ fibroblast growth factor receptor 2b (KGF-R/FGF-
R2b); these receptors are down-modulated by E5, through reduction of transcripts and 
protein [101, 102].  
- connexin 43 interferes with E5, in order to inhibit gap junction-mediated 
communication between epithelial cells in monolayer [103] and in raft cultures [104]; 
this makes the transformed cells more insensitive to homeostatic growth control signals 
from adjacent normal cells. Moreover, E5 seems to be involved in induction of cell 
fusion [105, 106, 107] a critical event in the early stage of HPV-associated cervical 
cancer. There are experimental data which support E5 role in cervical cancer. It seems 
this viral protein increases the efficiency of keratinocytes immortalization induced by 
E6 and E7 oncogenes [108] and affects cell-cell communications [109] 
In early infection, E5 appears to inhibit programmed cell death [110] using different 
mechanisms like: (a) down regulation of the total amount of Fas receptor and reduction of 
Fas surface location; and (b) alteration of the formation of Death-Inducing Signalling Complex 
(DISC) triggered by TRAIL [111]. While E5 did not down-regulate TRAIL receptor 
expression, it was found to inhibit TRAIL signaling by interfering with the formation of the 
TRAIL DISC and thereby inhibiting the cleavage of procaspases-3 and -8, as well as of PARP 
[111]. Therefore, it is possible that E5 interferes with the ability of the immune system to 
eliminate infected cells by impairing death receptor signaling. Together, the results of these 
studies provide strong evidence that E5 contributes to the evasion of immune surveillance 
during the early stages of HPV infection. 
In contrast, HPV16E5 sensitizes human keratinocytes to apoptosis induced by osmotic 
stress, perhaps due to cell membrane modifications caused by this strong hydrophobic 
molecule [111]. On the other hand, E5 can inhibit the ER stress pathway, cyclooxygenase-2 
(COX-2), XBP-1 and IRE1a, but this seems to be limited to the high risk genotypes, favoring 
viral replication and persistence [112]. 
The role of E5 in HPV transformation might be due to alteration of innate and adaptive 
immune responses. E5 protein seems to down-regulate MHC/HLA class I, through 
alkalinisation of the endomembrane compartments [113] and the direct interaction of E5 
with the heavy chain of the MHC class I complex [114, 115]. E5 gene is often deleted during 
viral DNA integration into the host cell genome. This might suggest a dispensable role of 
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of ET-1, leading to the chronic stimulation of keratinocyte proliferation;  
- keratinocyte growth factor receptor/ fibroblast growth factor receptor 2b (KGF-R/FGF-
R2b); these receptors are down-modulated by E5, through reduction of transcripts and 
protein [101, 102].  
- connexin 43 interferes with E5, in order to inhibit gap junction-mediated 
communication between epithelial cells in monolayer [103] and in raft cultures [104]; 
this makes the transformed cells more insensitive to homeostatic growth control signals 
from adjacent normal cells. Moreover, E5 seems to be involved in induction of cell 
fusion [105, 106, 107] a critical event in the early stage of HPV-associated cervical 
cancer. There are experimental data which support E5 role in cervical cancer. It seems 
this viral protein increases the efficiency of keratinocytes immortalization induced by 
E6 and E7 oncogenes [108] and affects cell-cell communications [109] 
In early infection, E5 appears to inhibit programmed cell death [110] using different 
mechanisms like: (a) down regulation of the total amount of Fas receptor and reduction of 
Fas surface location; and (b) alteration of the formation of Death-Inducing Signalling Complex 
(DISC) triggered by TRAIL [111]. While E5 did not down-regulate TRAIL receptor 
expression, it was found to inhibit TRAIL signaling by interfering with the formation of the 
TRAIL DISC and thereby inhibiting the cleavage of procaspases-3 and -8, as well as of PARP 
[111]. Therefore, it is possible that E5 interferes with the ability of the immune system to 
eliminate infected cells by impairing death receptor signaling. Together, the results of these 
studies provide strong evidence that E5 contributes to the evasion of immune surveillance 
during the early stages of HPV infection. 
In contrast, HPV16E5 sensitizes human keratinocytes to apoptosis induced by osmotic 
stress, perhaps due to cell membrane modifications caused by this strong hydrophobic 
molecule [111]. On the other hand, E5 can inhibit the ER stress pathway, cyclooxygenase-2 
(COX-2), XBP-1 and IRE1a, but this seems to be limited to the high risk genotypes, favoring 
viral replication and persistence [112]. 
The role of E5 in HPV transformation might be due to alteration of innate and adaptive 
immune responses. E5 protein seems to down-regulate MHC/HLA class I, through 
alkalinisation of the endomembrane compartments [113] and the direct interaction of E5 
with the heavy chain of the MHC class I complex [114, 115]. E5 gene is often deleted during 
viral DNA integration into the host cell genome. This might suggest a dispensable role of 
 
Oncogene and Cancer – From Bench to Clinic 192 
this gene in oncogenesis but the fact that E5 mRNA is the most abundant viral transcript 
prior integration sustains its role in early phases of tumorigenesis.  
6. E2 HPV 
The E2HPV protein exhibits complex functions independent of transcription; it can 
modulate the host cells in concert with the viral vegetative cycle. Recent data point out that 
E2HPV could be involved in early carcinogenesis [13]. E2 is a repressor of E6 and E7 
transcription in the HPV context. E2HPV is involved in viral transcription and replication 
[116, 117], forming together with E1 a complex with viral origin of replication and recruiting 
cellular DNA replication machinery (DNA polymerases, replication protein A, replication 
protein C, topoisomerase I/II and proliferating-cell nuclear antigen) in order to facilitate 
viral DNA replication [116]. It was noted that E2 protein is expressed at relatively high 
levels in differentiated cells of the intermediate layers of CIN lesions; on the other hand, its 
expression is decreased with progression of the lesions and is absent in most of the cancers 
in situ, being inversely correlated with expression of E7 [13, 118]. E2 is an unstable protein 
expressed in both the nuclei and cytoplasm of infected cells, and is degraded through the 
proteasome [119, 120]. In most cases, HPV integration occurs by breaking the E2 gene 
region. Re-expression of E2 in cervical carcinoma cell lines appears to be detrimental to cell 
proliferation due to the induction of G1 cell cycle arrest through repression of the 
endogenous E6/E7 expression, as well as due to induction of cellular senescence and 
apoptosis [121, 122]. The fact that E2 can regulate the activities of E6 and E7 via 
transcriptional control or by direct interaction [28], suggests that HPV genome integration 
may result from a strong selective pressure on the virus to avoid E2-induced apoptosis 
while modulating the survival of infected cells through the activities of E6 and E7. 
E2 could enhance cellular DNA replication through abrogation of a mitotic checkpoint [123] 
and blocking the cell cycle in G2/M [124]; E2 activates the spindle assembly checkpoint and 
induces abnormal chromosome segregation after anaphase, leading to aneuploidy or DNA 
breaks [13]. The potential role of E2 to induce abnormal mitoses links E2 to HPV-associated 
carcinogenesis. This hypothesis is sustained by the fact that only E2 proteins from high-risk 
HPVs could induce abnormal mitotic phenotypes, in contrast to the E2 proteins from the 
low-risk HPV11 and 6 which are inactive [124].   
7. Prevention of cervical carcinoma 
The high risk human papillomaviruses are associated with cervical cancers and play an 
essential role in the pathogenesis of the disease. Although commercial prophylactic HPV 
vaccines are now available, they do not have therapeutic effect against established HPV 
infections and HPV-associated lesions which account for high morbidity and mortality 
worldwide. Advanced cervical cancer remains a public health issue despite the availability of 
preventive vaccines and population-based screening because they target a very young teenage 
population with a delayed impact on cervical cancer due to the peak of cervical cancer 
incidence at ages 45–55 [125]. Viral oncoproteins are critical for the induction and maintenance 
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of cellular transformation in HPV-infected cells. Therefore, E6 and E7 are considered the ideal 
targets for therapeutic HPV vaccines. By contrast with the commercial preventive HPV 
vaccines (Gardasil and Cervarix) which use HPV virus-like particles to generate neutralizing 
antibodies, therapeutic vaccines can eliminate preexisting lesions and infections by generating 
cellular immunity against HPV-infected cells. Consequently, many therapeutic vaccine 
strategies have focused primarily on stimulating the production and activation of T cells that 
can recognize infected cells expressing the target antigens (E6 and E7).  
A variety of vaccine strategies have been employed to target immune responses to these 
proteins. Various therapeutic HPV vaccines for cervical cancer, including live vector-, 
peptide-, protein-, nucleic acid-, or cell-based vaccines targeting the E6HPV and/or E7 
antigens were developed.  
Live vector-based vaccines (bacterial and viral vectors) are attractive due to their high 
immunogenicity and efficiency in delivering antigens or DNA encoding antigens of interest. 
Among them, ADXS11-001 (Listeria-based vaccine) targets E7 and is well tolerated by patients 
in end-stage of cervical cancer, who had failed prior chemotherapy, radiotherapy and/or 
surgery (phase I trial in patients with stage IVb cervical cancer) [126]. On the other hand, TA-
HPV (a recombinant vaccinia virus expressing HPV-16/18 E6/E7 fusion protein), induces HPV 
antigen-specific T cell-mediated immune response (phase I/II trial in patients with Ib or IIa 
cervical cancer) [127]. MVA-E2 and MVA-HPV-IL2 (Modified Vaccinia Ankara-based vaccines 
expressing HPV16 E6/E7 and IL-2) showed some promises as 50% of the treated patients 
presented complete healing of lesions and E6 and E7 antigen levels below the detection limit of 
6 months post vaccination (phase II trial in patients with CIN III) [128].   
Cell-based vaccines (dendritic cells-DCs, modified tumor cells) are highly immunogenic and 
useful in expressing the relevant tumor antigens. Vaccination with E7-presenting DCs 
transfected with siRNA targeting Bim (Bcl-2-interacting mediator) was capable of 
generating a strong E7-specific CTL response and a marked therapeutic effect in vaccinated 
mice [129]. The vaccine was in clinical pilot study in patients with late stage cervical cancer 
[130] or phase I trial in patients with stage Ib or IIa cervical cancer [131], or with recurrent 
cervical cancer [132].  
Peptide-based vaccines can combine multiple epitopes and enhance peptides for MHC 
binding. The peptide-based vaccine potency is increased by using adjuvants such as GM-
CSF, 4-1BB ligand, and Montanide ISA 51) [133, 134]. Several vaccines from this category are 
in different phase trials: Lipopeptide - lipidated E7 (HLA-A* 0201 - restricted epitope, a.a. 
86– 93 lipopeptide) in phase I trial in patients with refractory cervical or vaginal cancer; 
Peptide & Montanide ISA -51 (HLA-A * 0201- HPV16 E7 epitopes restricted, a.a. 12 to 20 ± 
a.a. 86 -93) ligated to PADRE, adjuvant Montanide ISA 51, in phase I/II trial in patients with 
recurrent or residual cervical cancer. TriVax- HPV16-E7 epitope (E7 49-57 with CD40 mAb) 
in tumor-bearing mice [135] has not yet been tested in clinical trials. 
The protein-based vaccines take the advantage of using fully purified proteins which are 
able to induce humoral and cellular immune response. Conformational epitopes of injected 
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this gene in oncogenesis but the fact that E5 mRNA is the most abundant viral transcript 
prior integration sustains its role in early phases of tumorigenesis.  
6. E2 HPV 
The E2HPV protein exhibits complex functions independent of transcription; it can 
modulate the host cells in concert with the viral vegetative cycle. Recent data point out that 
E2HPV could be involved in early carcinogenesis [13]. E2 is a repressor of E6 and E7 
transcription in the HPV context. E2HPV is involved in viral transcription and replication 
[116, 117], forming together with E1 a complex with viral origin of replication and recruiting 
cellular DNA replication machinery (DNA polymerases, replication protein A, replication 
protein C, topoisomerase I/II and proliferating-cell nuclear antigen) in order to facilitate 
viral DNA replication [116]. It was noted that E2 protein is expressed at relatively high 
levels in differentiated cells of the intermediate layers of CIN lesions; on the other hand, its 
expression is decreased with progression of the lesions and is absent in most of the cancers 
in situ, being inversely correlated with expression of E7 [13, 118]. E2 is an unstable protein 
expressed in both the nuclei and cytoplasm of infected cells, and is degraded through the 
proteasome [119, 120]. In most cases, HPV integration occurs by breaking the E2 gene 
region. Re-expression of E2 in cervical carcinoma cell lines appears to be detrimental to cell 
proliferation due to the induction of G1 cell cycle arrest through repression of the 
endogenous E6/E7 expression, as well as due to induction of cellular senescence and 
apoptosis [121, 122]. The fact that E2 can regulate the activities of E6 and E7 via 
transcriptional control or by direct interaction [28], suggests that HPV genome integration 
may result from a strong selective pressure on the virus to avoid E2-induced apoptosis 
while modulating the survival of infected cells through the activities of E6 and E7. 
E2 could enhance cellular DNA replication through abrogation of a mitotic checkpoint [123] 
and blocking the cell cycle in G2/M [124]; E2 activates the spindle assembly checkpoint and 
induces abnormal chromosome segregation after anaphase, leading to aneuploidy or DNA 
breaks [13]. The potential role of E2 to induce abnormal mitoses links E2 to HPV-associated 
carcinogenesis. This hypothesis is sustained by the fact that only E2 proteins from high-risk 
HPVs could induce abnormal mitotic phenotypes, in contrast to the E2 proteins from the 
low-risk HPV11 and 6 which are inactive [124].   
7. Prevention of cervical carcinoma 
The high risk human papillomaviruses are associated with cervical cancers and play an 
essential role in the pathogenesis of the disease. Although commercial prophylactic HPV 
vaccines are now available, they do not have therapeutic effect against established HPV 
infections and HPV-associated lesions which account for high morbidity and mortality 
worldwide. Advanced cervical cancer remains a public health issue despite the availability of 
preventive vaccines and population-based screening because they target a very young teenage 
population with a delayed impact on cervical cancer due to the peak of cervical cancer 
incidence at ages 45–55 [125]. Viral oncoproteins are critical for the induction and maintenance 
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of cellular transformation in HPV-infected cells. Therefore, E6 and E7 are considered the ideal 
targets for therapeutic HPV vaccines. By contrast with the commercial preventive HPV 
vaccines (Gardasil and Cervarix) which use HPV virus-like particles to generate neutralizing 
antibodies, therapeutic vaccines can eliminate preexisting lesions and infections by generating 
cellular immunity against HPV-infected cells. Consequently, many therapeutic vaccine 
strategies have focused primarily on stimulating the production and activation of T cells that 
can recognize infected cells expressing the target antigens (E6 and E7).  
A variety of vaccine strategies have been employed to target immune responses to these 
proteins. Various therapeutic HPV vaccines for cervical cancer, including live vector-, 
peptide-, protein-, nucleic acid-, or cell-based vaccines targeting the E6HPV and/or E7 
antigens were developed.  
Live vector-based vaccines (bacterial and viral vectors) are attractive due to their high 
immunogenicity and efficiency in delivering antigens or DNA encoding antigens of interest. 
Among them, ADXS11-001 (Listeria-based vaccine) targets E7 and is well tolerated by patients 
in end-stage of cervical cancer, who had failed prior chemotherapy, radiotherapy and/or 
surgery (phase I trial in patients with stage IVb cervical cancer) [126]. On the other hand, TA-
HPV (a recombinant vaccinia virus expressing HPV-16/18 E6/E7 fusion protein), induces HPV 
antigen-specific T cell-mediated immune response (phase I/II trial in patients with Ib or IIa 
cervical cancer) [127]. MVA-E2 and MVA-HPV-IL2 (Modified Vaccinia Ankara-based vaccines 
expressing HPV16 E6/E7 and IL-2) showed some promises as 50% of the treated patients 
presented complete healing of lesions and E6 and E7 antigen levels below the detection limit of 
6 months post vaccination (phase II trial in patients with CIN III) [128].   
Cell-based vaccines (dendritic cells-DCs, modified tumor cells) are highly immunogenic and 
useful in expressing the relevant tumor antigens. Vaccination with E7-presenting DCs 
transfected with siRNA targeting Bim (Bcl-2-interacting mediator) was capable of 
generating a strong E7-specific CTL response and a marked therapeutic effect in vaccinated 
mice [129]. The vaccine was in clinical pilot study in patients with late stage cervical cancer 
[130] or phase I trial in patients with stage Ib or IIa cervical cancer [131], or with recurrent 
cervical cancer [132].  
Peptide-based vaccines can combine multiple epitopes and enhance peptides for MHC 
binding. The peptide-based vaccine potency is increased by using adjuvants such as GM-
CSF, 4-1BB ligand, and Montanide ISA 51) [133, 134]. Several vaccines from this category are 
in different phase trials: Lipopeptide - lipidated E7 (HLA-A* 0201 - restricted epitope, a.a. 
86– 93 lipopeptide) in phase I trial in patients with refractory cervical or vaginal cancer; 
Peptide & Montanide ISA -51 (HLA-A * 0201- HPV16 E7 epitopes restricted, a.a. 12 to 20 ± 
a.a. 86 -93) ligated to PADRE, adjuvant Montanide ISA 51, in phase I/II trial in patients with 
recurrent or residual cervical cancer. TriVax- HPV16-E7 epitope (E7 49-57 with CD40 mAb) 
in tumor-bearing mice [135] has not yet been tested in clinical trials. 
The protein-based vaccines take the advantage of using fully purified proteins which are 
able to induce humoral and cellular immune response. Conformational epitopes of injected 
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proteins are recognized by B cell receptors, triggering specific immunoglobulin synthesis 
row. Proteins are retrieved and processed by antigen presenting cells (dendritic cells, 
macrophages, etc.) in cooperation with T helper lymphocytes (by presenting peptides 
conjugated with MHC class II molecules) and cytotoxic T lymphocytes (by presenting 
peptides conjugated with MHC class I molecules). Adjuvants (Iscomatrix, AS02B, Poly 
ICLC) [136, 137] and fusion immunostimulatory proteins (heat shock protein derived from 
Mycobacterium bovis) improve CTL responses of HPV protein-based vaccines [138].  
Nucleic acid-based vaccines are based on the direct introduction into the host cell of 
information encoding the antigen of interest, synthesized in situ. Recombinant DNA is 
introduced into tissues by intramuscular inoculation. Dendritic cells serves as central 
players for DNA vaccine development. pNGVL4a encodes the signal sequence Sig linked to 
a weakened form of HPV16 E7 fused to HSP70. It is used in phase I trial in patients with 
CIN II/III [139]. VGX-3100 vaccine expressing E6 and E7 HPV16/18 proteins was used in 
Phase I trial in patients with CIN II/III post-surgical or ablative treatment [140]. Regarding to 
the potential of E5 to contribute to HPV-associated carcinogenic process, it was suggested its 
role during the early tumorigenesis stage. Taking into account a limited immune response in 
malignat stage as a result in down-regulation of MHC class I and II molecules, a therapeutic 
vaccine targeting E5-expressing cells might be a good strategy to prevent the progression of 
premalignant lesions toward invasive cervical cancers [141]. Using a recombinant 
adenovirus which expresses E5HPV16 (AdV-based E5) in syngenic animals, it was observed 
a reduction of tumor growth correlated with tumor protection through CD8 T cells  [142], 
but HPV16E5 25-33 peptide plus CpG oligodeoxynucleotides (ODN) proved to be more 
effective as vaccine [143]. The construction of different DNA vectors based on epitopes of E5 
HPV oncogene (now under evaluation in animal models) was also described [144]. The 
immune effector cells in premalignanant lesions may eradicate tumor cells more efficiently 
than in the invasive cervical cancers. 
8. Conclusions 
The studies of HPV E6 and E7 oncogenes and the proteins coded will continue in order to 
discover new diagnostic and prognostic tools for cervical cancer. On the other hand, 
scientific studies will probably decipher new pathways of HPV oncogenesis molecular 
network and these will enrich the knowledge in this field.  
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proteins are recognized by B cell receptors, triggering specific immunoglobulin synthesis 
row. Proteins are retrieved and processed by antigen presenting cells (dendritic cells, 
macrophages, etc.) in cooperation with T helper lymphocytes (by presenting peptides 
conjugated with MHC class II molecules) and cytotoxic T lymphocytes (by presenting 
peptides conjugated with MHC class I molecules). Adjuvants (Iscomatrix, AS02B, Poly 
ICLC) [136, 137] and fusion immunostimulatory proteins (heat shock protein derived from 
Mycobacterium bovis) improve CTL responses of HPV protein-based vaccines [138].  
Nucleic acid-based vaccines are based on the direct introduction into the host cell of 
information encoding the antigen of interest, synthesized in situ. Recombinant DNA is 
introduced into tissues by intramuscular inoculation. Dendritic cells serves as central 
players for DNA vaccine development. pNGVL4a encodes the signal sequence Sig linked to 
a weakened form of HPV16 E7 fused to HSP70. It is used in phase I trial in patients with 
CIN II/III [139]. VGX-3100 vaccine expressing E6 and E7 HPV16/18 proteins was used in 
Phase I trial in patients with CIN II/III post-surgical or ablative treatment [140]. Regarding to 
the potential of E5 to contribute to HPV-associated carcinogenic process, it was suggested its 
role during the early tumorigenesis stage. Taking into account a limited immune response in 
malignat stage as a result in down-regulation of MHC class I and II molecules, a therapeutic 
vaccine targeting E5-expressing cells might be a good strategy to prevent the progression of 
premalignant lesions toward invasive cervical cancers [141]. Using a recombinant 
adenovirus which expresses E5HPV16 (AdV-based E5) in syngenic animals, it was observed 
a reduction of tumor growth correlated with tumor protection through CD8 T cells  [142], 
but HPV16E5 25-33 peptide plus CpG oligodeoxynucleotides (ODN) proved to be more 
effective as vaccine [143]. The construction of different DNA vectors based on epitopes of E5 
HPV oncogene (now under evaluation in animal models) was also described [144]. The 
immune effector cells in premalignanant lesions may eradicate tumor cells more efficiently 
than in the invasive cervical cancers. 
8. Conclusions 
The studies of HPV E6 and E7 oncogenes and the proteins coded will continue in order to 
discover new diagnostic and prognostic tools for cervical cancer. On the other hand, 
scientific studies will probably decipher new pathways of HPV oncogenesis molecular 
network and these will enrich the knowledge in this field.  
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1. Introduction 
Gene amplification is a copy number increase of a restricted region of a chromosome arm. 
Amplified chromosomal regions are present in acentric mini extra-chromosome (double 
minutes, DMs) or within a chromosome as repetitive arrays (homogeneously staining 
regions, HSRs); or distributed at various locations in the genome (scattered-type) (Fig. 1). 
 
Figure 1. Typical amplification products in mammalian cells. 
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A schematic illustration of four-chromosome genome (above) and three types of 
amplification products (below) are depicted. Amplified regions are indicated in red, and 
black circles represent centromeres. See text for details. 
 
Figure 2. Breakage-fusion-bridge (BFB) cycles 
The BFB cycle can be initiated by a DNA double-strand break. After DNA replication, the 
ends of the sister chromatids can fuse, giving rise to a dicentric chromosome. At anaphase, if 
the two centromeres go to the two opposite poles of the mitotic spindle, the dicentric 
chromosome can be broken. An asymmetric break will lead to a formation partially deleted 
or duplicated broken chromosomes. Subsequent cycles involving the chromosome with the 
duplication cause the increase in the copy number of the region of interest as inverted 
repeats. BFB cycles end when the broken chromosome ends are stabilized. 
Oncogene amplification is common in human cancers and contributes to tumor progression 
and therapeutic resistance (Albertson, 2006; Tanaka and Yao, 2009). For example, ERBB2 
amplification is often detected in advanced breast cancers, and overproduction of ERBB2 
can accelerate tumor progression (Di Fiore et al., 1987; Muller et al., 1988; Slamon et al., 
1987). Amplifications of MYC, CCND1, EGFR, MDM2, MYCN, JUN, TNK2, or ESR1 are also 
associated with aggressive phenotypes of tumors. BCR-ABL fusion gene is amplified in 
patients showing therapeutic resistance to Imatinib mesylate (Gorre et al., 2001). 
Amplifications of DHFR, TYMS, or MET are also associated with therapeutic resistance. 
A variety of models are proposed to explain the amplification process, including unequal 
sister-chromatid exchange, localized over replication, fold-back priming, rolling-circle 
replication, and breakage-fusion-bridge (BFB) cycle (Kobayashi et al., 2004; McClintock, 
1941; Rattray et al., 2005; Tower, 2004; Watanabe and Horiuchi, 2005). Cytogenetic features 
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of BFB cycle have been repeatedly observed in tumor cells (Fig.2). BFB cycle is the most 
popular model to explain intra-chromosomal amplification (Mondello et al., 2010; Tanaka 
and Yao, 2009), especially in the early stage of the amplification. In cancer cells, HSRs are 
often organized as an inverted ladder associated with a deletion that spans from the 
amplicon toward a telomere (Debatisse and Malfor, 2005). According to the BFB model, such 
a complex rearrangement results from the following repeating cycle: an initial DSB; 
replication of the broken molecule; fusion of sister chromatids; formation of a bridge during 
anaphase; and asymmetrical breakage due to mechanical tension, which generates one 
chromatid with an inverted repeat at the broken end. 
In extra-chromosomal amplification, replication-based models are often proposed. Breakage 
at stalled replication forks is proposed to cause DMs formation including EGFR gene (Vogt 
et al., 2004). Extra-rounds of replication are thought to lead to DMs containing N-myc gene. 
In N-myc amplification, extra-round of replication is expected to form an extra-
chromosomal element leading to integration followed by intra-chromosomal amplification 
(Savelyeva and Schwab, 2001). However, only by these amplification models themselves, it 
is difficult to explain the entire processes of the amplification. 
2. Barrier to efficient analyses 
Despite their biological and clinical importance, mechanisms for amplifying oncogenes 
remain largely unknown. This is because the whole process of gene amplification has been 
difficult to analyze because of additional kinds of amplification processes and secondary 
chromosome rearrangements (Haber and Debatisse, 2006). There are at least three reasons 
for this difficulty: (1) previous approaches to understand mechanisms for amplification were 
based on the structural analysis of complex end products; (2) few model systems for gene 
amplification are available that allow chromosomal engineering, as is possible in yeast 
(Lengauer et al., 1998); (3) spontaneous gene amplification occurs at very low frequency. 
The use of genome-wide scanning techniques, such as array comparative genomic 
hybridization (array CGH) and next-generation DNA sequencing, has recently 
demonstrated that most solid tumors contain amplified portions of their genomes 
(Albertson, 2006). However, even these recent genomic technologies cannot unambiguously 
assign sequences in amplified regions and accurately resolve their chromosomal structure. 
Thus, amplified regions have been largely refractory to standard human genetic analyses. 
3. Model systems for understanding common features of gene 
amplification 
3.1. DSB and inverted repeats 
Long series of studies have shown that DNA double-strand break (DSB) and inverted 
repeats play an important role in gene amplification. DNA double-strand break (DSB) is one 
of the harmful forms of DNA damage, and can induce several types of chromosomal 
aberrations, including gene amplification, when not correctly repaired. Amplification is 
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aberrations, including gene amplification, when not correctly repaired. Amplification is 
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triggered by DNA-damaging agents, which can directly or indirectly cause DSBs (Kuo et al., 
1994; Paulson et al., 1998; Poupon et al., 1996; Yunis et al., 1987). In mammalian genomes, 
there are regions prone to breakage known as common fragile sites (CFSs) (Debatisse et al., 
2012; Glover et al., 2005). CFSs are involved in chromosomal aberrations, including gene 
amplification, and have been shown to play a major role in the early steps in gene 
amplification (Ciullo et al., 2002; Coquelle et al., 1997; Hellman et al., 2002; Kuo et al., 1998). 
In cooperation with DSBs, short inverted repeats could generate a palindromic dicentric 
chromosome, leading to gene amplification. 
Model systems that use site-specific endonucleases, such as I-SceI or HO endonucleases, 
have been constructed in yeast and in mammalian cells. Yao's group first constructed a 
plasmid-based system in yeast containing an HO endonuclease cutting site and an adjacent 
inverted repeat (Butler et al., 1996). This system efficiently formed a palindromic mini-
chromosome after induction of the endonuclease. They next used Chinese hamster ovary 
(CHO) cells and inserted a DHFR transgene into a chromosome of the cells with an I-Scel 
cutting site and an adjacent inverted repeat (Tanaka et al., 2002). This system formed a 
palindromic dimer after I-Scel cutting and consequently caused intra-chromosomal 
amplification, suggesting the formation of a dicentric chromosome and the involvement of 
subsequent BFB cycles. 
We developed a new approach in which we design amplification processes and test whether 
the processes can produce the amplification seen in nature. Previously, in yeast, we 
constructed a system designed to induce a rapid amplification mode, double rolling-circle 
replication (DRCR) via chromosomal breaks induced by HO endonuclease (Watanabe and 
Horiuchi, 2005) (Fig.3). DRCR is a continuous process in which two replication forks chase 
each other (Fig.3A), and was first confirmed by Volkert and Broach for amplification of 
yeast 2 plasmid (Volkert and Broach, 1986). To induce DRCR, we used break-induced 
replication (BIR), a nonreciprocal recombination-dependent replication process that is an 
effective mechanism to repair a broken chromosome (Fig.3B). The DRCR amplification is 
selected with an amplification marker, leu2d, which has a slight transcription activity and 
complements leucine auxotrophy if amplified (Erhart and Hollenberg, 1983). This system 
produced intra-/extra-chromosomal products resembling HSR and DMs seen in mammalian 
cells (Fig.3C). The HSR-type products contain up to ~100 copies of leu2d gene, which 
occupies 730kb (the rest of chromosome VI comprises 275 kb). Interestingly, HSR/DMs 
products were generated at low frequency without deliberate DNA cleavage, depending on 
the chromosome structure with the inverted repeats. These features strongly suggest that 
the processes described here may contribute to natural gene amplification in higher 
eukaryotes and natural amplification involves DRCR. 
Lobachev et al constructed a yeast strain having an inverted repeat of Alu sequences, and 
showed that the repeat are fragile sites (Lobachev et al., 2002). The Alu inverted repeats can 
be cleaved and subsequently generate hairpin ends, which can be opened up by the 
Mre11/Rad50/Xrs2 complex in concert with the Sae2 protein. His group next demonstrated 
that Alu inverted repeats can trigger intra- and extra-chromosomal amplification in yeast 
(Narayanan et al., 2006). 
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Figure 3. Gene amplification system based on DRCR utilizing break-induced replication (BIR). 
(A) Double rolling-circle replication (DRCR). Two replication forks chase each other. One 
replication fork can replicate a template for the other fork and so amplification proceeds. (B) 
Structure of the amplification cassette and a model for DRCR amplification. This cassette 
contains two PCR-amplified sequences (white and gray arrows) derived from the nearby 
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replication (DRCR) via chromosomal breaks induced by HO endonuclease (Watanabe and 
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each other (Fig.3A), and was first confirmed by Volkert and Broach for amplification of 
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replication (BIR), a nonreciprocal recombination-dependent replication process that is an 
effective mechanism to repair a broken chromosome (Fig.3B). The DRCR amplification is 
selected with an amplification marker, leu2d, which has a slight transcription activity and 
complements leucine auxotrophy if amplified (Erhart and Hollenberg, 1983). This system 
produced intra-/extra-chromosomal products resembling HSR and DMs seen in mammalian 
cells (Fig.3C). The HSR-type products contain up to ~100 copies of leu2d gene, which 
occupies 730kb (the rest of chromosome VI comprises 275 kb). Interestingly, HSR/DMs 
products were generated at low frequency without deliberate DNA cleavage, depending on 
the chromosome structure with the inverted repeats. These features strongly suggest that 
the processes described here may contribute to natural gene amplification in higher 
eukaryotes and natural amplification involves DRCR. 
Lobachev et al constructed a yeast strain having an inverted repeat of Alu sequences, and 
showed that the repeat are fragile sites (Lobachev et al., 2002). The Alu inverted repeats can 
be cleaved and subsequently generate hairpin ends, which can be opened up by the 
Mre11/Rad50/Xrs2 complex in concert with the Sae2 protein. His group next demonstrated 
that Alu inverted repeats can trigger intra- and extra-chromosomal amplification in yeast 
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Figure 3. Gene amplification system based on DRCR utilizing break-induced replication (BIR). 
(A) Double rolling-circle replication (DRCR). Two replication forks chase each other. One 
replication fork can replicate a template for the other fork and so amplification proceeds. (B) 
Structure of the amplification cassette and a model for DRCR amplification. This cassette 
contains two PCR-amplified sequences (white and gray arrows) derived from the nearby 
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genomic region, forming two inverted pairs (a) and (b). The amplification marker, leu2d, has 
a slight transcription activity, and it will complement leucine auxotrophy if amplified. This 
yeast strain has galactose-inducible HO endonuclease gene. Following HO cutting, two 
chromosomal ends can invade each other, initiating two break-induced replication (BIR) 
events as in the insert box and subsequent DRCR. The DRCR process would terminate by 
recombination between bidirectionally elongated arms. (C) Southern analysis of uncut 
chromosomal DNA from Leu+ survivors with the leu2d probe. The expression of HO 
endonuclease was induced on galactose medium without leucine (HO-induced). PFGE was 
performed with higher and lower size ranges. The lanes marked in red and green indicate 
intra- and extra-chromosomal amplification, respectively. Pre-ind.: preinduction conditions 
(cultured on glucose plates containing leucine). (D) Model for the production of extra-
chromosomal products. These products are proposed to result from degradation of one 
broken end and the subsequent intramolecular BIR. 
3.2. Replication stress within repeated sequences 
Recently, DNA replication stress within repeated sequences is reported to contribute 
importantly to genome instability. Two recent yeast papers have shown that nearby 
inverted repeats recombine spontaneously to fuse, leading to the formation of dicentric 
and acentric chromosomes (Branzei and Foiani, 2010a; Mizuno et al., 2009; Paek et al., 
2009). This fusion process does not appear to require DSB formation, and is likely caused 
by DNA replication-based mechanism involving an aberrant switch of replication 
templates. 
Another example involves the re-replication event, the inappropriate firing of replication 
origins. Green et al. developed an elegant system in yeast that enables a locus-specific and 
transient re-replication by conditionally deregulating the replication origin (Green et al., 
2010). They demonstrate that re-replication can generate duplication in cooperation with 
Ty repetitive elements, suggesting that this process is a potent inducer of gene 
amplification. 
We have examined whether gene amplification can be induced when recombinational 
processes between inverted sequences are coupled with DNA replication. To efficiently 
induce the recombinational processes, Cre-lox site-specific recombination was used to 
design amplification system based on DRCR (Watanabe et al., 2011). This system 
successfully yielded HSR/DM-type products in yeast (Fig.4) and Chinese hamster ovary 
(CHO) cells (Fig.5). We first predicted that, if recombination occurs between un-replicated 
and recently replicated regions during replication (Fig.4A), the replication fork would make 
an additional copy of the replicated region. To induce DRCR, two sets of the 
recombinational process were utilized (Fig.4B and 4C). In yeast, the Cre induction caused a 
>7000-fold increase in the frequency of survivors and, surprisingly, over 10% of the Cre 
recombination-induced cells undergo gene amplification (Fig.4D). The HSR-type products 
appear to contain approximately 90-140 copies of the leu2d gene, corresponding to a 3.6~5.6-
fold increase in the length of the original (275 kb) chromosome VI (Fig.4E). 
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For DRCR system in CHO cells, we constructed an amplification cassette on a rat genomic 
bacterial artificial chromosome (BAC), and integrated it into a specific site on a CHO cell 
chromosome using the Flp-FRT (Flp recombination target site) system (Fig.5A). An 
amplification marker, a mouse dihydrofolate reductase (DHFR) gene, provides methotrexate 
(MTX) resistance when amplified. This system successfully produced HSR/DM/Scattered-
type amplification (Fig.5B-K). 
 
Figure 4. Gene amplification in yeast induced by Cre recombination. 
(A) Recombinational process coupled with replication. The gray and black lines indicate the 
un-replicated and recently-replicated regions at the time of recombination, respectively. If 
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genomic region, forming two inverted pairs (a) and (b). The amplification marker, leu2d, has 
a slight transcription activity, and it will complement leucine auxotrophy if amplified. This 
yeast strain has galactose-inducible HO endonuclease gene. Following HO cutting, two 
chromosomal ends can invade each other, initiating two break-induced replication (BIR) 
events as in the insert box and subsequent DRCR. The DRCR process would terminate by 
recombination between bidirectionally elongated arms. (C) Southern analysis of uncut 
chromosomal DNA from Leu+ survivors with the leu2d probe. The expression of HO 
endonuclease was induced on galactose medium without leucine (HO-induced). PFGE was 
performed with higher and lower size ranges. The lanes marked in red and green indicate 
intra- and extra-chromosomal amplification, respectively. Pre-ind.: preinduction conditions 
(cultured on glucose plates containing leucine). (D) Model for the production of extra-
chromosomal products. These products are proposed to result from degradation of one 
broken end and the subsequent intramolecular BIR. 
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2009). This fusion process does not appear to require DSB formation, and is likely caused 
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2010). They demonstrate that re-replication can generate duplication in cooperation with 
Ty repetitive elements, suggesting that this process is a potent inducer of gene 
amplification. 
We have examined whether gene amplification can be induced when recombinational 
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induce the recombinational processes, Cre-lox site-specific recombination was used to 
design amplification system based on DRCR (Watanabe et al., 2011). This system 
successfully yielded HSR/DM-type products in yeast (Fig.4) and Chinese hamster ovary 
(CHO) cells (Fig.5). We first predicted that, if recombination occurs between un-replicated 
and recently replicated regions during replication (Fig.4A), the replication fork would make 
an additional copy of the replicated region. To induce DRCR, two sets of the 
recombinational process were utilized (Fig.4B and 4C). In yeast, the Cre induction caused a 
>7000-fold increase in the frequency of survivors and, surprisingly, over 10% of the Cre 
recombination-induced cells undergo gene amplification (Fig.4D). The HSR-type products 
appear to contain approximately 90-140 copies of the leu2d gene, corresponding to a 3.6~5.6-
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bacterial artificial chromosome (BAC), and integrated it into a specific site on a CHO cell 
chromosome using the Flp-FRT (Flp recombination target site) system (Fig.5A). An 
amplification marker, a mouse dihydrofolate reductase (DHFR) gene, provides methotrexate 
(MTX) resistance when amplified. This system successfully produced HSR/DM/Scattered-
type amplification (Fig.5B-K). 
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(A) Recombinational process coupled with replication. The gray and black lines indicate the 
un-replicated and recently-replicated regions at the time of recombination, respectively. If 
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recombination occurs between loxP sites marked red and blue (i), the replication template is 
switched and thereafter the replicated region is replicated again (ii). (B) DRCR induction. If 
both bidirectional DNA replications undergo the processes as described in (A), DRCR can be 
induced. Two different types of lox sequence, the wild-type loxP (lox for short) and a 
mutant-type loxm2 (m2 for short) were used. Cre recombination occurs between identical 
sites (lox-lox or m2-m2) but not between different sites (lox-m2). (C) Structure of the 
amplification cassette and a model for DRCR amplification. (D) Frequency of Leu+ colony 
formation. (E) Southern analysis of uncut chromosomal DNA from Leu+ survivors with the 
leu2d probe. The expression of Cre recombinase was induced in galactose medium for 90 
min (Cre-induced). PFGE was performed with a wide-size range. The lanes marked in red 
and green indicate intra- and extra-chromosomal amplification, respectively. (D) Model for 
the production of extra-chromosomal products. These products are proposed to result from 
a single recombinational process coupled with DNA replication. 
 
Figure 5. Gene amplification in CHO cells induced by Cre recombination. 
(A) Structure of the modified BAC and construction of the CHO strain for gene 
amplification. The sizes (kb) of the three regions in the structure are indicated below. (B) to 
(K) Metaphase FISH analysis with FITC-labeled probes (green). As a positive control (B), the 
CHO DR1000L-4N strain that contains ~170 copies of DHFR was probed with a pSV2-dhfr 
plasmid. The BAC-CHO strain (C; negative control) without Cre induction and MTX 
selection and MTX-resistant clones (D-K) were probed with the BAC in (A). DNA is 
counterstained with DAPI (blue). The scale bars represent 10 µm. These amplified products 
would be derived from the integrated BAC construct. 
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Figure 6. Model for HSR/DM production in the CHO system. 
A model for the HSR and DMs production by Cre recombination coupled with replication. 
See in the text. 
Our Cre-lox system can induce tissue-specific amplification, and therefore may allow a 
direct approach to examine which genetic elements contribute to oncogenesis or malignant 
potential in each tissue when amplified. In addition, our CHO system showed scattered-
type amplification products resembling those seen in cancer cells, although in non-
cancerous cell line. From these results, we reasoned that DRCR are centrally involved in 
amplification of drug-resistance genes and oncogene. This system can serve as a good model 
for amplification in mammalian cells and contribute to a better understanding of oncogene 
amplification and development of anticancer strategies in the future. 
The formation of HSR/DM-type products can be explained by Cre recombination coupled 
with replication in two alternative ways, by trans- or cis-recombination, which can induce 
either DRCR or convergent replication, respectively (Fig.6). The scattered-type amplification 
may be generated by reintegration of DM-type products into ectopic chromosomes through 
interspersed repetitive elements. In gene amplification in mammalian cells, BFB cycles 
would form megabase-sized inverted repeats, which may induce DRCR if homology-based 
recombination is coupled with DNA replication. Recently, a similar process, replication 
template exchange, was reported to lead to acentric or dicentric chromosome formation in 
yeast, indicating an important contribution to genome instability (Branzei and Foiani, 2010a; 
Mizuno et al., 2009; Paek et al., 2009). We propose that such processes can occur in cultured 
cells and tumor cells through genome instability associated with deregulated replication 
(Aguilera and Gomez-Gonzalez, 2008; Branzei and Foiani, 2010b). 
3.3. Rearrangements in amplified regions 
In amplified chromosomal regions, intensive chromosome rearrangements are frequently 
observed, leading to the increase in the gene copy number and to the decrease in size of 
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formation. (E) Southern analysis of uncut chromosomal DNA from Leu+ survivors with the 
leu2d probe. The expression of Cre recombinase was induced in galactose medium for 90 
min (Cre-induced). PFGE was performed with a wide-size range. The lanes marked in red 
and green indicate intra- and extra-chromosomal amplification, respectively. (D) Model for 
the production of extra-chromosomal products. These products are proposed to result from 
a single recombinational process coupled with DNA replication. 
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Figure 6. Model for HSR/DM production in the CHO system. 
A model for the HSR and DMs production by Cre recombination coupled with replication. 
See in the text. 
Our Cre-lox system can induce tissue-specific amplification, and therefore may allow a 
direct approach to examine which genetic elements contribute to oncogenesis or malignant 
potential in each tissue when amplified. In addition, our CHO system showed scattered-
type amplification products resembling those seen in cancer cells, although in non-
cancerous cell line. From these results, we reasoned that DRCR are centrally involved in 
amplification of drug-resistance genes and oncogene. This system can serve as a good model 
for amplification in mammalian cells and contribute to a better understanding of oncogene 
amplification and development of anticancer strategies in the future. 
The formation of HSR/DM-type products can be explained by Cre recombination coupled 
with replication in two alternative ways, by trans- or cis-recombination, which can induce 
either DRCR or convergent replication, respectively (Fig.6). The scattered-type amplification 
may be generated by reintegration of DM-type products into ectopic chromosomes through 
interspersed repetitive elements. In gene amplification in mammalian cells, BFB cycles 
would form megabase-sized inverted repeats, which may induce DRCR if homology-based 
recombination is coupled with DNA replication. Recently, a similar process, replication 
template exchange, was reported to lead to acentric or dicentric chromosome formation in 
yeast, indicating an important contribution to genome instability (Branzei and Foiani, 2010a; 
Mizuno et al., 2009; Paek et al., 2009). We propose that such processes can occur in cultured 
cells and tumor cells through genome instability associated with deregulated replication 
(Aguilera and Gomez-Gonzalez, 2008; Branzei and Foiani, 2010b). 
3.3. Rearrangements in amplified regions 
In amplified chromosomal regions, intensive chromosome rearrangements are frequently 
observed, leading to the increase in the gene copy number and to the decrease in size of 
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the amplification unit (Debatisse and Malfor, 2005; Mondello et al., 2010). Nuclear blebs 
and micronuclei are frequently observed in cells with gene amplification and found to 
contain amplified sequences and thus may be a location for rearrangement of amplified 
region. However, how the rearrangements proceed is a long-standing question. In 
oncogene amplification, the complex patterns of amplification generated by the 
rearrangements are closely associated with poor prognosis in cancer (Chin et al., 2006; 
Hicks et al., 2006). Interestingly, we have observed the rearrangement in all our DRCR 
systems (Fig.7A and 7B). Sequences flanked by inverted repeats, which are formed by 
DRCR amplification, were subject to frequent inversion. We call this phenomenon DRCR-
dependent inversion. To explore the link between the rearrangements and the DRCR 
process, we constructed a system that can turn on or off the occurrence of DRCR, using 
yeast 2 plasmid (Okamoto et al., 2011). This system demonstrated that inversions, 
deletions, or duplications could be intensively induced in a DRCR-dependent  
manner. This result suggests that DRCR may cause the rearrangements in amplification in 
nature. 
DRCR-dependent inversion is an interesting phenomenon, but the mechanism remains 
unknown. DRCR is expected to form an unstable structure, a palindromic structure. We 
propose that DRCR-dependent inversion may disrupt the palindromic structure and 
substantially stabilize the highly repetitive array (Fig.7B). We also proposed a model in 
which DRCR markedly stimulates recombinational events (Fig.7C). In eukaryotes, a protein 
complex, cohesin, bundles newly replicated sister chromatids until anaphase and regulates 
the separation of sister chromatids during cell division (Nasmyth, 1999). In DRCR process, 
however, one of newly replicated sister chromatids is used as a template for another 
replication fork, and therefore cohesin would fail to bundle the sister chromatids together. 
These cohesion-free regions are expected to be recombinogenic based on some data 
indicating activated recombination under cohesion-deficient conditions (Grossenbacher-
Grunder & Thuriaux, 1981; Kobayashi et al. 2004). 
Recently, a chromosome catastrophe phenomenon termed chromothripsis, in which 
numerous rearrangements are apparently acquired in one single catastrophic event, was 
observed in multiple cancers (Liu et al., 2011). The formation of intensive rearrangements 
has been proposed to involve a replication-based mechanism, the fork stalling and template 
switching (FoSTeS) model (Lee et al., 2007). The FoSTeS process may be engaged also in the 
intensive rearrangements in amplified chromosomal regions. 
In cancer and drug-resistant cells, BFB cycles form large regular inverted repeats in the early 
stages of amplification, and thereafter these repeats rapidly change into shorter highly 
amplified units. However, it remains largely unknown how complex end products can be 
rapidly generated after BFB cycles. We expect that DRCR process play a key role in linking 
BFB cycles to complex end products. DRCR process may be initiated by DSBs or DNA 
replication stress within inverted chromosome regions formed through BFB cycles. This 
involvement of DRCR is supported by a recent data that HSR was lengthened more rapidly 
than expected from BFB cycle model (Harada et al., 2011). 
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Figure 7. DRCR-dependent rearrangements 
(A) Southern analysis of XhoI-digested DNA of some HSR-type samples in our BIR-based 
DRCR system with the leu2d probe. The fragment sizes in black and red indicate the 
expected and unexpected band. (B) Schematic representation of the expected structure 
derived through the DRCR process and XhoI-restriction maps of the representative HSR-
type structure. (C) Model of the recombinogenic feature of DRCR. While cohesin complexes 
bundle newly replicated sister chromatids in normal DNA replication, in DRCR, cohesin 
would fail to bundle the sister chromatids together, leading to the exposure of 
recombinogenic region. 
4. Concluding remarks 
The processes of oncogene amplification are difficult to analyze because of the infrequency of 
amplification and the plasticity of amplified products. The development of model systems is 
one of the best approaches to overcome the difficulties in elucidating the molecular 
mechanisms. The model systems can serve as a good model for a better understanding of 
oncogene amplification and contribute to development of anticancer strategies in future. 
Gene amplification is a hallmark of most advanced solid tumors and amplified genes are 
useful therapeutic targets. Immortalized cells can undergo amplification when selected with 
appropriate drugs (10-4 to 10-7), whereas gene amplification has never been detected in 
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the amplification unit (Debatisse and Malfor, 2005; Mondello et al., 2010). Nuclear blebs 
and micronuclei are frequently observed in cells with gene amplification and found to 
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region. However, how the rearrangements proceed is a long-standing question. In 
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rearrangements are closely associated with poor prognosis in cancer (Chin et al., 2006; 
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systems (Fig.7A and 7B). Sequences flanked by inverted repeats, which are formed by 
DRCR amplification, were subject to frequent inversion. We call this phenomenon DRCR-
dependent inversion. To explore the link between the rearrangements and the DRCR 
process, we constructed a system that can turn on or off the occurrence of DRCR, using 
yeast 2 plasmid (Okamoto et al., 2011). This system demonstrated that inversions, 
deletions, or duplications could be intensively induced in a DRCR-dependent  
manner. This result suggests that DRCR may cause the rearrangements in amplification in 
nature. 
DRCR-dependent inversion is an interesting phenomenon, but the mechanism remains 
unknown. DRCR is expected to form an unstable structure, a palindromic structure. We 
propose that DRCR-dependent inversion may disrupt the palindromic structure and 
substantially stabilize the highly repetitive array (Fig.7B). We also proposed a model in 
which DRCR markedly stimulates recombinational events (Fig.7C). In eukaryotes, a protein 
complex, cohesin, bundles newly replicated sister chromatids until anaphase and regulates 
the separation of sister chromatids during cell division (Nasmyth, 1999). In DRCR process, 
however, one of newly replicated sister chromatids is used as a template for another 
replication fork, and therefore cohesin would fail to bundle the sister chromatids together. 
These cohesion-free regions are expected to be recombinogenic based on some data 
indicating activated recombination under cohesion-deficient conditions (Grossenbacher-
Grunder & Thuriaux, 1981; Kobayashi et al. 2004). 
Recently, a chromosome catastrophe phenomenon termed chromothripsis, in which 
numerous rearrangements are apparently acquired in one single catastrophic event, was 
observed in multiple cancers (Liu et al., 2011). The formation of intensive rearrangements 
has been proposed to involve a replication-based mechanism, the fork stalling and template 
switching (FoSTeS) model (Lee et al., 2007). The FoSTeS process may be engaged also in the 
intensive rearrangements in amplified chromosomal regions. 
In cancer and drug-resistant cells, BFB cycles form large regular inverted repeats in the early 
stages of amplification, and thereafter these repeats rapidly change into shorter highly 
amplified units. However, it remains largely unknown how complex end products can be 
rapidly generated after BFB cycles. We expect that DRCR process play a key role in linking 
BFB cycles to complex end products. DRCR process may be initiated by DSBs or DNA 
replication stress within inverted chromosome regions formed through BFB cycles. This 
involvement of DRCR is supported by a recent data that HSR was lengthened more rapidly 
than expected from BFB cycle model (Harada et al., 2011). 
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DRCR system with the leu2d probe. The fragment sizes in black and red indicate the 
expected and unexpected band. (B) Schematic representation of the expected structure 
derived through the DRCR process and XhoI-restriction maps of the representative HSR-
type structure. (C) Model of the recombinogenic feature of DRCR. While cohesin complexes 
bundle newly replicated sister chromatids in normal DNA replication, in DRCR, cohesin 
would fail to bundle the sister chromatids together, leading to the exposure of 
recombinogenic region. 
4. Concluding remarks 
The processes of oncogene amplification are difficult to analyze because of the infrequency of 
amplification and the plasticity of amplified products. The development of model systems is 
one of the best approaches to overcome the difficulties in elucidating the molecular 
mechanisms. The model systems can serve as a good model for a better understanding of 
oncogene amplification and contribute to development of anticancer strategies in future. 
Gene amplification is a hallmark of most advanced solid tumors and amplified genes are 
useful therapeutic targets. Immortalized cells can undergo amplification when selected with 
appropriate drugs (10-4 to 10-7), whereas gene amplification has never been detected in 
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normal cells (<10-9) (Tlsty et al., 1989; Wright et al., 1990). This observation strongly suggests 
the defect in control of genome integrity in cancer cells. 
Furthermore, cancer cells are often dependent on (addicted to) only one or a few genes 
conferring malignancy and growth advantage, although the cells involve multiple genetic 
and epigenetic abnormalities (Weinstein and Joe, 2006). This phenomenon, called ‘oncogene 
addiction’, is frequently observed with oncogenes associated with amplification, such as 
MYC, ERBB2, CCND1, and BCR-ABL, indicating that the enhanced expression of amplified 
genes would become a meaningful therapeutic targets. 
The direct involvement of DRCR-related processes in oncogene amplification has yet to be 
demonstrated. Amplified oncogenes manifest a structural diversity. MYC gene is thought to 
amplify first as DMs, and thereafter integration into a chromosome can lead to HSR 
amplification consisting of direct or inverted repeats. Although many tumor cells would 
undergo BFB cycles, which form inverted array, amplification of MYCN and ERBB2 can be 
found as HSR with direct tandem repeats (Albertson, 2006). Amplified EGFR genes are 
present on DMs (Albertson, 2006), and BCR-ABL amplification was found on a chromosome 
(Gorre et al., 2001). These amplifications could not be explained by only one versatile 
process, but DRCR-related process may contribute to a variety of oncogene amplification. 
HSR and DMs in MYC amplification might be produced via DRCR and its related process 
like convergent replication, respectively (Fig.6). Furthermore, Our system can be adapted to 
simple rolling-circle replication (RCR) by replacing inverted sequences in our amplification 
cassettes to direct ones. This RCR forms direct tandem array as seen in amplification of 
MYCN and ERBB2. The DRCR-related processes can be initiated by any important triggers, 
such as DSB, inverted repeats, and replication stress, which genome instability in tumor or 
cancer cells could provide. These trigger reactions may occur via interspersed repetitive 
elements, including Alus, and short or long interspersed nucleotide element (SINE/LINE). 
The DRCR-related processes can generate intensive chromosome rearrangement, a common 
feature of oncogene amplification. Thus, we propose that DRCR-related processes can 
provide broad contributions to oncogene amplification at multiple phases. 
We also believe that optimization and improvement of the model amplification systems 
could provide benefits for the production of therapeutic proteins. Thus, works that utilize 
the model systems will have great impact not only on scientific understanding but also in 
the medical, industrial and economic fields. 
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1. Introduction 
Acute myeloid leukemia (AML) is characterized by the malignant transformation of 
myeloid cells from myeloblasts to a pathological cell clone. These pathological cell clones 
lose their ability to differentiate and mature, are no longer subject to regulatory mechanisms 
and suppress other components of normal hemopoiesis. AML does not fall under a single 
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immunophenotype, as well as cytogenetic and molecular genetic abnormalities. It includes a 
number of subtypes, which can be further classified according to the FAB and World Health 
Organization (WHO) criteria. 
Acute myeloid leukemia represents 15% to 20% of all childhood leukemias, approximately 
33% of adolescent leukemias, and approximately 50% of adult leukemias. After a peak 
during the first 2 years of life, the subsequent annual incidence of AML slowly increases 
after 9 years of age (incidence rate 5/1 million in 5 to 9-year-olds, 9/1 million in 15 to 19-year-
olds). In general, the biological features, other than age, of pediatric and adult AML appear 
to be similar, but the differences have not been reviewed systematically [1]. 
The rate of therapy-related AML (that is, AML caused by previous chemotherapy) is rising; 
therapy-related disease currently accounts for approximately10–20% of all cases of AML [2]. 
The incidence of secondary leukemias is increasing because of aging of the population (MDS 
is more frequent in elderly people) and widespread of successful use of chemoradiotherapy 
in cancer patients (solid tumors or hematological malignancies). The majority of secondary 
leukemias resulting from the use of cytotoxic drugs. Therapy – related AML is 
heterogeneous collection of diseases characterised by distinct chromosomal abnormalities. 
One subset of therapy related AMLs is associated with exposure to alkylating agents. The 
chromosomal abnormalities 5q- and monosomy 7 are commonly observed in leukemic cells 
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exposure to epipodophyloltoxin drugs teniposid and etoposid. A high proportion of 
epipodophyllotoxin - associated AMLs are of the M4 (monocytic) or M5 (myelomonocytic) 
subtype and have abnormalities at chromosome band 11q23 involving rearrangement of the 
MLL gene. The same genetic abnormality is also found in some secondary AMLs associated 
with exposure to antracyclines. These two classes of chemotherapeutic agents share a 
common mechanism of action that involves binding to and inhibition of DNA 
topoisomerase II.  
Acute myeloid leukemia is a curable disease; the chance of cure for a specific patient 
depends on a number of prognostic factors. The current five-year survival rates of adult 
patients under age 60 range from 30% - 40%; for pediatric patients, five-year survival rates 
are up to 65% [3, 4]. 
The cure rates in pediatric AML have been achieved not only by the more effective use of 
anti-leukemic agents but also by improvements in supportive care and better risk-group 
stratification. Recurrent cytogenetic and genetic aberrations and early responses to 
treatment are important prognostic factors in AML and therefore are used for risk group 
stratification.  
The prognostic value of cytogenetics is well established in all age groups. The biologic data 
differ considerably between infants and older age groups but only slightly between 
children, adolescents, and young adults. The distribution of cytogenetic aberrations in 
infants is different from that in older patients. Infants have almost no favorable aberrations 
but have frequent 11q23 aberrations and complex karyotypes, which is similar to older AML 
patients (>60 years)[1]. Schochet et al. [5] analyzed the effect of age and cytogenetics on 
clinical outcome in adult patients (>16 years). They found that both age and cytogenetics 
were independent prognostic parameters in AML; however, up to the age of 49 years, age 
had no major impact on prognosis, whereas the karyotype did. Therapy today consists of a 
limited number of intensive courses of chemotherapy based on cytarabine and an 
anthracycline. An important problem in the treatment of AML remains the high frequency 
of treatment-related deaths and long-term side effects [6,7]. 
This problem hampers further therapy-intensification, and most investigators therefore feel 
that we have reached a plateau in the number of patients that can be cured with current 
chemotherapy regimens. Our efforts should therefore focus on clarifying the biology of 
pediatric AML. This knowledge can be used for novel classification and risk-group 
stratification. In addition, it creates the potential for targeted, i.e., more leukemia-specific, 
therapy. It is anticipated that such therapies will increase the cure-rate and decrease the 
toxicity of treatment of patients with AML [4]. 
Leukemias bearing translocations involving chromosome 11q23 are of particular interest 
due to unique clinical and biological characteristics. The development of acute leukemias is 
associated with MLL gene alterations in about 10% of all leukemia cases of acute 
lymphoblastic leukemia and acute myeloid leukemia) [8].  
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MLL alterations correlate with specific disease subtypes (acute myeloid and acute 
lymphocytic leukemias), a specific gene expression profile [9, 10], and outcomes (favorable 
or poor), depending on the particular MLL alteration [11]. Certain MLL alterations are 
independent unfavorable prognostic factors, and patients are usually treated according to 
high-risk protocols. For this reason, identifying MLL alterations has relevant implications for 
therapy decision-making. In pediatric AML, optimized intensive regimens for AML have 
also improved outcomes for MLL-rearranged AML. Patients have an intermediate outcome, 
with a 5 y OS (probability of overall survival at 5 years from diagnosis) ranging from 42-62% 
[12]. Therefore, further insights into the biology of MLL-rearranged AML, the development 
of reliable methods for screening in laboratory settings, and safe testing of new potential 
MLL-targeted therapies could have a significant impact on the overall outcomes for adult 
and pediatric patients. 
The MLL gene was identified in 1991; a year later, it was completely characterized and 
cloned. The origin of the previous ALL1 designation dates back to 1970, when van den Bergh 
described the reconstruction of the gene area for the first time in a patient with 
lymphoblastic leukemia [13]. Scientists later completed the characterization of the gene, and 
the gene was named MLL (mixed-lineage leukemia) based on the 11q23 translocation, which 
is observed in myelogenous and lymphoblastic types of leukemia. MLL has other synonyms 
as well, such as HRX (human trithorax) and Htrx1, which express its homology with the 
trithorax (trx) gene in Drosophila melanogaster. The MLL (ALL1, HRX, Htrx1) gene is located 
on the long arm of chromosome 11 (11q23), telomerically to the PLFZ gene and 
centromerically from the RCK gene (Figure 1).  
 
Figure 1. Chromosome 11. The red mark indicates the position of the MLL gene.  
The MLL gene consists of 36 exons over 100 kb. The product of the resulting 12 kb mRNA is 
a protein with 3968 amino acids and a molecular mass of approximately 430 kD. It is 
transcribed from centromere to telomere. Most, but not all, breaks in the MLL gene are 
localized in the 8.3 kb breakpoint region (bcr – breakpoint cluster region). The bcr region can 
be divided into a centromeric portion and a telomeric portion. Breaks in the MLL gene in 
infant leukemia and t-AML occur primarily in the telomeric part, while breaks in patients 
with de novo AML are closer to the centromere [1] (Figure 2).  
Several translocation partners of MLL were found recently to coexist in a super elongation 
complex (SEC) that includes known transcription elongation factors such as eleven-nineteen 
lysine-rich leukemia (ELL) and positive transcription elongation factor b (P-TEFb). The SEC 
is required for HOX (homeobox domain gene) gene expression in leukemic cells, suggesting 
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Several translocation partners of MLL were found recently to coexist in a super elongation 
complex (SEC) that includes known transcription elongation factors such as eleven-nineteen 
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that chromosomal translocations involving MLL could lead to the overexpression of HOX 
and other genes through the involvement of the SEC [14]. 
 
Figure 2. The structure of the MLL gene. Structure of the MLL gene: exon 1-34. Bcr (breakage region) 
region: exons 5-11, BP – break point. 
The MLL protein is expressed in different tissues, such as the brain, colon, liver, spleen, 
thymus, kidneys, tonsils, heart, lungs, testes and thyroid. Genetic mutations of the MLL 
gene seem to occur preferentially in hematopoietic cells, suggesting that this system enables 
special permissivity, allowing for the survival and development of leukemic clones of 
different MLL fusion proteins. Specific signals are derived from stromal cells during fetal 
liver and definitive hematopoiesis. This enables the activation of anti-apoptotic pathways 
and stem cell maintenance necessary to receive survival signals caused by the presence of 
oncogenic MLL fusion proteins [15, 16]. 
The MLL protein is involved in chromatin regulation. It is specifically hydrolyzed by the 
endopeptidase Taspase1 and methylates histone core particles at histone H3 lysine 4 
residues [17-19]. Therefore, MLL is part of an epigenetic system that co-regulates mitotic 
gene-expression signatures during embryonic development and tissue differentiation in 
mammalian organisms. The MLL complex binds to different promoters in various tissues. 
Recently, a genome-wide array study revealed that MLL was bound to more than 2000 
different promoter regions [20]. This protein belongs to the group of Trithorax (trx-G) 
proteins, which are responsible for maintaining gene expression during growth. It is 
assumed that the MLL protein controls the expression of HOX genes. Several HOX genes are 
involved in the regulation of normal and leukemic hemopoiesis. The products of HOX genes 
are localized in the nucleus and represent a major class of transcription factors controlling 
cell proliferation/differentiation during early embryonic development [21].   
2. Etiology and pathogenesis of causative MLL gene abnormalities in 
AML  
The cause of 11q23MLL+ AML is unknown, but important factors include ionizing 
radiation (the highest incidence was observed five to seven years after radiation exposure), 
chemicals (such as benzene and various organic solvents), drugs (cytostatic drugs in 
particular), physical agents (such as electromagnetic fields), and environmental factors to 
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which the fetus is exposed in utero. In infant AML, a prenatal origin has been suggested by 
data from neonatal bloodspots on Guthrie cards [22, 23]. The 11q23 locus is particularly 
sensitive to cleavage after treatment with topoisomerase-II inhibitors. Because DNA 
topoisomerase II seems to be highly expressed in the developing fetus, exposure to 
inhibitors of DNA topoisomerase II could induce MLL AML in utero. A large case-control 
study of maternal diet and infant leukemia showed that the amount of maternal 
consumption of food containing DNA topoisomerase II inhibitors was correlated with the 
risk of developing MLL-rearranged AML [24].  
The pathogenesis of AML is related to oncogenic fusion proteins, the formation of which 
results from chromosomal translocations or inversions [25] (Table 1).  
 
Chromosomal aberation FAB subtype AML Frequency Fusion gene 
t(8;21) (q22;q22) AML- M2 18% (30%) AML1- ETO 
t(15;17) (q21-q11-22) AML- M3 10% (98%) PML- RARα 
t(11;17) (q23;q21) AML- M3 rare PLZF- RARα 
Inv(16) or t(16;16) AML- M4Eo 8% (~100%) CBFβ- MYH11 











t(6;9) (p23;q34) AML- M1,M2,M4,M5 1% DEK- KAN 
t(16;21) (p11;q22) AML < 1% TLS(FUS)- ERG 
t(16;21) (q24;q22) t-AML, MDS < 1% AML1- MTG16 
t(3;21) AML < 1% AML1- EVI1, EAP, MDS1 
t(7;11) (p15;p15) AML- M2, M4 < 1% NUP98- HOX49 
t(1;11) (q23;p15) AML- M2 < 1% NUP98- PMX1 
t(8;16) (p11;p13) AML- M4, M5 < 1% MOZ- CBP 
Inv(8) (p11;q13) AML- M0, M1, M5 < 1% MOZ- TIF2 
t(8;22) (p11;p13) AML- M5 < 1% MOZ- p300 
t(12;22) (p13;q23) AML- M4, CML < 1% TEL- MN1 
t(5;12) (q33;p12) CMMol 2-5% TEL- PDGFRβ 
t(1;19) (q23;p13) AML- M7 < 1% OTT- MAL 
* The percentage of translocation in AML subtypes. Values in brackets indicate the frequency within the morphological 
or immunological disease subtype. 
** Percentage refers to the frequency of reciprocal translocation chromosome products resulting. AML - acute 
myelogenous leukemia, t-AML (therapy-related AML) - AML associated with therapy, MDS - myelodysplastic 
syndrome; CMMoL - chronic myelomonocytic leukemia  
Table 1. Common gene fusions caused by chromosomal abnormalities and associated with acute 
myeloid leukemia.  
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The WHO suggested characterizing 11q23/MLL+ AML within ALL as a separate entity with 
recurrent cytogenetic translocations in 1999. This hypothesis was supported by microarray 
analyses, which proved that 11q23/MLL+ AML has a unique profile of gene expression and 
that MLL+ leukemic blasts resemble very immature progenitor cells [9]. AML with MLL 
gene alterations is characterized by a high degree of clinical and immunological 
heterogeneity, resulting in immunophenotype variability. This variability originates in 
myeloid cells/monocytes [26]. The prognosis of AML is unfavorable and varies depending 
on the type of translocation and the phenotype and age of the patient. The prognostic effect 
of 11q23 aberrations may depend on MLL partner genes. Many studies have shown that the 
translocations of t(6;11)(q27;q23) and t(10;11)(p12;q23) are associated with an unfavorable 
prognosis; however, the t(9;11)(p22;q23) translocation is associated with a significantly 
longer patient survival rate [27, 28]. However, none of the 11q23 aberrations has a favorable 
prognosis. When different MLL fusion protein complexes were characterized, a novel cancer 
mechanism was uncovered. It has been known since 1999 that direct MLL fusion proteins 
are able to deregulate HOX genes, except when reciprocal MLL fusion proteins are present 
[29-31]. The leukemogenesis concept suggests that all MLL fusion proteins increase and 
maintain a high level of transcription of MEIS1 (myeloid ecotropic viral integration site 1 
homolog) and HOXA (homeobox A cluster) gene family members. The functional 
importance became the association of MEN1, LEDGF and MYB proteins at the N-terminal 
location of the MLL fusion [32-35]. Changes in the regulation of HOXA gene expression 
influence the function of the hematopoietic system during its development and therefore 
contribute to the initiation of leukemogenesis. HOXA genes are not deactivated, but a high 
expression of the MEIS1 gene was observed [36]. Stam et al. [37] described low HOXA gene 
expression in pediatric leukemia patients with chromosomal translocation t(4;11), which is 
associated with a worse prognosis. Stumpel et al. [38] studied the methylation of promoter 
regions in samples with t(4;11), t(11;19) and t(9;11). His data indicated that different 
epigenetic mechanisms accompany the development of leukemia. Recent studies identified 
two mechanisms for leukemia development. One is the changing of epigenetic imprints, 
initiated by the presence of MLL-MLLT3, MLL-MLLT10, MLL-MLLT1 or the reciprocal AFF1-
MLL fusion protein through activation of P-TEFb kinase. The second function of the MLL–
AFF1 (ALL1-fused gene from chromosome 4 (AF4)) fusion protein is the ability to block 
apoptosis and to transcriptionally activate HOXA genes and TERT (telomerase reverse 
transcriptase) [39]. There is evidence that for all MLL-rearranged leukemias, this is the 
typical activation pattern of HOXA and MEIS1 genes. Faber et al. [40] documented that 
overexpression of HOXA9 (homeobox A9) in complex with MEIS1 is able to drive the 
myeloid phenotype in mice.  
3. Distribution of MLL gene alterations  
AML with MLL gene alterations (11q23/MLL+AML) represents 3-4% of all AML cases and 
occurs most frequently in young people with “de novo” AML (5-7%) and in treatment-
induced AML (t-AML) patients (10-15%). It is rarely seen in older patients (aged 60 and up) 
[5]. AML with MLL gene conversions occurs more frequently in infants than in adults and is 
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usually manifested through the AML M4M5 phenotype [41] Overall, the incidence of MLL 
gene conversions in children with AML varies within the range of 35-50% [42]. The 
percentages of representation are slightly different between individual studies because the 
sensitivity of 11q23MLL+ AML detection depends on the method of testing. The MLL gene 
is also a relatively frequent target of cryptic alterations, which were not always identified in 
the past using conventional karyotyping [8]. According to a report by Marschalek, more 
than 70 different fusion partner genes have been characterized at the molecular level. The 
analyzed MLL fusion alleles were classified according to their occurrence in ALL and AML 
patients. Of all MLL rearrangements, 80% are caused by AF4 (80%), AF9 (16%), ENL (11%), 
AF10 (7%) and ELL (4%). The remaining 20% of MLL-rearranged leukemia patients 
displayed 59 different fusion partners, most of which were identified in single patients [8]. 
Approximately 50% of pediatric AML cases with an MLL consist of t(9,11)(p22,q23). The 
other 50% primarily include t(6,11)(q27,q23), t(10,11)(p12,q23), t(11,19)(q23,p13.1) and 
t(1,11)(q21,q23) [43]. This distribution is almost identical with adult AML, with the 
exception of t(6,11)(q27,q23), which has a greater distribution in adult MLL-rearranged AML 
[5]. Although MLL rearrangements are predominantly found in AML, they are also detected 
in 6% of pediatric ALL cases.  
4. Conversion mechanism from an MLL proto-oncogene to an oncogene  
Extensive cytogenetic and molecular studies have revealed that 11q23/MLL is a highly 
promiscuous locus. Based on the results of research from the past 19 years, 71 different MLL 
translocation partner genes and their specific breakpoint regions have been characterized 
(published and unpublished data [8]). Of these, 43 (60.5%) are reciprocal chromosomal 
translocations, 4 (5.7%) are 11q23ter deletions and 8 (11.3%) are 11q inversions. In 13 (18.3%) 
MLL fusion partners, more than two DNA strand breaks and the insertion of 11q23 material 
into another chromosome were identified. A very rare situation of three different MLL 
fusion partners has been described in 4.2% of all cases [44]. The MLL “recombinome” 
currently consists of 104 different areas of fusion [45]. The question remains: How many of 
them do we not yet know?  
The MLL proto-oncogene can be transformed into an oncogene via several mechanisms, 
such as: 
 chromosomal translocations   
 complex chromosomal alterations, such as deletions, inversions in the area of 11q, MLL 
gene insertions into other chromosomes or the insertion of chromatin material into the 
MLL gene 
 partial tandem duplications  
 amplifications and gains    
A. Translocations 
The MLL gene is frequently involved in chromosomal translocations with other genes, 
leading to a break within the MLL locus and a partner gene, resulting in the emergence of a 
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The WHO suggested characterizing 11q23/MLL+ AML within ALL as a separate entity with 
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prognosis. When different MLL fusion protein complexes were characterized, a novel cancer 
mechanism was uncovered. It has been known since 1999 that direct MLL fusion proteins 
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contribute to the initiation of leukemogenesis. HOXA genes are not deactivated, but a high 
expression of the MEIS1 gene was observed [36]. Stam et al. [37] described low HOXA gene 
expression in pediatric leukemia patients with chromosomal translocation t(4;11), which is 
associated with a worse prognosis. Stumpel et al. [38] studied the methylation of promoter 
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transcriptase) [39]. There is evidence that for all MLL-rearranged leukemias, this is the 
typical activation pattern of HOXA and MEIS1 genes. Faber et al. [40] documented that 
overexpression of HOXA9 (homeobox A9) in complex with MEIS1 is able to drive the 
myeloid phenotype in mice.  
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usually manifested through the AML M4M5 phenotype [41] Overall, the incidence of MLL 
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patients. Of all MLL rearrangements, 80% are caused by AF4 (80%), AF9 (16%), ENL (11%), 
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other 50% primarily include t(6,11)(q27,q23), t(10,11)(p12,q23), t(11,19)(q23,p13.1) and 
t(1,11)(q21,q23) [43]. This distribution is almost identical with adult AML, with the 
exception of t(6,11)(q27,q23), which has a greater distribution in adult MLL-rearranged AML 
[5]. Although MLL rearrangements are predominantly found in AML, they are also detected 
in 6% of pediatric ALL cases.  
4. Conversion mechanism from an MLL proto-oncogene to an oncogene  
Extensive cytogenetic and molecular studies have revealed that 11q23/MLL is a highly 
promiscuous locus. Based on the results of research from the past 19 years, 71 different MLL 
translocation partner genes and their specific breakpoint regions have been characterized 
(published and unpublished data [8]). Of these, 43 (60.5%) are reciprocal chromosomal 
translocations, 4 (5.7%) are 11q23ter deletions and 8 (11.3%) are 11q inversions. In 13 (18.3%) 
MLL fusion partners, more than two DNA strand breaks and the insertion of 11q23 material 
into another chromosome were identified. A very rare situation of three different MLL 
fusion partners has been described in 4.2% of all cases [44]. The MLL “recombinome” 
currently consists of 104 different areas of fusion [45]. The question remains: How many of 
them do we not yet know?  
The MLL proto-oncogene can be transformed into an oncogene via several mechanisms, 
such as: 
 chromosomal translocations   
 complex chromosomal alterations, such as deletions, inversions in the area of 11q, MLL 
gene insertions into other chromosomes or the insertion of chromatin material into the 
MLL gene 
 partial tandem duplications  
 amplifications and gains    
A. Translocations 
The MLL gene is frequently involved in chromosomal translocations with other genes, 
leading to a break within the MLL locus and a partner gene, resulting in the emergence of a 
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new fusion gene. MLL fusion proteins (the products of fusion genes) are often associated 
with the development of acute myelogenous types of leukemia, and their oncogenic 
characteristics have been extensively studied in vitro and in vivo in mouse models [28]. The 
MLL gene represents more complex rearrangements, with at least three or more DNA 
double-strand breaks. The reciprocal MLL fusion is cryptic in these cases; an MLL fusion 
gene cannot be detected. Complex rearrangements can be divided into three subgroups. The 
first group represents the participation of three independent chromosomes in complex 
translocation and results in three different fusion genes [45]. The most frequently fused 
genes are AFF1/AF4, MLLT3/AF9, MLLT1/ENL, MLLT1/AF1Q and ELL. The second group is 
built from reciprocal chromosomal translocations containing deletions on either of the 
involved chromosomes. The third group consists of chromosomal fragment insertions. In 
this type, a portion of chromosome 11 (including part of the MLL gene) is inserted into 
another chromosome. Translocations with transcription oriented toward the centromere 
belong to this subgroup. In these cases, three independent fusion genes are generated. There 
is also spliced fusion, generated by fusing the 5´- location of the MLL gene to the upstream 
region of a TPG (translocation partner gene). Approximately 50% of all recombination 
events are spliced fusions [44]. The final group of 3´MLL fusion represents head-to-head 
fusion. The transcriptional orientation of the fused transcriptional genes is opposite of the 
orientation of the MLL gene. This genetic situation often results in LOH. All known 
translocation participating genes (TPGs) were classified according to their cellular function. 
They can build membrane proteins and nuclear proteins. As membrane proteins, these TPGs 
function as extracellular proteins, cell adhesion proteins with functions in the organization 
of focal adhesion plaques, endocytotic proteins (EPS15 (epidermal growth factor receptor 
substrate 15) and PICALM (phosphatidylinositol binding clathrin assembly protein) 
proteins)), proteins involved in diverse signaling pathways (AF6 (actin-filament-binding), 
ABI1(abl-interactor 1) , GPHN (gephyrin), KIAA0284 (centrosomal protein 170kDa) and 
MYO1F (myosin IF) proteins), the organization and regulation of the cytoskeleton, metabolic 
functions and pre-apoptotic proteins (MLLT11/AF1Q (myeloid/lymphoid or mixed-lineage 
leukemia fused to ALL1 fused gene from chromosome 1q) protein). As nuclear proteins, 
they can control the cell cycle and take part in the organization of the nuclear cytoskeleton 
during cytokinesis (SEPTINS (cytoskeletal GTP-binding) protein), nucleic acid binding 
(TNRC18- trinucleotide repeat containing 18), chromosome association (CASC5- cancer 
susceptibility candidate 5), chromatin regulation (CREBBP- CREB binding protein), 
transcription factors (AF17 (ALL1-fused gene from chromosome 17), FOXO3 forkhead box 
O3)., FOXO4 forkhead box O3 , FRYL (furry homolog-like), MAML2 (mastermind-like 2) 
and TET1 (tet methylcytosine dioxygenase 1)) and regulation factors. Recurrence of MLL 
rearrangements was observed in approximately 44% of all TPGs. The most frequent 
translocations within 11q23/MLL+ AML are illustrated in Figure 3 and Figure 4. 
B. Partial tandem duplication (PTD) and MLL gene amplification    
Approximately 7.5% of AML patients with a normal karyotype are hiding a PTD of the MLL 
gene. An MLL gene PTD is uniquely distinguished from other MLL gene alterations that 
result in chimeric gene fusions. In the PTD of the MLL gene, all of the protein domains 
encoded by the MLL gene are retained [46]. MLL PTD is common in adult AML patients but 
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not in pediatric AML patients. It has also been identified at a low level in healthy humans 
[47]. The frequency of MLL gene PTD in infants with AML, as well as in older children with 
AML, is not well established. In adult patients with the de novo form of AML and a normal 
karyotype, the presence of an MLL gene PTD versus its absence is associated with poor 
prognosis (shorter remission time) [48, 38] (Figures 5 and 6). 
 
Figure 3. Complex karyotype with translocation MLL/AF6. Complex karyotype: 45,XY,- 
4,der(7)t(4;7)(q?12;q?11),+dimin/45,XY,idem,t(6;11)(q27;q23). 
 
Figure 4. The results of fluorescence analysis of interphase nuclei obtained by taking a photograph with 
the CCD camera in a fluorescent microscope. 
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not in pediatric AML patients. It has also been identified at a low level in healthy humans 
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karyotype, the presence of an MLL gene PTD versus its absence is associated with poor 
prognosis (shorter remission time) [48, 38] (Figures 5 and 6). 
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Figure 5. The MLL gene and MLL PTD. Above: the old nomenclature exon. Below: the new numbering.  
 
Figure 6. Sequence of MLL PTD from sequencing, showing a break in exon8/exon2 (exon3/exon11).  
Previous studies have associated an MLL gene PTD with AML subtypes M1 and M2. 
Presently, according to FAB (the most widely used classification of AML, derived from the 
French-American-British group in 1976), the association of an MLL gene PTD with any 
specific FAB subtype of AML has not been confirmed. On the contrary, MLL translocations 
occur predominantly in the myelomonocytic (M4) and monocyte (M5) AML subtypes [49]. 
Some AML patients have an increased number of MLL gene copies in the form of double 
minute chromosomes, also called homogeneously staining regions. MLL gene amplification 
may occur through skipping translocations, in which the amplicon of chromosome 11 is 
integrated into one or more other chromosomes, creating multiple copies of the MLL gene. 
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In general, the amplification of the gene leads to an overgrowth of structurally normal 
copies of the gene, resulting in overproduction of the oncogene-stimulating protein. These 
extra proto-oncogene copies increase the amount of the gene product in a cell, thereby 
inducing unlimited cell proliferation. Gene amplification is usually manifested 
cytogenetically, either in an intra-chromosomal manner as a homogeneously staining region 
(HSR – homogeneously staining region) or in an extrachromosomal manner as double 
minute chromosomes (dmin). Identification of genes in the amplified region allows us to 
perform fluorescent in situ hybridization (Figure 7). 
 
Figure 7. The results obtained from the analysis of a fluorescent CCD camera. Left: interphase nucleus. 
Right: mitosis. Amplification of MLL (9 copies) in a patient with karyotype 44, XY, -5, hsr (11) (q23), -18, 
+21, + mar (C). 
The amplification of genes, a common occurrence in a wide range of tumors, is rarely 
observed in acute leukemia. Gene amplification is identified in approximately 1% of patients 
with AML by conducting a cytogenetic analysis in the form of dmin (the area of the MLL 
gene) [50]. 
It was found that patients with the MLL gene amplification share several common 
characteristics: they are older than 60 and have a de novo form of AML, a complex karyotype, 
and a short survival rate; 90% of them also have a 5q deletion.  
5. Detection methods for MLL gene conversions  
In diagnostic procedures, methods such as cytogenetic analysis, fluorescent in situ 
hybridization (FISH), and reverse transcriptase-polymerase chain reaction (RT-PCR) are 
routinely used for the identification of various regroupings within the MLL gene. Genomic 
molecular methods are also used, such as array comparative genomic hybridization (aCGH). 
Recently, the spectrum of diagnostics methods was expanded by long-distance inverse PCR 
(LDI-PCR), which detects rearrangements within the MLL gene at the molecular level [45]. 
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The amplification of genes, a common occurrence in a wide range of tumors, is rarely 
observed in acute leukemia. Gene amplification is identified in approximately 1% of patients 
with AML by conducting a cytogenetic analysis in the form of dmin (the area of the MLL 
gene) [50]. 
It was found that patients with the MLL gene amplification share several common 
characteristics: they are older than 60 and have a de novo form of AML, a complex karyotype, 
and a short survival rate; 90% of them also have a 5q deletion.  
5. Detection methods for MLL gene conversions  
In diagnostic procedures, methods such as cytogenetic analysis, fluorescent in situ 
hybridization (FISH), and reverse transcriptase-polymerase chain reaction (RT-PCR) are 
routinely used for the identification of various regroupings within the MLL gene. Genomic 
molecular methods are also used, such as array comparative genomic hybridization (aCGH). 
Recently, the spectrum of diagnostics methods was expanded by long-distance inverse PCR 
(LDI-PCR), which detects rearrangements within the MLL gene at the molecular level [45]. 
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Classical cytogenetics is used to determine a completed karyotype picture of the disease 
and to monitor the progress of the disease. It provides a full overview of qualitative and 
quantitative karyotype abnormalities and reveals primary and secondary clonal changes. 
Classical cytogenetics can reveal five most frequent MLL rearrangements include 
t(4;11)(q21;q23), AFF1(AF4)/MLL; t(6;11)(q27;q23), MLLT4(AF6)/MLL; t(9;11)(p22;q23), 
MLLT3(AF9)/MLL; t(11;19)(q23;p13.1), MLL/ELL; and t(11;19)(q23;p13.3), 
MLL/MLLT1(ENL).Typically, conventional cytogenetics has been used to detect 
rearrangements involving the MLL gene. However, conventional cytogenetics may fail to 
detect nearly one-third of MLL rearrangements; therefore, fluorescence in situ hybridization 
(FISH) has emerged as the modality of choice for detection of such rearrangements. 
Fluorescent in situ hybridization (FISH) is a method of molecular cytogenetics that enables 
the detection of specific nucleotide sequences ranging from one to several hundred 
kilobases. The principle of this method lies in the ability of a single-strand DNA probe to 
bind with a complementary segment of single-stranded patient DNA. Using specific probes 
enables us to identify chromosome numbers and to identify specific chromosomal regions 
(loci). By running FISH on metaphase as well as interphase cells, one of the biggest 
problems of classical cytogenetic analysis has been overcome. The LSI® MLL Dual Color, 
Break Apart Rearrangement Probe (Vysis) is used for the detection of alterations, 
amplifications and deletions within the MLL gene.  
Reverse transcriptase PCR (RT-PCR) is particularly useful if the internal organization of 
exons and introns within the gene is not known. The first step is isolating the mRNA of the 
respective gene from the tissue. Using a reverse transcriptase enzyme and an oligo dT 
primer, complementary DNA (cDNA) is created from an mRNA molecule, which then 
serves as a template for PCR. Using the appropriate primers allows for further amplification 
of a specific cDNA sequence. The resulting product is then visualized on an agarose gel. 
Multiplexed reverse transcription PCR (MRT-PCR) Anderson et al., 2001, developed this 
quick and accurate method to identify the six most common MLL gene translocations: 
MLL/AF4 (acute lymphoblastic leukemia), MLL/AF6, MLL/AF9, MLL/AF10, MLL/ENL, and 
MLL/ELL. MRT-PCR is based on two individual steps. The first step uses a mix of external 
(out) primers, and the second step uses a mix of internal (in) primers, which allows for the 
detection of six fusion genes in two multiplex PCR reactions. Thus, each sample is tested for 
the presence of the fusion gene twice. Primers are designed so that in the first step, there is a 
significantly greater amount of the product formed than in the second step, which increases 
the specificity of this method. If necessary, the MRT-PCR analysis can be extended by 
investigating other fusion genes [51]. 
5.1. Long-distance inverse PCR (LDI-PCR )  
The different MLL translocation partner genes are identified by cytogenetic analyses, and 
only the most common MLL translocations are investigated by RT-PCR or by MRT-PCR 
analyses. However, the infrequent or unknown MLL translocations were excluded from 
further analyses. Therefore, it was a goal to establish a universal method that enables the 
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detection of MLL rearrangements with genomic DNA. Mayer et al. [52] designed a universal 
long-distance inverse-PCR approach for clinical use and verified it as a very suitable method 
for the identification of known and unknown translocation partner genes (TPGs) and the 
establishment of patient-specific MLL fusion sequences (Figure 8).  
 
Figure 8. Principles of the LDI-PCR method. A. The schema summarizes how the genomic DNA is first 
restricted using distinct combinations of restriction enzymes (R: restriction site), then re-ligated to form 
two DNA circles that can be amplified with a specific set of oligonucleotides (A-B, A-C, A-D, and A-E). 
The primer combination B-F serves as internal control. B. BamHI restriction recognition site. 
Translocation-bearing cells yield both wild-type and derivative templates, differing in size and 
detectible on the gel. PCR amplimers can be analyzed by sequence analysis using oligonucleotides. 
LDI-PCR allows for the identification of a new class of MLL recombinations and for the 
discovery of new fusion genes, providing new insight into the origination mechanisms of 
MLL rearrangements. In this method, 1 μg of genomic DNA from the patient is isolated and 
digested with the restriction enzyme BamHI. The residual enzymatic activity is removed by 
phenol extraction and ethanol precipitation. After digestion, the DNA samples are re-ligated 
to form DNA circles (at 16ºC overnight in the presence of T4 DNA ligase). All ligation 
reactions are terminated at 65ºC for 10 minutes. MLL gene-specific oligonucleotides are 
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detection of MLL rearrangements with genomic DNA. Mayer et al. [52] designed a universal 
long-distance inverse-PCR approach for clinical use and verified it as a very suitable method 
for the identification of known and unknown translocation partner genes (TPGs) and the 
establishment of patient-specific MLL fusion sequences (Figure 8).  
 
Figure 8. Principles of the LDI-PCR method. A. The schema summarizes how the genomic DNA is first 
restricted using distinct combinations of restriction enzymes (R: restriction site), then re-ligated to form 
two DNA circles that can be amplified with a specific set of oligonucleotides (A-B, A-C, A-D, and A-E). 
The primer combination B-F serves as internal control. B. BamHI restriction recognition site. 
Translocation-bearing cells yield both wild-type and derivative templates, differing in size and 
detectible on the gel. PCR amplimers can be analyzed by sequence analysis using oligonucleotides. 
LDI-PCR allows for the identification of a new class of MLL recombinations and for the 
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MLL rearrangements. In this method, 1 μg of genomic DNA from the patient is isolated and 
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to form DNA circles (at 16ºC overnight in the presence of T4 DNA ligase). All ligation 
reactions are terminated at 65ºC for 10 minutes. MLL gene-specific oligonucleotides are 
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designed according to GenBank accession no. AJ235379 DNA sequences. For digestion and 
re-ligation of DNA, the five oligonucleotides (A-E) are used in four combinations (A-B, A-C, 
A-D and A-E). A positive control containing the oligonucleotides B and F is included in each 
analysis to amplify a 7.9 kb DNA fragment of the MLL breakpoint cluster region. All LDI-
PCR reactions are performed using the TripleMaster PCR system. PCR amplimers are 
separated on 0.8% agarose gels. Non-germline PCR amplimers are isolated from the gel and 
subjected to DNA sequence analyses to obtain the patient-specific fusion sequences. 
Annotation of fused MLL sequences is carried out by blasting the human genome database 
(Genomic BLAST, www.ncbi.nlm.nih.gov/genome/seq/Blast). The presence of a rearranged 
MLL allele can be identified by digestion and re-ligation of the two MLL alleles. Three 
different DNA circles are formed (der(11) and der(TP), TP presets translocation partner) that 
can be amplified by the designated primer combinations A-L. The DNA sequences of 
oligonucleotides A-L are available at www.biozentrum.unifrankfurt.de/PharmBiol/ 
Mitarbeiter/Marschalek/ download.html. In some cases, is necessary to analyze the cDNA to 
validate an MLL spliced fusion or to investigate alternative splice products from an MLL 
fusion gene. Because these identified fusion gene sequences are patient-specific and exist in 
only one copy per leukemic cell, they can be used as reliable markers for minimal residual 
disease studies and for minimal residual disease monitoring by quantitative PCR 
techniques. 
Analyses of novel identified MLL fusion genes provide a rich source for future analyses of 
oncogenic MLL protein variants. These MRD markers contribute to stratification and 
improved treatment and outcomes of leukemia patients.  
6. Outcomes of these methods  
Translocations of the Mixed Lineage Leukemia (MLL) gene at 11q23 are found in both acute 
lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML). The MLL gene 
contains an 8 kb breakpoint cluster region in which virtually all rearrangements occur. To 
date, more than 70 different fusion partners have been identified, although some of them 
have been observed only as a single case. The majority of MLL gene rearrangements are 
associated with infant ALL. Acute lymphoblastic leukemia (ALL) diagnosed within the first 
12 months of life accounts for 2.5% to 5% of pediatric ALL cases and displays unique 
biologic, clinical, and prognostic features that are different from those of older children with 
ALL. Approximately 80% of infant cases harbor rearrangements of the MLL (chromosome 
band 11q23) [53]. Infants with ALL are treated with an intensive regimen of ALL- and AML-
like chemotherapy, with the proportion of MLL-rearranged cases being responsible for the 
poor outcome in this age group [54].In contrast, in 75% of the MLL-rearranged pediatric 
AML cases, 4 partners are involved: AF9/MLLT3 on chromosome 9p21, AF10/MLLT10 on 
10p12, ELL on 19p13.1, and AF6/MLLT4 on 6q27 [55]. In infant AML, AF9 and AF10 are 
among the most frequent MLL fusion partners [9]. New translocation partners are still being 
reported, adding to the diversity of MLL-rearranged leukemia. Recently, ABI2 on 
chromosome 2q33.2 has been identified as a new MLL translocation partner in an infant with 
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AML-M5 leukemia refractory to standard induction chemotherapy. This important c-Abl 
regulator is a functional homologue of ABI1, a recurrent MLL-translocation partner located 
on chromosome 10p11.2, and is implicated as a tumor suppressor by its inhibitory function 
in c-Abl signaling [56, 57].  
Rearrangements of the MLL gene are found in most cases of infant AML and, regardless of 
age, confer an intermediate risk. The treatment of MLL-rearranged ALL in children includes 
intensified chemotherapy. MLL-rearranged AML is a heterogeneous disease in both biology 
and outcome. In addition to translocation partners, other variables such as 
hyperleucocytosis, age (older than 10), additional cytogenetic aberrations and early response 
to treatment have prognostic relevance and are independent prognostic factors. In general, 
certain MLL rearrangements are associated with poor outcomes in pediatric and adult acute 
myeloid leukemia. However, patients with MLL-rearranged AML have intermediate 
outcomes when treated with the optimized treatment regimens, with a 5-year event-free 
survival probability (5y-EFS) ranging from 32-54%. Currently, hematopoietic stem cell 
transplantation is no longer advised during the first remission for favorable MLL 
rearrangements. Recently, there have been new prognostic subgroups identified within 
11q23. A favorable example is t(1,11)(q21,q23). It has an excellent clinical outcome (5y-EFS of 
92% and 5y-OS of 100%) [58]. In contrast, subgroups t(10,11)(p12,q23) and t(6,11)(q27,q23) 
have poor prognoses, with 5y-EFS rates of 31 and 11%, and 5y-OS rates of 45 and 22% [12]. 
Adults with t(6,11)(q27,q23) also have poor outcomes [59]. Within the most common 
subgroup t(9,11)(p22,q23), the prognosis appears to be related to morphology, as a group 
with acute monoblastic leukemia (AML FAB M5) had a significantly better outcome than 
groups with other FAB subtypes [12].   
As with other types of leukemia, the cause of MLL-rearranged AML is unknown. The 
pathogenesis of AML requires both type-I and type-II mutations. MLL rearrangements 
belong to type-II mutations [60] and lead to the impaired differentiation of hematopoietic 
cells. Type-I mutations mainly reflect molecular mutation hotspots in specific genes (FLT3, 
KIT, NRAS, KRAS, PTPN11), which are involved in the proliferation of hematopoietic cells 
[12]. Although MLL-rearranged AML harbored one of the lowest frequencies of type-I 
aberrations (43%), mutations in the RAS-signaling pathway interestingly represented the 
vast majority in MLL-rearranged AML. Cases are routinely screened for MLL 
rearrangements by conventional cytogenetics and FISH; however, these techniques do not 
guarantee 100% sensitivity. Thus, GEP (gene expression profiling) and LDI-PCR (long-
distance inverse PCR) could be used to identify cases not detected with FISH, although 
these techniques are currently used only in research settings. As the outcome of AML is also 
dependent on translocation partners, Balgobind et al. [12] suggest that for the next risk 
group stratification, all MLL-rearranged cases should be screened for the favorable 
prognostic subgroups t(1,11)(q21,q23) and t(9,11)(p22,q23) with FAB5 and the poor 
prognostic subgroups t(10,11)(p12,q23) and t(6,11)(q27,q23). It can be assumed that a 
systematic analysis of the MLL recombinome will allow conclusions on certain aspects of the 
mechanisms of leukemogenesis to be drawn by identifying the MLL fusion proteins. This 
points to the translocation partner as having a role in the disease phenotype and functional 
heterogeneity of MLL fusions, but the molecular details of these associations are unclear.  
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The monitoring of MRD by RT-PCR detection of leukemia-specific targets (e.g., gene 
fusions, gene mutations, overexpressed genes) or by multi-parameter flow cytometry 
identifying leukemia-associated aberrant phenotypes remains an active field of 
investigation. Despite technical developments, there is still a paucity of large prospective 
trials demonstrating its clinical utility, except for APL (acute promyelocytic leukemia). 
Potentially useful applications of MRD monitoring include early assessment of response to 
therapy to improve risk stratification and guide post-remission therapy and post-treatment 
monitoring to detect impending relapse and to guide preemptive therapy. Real-time 
quantitative (RQ)–PCR assays have been developed for other fusion gene targets such as 
MLLT3-MLL and DEK-NUP214, but the data are very scarce due to the low frequencies of 
these leukemias [61]. In AML, there is a need for new agents that target specific biological 
markers with crucial roles in the development of leukemia and that are related to outcome. 
Benefits from specific treatments have been shown for specific AML FAB 3 - APL with 
ATRA and for CML and Ph+ ALL, imatinib mesylate. 
There are several recently developed agents that may target the MLL complex or 
downstream targets, such as FLT3, tyrosine kinase, which is highly expressed in MLL-
rearranged AML. FLT3 inhibitors such as PKC412 showed potential in phase I/II trials of 
adult AML. Other targets include Glycogen synthase kinase 3–GSK3 inhibitors, RAS 
pathways, and inhibitors of MEK. Some of these new agents likely will not fully block 
leukemic transformation, but may have an additive effect with current treatment strategies 
by targeting the proliferative advantages of these leukemic cells [62]. Another possibility is 
to directly target the MLL complex or proteins recruited by the MLL complex. However, 
further safety studies are warranted because genetic disruptions in mice resulted in 
embryonic lethality [63]. Another possibility could be downstream targets of MLL-
rearranged AML, such as the upregulation of HOX genes. Recent studies suggest that MLL-
rearranged leukemias are largely driven by epigenetic dysregulation. Several epigenetic 
regulators that modify DNA or histones have been implicated in MLL-fusion driven 
leukemogenesis, including DNA methylation, histone acetylation, and histone methylation. 
The histone methyltransferase DOT1L has emerged as an important mediator of MLL-
fusion–mediated leukemic transformation. The clinical development of targeted inhibitors 
of these epigenetic regulators may therefore hold promise for the treatment of MLL-
rearranged leukemia [64].   
7. Conclusion  
Acute myeloid leukemia is a heterogeneous group of leukemias that result from the clonal 
transformation of hematopoietic precursors through the acquisition of many chromosomal 
rearrangements and multiple gene mutations. The cytogenetic aberrations are commonly 
used as diagnostic and prognostic markers for specific subgroups; in addition, they also 
have important impacts on achieving complete remission, risk of relapse and overall 
survival of patients.   
Among these aberrations is a subgroup of MLL aberrations that have a heterogeneous 
impact on prognosis, predicting good, intermediate or poor outcomes. This outcome is 
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dependent on different factors, such as translocation partner, age, WBC, and additional 
cytogenetic aberrations. For this reason, identifying the translocation partner with the 
methods discussed above has a crucial significance for the stratification of clinical risk 
groups, tailoring the intensity of treatment strategy and the overall outcome. Cases with 
favorable prognosis (t(1,11)(q21,q23)) may benefit from less intensive treatment, and cases 
with poor prognosis (t(6,11)(q27,q23) and t(10,11)(p21,q23)) need adjustment and alternative 
treatment approaches to improve outcome.  It is commonly accepted that the AML 
phenotype results from multiple genetic/epigenetic lesions affecting differentiation, 
proliferation, and apoptosis. Distinguishing a particular gene signature for MLL-rearranged 
leukemias sheds light on the molecular mechanisms and potential therapeutic targets of 
these leukemias. It may also prove to have a useful role in both diagnosis and prognosis. 
Further investigation into the genetic aberrations of AML cells may provide the knowledge 
needed to develop new compounds directed against leukemia-specific targets. 
Consequently, the targeting of a single aberrant protein is unlikely to eradicate the leukemic 
clone. Although several molecularly-targeted therapies have been shown to be active in 
AML, it is clear from early clinical studies that most of these novel agents will need to be 
used in combination with conventional cytotoxic therapy.  
However, although subgroup-directed and rationally targeted therapy offers possibilities 
for the improved care of patients with AML, it will also have implications for the design of 
clinical trials. In the long term, this may require large randomized trials with international 
subgroup-specific protocols.  
The relationship of outcome with specific translocation partners requires that partners be 
searched for in the diagnostic work-up of AML and followed-up during treatment. 
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1. Introduction 
1.1. The concepts of recognition of non-self by innate immune receptors 
Immunity may be regarded as the most sophisticated part of the tissue repair process. In 
order to reach the “restitutio ad integrum” of tissues while minimizing the general 
consequences of external aggression, multicellular organisms have evolved mechanisms that 
allow rapid detection of non-self or injured self. Early recognition represents the first stage 
of protection against pathogens that enables any cell to elicit promptly various forms of 
protective responses that altogether represent the so-called “innate immune response”. In 
addition, the innate immune response turns on two types of specialized effector immune 
cells responsible for the adaptive immune response, the T and the B lymphocytes 
During the last two decades, two concepts have emerged in an effort to elucidate the basis of 
the key-initiating step, i.e., the molecular recognition of non-self. On one side, it was first 
reasoned, and later amply demonstrated, that the structures that are recognized early by the 
so-called innate immunity must share some important features that allows their recognition 
as non-self. This led to the model of “Pathogen Associated Molecular Patterns” (or PAMPs), 
which implies that distinction relies on differences in shape of molecules shared by 
pathogens, as they have been conserved during the evolution to fulfill important functions. 
On the other side, the concept of Pathogen Recognition Receptors (PRRs) was built on the 
assumption that a limited number of germline-encoded receptors should have the capacity 
to detect the differences in shape displayed by the PAMPs. In agreement with the model, 
each of the main categories of PRRs displays features that are well suited for discriminating 
non-self. 
The lectins are either soluble or membrane-bound proteins that recognize saccharides 
through single or multiple Carbohydrate Recognition Domains (CRD). Given the differences 
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in enzymatic equipment for polysaccharide synthesis, and therefore in the nature (and the 
shape) of saccharides expressed at the surface of pathogens when compared to eukaryotic 
cells, those structures represent ideal targets for pathogen detection.  
The cytoplasmic nucleotide-binding oligomerization domain (NOD)-like receptors (NLR) 
share domain architecture comprising a nucleotide-binding domain (NBD) and a leucine-
rich repeat (LRR) domain. NOD1 and NOD2 recognize distinct building blocks of 
peptidoglycan (PGN) found in bacterial walls. 
The RIG-I (retinoic acid inducible gene-I, DDX58) and MDA5 (melanoma-differentiation-
associated gene-5, RH116) represent the RIG-I-like helicases (RLH) family of cytosolic 
sensors that specifically recognizes double stranded RNA (dsRNA), while AIM2 (absent in 
melanoma 2) appears to be essential for mediating inflammatory reactions triggered by 
cytoplasmic DNA that signs the presence of pathogens. Recently, a complex formed of three 
helicases DDX1-DDX21-DHX36 [1] and a fourth helicase DHX9 [2] have been shown to 
detect dsRNA in the cytosol of myeloid dendritic cells (mDCs). 
Last but not least, the membrane-bound Toll-like receptors constitute a family of 10 
members in human (11 in mouse) that share a LRR extracellular domain involved in the 
binding of PAMPs. TLR1, 2, 4, 5 and 6 are expressed at the cell surface membrane and 
recognize pathogens-derived lipids, lipopolysaccharides, PGN or proteins. In contrast, 
TLR3, 7, 8 and 9 recognize (poly)nucleotides in endolysosomes. 
2. Toll-like receptor 3: a PRR that activates various types of cells in 
response to dsRNA 
TLR3 is a highly glycosylated type I membrane receptor that appears to be dedicated to the 
recognition of dsRNA [3] that represents a replication intermediate for many viruses. TLR3 
is thus involved in the innate immune response against various viruses [4], and plays a non-
redundant role in HSV-1 infection of the CNS [5]. Like all TLRs, TLR3 possesses an 
extracellular domain made of (23) LRRs and a cytoplasmic toll/IL-1 receptor (TIR) domain 
required for downstream signaling. Compared with other PRRs also responsive to RNA, the 
specificity of TLR3 resides in its location at the membrane of endolysosomes and in its 
affinity for a large range of dsRNA sizes (form > 50 bp to over 2000 bp). In contrast, RIG-I 
and MDA5 are activated by the presence in the cytoplasm of short or long dsRNA, 
respectively, while the membrane-bound TLR7 detects the presence of single stranded RNA 
(i.e. bacterial mRNA). 
The trachea, the pancreas and the placenta are the three organs that show the highest 
expression of TLR3 mRNA (http://www.ncbi.nlm.nih.gov/geoprofiles). However, TLR3 can 
also be detected by immunohistochemistry in many tissues, including the skin [6], the 
muscles [7], and the kidneys [8]. At the cellular level, myeloid dendritic cells and 
macrophages, but not other leukocytes, including monocyte precursors have been found to 
express TLR3. TLR3 is also present in non-immune cells such as epithelial cells of various 
origins (lung [9], intestine [10], breast [11], kidney [12], pancreas [13]) but also in 
 
Dual Role of TLR3 in Inflammation and Cancer Cell Apoptosis 249 
mesenchymal cells [14] and in endothelial cells [15]. Of interest, TLR3 is the TLR that is 
expressed most strongly in the brain, especially in astrocytes, glia, and neurons[16].  
External dsRNA appears to be first internalized by cells through the binding on surface 
scavenger receptors [17]. In endolysosomes, dsRNA binding leads to TLR3 dimerization and 
to recruitment through TIR domains homotypic interaction of a single adaptor, TRIF (TIR 
domain-containing adapter protein inducing interferon beta). TRIF in turns recruits several 
signaling kinases that activate different transcription factors: 1) through the activation of 
tumor necrosis factor receptor (TNFR)-associated factor (TRAF6) E3 ubiquitin ligase, TRIF 
recruits the transforming growth factor--activated kinase 1 (TAK1) which mediates 
downstream NF-kB activation[18]. 2) Protein kinase R (PKR) is associated with TAK1 and 
contributes to the activation of the p38 mitogen-activated protein kinase pathway by 
interaction with MKK6 [19]. 3) TRIF also recruits TBK1 and IKK through TRAF3, which 
phosphorylates IRF3 [20, 21] Activated IRF3 translocates into the nucleus and induces 
expression of Type I IFN [22]. 4) The receptor interacting protein 1 kinase (RIP1K) is also 
essential for NF-kB activation but not for IRF3 activation by TRIF [23, 24].  
3. Activities of TLR3 ligands on cancer cells 
3.1. Inflammatory and proliferative responses of cancer cells 
Many types of cancer cells express TLR3. This was established by immunohistochemistry on 
tumor tissue sections of breast carcinoma [25], oral squamous cell carcinoma [26], cervical 
carcinoma [27], ovarian carcinoma [28], prostate carcinoma, head and neck carcinoma [29]. 
Furthermore, the level of TLR3 expression by prostate cancer cells was shown to be 
significantly associated with higher probability of biochemical recurrence [30]. We have also 
observed TLR3 staining on lung squamous cell carcinoma and on a portion of HCC (our 
unpublished data). Furthermore, overexpression of TLR3 has been detected by flow 
cytometry, by western blot and/or by qPCR in melanoma cells [31, 32], esophageal 
squamous cell carcinoma[33], head and neck carcinoma cells [34] and multiple myeloma 
cells [35].  
Like normal cells, human cancer cell lines will respond to TLR3 ligand by secreting 
inflammatory cytokines, IFN-I and chemokines. As an example, we found that NSCLC, 
OSCC and HCC cell lines could secrete IL-6, IL-8, RANTES, IP-10, and IFN-I, although at 
different levels depending on the line under consideration (our unpublished data). 
Likewise, prostate cancer cells secrete IL-8, chemokine (C-C motif) ligand 3, CCL3, CCL5 
and IP-10 in response to Poly(I:C) [36], and head and neck cancer cells secrete IL-1, IL-6 
and IL-8 [29]. 
Few data have been published regarding the changes of surface membrane protein 
expression by cancer cells after TLR3 activation. Nevertheless, two reports have shown that 
CD54 is upregulated, while MHC-I expression remained constant [29, 37]. 
Regarding cancer cells migration in response to TLR3 stimulation, divergent results have 
been reported. Studying nasopharyngeal carcinoma (NPC), Zhang et al. observed that TLR3 
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agonist downregulated the expression of chemokine receptor CXCR4 and inhibited cell 
migration in response to CXCR4 ligand stromal cell-derived factor-1alpha (SDF-1alpha) in 
chemotaxis assays [38]. Moreover, TLR3 activation reduced the capacity of NPC cells to 
form metastasis in draining lymph nodes when injected in athymic mice. In contrast, 
stimulation of TLR3-expressing head and neck OC2 cells with Poly(I:C) was found to induce 
the secretion of CCL5 and to promote CCL5-mediated migration in OC2 cells [26]. Similarly, 
Goto et al. showed that Poly(I:C) enhanced the migration of melanoma cells in vitro [32]. 
Related to those observations, we regularly observe significant changes in the morphology 
of cultured cancer cells in the presence of Poly(I:C), but little is known yet on the effects of 
TLR3 activation on the cytoskeleton. 
Lastly, rare examples of cancer cells proliferating in response to TLR3 activation have 
been published. For example, one multiple myeloma cancer cell lines showed an NF-kB-
dependent proliferation in response to Poly(I:C) [39]. Moreover, indirect evidences led to 
the conclusion that TLR3 might support the proliferation of some head and neck cancer 
cell lines proliferation through c-Myc upregulation [40], and of papillary thyroid 
carcinoma [41]. 
3.2. Anti-proliferative effects on cancer cell 
Direct inhibition of tumor growth by TLR3 agonists has been reported in vitro for human 
breast, melanoma, prostate, head and neck, multiple myeloma, clear renal carcinoma, colon, 
lung, and cervical cancer cells [11, 31, 42-51]. Two mechanisms contribute to the inhibition of 
tumor growth upon TLR3 activation; (i) decrease of proliferation and (ii) induction of 
apoptotic cell death.  
3.2.1. TLR3 decreases proliferation of cancer cells by blocking progression through the cell 
cycle  
Decrease of tumor cell proliferation in response to TLR3 activation by Poly(I:C) dsRNA has 
been demonstrated by BrDu incorporation experiments for breast and prostate cancer cells 
[11, 46], and by Ki-67 staining in prostate cell lines [51], and likely participates to the dsRNA 
anti-tumoral effect in the other types of cancers listed above. The blockade of cell cycle 
appears to result form the combined downregulation of cyclin D1 and upregulation of 
cyclin-dependent kinase inhibitor p27 [11, 46, 52] and/or the inhibition of the Akt signaling 
pathway [51]. 
3.2.2. TLR3 triggers the apoptosis of cancer cells 
a. General considerations on apoptosis  
Apoptosis is an evolutionarily programmed cell death that was first described by Kerr and 
colleagues in 1972 [53]. It is crucial for successful embryonic development and for the 
maintenance of normal cellular homeostasis in adult organisms. Deregulation of apoptosis is 
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involved in an extensive variety of diseases such as cancer and autoimmunity, but also in 
immunodeficiency, degenerative diseases, or infertility. 
Apoptotic cell death results from the dismantlement of the cell by the sequential activation 
of cysteine proteases, called caspases, that cleaves numerous proteins in the cell. Two major 
pathways of apoptosis have been identified: the “extrinsic pathway” and the “intrinsic 
pathway”. The first one is typically triggered by ligation of cell surface Death Receptors of 
the TNFRI superfamilly (such as TRAIL-R or FAS) which allows the formation of a 
supramolecular complex called DISC (for Death Inducing Signaling Complex) in which 
FADD plays a key role in the recruitment and the activation of the initiator caspase-8 (and 
also caspase-10) inside this platform. Inactive caspase-8 monomers are forced to dimerize 
when in close proximity inside the DISC, which triggers their catalytic activity leading to 
autocleavage and stabilization of caspase-8 in its active form. The “intrinsic pathway”, also 
called the “mitochondrial pathway” is typically initiated by a diverse range of stress 
condition such as DNA damage, ER stress, or withdrawal, and leading to mitochondria 
alterations and cytochrome C release, and activation of the initiator caspase-9 in a molecular 
platform called Apoptosome. The “extrinsic” and “intrinsic” pathways are tightly regulated 
by FLIP and BCL-2 family proteins, respectively, and converge to the activation of the 
executioner caspase-3 and -7 that cleave essential proteins required for cellular homeostasis. 
In “Type I cells”, such as lymphocytes, activation of caspase-8 directly catalyzes the 
maturation of caspase-3 and triggers cell death. In other cells, such as hepatocytes, caspase-8 
activation cleaves the BH3-only protein BID, generating a mitochondrion-permeabilizing 
fragment (t-BID for truncated BID) which creates an amplification loop of the death signal 
that is required for cell death to occur. These cells are called “Type II cells”. 
b. TLR3 activates the extrinsic pathway of apoptosis in cancer cells 
The first demonstration that TLR3 activation by dsRNA Poly(I:C) can directly induce 
apoptotic death of cancer cells in vitro was recently achieved by our group in 2006, in a 
model of breast carcinoma cell lines [11]. Since this first observation, an increasing number 
of studies has been started, and to date, the direct inhibitory effect of TLR3 ligands on tumor 
cell survival has been reported on melanoma, head and neck, prostate, clear renal 
carcinoma, multiple myeloma, colon, cervical, and lung cancer cells. Moreover, the 
relevance of TLR3 expression in cancer cells for dsRNA antitumor effects has now been 
demonstrated in immunodeficient mouse models and has been validated as a biomarker for 
the therapeutic efficacy of dsRNA on metastatic relapse [25].This indicates that TLR3 
targeting could represent an opportunity for the development of novel cancer therapy 
strategies. 
Several studies have clearly demonstrated that TLR3-induced apoptosis in cancer cells is 
dependent on caspase-8 activation [44, 50, 54, 55], suggesting that TLR3 activation triggers 
the “extrinsic pathway” of apoptosis. Interestingly, caspase-8 activation and apoptosis 
triggering in response to TLR3 activation is independent of the classical Death Receptors 
since invalidation of these receptors by siRNA or by neutralizing antibodies do not block 
TLR3-mediated caspase-8-dependent apoptosis [54, 55]. 
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The canonical activation of caspase-8 by Death Receptor relies on a particular domain 
shared by these receptors at their C-terminal side, and called Death Domain (DD). This DD 
is crucial for the assembling of the DISC through its association with the DD of the adapter 
FADD which in turn recruits caspase-8 through homotypic interaction between their 
respective Death Effector Domain (DED). However, TLR3 does not contain such a DD, and 
the mechanism by which TLR3 activates caspase-8 remained unexplained until recently. 
c. TLR3 behaves like a Death Receptor in cancer cells 
Clues to understand how TLR3 activates caspase-8 came from cell death models of ectopic 
TRIF transfection [56, 57]. Genetic modifications of TRIF allowed to conclude that the RHIM 
(RIP Homotypic Interaction Motif) C-terminal domain of TRIF is crucial for TRIF-induced 
caspase-8 activation. This domain was previously shown to be required for homotypic 
association with the RHIM domain of RIP1 kinase and for NF-kB signaling triggering [23]. 
Interestingly, RIP1 contains also a DD, and the hypothesis of a molecular platform 
containing TRIF/RIP1/FADD/caspase-8 and mediating apoptosis was born. However, 
evidences of the molecular assembly of this platform to TLR3 in physiologic conditions were 
lacking. 
Our group and that of Martin Leverkus recently highlighted the molecular mechanism of 
TLR3-mediated cell death [54, 55]. In these two independent studies, TLR3 activation by 
dsRNA Poly(I:C) lead to the formation of a DISC-like complex containing caspase-
8/FADD/FLIP/RIP1 and TRIF - RIP1 playing a crucial role in the formation of this complex - 
confirming at a physiologic level the previous studies. Generation of new anti-TLR3 
monoclonal antibodies allowed us to establish that TLR3 was also present in the complex 
[55], indicating that even in absence of a DD in its C-terminal side, TLR3 is able to directly 
engage the “extrinsic pathway” of apoptosis by recruiting the initiator caspase-8 to itself, a 
characteristic initially observed for the death receptors TRAIL-R or FAS. We propose that 
dsRNA-mediated TLR3 dimerization allows the recruitment of TRIF through TIR homotypic 
interaction which in turn allows the recruitment of the DD-containing RIP1, the adapter 
FADD, and caspase-8 to trigger apoptosis (Figure 1a). 
However, when we investigated the role of FADD in TLR3-mediated caspase-8 activation 
we were struck by the fact that invalidation of FADD by siRNA transfection did not prevent 
TLR3-induced caspase-8 activation and apoptosis whereas FAS- or TRAIL-R-dependent 
apoptosis were prevented [55]. FADD possesses both a DD and a DED, and was therefore 
expected to provide the molecular link between RIP1 and caspase-8. Additional works are 
required to elucidate the role of FADD in the TLR3-dependent caspase-8-containing 
complex, but we can hypothesize that another adapter (such as FAF1 [58]) might exert a 
redundant function, or that RIP1-caspase-8 association is direct and does not require an 
adaptor molecule (which was previously observed in vitro with purified proteins [59]) 
d. Several molecular checkpoints negatively regulates TLR3-induced apoptosis 
When screening the effect of dsRNA on lung tumor cell lines, we observed that not all the 
cells were sensitive to dsRNA-induced apoptosis, even when they express a functional  
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TLR3. Moreover, normal lung epithelial cells were also resistant to apoptosis, indicating that 
physiologic negative regulators of the TLR3 apoptotic pathway exist in the cells. Two major 
and complementary checkpoints can be inferred from the literature. 
 
Figure 1. Hypothetical model of TLR3-triggered apoptosis: mechanisms. a, TLR3 activation by 
dsRNA induces the formation of an atypical caspase-8-activating complexe containing caspase-
8/FADD/RIP1/TRIF and TLR3. Successive homotypic interactions are required for TLR3 to recruit 
caspase-8. TLR3 possesses a TIR domain that binds to the adaptor TRIF through homotypic TIR domain 
interaction, while TRIF possesses a RHIM (RIP Homotypic Interaction Motif ) domain in its C-terminal 
side allowing its association with the RHIM domain of RIP1. Then, RIP1 can recruit FADD through 
homotypic interaction between their Death Domain (DD), and FADD recruits caspase-8 through theur 
respective Death Effector Domain (DED). b, Regulatory mechanisms of caspase-8 recruitment and 
activation by TLR3. In addition to RIP1, the adaptor TRIF recruits an ubiquitin ligase complexe 
containing the adaptor TRADD and the ubiquitin ligases TRAF2 and cIAPs which drives ubiquitination 
of RIP1, a post-translational modification required for NF-kB activation, that limits its association with 
caspase-8 by directly preventing and/or destabilizing the binding. In absence of cIAPs, which can be 
achieved by smac mimetics (SMs) treatments that triggers cIAPs auto-ubiquitination and degradation 
by the proteasome, RIP1 is not ubiquitinated which favours the recruitment of caspase-8. In presence of 
FLIP at sufficient level, the affinity of FLIP for caspase-8 favours the formation of FLIP-caspase-8 
heterodimers, hence preventing the formation of apoptotic caspase-8 homodimers. cIAPs and FLIP may 
constitute two different molecular checkpoints acting at two different levels for the negative regulation 
of caspase-8 recruitment by TLR3. 
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physiologic negative regulators of the TLR3 apoptotic pathway exist in the cells. Two major 
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Figure 1. Hypothetical model of TLR3-triggered apoptosis: mechanisms. a, TLR3 activation by 
dsRNA induces the formation of an atypical caspase-8-activating complexe containing caspase-
8/FADD/RIP1/TRIF and TLR3. Successive homotypic interactions are required for TLR3 to recruit 
caspase-8. TLR3 possesses a TIR domain that binds to the adaptor TRIF through homotypic TIR domain 
interaction, while TRIF possesses a RHIM (RIP Homotypic Interaction Motif ) domain in its C-terminal 
side allowing its association with the RHIM domain of RIP1. Then, RIP1 can recruit FADD through 
homotypic interaction between their Death Domain (DD), and FADD recruits caspase-8 through theur 
respective Death Effector Domain (DED). b, Regulatory mechanisms of caspase-8 recruitment and 
activation by TLR3. In addition to RIP1, the adaptor TRIF recruits an ubiquitin ligase complexe 
containing the adaptor TRADD and the ubiquitin ligases TRAF2 and cIAPs which drives ubiquitination 
of RIP1, a post-translational modification required for NF-kB activation, that limits its association with 
caspase-8 by directly preventing and/or destabilizing the binding. In absence of cIAPs, which can be 
achieved by smac mimetics (SMs) treatments that triggers cIAPs auto-ubiquitination and degradation 
by the proteasome, RIP1 is not ubiquitinated which favours the recruitment of caspase-8. In presence of 
FLIP at sufficient level, the affinity of FLIP for caspase-8 favours the formation of FLIP-caspase-8 
heterodimers, hence preventing the formation of apoptotic caspase-8 homodimers. cIAPs and FLIP may 
constitute two different molecular checkpoints acting at two different levels for the negative regulation 
of caspase-8 recruitment by TLR3. 
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d.1. The upstream antiapoptotic IAPs-dependent checkpoint 
The mammalian Inhibitor of APoptosis (IAP) proteins, c-IAP1, c-IAP2, and XIAP, are critical 
regulators of cell death through their direct activity towards caspases. IAPs are also well 
known modulators of inflammatory signaling and immunity. These proteins consist of three 
N-terminal Baculovirus IAP Repeat (BIR) domains, a C-terminal Really Interesting New 
Gene (RING) domain that confers E3 ubiquitin ligase activity, and a CAspase-Recruitment 
Domain (CARD) – in c-IAP1 and c-IAP2 – required for autoinhibition of their ligase activity 
at steady state. Notably, c-IAP1 and c-IAP2 regulate ubiquitin-dependent innate immune 
signaling in aval of TLRs or TNF-R, such as the activation of nuclear factors NF-kB, through 
their ubiquitin ligase activity toward key molecules of the signaling pathways. Based on the 
contribution of IAPs in cancer cell survival, small pharmacological inhibitors have recently 
been developed. These antagonist molecules, dubbed Smac-mimetics (SMs), mimic the N-
terminal IAP-binding motif of SMAC (an endogenous mitochondrial IAP inhibitor), and 
selectively bind the BIR2 and BIR3 domains of IAPs. In particular, interaction of SMs with c-
IAP1and c-IAP2 results in auto-ubiquitination activity and rapid proteasomal degradation 
[60-62]. 
The use of SMs shed new light on cIAPs functions. Notably, it has been demonstrated that 
non-degradative K63-linked ubiquitination of RIP1 by cIAPs is required for efficient NF-kB 
activation and prosurviving signaling in response to TNFR-I activation [61, 63, 64]. 
Moreover, RIP1 ubiquitination by cIAPs prevents RIP1 from binding caspase-8 and blocks 
apoptosis after TNF stimulation [63, 65, 66]. Hence, cIAPs dependent RIP1 ubiquitination 
functions as an early checkpoint to protect from TNF-RI-induced cell death until a later 
checkpoint take place via the expression of pro-survival genes through the NF-kB pathway 
(reviewed in [67]). Ubiquitination of RIP1 is also important for TLR3-induced NF-kB 
activation, and like for TNF signalling, the adaptor TRADD and the ubiquitin ligase TRAF2 
are required for efficient RIP1 ubiquitination [68, 69]. 
Recently, two groups described a new RIP1-mediated death platform, termed the 
ripoptosome, which is formed upon downregulation of cIAPs and XIAP by SMs treatment 
or genotoxic stress [54, 70]. They showed that invalidation of IAPs allows the self-
assembling of a cytosolic molecular complex containing RIP1, FADD and caspase-8, 
independently of Death Receptor signaling, and mediating apoptotic cell death. 
Interestingly, IAPs inhibition by SMs treatment sensitizes a variety of cancer cells 
(melanoma, nasopharyngeal carcinoma, cervix, NSCLC…) to TLR3-mediated apoptosis [44, 
49, 50, 54, 55]. cIAP1 and cIAP2 play non-redundant roles in this apoptotic process since 
specific invalidation of cIAP1 or cIAP2 can potentiate the deleterious effect of dsRNA. Two 
non-mutually exclusive models can be proposed to explain the sensitizing effect of cIAP 
invalidation. In the first one, cIAP elimination by SMs allows the formation of the 
ripoptosome which can bind to TRIF following TLR3 stimulation by dsRNA treatment, and 
favouring induction of apoptosis. In the second one, TLR3 ligation allows the recruitment of 
the adapter TRIF that functions as a platform to recruit signaling molecules such as RIP1, 
TRAF2, cIAPs, and TRADD for activation of the NF-kB pathway. In absence of cIAP, 
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ubiquitination of RIP1 is defective which favours (or stabilizes) its association with caspase-
8 and induces apoptosis (Figure 1b). This second model is supported by the fact that TLR3-
induced apoptosis can occur without a prior invalidation of cIAPs in some tumor cells, and 
that ripoptosome formation may not be a prerequisite for caspase-8 activation.  
d.2. The downstream antiapoptotic FLIP-dependent checkpoint 
Two FLIP isoforms exist in the cell: FLIPS (short form) et FLIPL (long form). FLIPL is similar 
to caspase-8 but lacks the catalytic site. FLIPS contains the two DED and is structurally 
related to the FLIP inhibitor from viruses. FLIPS and FLIPL bind FADD and block caspase-8-
mediated apoptosis in response to death receptor ligation [71, 72]. FLIP represents one of the 
most important anti-apoptotic proteins whose expression is tightly regulated by the NF-kB 
pathway for blocking TNF-mediated caspase-8-dependent apoptosis [73]. Moreover, 
heterodimers FLIP-caspase-8 assemble preferentially in the cell because of a greater affinity 
and/or stability than caspase-8 homodimers [74]. 
Like classical death receptors of the TNFR family, TLR3-induced caspase-8-mediated 
apoptosis is negatively regulated by FLIP. Indeed, FLIP invalidation by specific shRNA 
potentiates TLR3-dependent caspase-8 activation and apoptosis in different tumor cell lines 
([54] and unpublished data). At the contrary, FLIPL overexpression blocks the apoptotic 
effect of dsRNA poly(I:C) treatment [54, 55]. In contrast to TNF-RI pathway, for which the 
role and the regulation of FLIP have been extensively studied, TLR3-mediated FLIP 
regulation as well as the mechanism of FLIP-dependent blockade of pro-apoptotic activation 
of caspase-8 are not clear and require further investigations. However, we can hypothesis 
(from death receptor signalling literature) that FLIP inhibit TLR3-induced apoptosis through 
associating with caspase-8 to form FLIP-caspase-8 heterodimers, and hence, preventing the 
formation of apoptotic caspase-8 homodimers (Figure 1b) 
Although both IAPs- and FLIP-dependent checkpoints are likely to protect cells form TLR3-
triggered apoptosis, it remains unknown to which extent they each contribute to the 
resistance of normal cells and of different tumor cells. For example, it would be interesting 
to determine whether the higher sensitivity to TLR3-induced apoptosis of metastatic head 
and neck cancer cells relative to primary tumors [75] could be explained by differences in 
the efficacy of either or both of those two molecular barriers. 
3.2.3. TLR3 and necroptosis 
It is important to note that although FLIPL prevents apoptotic activation of caspase-8, FLIPL-
caspase-8 heterodimers are proteolytically active, which is not true for FLIPS-caspase-8 
heterodimers [74, 76, 77]. This non-apoptotic protease activity of FLIPL-caspase-8 
heterodimers is required to protect from lethality of mouse embryos during development, 
indicating that caspase-8 plays a survival role [78]. Indeed, caspase-8 knock-out is lethal at 
around embryonic day 10.5 due to alteration in the development of yolk sac vasculature [79, 
80]. A molecular mechanism of caspase-8-induced survival has been recently highlighted, 
and indicates that FLIPL-caspase-8 heterodimers confers protection from necroptosis [78, 81], 
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the efficacy of either or both of those two molecular barriers. 
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It is important to note that although FLIPL prevents apoptotic activation of caspase-8, FLIPL-
caspase-8 heterodimers are proteolytically active, which is not true for FLIPS-caspase-8 
heterodimers [74, 76, 77]. This non-apoptotic protease activity of FLIPL-caspase-8 
heterodimers is required to protect from lethality of mouse embryos during development, 
indicating that caspase-8 plays a survival role [78]. Indeed, caspase-8 knock-out is lethal at 
around embryonic day 10.5 due to alteration in the development of yolk sac vasculature [79, 
80]. A molecular mechanism of caspase-8-induced survival has been recently highlighted, 
and indicates that FLIPL-caspase-8 heterodimers confers protection from necroptosis [78, 81], 
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a form of programmed necrotic cell death, which is regulated by RIP1 and RIP3 [82, 83]. To 
prevent necroptosis, caspase-8 protease activity is required to cleave and inactivate RIP1 and 
RIP3, but also CYLD, a deubiquitinating enzyme that removes Lys 63-linked polyubiquitin 
chains on RIP1 and regulates the interaction between RIP1 and caspase-8 [66, 84]. 
Necroptosis can be triggered by death receptor ligation in condition of caspase-8 inhibition, 
and is inhibited by necrostatin-1, a specific inhibitor of RIP1 kinase activity [85]. Necroptotic 
cell death is currently under intensive investigations (for review see [86-88]) 
Since TLR3 behaves like a death receptor and activates caspase-8 through the recruitment of 
RIP1, it is reasonable to assume that TLR3 could also induce necroptotic cell death in 
condition of caspase-8 inhibition. Indeed, it has been reported that Poly(I:C)-induced TLR3 
activation can trigger necroptosis in presence of the pan-caspases inhibitor Z-VAD [54], this 
cell death is inhibited by necrostatin-1 treatment. FLIP isoforms play differential roles in this 
type of cell death, FLIPL preventing both apoptosis and necroptosis while FLIPs is an 
inhibitor of only apoptosis [54]. However, TLR3-mediated necroptosis seems to be cell 
specific and probably depends on the expression of RIP3 [54, 55], which is also true for other 
inductors of necroptosis. Nevertheless, these data indicate that TLR3 activation can trigger 
the formation of a “necroptosome” containing at least RIP1 and RIP3 which could have 
relevant function in virus-infected cell death and in immune responses. Further studies are 
required to address the role of necroptosis in virus-induced diseases and in TLR3-mediated 
tumor growth inhibition. 
3.3. dsRNA in clinical trials 
It is known for long time that in human and primate, Poly(I:C) has a short half-life(~6min) 
because of rapid hydrolysis by RNase from serum, and its capacity to induce IFN 
production is weak compare to what is observed in mouse models [89, 90]. Moreover, no 
GMP preparation are currently available and poly(I:C) has too much toxicity by causing 
fever, renal failure, coagulopathies and hypersensitivity reactions [90], indicating that 
Poly(I:C) can’t be used in clinic. However, two type of Poly(I:C) analogues are currently 
evaluated in several clinical trials: Poly-ICLC that correspond to Poly(I:C) complexed with 
polylysine and carboxymethylcellulose, and Poly(I:C12U) or Ampligen (Hemispherx 
Biopharma of Philadelphia) which is a Poly(I:C) modified by introduction of unpaired bases 
(uracil). Poly-ICLC is 4- to 10-fold more resistant to hydrolysis than Poly(I:C), with a longer 
half-life in serums of primate, and a great inducer of IFN [91]. Poly(I:C12U) is a GMP-grade 
molecule that, in contrast to Poly-ICLC, undergoes accelerated hydrolysis because of regular 
regions of mismatching. However, Poly(I:C12U) maintains pharmacological activity [92]. 
Poly-ICLC remains toxic – notably with doses greater than 12 mg/m2 – whereas Poly(I:C12U) 
showed no evidence of dose-limiting organ toxicity. Indeed, Poly(I:C12U) has been 
previously tested in the treatment for chronic fatigue syndrome and AIDS without apparent 
toxicity [92]. Moreover, Poly(I:C12U) is shown to specifically target TLR3 [93]. 
Owing to its strong capacity to activate the adaptive immunity notably through its action on 
dendritic cells, dsRNA ligands are currently tested in several clinical trials mainly as 
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adjuvant for antigen peptide vaccinations against various types of cancer [94]. The antigen 
peptide will be mainly taken up by the dendritic cells that play a major role in the innate 
immune response as professional Antigen-Presenting Cells (APCs). The peptide is then 
processed by APCs, and epitopes presented at the cell surface through MHC class I 
molecules for antigen cross-presentation to CD8+ T-cells. The adjuvant (here the dsRNA 
ligands) plays an important role for the up-regulation of co-stimulatory molecules by 
dendritic cells and their maturation, leading to direct activation of CD8+ and CD4+ T-cells 
through MHC class II and I molecules respectively, and indirectly to NK cells. Several phase 
0/I/II clinical trials - http://www.clinicaltrials.gov/ - are in progress in which Poly-ICLC is 
used in ~ 80% of the studies as adjuvant for antigen-peptide vaccination such as TARP for 
prostate cancer, MUC1 for triple negative breast cancer or prostate cancer, or NY-ESO1 for 
ovarian cancer or melanoma. Poly-ICLC is also used in combination with radiotherapy for 
low-grade recurrent B and T cell lymphoma, and for brain and central nervous system 
tumors in phase I and II clinical phase. Interestingly, a phase II clinical trial from the North 
American Brain Tumor Consortium for 30 patients with newly diagnosed supratentorial 
glioblastoma showed that treatment with radiotherapy in combination with Poly-ICLC 
followed by Poly-ICLC as a single agent was relatively well-tolerated and enhanced the 
survival of patients compared to historical studies using radiotherapy alone [95]. Then, the 
New Approaches to Brain Tumor Therapy (NABTT) consortium assigned 365 patients with 
newly diagnosed glioblastoma in phase II clinical trial for testing novel agents in 
combination with radiation + temozolomide and compared the results with the data from 
the European Organization for Research and Treatment of Cancer (EORTC) phase II study 
[96, 97]. It is interesting to note that patients treated with radiation + temozolomide + Poly-
ICLC had significantly longer survival than patients treated with only radiation + 
temozolomide between 2000 and 2002 [96]. However, these encouraging data have to be 
interpreted with circumspection because of the changing patterns of care. Concerning 
Ampligen product, only two clinical trials (phase I/II) are in progress (recruiting status) in 
which the dsRNA Ampligen is used as adjuvant for oxidized tumor cell lysate vaccination 
for patients with ovarian, fallopian tube, or primary peritoneal cancer, or as adjuvant for 
HER2 protein vaccination for patients with HER2-positive breast cancers. 
4. Integrated view of the activities of TLR3 ligand in cancer 
TLR3 agonist would have multiple cellular targets that could all contribute to the efficacy of 
their use in cancer.  
As described above, targeting TLR3 expressed by tumor cells could trigger apoptosis and/or 
block cell cycle progression. It can also elicit the secretion of chemokines, which may recruit 
immune effectors at the site of the tumor and thereby enhance anticancer immune responses 
[36], or reduce the sensitivity of cancer cells to immuno-chemotherapy [98].Furthermore, 
many of the cytokines secreted by TLR3-stimulated cancer cells, and particularly the type I 
IFNs will enhance the intratumoral innate immune responses, while the upregulation of 
CD54 on cancer cells may also enhance the cytotoxic activity T cells, as it has been observed 
in vitro [37]. 
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adjuvant for antigen peptide vaccinations against various types of cancer [94]. The antigen 
peptide will be mainly taken up by the dendritic cells that play a major role in the innate 
immune response as professional Antigen-Presenting Cells (APCs). The peptide is then 
processed by APCs, and epitopes presented at the cell surface through MHC class I 
molecules for antigen cross-presentation to CD8+ T-cells. The adjuvant (here the dsRNA 
ligands) plays an important role for the up-regulation of co-stimulatory molecules by 
dendritic cells and their maturation, leading to direct activation of CD8+ and CD4+ T-cells 
through MHC class II and I molecules respectively, and indirectly to NK cells. Several phase 
0/I/II clinical trials - http://www.clinicaltrials.gov/ - are in progress in which Poly-ICLC is 
used in ~ 80% of the studies as adjuvant for antigen-peptide vaccination such as TARP for 
prostate cancer, MUC1 for triple negative breast cancer or prostate cancer, or NY-ESO1 for 
ovarian cancer or melanoma. Poly-ICLC is also used in combination with radiotherapy for 
low-grade recurrent B and T cell lymphoma, and for brain and central nervous system 
tumors in phase I and II clinical phase. Interestingly, a phase II clinical trial from the North 
American Brain Tumor Consortium for 30 patients with newly diagnosed supratentorial 
glioblastoma showed that treatment with radiotherapy in combination with Poly-ICLC 
followed by Poly-ICLC as a single agent was relatively well-tolerated and enhanced the 
survival of patients compared to historical studies using radiotherapy alone [95]. Then, the 
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newly diagnosed glioblastoma in phase II clinical trial for testing novel agents in 
combination with radiation + temozolomide and compared the results with the data from 
the European Organization for Research and Treatment of Cancer (EORTC) phase II study 
[96, 97]. It is interesting to note that patients treated with radiation + temozolomide + Poly-
ICLC had significantly longer survival than patients treated with only radiation + 
temozolomide between 2000 and 2002 [96]. However, these encouraging data have to be 
interpreted with circumspection because of the changing patterns of care. Concerning 
Ampligen product, only two clinical trials (phase I/II) are in progress (recruiting status) in 
which the dsRNA Ampligen is used as adjuvant for oxidized tumor cell lysate vaccination 
for patients with ovarian, fallopian tube, or primary peritoneal cancer, or as adjuvant for 
HER2 protein vaccination for patients with HER2-positive breast cancers. 
4. Integrated view of the activities of TLR3 ligand in cancer 
TLR3 agonist would have multiple cellular targets that could all contribute to the efficacy of 
their use in cancer.  
As described above, targeting TLR3 expressed by tumor cells could trigger apoptosis and/or 
block cell cycle progression. It can also elicit the secretion of chemokines, which may recruit 
immune effectors at the site of the tumor and thereby enhance anticancer immune responses 
[36], or reduce the sensitivity of cancer cells to immuno-chemotherapy [98].Furthermore, 
many of the cytokines secreted by TLR3-stimulated cancer cells, and particularly the type I 
IFNs will enhance the intratumoral innate immune responses, while the upregulation of 
CD54 on cancer cells may also enhance the cytotoxic activity T cells, as it has been observed 
in vitro [37]. 
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Among the human immune cells, TLR3 is mostly expressed by myeloid Dendritic Cells 
(mDC) [99], which represent the major Antigen-Presenting Cells, and by macrophages. 
However, TLR3 is only one of the dsRNA receptor present in mDC, altogether with RIG-I, 
MDA-5 and the two helicases complexes DDX1-DDX21-DHX36 and DHX9. In the presence 
of Poly(I:C), human mDC undergo phenotypic maturation and produce high amounts of IL-
12 p70 [100, 101]. Moreover, TLR3 activation had been shown to enhance the antigen cross-
presentation capability of mouse CD8+ DC [102]. Recently, a subset of human mDC 
expressing BDCA3+ was found to internalize material from dead cells in vitro, and to cross-
present exogenous antigens to CD8+ T cells upon treatment with poly(I:C) [103]. 
Activation of human T cells by Poly(I:C) is generally regarded as an indirect consequence of 
TLR3 DC stimulation. However, TLR3 can also be expressed by T cells, at least on 
gamma/delta T cells, and acts as co-stimulatory receptor to enhance proliferation and/or 
cytokine production of T-cell receptor-stimulated T lymphocytes [104].The clinical grade 
poly(I:C)-analogue (Ampligen) was reported to promote optimal human DC maturation and 
Th1-type T cell responses in vitro [105]. 
Moreover, Poly(I:C) was reported to induce CD4+ human T cells synthesis of both IL-17A 
and IL-21 and was able to drive the differentiation of naive T helper cells into an IL-21-
producing phenotype [106].TLR3 has also been described to directly increase IFN-gamma 
production by human Ag-specific CD8+ T cells [107]. Regarding human NK cells, in contrast 
to the initial description [108], their activation by dsRNA now appears to be secondary to 
IFN-gamma production by mDC in response to TLR3 stimulation [109, 110]. Thus, the 
combined activities of TLR3 on human mDC and T cells are likely to help developing Th1-
polarized and strong cytotoxic T cells responses.  
Indeed, syngeneic mouse tumor models have shown the importance of TLR3 expressed on 
non-cancer cells not only in tumor immunosurveillance but also for the control of tumor 
growth. Protection conferred by tumor vaccine including Poly(I:C) was mediated by 
primary and memory CD8+ T cells that has been robustly activated by antigen cross-
presenting DC [111-115], and by IFN-I-activated NK cells [115]. Moreover, in a mouse model 
of established pulmonary metastasis, Poly(I:C) elicited a Th1-like, Th17-like, and cytotoxic 
immune environment following the activation of DCs and the production of IFN type [116]. 
Those animal models allowed also to show that combining Poly(I:C) with CD40 signaling 
dramatically increased the efficacy of mouse tumor vaccine [117, 118]. Such adjuvant 
combination was also able to convert mouse ovarian cancer-infiltrating dendritic cells from 
immunosuppressive to immunostimulatory cells [119] 
TLR3 agonist might also restrain tumor-driven blood supply, as multiple human endothelial 
cell types express surface TLR3, and as dsRNA-induced TLR3 activation inhibits in vitro 
angiogenesis [120]. Moreover, siRNA was found to inhibit in a sequence-independent, and 
possibly TLR3-dependent manner, the dermal neovascularization in mice [121] and the 
proliferation and morphogenesis of endothelial cells in a mouse model of hepatocellular 
carcinoma in vivo [122].  
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Figure 2. (1)TLR3 can stimulate cancer cells to secrete proinflammatory cytokine sand chemokines that 
attract and activate immune cells, respectively; (2)TLR3 can inhibit the proliferation of cancer cells; (3) 
TLR3 can trigger the apoptosis of cancer cells and the release of apoptotic bodies; (4)TLR3 can activate 
DC; (5) TLR3 can enhance the efficacy of DC to generate Th1 cells and cytotoxic T cells; (6) TLR3 can 
help NK cells to become cytotoxic; (7) TLR3 can inhibit tumor-driven neoangiogeneis; (8) TLR3 can 
switch MSC from immunosuppressive to immunosupportive phenotype. 
Lastly, Toll-Like Receptor 3, which is strongly expressed by human mesenchymal stem cells 
(MSC), inhibits their Notch-dependent immunosuppressive effect on T cells [14]. In 
addition, in response to TLR3-triggering, MSC sustain and amplify the functions of 
neutrophils and may consequently contribute to local inflammation [123]. 
Many of the above-mentioned mechanisms summarized in figure 2 probably contribute to 
the remarkable activity of Poly(I:C) used as vaccine adjuvant in several mouse tumor 
models [113, 124].Indeed, compared with other TLR agonists, DC stimulated with poly(I:C) 
displayed the strongest activity in stimulating proinflammatory responses and the 
production of tumor-specific CD8(+) T cells in several mouse tumor models [125] 
Interestingly, the combination of TLR3 with TLR7 ligands increased the capacity of mouse 
DC to establish an in vivo anti-tumoral response [126]. 
5. Conclusions and prospectives 
Since the first description of TLR in mouse, the members of this family of receptors have 
been linked to the activation of the innate immunity (Medzhitov et al., 1997). It was 
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therefore natural to study the adjuvancy capabilities of TLR ligands for vaccines, including 
anti-tumor vaccines. However, the ongoing recognition of the multiple levels of action of 
TLR on immune and non-immune cells indicates that a better understanding of the result of 
these combined activities will be required to anticipate how TLR agonist might interfere 
with cancer progression.  
Regarding TLR3 agonists, evidences coming not only from in vitro experiments and from 
preclinical mouse models, but also from clinical data strongly suggest that they could be 
useful in cancer. In particular, the discovery that TLR3 behaves as a death receptor 
selectively in cancer cells makes it similar to TRAIL receptors that are currently targeted in 
phase II clinical trials. However, answering a few key questions summarized in table1 will 
be required in order to determine whether and how TLR3 may become a successful target in 
cancer. 
 
1. Which are the molecular mechanisms that underlie the sensitivity vs. the resistance of 
normal and cancer cells to TLR3-triggered apoptosis? 
Answer to this question should help to identify a priori tumors that would benefit from TLR3 
agonist treatment 
2. What is the net effect of the pro-apoptotic activity on cancer cells and the 
immunostimulatory effect of TLR3 ligand on tumor progression? 
This important question has not been addressed yet as, in contrast with human tumors, mouse 
tumor appears to be rather resistant to TLR3-triggerd apoptosis 
3. Could TLR3 agonist synergize which (chemotherapeutic) drugs and allow increasing 
their efficacy while limiting their toxicity? 
This question must also be addressed in a syngeneic tumor model that associates a tumor sensitive 
to TLR3-triggered apoptosis and a fully functional immune system 
Table 1. Unsolved questions related to tlr3 and cancer 
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useful in cancer. In particular, the discovery that TLR3 behaves as a death receptor 
selectively in cancer cells makes it similar to TRAIL receptors that are currently targeted in 
phase II clinical trials. However, answering a few key questions summarized in table1 will 
be required in order to determine whether and how TLR3 may become a successful target in 
cancer. 
 
1. Which are the molecular mechanisms that underlie the sensitivity vs. the resistance of 
normal and cancer cells to TLR3-triggered apoptosis? 
Answer to this question should help to identify a priori tumors that would benefit from TLR3 
agonist treatment 
2. What is the net effect of the pro-apoptotic activity on cancer cells and the 
immunostimulatory effect of TLR3 ligand on tumor progression? 
This important question has not been addressed yet as, in contrast with human tumors, mouse 
tumor appears to be rather resistant to TLR3-triggerd apoptosis 
3. Could TLR3 agonist synergize which (chemotherapeutic) drugs and allow increasing 
their efficacy while limiting their toxicity? 
This question must also be addressed in a syngeneic tumor model that associates a tumor sensitive 
to TLR3-triggered apoptosis and a fully functional immune system 
Table 1. Unsolved questions related to tlr3 and cancer 
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1. Introduction 
1.1. Cancer is a genetic disease  
Cancer is a major health concern of our time, being responsible for more than 25% of deaths 
worldwide. The past two decades have produced strong evidence for the genetic basis of 
cancer. Cancer develops as a clonal disease occuring by the accumulation in multiple steps 
of genetic (or epigenetic) changes in oncogenes, tumor suppressor genes and “guardian” 
genes that support expansion of a new clone over the old one. Subsequently, it is the natural 
selection which helps expansion of a new clone carrying characteristics advantageous for 
proliferation [1, 2, 3].  
Nevertheless, the events contributing to cancer are not restricted to the cancer cells. The 
most encountered example is the case of NFkB (nuclear factor kappa-light-chain-enhancer of 
activated B cells) which is a protein complex that controls the transcription of DNA, that 
may be up-regulated in hepatocytes through different changes in the expression of TNF 
(Tumor Necrosis Factor) from the neighboring stromal inflammatory cells, and thus can 
become a key contributor in many cancer cells [3].  
Recently, it has been estimated that up to seven rate-limiting genetic / epigenetic events are 
needed for the development of a common human cancer [4]. These can appear in multiple 
different combinations depending on which particular tissue or cell-specific “anticancer” 
barriers are to be circumvented.  
A lot of knowledge about cancer was obtained from studying rare familial “monogenic” 
cancer syndromes. Although the most of the cancer cases appear to be “sporadic”, when 
cancer- causing gene mutations occurred only in adult somatic cells, these cases also proved 
to be important for understanding this intricate disease. Other important aspect refferes to 
the fact that many key molecular factors to cancer progression may not be deregulated at the 
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gene level. Downstream signaling proteins may become up-regulated by alterations in 
upstream growth factor signaling, altered catabolism, genes inactivated by epigenetic 
factors, protein expression altered by enzyme activity, degradation, chaperones, etc [4]. 
The idea that genes determine the growth behavior of a cell is now widely accepted, with 
abnormal growth reflecting the action of abnormal genes. The transformation of a normal 
cell to a cancer cell starts with changes in growth regulatory genes, and in the course of 
tumor progression further escape from normal growth control is caused by additional 
alterations in genes that direct cell multiplication and cell survival. Therefore, either somatic 
or germline mutations are both considered the root cause of cancer. These heritable changes 
in cancer cells are subsequently the targets for current attempts to develop effective and 
specific therapies for this disease [2]. As a general rule, one can say that most things related 
to cancer are a matter of timing and are determined by many other factors like the cell of 
origin, the mutations accumulated and the environment, together referred to as the 
molecular “road map” leading to cancer.  
At this time, more than 1% of all human genes are believed to be “cancer genes”. 
Approximately 90% of them represent somatic mutations in cancer, 20% bear germ-line 
mutations that predispose to cancer and 10% show both somatic and germ-line mutations 
[1]. Therefore, it was assumed that there are far fewer “pathways” implicated in cancer than 
genes. The identification of disease-related genes has led to a number of available genetic 
tests that detect disease or an individual’s risk of disease. Gene tests are available for 
different disorders and also in cancer testing, some good examples being for the BRCA1 
genes related to the breast cancer, or for MEN1 and RET genes which are linked with 
endocrine tumors. Once more disease linked-genes are discovered, more gene tests are 
expected to become available [1].  
1.1.1. The origin of cancer  
Cancer had been recognized throughout recorded history and was known to the ancient 
Egyptians, from around 1600 BC, but it was not studied until the seventeenth century, when 
the formal study of cancer (oncology) was first documented [1]. Nevertheless, only rather 
recently were registered spectacular progresses in describing the fundamental molecular 
basis of cancer, following the entry of molecular biology and especially of genetics.  
Usually, cancer is behaving exactly as a clonal disease, beginning with a mutational episode 
in a single cell and then develops in multiple stages through the acquisition of further 
mutations which are inherited through division, by the progeny of that cell. As the same 
outcome can also arise by epigenetic factors that alter chromatin structure, without altering 
the coding DNA, mutations are not the only way in which a cancer cell acquires inactivation 
or activation of a key gene/ protein. Therefore, sometimes the term “epimutations” is used 
to encompass both major routes by which cancer cells acquire aberrant expression/activity of 
key genes and proteins.  
The adult human has been estimated to contain in average as many as 1014 cells, most of 
which could theoretically become a cancer cell given the right sort of genetic (mutations) 
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and epigenetic changes. Replicating cells may be most vulnerable to cancer-causing 
mutations.  Even if some cell type, of which adult nerve cell are good examples, may avoid 
becoming cancer cell because they are essentially non-proliferating in the adult, most cells 
either regularly do or can at a pinch replicate [1]. It seems that most adult cells survive on 
average for 4-6 weeks and then have to be replaced. Also, over a thousand billion cells may 
die each day and are renewed either by replication of existing cells or from stem cells 
precursors. Given that every cell gets a significant amount of daily DNA damage and 1011 or 
more of them will replicate each day- that is a lot of potential cancer cells. Keeping this in 
mind a cancer might be expected to be a frequent incidence although so far this only 
happens in 1 in 3 people and usually even then only after 60 or 70 years of potentially 
mutation-causing events [1].  
It was well documented that there is a geographical variation in cancer incidence and death, 
and this likely reflects socioeconomic factors. The different roles of genetic predisposition, 
gene-environment interaction and infectious agents shared importance in causing cancer. 
Recent research points to the considerable overlap between the behavior of cancer cells and 
that of cells during normal physiological wound healing and during embryogenesis. 
Similarities refers to replication, less differentiated state, invasion/migration, with the major 
differences reflecting the lack of control and the unscheduled nature of replication which 
characterizes cancer. One intrigued question addressed later was how the organism is able 
to distinguish between normal growth and tissue repair (normal cell cycle) on one hand and 
neoplastic growth (cancer cell cycles) on the other. Several theories [2, 3] sustain that for the 
initial expansion of a clone of cells more than one mutation is needed. Efforts in several 
science laboratories sustain that in certain cases the mutational route to cancer may be rather 
short (in molecular terms) with as few as two interlocking mutations required for initiation 
or progression of cancer- especially in animal models, unlike in man where at least one of 
these lesions involves particularly “dangerous” oncogenes such as c-myc. Therefore, it is 
believed that at least in some cases the genetic basis of a given cancer may be remarkably 
simple. Reference genome for man and other model organisms from the last decade has 
helped the explosion of new knowledge in human genetics.  
1.2. The origin of oncogenes 
An oncogene is a gene that contributes to converting a normal cell into a cancer cell when 
mutated or expressed at abnormally-high levels. Although the discovery of the origin of 
oncogenes came in parallel with the study of retroviruses, known in general as cancer 
inductors, not all retroviruses are tumor viruses [4, 5]. Even from early 1972 many 
researchers set out to explore the "oncogene hypothesis" proposed by Robert J. Huebner and 
George J. Todaro of the National Cancer Institute [6]. Looking for one mechanism to explain 
the induction of cancer by many different agents, Huebner and Todaro had suggested that 
there are the retroviral oncogenes as part of the genetic baggage of all cells, perhaps 
acquired through viral infection early in evolution. They supposed that the oncogenes 
would be innocuous as long as they remained quiescent. When stimulated into activity by a 
carcinogenic agent, however, they could convert cells to cancerous growth. It was reasoned 
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gene level. Downstream signaling proteins may become up-regulated by alterations in 
upstream growth factor signaling, altered catabolism, genes inactivated by epigenetic 
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and epigenetic changes. Replicating cells may be most vulnerable to cancer-causing 
mutations.  Even if some cell type, of which adult nerve cell are good examples, may avoid 
becoming cancer cell because they are essentially non-proliferating in the adult, most cells 
either regularly do or can at a pinch replicate [1]. It seems that most adult cells survive on 
average for 4-6 weeks and then have to be replaced. Also, over a thousand billion cells may 
die each day and are renewed either by replication of existing cells or from stem cells 
precursors. Given that every cell gets a significant amount of daily DNA damage and 1011 or 
more of them will replicate each day- that is a lot of potential cancer cells. Keeping this in 
mind a cancer might be expected to be a frequent incidence although so far this only 
happens in 1 in 3 people and usually even then only after 60 or 70 years of potentially 
mutation-causing events [1].  
It was well documented that there is a geographical variation in cancer incidence and death, 
and this likely reflects socioeconomic factors. The different roles of genetic predisposition, 
gene-environment interaction and infectious agents shared importance in causing cancer. 
Recent research points to the considerable overlap between the behavior of cancer cells and 
that of cells during normal physiological wound healing and during embryogenesis. 
Similarities refers to replication, less differentiated state, invasion/migration, with the major 
differences reflecting the lack of control and the unscheduled nature of replication which 
characterizes cancer. One intrigued question addressed later was how the organism is able 
to distinguish between normal growth and tissue repair (normal cell cycle) on one hand and 
neoplastic growth (cancer cell cycles) on the other. Several theories [2, 3] sustain that for the 
initial expansion of a clone of cells more than one mutation is needed. Efforts in several 
science laboratories sustain that in certain cases the mutational route to cancer may be rather 
short (in molecular terms) with as few as two interlocking mutations required for initiation 
or progression of cancer- especially in animal models, unlike in man where at least one of 
these lesions involves particularly “dangerous” oncogenes such as c-myc. Therefore, it is 
believed that at least in some cases the genetic basis of a given cancer may be remarkably 
simple. Reference genome for man and other model organisms from the last decade has 
helped the explosion of new knowledge in human genetics.  
1.2. The origin of oncogenes 
An oncogene is a gene that contributes to converting a normal cell into a cancer cell when 
mutated or expressed at abnormally-high levels. Although the discovery of the origin of 
oncogenes came in parallel with the study of retroviruses, known in general as cancer 
inductors, not all retroviruses are tumor viruses [4, 5]. Even from early 1972 many 
researchers set out to explore the "oncogene hypothesis" proposed by Robert J. Huebner and 
George J. Todaro of the National Cancer Institute [6]. Looking for one mechanism to explain 
the induction of cancer by many different agents, Huebner and Todaro had suggested that 
there are the retroviral oncogenes as part of the genetic baggage of all cells, perhaps 
acquired through viral infection early in evolution. They supposed that the oncogenes 
would be innocuous as long as they remained quiescent. When stimulated into activity by a 
carcinogenic agent, however, they could convert cells to cancerous growth. It was reasoned 
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that if the hypothesis was correct, the src (sarcoma) gene might be found in the DNA of 
normal cells. The copy of src could therefore be identified in the DNA from uninfected 
chickens and other birds. The next purpose was to find DNA related to src in mammals, 
including human beings, and in fishes. All vertebrates revealed to possess a gene related to 
src, and the oncogene hypothesis was consequently declared to be correct. But, on closer 
inspection, however, the gene that was discovered in vertebrates proved not to be a 
retrovirus gene at all. It was a cellular gene, which is now called c-src. The most convincing 
evidence for this conclusion came from the finding that the protein-encoding information of 
c-src is divided into several separate domains, called exons, by intervening regions known 
as introns. A split configuration of this kind is typical of animal-cell genes but not of the 
genes of retroviruses. Apart from their introns, the versions of c-src found in fishes, birds 
and mammals are all closely related to the viral gene v-src and to one another. It appears the 
vertebrate src gene has survived long periods of evolution without major change, implying 
that it is important to the well-being of the species in which it persists [6]. As a result, the 
genetic view of cancer-genes has for a long time its origins in virology. Retroviral oncogenes 
constitute the bridge between virus-induced tumors and tumors of all other etiologies: a 
cellular oncogene activated by viral transduction is a mere special example of the general 
phenomenon of genetic alterations that can convert important and useful growth regulators 
of the cell into driving forces of unbridled growth. Studies on tumor viruses had shown that 
viral genomes could carry individual genes that, when expressed in host cells, are both 
necessary and sufficient for the induction of oncogenic transformation. Such oncogenes 
became particularly interesting in retroviruses, because they turned out to be recent 
acquisitions from cellular genomes, pieces of host genetic information that were mutated, 
transduced and expressed as part of the viral life cycle.  
It was thus supposed that the biologically active cellular oncogenes are mutant forms of 
normal proto-oncogenes that differ in the regulation of their expression or in the structure 
and function of their gene products. Nevertheless, biologically active cellular oncogenes 
were also identified by the ability of tumor DNAs to induce transformation in gene 
transfer assays. Such experiments have led to the identification of more than a dozen 
distinct human oncogenes that are activated either by point mutations or by DNA 
rearrangements in human neoplasm, or by DNA rearrangements that occur in the process 
of gene transfer. Both somatic mutations and DNA rearrangements of such oncogenes 
activated in human tumors suggest implication of cellular oncogene activation in the 
pathogenesis of human cancers. Accordingly, in the last decade, many researchers focused 
their attention to studies extremely helpful in elucidating these questionable aspects by 
implying model organisms.  
1.2.1. Classification of cancer-genes 
The genetic injure present in a parental tumorigenic cell, if not correctable, is maintained 
such that it is a heritable trait of all subsequent generations cells. Most, if not all cancer cells 
contain genetic damage that appears to be the responsible event leading to tumorigenesis. 
Two types of genetic damage are generally found in cancer cells:  
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A. Dominant genetic damage- and the involved genes have termed  
proto-oncogenes 
A proto-oncogene is a gene whose altered protein product has the capacity to induce 
cellular transformation. The distinction between proto-oncogene and oncogene relates to the 
activity of the protein product of the gene. Therefore, an oncogene is believed to be a gene 
that has sustained some genetic damage and produces a protein capable of cellular 
transformation. The process of activation of proto-oncogenes to oncogenes can include 
retroviral transduction or retroviral or transposon integration, point mutations, insertion 
mutations, gene amplification, chromosomal translocation and/or protein-protein 
interactions. In general, proto-oncogenes have been classified based upon sequence 
homology to other known proteins or based on their normal function within cells [6]. As 
predicted, proto-oncogenes have been identified at all levels of the various signal 
transduction cascades that control cell growth, proliferation and differentiation. A common 
rule ascertains that proto-oncogenes which were originally identified as inhabitants in 
transforming retroviruses are designated as c- indicative of the cellular origin as opposed to 
v- to signify original identification in retroviruses. The list of proto-oncogenes identified to 
date is rather lengthy [3, 6].  
B. Recessive genetic damage- and the involved genes are variously termed tumor 
suppressors/ growth suppressors/ recessive oncogenes or anti-oncogenes  
There is an equally important category of cancer genes that contribute to tumorigenesis 
through a loss of function named tumor suppressor genes. In contrast to the growth 
stimulatory oncogenes, tumor suppressors normally function as attenuators and as 
inhibitors of growth. This category includes any gene that has the potential of becoming a 
constitutive growth stimulator and determinant of oncogenic cellular properties. The 
oncogenicity of these genes is therefore correlated with a gain of function.  
The normal versions of both oncogenes and tumor suppressor genes serve in diverse 
regulatory systems of the cell. Most proto-oncogenes encode for components of signal 
transduction pathways that convert an extracellular stimulus into a programmed pattern of 
gene expression. A functional relatedness of tumor suppressors is less apparent; some 
domains of tumor suppressor gene action include cell surface properties, signal 
transduction, gene transcription, DNA repair, and checkpoints for cell division [6]. 
1.3. Identification of new target cancer-related genes by insertional mutagenesis  
Insertional mutagenesis is a good mechanism for identifying new cellular proto-oncogenes, 
especially when correlating with neoplasms induction by different viruses or transposons. 
The activation of a candidate oncogene by such an insertion not only provides a means of 
identifying such potential oncogenes, but also permits their isolation as molecular clones for 
subsequent investigation. After integrating its viral/ transposon DNA, the virus/ transposon 
itself represents a marker that could help to isolate surrounding molecular clones. These 
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A. Dominant genetic damage- and the involved genes have termed  
proto-oncogenes 
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subsequent investigation. After integrating its viral/ transposon DNA, the virus/ transposon 
itself represents a marker that could help to isolate surrounding molecular clones. These 
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clones can furthermore provide the flanking genomic sequences, which can reveal the 
targeted proto-oncogene activated/ targeted by the insertion. A good example for this 
mechanism is provided by wnt-1 (previously called int-1) which is usually activated upon 
integration of MMTV proviral DNA in mouse mammary carcinomas, first isolated in the 
laboratory by Harold Varmus in 1982 [7]. The MMTV virus LTR end usually acts as an 
enhancer to elevate wnt-1 expression. The flanking DNA could have be cloned and then 
sequenced and it helped to elucidate the targeted wnt-1 gene sequence. So it was revealed 
that the wnt-1 genomic locus contains a transcriptional unit that was activated in tumors, 
either by upstream or downstream MMTV DNA insertion. The wnt-1 thus appeared to be a 
cellular oncogene because of its frequent activation by insertional viral spontaneous 
mutagenesis. But the designation of wnt-1 as a real oncogene was later decided when it was 
shown that introduction of this gene into cultured mammary epithelial cells induced 
abnormal growth characteristic of neoplastic transformation [8]. Although it was initially 
identified by indirect criteria of structural alteration in tumors, this demonstration of the 
biological activity of wnt-1 provided important subsequent justification for this approach for 
oncogenes isolation. Provirus insertional mutagenesis was also implicated in activation of 
other cellular proto-oncogenes, encoding for different growth factors. For example, the 
gibbon ape leukemia cell line MLA144 constitutively produces the interleukin-2 growth 
factor (T-cell growth factor), which appeared to be required for proliferation of these cells. 
Subsequent analysis of the interleukin-2 gene revealed that its constitutive expression is a 
consequence of the integration of gibbon ape leukemia virus DNA in the 3’ untranslated 
gene region [8].  
Most recently studies revealed that one of the best examples of how a transposon insertion 
could facilitate for oncogene/ candidate-cancer gene identification is given by numerous 
studies from Drosophila melanogaster. Using genetic methods in Drosophila null alleles of the 
P-transposon tagged genes can be generated by remobilizing the transposons and screening 
for transposon’s imprecise excisions. Different studies have also highlighted the power of D. 
melanogaster P-derivative transposons for examining cooperative interactions between tumor 
suppressors and oncogenes and for generating in vivo models of tumor development and 
metastasis [9]. Therefore, Drosophila is currently widely used as a model organism to explore 
the functions of different genes particularly those ones which are structural homologs of 
human oncogenes and tumor suppressor genes involved in a variety of tumors.  
1.4. How similar are the fruit flies and humans 
The fundamental aspects of the cellular biology, regulation the gene expression, neuronal 
connectivity, synaptogenesis, cellular signaling and cellular death are commonly accepted 
as being similar between humans and fruit flies. The structural homology between 
Drosophila and human genes has been revealed immediately after sequencing the 
D.melanogaster genome [10], and the human genome. Thereafter, the interest was focused on 
considerable studies using Drosophila as an experimental model for different human 
diseases. Numerous studies have been done to identify genes implicated in human 
pathologies that could be investigated in Drosophila. The most detailed study was done by 
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Reiter and collaborators [11] in 2001. Using the Online Mendelian Inheritance in Man 
(Homophila) database, Reiter and coworkers found that 714 of the 929 (77%) OMIM human 
disease gene entries have highly similar cognates in Drosophila, which were referring 
hereafter as “related genes”. These data can be accessed through 
http://superfly.ucsd.edu/homophila, and the query can be made by key word, disease name, 
fly gene, and OMIM number (Table 1).  
Table 1. How to query the Homophila database. The user enters the text query in the form of human 
disease name, OMIM number, fly gene name, or keyword search through the human disease entry box. 
A window with information on the disease name, and human and fly genes that match the key word 
query is opened. The user then can examine the details of an individual human-to-Drosophila BLAST 
comparison to get more information on the specific BLAST score, alignment, and other hits to this gene. 
In addition, transposons’ (P-element) information is found at this level [after 11].  
A list of disease phenotypes resulting from mutations in genes that are highly related to 
Drosophila genes has been categorized into various subclasses based on clinical phenotypes. A 
large number of human disease genes sharing Drosophila counterparts involved in different 
disorders such as: cancer, non-myelin associated neurological disorders, other developmental 
defects etc, has been therefore identified. Additional notable result of their study was that the 
great majority of Drosophila genes related to human disease genes (e.g. 395 genes out of 548) 
had not been analyzed by loss-of-function genetics by that time. Moreover, they found that 
many of these Drosophila related counterpart genes are marked by P-elements insertions in or 
near them (e.g., within 1 kb of the gene-coding region) and the P-element insertions were the 
only known alleles of those genes. Immediately after this study was published, using routine 
genetic methods in Drosophila, the possibility to create null alleles of these 56 P-element tagged 
genes was starting in different laboratories by remobilizing the P-elements and screening for 
imprecise excisions that delete all or parts of the coding regions. Thus, loss-of-function analysis 
has become possible for identifying the function of these “related genes”. Without the 
complete comparisons of the genomes in a database like Homophila, it would not be 
immediately obvious that genes e.g. responsible for human deafness could be functionally 
analyzed in an organism like Drosophila [11]. Surprisingly, the human genome is predicted to 
have only little over twice the number of genes found in flies and a comparison of both 
proteomes indicates 67% similarity at the amino acid level [10].  
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Table 1. How to query the Homophila database. The user enters the text query in the form of human 
disease name, OMIM number, fly gene name, or keyword search through the human disease entry box. 
A window with information on the disease name, and human and fly genes that match the key word 
query is opened. The user then can examine the details of an individual human-to-Drosophila BLAST 
comparison to get more information on the specific BLAST score, alignment, and other hits to this gene. 
In addition, transposons’ (P-element) information is found at this level [after 11].  
A list of disease phenotypes resulting from mutations in genes that are highly related to 
Drosophila genes has been categorized into various subclasses based on clinical phenotypes. A 
large number of human disease genes sharing Drosophila counterparts involved in different 
disorders such as: cancer, non-myelin associated neurological disorders, other developmental 
defects etc, has been therefore identified. Additional notable result of their study was that the 
great majority of Drosophila genes related to human disease genes (e.g. 395 genes out of 548) 
had not been analyzed by loss-of-function genetics by that time. Moreover, they found that 
many of these Drosophila related counterpart genes are marked by P-elements insertions in or 
near them (e.g., within 1 kb of the gene-coding region) and the P-element insertions were the 
only known alleles of those genes. Immediately after this study was published, using routine 
genetic methods in Drosophila, the possibility to create null alleles of these 56 P-element tagged 
genes was starting in different laboratories by remobilizing the P-elements and screening for 
imprecise excisions that delete all or parts of the coding regions. Thus, loss-of-function analysis 
has become possible for identifying the function of these “related genes”. Without the 
complete comparisons of the genomes in a database like Homophila, it would not be 
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2. Why studying cancer in the fruit flies? 
The expansion of human cancer is a multistep route, involving the cooperation of mutations 
in signaling, cell-cycle and cell-death pathways, as well as interactions between the tumor 
and the microenvironment. In this context, to in vivo explore the steps of tumorigenesis, 
simple animal models are needed. The genetically amenable, multicellular organism, the 
vinegar fly, D.melanogaster, can be used to elucidate the functions of different human 
structural homologues whose mutations were identified in different types of cancers [12]. 
This choice is not surprisingly taking into account the research history in Drosophila and the 
contributions of the Drosophila genetics for understanding the signaling pathways 
implicated in oncogenesis, such as: Ras/MAPK, Notch, Wnt/wingless, hedgehog and BMP.  
D. melanogaster is an experimental model organism currently largely used for cancer 
research [13]. In 1916, decades before Drosophila would become one of the most popular 
models for studying many aspects of modern biology, the discovery of melanotic tumor-like 
granules in mutant larvae, by Bridges and Stark, first suggested that flies could develop 
tumors [14]. It took more than 50 years of genetic analysis to obtain convincing data which 
prove that insects can suffer from cancer [15]. Later, spontaneous mutations were identified 
causing the death of the animals at larval stages, because of overproliferation of certain 
internal tissues [16, 17]. Another study [18] showed that homozygous mutations in a series 
of genes from Drosophila can cause the appearance of tissue-specific tumors, which can affect 
either the embryonic or the larval development. Among these genes, the lethal (2) giant larvae 
(l(2)gl), has been the most studied. Homozygous mutations in l(2)gl produce malignant 
tumors in the brain and the imaginal discs. The l(2)gl gene was cloned, introduced back into 
the genome of l(2)gl-deficient animals and shown to restore the normal development [19], a 
process called “rescue-phenotype”. A mosaic screen for over-proliferation mutants has been 
used successfully to identify several novel tumor suppressors in flies, including the large 
tumor suppressor (lats; also known as wts) gene. Somatic cells mutant for lats undergo 
extensive proliferation and form large tumor outgrowths with morphological characteristics 
similar to those of human tumors, confirming that Drosophila can grow tumors that are 
comparable with those found in humans. The human homolog of the lats gene (LATS1) 
could be used to suppress tumor growth and rescue developmental defects in lats mutant 
flies, including embryonic lethality [20]. Studies in Drosophila of such genes provided 
information that was directly relevant to tumorigenesis in humans.  
In 2009, the second BioMed Conference from Barcelona entitled "Modelling Cancer in 
Drosophila" emphasizes again Drosophila as a model to elucidate human cancers. It was for 
the first time when a group of scientists came together to discuss the ways in which the fruit 
fly could provide novel contributions to the field of human cancers. For some of the 
presentations, discoveries in Drosophila were later validated in mammalian system or in 
humans [21]. So that, there is a large spectrum of candidate genes implicated in human 
pathologies that can be studied in Drosophila, and the lack of redundancy can simplify the 
analysis of biological process in the fly [22]. The functional orthology between Drosophila 
and human genes can be proved by rescue phenotype experiments (the equivalent of gene 
therapy) and it is working and gives surprising results.  
 
A Different Approach for Cellular Oncogene Identification Came from Drosophila Genetics 279 
2.1. Testing for preserved function between Drosophila genes and human 
counterparts  
There are a number of ways to test the function of a foreign gene/ protein in transgenic 
Drosophila. Homologs of a fly gene for which mutants exist can be tested for the ability to 
rescue the fly mutant phenotype. If the fly counterpart has dominant effects or if one might 
expect dominant effects as a result of the function of the protein in vertebrates (such as for a 
dominant oncogene or disease gene), then another test is to determine whether the 
vertebrate homolog can induce similar dominant phenotypes in flies. There are examples of 
dominant oncogenic mutations leading to a form of the protein that also functions 
dominantly in the fly [23]. In some cases, expression of vertebrate/human genes in fruit flies 
has demonstrated that a conserved function of the vertebrate and fly genes is 
autoregulation; thus, the vertebrate protein (frequently a transcription factor) turns on 
expression of the endogenous fly counterpart. If one has mutants in the fly gene involved. 
Then, it is possible to test for functional conservation in the genetic background of a protein 
null mutant of the fly gene and, hence, address broader aspects of functional conservation.  
Herein are presented some results of a study concerned on the clarification of the putative 
functional conservation between DmManf gene from Drosophila (previously called ARP-like 
for arginine-rich protein-like), and its counterpart- the human Manf gene (Mesencephalic 
astrocyte-derived neuroptrophic factor), which was found to be implicated in various human 
pathologies, including cancer.  
2.2. Exploration of the DmManf in comparison with Manf putative oncogene 
from human 
Mesencephalic astrocyte-derived neurotrophic factor, DmManf gene is referred in FlyBase by 
the symbol CG7013 (CG, computed gene). It has the cytological map location 89B19, in the 
right arm of the 3rd chromosome. The molecular function is unknown. Previously, it was 
shown that a P{EP} transposon insertion at the position –157 upstream of the 5’UTR region 
of the Manf gene does not affect the Manf gene function [24].  
The DmManf gene contains 1436 nucleotides and encodes for a protein of 173 amino acids. In 
the fruit-fly stock EP(3)3171 the DmManf gene is associated with a P derivative transposon. 
In general, transposable elements insertion’s are extremely powerful means of gene 
disruption. The transposon associated with DmManf gene was symbolized by P{EP}EP3171 
and was first inserted in the 5’UTR region of DmManf gene, and then, could be mobilized 
generating mutant alleles of the targeted gene.  
The human Manf counterpart gene, previously named ARP (from Arginine-Rich Protein) is 
located in the chromosomal band 3p21.2, a region that is frequently deleted in a variety of 
solid tumors. It encodes for a protein highly conserved in evolution. First oncological 
information was given by Shridhar and coworkers [25, 12] who reported an ATG-to-AGG 
transversion in codon 50 of the ARP gene or deletion of codon 50 in different tumor types 
including 10 of 21 sporadic renal cell carcinomas. Later (1997), they observed the same 
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mutations in 11 of 37 pancreatic tumors. Either of the changes abolishes a methionine 
residue and gives rise to an uninterrupted string of AGG trinucleotides in the ARP gene and 
arginines in its predicted protein product. The finding of 4 other nucleotide substitutions in 
codon 50 that replaced methionine with 4 different amino acids other than arginine 
suggested that loss of this methionine residue is critical to a carcinogenic role of this gene.  
Their finding of an AGG-to-AAG (arg-to-lys) mutation in the adjacent codon 51 in 2 tumors 
emphasized further the importance of this region. Other evidence [25] suggested that only a 
single copy of the ARP/Manf gene is mutated in the cancer cells, indicating its possible 
causal role as an oncogene.  
Mesencephalic astrocyte-derived neurotrophic factor sequences are referring to a family of 
small proteins of approximately 170 residues which contain four di-sulfide bridges that are 
highly conserved, from nematodes to humans (Table 2).  
 
 Genes Proteins  
1 MANF,  H.sapiens
mesencephalic astrocyte-derived neurotrophic factor
NP_006001.3 
182 aa
2 MANF,  P.troglodytes
mesencephalic astrocyte-derived neurotrophic factor
XP_001169644.1 
246 aa
3 MANF,  C.lupus
mesencephalic astrocyte-derived neurotrophic factor
XP_850540.1 
179 aa
4 MANF,  B.taurus
mesencephalic astrocyte-derived neurotrophic factor
NP_001094681.1 
179 aa
5 Manf,  M.musculus
mesencephalic astrocyte-derived neurotrophic factor 
NP_083379.2 
179 aa 
6 Manf,  R.norvegicus
mesencephalic astrocyte-derived neurotrophic factor
XP_236614.3 
179 aa
7 Manf,  D.rerio
mesencephalic astrocyte-derived neurotrophic factor
NP_001070097.1 
180 aa
9 Manf,  D.melanogaster
Mesencephalic astrocyte-derived neurotrophic factor
NP_477445.1 
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Table 2. HomoloGene report showing the putative homologs of mesencephalic astrocyte-derived 
neurotrophic factor. The identification number of the protein, the size and their conserved domain 
architectures are are assigned (www.ncbi.nlm.nih.gov/homologene).  
The amino acid sequences of this highly conserved protein in evolution shows 51% identity 
on average between Drosophila Manf gene and the human Manf (Fig. 1).  
The higher homology revealed by the comparison of the whole aminoacid sequences of the 
Drosophila and human proteins (51% identity, 71% positives) as compared to the amino acids 
of the Saposin_like domains (41% identity, 58% positives) suggests that, in addition to the 
Saposin_like domain, there are other motifs which highlight the similarity or even identity 
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between the compared aminoacid sequences. These motifs could be important for a 
particular function of the protein and suggest a similar function of the two proteins. This 
remark is in agreement with a similar situation that was encountered when Drosophila lats 
and human LATS1 were compared [20]. Although the overall sequence similarity in the 
amino-terminal regions of these two proteins was lower (22% identity and 42% similarity) 
than in the kinase carboxy-terminal (74% sequence identity), stretches of highly conserved 
sequences have been identified in both proteins, and finally, they proved that the genes are 
even functionally conserved. Another similar study presents the case of Mgstl which 
encodes a protein similar to human mGST. Because the identity between both genes was 
45% but their hydrophobic profiles were also very similar, the authors’ expectation was that 
these genes share a functional similarity [26].  
 
Figure 1. Comparison between D.melanogaster Manf and human Manf sequences. „Query”= protein 
from human and „Sbjct= protein from Drosophila. Amino acids from Saposin-like domain are 
surrounded by green; bordered in blue is EF-hand domain. For detailes, see text.  
To study whether DmManf holds not only a structural, but also a true in vivo functional 
similarity with its human counterpart, we mobilized the P{EP}EP3171-element from the 
EP(3)3171 line to obtain specific mutant alleles of the DmManf gene. Different mechanisms 
of repairing the double-strand break generated by the P{EP} excision induced a variety of 
new genetic variants, including loss-of-function DmManf alleles [27].  
In this study we took advantage of our first reported loss-of-function mutant DmManf allele, 
namelythe ManfΔ1151 (GenBank ID: DQ649527). The ManfΔ1151 allele was isolated in Ex.35 
mutant line (Fig. 2). By DNA sequencing of the specific mutant amplicon we discovered that 
the Ex.35 mutant line contains a deletion of 1278 bp that removes part of the intergenic 
region, the 5’UTR and almost the whole coding region of the DmManf gene, leaving behind 
the distal end of the last exon and the 3’UTR region (Fig.2 Ba) and is affecting only the 
DmManf gene.  
The ManfΔ1151 allele from Ex.35 line proved to be homozygous lethal. To define the lethal 
phase during development, we took advantage of the GFP (Green Fluorescent Protein) marker 
present in the Drosophila balancer chromosome TM3SerGFP, which could help distinguishing, 
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mutations in 11 of 37 pancreatic tumors. Either of the changes abolishes a methionine 
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Figure 2. The structure and deletion breakpoints of P{EP}EP3171 homozygous lethal allele found in 
Ex.35 line. A: The genomic context including Drosophila Manf and CG14879 genes separated by 141bp 
intergenic region and transcribed in opposite direction. Δ stands for P{EP}EP3171 original insertion site. 
Exons are indicated by filled boxes, introns by empty boxes. Nucleotide numbers are assigned for the 
exons. B): The lethal ManfΔ1151 alele genomic deletion is indicated by the dashed line. The numbers of 
nucleotides are assigned for each exon [after 27].  
under an UV source, the GFP heterozygous individuals and non-GFP homozygous 
individuals. Therefore, after letting Drosophila females from Ex.35 line to lay eggs onto Petri 
dishes containing appropriate culture medium, we followed the development of the 
embryos and larvae comparing the numbers of the heterozygous and homozygous 
individuals. Starting with 594 embryos, we noticed that the number of the homozygotes was 
continuously decreasing during the subsequent developmental stages. As it revealed, the 
homozygous lethality was polyphasic, the homozygotes mostly died in the embryonic and 
1st instar larval (L1) phases, although L2 stage escapers were also found. Among the counted 
3rd stage larvae, two non-GFP excapers were found. One of them was transferred onto 
another culture plate and observed for several days. This mutant L3 larva contained some 
internal „holes”, i.e. empty, transparent spaces similar to that ‘‘empty’’ spaces found in 
another DmManf specific mutant, from a similar study [23]. First these homozygous larvae 
atypically wander away from the food, and then move more slowly, and finally freeze 
immobilized but still responding to touch. It was unable to enter the pupal stage and died 
keeping the phenotype described before. Homozygous mutant adults for ManfΔ1151 allele 
were never found. These empty „holes” remained unchanged during the observation 
period, suggesting that the pupae died inside, probably after several unsuccessful 
encapsulation immune reactions by which lammellocytes should encapsulate melanise and 
kill the parasites, fungi or even abnormal cells- such as tumor cells (Fig. 3).  
Most of the Drosophila overgrowing mutations are late larval or pupal lethal and affect the 
adult organ rudiments, imaginal discs, while leaving the other larval tissues necessary for 
larval survival mostly unaffected [28, 16]. The majority of such mutations display a 
prolonged larval period, also seen in the case of ManfΔ1151mutant, which can be explained by 
the presence of non-differentiating growing imaginal rudiments preventing ecdysone 
release [29].  
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While DmManf recently [23] was found to be required during the maturation of the 
embryonic nervous system for maintenance of neuronal connectivity, there were also 
indications (http://superfly.ucsd.edu/homophila/) of a possible role of Manf /ARP in human 
tumor formation [12, 25].  
  
Figure 3. Heterozygote and homozygote pupae from Ex.35 line. a) Ex.35 heterozygous control pupae 
(genotype: ManfΔ1151/TM3SerGFP); b) Ex.35 homozygous pupae (genotype: ManfΔ1151/ ManfΔ1151); arrows 
show the internal holes in the dead pupa.  
A wealth of data support the view that cancer is a multistage disease progressing via the 
accumulation of multiple genetic changes lesions that compromise the normal control of cell 
proliferation, survival, differentiation, migration and social interactions with neighboring cells 
[1]. It is also important to note that apparently phenotypically similar cancers may arise 
through different combinations of lesions: there are likely many different routes to cancer even 
in the same cell type. Many key cancer –relevant signaling pathways may be activated or 
inactivated by mutations at various points that could result in largely identical cell behavior.  
From this point of view, interesting cancer-like phenotypes were observed for different 
mutants previously obtained after P{EP}EP3171 transposon mobilization, from the DmManf 
gene vicinity [27]. The most aggressive cancer-like phenotypes which appeared in our 
mutants either killed the adult flies, e.g. in the case of Ex.29 mutant (Fig. 4) or let the adults 
survive, although they expressed in all the body melanotic tissue/nodules, in both females 
and male, e.g. in the case of A26.1 mutant (Fig. 6). Symbols and numbers in the mutant 
names designate different lines obtained from different P{EP}EP3171 mobilization 
experiments  [27]. 
   
Figure 4. Larval and pupal phenotypes found in the Ex.29 mutant. a. Larvae and pupae containing 
melanotic masses; b. dissected homozygous mutant larva in the IIIrd instar enclosing melanotic masses; 
c. The gut surrounded by melanotic masses. The arrows label melanotic masses. The Ex.29/Ex.29 
homozygote mutants never developed as adults.  
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The appearances of the melanotic masses in flies were extensively characterized. Although 
the Toll pathway seems to be responsible for the formation of melanotic masses in Drosophila 
[30], other genes could also be implicated upstream of downstream of this well 
characterized pathway. Spectacular results were obtained by investigating the ultra-
structure of the interesting melanotic masses found in case of Ex.29 mutant under the 
electron microscope. After dissecting normal and melanotic gut of the Ex29/Ex29 
homozygote mutant 3rd instar larvae, several sections were examined under the electron 
microscope (Fig. 5). We noticed that in the cells of control normal gut the nucleus revealed a 
typical structure with nuclear envelope, caryoplasm and nucleolus (Fig 5a). Caryoplasma, 
the fundamental substance of this nucleus appeared typical, as a protein gel with the 
embedded chromosomes and a nucleolus. Chromatin displayed a fibrillar structure, 
consisting mainly of DNA associated with histones and non-histone proteins. Chromatic 
substance of the nucleus become visible as a network, resulting from a strong 
despiralization, hydration, swelling, dragging and overlapping events of the chromosomes. 
In some parts, the chromatic substance disclosed more condensed probably corresponding 
to heterochromatic areas.   
   
Figure 5. Electron microscopic images after micro-dissection of Ex.29 homozygote 3rd instar larval gut; 
a. Nucleus and nucleolus of a normal gut cell. Magnification is 8640X; b. Dissection through melanotic 
“young tumor”- light black masses; the nucleus has a lobated edge, magnification 8640X; c. Dissection 
through melanotic “old tumor” -dark black masses, showing a nucleus without nucleolus. 
Magnifications 12400X. N- Nucleus; n- nucleolus; NE- nuclear envelope, V- vacuole; Cr- chromatin.  
Nucleolus, another important cellular structure displayed an oval shape with irregular 
contour (Figs. 5a, 5b), without specific membrane, being surrounded by a network of 
chromatic filaments of nuclear origin which twisted into perinucleolar chromatin. As 
typical, is prearranged in a fibrillar-granular structure consisting of fibrils and ribo-nucleo-
proteinic granules, like ribosomes.  
In contrast, in the „old tumor” dark black masses, resembling senescent cells (Fig. 5c) 
appeared having ceased its function, many structural changes occurring probably due to the 
intensification of autolitic processes. As a result, the cytoplasmic content decreased 
significantly, most of the cellular volume being replaced by the vacuolar system. In this cell 
the nucleus still persists, although the nucleolus have disappeared. Only a few blocks of 
chromatin and an increased number of autolytic vacuoles can be detected. These changes 
lead to the idea that such a cell is doomed to apoptosis. Other notable melanotic-like nodule 
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phenotype was observed in case of the A26.3 mutant stock, which contains DmManfA26.3 
allele, carrying a residual part from the original P element insertion (GenBank ID: 
HQ623183). The stereomicroscopic examination of these mutants showed mild melanotic 
masses in the larvae (Fig. 6).  
  
Figure 6. The A26.3 mutant phenotype is shown. a. Melanotic nodules in the adult flies, both in males 
and females. b dissected adult female carrying black melanotic nodules/ pseudo-tumors.  
Particular mutants expressing characteristic melanotic phenotype were also obtained in 
other insertional/ excisional P element mutagenesis experiments [31]. As it was shown 
previously, mutations in ~30 genes that regulate different pathways and developmental 
processes in Drosophila can cause a melanotic phenotype in larvae. The observed melanotic 
masses were generally linked to the hemocyte-mediated immune response. In general, the 
melanotic masses can be subdivided into melanotic nodules engaging the hemocyte-
mediated encapsulation and into melanizations that are not encapsulated by hemocytes [31]. 
With rare exception, the encapsulation is carried out by lamellocytes. Encapsulated nodules 
are found in the hemocoel or in association with the lymph gland, while melanizations are 
located in the gut, salivary gland, and tracheae. These results can show that the phenotype 
of each mutant not only reflects its connection to a particular genetic pathway but also point 
to the tissue-specific role of the individual gene.  
Half a century ago, melanotic tumors in Drosophila larvae and adults were viewed as the 
equivalent of cancer and as events of controlled histological differentiation that could be 
manipulated genetically. The participation of blood cells in the formation of some melanotic 
tumors was reported at about the same time [32, 33]. Black melanotic spots are found in a 
number of different mutants and have been called, interchangeably, melanotic tumors or 
pseudotumors. These ‘‘tumors’’ are usually not invasive and involve tumorous overgrowth 
only in some instances. Therefore it is generally accepted to use the term ‘‘melanotic 
masses’’ to describe the phenotype generally and ‘‘melanotic nodules’’ and ‘‘melanizations’’ 
to describe more specific phenotypes.  
Experiments in our laboratory indicated that an artificial transposon, P{EP}EP3171, when 
mobilized [27] could induce variable mutant genotypes and phenotypes resulting in a 
polyallelic series of the DmManf and/ or other interactor genes, including melanotic masses 
and nodules. This is not particularly suprising, taking into account other genes, e.g. the deep 
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orange (dor) gene, whose poly-alellic series affect different functions resulting in lethality, 
male sterility, sterility with maternal effect, or simple changes in the eye color [34]. We also 
found Drosophila mutants with paternal effect sterility, which could give away DmManf 
gene’s pleiotropic functions. By investigating all these isolated alleles we can reach 
comprehensive understanding of the role of the DmManf gene.  
2.3. Application of the rescue phenotype (gene therapy) technique in flies 
Gene therapy consists of the insertion of genes into an individual's cells and tissues to treat a 
disease, and hereditary diseases, in which a defective mutant allele is replaced by a 
functional one. Although the technology is still in its infancy, the researchers have already 
successfully tested it in Drosophila, for homozygous lethal mutations of the l(2)gl [19] or the 
lats gene [35], which could be saved by the orthologous genes from human: Hugl-1, scrib, dlg 
[36] etc. Therefore, when expressing a foreign gene in the fly in a tissue that normally does 
not express any such gene, screening of interacting proteins will be useful for understanding 
the function of the gene in its normal cellular context. It is important to assess whether any 
phenotypic effects observed in the fly accurately reflect conserved functions of the 
vertebrate protein under scrutiny. For example, will vertebrate anti-apoptotic genes block 
Drosophila programmed cell death? Will the vertebrate homolog, like its fly counterpart, 
direct ectopic tissue formation in the fly? If the vertebrate cDNA induces a dominant effect, 
is that effect the result of elevated levels of a normal activity of the protein (a hypermorphic 
effect) or of a new activity of the protein that may have little to do with its normal function 
(a neomorphic effect). Neomorphic effects, for example, might be the result of subcellular 
mislocalization of the vertebrate protein in the fly. To what degree does the pathology of a 
human disease gene reflect biological effects known to occur in humans or vertebrate 
models, and can these effects be faithfully replicated in the fly model? These are, of course, 
specific issues that vary for any one gene of interest, and they are critical to consider.  
2.3.1. DmManf is the true ortholog of the human Manf putative oncogene  
To investigate whether human Manf is able to compensate for the loss of function of 
DmManf mutants, we carried out rescue experiments with UAS-HsManf transgenic flies. We 
applied the gene therapy (rescue phenotype) procedure to the Ex.35 mutant which contains 
the loss-of-function allele ManfΔ1151, and shows lethal phenotype. First, we verified if the 
ManfΔ1151 mutant lethality was solely the result of the DmManf deletion, by inducing the 
ubiquitous ectopic expression of UAS-DmManf in the DmManfΔ1151 homozygote mutant 
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Herein is described a pilot experiment that supports the evolutionary conservation of the 
Manf gene functions’ in the fruit fly- Drosophila melanogaster and its important role in 
deciphering human pathologies. Our results complement previous results [23] when 
DmManf mutant (namely DmManfΔ96) lethality rescue- phenotype experiment resulted in 
complete larval rescue up to the pupal stage [23]. These authors were using 69B-GAL4 
driving the transgenic DmManf expression in epidermis and CNS, proving the importance 
of DmManf expression in both tissues in the fly. They also proved that DmManf is required 
for the maintenance of the DA neurites but not the neurites of serotonergic or the 
subpopulation of motoneurons. Surprisingly, despite the axonal degeneration in DmManf Δ96 
mutant larvae, the cell body of DA neurons persists. Moreover, some DA neurons but not 
their neurites persist even when their death was ectopically triggered by over expression of 
the proapoptotic proteins. Thus, programmed cell death in the Drosophila DA neurons seems 
to follow a ‘‘dying-back’’ pattern where the neurites degenerate first followed by the death 
of the cell body [23, 37]. Whether DmManf is a bona fide NTF promoting the survival of DA 
neurons remains, however, open as the mutant larvae died before it could be judged [23]. By 
TEM analysis, the elimination of DmManf causes cell death resembling caspase independent 
cell death, characterized by swelling of organelles, and the appearance of ‘‘empty’’ spaces [23, 
38]. Similar observations were also found in the case of our mutant Ex.35, which contains the 
DmManfΔ115 allele (see Fig. 3).  
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By the experiments involving DmManf gene from Drosophila presented here, some scientific 
data about the yet unknown role of this gene was obtained. We completed a first pilot 
phenotypic rescue of our DmManf deficient animals. It still remained unclear if the DmManf 
is a true oncogene or a tumor-suppressor gene. We assumed that a real cancerous 
phenotype could have not appeared in the Ex.35 mutant, either because DmManf gene might 
not be a canonical oncogene, or because while DmManf although preserved a particular 
function in the cancerous process, other additional mutations were simultaneously needed 
for the cancerous phenotype to appear. It is accepted that for the initial expansion of a cell 
clone more than one mutation is usually needed. Work in several laboratories sustain that in 
certain cases the mutational route to cancer may be either short (in genetic terms) with as 
few as two interlocking mutations required for initiation or progression of cancer, or long, 
and these instances can be easily clarified routinely in studies which involve animal models.  
3. Materials and methods 
Drosophila strains: For genetic nomenclature, cytology and description of mutations and 
chromosomes see [39] and Flybase [40]. Drosophila strains used are: w;EP(3)3171/TM3SbSer 
[24], w;TM3SerGFP/TM6TbSb, Ex.35/TM3, Ex.29/TM3, A26.3/TM3, Actin-GAL4/SM6Cy. For 
the phenotypic rescue experiments, the transgenic stocks UAS-DmManf and UAS- 
HumanManf were received as gifts from Dr. T.I.Heino. Fly crosses were done on standard 
cornmeal-yeast-agar medium, at 25°C.  
Phenotypic rescue experiments. The transgenic lines for UAS-DmManf and UAS-HsManf 
were recombined together with Actin-GAL4 driver, a GAL4 line of ubiquitous expression, 
on the DmManfΔ115 mutant background. For each experiment 3 independent crosses were 
made and transferred twice to fresh vials; progeny from all vials of each cross was counted, 
and the proportion of rescued adults relative to all adults was calculated.  
StereoMicroscopy and Image Analyses: Larval and pupal images were taken through an 
Olympus SZX7 stereo-microscope equipped with an Olympus DP70 camera.  
Electron Microscopy (EM) Analyses. The gut and melanotic tissues isolated from dissected 
Ex.29 homozygous larvae were fixed in 4% glutar-aldehyde in 0.1M sodium cacodylate 
buffer, pH7.3, 4h at 40oC and post-fixed in 1.5 % osmium tetroxide in the same buffer. They 
were then dehydratated in a graded ethanol series (30%, 50%, 70%, 90%, 95% and 100%) and 
embedded in Epon 812. The samples were sectioned on an ultra microtome, stained in 4% 
aqueous uranyl acetate, post-stained with lead citrate and examined with a Philips 201 
electron microscope.  
4. Conclusions 
Cancer can be measured as a complex multistep pathology that requires the accumulation of 
several mutations giving to cells an aberrant proliferative advantage, improved resistance to 
pro-apoptotic stimuli and loss of differentiation markers. Increasing evidences underline the 
importance of the tumor microenvironment in the growth of cancer cells. Since it has been 
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shown to exert both pro- and anti-tumoral effects, the role of the immune system in fighting 
cancer progression has been contradictory. Due to the simplicity of genetic manipulations, 
Drosophila research could bring meaningful insights to our understanding of the 
mechanisms of communication between cancerous and normal cells, as well as between the 
tumor tissue and the immune system. Although it still remained unclear if the Manf gene 
from Drosophila is a true oncogene or a tumor-suppressor gene, we assumed that DmManf 
gene could play a particular function in the process and probably other additional 
mutations are simultaneously needed for the cancerous phenotype to become visible. Efforts 
to use Drosophila to explore issues specific to cancer will keep on growing. Drosophila is 
being used for what it does best: identifying novel oncogenes and tumor suppressors, and 
linking cancer-related genes together into complex signaling pathways [9]. The use of whole 
organisms in vivo is generally considered as being essential for understanding the 
tumorigenesis.  
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1. Introduction 
1.1. c-fms and breast cancer 
In the development and progression of breast cancers, both the c-fms proto-oncogene (which 
encodes the tyrosine kinase receptor for CSF-1) as well as CSF-1 (colony stimulating factor-
1), play an important role. Evidence from transgenic models suggests that c-fms encodes for 
the sole receptor for CSF-1 (Dai et al, 2002). We and others have found that c-fms and/or CSF-
1 are expressed by the tumor epithelium in several human epithelial cancers (Kacinski et al, 
1988, 1990, 1991;  Rettenmier et al, 1989; Filderman et al, 1992; Ide et al, 2002); elevated levels 
of c-fms and CSF-1 are associated with poor prognosis (Kacinski et al, 1988;  Tang et al, 1990; 
Price et al, 1993; Chambers  et al, 1997, 2009; Scholl et al, 1993; Kluger et al, 2004; Sapi 2004). In 
human breast cancer, 94% of in situ and invasive lesions express c-fms (Kacinski et al, 1991; 
Flick et al, 1997), while 36% express both CSF-1 and c-fms (Kacinski et al, 1991; Scholl et al, 
1993). Among breast cancer patients, serum levels of CSF-1 are frequently elevated in those 
with metastases (Kacinski et al, 1991). In breast tumors, nuclear CSF-1 staining is associated 
with poor survival (Scholl et al, 1994), and c-fms expression confers an increased risk for local 
relapse (Maher et al, 1998). In a large breast cancer tissue array, c-fms (Kluger et al, 2004) is 
strongly associated with lymph node metastasis, and poor survival. This strong correlation 
with prognosis suggests an etiologic role for c-fms/CSF-1 in tumor invasion and metastasis.  
Tumor-associated macrophages bearing CSF-1 promote progression of breast cancer 
(Pollard 2004). In mice bearing human breast cancer xenografts, targeting mouse (host) c-fms 
with siRNA, or CSF-1 with antisense, siRNA or antibody suppressed primary tumor growth 
by 40-50% (Aharinejad et al, 2004; Paulus et al, 2006), and improved their survival 
(Aharinejad et al, 2004). Hence, paracrine signaling by macrophages bearing CSF-1 also 
plays a critical role in breast cancer progression. Transgenic models suggest that the absence 
 The Author(s). Lic n ee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
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of CSF-1 results in delay of tumor invasion and metastasis, while targeting CSF-1 to 
mammary epithelium in these models enables macrophage infiltration and invasive breast 
cancer to develop and metastasize (Lin et al, 2001). 
We have reported that glucocorticoids (GC) up-regulate c-fms expression both in breast 
cancer cells (Kacinski et al, 1991; Flick et al, 2002; Sapi et al, 1995), and in primary organ 
cultures of breast cancer specimens (Kacinski et al, 2001). In a study of 329 breast cancer 
patients, 52% of the breast cancer tissues had functional glucocorticoid receptor (GR) 
(Allegra et al, 1979). This allows for breast cancer responsiveness to circulating, endogenous 
GCs.  
In the in vivo environment, with endogenous GCs, we observed extensive metastatic spread 
by breast cancer cells over-expressing c-fms, compared to controls (Toy et al, 2005). 
Parenchymal invasion was demonstrated only by the c-fms overexpressing cells. 
Interrupting the autocrine loop between c-fms and CSF-1 inhibits GC-stimulated 
invasiveness, motility, and adhesiveness in vitro of breast cancer cells (Toy et al, 2010). This 
mechanism of increasing c-fms by GC becomes aberrantly up-regulated in invasive, 
metastatic breast cancer.  
1.2. Regulation of c-fms expression 
Regulation of c-fms expression is a complex process. Both transcriptional and post-
transcriptional regulations are involved to maintain a proper level of c-fms expression. This 
chapter summarizes the research over the last 20 years concerning post-transcriptional 
regulation of c-fms and its expression in breast cancer. 
1.3. Stability of c-fms transcripts in breast cancer cells 
c-fms expression is high in metastatic breast cancer cells, but not detectable in the normal 
breast cells and non-invasive precursors of breast neoplasms (Kacinski et al, 1988, 1990). 
Unusually long half-life of c-fms mRNA partially contributes high expression in metastatic 
breast cancer cells (Chambers et al, 1994, Woo et al, 2011). GCs increase the c-fms mRNA 
half-life from 9.6 h to 18.9 h in BT20 breast cancer cells (Woo et al, 2011). In highly invasive 
MDA-MB-231 breast cancer cells, c-fms mRNA half-life increases up to 27 h in response to 
GC treatment (Figure 1). 
1.4. Post-transcriptional regulation of c-fms expression by 3’UTR 
mRNA 3’UTR contains cis-acting regulatory sequences which are involved in regulation of 
mRNA stability and polyadenylation (Mignone et al, 2003; Bashirullah et al, 2001), mRNA 
degradation (Bevilacqua et al, 2003), translation, and subcellular localization of mRNAs 
(Loya et al, 2008; Jansen, 2001). Mutations in 3’UTR could result in diseases and are 
proposed as ‘a molecular hotspot for pathology (Chen et al, 2006; Conne et al, 2000). Post-
transcriptional regulation exerted by 3’UTR is considered an important counterpart to 
transcriptional regulation for maintaining the proper level of gene products in the cell.  
 








Probe – free probe, yRNA – yeast RNA as negative control, Total RNA was isolated after dexamethasone treatment at 
the indicated time. 
Figure 1. RNase protection analysis of c-fms mRNA in MDA-MB-231 cells treated by 400 nM 
dexamethasone. 
Human c-fms mRNA 3’UTR encodes 774 nt and contains unique regions including a non-
AU-rich-69 nt sequence (3499-3567) which we have described and characterized (Woo et al, 
2009, 2011), and also several putative target sequences for miRNA binding (Figure 2). The 69 
nt sequence contains 3 islets of pyrimidine-rich sequences (CUUU). Mutations in these 
pyrimidine-rich sequences in 69 nt disrupted vigilin and HuR binding (Woo et al, 2009, 
2011). 
In metazoans, the 69 nt sequence within the 3'-UTR of c-fms mRNA is partially conserved 
between human, mouse, and rat (Figure 2). This region does not contain conventional AU-
rich elements (ARE) (Woo et al, 2009). Overall, the 69 nt sequence is slightly pyrimidine-rich 
(>57-61%) and we proposed that primary sequence as well as loop structure may be 
important for protein binding (Woo et al, 2011; Kanamori et al, 1998). Indeed, this 69 nt 
region is predicted to form a stable loop structure (Figure 3). 
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The 69 nt sequence (3499-3567) is partially conserved in human, rat, and mouse. 
Figure 2. Alignment of c-fms mRNA 3’UTRs of human, rat, and mouse. Six regions are predicted as 
targets by eight miRNAs.  
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Figure 3. RNA loops of 69 nt are predicted by mfold (http://mfold.rna.albany.edu/?q=mfold). 
1.5. microRNAs for c-fms mRNA regulation 
MicroRNAs (miRNAs) are 21-23 nucleotide single-stranded RNAs, that in general down-
regulate translation and enhance mRNA degradation (Huntzinger and Izaurralde, 2011; 
Braun et al, 2011). As a consequence, miRNAs are involved in the regulation of several 
biological functions (differentiation, hematopoiesis, tumorigenesis, apoptosis, development, 
proliferation, and growth) (Kim, 2005). They are predicted to regulate more than 60% of 
human mRNA (Friedman et al, 2009). It has been found that mRNAs with long 3’UTRs are 
more susceptible to miRNA regulation than those with short 3’UTRs as the latter lack the 
number of binding sites necessary for multiple miRNA binding and regulation (Stark et al, 
2005). 
Bioinformatics analysis predicted eight miRNAs (miR-339-5p, miR-449, miR-34, miR-610, 
miR-22, miR-134, miR-155, and miR-217) targeting six regions in c-fms mRNA 3’UTR (Figure 
2). These six target regions are also highly conserved in human, mouse and rat. Among 
those, two miRNAs (miR-610 and miR-155) were selected by us for further analysis. C-fms 
mRNA level is higher in BT20 epithelial breast cancer cells than in Hey epithelial ovarian 
cancer cells (Figure 4). In contrast, miR-610 and miR-155 RNA levels show opposite 
expression patterns with their RNA levels lower in BT20 than in Hey cells. Using a 
luciferase RNA-fused c-fms mRNA 3’UTR reporter system, introduction of miR-610 
inhibitors in BT20 cells increased luciferase RNA level by 5.5-fold and luciferase activity by 
1.3-fold. The down-regulation of mir-610 has more effects on luciferase RNA levels than 
translational repression. Some reports describe miRNA effects to be mainly on translational 
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repression, while others describe an effect primarily on mRNA decay. Guo et al (2010) 
reported that the predominant effect of mammalian miRNAs is on mRNA decay which 
results reduced translation. In contrast, in zebrafish, miR-430 reduced translation initiation 
prior to inducing mRNA decay (Bazzini et al, 2012). Djuranovic et al (2012) reported miRNA-
mediated translational repression is followed by mRNA deadenylation. Recently, the 
concept of mRNA destabilization by miRNAs gained support by genome-wide observation 
studies (Huntzinger and Izaurralde, 2011).  
 
Figure 4. (A) c-fms mRNA level is higher in BT20 than in Hey cells. (B) miR-610 RNA level is higher in 
Hey than in BT20 cells. (C) miR-155 RNA level is higher in Hey than BT20 cells. (D) Using a luciferase 
RNA-fused c-fms mRNA 3’UTR reporter system, introduction of miR-610 inhibitor increased luciferase 
RNA level by 5.5-fold and (E) luciferase activity by 1.3-fold in BT20 cells.  
1.6. RNA-binding proteins for c-fms mRNA metabolism and translation 
The first evidence supporting post-transcriptional regulation of c-fms mRNA by RNA-
binding proteins was reported in human monocytes (HL-60 cells) (Weber et al, 1989). In their 
study, TPA (12-O-tetradecanoylphorbol-13-acetate)-induced monocytic differentiation did 
not change c-fms transcription, but increased c-fms mRNA level. In addition, treatment of 
protein synthesis inhibitor cycloheximide decreased half-life of c-fms mRNA in TPA-
induced HL-60 cells. From this observation, they proposed that a labile protein(s) is 
involved in stabilization of c-fms mRNA.  
Chambers et al. (1993) reported the existence of mRNA regulatory proteins involved in c-fms 
mRNA destabilization in dexamethasone (Dex) or cyclosporin A (CsA) treated HL-60 cells. 
Dex or CsA blocked TPA-induced monocytic differentiation as well as TPA-induced 
adherence and further differentiated morphology. In TPA-induced HL-60 cells, c-fms mRNA 
half life was decreased after the addition of Dex or CsA. The effects of cycloheximide of c-
fms mRNA decay in this setting suggested the existence of labile destabilizing protein(s). 
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Furthermore, in breast carcinoma cells (BT20 and SKBR3), Dex-treatment at later time points 
increased c-fms mRNA level without affecting c-fms transcription. Addition of protein 
synthesis inhibitors prevented Dex-induced increase of c-fms mRNA level suggesting the 
presence of Dex-inducible stabilizing protein(s) in breast carcinoma cells (Chambers et al, 
1994). 
RNA-binding proteins: About 1,500 RNA-binding proteins (RBPs) have been identified, 
which bind to mRNA and modulate mRNA stability and translation. mRNA primary 
sequences as well as loop structures are known to facilitate regulatory protein binding for 
post-transcriptional regulation.  
HuR – HuR, one of the most extensively studied RBPs, encoded by ELAVL1 (embryonic 
lethal, abnormal vision, Drosophila-like 1) binds cis-acting AU-rich elements (AREs) (Barreau 
et al, 2005) and also non-ARE-containing sequences including pyrimidine-rich sequences 
(Woo et al, 2009) in target mRNAs. HuR stabilizes and increases half-life of target mRNAs 
and therefore enhances their translation (Srikantan and Gorospe, 2011). Our study indicates 
that HuR binds c-fms mRNA 3’UTR and enhances mRNA stability and translation (Woo et 
al, 2009). 
In human breast-cancer tissues, HuR is expressed mostly in nucleus (>90%), but expression 
in cytoplasm is also found. High nuclear expression of HuR is a poor prognostic factor both 
in breast and ovarian cancer (Woo et al, 2009; Yi et al, 2009).   
Vigilin – Vigilin, a high-density lipoprotein-binding protein, contains 15 K-homology (KH) 
domains (Goolsby and Shapiro, 2003). The KH domain protein family interacts with ARE-
containing mRNAs and enhances mRNA degradation and consequently down-regulates  
 
Figure 5. (A) Metabolic labeling and immunoprecipitation of CSF-1R. (B) Immunoblot of Vigilin in both 
nuclear (Nuc) and cytoplasmic (Cyto) fractions of MCF10A and MDA-MB-231BO cells. Absence of 
tubulin in nuclear fraction and presence of tubulin in cytoplasmic fraction indicate no cross-
contamination in both fractions. 
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repression, while others describe an effect primarily on mRNA decay. Guo et al (2010) 
reported that the predominant effect of mammalian miRNAs is on mRNA decay which 
results reduced translation. In contrast, in zebrafish, miR-430 reduced translation initiation 
prior to inducing mRNA decay (Bazzini et al, 2012). Djuranovic et al (2012) reported miRNA-
mediated translational repression is followed by mRNA deadenylation. Recently, the 
concept of mRNA destabilization by miRNAs gained support by genome-wide observation 
studies (Huntzinger and Izaurralde, 2011).  
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translation (Gherzi et al, 2004). In contrast, vigilin interacts largely with unstructured 
pyrimidine-rich sequences in mRNA 3’UTR (Kanamori et al, 1998; Woo et al, 2011). We 
found that vigilin decreases c-fms mRNA half-life and down-regulates translation. Ectopic 
expression of vigilin in breast cancer cells showed that the effects of down-regulation is 
more pronounced on c-fms protein level than on the mRNA level (Woo et al, 2011). Metabolic 
labeling and immunoprecipitation of c-fms protein showed that vigilin overexpression 
down-regulated c-fms protein level in BT20 cells (Figure 5A). In contrast, suppression of 
vigilin by shRNA up-regulated c-fms protein level. 
Furthermore, immunoblot analysis showed that vigilin expression was lower in metastatic 
breast cancer MDA-MB-231BO cells than in non-tumorigenic epithelial breast MCF10A cells 
(Figure 5B). This indicates that a possible suppressive role of vigilin in invasive characters of 
breast cancer cells.  
Both in vitro and in vivo studies indicate that vigilin and HuR competitively bind to the 
pyrimidine-rich 69 nt sequence of c-fms mRNA 3’UTR (Figure 4, Woo et al, 2009, 2011). In 
vitro competition assay showed that affinity of vigilin to the 69 nt sequence is at least 3-fold 
higher than that of HuR (Figure 6).  
 
Figure 6. (A) Competition assay between vigilin and HuR by UV crosslink. (B) Co-
immunoprecipitation assay. Vigilin and HuR do not present in the same mRNP complexes. IP assays 
were carried out using cellular lysates from MDA-MB-231 cells in either RNase-free or RNase-treated 
conditions using anti-human HuR mAb, or IgG. The presence of HuR in the IP materials was monitored 
by immunoblot. H.C. – heavy chain of IgG. L.C. – Light chain of IgG. 
1.7. Effects of HuR and vigilin on invasiveness of breast cancer cells 
Increased c-fms/CSF-1 levels correlate with the invasive breast cancer phenotype, and with 
prognosis (Toy, 2005; Toy et al, 2010; Sapi, 2004; Kluger et al, 2004; Scholl et al, 1994, 1993; 
Maher et al, 1998). We studied the ability of BT20 breast cancer cells to invade through a 
human derived simple matrix in vitro. The invasion of BT20 cells was significantly inhibited 
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by the over-expression of vigilin, resulting in a 48% decrease compared to control (Figure 7). 
In contrast, over-expression of HuR increased invasiveness by 34%. Our findings suggest 
that vigilin can negatively impact, through suppression of c-fms expression, breast cancer 
cell invasiveness. In contrast, HuR enhances breast cancer cell invasiveness. 
 
Figure 7. Vigilin and HuR regulate in vitro invasiveness of BT20 breast cancer cells. This findings 
correlate with relative c-fms expression. 
1.8. Post-translational modification: dimerization and tyrosine-phosphorylation 
of CSF-1R activation of PIP3/Akt signal transduction pathway 
Activation of CSF-1R, product of the c-fms gene, requires ligand-induced non-covalent 
dimerization and phosphorylation of tyrosine residues in CSF-1R (Xiong et al, 2011; Li and 
Stanley, 1991). Here, we focus on one of the major signaling transduction pathways which 
result from CSF-1R activation. Phosphorylated CSF-1R interacts with PI3K 
(Phosphatidylinositol 3-kinases) (Shurtleff et al, 1990). In turn, PI3K converts PIP2 
(Phosphatidylinositol-3,4-bisphosphate) to PIP3 (Phosphatidylinositol-3,4,5-tisphosphate). 
PIP3 interacts with Akt (protein kinase B, PBK), and activates downstream components in 
the PIP3/Akt signaling pathway. As a result, several physiological consequences are 
regulated including cell proliferation, apoptosis, and growth. An activated PIP3/Akt 
pathway is a common event in human cancer. (Arcaro and Guerreiro, 2007). 
In breast cancer cells, multiple components are known to activate phosphorylation of CSF-
1R. Endogenous cytokine CSF-1, functioning as an autocrine signal, can bind to the 
extracellular domain of CSF-1R and activate the cytoplasmic kinase domain leading to 
autophosphorylation of tyrosine-residues in CSF-1R. There is evidence to suggest that 
endogenous CSF-1 can also bind CSF-1R without interaction on the membrane surface. 
Exogenous CSF-1, from other sources such as macrophages, osteoclasts, or fibroblasts, can 
function in a paracrine manner to activate CSF-1R on the membrane surface. Consequently, 
phosphorylation of tyrosine residues in CSF-1R activates cell proliferation and invasive 
potential (Yu et al, 2012; Sapi et al, 1996). Our study indicates glucocorticoids 
(dexamethasone) and starvation also activate CSF-1R auto-phosphorylation (Figure 8).  
CSF-1R is localized both in the cytoplasm, plasma membrane, and nuclear envelope 
(Zwaenepoel et al, 2012). CSF-1R in the nuclear envelope becomes phosphorylated in 
response to CSF-1. Phosphorylated CSF-1R in the nuclear envelope triggers the 
phosphorylation of Akt and p27 inside the nucleus. 
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by the over-expression of vigilin, resulting in a 48% decrease compared to control (Figure 7). 
In contrast, over-expression of HuR increased invasiveness by 34%. Our findings suggest 
that vigilin can negatively impact, through suppression of c-fms expression, breast cancer 
cell invasiveness. In contrast, HuR enhances breast cancer cell invasiveness. 
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of CSF-1R activation of PIP3/Akt signal transduction pathway 
Activation of CSF-1R, product of the c-fms gene, requires ligand-induced non-covalent 
dimerization and phosphorylation of tyrosine residues in CSF-1R (Xiong et al, 2011; Li and 
Stanley, 1991). Here, we focus on one of the major signaling transduction pathways which 
result from CSF-1R activation. Phosphorylated CSF-1R interacts with PI3K 
(Phosphatidylinositol 3-kinases) (Shurtleff et al, 1990). In turn, PI3K converts PIP2 
(Phosphatidylinositol-3,4-bisphosphate) to PIP3 (Phosphatidylinositol-3,4,5-tisphosphate). 
PIP3 interacts with Akt (protein kinase B, PBK), and activates downstream components in 
the PIP3/Akt signaling pathway. As a result, several physiological consequences are 
regulated including cell proliferation, apoptosis, and growth. An activated PIP3/Akt 
pathway is a common event in human cancer. (Arcaro and Guerreiro, 2007). 
In breast cancer cells, multiple components are known to activate phosphorylation of CSF-
1R. Endogenous cytokine CSF-1, functioning as an autocrine signal, can bind to the 
extracellular domain of CSF-1R and activate the cytoplasmic kinase domain leading to 
autophosphorylation of tyrosine-residues in CSF-1R. There is evidence to suggest that 
endogenous CSF-1 can also bind CSF-1R without interaction on the membrane surface. 
Exogenous CSF-1, from other sources such as macrophages, osteoclasts, or fibroblasts, can 
function in a paracrine manner to activate CSF-1R on the membrane surface. Consequently, 
phosphorylation of tyrosine residues in CSF-1R activates cell proliferation and invasive 
potential (Yu et al, 2012; Sapi et al, 1996). Our study indicates glucocorticoids 
(dexamethasone) and starvation also activate CSF-1R auto-phosphorylation (Figure 8).  
CSF-1R is localized both in the cytoplasm, plasma membrane, and nuclear envelope 
(Zwaenepoel et al, 2012). CSF-1R in the nuclear envelope becomes phosphorylated in 
response to CSF-1. Phosphorylated CSF-1R in the nuclear envelope triggers the 
phosphorylation of Akt and p27 inside the nucleus. 
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Figure 8. (A) Signal transduction through pCSF-1R/PI3K regulates cell growth and angiogenesis. Both 
autocrine and paracrine signals (sCSF-1, glucocorticoids, and starvation) trigger dimerization and 
autophosphorylation of CSF-1R, which interacts with PI3K. The PI3K generates PIP3, which binds to 
Akt. Activation of PIP3/Akt activates downstream components and regulates growth, apoptosis and cell 
cycle. (B) Dexamethasone induces autophosphorylation of CSF-1R in starved MDA-MB-231 cells. 
2. Discussion 
Post-transcriptional and translational regulation of c-fms expression by vigilin and HuR 
in breast cancer cells: mRNA translation and decay are complex multi-staged processes. 
Mature mRNAs either enter translation or degradation pathways depending on the 
developmental stages of the cell. We have reported vigilin and HuR, both nuclear-
cytoplasmic shuttling RNA-binding proteins, to be involved in post-transcriptional as well 
as translational regulation of c-fms mRNA (Woo et al, 2009, 2011). Vigilin binds the 
pyrimidine-rich 69 nt sequence in the c-fms mRNA 3’UTR, to which HuR also binds. Both in 
vitro and in cell studies indicate that they compete for the same 69 nt sequence in the c-fms 
mRNA 3’UTR and that dynamic changes in the ratio of vigilin to HuR can influence their 
ability to associate with the c-fms mRNA and post-transcriptionally regulate cellular c-fms 
levels. While vigilin down-regulates c-fms translation as well as mRNA stability, HuR, in 
contrast, has opposite effect on c-fms levels; i.e., HuR up-regulates c-fms mRNA stability 
resulting increased c-fms protein levels. In our previous study, the polysome profile 
indicates vigilin is associated with free mRNPs and low MW monosomes. In contrast, HuR 
was detected with high MW polysomes (Woo et al, 2011). Vigilin also represses translation 
of reporter RNA (luciferase RNA fused with c-fms mRNA 3’UTR sequence) in the rabbit 
reticulocyte lysate cell-free translation system (Woo et al, 2011).  
Translation can be divided in three phases; initiation, elongation, and termination. 
Translation initiation is a complicated process for which a large number of eukaryotic 
initiation factors (eIFs) have been identified (Sonnenberg and Hinnebusch, 2009). 
Translation initiation starts with the assembly of a 48S quaternary initiation complex 
comprised of the 40S ribosomal subunit, eIFs, tRNAMet, and m7G cap of the mRNA.  In 
general, this 48S initiation complex scans and base pairs with the AUG initiation codon in 
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5’UTR of mRNA. This results in formation of the 80S ribosome and is continued in the 
elongation step of peptide synthesis.    
In a ‘closed-loop’ mRNP model for cap-dependent translational regulation, PABPs bind both to the 
poly A+ tail at the 3’UTR and eIF4G of the translation initiation complex at the 5’-cap 
(Huntzinger and Izaurralde, 2011). This mRNA circularization attracts ribosomes to form a 
translation initiation complex. Subsequently, after translation termination, joining of the 5’- 
and 3’-ends of the mRNA facilitates the transfer of ribosomal subunits from the 3’ to the 5’-
end.  
Our results have demonstrated presence of vigilin in free mRNP fractions in human BT20 
breast cancer cells. While vigilin association with free mRNPs may prevent ‘closed-loop’ 
formation and consequently inhibit c-fms protein translation, it was also found to associate 
with tRNAs and elongation factors (Kruse et al, 2003; Vollbrandt et al, 2004). Binding of 
vigilin with these components may deplete the available tRNAs and elongation factors for 
translation elongation. We propose a model that the impaired translation resulting from 
vigilin binding may expose both 5’- and 3’-ends of the mRNA through reduced 
circularization and increase its rate of degradation (Figure 9). In contrast, we propose that 
HuR binding to c-fms mRNA 3’UTR may enhance ‘closed-loop’ formation which increases 
the c-fms mRNA stability and also translation initiation efficiency. Immunoblot analysis 
indicates that vigilin is, in general, less expressed in breast cancer cells than in non-
tumorigenic breast cells (Woo et al, 2011). This indicates that down-regulation of vigilin may 
be partly responsible for increased c-fms level in breast cancer cells. In summary, RNA 
binding proteins, such as vigilin and HuR are critical regulators for determining the fate of 
proto-oncogene c-fms mRNA, either to be translated or decayed.  
 
Figure 9. Competition between HuR and vigilin for binding 69 nt of c-fms mRNA 3’UTR regulates 
translational machinery formation. Binding of HuR to 69 nt may induce ‘closed-loop’ formation. In 
contrast, binding of vigilin to 69 nt could prevent ‘closed-loop’ formation. 
Future research in post-transcriptional and translational regulation of c-fms in breast 
cancer: Translational inhibition and mRNA degradation are coordinated processes in which 
translation initiation is inhibited and translation factors (eIFs) are exchanged with 
repression/degradation complex (hDcp1/2, Hedls) (Fenger et al, 2005), resulting in mRNA 
degradation by exonucleases (Xrn1 and exosomes) (Balagopal and Parker, 2009). In general, 
3’-deadenylation leads to 5’-decapping followed by exonucleolytic digestion at either ends 
 
Oncogene and Cancer – From Bench to Clinic 304 
 
Figure 8. (A) Signal transduction through pCSF-1R/PI3K regulates cell growth and angiogenesis. Both 
autocrine and paracrine signals (sCSF-1, glucocorticoids, and starvation) trigger dimerization and 
autophosphorylation of CSF-1R, which interacts with PI3K. The PI3K generates PIP3, which binds to 
Akt. Activation of PIP3/Akt activates downstream components and regulates growth, apoptosis and cell 
cycle. (B) Dexamethasone induces autophosphorylation of CSF-1R in starved MDA-MB-231 cells. 
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Translation initiation is a complicated process for which a large number of eukaryotic 
initiation factors (eIFs) have been identified (Sonnenberg and Hinnebusch, 2009). 
Translation initiation starts with the assembly of a 48S quaternary initiation complex 
comprised of the 40S ribosomal subunit, eIFs, tRNAMet, and m7G cap of the mRNA.  In 
general, this 48S initiation complex scans and base pairs with the AUG initiation codon in 
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5’UTR of mRNA. This results in formation of the 80S ribosome and is continued in the 
elongation step of peptide synthesis.    
In a ‘closed-loop’ mRNP model for cap-dependent translational regulation, PABPs bind both to the 
poly A+ tail at the 3’UTR and eIF4G of the translation initiation complex at the 5’-cap 
(Huntzinger and Izaurralde, 2011). This mRNA circularization attracts ribosomes to form a 
translation initiation complex. Subsequently, after translation termination, joining of the 5’- 
and 3’-ends of the mRNA facilitates the transfer of ribosomal subunits from the 3’ to the 5’-
end.  
Our results have demonstrated presence of vigilin in free mRNP fractions in human BT20 
breast cancer cells. While vigilin association with free mRNPs may prevent ‘closed-loop’ 
formation and consequently inhibit c-fms protein translation, it was also found to associate 
with tRNAs and elongation factors (Kruse et al, 2003; Vollbrandt et al, 2004). Binding of 
vigilin with these components may deplete the available tRNAs and elongation factors for 
translation elongation. We propose a model that the impaired translation resulting from 
vigilin binding may expose both 5’- and 3’-ends of the mRNA through reduced 
circularization and increase its rate of degradation (Figure 9). In contrast, we propose that 
HuR binding to c-fms mRNA 3’UTR may enhance ‘closed-loop’ formation which increases 
the c-fms mRNA stability and also translation initiation efficiency. Immunoblot analysis 
indicates that vigilin is, in general, less expressed in breast cancer cells than in non-
tumorigenic breast cells (Woo et al, 2011). This indicates that down-regulation of vigilin may 
be partly responsible for increased c-fms level in breast cancer cells. In summary, RNA 
binding proteins, such as vigilin and HuR are critical regulators for determining the fate of 
proto-oncogene c-fms mRNA, either to be translated or decayed.  
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of mammalian poly-A+-mRNAs (Franks and Lykke-Anderson, 2008; Zheng et al, 2008). In 
human cells, deadenylation is initiated by deadenylase complex (Pan2/3, Caf1, and Ccr4) 
(Zheng et al, 2008). Deadenylated oligo(A) mRNPs are further processed by decapping 
complex (including Xrn1 for 5’-to-3’ decay) or exosomes (for 3’-to-5’ decay). In yeast, 
decapping activators (Dhh1, Pat1, Lsm1-7, Edc1-3, Scd6) were identified which enhance 
decapping (Nissan et al, 2010). Mutated or excess nontranslating mRNAs are stored and 
degraded in processing bodies (P-bodies, GW-bodies, or Dcp-bodies) and/or stress granules 
(SGs). During inhibition of translation initiation, elevated numbers of P-bodies and SGs are 
observed (Shyu et al, 2008). Nontranslating mRNPs accumulate both in P-bodies and SGs. 
Decapping complex (hDcp1/2, Hedls) and mRNA decay fragments are found in P-bodies 
suggesting presence of 5’-to-3’ exonuclease activities (Xrn1). Deadenylation complex 
(Pan2/3, Caf1, Ccr4) is also present in mouse P-bodies. On the other hand, translation 
initiation components (eIFs) and RNA-binding proteins (Ataxin-2, Pab1, TIA-R, TIA-1) are 
found in SGs (Buchan and Parker, 2009). Another very important aspect of mRNA stability 
is mRNA binding proteins. They can stimulate decapping and degradation processes. Over-
expression of cold-inducible RNA-binding protein (CIRP), which represses translation, 
induces SGs (De Leeuw et al, 2007). In contrast, HuR was shown to release translational 
repression by helping human mRNA associated with P-bodies to re-enter polysomes 
(Bhattacharyya et al, 2006). In mammalian cells, P-bodies and SGs often dock together 
during translation inhibition. Since vigilin was shown to repress c-fms translation, it is 
crucial to understand mechanisms of transitions of c-fms mRNPs between P-bodies, SGs and 
 
Figure 10. Proposed model for post-transcriptional regulation of c-fms by HuR and vigilin. HuR 
enhances closed-loop formation and increases c-fms mRNA stability and translation. In contrast, vigilin 
prevent closed-loop formation and attracts mRNA degradation complex and down-regulates 
translation. SG – stress granule 
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polysomes. A model for these mechanisms is proposed in Figure 10. Elucidating the 
molecular mechanisms of these exchanges from one state to another is critical to the 
understanding of regulation of c-fms protein levels in breast cancer. 
3. Conclusion 
In the design of clinical therapeutics, suppression of pathogenic gene expression requires 
high specificity to prevent off-target toxicity. In order to achieve this, detailed regulatory 
mechanisms of target gene expression should be elucidated. Understanding the regulatory 
mechanisms and specific proteins through which vigilin effects translational down-
regulation of proto-oncogene c-fms in breast cancer can result in more accurate control of its 
expression. 
Based on information available from the last 20 years of research and our recent data, it is 
now possible to elucidate vigilin’s role in translational down-regulation of c-fms mRNA in 
breast cancer. Information obtained from this research will support a model on the manner 
in which interaction between a specific mRNA (c-fms) and proteins (vigilin and HuR) 
regulates c-fms at a translational level. These findings will bring us one step closer to 
development of a targeted therapy based on these mechanisms. 
4. Methods 
4.1. Cell culture 
A human breast carcinoma cell line BT20 was maintained in MEM (Sigma) supplemented 
with 0.1 mM non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, 1.5 g/L 
sodium bicarbonate, and 10% fetal bovine serum (Invitrogen) in 5% CO2 at 37°C. A human 
breast carcinoma cell line MDA-MB-231 was cultured in DMEM (Sigma) supplemented with 
10% fetal bovine serum. For studies using glucocorticoids, cells were grown in starvation 
medium with 100 nM Dex (Sigma-Aldrich) for 72 h and collected for immunoblot analysis. 
A human ovarian cancer cell line Hey was grown in DMEM/F12 (Sigma) supplemented with 
10% fetal bovine serum. 
4.2. Total RNA isolation for semi-quantitative real-time RT-PCR analysis 
Cells were grown in 6-well plate for 2-3 days before harvesting. Total RNA was extracted 
with 500 ul Trizol (Invitrogen) per well. After Trizol extraction, 150 ul of supernatant was 
carefully removed to avoid genomic DNA contamination. Supernatant was re-extracted by 
equal volume of chloroform and 100 ul of supernatant was carefully removed and ethanol 
precipitated for cDNA synthesis.  
4.3. Semi-quantitative real-time RT-PCR analysis for c-fms mRNAs 
Total RNA was oligo-dT18 primed by M-MuLV reverse transcriptase (New England Biolab). 
For PCR analysis, reverse transcriptase reaction was diluted by 10-fold and 2 ul was used for 
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of mammalian poly-A+-mRNAs (Franks and Lykke-Anderson, 2008; Zheng et al, 2008). In 
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suggesting presence of 5’-to-3’ exonuclease activities (Xrn1). Deadenylation complex 
(Pan2/3, Caf1, Ccr4) is also present in mouse P-bodies. On the other hand, translation 
initiation components (eIFs) and RNA-binding proteins (Ataxin-2, Pab1, TIA-R, TIA-1) are 
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induces SGs (De Leeuw et al, 2007). In contrast, HuR was shown to release translational 
repression by helping human mRNA associated with P-bodies to re-enter polysomes 
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during translation inhibition. Since vigilin was shown to repress c-fms translation, it is 
crucial to understand mechanisms of transitions of c-fms mRNPs between P-bodies, SGs and 
 
Figure 10. Proposed model for post-transcriptional regulation of c-fms by HuR and vigilin. HuR 
enhances closed-loop formation and increases c-fms mRNA stability and translation. In contrast, vigilin 
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polysomes. A model for these mechanisms is proposed in Figure 10. Elucidating the 
molecular mechanisms of these exchanges from one state to another is critical to the 
understanding of regulation of c-fms protein levels in breast cancer. 
3. Conclusion 
In the design of clinical therapeutics, suppression of pathogenic gene expression requires 
high specificity to prevent off-target toxicity. In order to achieve this, detailed regulatory 
mechanisms of target gene expression should be elucidated. Understanding the regulatory 
mechanisms and specific proteins through which vigilin effects translational down-
regulation of proto-oncogene c-fms in breast cancer can result in more accurate control of its 
expression. 
Based on information available from the last 20 years of research and our recent data, it is 
now possible to elucidate vigilin’s role in translational down-regulation of c-fms mRNA in 
breast cancer. Information obtained from this research will support a model on the manner 
in which interaction between a specific mRNA (c-fms) and proteins (vigilin and HuR) 
regulates c-fms at a translational level. These findings will bring us one step closer to 
development of a targeted therapy based on these mechanisms. 
4. Methods 
4.1. Cell culture 
A human breast carcinoma cell line BT20 was maintained in MEM (Sigma) supplemented 
with 0.1 mM non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, 1.5 g/L 
sodium bicarbonate, and 10% fetal bovine serum (Invitrogen) in 5% CO2 at 37°C. A human 
breast carcinoma cell line MDA-MB-231 was cultured in DMEM (Sigma) supplemented with 
10% fetal bovine serum. For studies using glucocorticoids, cells were grown in starvation 
medium with 100 nM Dex (Sigma-Aldrich) for 72 h and collected for immunoblot analysis. 
A human ovarian cancer cell line Hey was grown in DMEM/F12 (Sigma) supplemented with 
10% fetal bovine serum. 
4.2. Total RNA isolation for semi-quantitative real-time RT-PCR analysis 
Cells were grown in 6-well plate for 2-3 days before harvesting. Total RNA was extracted 
with 500 ul Trizol (Invitrogen) per well. After Trizol extraction, 150 ul of supernatant was 
carefully removed to avoid genomic DNA contamination. Supernatant was re-extracted by 
equal volume of chloroform and 100 ul of supernatant was carefully removed and ethanol 
precipitated for cDNA synthesis.  
4.3. Semi-quantitative real-time RT-PCR analysis for c-fms mRNAs 
Total RNA was oligo-dT18 primed by M-MuLV reverse transcriptase (New England Biolab). 
For PCR analysis, reverse transcriptase reaction was diluted by 10-fold and 2 ul was used for 
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20 ul PCR reaction. GAPDH mRNA was amplified in PCR reaction as internal loading 
control.  
c-fms PCR primers (forward primer = 5’-GGAGTTGACGACAGGGAGTACCAC-3’, reverse 
primer = 5’- ACGAGGCCAACACCATGAGAACAG-3’).  
GAPDH PCR primers (forward primer = 5’-CGGGAAACTGTGGCGTGATGGC-3’, reverse 
primer = 5’-AGGAGACCACCTGGTGCTCAGTG-3’).  
c-fms mRNA expression level was calculated with the ∆∆CT method (Schmittgen and Livak, 
2008). 
4.4. Stem-loop real-time RT-PCR analysis for miR-610 and miR-155 
quantification 
miRNA expression was determined by the stem-loop qRT-PCR analysis to increase the 
specificity of miRNA amplification (Chen et al, 2005). cDNAs for miR-610, miR-155, and 
tRNAGlu specific were synthesized using sequence specific stem-loop forming primers. After 
10-fold dilution of reverse transcriptase reaction, 2 ul was used for 20 ul real-time PCR. 
tRNAGlu was used as internal loading control.  
miR-610 reverse transcription primer = 5’-gtcgtatccagtgcagggtccgaggtattcgcact 
ggatacgactcccag-3’) 
miR-610 PCR primers (forward primer = 5’- GGCGCTGAGCTAAATGTGTGC-3’, reverse 
primer = 5’- GTGCAGGGTCCGAGGT-3’) 
miR-155 reverse transcription primer = 5’- gtcgtatccagtgcagggtccgaggtattcgcact 
ggatacgacacccct-3’ 
miR-155 PCR primers (forward primer = 5’- GGCGCTTAATGCTAATCGTGATAG-3’, 
reverse primer = 5’- GTGCAGGGTCCGAGGT-3’) 
tRNAGlu reverse transcription primer = 5’- 
GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACT GGATACGAC GGTGAAAG-3’ 
tRNAGlu PCR primers (forward primer = 5’- CTGGTTAGTACTTGGACGGGAGAC -3’, 
reverse primer = 5’- gtgcagggtccgaggt -3’) 
4.5. Analysis of c-fms mRNA Half Life 
The c-fms mRNA half-life was determined by RNase protection assay (RPA) (Bordonaro et 
al, 1994). Radioactive-labeled antisense RNA probes of c-fms mRNA was generated by in 
vitro transcription. c-fms cDNA (237nt, 1789-2025) with 67nt random sequence and 23nt T7 
promoter at 3’-end was generated by PCR and used as a templete for in vitro transcription. 
Probes with specific activity of 1x105 cpm were hybridized with 10 g of total RNA in 
hybridization buffer (80% deionized formamide, 40 mM PIPES pH6.4, 400 mM NaCl, and 1 
mM EDTA) at 42oC overnight. Next morning, unbound RNA was digested by RNase A and 
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T1 at 37oC for 1 h. After proteinase K treatment at 37oC for 30 min, samples were extracted 
by phenol-chloroform and precipitated in ethanol. Samples were analyzed on a 5% 
acrylamide/8M urea gel and exposed on X-ray film. 
4.6. Metabolic labeling and immunoprecipitation of c-fms proteins 
The BT20 cultures at 75-80% confluence were washed with PBS and incubated in labeling 
medium (Met,Cys-free RPMI1640 (Sigma R-7513), 5% dialyzed FCS, 500ug/ml Glutamine) 
for 40 min to deplete endogenous methionine and cysteine in cell. For metabolic labeling, 5 
ml labeling medium and 50 ul (500 uCi) of 35S-Methionine/35S-Cysteine per T75 flask was 
added and incubated for 30-40 min. After brief chase in chase medium (labeling medium 
with 500µg/ml Cysteine-HCl and 100µg/ml Methionine), cells were harvested and lysed in 
IP buffer (1% Triton x-100, 0.05% NP-40 in TBS, protease inhibitors). For 
immunoprecipitation of c-fms proteins, 5 ug of c-fms monoclonal antibody and 50 µl of 
Protein A/G-agarose (50% slurrry) (Santa Cruz) were added to cell lysates and incubated 
overnight at 4oC. Next morning, agarose beads was washed extensively with IP buffer and 
protein was eluted by SDS sample buffer. Labeled protein was analyzed in 10% SDS-PAGE. 
4.7. Gain-of-function and loss-of-function assay 
Plasmids encoding a control shRNA or shRNA directed against vigilin were purchased from 
Origene. The shRNAs correspond to coding region nucleotides 614–642 (5'-AAGCTCG 
GAAGGACATTGTTGCTAGACTG-3') and 829–863 (5'-CATGAAGTCTTACTCATCTCTG 
CCGAGCAGGACAA-3'), respectively, of human vigilin (GenBank BC001179). An shRNA 
containing a non-specific 29nt GFP sequence (TR30003, Origene) was used as a transfection 
control (Empty). For RNAi, 5 ×106 cells were transfected with 10 g shRNA plasmid using 
Fugene HD (Roche) according to the manufacturer's instructions. Transfected cells were 
maintained in culture medium for 3-4 days to permit knockdown before assays.   
For vigilin overexpression, pTetCMV-Fo(AS)-vigilin (Cunningham et al, 2000) was 
transfected using Fugene HD (Roche). The BT20 cells at 75-80% confluence in 6-well plates 
were transfected with 5 g of plasmids. The overexpression effects were monitored for 3-4 
days by qRT-PCR and western blot analyses.  
4.8. UV crosslinking and label transfer with c-fms mRNA 3’UTR 
UV cross-linking of HuR and vigilin was performed as described previously (Urlaub et al, 
2000) with modifications.  RNAs of c-fms 3’UTR labeled with 32P-UTP were incubated with 
recombinant HuR or recombinant vigilin proteins. The 15 l reaction mixture contained 5 
mM HEPESpH7.6, 1.25 mM MgCl2, 3.8% glycerol, 0.02 mM DTT, 1 mM EDTA, 25 mM KCl, 
50 ng yeast tRNA, 50 ng heparin, 1 mM ATP, and 32P-labeled RNA probe (50,000 cpm). After 
incubation at 30oC for 20 min, reaction mixture in a 96-well polystyrene plate on ice was 
illuminated at 254 nm, 125 mJoule for 120 seconds using a GS Gene Linker UV Chamber 
(Bio-Rad). After crosslink, excess RNA was digested by RNase A for 30 min at 37oC. 
Crosslinked protein was fractionated in 10% SDS-PAGE. 
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al, 1994). Radioactive-labeled antisense RNA probes of c-fms mRNA was generated by in 
vitro transcription. c-fms cDNA (237nt, 1789-2025) with 67nt random sequence and 23nt T7 
promoter at 3’-end was generated by PCR and used as a templete for in vitro transcription. 
Probes with specific activity of 1x105 cpm were hybridized with 10 g of total RNA in 
hybridization buffer (80% deionized formamide, 40 mM PIPES pH6.4, 400 mM NaCl, and 1 
mM EDTA) at 42oC overnight. Next morning, unbound RNA was digested by RNase A and 
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T1 at 37oC for 1 h. After proteinase K treatment at 37oC for 30 min, samples were extracted 
by phenol-chloroform and precipitated in ethanol. Samples were analyzed on a 5% 
acrylamide/8M urea gel and exposed on X-ray film. 
4.6. Metabolic labeling and immunoprecipitation of c-fms proteins 
The BT20 cultures at 75-80% confluence were washed with PBS and incubated in labeling 
medium (Met,Cys-free RPMI1640 (Sigma R-7513), 5% dialyzed FCS, 500ug/ml Glutamine) 
for 40 min to deplete endogenous methionine and cysteine in cell. For metabolic labeling, 5 
ml labeling medium and 50 ul (500 uCi) of 35S-Methionine/35S-Cysteine per T75 flask was 
added and incubated for 30-40 min. After brief chase in chase medium (labeling medium 
with 500µg/ml Cysteine-HCl and 100µg/ml Methionine), cells were harvested and lysed in 
IP buffer (1% Triton x-100, 0.05% NP-40 in TBS, protease inhibitors). For 
immunoprecipitation of c-fms proteins, 5 ug of c-fms monoclonal antibody and 50 µl of 
Protein A/G-agarose (50% slurrry) (Santa Cruz) were added to cell lysates and incubated 
overnight at 4oC. Next morning, agarose beads was washed extensively with IP buffer and 
protein was eluted by SDS sample buffer. Labeled protein was analyzed in 10% SDS-PAGE. 
4.7. Gain-of-function and loss-of-function assay 
Plasmids encoding a control shRNA or shRNA directed against vigilin were purchased from 
Origene. The shRNAs correspond to coding region nucleotides 614–642 (5'-AAGCTCG 
GAAGGACATTGTTGCTAGACTG-3') and 829–863 (5'-CATGAAGTCTTACTCATCTCTG 
CCGAGCAGGACAA-3'), respectively, of human vigilin (GenBank BC001179). An shRNA 
containing a non-specific 29nt GFP sequence (TR30003, Origene) was used as a transfection 
control (Empty). For RNAi, 5 ×106 cells were transfected with 10 g shRNA plasmid using 
Fugene HD (Roche) according to the manufacturer's instructions. Transfected cells were 
maintained in culture medium for 3-4 days to permit knockdown before assays.   
For vigilin overexpression, pTetCMV-Fo(AS)-vigilin (Cunningham et al, 2000) was 
transfected using Fugene HD (Roche). The BT20 cells at 75-80% confluence in 6-well plates 
were transfected with 5 g of plasmids. The overexpression effects were monitored for 3-4 
days by qRT-PCR and western blot analyses.  
4.8. UV crosslinking and label transfer with c-fms mRNA 3’UTR 
UV cross-linking of HuR and vigilin was performed as described previously (Urlaub et al, 
2000) with modifications.  RNAs of c-fms 3’UTR labeled with 32P-UTP were incubated with 
recombinant HuR or recombinant vigilin proteins. The 15 l reaction mixture contained 5 
mM HEPESpH7.6, 1.25 mM MgCl2, 3.8% glycerol, 0.02 mM DTT, 1 mM EDTA, 25 mM KCl, 
50 ng yeast tRNA, 50 ng heparin, 1 mM ATP, and 32P-labeled RNA probe (50,000 cpm). After 
incubation at 30oC for 20 min, reaction mixture in a 96-well polystyrene plate on ice was 
illuminated at 254 nm, 125 mJoule for 120 seconds using a GS Gene Linker UV Chamber 
(Bio-Rad). After crosslink, excess RNA was digested by RNase A for 30 min at 37oC. 
Crosslinked protein was fractionated in 10% SDS-PAGE. 
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4.9. Invasion assay 
The Membrane Invasion Culture System (MICS chamber) was used to quantitate, the degree 
of invasion of MDA-MB-231 transiently transfected vigilin or HuR overexpressing clones. 
Breast cancer cells were cultured in the presence of 100 nM Dex and remained under starved 
conditions for transfection duration prior to the invasion assays. Parent or transfected cells, 
1x105 per well in a 6-well plate, were seeded onto 10-m pore filters coated with a human 
defined matrix containing 50 g/ml human laminin, 50 g/ml human collagen IV, and 2 
mg/ml gelatin in 10 mM acetic acid.  
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1. Introduction 
The question of which regions of the human genome constitute its functional elements—
those expressed as genes or serving as regulatory elements—has long been a central topic in 
biology. In the 1970s and 1980s, early cloning-based methods revealed the presence of more 
than 7000 genes in human genome [1], and large-scale analyses of expressed sequence tags 
(ESTs) in the 1990s suggested that the estimated number of human genes range from 35,000 
to 100,000 [2]. The completion of the human genome project narrowed the focus 
considerably by highlighting the surprisingly small number of protein-coding genes, which 
is now conventionally cited as less than 25,000 [3]. While the number of protein-coding 
genes (20,000–25,000) has maintained broad consensus, recent studies of the human 
transcriptome have revealed an astounding number of non-coding RNAs (ncRNAs) [4-6]. In 
fact, the increased sensitivity of genome tiling arrays provides an even more detailed view, 
revealing that the extent of non-coding sequence transcription is at least four times greater 
than coding sequence, and that the abundance of non-coding transcripts had been 
previously overlooked. The RNA world hypothesis proposes that early life was based on 
RNAs, which subsequently devolved the storage of information to more stable DNA, and 
catalytic functions to more versatile proteins. Consequently, despite crucial roles in the 
ancient processes of translation and splicing, RNA is assumed to have been largely relegated 
to an intermediate between gene and protein, encapsulated in the central dogma ‘DNA 
makes RNA makes protein’ [7]. However, the finding that most of the genome in complex 
organisms is transcribed and the discovery of new classes of regulatory non-coding RNAs 
(ncRNAs) challenges this assumption and suggests that RNAs have continued to evolve and 
expand alongside proteins and DNA. 
ncRNAs are considered as RNA transcripts that do not encode for a protein. In the past 
decade, a great diversity of ncRNAs has been observed. Depending on the type of ncRNA, 
transcription can occur by any of the three RNA polymerases (RNA Pol I, RNA Pol II, or 
RNA Pol III). General conventions divide ncRNAs into two main categories: small ncRNAs 
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less than 200 bp and long ncRNAs greater than 200 bps [8]. Within these two categories, 
there are also many individual classes of ncRNAs (Table1), although the degree of 
biological and experimental support for each class ranges substantially and should be 
evaluated individually. The relevance of ncRNAs in gene regulation has been rapidly 
unveiling during the last decade. However, the functional elements in the primary sequence 
of noncoding genes that determine their role as RNA molecules remain unknown. Protein-
coding genes have a defined language with a set of grammatical rules: three nucleotides 
forms a codon that translates into a specific amino acid [9]. Aberrations in codons of a 
protein-coding gene can be interpreted in terms of the amino acids they encode. We can 
recognize a mutation in a codon and determine its contribution to a given disease. In 
contrast to the genetic code for protein synthesis, ‘the ncRNA alphabet’ – a specific set of 
RNA sequences or structural motifs important for ncRNA function – remains to be largely 
elucidated. However, it has become increasingly apparent that the ncRNAs are of crucial 
functional importance for normal development, physiology and disease [10]. The functional 
relevance of the ncRNAs is particularly evident for a class of small non-coding RNAs called 
microRNAs (miRNAs) [11-12]. In human diseases, particularly cancer, it has been shown 
that epigenetic and genetic defects in miRNAs and their processing machinery are a 
common hallmark of disease [13-16]. However, miRNAs are just the tip of the iceberg, and 
other ncRNAs such as small nucleolar RNAs (snoRNAs), PIWI-interacting RNAs (piRNAs), 
large intergenic non-coding RNAs (lincRNAs) and, overall, the heterogeneous group of long 
non-coding RNAs (lncRNAs), might also contribute to the development of many different 
human disorders. Here we discuss the most recent genetic studies on ncRNAs and their 
related proteins in the context of cancer and we will analyze the new regulatory elements of 
the noncoding language to interpret their contribution to the pathogenesis of cancer. 
2. MicroRNAs 
In 1993, Victor Ambros and colleagues discovered a gene, lin-4, that affected development in 
Caenorhabditis elegans and found that its product was a small nonprotein-coding RNA [31]. 
The number of known small RNAs in different organisms such as Caenorhabditis elegans, 
Drosophila melanogaster, plants, and mammals—including humans—has since expanded 
substantially, mainly as a result of the cloning and sequencing of size-fractionated RNAs. 
MiRNAs are single stranded RNAs (ssRNAs) of 19–25 nucleotides in length that are 
generated from endogenous hairpin transcripts [32]. They play an important role in the 
negative regulation of gene expression by base-pairing to partially complementary sites on 
the target messenger RNAs (mRNAs), usually in the 3’ untranslated region (UTR). Binding 
of a miRNA to the target mRNA typically leads to translational repression and 
exonucleolytic mRNA decay, although highly complementary targets can be cleaved 
endonucleolytically. A genomic analysis of miRNAs has revealed that more than 50% of 
mammalian miRNAs are located within the intronic regions of annotated protein-coding or 
non-protein-coding genes [33]. These miRNAs could therefore use their host gene 
transcripts as carriers, although it remains possible that some are actually transcribed 
separately from internal promoters. Other miRNAs, located in intergenic regions, 
apparently have their own transcriptional regulatory elements and thus constitute  
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Table 1. Non coding RNA in human genome. 
independent transcription units. Animal miRNAs are processed from longer primary 
transcripts (pri-miRNAs) that can contain multiple miRNAs [34,35]. Few pri-miRNA 
transcripts have been studied in detail, but in general miRNAs are regulated and 
transcribed similar to protein encoding genes by (Pol) II with the exception of the rapidly 
evolving RNA polymerase (Pol) III transcribed miRNA cluster [36]. MiRNA processing 
occurs in three essential steps (Figure 1). First, the nuclear endoribonuclease protein Drosha 
recognizes the miRNA hairpins in the primary transcript and cleaves each hairpin ~11 nt 
from its base [37-38]. It has been proposed that Drosha may recognize the pri-miRNA 
through the stem-loop structure and then cleave the stem at a fixed distance from the loop to 
liberate the pre-miRNA. How is the Drosha enzyme able to discriminate the pri-miRNA 
stem-loop structure from the other stem-loop cellular RNAs? Both cell culture experiments 
and in vitro Drosha cleavage assays have shown that proteins associated with Drosha confer 
specificity to this process. In fact, Drosha has been found to be part of a large, ~650-kDa 
protein complex known as the Microprocessor [39], where Drosha interacts with its cofactor 
DGCR8 (the DiGeorge syndrome critical region gene 8 protein) in the human and interacts 
with Pasha in Drosophila melanogaster [40]. The next step in miRNA biogenesis is recognition 
of the ~60 nt pre-miRNA by exportin-5 and export into the cytoplasm in a ran-guanine-GTP-
dependent manner [41-43]. The Exp5/Ran-GTP complex has a high affinity for pre-miRNAs, 
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Figure 1. miRNA biogenesis and function. The primary miRNA (pri-miRNA) is transcribed by RNA 
pol II from its genomic location and cleaved by the microprocessor complex, which comprises Drosha 
and DGCR8. The resulting pre-miRNA is actively transported to the cytoplasm by exportin 5 (Expt.5), 
where the pre-miRNA undergoes further processing into the mature miRNA by Dicer and its co-factors, 
protein activator of interferon-induced protein kinase (PACT) and TAR RNA binding protein (TRBP). 
Normally, one strand of this duplex is degraded (miRNA star), whereas the other strand accumulates as 
a mature miRNA. From the miRNA-miRNA duplex, only the miRNA enters preferentially in the 
protein effector complex, formed by the RNA-induced silencing complex (RISC) and miRgonaute and 
binds with partial complementarity to the 3′ untranslated region (UTR) of target messenger RNAs 
(mRNAs) to mediate translational repression. 
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protecting them from the moment they are generated in the nucleus until they are ready for 
the next cleavage step in the cytoplasm, where GTP is hydrolyzed to guanosine diphosphate 
(GDP); at that point, the Exp5/Ran-GDP complex releases its cargo. Third, the 
endoribonuclease protein Dicer cleaves the pre-miRNA into ~22 nt duplexes and, with the 
help of cofactors such as TAR RNA binding protein (TRBP) and protein activator of the 
interferon-induced protein kinase (PACT), preferentially incorporates one of the duplex 
strands Into the RNA induced-silencing complex (RISC) [44-50]. The final product is a 
miRNA-miRNA duplex that needs to be unwound to act as a single-stranded guide in the 
RISC to recognize its target mRNAs. It was originally proposed that an ATP-dependent 
helicase (known as unwindase) separates the two small RNA strands, after which the 
resulting single-stranded guide is loaded into Ago proteins. However, it was later shown 
that Drosophila Ago2 [51], as well as human Ago2 [52], directly receive double-stranded 
small RNA from the RISC-loading complex. Ago2 then cleaves the passenger strand, 
thereby liberating the single-stranded guide to form mature Ago2-RISC. In mammals, 
miRNAs guide the RISC to complementary target sites in mRNAs, where 
endonucleolytically active Ago proteins cleave the RNA [53] (Figure 1). Finally, RISC can 
cleave [54-55] degrade [56-57] or suppress translation [58-59] of target mRNAs depending 
on the complementarity between miRNA and mRNA. Imperfect base pairing between small 
RNAs and their target mRNAs leads to repression of translation and/or deadenylation 
(removal of the polyA tail of the target), followed by destabilization of the target [60], 
whereas perfect base pairing usually leads to mRNA degradation. 
3. MicroRNAs and cancer 
Cancer is a multistep process in which normal cells experience genetic changes that progress 
them through a series of pre-malignant states (initiation) into invasive cancer (progression) 
that can spread throughout the body (metastasis). The dysregulation of genes involved in 
cell proliferation, differentiation and/or apoptosis is associated with cancer initiation and 
progression. Genes linked with cancer development are characterized as oncogenes and 
tumor suppressors. Recently, the definition of oncogenes and tumor suppressors has been 
expanded from the classical protein coding genes to include miRNAs [61-62]. MiRNAs have 
been found to regulate more than 60% of mRNAs and have roles in fundamental processes, 
such as development [63], differentiation [64], cell proliferation [65], apoptosis [66], and 
stress responses [67]. Over the past few years, many miRNAs have been implicated in 
various human cancers. The first evidence that miRNAs are involved in cancer comes from 
the finding that miR-15 and miR-16 are downregulated or deleted in most patients with 
chronic lymphocytic leukemia [68]. This discovery has projected miRNAs to the center stage 
of molecular oncology and, in the past few years, a myriad of genome-wide miRNA 
expression profiling analyses have shown a general dysregulation of miRNA expression in 
all tumors (Table 2) [69]. Surprisingly, the use of miRNA profiles is newly becoming highly 
preferred to the traditional mRNA signature for a variety of reasons. First, the remarkable 
stability of miRNAs, due to their short length, has allowed scientists to perform analyses 
also in samples considered to be technically challenging, such as formalin fixed specimens. 
High sensitive and refined miRNA detection technique provide high reliability in the use of 
miRNAs as a diagnostic tools. Finally, miRNA fingerprints have demonstrated the ability to 
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identify the tissue of origin for cancer that have already spread in multiple metastatic sites, 
thereby reducing patient’s psychological burden and overall procedure costs. To date, over 
1000 miRNAs have been reported in humans (miRbase: 1527 at November 2011), and both 
loss and gain of miRNA functions contribute to cancer development through a range of 
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Table 2. miRNA profiling in cancer. 
4. Oncogenic microRNAs 
Although studies linking miRNA dysfunctions to human diseases are in their infancy, a 
great deal of data already exists, establishing an important role for miRNAs in the 
pathogenesis of cancer. Many miRNAs have been shown to function as oncogenes in the 
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majority of cancers profiled to date (Table 3). MiR-21 displays a strong evolutionary 
conservation across a wide range of vertebrate species in mammalian, avian and fish clades 
[70]. It has been demonstrated that a primary transcript containing miR-21 (i.e., pri-miR-21) is 
independently transcribed from a conserved promoter that is located within the intron of 
the overlapping protein-coding gene TMEM49 [71]. Several studies suggest that this miRNA 
is oncogenic [72-74] and that it may act as an antiapoptotic factor. For example, Chan et al. 
have found that miR-21 is commonly and markedly up-regulated in human glioblastoma 
and that inhibiting miR-21 expression leads to caspase activation and associated apoptotic 
cell death [72]. Moreover, Zhu and collaborators provided the first evidence that miR-21 
regulates invasion and metastasis, at least in part, by targeting metastasis-related tumor 
suppressor genes such as TPM1, programmed cell death 4 (PDCD4) and maspin [73]. 
Furthermore, examination of human breast tumor specimens revealed an inverse correlation 
of miR-21 with PDCD4 and maspin [74]. The final proof of miR-21 oncogenic activity came 
from the Slack laboratory where the first conditional knock-in of miR-21 overexpressing 
mice was generated. The mice developed a severe pre-B-cell lymphoma but when miR-21 
was reduced to endogenous levels, the mouse tumors completely disappeared, defining the 
concept of  “oncomiR addition” [75].  
Another important oncogenic miRNA is represented by miR-155. Several groups have 
shown that miR-155 is highly expressed in pediatric Burkitt’s lymphoma [76], Hodgkin’s 
disease [77], primary mediastinal non-Hodgkin’s lymphoma [77], chronic lymphocytic 
leukemia (CLL) [78], acute myelogenous leukemia (AML) [79], lung cancer [80], pancreatic 
cancer [81], and breast cancer [80]. Dr. Croce laboratory reported that miR-155 transgenic 
mice develop acute lymphoblastic leukemia/high-grade lymphoma and that most of these 
leukemias start at approximately nine months, irrespective of the mouse strain, preceded by 
a polyclonal pre-B-cell proliferation [82]. 
Another example of “oncomiR” is represented by miR-221&222 cluster that is highly 
upregulated in a variety of solid tumors, including thyroid cancer [83], hepatocarcinoma 
[84], estrogen receptor negative breast tumor [85], and melanoma [86]. Elevated miR-
221&222 expression has been causally linked to proliferation [85-87], apoptosis [88-89], and 
migration [89] of several cancer cell lines. We recently reported that the hepatocyte growth 
factor receptor (MET) oncogene, through c-Jun transcriptional activation, upregulates miR-
221&222 expression, which, in turn, by targeting PTEN and TIMP3, confers resistance to 
tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and enhances 
tumorigenicity of lung and liver cancer cells [89]. The results suggest that therapeutic 
intervention involving the use of miRNAs should not only sensitize tumor cells to drug-
inducing apoptosis but also inhibit their survival, proliferation, and invasion [89]. 
The miR-106b-25 polycistron is composed of the highly conserved miR-106b, miR-93, and 
miR-25 that accumulate in different types of cancer, including gastric, prostate, and 
pancreatic neuroendocrine tumors, as well as neuroblastoma and multiple myeloma. 
Petrocca and collaborators [90] demonstrated that E2F1 regulates miR-106b, miR-93, and 
miR-25, inducing their accumulation in gastric tumors. Conversely, miR-106b and miR-93 
control E2F1 expression, establishing a negative feedback loop that may be important in 
preventing E2F1 self-activation and apoptosis. On the other hand, miR-106b, miR-93, and 
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miR-25 overexpression causes a decreased response of gastric cancer cells to TGFβ by 
downregulating p21 and Bim, the two most downstream effectors of TGFβ-dependent cell 
cycle arrest and apoptosis, respectively.  
Another example of a miRNA locus with oncogenic properties is represented by the miR-17-
92 cluster, which consists of six miRNAs: miR-17-5p, -18, -19a, -19b, -20a, and -92-1. The 
miR-17-92 cluster is located in a region frequently amplified in several types of lymphoma 
and solid tumors [91-92]. It has been shown that mice deficient for miR-17-92 die shortly 
after birth with lung hypoplasia and a ventricular septal defect. This cluster is also essential 
for B cell development; its absence, in fact, leads to increased levels of the proapoptotic 
protein Bim and inhibits B cell development at the pro-B-to-pre-B transition [93]. All 
together these studies indicate that many miRNAs have oncogenic activity. Importantly, 
their knockdown through the use of antisense oligonucleotides, inhibits the development of 
cancer-associated phenotypes, laying the groundwork for the creation of miRNA-based 
therapies [94-96]. 
5. Tumor suppressor microRNAs 
The first evidence that miRNAs are involved in cancer comes from the finding that miR-15 
and miR-16 are downregulated or deleted in most patients with chronic lymphocytic 
leukemia (CLL) (Table 4) [68]. They are transcribed as a cluster (miR-15a–miR-16-1) that 
resides in the 13q14 chromosomal region. Deletions or point mutations in region 13q14 
occur at high frequency in CLL, lymphoma, and several solid tumors [97]. Their expression 
is inversely correlated to BCL2 expression in CLL [98]. The tumor suppressor function of 
miR-15a/16-1 has also been addressed in vivo. In immunocompromised nude mice, ectopic 
expression of miR-15a/16-1 was found to cause dramatic suppression of tumorigenicity of 
MEG-01 leukemic cells that exhibited a loss of endogenous expression of miR-15a/16-1. 
Furthermore, Klein et al. [99] generated transgenic mice with a deletion of the miR-15a–miR-
16-1 cluster, causing development of indolent B-cell-autonomous, clonal 
lymphoproliferative disorders, recapitulating the spectrum of CLL-associated phenotypes 
observed in humans. Recently, Bonci et al. reported that the miR-15a–miR-16-1 cluster 
targets not only BCL2 but also CCND1 (encoding cyclin D1) and WNT3A mRNA, which 
promote several prostate tumorigenic features, including survival, proliferation, and 
invasion [100]. Together, these data suggest that miR-15a/16-1 genes are natural antisense 
interactors of BCL2 and probably other oncogenes and that they can be used to suppress 
tumor growth in therapeutic application for a variety of tumors [100]. 
In mammalians, the miR-34 family comprises three processed miRNAs that are encoded by 
two different genes: miR-34a is encoded by its own transcript, whereas miR-34b and miR-
34c share a common primary transcript. The miR-34 family has been shown to form part of 
the p53 tumor-suppressor network: their expression is directly induced by p53 in response 
to DNA damage or oncogenic stress [101-102]. He et al. identified different miR-34 targets 
such as cyclin E2 (CCNE2), CDK4, and MET. Silencing these selected miR-34 targets through 
the use of small interfering RNAs (siRNAs) led to a substantial cell cycle arrest in G1. 
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Moreover, ectopic miR-34 delivery caused a decrease in levels of phosphorylated 
retinoblastoma gene product (Rb), consistent with lowered activity of both CDK4 and 
CCNE2 complexes [102]. BCL2 and MYCN were also identified as miR-34a targets and 
likely mediators of the tumor suppressor phenotypic effect in neuroblastoma [103]. It has 
been also reported that p53 activation suppressed the EMT-inducing transcription factor 
SNAIL via induction of the miR-34a/b/c genes. In fact, suppression of miR-34a/b/c by anti-
miRs caused up-regulation of SNAIL and cells displayed EMT markers, enhanced migration 
and invasion [104]. 
MicroRNA-122 (miR-122) is a liver-specific microRNA and is frequently downregulated in 
liver cancer [105]. Xu et al. reported that restoration of miR-122 in hepatocellular carcinoma 
cells could render cells sensitive to chemotherapeutic agents adriamycin or vincristine 
through downregulating  antiapoptotic gene Bcl-w and cell cycle related gene cyclin B1 
[106]. Another group found that over-expression of miR-122 inhibits hepatocellular 
carcinoma cell growth and promotes the cell apoptosis by affecting Wnt/β-catenin signalling 
pathway [107]. Coulouarn et al. showed that miR-122 is specifically repressed in a subset of 
primary hepatocellular tumors that are characterized by poor prognosis [108]. They further 
reported that loss of miR-122 resulted in an increase of cell migration and invasion and that 
restoration of miR-122 reverses this phenotype [108]. The final understanding of the tumor 
suppressor role for mir-122 role in liver cancer came from a recent study where miR-122 
knockout mice were studied. When miR-122 KO mice aged, hepatic inflammation ensued, 
preceding the progressive onset of fibrosis and, eventually, tumors resembling human liver 
cancer. These pathologic manifestations were associated with hyperactivity of oncogenic 
pathways and hepatic infiltration of inflammatory cells that produce pro-tumorigenic 
cytokines, including IL-6 and TNF [109]. 
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6. MetastamiRs 
Metastasis is the result of cancer cells detaching from a primary tumor, consequently 
adapting to distant tissues and organs, and forming a secondary tumor [110] and this ability 
of cancer cells to metastasize is a hallmark of malignant tumors [111-112]. To successfully 
metastasize, a tumor cell must complete a complex set of processes, including invasion, 
survival and arrest in the circulatory system, and colonization of foreign organs. Despite 
great advancements in knowledge of metastasis biology, the molecular mechanisms are still 
not completely understood. Several miRNAs have been shown to initiate invasion and 
metastasis by targeting multiple proteins that are major players in these cellular events, thus 
they have been denominated as metastamiRs (Table 5). It seems that these metastasis-
associated miRNAs do not influence primary tumor either in development or initiation 
steps of tumorigenesis, but they regulate key steps in the metastatic program and processes, 
such as epithelial-mesenchymal transition (EMT), apoptosis, and angiogenesis. Ma et. al 
reported that miR-10b is highly expressed in metastatic breast cancer cells and positively 
regulates cell migration and invasion. Overexpression of miR-10b in otherwise non-
metastatic breast tumors initiates robust invasion and metastasis [113]. The team led by Joan 
Massague found that miR-335, miR-126, and miR-206 are metastasis-suppressors in breast 
cancer [114]. MiR-126 and miR-206 restoration reduced overall tumor growth and 
proliferation, whereas miR-335 inhibits metastatic cell invasion through targeting of the 
progenitor cell transcription factor SOX4 and extracellular matrix component tenascin C 
[114]. Others miRNAs with prominent roles in breast cancer metastasis have been reported. 
It has been reported that miR-31 inhibited multiple steps of metastasis including invasion, 
anoikis, and colonization leading to almost complete reduction of lung metastasis [115]. 
Clinically, miR-31 levels were lower in breast cancer patients with metastasis. In addition, 
miR-9, which is up-regulated in breast cancer cells, directly targets CDH1, the E-cadherin-
encoding messenger RNA, leading to increased cell motility and invasiveness [116].  
Another important aspect of the metastatic dissemination is represented by the epithelial-to-
mesenchymal transition (EMT) that allow neoplastic cells to abandon their primary site and 
survive in the new tissue. During EMT, an epithelial neoplastic cell looses cell adhesion by 
repressing E-cadherin expression and thereby the cell increases its motility. Numerous 
studies have shown that different microRNAs are modulated during EMT and one of the 
best-studied example is represented by the miR-200 family. These miRs are commonly lost 
in aggressive tumors such as lung, prostate, and pancreatic cancer. It has been shown that 
miR-200 family members directly target ZEB1 and ZEB2, transcription repressors of E-
cadherin [117]. In fact, in the highly aggressive mouse lung cancer model where KRAS is 
constitutively activated and p53 function is perturbed, miR-200 ectopic expression 
prevented metastasis by repressing ZEB1 and ZEB2 and preventing E-cadherin down-
regulation [117]. However, overexpression of the miR-200 family is associated with an 
increased risk of metastasis in breast cancer and this overexpression promotes metastatic 
colonization in mouse models, phenotypes that cannot be explained by E-cadherin 
expression alone [118]. By using proteomic profiling of the targets of mesenchymal-to-
ephitelial (MET)-inducing miR-200, the authors discovered that miR-200 globally targets 
secreted proteins in breast cancer cells. Between the 38 modulated target genes, Sec23a, 
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which is involved in transporting protein cargo from the endoplasmic reticulum to the 
Golgi, shows a superior association with human metastatic breast cancer as compared to the 
currently recognized miR-200 targets ZEB1 and the EMT marker E-cadherin. EMT is first 
acquired in the onset of transmigration and then reversed in the new metastatic site. Korpal 




Table 5. metastamiRS 
7. Other non-coding RNAs: Biology and implications in cancer 
7.1. snoRNAs: From post-transcriptional modification to cancer 
Small nucleolar RNAs (snoRNAs) have, for many years, been considered one of the best-
characterized classes of non-coding RNAs (ncRNAs) [120-123] but despite the common 
assumption that snoRNAs only have cellular housekeeping functions, in the past few years, 
independent reports have converged in implicating snoRNAs in the control of cell fate and 
oncogenesis [124-130]. SnoRNAs are small RNAs of 60-300nt in lenght that specifically 
accumulate in the nucleolar compartment of the cell where are in charge of the 2′-O-ribose 
methylation and pseudouridylation of specific ribosomal RNA nucleotides, essential 
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modification for the efficient and accurate production of the ribosome [120-122]. The 
snoRNAs carry out their function in the form of small nucleolar ribonucleoproteins 
(snoRNPs), each of which consists of a box C/D or box H/ACA guide RNA, and four 
associated C/D or H/ACA snoRNP proteins (Figure 2). In both cases, snoRNAs hybridize 
specifically to the complementary sequence in the rRNAs, and the associated protein 
complexes then carry out the appropriate modification on the nucleotide that is identified by 
the snoRNAs. Biogenesis of vertebrate snoRNPs is remarkable and highly variable: in fact 
snoRNA gene organization ranges from independently transcribed genes, endowed with 
their own promoter elements, to intronic coding units lacking an independent promoter. In 
both yeast and animals, processing of intron-encoded snoRNAs is largely splicing-
dependent; in contrast, the production of plant snoRNAs from introns seems to rely on a 
splicing-independent process [131]. Moreover, in both contexts (intergenic or intronic), 
genes can be either single or part of clusters. In the latter case, the generation of individual 
snoRNAs involves the enzymatic processing of polycistronic precursor RNAs. Such a 
processing, at least in yeast, appears to involve the same combination of endo- and 
exoribonucleases required for the maturation of monocistronic pre-snoRNAs [132-134]. The 
first indication that snoRNAs might have important roles in human disease was provided 
by the genetic studies on Prader–Willi syndrome (PWS), an inherited human disorder 
characterized by a complex phenotype, including mental retardation, decreased muscle tone 
and failure to thrive at birth, short stature, hypogonadism, sleep apnea, behavioral problems 
and hyperphagia (an insatiable appetite) that can lead to severe obesity [135]. The disease is 
caused by the genomic loss of the imprinted chromosomic 15q11-q13 locus which is 
normally only active on the paternal allele. The only characterized and conserved genes 
within this 121-kb-long genomic interval are the numerous HBII-85 snoRNA gene copies, 
thus suggesting that loss of expression of these repeated small C/D RNA genes might play a 
role in conferring some (or even all) phenotypes of the human disease and PWS-like 
phenotypes in mice (neonatal lethality, growth retardation and hypotonia). In fact, it has 
been shown that a site-specific deletion of the entire murine MBII-85 gene cluster led to 
post-natal growth retardation with low postnatal lethality (<15%) only seen in some genetic 
backgrounds, but no obesity [136]. Although all the imprinted C/D RNAs that have been 
tested accumulate within the nucleolus, none of them appear to act as RNA guides to 
modify rRNAs or spliceosomal U-snRNAs; they are called ‘orphan C/D RNAs’. So far, the 
MBII-52 gene clusters have attracted much attention, given that the neuronal-specific MBII-
52 small RNA is predicted to interfere (A-to-I RNA editing and/or alternative RNA splicing) 
with the post-transcriptional regulation of the pre-mRNA that encodes the 5-HT2C (5-
hydroxytryptamine 2C) receptor, playing a key role in regulating serotonergic signal 
transduction [137-138]. These observations raised the possibility that snoRNAs could have 
functions completely independent from their traditional activities and carry out other 
regulatory roles. The first insights into the potential roles of snoRNAs in cancer began with 
a study that identified C/D box snoRNA U50 and its host gene U50HG at the breakpoint in 
the t(3;6) (q21;q15) translocation in a diffuse large B cell lymphoma [139]. Moreover, 
snoRNAU50 gene has been found to undergo to a frequent copy number loss and a 
transcriptional downregulation in breast and prostate cancer samples [139,140]. In addition, 
a 2-bp deletion in U50 sequence also occurred both somatically and in germline, leading to 
increased incidence of homozygosity for the deletion in cancer cells [140]. 
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Figure 2. snoRNAs. A. Boxed sequences C and D (named from conserved, nuclease-resistant sequences 
that were originally identified in snoRNA U3) are hallmarks of the C/D box snoRNAs; boxed sequences 
H (Hinge region) and ACA are hallmarks of the H/ACA box snoRNAs. These conserved boxed 
sequences are important for the associations with protein components that are required to form the 
functional small nucleolar ribonucleoprotein (snoRNP) complexes and for accumulation in the 
nucleolus. C/D box snoRNAs associate with several proteins, including fibrillarin, which is the methyl 
transferase that is involved in the 2′-O-methylation of particular ribonucleotides, and H/ACA box 
snoRNAs associate with proteins such as the pseudouridine synthase dyskerin. Antisense sequences 
within the C/D box and H/ACA box snoRNAs guide the snoRNP complex to the appropriate nucleotide 
within the target RNA (most often ribosomal RNA). In a minority of cases both C/D-associated and 
C′D′-associated antisense sequences within the same C/D box snoRNA can act as guides for 2′-O-
methylation of the target RNA. The eukaryotic H/ACA box snoRNAs contain two hairpin domains with 
complementary regions flanking the uridine to be converted in the target rRNA, at a position 14–16 
nucleotides upstream of the conserved H and/or ACA box. Most mammalian snoRNAs are encoded 
within the introns of genes producing 5′ terminal oligopyrimidine (5′TOP) RNAs. B. Organization of 
snoRNA genes in representative eukaryotic genomes C. Small nucleolar RNAs (snoRNAs) in vertebrate 
are predominantly located in introns. Following splicing, debranching and trimming, mature snoRNAs 
are either exported, in which case they function in ribosomal RNA (rRNA) processing, or remain in the 
nucleus, where they are involved in alternative splicing and additional yet unknown functions.  
SnoRNA42 (SNORA42) is located on chromosome 1q22 which is a commonly frequent 
amplified genomic region in lung cancer and overexpression of SNORA42 is frequently and 
remarkably found in NSCLC cells [141]. In addition, SNORA42 exhibited close correlations 
between its increases of copy number and expression level, suggesting that SNORA42 
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overexpression could be activated through its amplification. Importantly, engineered 
repression of SNORA42 caused marked repression of lung cancer growth in vitro and in 
vivo and it is associated with increased apoptosis by a p53-dependent pathway. Although 
not exhibiting apoptosis, p53 null and mutant p53 cancer cells with reduced levels of 
SNORA42 also show inhibited proliferation and growth,  suggesting that SNORA42 
knockdown can inhibit cell proliferation in p53-dependent or -independent manner. These 
independent studies on U50 and SNORA42 provide evidence for the functional importance 
of snoRNAs in cancer, and they show that snoRNAs can promote, as well as suppress, 
tumour development. In 2002, Wu and coworkers demonstrated that the expression of 
snoRNAs 5S was differentially displayed in different tissues and noticeably was highly 
expressed in normal brain, but its expression drastically decreased in meningioma [142]. 
Recently, genome-wide approaches identified six snoRNAs (SNORD33, SNORD66, 
SNORD73B, SNORD76, SNORD78, and SNORA42) that were statistically differently 
expressed between the non small cell lung cancer tumor and paired noncancerous samples 
[143]. Specifically, all these snoRNAs displayed a strong up-regulation in lung tumor 
specimens and the majority of them is located in commonly frequent genomic amplified 
regions in lung cancer: SNORD33 is located in chromosome 19q13.3 that contain potential 
oncogenes in lung cancer, while SNORD66 and SNORD76 are situated in chromosomal 
regions 3q27.1 and 1q25.1, respectively 3q27.1 and 1q25.1 are two of the most frequently 
amplified chromosomal segments in solid tumors, particularly NSCLC [143]. 
As well as the initial evidence that snoRNAs are involved in cancer development, there are 
some preliminary data showing that the genes that host snoRNAs might also contribute to 
the aetiology of this disease. A research screening for potential tumor-suppressor genes 
identified that Growth arrest-specific transcript 5 (gas5) gene as almost undetectable in 
actively growing cells but highly expressed in cells undergoing serum starvation or density 
arrest [144-145]. Gas5 is a multi-snoRNA host gene which encodes 9 (in mouse) or 10 (in 
human) snoRNAs and like all known snoRNA host genes exhibit characteristics which 
belong to the class of genes encoding 5′ terminal oligopyrimidine (5′TOP) mRNAs [146]. The 
first and stronger evidence that GAS5 is related to cancer is the identification that GAS5 
transcript levels are significantly reduced in breast cancer samples relative to adjacent 
unaffected normal breast epithelial tissues and some, but not all, GAS5 transcripts sensitize 
mammalian cells to apoptosis inducers [147]. Other studies have also showed that GAS5 
reduced expression is associated with poor prognosis in both breast cancer and head and 
neck squamous cell carcinoma [148]. Of note, GAS5 has been also identified as a novel 
partner of the BCL6 in a patient with diffuse large B-cell lymphoma, harboring the 
t(1;3)(q25;q27) [149]. Another example of a mature spliced transcript that harbors C/D-box 
snoRNAs and can function independently of the snoRNAs is represented by the transcript 
Zfas1 [150]. This gene intronically hosts three C/D box snoRNAs (Snord12, Snord12b, and 
Snord12c) and has been identified as one of the most differentially expressed gene during 
mouse mammary development. siRNA-mediated downregulation of Zfas1 mRNA in a 
mouse mammary cell line increased proliferation and differentiation without substantially 
affecting the levels of the snoRNA hosted within its intron. The human homologue, ZFAS1 
(also known as ZNFX1-AS1), which is predicted to share secondary structural features with 
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Figure 2. snoRNAs. A. Boxed sequences C and D (named from conserved, nuclease-resistant sequences 
that were originally identified in snoRNA U3) are hallmarks of the C/D box snoRNAs; boxed sequences 
H (Hinge region) and ACA are hallmarks of the H/ACA box snoRNAs. These conserved boxed 
sequences are important for the associations with protein components that are required to form the 
functional small nucleolar ribonucleoprotein (snoRNP) complexes and for accumulation in the 
nucleolus. C/D box snoRNAs associate with several proteins, including fibrillarin, which is the methyl 
transferase that is involved in the 2′-O-methylation of particular ribonucleotides, and H/ACA box 
snoRNAs associate with proteins such as the pseudouridine synthase dyskerin. Antisense sequences 
within the C/D box and H/ACA box snoRNAs guide the snoRNP complex to the appropriate nucleotide 
within the target RNA (most often ribosomal RNA). In a minority of cases both C/D-associated and 
C′D′-associated antisense sequences within the same C/D box snoRNA can act as guides for 2′-O-
methylation of the target RNA. The eukaryotic H/ACA box snoRNAs contain two hairpin domains with 
complementary regions flanking the uridine to be converted in the target rRNA, at a position 14–16 
nucleotides upstream of the conserved H and/or ACA box. Most mammalian snoRNAs are encoded 
within the introns of genes producing 5′ terminal oligopyrimidine (5′TOP) RNAs. B. Organization of 
snoRNA genes in representative eukaryotic genomes C. Small nucleolar RNAs (snoRNAs) in vertebrate 
are predominantly located in introns. Following splicing, debranching and trimming, mature snoRNAs 
are either exported, in which case they function in ribosomal RNA (rRNA) processing, or remain in the 
nucleus, where they are involved in alternative splicing and additional yet unknown functions.  
SnoRNA42 (SNORA42) is located on chromosome 1q22 which is a commonly frequent 
amplified genomic region in lung cancer and overexpression of SNORA42 is frequently and 
remarkably found in NSCLC cells [141]. In addition, SNORA42 exhibited close correlations 
between its increases of copy number and expression level, suggesting that SNORA42 
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overexpression could be activated through its amplification. Importantly, engineered 
repression of SNORA42 caused marked repression of lung cancer growth in vitro and in 
vivo and it is associated with increased apoptosis by a p53-dependent pathway. Although 
not exhibiting apoptosis, p53 null and mutant p53 cancer cells with reduced levels of 
SNORA42 also show inhibited proliferation and growth,  suggesting that SNORA42 
knockdown can inhibit cell proliferation in p53-dependent or -independent manner. These 
independent studies on U50 and SNORA42 provide evidence for the functional importance 
of snoRNAs in cancer, and they show that snoRNAs can promote, as well as suppress, 
tumour development. In 2002, Wu and coworkers demonstrated that the expression of 
snoRNAs 5S was differentially displayed in different tissues and noticeably was highly 
expressed in normal brain, but its expression drastically decreased in meningioma [142]. 
Recently, genome-wide approaches identified six snoRNAs (SNORD33, SNORD66, 
SNORD73B, SNORD76, SNORD78, and SNORA42) that were statistically differently 
expressed between the non small cell lung cancer tumor and paired noncancerous samples 
[143]. Specifically, all these snoRNAs displayed a strong up-regulation in lung tumor 
specimens and the majority of them is located in commonly frequent genomic amplified 
regions in lung cancer: SNORD33 is located in chromosome 19q13.3 that contain potential 
oncogenes in lung cancer, while SNORD66 and SNORD76 are situated in chromosomal 
regions 3q27.1 and 1q25.1, respectively 3q27.1 and 1q25.1 are two of the most frequently 
amplified chromosomal segments in solid tumors, particularly NSCLC [143]. 
As well as the initial evidence that snoRNAs are involved in cancer development, there are 
some preliminary data showing that the genes that host snoRNAs might also contribute to 
the aetiology of this disease. A research screening for potential tumor-suppressor genes 
identified that Growth arrest-specific transcript 5 (gas5) gene as almost undetectable in 
actively growing cells but highly expressed in cells undergoing serum starvation or density 
arrest [144-145]. Gas5 is a multi-snoRNA host gene which encodes 9 (in mouse) or 10 (in 
human) snoRNAs and like all known snoRNA host genes exhibit characteristics which 
belong to the class of genes encoding 5′ terminal oligopyrimidine (5′TOP) mRNAs [146]. The 
first and stronger evidence that GAS5 is related to cancer is the identification that GAS5 
transcript levels are significantly reduced in breast cancer samples relative to adjacent 
unaffected normal breast epithelial tissues and some, but not all, GAS5 transcripts sensitize 
mammalian cells to apoptosis inducers [147]. Other studies have also showed that GAS5 
reduced expression is associated with poor prognosis in both breast cancer and head and 
neck squamous cell carcinoma [148]. Of note, GAS5 has been also identified as a novel 
partner of the BCL6 in a patient with diffuse large B-cell lymphoma, harboring the 
t(1;3)(q25;q27) [149]. Another example of a mature spliced transcript that harbors C/D-box 
snoRNAs and can function independently of the snoRNAs is represented by the transcript 
Zfas1 [150]. This gene intronically hosts three C/D box snoRNAs (Snord12, Snord12b, and 
Snord12c) and has been identified as one of the most differentially expressed gene during 
mouse mammary development. siRNA-mediated downregulation of Zfas1 mRNA in a 
mouse mammary cell line increased proliferation and differentiation without substantially 
affecting the levels of the snoRNA hosted within its intron. The human homologue, ZFAS1 
(also known as ZNFX1-AS1), which is predicted to share secondary structural features with 
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mouse Zfas1, is expressed at high levels in the mammary gland and is downregulated in 
breast cancer. Taken together, these findings indicates that snoRNA host genes might have 
important functions in regulating cellular homeostasis and, potentially, cancer biology but 
more studies are needed to understand their involvement in molecular basis of disease and 
classify them as sources of potential biomarkers and therapeutic targets. 
Another important aspect of the association between snoRNAs and tumorigenesis is 
represented by the involvement of their associated proteins in cancer. A point mutations in 
the DKC1 gene is the cause of a rare X-linked recessive disease, the dyskeratosis congenita 
(DC) [151-152]. Individuals with DC display features of premature aging, as well as nail 
dystrophy, mucosal leukoplakia, interstitial fibrosis of the lung, and increased susceptibility 
to cancer. DKC1 codes for dyskerin, a putative pseudouridine synthase, which carries out 
two separate functions, both fundamental for proliferating cells. One function is the pseudo-
uridylation of ribosomal RNA (rRNA) molecules as a part of the H/ACA ribonucleoprotein 
complex, and the other is the stabilization of the telomerase RNA component necessary for 
telomerase activity. Dkc1 mutant mice recapitulate the major features of DC, including an 
increased susceptibility to tumor formation. Early generation (G1 and G2) of Dkc1 mutant 
mice showed a full spectrum of DC and presented alterations in rRNA modification, 
whereas defects in telomere length were not evident until G4 mice, suggesting that 
deregulated ribosome function is important for the initiation of DC and that impairment in 
telomerase activity in Dkc1 mutant mice may modify and/or exacerbate the disease in later 
generations. To this regard, DKC1 was identified as one of only seventy genes that, 
collectively, constitute a gene expression profile that strongly correlates with the 
development of aneuploidy and is associated with poor clinical prognosis in a variety of 
human cancers. Therefore, one hypothesis is that an alteration of physiologic dyskerin 
function, irrespective of the mechanism, may perturb mitosis and contribute to 
tumorigenesis but this idea will require more detailed investigation. Another possibility is 
related to the strong effect of dyskerin loss on H/ACA accumulation. Recent finding in fact 
have shown that some H/ACA box and C/D box can be processed to produce small RNAs, 
at least some of which can function like miRNAs [153]. Such processing may be of crucial 
importance, as miRNAs have important roles in the development of many cancers as 
previously discussed. To date, Xiao and colleagues have recently reported that an H/ACA 
box snoRNA- derived miRNA, miR-605, has a key role in stress-induced stabilization of the 
p53 tumour suppressor protein [154]. p53 transcriptionally activates its negative regulator, 
MDM2, in addition to miR-605. miR-605 counteracts MDM2 through post-transcriptional 
repression; under conditions of stress, this snoRNA-derived miRNA offsets the MDM2 
negative-feedback loop, generating a positive-feedback loop to enable the rapid 
accumulation of p53. However, whether this regulation of p53 by miR-605 is relevant to 
cancer biology has not yet been addressed. Like dyskerin, NHP2 and NOP10 proteins, both 
components of the H/ACA snoRNPs, are also significantly up-regulated in sporadic cancers 
and high levels may be associated with poor clinical prognosis. Moreover, germline NHP2 
and NOP10 mutations give rise to autosomal recessive forms of dyskeratosis congenita, and 
cancer susceptibility is also a feature of these genetic forms of the disease. Since the 
functions of several snoRNAs have not yet been identified (orphan snoRNAs), it is possible 
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that disruption of snoRNP biogenesis by any mechanism may affect an array of important 
cellular processes, and could potentiate cancer development and/or progression.  
7.2. piRNAs: Guardians of the genome 
Piwi-interacting RNAs (piRNAs) are germline-specific small silencing RNAs of 24–30 nt in 
length, that suppress transposable elements (TE) activity and maintain genome integrity 
during germline development, a role highly conserved across animal species [155-156]. TEs 
are genomic parasites that threaten the genomic integrity of the host genome: they are able 
to move to new sites by insertion or transposition and thereby disrupt genes and alter the 
genome [157]. In animals, endogenous siRNAs also silence TEs, but the piRNA pathway is 
at the forefront of defense against transposons in germ cells [158]. piRNAs specifically 
associate with PIWI proteins, which are germline-specific members of the AGO protein 
family, AGO3, Aubergine (Aub) and Piwi, and form a piRNA-induced silencing complex 
(piRISC) which will guide the TE silencing [159-162]. Any mutations in each of the three 
members of the PIWI family lead to transposon derepression in the germline, indicating that 
they act non-redundantly during TE silencing. Initial screening of piRNA sequences 
revealed that there are hundreds of thousands, if not millions, of individual piRNA 
sequences [163-165]. Furthermore, they are characterized by the absence of specific sequence 
motifs or secondary structures such as miRNA precursors. Despite their large diversity, 
most piRNAs can be mapped to a relatively small number of genomic regions called piRNA 
clusters. Each cluster extends from several to more than 200 kilobases, it contains multiple 
sequences that generate piRNAs and some piRNAs map to both genomic strands, 
suggesting bidirectional transcription [163-165] Indeed, analysis of piRNA clusters in 
different Drosophila species has shown that, although the clusters locations are conserved, 
their sequence content has evolved very quickly suggesting adjustments in the piRNAs 
patrimony in order to suppress new active transposons invading the species. Therefore, 
piRNA clusters may be considered as repositories of information, enabling production of 
many mature piRNAs that target diverse TEs. Two main pathways, highly conserved in 
many animal species, have been discovered to be responsible for the biogenesis of the 
piRNAs: the primary pathways and the Ping-Pong amplification (Figure 3) [166-168]. First, 
the primary piRNA biogenesis pathway provides an initial pool of piRNAs that target 
multiple TEs. Next, the Ping-Pong cycle further shapes the piRNA population by amplifying 
sequences that target active transposons. It is currently unclear how primary piRNAs are 
produced from piRNA clusters but it is likely that piRNA precursors are single-stranded 
and therefore do not require Dicer for their processing. Interestingly, piRNAs that associate 
with each member of the PIWI protein family have a distinct size, suggesting that PIWI 
proteins can act as ‘rulers’ that define the size of mature piRNAs. Several additional proteins 
(e.s. Zucchini, Armitage and Yb) have also been identified that are involved in primary 
piRNA biogenesis and mutations in and/or depletion of any of these three proteins 
eliminates primary piRNAs associated with PIWI proteins. In some cell types, such as 
somatic follicle cells of the D. melanogaster ovary, primary piRNA biogenesis is the only 
mechanism that generates piRNAs. However, in germline cells of the D. melanogaster ovary 
and in the pre-meiotic spermatogonia in mice, there is another mechanism called the Ping-
Pong cycle that amplifies specific sequences generated by the primary biogenesis pathway 
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mouse Zfas1, is expressed at high levels in the mammary gland and is downregulated in 
breast cancer. Taken together, these findings indicates that snoRNA host genes might have 
important functions in regulating cellular homeostasis and, potentially, cancer biology but 
more studies are needed to understand their involvement in molecular basis of disease and 
classify them as sources of potential biomarkers and therapeutic targets. 
Another important aspect of the association between snoRNAs and tumorigenesis is 
represented by the involvement of their associated proteins in cancer. A point mutations in 
the DKC1 gene is the cause of a rare X-linked recessive disease, the dyskeratosis congenita 
(DC) [151-152]. Individuals with DC display features of premature aging, as well as nail 
dystrophy, mucosal leukoplakia, interstitial fibrosis of the lung, and increased susceptibility 
to cancer. DKC1 codes for dyskerin, a putative pseudouridine synthase, which carries out 
two separate functions, both fundamental for proliferating cells. One function is the pseudo-
uridylation of ribosomal RNA (rRNA) molecules as a part of the H/ACA ribonucleoprotein 
complex, and the other is the stabilization of the telomerase RNA component necessary for 
telomerase activity. Dkc1 mutant mice recapitulate the major features of DC, including an 
increased susceptibility to tumor formation. Early generation (G1 and G2) of Dkc1 mutant 
mice showed a full spectrum of DC and presented alterations in rRNA modification, 
whereas defects in telomere length were not evident until G4 mice, suggesting that 
deregulated ribosome function is important for the initiation of DC and that impairment in 
telomerase activity in Dkc1 mutant mice may modify and/or exacerbate the disease in later 
generations. To this regard, DKC1 was identified as one of only seventy genes that, 
collectively, constitute a gene expression profile that strongly correlates with the 
development of aneuploidy and is associated with poor clinical prognosis in a variety of 
human cancers. Therefore, one hypothesis is that an alteration of physiologic dyskerin 
function, irrespective of the mechanism, may perturb mitosis and contribute to 
tumorigenesis but this idea will require more detailed investigation. Another possibility is 
related to the strong effect of dyskerin loss on H/ACA accumulation. Recent finding in fact 
have shown that some H/ACA box and C/D box can be processed to produce small RNAs, 
at least some of which can function like miRNAs [153]. Such processing may be of crucial 
importance, as miRNAs have important roles in the development of many cancers as 
previously discussed. To date, Xiao and colleagues have recently reported that an H/ACA 
box snoRNA- derived miRNA, miR-605, has a key role in stress-induced stabilization of the 
p53 tumour suppressor protein [154]. p53 transcriptionally activates its negative regulator, 
MDM2, in addition to miR-605. miR-605 counteracts MDM2 through post-transcriptional 
repression; under conditions of stress, this snoRNA-derived miRNA offsets the MDM2 
negative-feedback loop, generating a positive-feedback loop to enable the rapid 
accumulation of p53. However, whether this regulation of p53 by miR-605 is relevant to 
cancer biology has not yet been addressed. Like dyskerin, NHP2 and NOP10 proteins, both 
components of the H/ACA snoRNPs, are also significantly up-regulated in sporadic cancers 
and high levels may be associated with poor clinical prognosis. Moreover, germline NHP2 
and NOP10 mutations give rise to autosomal recessive forms of dyskeratosis congenita, and 
cancer susceptibility is also a feature of these genetic forms of the disease. Since the 
functions of several snoRNAs have not yet been identified (orphan snoRNAs), it is possible 
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that disruption of snoRNP biogenesis by any mechanism may affect an array of important 
cellular processes, and could potentiate cancer development and/or progression.  
7.2. piRNAs: Guardians of the genome 
Piwi-interacting RNAs (piRNAs) are germline-specific small silencing RNAs of 24–30 nt in 
length, that suppress transposable elements (TE) activity and maintain genome integrity 
during germline development, a role highly conserved across animal species [155-156]. TEs 
are genomic parasites that threaten the genomic integrity of the host genome: they are able 
to move to new sites by insertion or transposition and thereby disrupt genes and alter the 
genome [157]. In animals, endogenous siRNAs also silence TEs, but the piRNA pathway is 
at the forefront of defense against transposons in germ cells [158]. piRNAs specifically 
associate with PIWI proteins, which are germline-specific members of the AGO protein 
family, AGO3, Aubergine (Aub) and Piwi, and form a piRNA-induced silencing complex 
(piRISC) which will guide the TE silencing [159-162]. Any mutations in each of the three 
members of the PIWI family lead to transposon derepression in the germline, indicating that 
they act non-redundantly during TE silencing. Initial screening of piRNA sequences 
revealed that there are hundreds of thousands, if not millions, of individual piRNA 
sequences [163-165]. Furthermore, they are characterized by the absence of specific sequence 
motifs or secondary structures such as miRNA precursors. Despite their large diversity, 
most piRNAs can be mapped to a relatively small number of genomic regions called piRNA 
clusters. Each cluster extends from several to more than 200 kilobases, it contains multiple 
sequences that generate piRNAs and some piRNAs map to both genomic strands, 
suggesting bidirectional transcription [163-165] Indeed, analysis of piRNA clusters in 
different Drosophila species has shown that, although the clusters locations are conserved, 
their sequence content has evolved very quickly suggesting adjustments in the piRNAs 
patrimony in order to suppress new active transposons invading the species. Therefore, 
piRNA clusters may be considered as repositories of information, enabling production of 
many mature piRNAs that target diverse TEs. Two main pathways, highly conserved in 
many animal species, have been discovered to be responsible for the biogenesis of the 
piRNAs: the primary pathways and the Ping-Pong amplification (Figure 3) [166-168]. First, 
the primary piRNA biogenesis pathway provides an initial pool of piRNAs that target 
multiple TEs. Next, the Ping-Pong cycle further shapes the piRNA population by amplifying 
sequences that target active transposons. It is currently unclear how primary piRNAs are 
produced from piRNA clusters but it is likely that piRNA precursors are single-stranded 
and therefore do not require Dicer for their processing. Interestingly, piRNAs that associate 
with each member of the PIWI protein family have a distinct size, suggesting that PIWI 
proteins can act as ‘rulers’ that define the size of mature piRNAs. Several additional proteins 
(e.s. Zucchini, Armitage and Yb) have also been identified that are involved in primary 
piRNA biogenesis and mutations in and/or depletion of any of these three proteins 
eliminates primary piRNAs associated with PIWI proteins. In some cell types, such as 
somatic follicle cells of the D. melanogaster ovary, primary piRNA biogenesis is the only 
mechanism that generates piRNAs. However, in germline cells of the D. melanogaster ovary 
and in the pre-meiotic spermatogonia in mice, there is another mechanism called the Ping-
Pong cycle that amplifies specific sequences generated by the primary biogenesis pathway 
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[163,169]. Mainly the Ping-Pong pathway engages AGO3 and Aubergine, both of which are 
accumulated in perinuclear structures located at the cytoplasmic face of the nuclear 
envelope in animal germline cells, named “nuage”. The pathway depends on the 
endoribonuclease or Slicer activity of AGO3 and Aubergine, which act catalytically one after 
the other, leading to a cleavage of the target RNAs between their tenth and eleventh 
nucleotides relative to the ‘guide’ small RNAs. This process results in the generation of 
repeated rounds of piRNA production having exactly the same sequence of the original 
primary piRNA. The ping-pong pathway amplifies piRNAs in D. melanogaster testes, 
especially those originating from TEs. Non-TE-derived piRNAs seem to be barely amplified 
by the amplification loop. This two steps of piRNA biogenesis can be compared with the 
function of the adaptive immune system in protecting against pathogens. The primary 
piRNA biogenesis pathway resembles the initial generation of the hypervariable antibody 
repertoire, whereas the amplification loop is analogous to antigen-directed clonal expansion 
of antibody-producing lymphocytes during the acute immune response. An emerging 
number of studies highlight the role of piRNAs or PIWI proteins in the regulation of 
tumorigenesis. First examples of the piRNA involvement in cancer is represented by the up-
regulation of HIWI, one of the four human Piwi homologues, in about 60 % of seminomas 
[170]. In fact, HIWI maps to a locus known as a germ cell tumor susceptibility locus 
(12aq24.33). HIWI overexpression has also been found in somatic cells such as soft-tissue 
sarcomas or ductal pancreas adenocarcinoma, and strongly correlates with bad prognosis  
and high incidence of tumor-related death, providing an example for a potential 
tumorigenic role of a piRNA-related protein in somatic cells [171,172]. In some cancers, 
PIWIL2 overexpression has been suggested to induced resistance in cells to cisplatin, which 
might arise because of increased chromatin condensation that prevents the normal process 
of DNA repair [173]. Furthermore, new high-throughput sequencing data revealed the 
presence of piRNAs in somotic cells, such as HeLa cells. These somatic piRNAs appear 
located in the nucleolus and in the cytoplasmic area surrounding the nuclear envolope and 
in contrast with the large population of known piRNAs in male germ cells, this population 
of piRNAs is dramatically smaller [174]. Another recent study demonstrated that the level of 
piR-651 is significantly higher in several cancer histotype including lung, mesothelium, 
breast, liver, and cervical cancer compared to non-cancerous adjacent tissues and inhibition 
of piR-651 induced block of gastric cancer cells at the G2/M phase [175,176]. Another 
example is represented by the downregulation of  piR-823 in gastric cancer tissues; its 
enforced expression inhibited gastric cancer cell growth in vitro and in vivo, suggesting a 
tumor suppressive properties for piR-823 [177]. Interestingly, piRNAs not are only involved 
in direct regulation by degradation of TE but they have also been linked to DNA 
methylation of the retrotraspon regions, extending piRNA functions beyond post-
transcriptional silencing. In fact, CpG DNA methylation, which is required for efficient 
transcriptional silencing of LINE and LTR retrotransposons in the genome, is decreased in 
the male germ line of mice with defective PIWI proteins. Specifically, mice with defective 
PIWI proteins fail to establish de novo methylation of TE sequences during 
spermatogenesis, leading to the hypothesis that the piRISC can also guide the de novo 
methylation machinery to TE loci. In this scenerio, piRNAs may present a perfect guide for 
discriminating TE sequences from normal protein-coding genes and marking them for DNA 
methylation; however, the biochemical details of how these two mechanisms of piRNA 
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action might be linked have not yet been revealed [178,179]. All together, these data 
revealed that PIWI-associated RNAs and PIWI pathway has a more profound function 
outside germline cells than was originally thought but many more studies are needed to 
clarify their specific role in tumorigenesis. 
 
Figure 3. piRNAs. A, schematic representation of the Drosophila egg chamber. B,piRNAs (which are 
24–32 nt in length) are processed from single-stranded RNA precursors that are transcribed largely from 
mono- or bidirectional intergenic repetitive elements known as piRNA clusters. Unlike miRNAs and 
siRNAs, piRNAs do not require Dicer for their processing. First, primary piRNAs are produced through 
the primary processing pathway and are amplified through the ping-pong pathway, which requires 
Slicer activity of PIWI proteins. Subsequently, additional piRNAs are produced through a PIWI-protein-
catalysed amplification loop (called the 'ping-pong cycle') via sense and antisense intermediates. 
Primary piRNA processing and loading onto mouse PIWI proteins might occur in the cytoplasm. The 
PIWI ribonucleoprotein (piRISC) complex functions in transposon repression through target 
degradation and epigenetic silencing. C, total number of piRNA clusters in different animal species 
according to the piRNA Database (http://pirnabank.ibab.ac.in/).  
8. The emergence of long non-coding RNAs 
Over the last decade, advances in genome-wide analyses of the eukaryotic transcriptome 
have revealed that most of the human genome is transcribed, generating a large repertoire 
of (>200 nt) long non-coding RNAs (lncRNA or lincRNA, for long intergenic ncRNA) that 
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PIWIL2 overexpression has been suggested to induced resistance in cells to cisplatin, which 
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action might be linked have not yet been revealed [178,179]. All together, these data 
revealed that PIWI-associated RNAs and PIWI pathway has a more profound function 
outside germline cells than was originally thought but many more studies are needed to 
clarify their specific role in tumorigenesis. 
 
Figure 3. piRNAs. A, schematic representation of the Drosophila egg chamber. B,piRNAs (which are 
24–32 nt in length) are processed from single-stranded RNA precursors that are transcribed largely from 
mono- or bidirectional intergenic repetitive elements known as piRNA clusters. Unlike miRNAs and 
siRNAs, piRNAs do not require Dicer for their processing. First, primary piRNAs are produced through 
the primary processing pathway and are amplified through the ping-pong pathway, which requires 
Slicer activity of PIWI proteins. Subsequently, additional piRNAs are produced through a PIWI-protein-
catalysed amplification loop (called the 'ping-pong cycle') via sense and antisense intermediates. 
Primary piRNA processing and loading onto mouse PIWI proteins might occur in the cytoplasm. The 
PIWI ribonucleoprotein (piRISC) complex functions in transposon repression through target 
degradation and epigenetic silencing. C, total number of piRNA clusters in different animal species 
according to the piRNA Database (http://pirnabank.ibab.ac.in/).  
8. The emergence of long non-coding RNAs 
Over the last decade, advances in genome-wide analyses of the eukaryotic transcriptome 
have revealed that most of the human genome is transcribed, generating a large repertoire 
of (>200 nt) long non-coding RNAs (lncRNA or lincRNA, for long intergenic ncRNA) that 
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map to intronic and intergenic regions [181,181]. Given their unexpected abundance, 
lncRNAs were initially thought to be spurious transcriptional noise resulting from low RNA 
polymerase fidelity [182]. However, the restricted expression of many long ncRNAs to 
particular developmental contexts, the often exhibiting precise subcellular localization  and 
the binding of transcription factors to non-coding loci, suggested that a significant portion of 
ncRNAs fulfills functional roles beyond transcriptional remodelling [183-187]. lncRNA 
typically refers to a polyadenylated long ncRNA that is transcribed by RNA polymerase II 
and is associated with epigenetic signatures common to protein-coding genes, such as 
trimethylation of histone 3 lysine 4 (H3K4me3) at the transcriptional start site (TSS) and 
trimethylation of histone 3 lysine 36 (H3K36me3) throughout the gene body [188-189]. 
lncRNAs also commonly exhibit splicing of multiple exons into a mature transcript, and 
their transcription occurs from an independent gene promoter and is not coupled to the 
transcription of a nearby or associated parental gene. RNA-Seq studies now suggest that 
several thousand uncharacterized lncRNAs are present in any given cell type [188-189], and 
that the human genome may harbor nearly as many lncRNAs as protein-coding genes 
(perhaps ~15,000 lncRNAs), although only a fraction is expressed in a given cell type. One 
main characteristic of the lncRNAs is their very low sequence conservation that had fueled 
the idea that they are not functional. This assertion needs to be carefully considered and 
takes in consideration several points. First, a recent study identified the presence of 1,600 
lncRNAs that show a strong evolutionary conservation and function ranging from from 
embryonic stem cell pluripotency to cell proliferation [189]. In contrast to the protein coding 
genes, long ncRNAs can exhibit shorter stretches of sequence that are conserved to maintain 
functional domains and structures. Indeed, many long ncRNAs with a known function, such 
as Xist, only exhibit high conservation over short sections of their length [190]. Third, rather 
than being indicative of non-functionality, low sequence conservation can also be explained 
by high rates of primary sequence evolution if long ncRNAs have, like promoters and other 
regulatory elements, more plastic structure–function constraints than proteins [190]. The 
diverse selection pressures acting on long ncRNAs probably reflect the wide range of their 
functions which can be regrouped in three major subclasses: chromatin remodeling, 
transcriptional modulation and nuclear architecture/subnuclear localization.  
long ncRNAs can mediate epigenetic changes by recruiting chromatin remodelling 
complexes to specific genomic loci resolving the paradox of how a small repertoire of 
chromatin remodelling complexes are able To specify the large array of chromatin 
modifications without any apparent specificity for the genomic loci [191,192]. A recent study 
found that 20% of 3300 human long non coding RNAs are bound by Polycomb Repressive 
Complex 2 (PRC2) [193]. Although the specific molecular mechanisms are not defined, there 
are several examples that can illustrate the silencing potential of lncRNAs (Figure 4). The 
first most known example is represented by the X-chromosome inactivation which is carried 
out by a number of lncRNAs including Xist and RepA, which bind PRC2 complex, and the 
antogonist of Xist, Tsix [194]. In pre-X-inactivation cells, Tsix competes with RepA for the 
binding of PRC2 complex; when the X-inactivation starts Tsix is downregulated and PRC2 
becomes available to RepA which can actively induced the transcription of Xist. The up-
regulated Xist in turn preferentially binds to PRC2 and spreads across the chromosome X 
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inducing PCR2-mediated trimethylated histone H3 lysine27. Another important example is 
represented by the hundreds of long ncRNAs which are sequentially expressed along the 
temporal and spatial developmental axes of the human homeobox (Hox) loci, where they 
define chromatin domains of differential histone methylation and RNA polymerase 
accessibility [195]. One of these ncRNAs, Hox transcript antisense RNA (HOTAIR), 
originates from the HOXC locus and silences transcription across 40 kb of the HOXD locus 
in trans by inducing a repressive chromatin state, which is proposed to occur by recruitment 
of the Polycomb chromatin remodelling complex PRC2 by HOTAIR (Figure 4). Recently, it 
has been proposed that HOTAIR has the ability to bind other histone-modifying enzymes 
such as the demethylase LSD1 [196]. In fact, knockdown of HOTAIR induces a rapid loss of 
LSD1 or PRC2 at hundreds of gene loci with the corresponding increase in expression. This 
model fits other chromatin modifying complexes, such as Mll, PcG, and G9a 
methyltransferase, which can be similarly directed by their associated ncRNAs [196]. As 
modulator of epigenetic landmark, it has been shown that HOTAIR has a profound effect on 
tumorigenesis. In fact, HOTAIR is upregulated in breast carcinoma and colon cancer and its 
correlates with metastasis and poor prognosis [197] Enforced expression of HOTAIR 
consistently changed the pattern of occupancy of Polycomb proteins from the typical 
epithelial mammary cells pattern to that of embryonic fibroblasts [198]. Another important 
effect of lncRNAs on chromatin modification that can highlight their impact on cancer is the 
relationship between the lncRNA ANRIL and the INK4b/ARF/INK4a locus, encoding for 
three tumor-suppressor genes highly deleted or silenced in a large cohort of tumors [199]. 
ANRIL, which is transcribed antisense to the protein coding genes of the locus, controls the 
epigenetic status of the locus by interacting with subunits of PRC1 and PRC2. High 
expression of ANRIL is found in some cancer tissues and is associated to a high levels of 
PCR-mediated trimethylated histone H3 lysine27. Inhibition of ANRIL releases PRC1 and 
PRC2 complexes from the locus, decreases the histone methylation status with the following 
increase of the protein coding gene transcription. Many other tumor suppressor genes that 
are frequently silenced by epigenetic mechanisms in cancer also have antisense partners, 
which can affect gene expression with different other mechanism. First, antisense ncRNAs 
can mask key cis-elements in mRNA by the formation of RNA duplexes, as in the case of the 
Zeb2 antisense RNA, which complements the 5′ splice site of an intron of Zeb2 mRNA [200]. 
Expression of the ncRNA prevents the splicing of the intron that contains an internal 
ribosome entry site required for efficient translation and expression of the ZEB2 protein 
with a further efficient translation (Figure 4). In this context, it has been evaluated that the 
prevalence of lncRNAs are antisense to introns, hypothesizing their role in the regulation of 
splicing or capable of generating mRNA duplexes that fuel the RISC machinery to silence 
gene expression. One major emergent theme is the involvement of the lncRNAs in the 
assembly or activity of transcription factors functioning as a scaffold for the docking of 
many proteins, mimicking functional DNA elements or modulation of PolII itself. The first 
example is represented by the suppression of CCND1 mediated by the lncRNAs through the 
recruitment and integration of the RNA binding protein TLS into a transcriptional 
programme. DNA damage signals induce the expression of long ncRNAs associated with 
the cyclin D1 gene promoter, where they act cooperatively to recruit the RNA binding  
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inducing PCR2-mediated trimethylated histone H3 lysine27. Another important example is 
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LSD1 or PRC2 at hundreds of gene loci with the corresponding increase in expression. This 
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ANRIL, which is transcribed antisense to the protein coding genes of the locus, controls the 
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expression of ANRIL is found in some cancer tissues and is associated to a high levels of 
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which can affect gene expression with different other mechanism. First, antisense ncRNAs 
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Figure 4. lncRNAs. Schematic representation of the control operated on protein coding gene by the 
lncRNAs at the level of chromatin remodelling, transcriptional control and post-transcriptional 
processing. A, lncRNAs (Xist, HOTAIR, ANRIL, etc) can recruit chromatin modifying complexes to 
specific genomic loci to localize their catalytic activity. In this case, the lncRNA recruits the Polycomb 
complex by inducing trimethylation of the lysine 27 residues (me3K27) of histone H3 to produce 
heterochromatin formation and repress gene expression. B, C, D, lncRNAs can regulate the transcriptional 
process through a range of mechanisms. First, lncRNAs tethered to the promoter of the cyclin D1 gene 
recruit the RNA binding protein TLS to modulate the histone acetyltransferase activity of CREB binding 
protein (CBP) and p300 to repress gene transcription. Second, an ultraconserved enhancer is transcribed as 
a long ncRNA, Evf2, which subsequently acts as a co-activator to the transcription factor DLX2, to regulate 
the Dlx6 gene transcription. Third, a lncRNA transcribed from the DHFR minor promoter form a triplex at 
the major promoter to reduce the access of the general transcription factor TFIID, and thereby suppress 
DHFR gene expression. E, a lncRNA is antisense to Zeb2 mRNA and mask the 5′ splice site resulting in 
intron retention. This retention results in an efficient Zeb2 translation related to the presence of an internal 
ribosome entry site (IRE) in the retained intron. 
protein TLS. The modified and promoter-docked TLS inhibits the histone acetyltransferase 
activities of CReB binding protein and p300 inducing the silencing of cyclin D1 expression 
(Figure 4) [201]. A different co-activator activity mediated by lncRNAs is also evident in the 
regulation of Dlx genes, important modulators of neuronal development and patterning 
[202]. Dlx5-6 expression is regulated by two ultraconserved enhancers one of which is 
transcribed in a lncRNA, named Evf-2. Evf2 forms a stable complex with the homodomein 
protein DLX-2 which in turn acts as a transcriptional enhancer of Dxl5-6 gene (Figure 4). In 
some cases, lncRNAs can also affect RNA polymerase activity by influencing the initiation 
complex in the choice of the promoter.  For example, in humans, a ncRNA transcribed from an 
upstream region of the dihydrofolate reductase (DHFR) locus forms a triplex in the major 
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promoter of DHFR to prevent the binding of the transcriptional co-factor TFIID (Figure 4). This 
could be a widespread mechanism for controlling promoter usage as thousands of triplex 
structures exist in eukaryotic chromosomes. Recently, lncRNAs have also shown their 
tumorigenic potential by modulating the transcriptional program of p53 [203]. An 3kb 
lncRNAs, linc-RNA-p21, transcriptionally activated by p53, has been shown to collaborate 
with p53 in order to control the gene expression in response to DNA damage. Specifically, 
silencing of lincRNA-p21 derepresses the expression of hundred of genes which are also 
derepressed following p53 knockdown. It has also been discovered that lincRNA-p21 
interacts with hnRNPK and this binding is essential for the modulation of p53 activity.  
The final category of lncRNAs is represented by those molecules capable to generate the 
formation of compartmentalized nuclear organelles, subnuclear membraneless nuclear 
bodies whose funtion is relative unknown. One of them is represented by cell-cycle 
regulated nuclear foci, named paraspeckles. In addition to protein components, two 
lncRNAs, NEAT1 and Men epsilon, have been detected as essential part of the paraspeckles. 
While depletion of NEAT or Men epsilon disrupts the paraspeckles, their overexpression 
strongly increases their number. There is a number of different lncRNAs that localize to 
different nuclear regions [204]. Metastasis-associated lung adenocarcinoma transcript 1 
(MALAT1) localizes to the splicing speckles, Xist and Kcnq1ot1 both, localize to the 
perinucleolar region during the S phase of the cell cycle, a class of repeat-associated 
lncRNAs (es SatIII) are associated to nuclear stress bodies which are produced on specifc 
pericentromeric heterochromatic domains containing SatIII gene itself.        
9. Conclusions 
Alterations in microRNAs and other short or long non-coding RNA (ncRNA) are involved in 
the initiation, progression, and metastasis of human cancer. Over the last decade, a growing 
number of non-coding transcripts have been found to have roles in gene regulation and RNA 
processing. The most well known small non-coding RNAs are the microRNAs, but the 
network of long and short non-coding transcripts is complex and is likely to contain as yet 
unidentified classes of molecules that form transcriptional regulatory networks. The field of 
small and long non coding RNAs is rapidly advancing toward in vivo delivery for therapeutic 
purposes. Advanced molecular therapies aimed at downmodulating or upmodulating the 
level of a given miRNA in model organisms have been successfully established. RNA-based 
gene therapy can be used to treat cancer by using RNA or DNA molecules as therapy against 
the mRNA of genes involved in cancer pathogenesis or by directly targeting the ncRNAs that 
participate in pathogenesis. The use of miRNAs is still being evaluated preclinically; no clinical 
or toxicologic studies have been published but the future is promising. Kota and collegues 
reported that systemic administration of this miRNA in a mouse model of HCC using adeno-
associated virus (AAV) results in inhibition of cancer cell proliferation, induction of tumor-
specific apoptosis, and dramatic protection from disease progression without toxicity (116). 
Recently, Pineau et al. (117) identified DNA damage-inducible transcript 4 (DDIT4), a 
modulator of the mTor pathway, as a bona fide target of miR-221. They introduced into liver 
cancer cells, by lipofection, LNA-modified oligonucleotides specifically designed for miR-221 
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modulator of the mTor pathway, as a bona fide target of miR-221. They introduced into liver 
cancer cells, by lipofection, LNA-modified oligonucleotides specifically designed for miR-221 
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(antimiR-221) and miR-222 (antimiR-222) knockdown. Treatment by antagomiRs, but not 
scrambled oligonucleotide, reduced cell growth in liver cancer cell lines that overexpressed 
miR-221 and miR-222 by 35% and 22%, respectively. Thus the use of synthetic inhibitors of 
miR-221 may prove to be a promising approach to liver cancer treatment (117). Despite recent 
progress in silencing of miRNAs in rodents, the development of effective and safe approaches 
for sequence-specific antagonism of miRNAs in vivo remains a significant scientific and 
therapeutic challenge. Recently, Elmen and collaborators (118) showed for the first time, that 
the simple systemic delivery of an unconjugated, PBS-formulated LNA-antimiR effectively 
antagonizes the liver-expressed miR-122 in nonhuman primates. Administration by 
intravenous injections of LNA-antimiR into African green monkeys resulted in the formation 
of stable heteroduplexes between the LNA-antimiR and miR-122, accompanied by depletion of 
mature miR-122 and dose-dependent lowering of plasma cholesterol. These findings 
demonstrate the utility of systemically administered LNA-antimiRs in exploring miRNA 
functions in primates and show the impressive potential of this strategy to overcome a major 
hurdle for clinical miRNA therapy. In conclusion, the discovery of small RNAs and their 
functions has revitalized the prospect of controlling expression of specific genes in vivo, with 
the ultimate hope of building a new class of gene-specific medical therapies. Just how 
significant are the ncRNAs? They appear to be doing something important and highly 
sophisticated; there are so many of them, their sequences are so highly conserved, their 
expression is tissue specific, and they have recognition sites on more than 30% of the entire 
transcriptome. It seems that ncRNAs were overlooked in the past simply because researchers 
were specifically looking for RNAs that code proteins. The above discussed data highlight that 
the complexity of genomic control operated by the ncRNAs is somewhat greater than 
previously imagined, and that they could represent a total new order of genomic control. In 
this scenario, understanding the precise roles of ncRNAs is a key challenge. The targeting of 
other ncRNAs, in addition to miRNAs, is still in its infancy, but new important developments 
are expected in this area. Therefore, small RNAs could become powerful therapeutic tools in 
the near future. 
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(antimiR-221) and miR-222 (antimiR-222) knockdown. Treatment by antagomiRs, but not 
scrambled oligonucleotide, reduced cell growth in liver cancer cell lines that overexpressed 
miR-221 and miR-222 by 35% and 22%, respectively. Thus the use of synthetic inhibitors of 
miR-221 may prove to be a promising approach to liver cancer treatment (117). Despite recent 
progress in silencing of miRNAs in rodents, the development of effective and safe approaches 
for sequence-specific antagonism of miRNAs in vivo remains a significant scientific and 
therapeutic challenge. Recently, Elmen and collaborators (118) showed for the first time, that 
the simple systemic delivery of an unconjugated, PBS-formulated LNA-antimiR effectively 
antagonizes the liver-expressed miR-122 in nonhuman primates. Administration by 
intravenous injections of LNA-antimiR into African green monkeys resulted in the formation 
of stable heteroduplexes between the LNA-antimiR and miR-122, accompanied by depletion of 
mature miR-122 and dose-dependent lowering of plasma cholesterol. These findings 
demonstrate the utility of systemically administered LNA-antimiRs in exploring miRNA 
functions in primates and show the impressive potential of this strategy to overcome a major 
hurdle for clinical miRNA therapy. In conclusion, the discovery of small RNAs and their 
functions has revitalized the prospect of controlling expression of specific genes in vivo, with 
the ultimate hope of building a new class of gene-specific medical therapies. Just how 
significant are the ncRNAs? They appear to be doing something important and highly 
sophisticated; there are so many of them, their sequences are so highly conserved, their 
expression is tissue specific, and they have recognition sites on more than 30% of the entire 
transcriptome. It seems that ncRNAs were overlooked in the past simply because researchers 
were specifically looking for RNAs that code proteins. The above discussed data highlight that 
the complexity of genomic control operated by the ncRNAs is somewhat greater than 
previously imagined, and that they could represent a total new order of genomic control. In 
this scenario, understanding the precise roles of ncRNAs is a key challenge. The targeting of 
other ncRNAs, in addition to miRNAs, is still in its infancy, but new important developments 
are expected in this area. Therefore, small RNAs could become powerful therapeutic tools in 
the near future. 
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1. Introduction 
Tumor metabolism and bioenergetics are important areas for cancer research and present 
promising targets for anticancer therapy. Growing tumors alter their metabolic profiles to 
meet the bioenergetic and biosynthetic demands of increased cell growth and proliferation. 
These alterations include the well-known aerobic glycolysis, the Warburg effect, which has 
been considered as the central tenet of cancer cell metabolism for more than 80 years [1]. 
Interest in cancer cell metabolism has been refueled by recent advances in the study of 
signaling pathways involving known oncogene and tumor suppressor genes, which reveal 
their close interaction with metabolic pathways [2-4]. For example, recent studies document 
an important role of glutamine catabolism in tumor stimulated by the oncogenic 
transcriptional factor c-MYC (herein termed MYC) which has been previously shown to 
stimulate glycolysis [5, 6]. Although glucose and glutamine serve as the main metabolic 
substrate for tumor cells, proline as a microenvironmental stress substrate has attracted lots 
of attention due to its unique metabolic system, its availability in tumor microenvironments 
and its responses to various stresses.    
1.1. Special features of proline metabolism 
Proline is the only proteinogenic secondary amino acid, and it has special functions in 
biology [7-11]. Proline metabolism is distinct from that of primary amino acids. The 
inclusion of an alpha-nitrogen within its pyrrolidine ring precludes its being the substrate 
for the usual amino acid-metabolizing enzymes, such as, the decarboxylases, 
aminotransferases, and racemases. Instead, proline metabolism has its own family of 
enzymes with their tissue and subcellular localization and their own regulatory 
mechanisms. As shown in the schematic of proline metabolic pathway (Figure 1), these 
enzymes include proline dehydrogenase/oxidase (PRODH/POX) and pyrroline-5-
carboxylate reductase (PYCR) catalyzing the interconversion of proline and Δ1-pyrroline-5-
carboxylate (P5C), P5C dehydrogenase (P5CDH) and P5C synthase (P5CS) mediating the 
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stimulate glycolysis [5, 6]. Although glucose and glutamine serve as the main metabolic 
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inclusion of an alpha-nitrogen within its pyrrolidine ring precludes its being the substrate 
for the usual amino acid-metabolizing enzymes, such as, the decarboxylases, 
aminotransferases, and racemases. Instead, proline metabolism has its own family of 
enzymes with their tissue and subcellular localization and their own regulatory 
mechanisms. As shown in the schematic of proline metabolic pathway (Figure 1), these 
enzymes include proline dehydrogenase/oxidase (PRODH/POX) and pyrroline-5-
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interconversion of P5C and glutamate, and ornithine aminotransferase (OAT) catalyzing the 
interconversion of P5C and ornithine. Glutamate can be converted to α-ketoglutarate (α-KG) 
entering the tricarboxylic acid (TCA) cycle, which is also the main pathway of glutamine 
catabolism. Ornithine can be converted to arginine entering the urea cycle. Thus proline 
metabolism is closely related with glutamine metabolism, TCA cycle, and urea cycle, the 
main metabolic pathways in human body. 
 
Figure 1. Proline metabolic pathway. Proline metabolism is closely related with glutamine 
metabolism, TCA cycle, urea cycle and pentose phosphate pathway (PPP). Abbreviations: P5C, Δ1 -
pyrroline-5-carboxylate; GSA, glutamic-gamma-semialdehyde; PRODH/POX, proline 
dehydrogenase/oxidase; PYCR, P5C reductase; P5CDH, P5C dehydrogenase; GS, glutamine synthase; 
GLS, glutaminase; P5CS, P5C Synthase; OAT, ornithine aminotransferase. The interconversion between 
P5C and GSA is spontaneous. 
Importantly, the interconversion between proline and P5C, catalyzed by PRODH/POX and 
PYCR, respectively, forms the “proline cycle” in the cytosol and mitochondria as shown in 
Figure 2, which acts as a redox shuttle transferring reducing and oxidizing potential. In the 
mitochondria, during the degradation of proline to P5C, PRODH/POX, the flavin adenine 
dinucleotide-containing enzyme tightly bound to mitochondrial inner membranes, donates 
electrons through its intervening flavine adenine dinucleotide into the electron transport 
chain (ETC) to generate ATP or ROS [7, 12, 13]. This characteristic of PRODH/POX serves as 
the basis of its function in human cancers, which will be discussed in detail in the following 
sections. P5C produced from the oxidation of proline, emerges from mitochondria and is 
converted back to proline in the cytosol using NADPH or NADH as cofactor, which 
interlock with the pentose phosphate pathway (Figure 1) or other metabolic pathways.  
Proline metabolism has been shown to play an important role in various human physiologic 
and pathologic situations. For example, in the early 1970s, P5C, the immediate product of 
proline catabolism was found to be also the immediate biosynthetic precursor [7]. And in 
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the 1980s, the conversion of P5C to proline was recognized to regulate redox homeostasis as 
mentioned above [8, 14, 15]. A variety of evidence has shown the inborn errors of the proline 
metabolic pathway in several human genetic diseases and their potential roles [11, 16], such 
as familial hyperprolinemias [11, 17], mutations of PRODH/POX in neuropsychiatric 
diseases [18, 19], mutations of PYCR1 in cutis laxa [20], mutations of P5CS in 
hyperammonemia [21, 22], and so on. During the last decade, our understanding of the roles 
of proline metabolism as represented by the regulation and functions of PRODH/POX in 
tumorigenesis and tumor progression has made significant advances, which will be main 
focus in this chapter.    
1.2. Proline availability in tumor microenvironment  
Proline is one of the most abundant amino acids in the cellular microenvironment. Together 
with hydroxyproline, proline constitutes more than 25% of residues in collagen, the 
predominant protein (80%) in the extracellular matrix (ECM) of the human body. Although 
proline can be obtained from the dietary proteins, an important source of proline is from the 
degradation of collagen in the ECM by sequential enzymatic catalysis of matrix 
metalloproteinases (MMPs) and prolidase [9, 23]. The upregulation of MMPs in tumors has 
been considered a critical step for tumor progression and invasion [24-26]. A number of 
reports have shown that proline concentration is increased in various tumors, which may 
result from the upregulated MMPs degrading collagen. Previous work from our lab showed 
that glucose depletion activated MMP-2 and MMP-9 in cancer cells, which accompanied an 
increase in intracellular proline levels [27].  
Autophagy-induced degradation of the intracellular protein, which has been shown to 
regulate cancer development and progression as a survival strategy of cancer cells [28, 29], 
may also provide an important source of free proline. Furthermore, proline can be 
biosynthesized from either glutamate or ornithine as shown in Figure 1 and Figure 2. Our 
latest finding showed that a large part of products from glutamine catabolism stimulated by 
MYC is proline [30], suggesting proline biosynthesis might serve as an additional source of 
proline availability in cancer. Taken together, the ample sources of proline in tumor 
microenvironment ensure its availability as an important stress substrate for metabolism in 
human cancers.  
2. PRODH/POX as a mitochondrial tumor suppressor 
2.1. PRODH/POX induces apoptosis through ROS generation 
PRODH, the gene encoding PRODH/POX was discovered to be a p53-induced gene in a 
screening study in 1997 [31]. Importantly, the p53-initiated apoptosis was later found to 
depend on the induction of PRODH/POX [32]. To further study the function of 
PRODH/POX, we developed a DLD1-POX colorectal cancer cell line (designated as DLD1-
POX tet-off cell line), which was stably transfected with the PRODH gene under the control 
of a tetracycline-controllable promoter [33]. When doxycycline (DOX) was removed from 
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interconversion of P5C and glutamate, and ornithine aminotransferase (OAT) catalyzing the 
interconversion of P5C and ornithine. Glutamate can be converted to α-ketoglutarate (α-KG) 
entering the tricarboxylic acid (TCA) cycle, which is also the main pathway of glutamine 
catabolism. Ornithine can be converted to arginine entering the urea cycle. Thus proline 
metabolism is closely related with glutamine metabolism, TCA cycle, and urea cycle, the 
main metabolic pathways in human body. 
 
Figure 1. Proline metabolic pathway. Proline metabolism is closely related with glutamine 
metabolism, TCA cycle, urea cycle and pentose phosphate pathway (PPP). Abbreviations: P5C, Δ1 -
pyrroline-5-carboxylate; GSA, glutamic-gamma-semialdehyde; PRODH/POX, proline 
dehydrogenase/oxidase; PYCR, P5C reductase; P5CDH, P5C dehydrogenase; GS, glutamine synthase; 
GLS, glutaminase; P5CS, P5C Synthase; OAT, ornithine aminotransferase. The interconversion between 
P5C and GSA is spontaneous. 
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chain (ETC) to generate ATP or ROS [7, 12, 13]. This characteristic of PRODH/POX serves as 
the basis of its function in human cancers, which will be discussed in detail in the following 
sections. P5C produced from the oxidation of proline, emerges from mitochondria and is 
converted back to proline in the cytosol using NADPH or NADH as cofactor, which 
interlock with the pentose phosphate pathway (Figure 1) or other metabolic pathways.  
Proline metabolism has been shown to play an important role in various human physiologic 
and pathologic situations. For example, in the early 1970s, P5C, the immediate product of 
proline catabolism was found to be also the immediate biosynthetic precursor [7]. And in 
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the 1980s, the conversion of P5C to proline was recognized to regulate redox homeostasis as 
mentioned above [8, 14, 15]. A variety of evidence has shown the inborn errors of the proline 
metabolic pathway in several human genetic diseases and their potential roles [11, 16], such 
as familial hyperprolinemias [11, 17], mutations of PRODH/POX in neuropsychiatric 
diseases [18, 19], mutations of PYCR1 in cutis laxa [20], mutations of P5CS in 
hyperammonemia [21, 22], and so on. During the last decade, our understanding of the roles 
of proline metabolism as represented by the regulation and functions of PRODH/POX in 
tumorigenesis and tumor progression has made significant advances, which will be main 
focus in this chapter.    
1.2. Proline availability in tumor microenvironment  
Proline is one of the most abundant amino acids in the cellular microenvironment. Together 
with hydroxyproline, proline constitutes more than 25% of residues in collagen, the 
predominant protein (80%) in the extracellular matrix (ECM) of the human body. Although 
proline can be obtained from the dietary proteins, an important source of proline is from the 
degradation of collagen in the ECM by sequential enzymatic catalysis of matrix 
metalloproteinases (MMPs) and prolidase [9, 23]. The upregulation of MMPs in tumors has 
been considered a critical step for tumor progression and invasion [24-26]. A number of 
reports have shown that proline concentration is increased in various tumors, which may 
result from the upregulated MMPs degrading collagen. Previous work from our lab showed 
that glucose depletion activated MMP-2 and MMP-9 in cancer cells, which accompanied an 
increase in intracellular proline levels [27].  
Autophagy-induced degradation of the intracellular protein, which has been shown to 
regulate cancer development and progression as a survival strategy of cancer cells [28, 29], 
may also provide an important source of free proline. Furthermore, proline can be 
biosynthesized from either glutamate or ornithine as shown in Figure 1 and Figure 2. Our 
latest finding showed that a large part of products from glutamine catabolism stimulated by 
MYC is proline [30], suggesting proline biosynthesis might serve as an additional source of 
proline availability in cancer. Taken together, the ample sources of proline in tumor 
microenvironment ensure its availability as an important stress substrate for metabolism in 
human cancers.  
2. PRODH/POX as a mitochondrial tumor suppressor 
2.1. PRODH/POX induces apoptosis through ROS generation 
PRODH, the gene encoding PRODH/POX was discovered to be a p53-induced gene in a 
screening study in 1997 [31]. Importantly, the p53-initiated apoptosis was later found to 
depend on the induction of PRODH/POX [32]. To further study the function of 
PRODH/POX, we developed a DLD1-POX colorectal cancer cell line (designated as DLD1-
POX tet-off cell line), which was stably transfected with the PRODH gene under the control 
of a tetracycline-controllable promoter [33]. When doxycycline (DOX) was removed from 
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the culture medium and the expression of PRODH/POX was induced, apoptotic cell death 
was initiated.  
 
Figure 2. Proline metabolism in cancer. 1. Proline cycle: Interconversion of proline and P5C forms the 
proline cycle in the cytosol and mitochondria. Proline cycle acts as a redox shuttle transferring reducing 
potential generated by the pentose phosphate pathway or other metabolic pathway into mitochondria 
for the production of either ROS or ATP responding to different stresses. 2. Proline availability in 
human tumor microenvironment: dietary proteins, glutamate and ornithine catabolism, and 
degradation of extracellular matrix by matrix metalloproteinases (MMPs) are all important sources of 
proline, especially the last one. 3. The central enzyme of proline metabolism, PRODH/POX, localized in 
the mitochondrial inner membrane, function as a mitochondrial tumor suppressor. PRODH/POX is 
induced by p53, PPARγ and its ligands, and suppressed by miR-23b* and oncogenic protein MYC. 
PRODH/POX overexpression could initiate apoptosis, inhibit proliferation and induce G2 cell cycle 
arrest through ROS generation, and suppress HIF-1 signaling through increasing α-KG production. 
Abbreviations: X-PRO, x-prolyl dipeptide; Pro, proline; Orn, ornithine; Gln, glutamine; Glu, glutamate. 
ROS, which include superoxide radical (O2-·), hydroxyl radicals (OH·) and the non-radical 
hydrogen peroxide (H2O2), play an important role in the induction of apoptosis [34]. 
PRODH/POX could donate electron to the ETC to generate ROS. In cells overexpressing 
PRODH/POX, the addition of proline increased ROS generation in a concentration-
dependent manner, and the proline-dependent ROS increased with PRODH/POX 
expression [35]. N-acetyl cysteine (NAC), a widely used antioxidant agent, dramatically 
reduced PRODH/POX-induced apoptosis, indicating PRODH/POX induces apoptosis 
through ROS generation [13]. By introducing the recombinant adenoviruses containing 
different antioxidant enzymes, such as manganese superoxide dismutase (MnSOD), Cu/Zn 
superoxide dismutase (CuZnSOD) or catalase (CAT) into the DLD1-POX tet-off cells, we 
found that only the expression of MnSOD, which localizes in the mitochondria, inhibited 
PRODH/POX-induced apoptosis, suggesting that it is superoxide as the form of ROS 
initially mediating PRODH/POX-induced apoptosis [13].  
Further investigation on the molecular signaling involved in PRODH/POX-induced 
apoptosis showed that PRODH/POX activated both intrinsic and extrinsic apoptotic 
pathways [35, 36]. The DLD-1-POX cells overproducing PRODH/POX exhibited the 
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mitochondria (intrinsic pathway) and death receptor (extrinsic pathway)-mediated 
apoptotic responses in a proline-dependent manner [35]. Intrinsic pathway induced by 
PRODH/POX includes the release of cytochrome c, activation of caspase-9, chromatin 
condensation, DNA fragmentation, and cell shrinkage. Extrinsic pathway induced by 
PRODH/POX involves the stimulation of the expression of tumor necrosis factor-related 
apoptosis inducing ligand (TRAIL), and death receptor 5 (DR5) and then cleavage of 
caspase-8 [36]. Both pathways culminate in the activation of caspase-3 and cleavage of 
substrates. NFATc1, a member of the nuclear factor of activated T cells (NFAT) family of 
transcription factors is partially responsible for the TRAIL activity stimulated by 
PRODH/POX [36]. All of these effects mediated by PRODH/POX could be partially reversed 
by MnSOD, further confirming the role of ROS/superoxides in PRODH/POX-induced 
apoptosis [36].   
Parallel studies showed that peroxisome proliferator activated receptor gamma (PPARγ) is 
another critical regulator of PRODH/POX, besides p53. PPARγ belongs to the nuclear 
hormone receptor superfamily and functions as a ligand-dependent transcription factor [37]. 
It is widely expressed in many malignant tissues, and its ligands can induce terminal 
differentiation, apoptosis, and cell growth inhibition in a variety of cancer cells [38-40]. 
Using a PRODH-promoter luciferase construct [41], we found that PPARγ was the most 
potent effector activating the PRODH promoter. PRODH/POX contributes greatly to 
apoptosis induced by the pharmacologic ligands of PPARγ through ROS signaling in 
human colorectal cancer cells and non-small cell lung carcinoma cells [41, 42]. 
More recently, we found that PRODH/POX was upregulated to contribute to ATP 
production under nutrient stress, such as glucose deprivation [27]. Under hypoxic 
conditions [43] or high levels of oxidized low-density lipoproteins (oxLDLs) [44], ROS 
produced by PRODH/POX contributes to autophagy as a survival signal. These effects seem 
paradoxical with PRODH/POX-induced apoptosis, but they can be well understood 
considering the temporal and spatial development of the evolving tumor, like the “two 
faces” of tumor suppressor p53 [45]. A detailed description of this point can be found in our 
recent review [9].   
2.2. PRODH/POX inhibits tumor cell growth through ROS generation 
In addition to initiating apoptosis, PRODH/POX also inhibits tumor cell growth and 
proliferation. In DLD1-POX tet-off cells, soft agar colony formation assays showed that the 
cells readily formed clones when PRODH/POX expression was inhibited by DOX, whereas 
the cloning ability of the cells was totally blocked when POX was overexpressed [46].  
Several signaling pathways associated with tumor growth are downregulated by 
PRODH/POX. First, PRODH/POX suppresses the phosphorylation of three major subtypes 
of the mitogen-activated protein kinase (MAPK) pathways, including MEK/ERK, JNK, p38 
[36]. In fact, MAPK pathways play an important role in a variety of cellular responses, 
including proliferation, differentiation, development, transformation, and apoptosis. The 
inhibition of MEK/ERK pathway is involved in PRODH/POX-induced apoptosis. Secondly, 
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the culture medium and the expression of PRODH/POX was induced, apoptotic cell death 
was initiated.  
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ROS, which include superoxide radical (O2-·), hydroxyl radicals (OH·) and the non-radical 
hydrogen peroxide (H2O2), play an important role in the induction of apoptosis [34]. 
PRODH/POX could donate electron to the ETC to generate ROS. In cells overexpressing 
PRODH/POX, the addition of proline increased ROS generation in a concentration-
dependent manner, and the proline-dependent ROS increased with PRODH/POX 
expression [35]. N-acetyl cysteine (NAC), a widely used antioxidant agent, dramatically 
reduced PRODH/POX-induced apoptosis, indicating PRODH/POX induces apoptosis 
through ROS generation [13]. By introducing the recombinant adenoviruses containing 
different antioxidant enzymes, such as manganese superoxide dismutase (MnSOD), Cu/Zn 
superoxide dismutase (CuZnSOD) or catalase (CAT) into the DLD1-POX tet-off cells, we 
found that only the expression of MnSOD, which localizes in the mitochondria, inhibited 
PRODH/POX-induced apoptosis, suggesting that it is superoxide as the form of ROS 
initially mediating PRODH/POX-induced apoptosis [13].  
Further investigation on the molecular signaling involved in PRODH/POX-induced 
apoptosis showed that PRODH/POX activated both intrinsic and extrinsic apoptotic 
pathways [35, 36]. The DLD-1-POX cells overproducing PRODH/POX exhibited the 
 
MiRNA and Proline Metabolism in Cancer 363 
mitochondria (intrinsic pathway) and death receptor (extrinsic pathway)-mediated 
apoptotic responses in a proline-dependent manner [35]. Intrinsic pathway induced by 
PRODH/POX includes the release of cytochrome c, activation of caspase-9, chromatin 
condensation, DNA fragmentation, and cell shrinkage. Extrinsic pathway induced by 
PRODH/POX involves the stimulation of the expression of tumor necrosis factor-related 
apoptosis inducing ligand (TRAIL), and death receptor 5 (DR5) and then cleavage of 
caspase-8 [36]. Both pathways culminate in the activation of caspase-3 and cleavage of 
substrates. NFATc1, a member of the nuclear factor of activated T cells (NFAT) family of 
transcription factors is partially responsible for the TRAIL activity stimulated by 
PRODH/POX [36]. All of these effects mediated by PRODH/POX could be partially reversed 
by MnSOD, further confirming the role of ROS/superoxides in PRODH/POX-induced 
apoptosis [36].   
Parallel studies showed that peroxisome proliferator activated receptor gamma (PPARγ) is 
another critical regulator of PRODH/POX, besides p53. PPARγ belongs to the nuclear 
hormone receptor superfamily and functions as a ligand-dependent transcription factor [37]. 
It is widely expressed in many malignant tissues, and its ligands can induce terminal 
differentiation, apoptosis, and cell growth inhibition in a variety of cancer cells [38-40]. 
Using a PRODH-promoter luciferase construct [41], we found that PPARγ was the most 
potent effector activating the PRODH promoter. PRODH/POX contributes greatly to 
apoptosis induced by the pharmacologic ligands of PPARγ through ROS signaling in 
human colorectal cancer cells and non-small cell lung carcinoma cells [41, 42]. 
More recently, we found that PRODH/POX was upregulated to contribute to ATP 
production under nutrient stress, such as glucose deprivation [27]. Under hypoxic 
conditions [43] or high levels of oxidized low-density lipoproteins (oxLDLs) [44], ROS 
produced by PRODH/POX contributes to autophagy as a survival signal. These effects seem 
paradoxical with PRODH/POX-induced apoptosis, but they can be well understood 
considering the temporal and spatial development of the evolving tumor, like the “two 
faces” of tumor suppressor p53 [45]. A detailed description of this point can be found in our 
recent review [9].   
2.2. PRODH/POX inhibits tumor cell growth through ROS generation 
In addition to initiating apoptosis, PRODH/POX also inhibits tumor cell growth and 
proliferation. In DLD1-POX tet-off cells, soft agar colony formation assays showed that the 
cells readily formed clones when PRODH/POX expression was inhibited by DOX, whereas 
the cloning ability of the cells was totally blocked when POX was overexpressed [46].  
Several signaling pathways associated with tumor growth are downregulated by 
PRODH/POX. First, PRODH/POX suppresses the phosphorylation of three major subtypes 
of the mitogen-activated protein kinase (MAPK) pathways, including MEK/ERK, JNK, p38 
[36]. In fact, MAPK pathways play an important role in a variety of cellular responses, 
including proliferation, differentiation, development, transformation, and apoptosis. The 
inhibition of MEK/ERK pathway is involved in PRODH/POX-induced apoptosis. Secondly, 
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PRODH/POX markedly reduces the expression of cyclooxygenase-2 (COX-2), and thus 
suppresses the production of prostaglandin E2 (PGE2) [47]. The addition of PGE2 partially 
reverses the apoptosis and inhibits tumor growth induced by PRODH/POX. 
Cyclooxygenase is an enzyme that catalyzes the key step of the conversion of free 
arachidonic acid to prostaglandins. It has been widely accepted that elevated COX2/PGE2 
signaling plays a critical role in the initiation and development of various solid tumors, 
especially colorectal cancer [48-50]. Thirdly, PRODH/POX inhibits the phosphorylation of 
epidermal growth factor receptor (EGFR). Activating mutants and overexpression of EGFR 
signaling contributes to carcinogenesis of various tumors by inducing cell proliferation and 
counteracting apoptosis [51]. Fourthly, Wnt/β-catenin signaling is decreased by 
PRODH/POX [47]. Constitutive activation of this signaling pathway is found in many 
human cancers, which regulates proliferation, differentiation and cell fate [52]. 
Phosphorylation of β-catenin by GSK-3β leads to its ubiquitination and proteasomal 
degradation. PRODH/POX decreases phosphorylation of GSK-3β and thereby increases 
phosphorylation of β-catenin, resulting in the reduced activity of Wnt/ β-catenin signaling. 
All of aforementioned changes induced by PRODH/POX are partially reversed by MnSOD, 
further indicating the critical role of ROS/superoxides in PRODH/POX-mediated effects. 
Furthermore, PRODH/POX induces G2 cell cycle arrest through affecting the regulators of 
cell cycle, such as geminin, cyclin-dependent kinase (CDC), and growth arrest and DNA 
damage inducible proteins (GADDs) [46]. Geminin is a nuclear protein that inhibits DNA 
replication, and has been used as a marker for G2 phase [53]. Its expression is up-regulated 
by PRODH/POX. CDC2 normally drives cells into mitosis and is the ultimate target of 
pathways that mediate rapid G2 arrest in response to DNA damage [54]. Although total 
CDC2 did not change with PRODH/POX expression, the phosphorylated CDC2 at tyrosine 
15 increased, whereas phosphorylation at threonine 161 decreased when PRODH/POX was 
overexpressed, indicating that CDC2 is in an inactive status. CDC25C, the phosphatase that 
removes the inhibitory phosphates from CDC2 and activates cyclinB-CDC2, is 
downregulated by PRODH/POX. Additionally, the most important regulators of G2 cell 
cycle arrest, GADDs [55] also play a role in PRODH/POX-induced G2 cell cycle arrest, 
including GADD34, GADD45a, GADDh, GADDg [46].    
2.3. PRODH/POX inhibits HIF signaling mainly through increasing α-KG 
production   
The above described PRODH/POX-mediated induction of apoptosis together with the 
suppression of cell growth suggests that PRODH/POX could function as a tumor 
suppressor. PRODH/POX protein is located in the mitochondrial inner membrane, and has 
an anaplerotic role through glutamate and α-KG for the TCA cycle (Fig.1). The identification 
of several mitochondrial tumor suppressors has demonstrated that one of the critical ways 
they exert their antitumor effects is through hypoxia inducible factor-1 (HIF-1) signaling, 
which mediates the transcriptional response to hypoxia as a transcriptional factor and plays 
an important role in angiogenesis and tumor growth [56, 57]. Similarly, PRODH/POX also 
downregulates HIF-1 signaling including its downstream gene VEGF in both normoxic and 
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hypoxic conditions [46]. This is another mechanism, along with those described above, by 
which PRODH/POX exerts its tumor-suppressing role. However, unlike the effects of 
PRODH/POX on other signaling pathways, its effect on HIF-1 signaling could not be 
reversed by MnSOD, suggesting ROS is not the mediator for HIF inhibition.  
The stability and transcriptional activity of HIF-1α are regulated through oxygen-sensitive 
modifications. Briefly, the posttranslational hydroxylation of specific prolyl and asparaginal 
residues in its α-subunits of HIF-1, catalyzed by prolyl hydroxylases (PHD), results in the 
degradation of HIF-1 through ubiquitinal and proteasomal degradation systems [58]. As an 
important substrate of PHD, the members of the 2-oxoglutarate (α-KG) dioxygenase family 
could increase the hydroxylation and degradation of HIF-1α [58]. HPLC analysis showed 
that α-KG was increased by overexpression of PRODH/POX [46]. When PRODH/POX 
expression is high, P5C, glutamate and α-KG are sequentially produced from proline, 
forming an important link between proline and the TCA cycle. The widely used cell-
permeating α-KG analogue, dimethyloxalylglycine, was shown to block the inhibition of 
HIF-1 signaling by PRODH/POX, suggesting the pivotal role of α-KG in the down-
regulation of HIF by PRODH/POX.   
In addition, several TCA cycle intermediates and glycolytic metabolites, such as succinate 
and fumarate, have been revealed to inhibit PHD activity and stabilize HIF-1 signaling [58-
61]. PRODH/POX expression could decrease succinate, fumarate and lactate as measured by 
gas chromatography-mass spectrometry (GC-MS) [46], which may also contribute to the 
impaired HIF-1 signaling.  
2.4. PRODH/POX suppresses tumor formation in vivo and is downregulated in 
human tumors  
The inhibitory effects of PRODH/POX on tumor cell growth are corroborated in a human 
colon cancer mouse xenograft model [46]. DLD-1 POX Tet-off cells were injected into 
immunodeficient mice. The expression of PRODH/POX was controlled by giving mice 
doxycycline in their drinking water. When PRODH/POX was suppressed by doxycycline, 
tumors readily formed in all the mice within a few days. By contrast, when PRODH/POX 
was overexpressed by removal of doxycycline in their drinking water, tumor development 
was greatly reduced and none of the mice developed tumors.  
Further investigation on a variety of cancer tissues along with normal tissue counterparts 
including kidney, bladder, stomach, colon and rectum, liver, pancreas, breast, prostate, 
ovary, brain, lung, skin, etc., showed that 61% of all tumors had decreased expression of 
PRODH/POX compared to normal tissues, especially the tumor from kidney and digestive 
tract [46, 47, 62], suggesting tumor could eliminate the tumor suppressor roles of 
PRODH/POX. Suppression of PRODH/POX was more significant in kidney and digestive 
tract. More interestingly, PRODH/POX protein levels showed more striking decrease than 
mRNA levels in renal cancers, implicating that PRODH/POX might be regulated at the post-
transcriptional level.  
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PRODH/POX markedly reduces the expression of cyclooxygenase-2 (COX-2), and thus 
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phosphorylation of β-catenin, resulting in the reduced activity of Wnt/ β-catenin signaling. 
All of aforementioned changes induced by PRODH/POX are partially reversed by MnSOD, 
further indicating the critical role of ROS/superoxides in PRODH/POX-mediated effects. 
Furthermore, PRODH/POX induces G2 cell cycle arrest through affecting the regulators of 
cell cycle, such as geminin, cyclin-dependent kinase (CDC), and growth arrest and DNA 
damage inducible proteins (GADDs) [46]. Geminin is a nuclear protein that inhibits DNA 
replication, and has been used as a marker for G2 phase [53]. Its expression is up-regulated 
by PRODH/POX. CDC2 normally drives cells into mitosis and is the ultimate target of 
pathways that mediate rapid G2 arrest in response to DNA damage [54]. Although total 
CDC2 did not change with PRODH/POX expression, the phosphorylated CDC2 at tyrosine 
15 increased, whereas phosphorylation at threonine 161 decreased when PRODH/POX was 
overexpressed, indicating that CDC2 is in an inactive status. CDC25C, the phosphatase that 
removes the inhibitory phosphates from CDC2 and activates cyclinB-CDC2, is 
downregulated by PRODH/POX. Additionally, the most important regulators of G2 cell 
cycle arrest, GADDs [55] also play a role in PRODH/POX-induced G2 cell cycle arrest, 
including GADD34, GADD45a, GADDh, GADDg [46].    
2.3. PRODH/POX inhibits HIF signaling mainly through increasing α-KG 
production   
The above described PRODH/POX-mediated induction of apoptosis together with the 
suppression of cell growth suggests that PRODH/POX could function as a tumor 
suppressor. PRODH/POX protein is located in the mitochondrial inner membrane, and has 
an anaplerotic role through glutamate and α-KG for the TCA cycle (Fig.1). The identification 
of several mitochondrial tumor suppressors has demonstrated that one of the critical ways 
they exert their antitumor effects is through hypoxia inducible factor-1 (HIF-1) signaling, 
which mediates the transcriptional response to hypoxia as a transcriptional factor and plays 
an important role in angiogenesis and tumor growth [56, 57]. Similarly, PRODH/POX also 
downregulates HIF-1 signaling including its downstream gene VEGF in both normoxic and 
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hypoxic conditions [46]. This is another mechanism, along with those described above, by 
which PRODH/POX exerts its tumor-suppressing role. However, unlike the effects of 
PRODH/POX on other signaling pathways, its effect on HIF-1 signaling could not be 
reversed by MnSOD, suggesting ROS is not the mediator for HIF inhibition.  
The stability and transcriptional activity of HIF-1α are regulated through oxygen-sensitive 
modifications. Briefly, the posttranslational hydroxylation of specific prolyl and asparaginal 
residues in its α-subunits of HIF-1, catalyzed by prolyl hydroxylases (PHD), results in the 
degradation of HIF-1 through ubiquitinal and proteasomal degradation systems [58]. As an 
important substrate of PHD, the members of the 2-oxoglutarate (α-KG) dioxygenase family 
could increase the hydroxylation and degradation of HIF-1α [58]. HPLC analysis showed 
that α-KG was increased by overexpression of PRODH/POX [46]. When PRODH/POX 
expression is high, P5C, glutamate and α-KG are sequentially produced from proline, 
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permeating α-KG analogue, dimethyloxalylglycine, was shown to block the inhibition of 
HIF-1 signaling by PRODH/POX, suggesting the pivotal role of α-KG in the down-
regulation of HIF by PRODH/POX.   
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61]. PRODH/POX expression could decrease succinate, fumarate and lactate as measured by 
gas chromatography-mass spectrometry (GC-MS) [46], which may also contribute to the 
impaired HIF-1 signaling.  
2.4. PRODH/POX suppresses tumor formation in vivo and is downregulated in 
human tumors  
The inhibitory effects of PRODH/POX on tumor cell growth are corroborated in a human 
colon cancer mouse xenograft model [46]. DLD-1 POX Tet-off cells were injected into 
immunodeficient mice. The expression of PRODH/POX was controlled by giving mice 
doxycycline in their drinking water. When PRODH/POX was suppressed by doxycycline, 
tumors readily formed in all the mice within a few days. By contrast, when PRODH/POX 
was overexpressed by removal of doxycycline in their drinking water, tumor development 
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ovary, brain, lung, skin, etc., showed that 61% of all tumors had decreased expression of 
PRODH/POX compared to normal tissues, especially the tumor from kidney and digestive 
tract [46, 47, 62], suggesting tumor could eliminate the tumor suppressor roles of 
PRODH/POX. Suppression of PRODH/POX was more significant in kidney and digestive 
tract. More interestingly, PRODH/POX protein levels showed more striking decrease than 
mRNA levels in renal cancers, implicating that PRODH/POX might be regulated at the post-
transcriptional level.  
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Sequencing the PRODH gene showed no somatic mutation or functionally significant single 
nucleotide polymorphisms (SNP) in tumor tissues. Hypermethylation analysis also didn’t 
show any differences of PRODH genomic DNA between tumor and normal tissues. 
Therefore, PRODH does not satisfy the canonical requisite for tumor suppressor genes 
which often show genetic or epigenetic mutations in human cancers. With the discovery of 
microRNAs (miRNAs), a new mechanism to regulate protein expression has been revealed. 
Considering the inconsistency between PRODH/POX mRNA and protein expression and 
the importance of miRNAs in cancer, the regulation of miRNAs on PRODH/POX 
represented a very promising hypothesis. 
3. MiRNA in cancer 
3.1. Biogenesis and function of miRNAs  
3.1.1. Discovery of miRNAs 
MiRNAs are a class of post-transcriptional regulators. They are conserved, endogenously 
expressed, non-coding small RNAs of 18-25 nucleotides in length. MiRNAs were first 
discovered in 1993 by Lee RC et al. [63] and Wightman R et al. [64] in the nematode 
Caenorhabditis elegans (C. elegans) as a regulator of developmental timing regarding the gene 
lin-14. They found that the lin-14 could be regulated by the small RNA products from lin-4, 
a gene that does not code for any protein but instead produces a pair of small RNAs. These 
lin-4 RNAs had antisense complementarity to multiple sites in the 3’ UTR of the lin-14 
mRNA. However, it did not attract substantial attention until seven years later when let-7 
was discovered to repress the expression of several mRNAs including lin-14 during 
transition in developmental stages in C. elegans [65]. Since then over 4000 miRNAs have 
been identified in eukaryotes including mammals, fungi and plants. More than 700 miRNAs 
have been found in humans.  
3.1.2. Processing and biogenesis of miRNAs 
In mammals, miRNA genes are usually transcribed as long primary transcripts (pri-
miRNAs) by RNA polymerase II from DNA [66]. The pri-miRNAs then are cropped into the 
hairpin-shaped miRNA precursors (pre-miRNAs) by the RNase III enzyme Drosha [67, 68]. 
A single pri-miRNA may contain one to six pre-miRNAs which are composed of about 70 
nucleotides. They are exported from the nucleus to the cytoplasm by exportin-5 (XPO5), a 
member of the Ran-dependent nuclear transport receptor family [69-71]. In cytoplasm, the 
pre-miRNA hairpin is subsequently cleaved by the endonuclease Dicer [72] into an 
imperfect miRNA:miRNA* duplex. Usually, only one strand of the duplex is incorporated 
into the RNA induced silencing complex (RISC) where the miRNA and its mRNA target 
interact. The thermodynamic stability, strength of base-pairing and the position of the stem-
loop determine which strand becomes mature miRNA to incorporate into the RISC [73-75]. 
The other strand is normally degraded and is denoted with an asterisk (*) due to its lower 
levels in the steady state. However, recent evidence indicates that both strands of duplex are 
viable and become functional miRNA that target different mRNA populations [62, 76-78]. 
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RISC is a multiprotein complex that incorporates mature miRNA to recognize 
complementary target mRNA. Once binding to target mRNA, miRNAs inhibit their target 
genes with the help of RISC. The key component of the RISC complex is the Argonaute 
(Ago) proteins, which are consistently found in RISC complexes from a variety of organisms 
[79]. Ago proteins directly interact with the miRNA [80, 81]. They are needed for miRNA-
induced silencing and contain two conserved RNA binding domains: a PAZ domain, that 
can bind the single stranded 3’ end of the mature miRNA, and a PIWI domain, that 
structurally resembles ribonuclease-H (RNaseH) and functions in slicer activity through 
interacting with the 5’ end of the guide strand [82]. Most eukaryotes contain multiple Ago 
family members, with different Ago often specialized for distinct functions [83]. The human 
genome encodes four Ago proteins and Ago2 is the only Ago capable of endonuclease 
cleavage of target transcripts directly [84, 85]. 
Additional components of RISC involved in miRNA processing include the Vasa intronic 
gene (VIG) protein, the fragile X mental retardation protein (FMRP), human 
immunodeficiency virus transactivating response RNA binding protein (TARBP), protein 
activator of the interferon induced protein kinase (PACT), the SMN complex, Gemin3 and 
DICER1, and so on [86-92]. However their generality or precise function in miRNA silencing 
remains to be determined.  
3.1.3. Stability of miRNAs 
Turnover of mature miRNA is needed for rapid changes in miRNA expression profiles. 
Besides inducing the cleavage of the target mRNAs, Ago proteins have been recently 
reported to regulate the stability of miRNAs [93-98]. Mature miRNAs are stabilized after 
incorporation into Ago proteins, and release from this complex leaves miRNAs vulnerable 
to decay by exonucleases [94, 95]. Ectopic overexpression of Ago proteins prevents 
degradation of miRNAs, and loss of Ago2 significantly reduces miRNA stability and 
differentially regulates miRNAs production [93, 96]. 
In addition to taking refuge in protein complexes, mature miRNAs can undergo protective 
modifications [97]. For example, as indicated by work in the model organism Arabidopsis 
thaliana, mature plant miRNAs appear to be stabilized by the addition of methyl groups at 
the 3' end which prevents uridylation of miRNAs [99]. The addition of adenines to 3’ end of 
miRNAs detected in many different plant and animal miRNAs also has a stabilizing effect 
on miRNAs [100-104]. 
3.1.4. Function of miRNAs     
MiRNAs inhibit the expression of their target genes through three different mechanisms 
[105, 106]. The first one is direct endonucleolytic cleavage of mRNAs supported by the slicer 
activity of specific Ago proteins present within RISC. As mentioned above, Ago2 is the only 
one of the four mammalian Ago proteins capable of directing cleavage [84, 85]. This 
mechanism is generally favored by a complete match of the so called seed-sequence of the 
miRNA (nucleotides 2-7 of 5’ end of miRNAs) and target mRNA [107], although some 
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Sequencing the PRODH gene showed no somatic mutation or functionally significant single 
nucleotide polymorphisms (SNP) in tumor tissues. Hypermethylation analysis also didn’t 
show any differences of PRODH genomic DNA between tumor and normal tissues. 
Therefore, PRODH does not satisfy the canonical requisite for tumor suppressor genes 
which often show genetic or epigenetic mutations in human cancers. With the discovery of 
microRNAs (miRNAs), a new mechanism to regulate protein expression has been revealed. 
Considering the inconsistency between PRODH/POX mRNA and protein expression and 
the importance of miRNAs in cancer, the regulation of miRNAs on PRODH/POX 
represented a very promising hypothesis. 
3. MiRNA in cancer 
3.1. Biogenesis and function of miRNAs  
3.1.1. Discovery of miRNAs 
MiRNAs are a class of post-transcriptional regulators. They are conserved, endogenously 
expressed, non-coding small RNAs of 18-25 nucleotides in length. MiRNAs were first 
discovered in 1993 by Lee RC et al. [63] and Wightman R et al. [64] in the nematode 
Caenorhabditis elegans (C. elegans) as a regulator of developmental timing regarding the gene 
lin-14. They found that the lin-14 could be regulated by the small RNA products from lin-4, 
a gene that does not code for any protein but instead produces a pair of small RNAs. These 
lin-4 RNAs had antisense complementarity to multiple sites in the 3’ UTR of the lin-14 
mRNA. However, it did not attract substantial attention until seven years later when let-7 
was discovered to repress the expression of several mRNAs including lin-14 during 
transition in developmental stages in C. elegans [65]. Since then over 4000 miRNAs have 
been identified in eukaryotes including mammals, fungi and plants. More than 700 miRNAs 
have been found in humans.  
3.1.2. Processing and biogenesis of miRNAs 
In mammals, miRNA genes are usually transcribed as long primary transcripts (pri-
miRNAs) by RNA polymerase II from DNA [66]. The pri-miRNAs then are cropped into the 
hairpin-shaped miRNA precursors (pre-miRNAs) by the RNase III enzyme Drosha [67, 68]. 
A single pri-miRNA may contain one to six pre-miRNAs which are composed of about 70 
nucleotides. They are exported from the nucleus to the cytoplasm by exportin-5 (XPO5), a 
member of the Ran-dependent nuclear transport receptor family [69-71]. In cytoplasm, the 
pre-miRNA hairpin is subsequently cleaved by the endonuclease Dicer [72] into an 
imperfect miRNA:miRNA* duplex. Usually, only one strand of the duplex is incorporated 
into the RNA induced silencing complex (RISC) where the miRNA and its mRNA target 
interact. The thermodynamic stability, strength of base-pairing and the position of the stem-
loop determine which strand becomes mature miRNA to incorporate into the RISC [73-75]. 
The other strand is normally degraded and is denoted with an asterisk (*) due to its lower 
levels in the steady state. However, recent evidence indicates that both strands of duplex are 
viable and become functional miRNA that target different mRNA populations [62, 76-78]. 
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RISC is a multiprotein complex that incorporates mature miRNA to recognize 
complementary target mRNA. Once binding to target mRNA, miRNAs inhibit their target 
genes with the help of RISC. The key component of the RISC complex is the Argonaute 
(Ago) proteins, which are consistently found in RISC complexes from a variety of organisms 
[79]. Ago proteins directly interact with the miRNA [80, 81]. They are needed for miRNA-
induced silencing and contain two conserved RNA binding domains: a PAZ domain, that 
can bind the single stranded 3’ end of the mature miRNA, and a PIWI domain, that 
structurally resembles ribonuclease-H (RNaseH) and functions in slicer activity through 
interacting with the 5’ end of the guide strand [82]. Most eukaryotes contain multiple Ago 
family members, with different Ago often specialized for distinct functions [83]. The human 
genome encodes four Ago proteins and Ago2 is the only Ago capable of endonuclease 
cleavage of target transcripts directly [84, 85]. 
Additional components of RISC involved in miRNA processing include the Vasa intronic 
gene (VIG) protein, the fragile X mental retardation protein (FMRP), human 
immunodeficiency virus transactivating response RNA binding protein (TARBP), protein 
activator of the interferon induced protein kinase (PACT), the SMN complex, Gemin3 and 
DICER1, and so on [86-92]. However their generality or precise function in miRNA silencing 
remains to be determined.  
3.1.3. Stability of miRNAs 
Turnover of mature miRNA is needed for rapid changes in miRNA expression profiles. 
Besides inducing the cleavage of the target mRNAs, Ago proteins have been recently 
reported to regulate the stability of miRNAs [93-98]. Mature miRNAs are stabilized after 
incorporation into Ago proteins, and release from this complex leaves miRNAs vulnerable 
to decay by exonucleases [94, 95]. Ectopic overexpression of Ago proteins prevents 
degradation of miRNAs, and loss of Ago2 significantly reduces miRNA stability and 
differentially regulates miRNAs production [93, 96]. 
In addition to taking refuge in protein complexes, mature miRNAs can undergo protective 
modifications [97]. For example, as indicated by work in the model organism Arabidopsis 
thaliana, mature plant miRNAs appear to be stabilized by the addition of methyl groups at 
the 3' end which prevents uridylation of miRNAs [99]. The addition of adenines to 3’ end of 
miRNAs detected in many different plant and animal miRNAs also has a stabilizing effect 
on miRNAs [100-104]. 
3.1.4. Function of miRNAs     
MiRNAs inhibit the expression of their target genes through three different mechanisms 
[105, 106]. The first one is direct endonucleolytic cleavage of mRNAs supported by the slicer 
activity of specific Ago proteins present within RISC. As mentioned above, Ago2 is the only 
one of the four mammalian Ago proteins capable of directing cleavage [84, 85]. This 
mechanism is generally favored by a complete match of the so called seed-sequence of the 
miRNA (nucleotides 2-7 of 5’ end of miRNAs) and target mRNA [107], although some 
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mismatches can be tolerated and still allow cleavage to occur [108, 109]. The 
complementarity of the seed region defines the targets of the miRNA because the seed 
region binds to the mRNA as governed by binding of complementary nucleotides. The 
second mechanism is by inhibiting protein translation but without degradation of the 
mRNA [110-112]. It seems to be the most prevalent in mammals [113]. In this mechanism, 
the seed region of the miRNA does not need to be fully complementary; yet, efficient 
translation repression by miRNAs often requires multiple miRNA-binding sites, as suggested 
by the observations that the identified mRNA targets of miRNAs contained multiple sites for 
miRNA binding, either the same miRNA or a combination of several different miRNAs [114, 
115]. However, many predicted mRNA targets of miRNAs contain only a single miRNA-
binding site in their 3’UTR [107], indicating that such single sites may lead to fine “tuning” of 
mRNA function [116]. Distinct from the slicer activity of the specific Ago in the first manner, 
translation repression by miRNAs is common to all members of the Ago protein family. The 
third mechanism is called mRNA decay independent of slicer [117, 118]. In this manner, 
miRNAs either promote mRNAs decapping and 5’ to 3’ degradation, or target mRNAs by an 
unknown decay pathway. In the former way, the protecting poly-A-tail and ‘‘cap’’ of the 
mRNAs are removed, resulting in their rapid destruction by RNA splicing enzymes.  
MiRNAs are now known to target thousands of genes. Bioinformatics analyses estimated 
that up to 30% of known human genes are under miRNAs’ control [107], whereas later 
reports increased this number to 74~92% [119]. A key issue in miRNAs function is the 
specificity of their interactions with their target mRNAs and how each interaction leads to 
discrete downstream consequences. Some miRNAs regulate specific individual targets, 
while others can function as master regulators of a process. Key miRNAs regulate the 
expression levels of hundreds of genes simultaneously, and many types of miRNAs regulate 
their targets cooperatively. Because of their potent and wide action on gene expression, 
miRNAs become critical regulators of cellular functions. They are involved in modulating a 
variety of biological processes, including cellular proliferation, differentiation, metabolic 
signaling, apoptosis and development. The aberrant expression or alteration of miRNAs has 
been linked to a range of human diseases, especially cancers.  
3.2. Dysregulation of miRNA in cancer  
In 2002, Calin et al. first demonstrated that miR-15 and miIR-16 are frequently deleted or 
down-regulated in chronic lymphocytic leukemia [120]. Subsequently, aberrant miRNA 
expression, and amplification or deletion of miRNAs are observed in various human tumors 
[121, 122]. MiRNAs are differentially expressed in cancer cells, in which they form distinct 
and unique miRNA expression patterns [123]. These properties make miRNAs become 
potential biomarkers for cancer diagnosis, in particular for the early detection of cancer 
[124]. The control of gene expression by miRNAs is seen in virtually all cancer cells. Their 
target genes are usually important proteins such as oncogenic factors (i.e., MYC, RAS), 
tumor suppressors (i.e., p53), or proteins regulating the cell cycle (i.e., the cyclin family). 
Even small changes in these crucial proteins can have profound effects on tumorigenesis or 
tumor development. Conversely, miRNAs are often critical downstream effectors of classic 
oncogene/tumor suppressor networks, such as MYC and p53 described below.  
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miRNAs can act as oncogenes or tumor suppressor genes in tumorigenesis depending on 
the targets they regulate. Oncogenic miRNAs repress known tumor suppressors, whereas 
tumor-suppressor miRNAs often negatively regulate protein-coding oncogenes (this has 
been reviewed in detail by others [125-127]). Oncogenic miRNAs are overexpressed in 
various human cancers. For example, the miR-17-92 cluster miRNAs which are transcribed 
as a polycistronic unit, are highly expressed in B-cell lymphoma and various solid cancer, 
such as breast, colon, lung, pancreas, prostate and stomach [128-130]. They function as 
oncogenes to promote proliferation, inhibit apoptosis, induce tumor angiogenesis, and 
augment the oncogenic effects of MYC [131-134]. Their effects on cell cycle and proliferation 
are at least in part through its regulation of E2F transcription factors [130, 135], and anti-
apoptotic effects are through their inhibition of BIM, PTEN and p21 [135]. MiR-221 and miR-
222 are frequently overexpressed in lung, liver and ERα- breast cancers. Their overexpression 
has been demonstrated to enhance tumorigenicity through suppressing the expression of 
different tumor suppressors, such as CDKN1B/C, BIM, PTEN, TIMP3 and FOXO3 [136, 137]. 
Overexpression of miR-504 promotes tumorgenicity of colon cancer in vivo, which directly 
targets tumor suppressor p53 and functions in apoptosis and cell cycle [138]. 
On the other hand, miRNAs that act as tumor suppressors are often found to be deleted or 
mutated in various human cancers. For example, Let-7 family miRNAs are frequently down-
regulated in various cancers, including lung and colorectal cancers [139]. They can directly 
suppress the expression of oncogenes, including RAS and MYC, and therefore show tumor 
suppressive functions [139, 140]. MiR-15a and miR-16-1 are often deleted or down-regulated in 
B-cell chronic lymphocytic leukemia (B-CLL). They negatively regulate anti-apoptotic protein 
BCL2. Therefore, decreased expression of miR-15a and miR-16-1 up-regulates BCL2 levels and 
reduces apoptosis, contributing to malignant transformation [141]. 
Based on the critical role of miRNAs in tumorigenesis, recent research efforts are directed 
towards translating these basic discoveries into clinical applications in diagnosis, prognosis 
and therapy through identifying and targeting dysregulated miRNAs. Both silencing the 
oncogenic miRNAs and restoring the expression of silenced tumor-suppressor miRNAs 
have yielded positive results in mouse models of cancer and thus becomes promising 
therapeutic strategy for cancer [142, 143]. The silencing of oncogenic miRNAs can be 
achieved by using antisense oligonucleotides (antagomirs or anti-miRs), sponges or locked 
nucleic acid (LNA) constructs [144]. By contrast, the restoration of tumor-suppressor 
miRNA expression can be achieved by the use of synthetic miRNA mimics, adenovirus 
vectors, and pharmacological agents [144]. Although the drug delivery, proper drug 
composition and off-target effects are still the current challenges in the clinical application of 
miRNAs, the future is bright for miRNA-based therapy.  
3.3. MiRNAs regulated by transcriptional factors, genetic and epigenetic changes 
3.3.1. MiRNAs regulated by oncogenic transcriptional factor MYC 
MiRNAs can be dysregulated by multiple transcription factors in cancer. Oncogenic 
transcriptional factor MYC regulates a variety of gene expression affecting a series of 
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mismatches can be tolerated and still allow cleavage to occur [108, 109]. The 
complementarity of the seed region defines the targets of the miRNA because the seed 
region binds to the mRNA as governed by binding of complementary nucleotides. The 
second mechanism is by inhibiting protein translation but without degradation of the 
mRNA [110-112]. It seems to be the most prevalent in mammals [113]. In this mechanism, 
the seed region of the miRNA does not need to be fully complementary; yet, efficient 
translation repression by miRNAs often requires multiple miRNA-binding sites, as suggested 
by the observations that the identified mRNA targets of miRNAs contained multiple sites for 
miRNA binding, either the same miRNA or a combination of several different miRNAs [114, 
115]. However, many predicted mRNA targets of miRNAs contain only a single miRNA-
binding site in their 3’UTR [107], indicating that such single sites may lead to fine “tuning” of 
mRNA function [116]. Distinct from the slicer activity of the specific Ago in the first manner, 
translation repression by miRNAs is common to all members of the Ago protein family. The 
third mechanism is called mRNA decay independent of slicer [117, 118]. In this manner, 
miRNAs either promote mRNAs decapping and 5’ to 3’ degradation, or target mRNAs by an 
unknown decay pathway. In the former way, the protecting poly-A-tail and ‘‘cap’’ of the 
mRNAs are removed, resulting in their rapid destruction by RNA splicing enzymes.  
MiRNAs are now known to target thousands of genes. Bioinformatics analyses estimated 
that up to 30% of known human genes are under miRNAs’ control [107], whereas later 
reports increased this number to 74~92% [119]. A key issue in miRNAs function is the 
specificity of their interactions with their target mRNAs and how each interaction leads to 
discrete downstream consequences. Some miRNAs regulate specific individual targets, 
while others can function as master regulators of a process. Key miRNAs regulate the 
expression levels of hundreds of genes simultaneously, and many types of miRNAs regulate 
their targets cooperatively. Because of their potent and wide action on gene expression, 
miRNAs become critical regulators of cellular functions. They are involved in modulating a 
variety of biological processes, including cellular proliferation, differentiation, metabolic 
signaling, apoptosis and development. The aberrant expression or alteration of miRNAs has 
been linked to a range of human diseases, especially cancers.  
3.2. Dysregulation of miRNA in cancer  
In 2002, Calin et al. first demonstrated that miR-15 and miIR-16 are frequently deleted or 
down-regulated in chronic lymphocytic leukemia [120]. Subsequently, aberrant miRNA 
expression, and amplification or deletion of miRNAs are observed in various human tumors 
[121, 122]. MiRNAs are differentially expressed in cancer cells, in which they form distinct 
and unique miRNA expression patterns [123]. These properties make miRNAs become 
potential biomarkers for cancer diagnosis, in particular for the early detection of cancer 
[124]. The control of gene expression by miRNAs is seen in virtually all cancer cells. Their 
target genes are usually important proteins such as oncogenic factors (i.e., MYC, RAS), 
tumor suppressors (i.e., p53), or proteins regulating the cell cycle (i.e., the cyclin family). 
Even small changes in these crucial proteins can have profound effects on tumorigenesis or 
tumor development. Conversely, miRNAs are often critical downstream effectors of classic 
oncogene/tumor suppressor networks, such as MYC and p53 described below.  
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miRNAs can act as oncogenes or tumor suppressor genes in tumorigenesis depending on 
the targets they regulate. Oncogenic miRNAs repress known tumor suppressors, whereas 
tumor-suppressor miRNAs often negatively regulate protein-coding oncogenes (this has 
been reviewed in detail by others [125-127]). Oncogenic miRNAs are overexpressed in 
various human cancers. For example, the miR-17-92 cluster miRNAs which are transcribed 
as a polycistronic unit, are highly expressed in B-cell lymphoma and various solid cancer, 
such as breast, colon, lung, pancreas, prostate and stomach [128-130]. They function as 
oncogenes to promote proliferation, inhibit apoptosis, induce tumor angiogenesis, and 
augment the oncogenic effects of MYC [131-134]. Their effects on cell cycle and proliferation 
are at least in part through its regulation of E2F transcription factors [130, 135], and anti-
apoptotic effects are through their inhibition of BIM, PTEN and p21 [135]. MiR-221 and miR-
222 are frequently overexpressed in lung, liver and ERα- breast cancers. Their overexpression 
has been demonstrated to enhance tumorigenicity through suppressing the expression of 
different tumor suppressors, such as CDKN1B/C, BIM, PTEN, TIMP3 and FOXO3 [136, 137]. 
Overexpression of miR-504 promotes tumorgenicity of colon cancer in vivo, which directly 
targets tumor suppressor p53 and functions in apoptosis and cell cycle [138]. 
On the other hand, miRNAs that act as tumor suppressors are often found to be deleted or 
mutated in various human cancers. For example, Let-7 family miRNAs are frequently down-
regulated in various cancers, including lung and colorectal cancers [139]. They can directly 
suppress the expression of oncogenes, including RAS and MYC, and therefore show tumor 
suppressive functions [139, 140]. MiR-15a and miR-16-1 are often deleted or down-regulated in 
B-cell chronic lymphocytic leukemia (B-CLL). They negatively regulate anti-apoptotic protein 
BCL2. Therefore, decreased expression of miR-15a and miR-16-1 up-regulates BCL2 levels and 
reduces apoptosis, contributing to malignant transformation [141]. 
Based on the critical role of miRNAs in tumorigenesis, recent research efforts are directed 
towards translating these basic discoveries into clinical applications in diagnosis, prognosis 
and therapy through identifying and targeting dysregulated miRNAs. Both silencing the 
oncogenic miRNAs and restoring the expression of silenced tumor-suppressor miRNAs 
have yielded positive results in mouse models of cancer and thus becomes promising 
therapeutic strategy for cancer [142, 143]. The silencing of oncogenic miRNAs can be 
achieved by using antisense oligonucleotides (antagomirs or anti-miRs), sponges or locked 
nucleic acid (LNA) constructs [144]. By contrast, the restoration of tumor-suppressor 
miRNA expression can be achieved by the use of synthetic miRNA mimics, adenovirus 
vectors, and pharmacological agents [144]. Although the drug delivery, proper drug 
composition and off-target effects are still the current challenges in the clinical application of 
miRNAs, the future is bright for miRNA-based therapy.  
3.3. MiRNAs regulated by transcriptional factors, genetic and epigenetic changes 
3.3.1. MiRNAs regulated by oncogenic transcriptional factor MYC 
MiRNAs can be dysregulated by multiple transcription factors in cancer. Oncogenic 
transcriptional factor MYC regulates a variety of gene expression affecting a series of 
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cellular processes in cancer including cell growth and proliferation, metabolism, cell-cycle, 
differentiation, apoptosis, angiogenesis and metastasis [145-147]. Recently, it was found that 
MYC is also an important regulator of miRNAs. Consistent with their ability to potently 
influence cancer phenotypes, the regulation of miRNAs by MYC affects virtually all aspects 
of the MYC oncogenic program.  
MYC directly activates the transcription of miR-17-92 polycistronic cluster though binding 
to an E-box within the first intron of the gene encoding the miR-17-92 primary transcript 
[148, 149]. Given its oncogenic role, the inhibition of key targets of miR-17-92 contributes to 
MYC-induced tumorigenesis. MiR-9 could also be activated directly by MYC, which 
regulates E-cadherin and cancer metastasis [150]. In contrast, MYC activity also results in 
repression of numerous miRNAs [151]. This repression involves the downregulation of 
miRNAs with antiproliferative, antitumorigenic and pro-apoptotic activity, such as let-7, 
miR-15a/16-1, miR-26a miR-29 or miR-34 family members [143, 151-153]. MiR-23a/b is an 
additional important example to be directly suppressed by MYC, which targets glutaminase 
to enhance glutamine catabolism [5]. MYC-driven reprogramming of miRNA expression 
patterns was shown to be a contributing factor in hepatoblastoma (HB), a rare embryonal 
neoplasm derived from liver progenitor cells [154]. Like an embryonic stem cell expression 
profile, undifferentiated aggressive HBs overexpress the miR-371-3 cluster with concomitant 
down-regulation of the miR-100/let-7a-2/miR-125b-1 cluster, which exerts antagonistic 
effects on cell proliferation and tumorigenicity. Chromatin immunoprecipitation (ChIP) and 
MYC inhibition assays in hepatoma cells demonstrated that both miR clusters are regulated 
by MYC in an opposite manner.  
Although further investigation is necessary, the current studies have indicated that MYC 
uses both transcriptional and post-transcriptional mechanisms to modulate miRNA 
expression [151, 155]. Primary transcript mapping and ChIP revealed that MYC associates 
directly with evolutionarily conserved promoter regions upstream of several miRNAs [151], 
such as the direct activation of miR-17-92 cluster and direct suppression of miR-23a/b 
described above. MYC is also able to modulate the maturation of specific miRNAs without 
affecting transcription of the pri-miRNAs. For example, MYC activity results in repression 
of mature let-7 miRNAs while the expression of let-7 primary transcripts is unchanged [151, 
156]. This phenomenon could be due to Lin28A and Lin28B being the direct target of MYC, 
which interacts with let-7 pre-miRNA stem-loops and may regulate let-7 at multiple levels 
including Drosha and Dicer processing [156, 157]. Additionally, interaction of Lin28A and 
Lin28B recruits the 3′ terminal uridylyl transferase 4 (TUT4) to pre-let-7, resulting in 
uridylation and subsequent decay of the pre-miRNA [158, 159].  
3.3.2. MiRNAs regulated by tumor suppressor p53 
The tumor suppressor p53 is another transcription factor that regulate the expression of a 
group of miRNAs mediating a variety of anti-proliferative processes [160]. The miR-34 
family, which consists of miR-34a, miR-34b and miR-34c, was initially reported to be 
induced directly by p53 [161] and mediate some of the p53 effects. ChIP and luciferase 
assays showed that p53 binds to p53 response elements (REs) in miR-34 promoters and 
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activates their transcription [162]. MiR-34 family members directly repress the expression of 
several targets involved in the regulation of cell cycle and in the promotion of cell 
proliferation and survival. These targets include cyclin E2, cyclin-dependent kinases 4 and 6 
(CDK4 and CDK6), BCL2 and hepatocyte growth factor receptor c-Met [161]. Later on, p53 
was reported to directly regulate the transcriptional expression of several additional 
miRNAs, including miR-145, miR-107, miR-192 and miR215, miR-149* [160, 163]. MiR-145 
negatively regulates oncogene MYC, which accounts partially for the miR-145-mediated 
inhibition of tumor cell growth both in vitro and in vivo [164]. MiR-107 contributes to the role 
of p53 in the regulation of hypoxia signaling and anti-angiogenesis through repressing the 
expression of HIF-1β, which interacts with HIF-1α subunits to form a HIF-1 complex, a key 
player in tumor formation. MiR-192 and miR-215 induce cell cycle arrest and reduce tumor 
cell growth through targeting a number of regulators of DNA synthesis and cell cycle 
checkpoints, such as CDC7, MDA2L1 and CUL5 [165]. MiRNA-149* targets glycogen 
synthase kinase-3α, resulting in increased expression of Mcl-1 and resistance to apoptosis in 
melanoma cells [163]. 
Moreover, p53 also enhances the post-transcriptional maturation of miRNAs. In response to 
doxorubicin, P53 interacts with the Drosha processing complex through the association with 
DEAD box RNA helicases p68 (also known as DDX5) and p72 (also known as DDX17), and 
facilitates the Drosha-mediated processing of pri-miRNAs to pre-miRNAs. These miRNAs 
include miR-16-1, miR-143 and miR-145 with growth-suppressive functions. 
Transcriptionally inactive p53 mutants interfere with a functional assembly between Drosha 
complex and p68, leading to attenuation of miRNA processing activity [166].  
3.3.3. MiRNAs regulated by other transcription factors 
Estrogen receptor alpha (ERα), a member of the nuclear receptor superfamily of 
transcription factors, was found to negatively regulate expression of miR-221 and miR-222 
by promoter binding and recruiting the corepressors NCoR and SMRT [137]. 
Overexpression of miR-221 and miR-222 conversely suppresses the expression of ERα, 
conferring estrogen-independent growth. They also suppress the expression of different 
tumor suppressors, such as CDKN1B, CDKN1C, BIM, PTEN, TIMP3, DNA damage-
inducible transcript 4, and FOXO3, to promote high proliferation [137]. Transcription factor 
c-Jun could also activate miR-221 and miR-222 [136]. 
Microarray-based expression profiles reveal that a specific spectrum of miRNAs is induced 
in response to low oxygen, at least some via a HIF-dependent mechanism, such as miR-210, 
miR-26a-2, miR-24 and miR-181c [167]. Of these, miR-210 as a direct transcriptional target of 
HIF-1α has emerged as a critical element of the cellular hypoxia response in a broad variety 
of cell types ranging from cancer cell lines to human umbilical vein endothelial cells [168-
170]. MiR-210 has diverse functions, including modulating angiogenesis [171], stem cell 
survival [172], and hypoxia-induced cell cycle arrest [173]. MiR-143 and miR-145 could be 
repressed by RAS-responsive element-binding protein 1 (RREB1), a zinc finger transcription 
factor which binds to RAS-responsive elements (RREs) of their promoters. Thus these two 
miRNAs are embedded in KRAS oncogenic network [174]. 
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cellular processes in cancer including cell growth and proliferation, metabolism, cell-cycle, 
differentiation, apoptosis, angiogenesis and metastasis [145-147]. Recently, it was found that 
MYC is also an important regulator of miRNAs. Consistent with their ability to potently 
influence cancer phenotypes, the regulation of miRNAs by MYC affects virtually all aspects 
of the MYC oncogenic program.  
MYC directly activates the transcription of miR-17-92 polycistronic cluster though binding 
to an E-box within the first intron of the gene encoding the miR-17-92 primary transcript 
[148, 149]. Given its oncogenic role, the inhibition of key targets of miR-17-92 contributes to 
MYC-induced tumorigenesis. MiR-9 could also be activated directly by MYC, which 
regulates E-cadherin and cancer metastasis [150]. In contrast, MYC activity also results in 
repression of numerous miRNAs [151]. This repression involves the downregulation of 
miRNAs with antiproliferative, antitumorigenic and pro-apoptotic activity, such as let-7, 
miR-15a/16-1, miR-26a miR-29 or miR-34 family members [143, 151-153]. MiR-23a/b is an 
additional important example to be directly suppressed by MYC, which targets glutaminase 
to enhance glutamine catabolism [5]. MYC-driven reprogramming of miRNA expression 
patterns was shown to be a contributing factor in hepatoblastoma (HB), a rare embryonal 
neoplasm derived from liver progenitor cells [154]. Like an embryonic stem cell expression 
profile, undifferentiated aggressive HBs overexpress the miR-371-3 cluster with concomitant 
down-regulation of the miR-100/let-7a-2/miR-125b-1 cluster, which exerts antagonistic 
effects on cell proliferation and tumorigenicity. Chromatin immunoprecipitation (ChIP) and 
MYC inhibition assays in hepatoma cells demonstrated that both miR clusters are regulated 
by MYC in an opposite manner.  
Although further investigation is necessary, the current studies have indicated that MYC 
uses both transcriptional and post-transcriptional mechanisms to modulate miRNA 
expression [151, 155]. Primary transcript mapping and ChIP revealed that MYC associates 
directly with evolutionarily conserved promoter regions upstream of several miRNAs [151], 
such as the direct activation of miR-17-92 cluster and direct suppression of miR-23a/b 
described above. MYC is also able to modulate the maturation of specific miRNAs without 
affecting transcription of the pri-miRNAs. For example, MYC activity results in repression 
of mature let-7 miRNAs while the expression of let-7 primary transcripts is unchanged [151, 
156]. This phenomenon could be due to Lin28A and Lin28B being the direct target of MYC, 
which interacts with let-7 pre-miRNA stem-loops and may regulate let-7 at multiple levels 
including Drosha and Dicer processing [156, 157]. Additionally, interaction of Lin28A and 
Lin28B recruits the 3′ terminal uridylyl transferase 4 (TUT4) to pre-let-7, resulting in 
uridylation and subsequent decay of the pre-miRNA [158, 159].  
3.3.2. MiRNAs regulated by tumor suppressor p53 
The tumor suppressor p53 is another transcription factor that regulate the expression of a 
group of miRNAs mediating a variety of anti-proliferative processes [160]. The miR-34 
family, which consists of miR-34a, miR-34b and miR-34c, was initially reported to be 
induced directly by p53 [161] and mediate some of the p53 effects. ChIP and luciferase 
assays showed that p53 binds to p53 response elements (REs) in miR-34 promoters and 
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activates their transcription [162]. MiR-34 family members directly repress the expression of 
several targets involved in the regulation of cell cycle and in the promotion of cell 
proliferation and survival. These targets include cyclin E2, cyclin-dependent kinases 4 and 6 
(CDK4 and CDK6), BCL2 and hepatocyte growth factor receptor c-Met [161]. Later on, p53 
was reported to directly regulate the transcriptional expression of several additional 
miRNAs, including miR-145, miR-107, miR-192 and miR215, miR-149* [160, 163]. MiR-145 
negatively regulates oncogene MYC, which accounts partially for the miR-145-mediated 
inhibition of tumor cell growth both in vitro and in vivo [164]. MiR-107 contributes to the role 
of p53 in the regulation of hypoxia signaling and anti-angiogenesis through repressing the 
expression of HIF-1β, which interacts with HIF-1α subunits to form a HIF-1 complex, a key 
player in tumor formation. MiR-192 and miR-215 induce cell cycle arrest and reduce tumor 
cell growth through targeting a number of regulators of DNA synthesis and cell cycle 
checkpoints, such as CDC7, MDA2L1 and CUL5 [165]. MiRNA-149* targets glycogen 
synthase kinase-3α, resulting in increased expression of Mcl-1 and resistance to apoptosis in 
melanoma cells [163]. 
Moreover, p53 also enhances the post-transcriptional maturation of miRNAs. In response to 
doxorubicin, P53 interacts with the Drosha processing complex through the association with 
DEAD box RNA helicases p68 (also known as DDX5) and p72 (also known as DDX17), and 
facilitates the Drosha-mediated processing of pri-miRNAs to pre-miRNAs. These miRNAs 
include miR-16-1, miR-143 and miR-145 with growth-suppressive functions. 
Transcriptionally inactive p53 mutants interfere with a functional assembly between Drosha 
complex and p68, leading to attenuation of miRNA processing activity [166].  
3.3.3. MiRNAs regulated by other transcription factors 
Estrogen receptor alpha (ERα), a member of the nuclear receptor superfamily of 
transcription factors, was found to negatively regulate expression of miR-221 and miR-222 
by promoter binding and recruiting the corepressors NCoR and SMRT [137]. 
Overexpression of miR-221 and miR-222 conversely suppresses the expression of ERα, 
conferring estrogen-independent growth. They also suppress the expression of different 
tumor suppressors, such as CDKN1B, CDKN1C, BIM, PTEN, TIMP3, DNA damage-
inducible transcript 4, and FOXO3, to promote high proliferation [137]. Transcription factor 
c-Jun could also activate miR-221 and miR-222 [136]. 
Microarray-based expression profiles reveal that a specific spectrum of miRNAs is induced 
in response to low oxygen, at least some via a HIF-dependent mechanism, such as miR-210, 
miR-26a-2, miR-24 and miR-181c [167]. Of these, miR-210 as a direct transcriptional target of 
HIF-1α has emerged as a critical element of the cellular hypoxia response in a broad variety 
of cell types ranging from cancer cell lines to human umbilical vein endothelial cells [168-
170]. MiR-210 has diverse functions, including modulating angiogenesis [171], stem cell 
survival [172], and hypoxia-induced cell cycle arrest [173]. MiR-143 and miR-145 could be 
repressed by RAS-responsive element-binding protein 1 (RREB1), a zinc finger transcription 
factor which binds to RAS-responsive elements (RREs) of their promoters. Thus these two 
miRNAs are embedded in KRAS oncogenic network [174]. 
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In general, miRNAs can be dysregulated by transcription factors and, therefore, genetic or 
epigenetic alterations that result in the dysregulation of transcription factors can cause 
miRNA dysregulation. Importantly, miRNAs can also be directly regulated by genetic or 
epigenetic alterations. 
3.3.4. MiRNAs regulated by genetic and epigenetic changes 
MiRNAs are frequently located in fragile regions of the chromosomes, such as common 
chromosomal-breakpoints that are associated with the development of cancer [175, 176]. 
These fragile regions are often missing, amplified or mutated in cancer cells, resulting in the 
genetic alterations of miRNAs. The genetic alterations can affect the production of the 
primary miRNA transcript, their processing to mature miRNAs and/or interactions with 
mRNA targets. The dysregulation of miR-15 and miR-16 in most B cell chronic lymphocytic 
leukemias, one of the first observations between miRNAs and cancer development, is the 
result from chromosome 13q14 deletion [120]. Interestingly, somatic translocations in 
miRNA target sites can also occur, representing a drastic means of altering miRNA function 
[177, 178]. 
In addition to the structural genetic alterations, dysregulation of miRNAs in cancer can 
occur through epigenetic changes, such as methylation of the CpG islands of their 
promoters, the modification of histone [179-181]. As the example, miR-127 is silenced by 
promoter methylation, which leads to the overexpression of BCL6, an oncogene involved in 
the development of diffuse large B cell lymphoma [179]. The expression of miR-127 could be 
restored by using hypomethylating agents such as azacytidine. MiRNA-200 family could 
serve as another example. The miR-200 family can be shifted to hypermethylated or 
unmethylated 5'-CpG island status corresponding to the epithelial-mesenchymal transition 
(EMT) and mesenchymal-epithelial transition (MET) phenotypes, respectively, which 
contributes to the evolving and adapting phenotypes of human tumors [181].  
4. miR-23b* targets PRODH/POX 
Although numerous targets of miRNAs have been identified, miRNA regulators of critical 
cancer proteins and pathways remain largely unknown. As described above, PRODH/POX 
is frequently reduced in a variety of human cancers, including renal cancer, and 
PRODH/POX protein but not mRNA level is markedly down-regulated in renal cancers [46, 
62]. The fact that miRNAs are critical post-transcriptional regulators, and miRNAs function 
as oncogenes to inhibit the expression of tumor suppressors raises attractive possibility that 
some specific miRNAs may regulate PRODH/POX and proline catabolism. Target-
prediction algorithms have been used to identify the protein targets of miRNAs or miRNAs 
regulators of known protein, followed by experimental validation to eliminate false 
positives [141]. The bioinformatic analysis according to target-prediction algorithms 
predicted that 91 potential miRNAs could target PRODH/POX mRNA 3’UTR [62]. In 
miRNA microarrays, 10 miRNAs showed an increased expression in renal cancer cells 
relative to normal cells. However, only miR-23b* was shown to significantly inhibit 
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PRODH/POX protein expression, but not mRNA level. This is consistent with many previous 
reports, that is, in mammals, miRNAs more often inhibit protein translation of the target 
mRNA, other than inducing its degradation [113]. Subsequently, miR-23b* directly binding to 
PRODH/POX mRNA 3’UTR was experimentally confirmed through luciferase assays by co-
transfecting the mimic miR-23b* and the luciferase reporter containing 3’UTR of PRODH/POX 
mRNA. Functional analysis showed that this miRNA impaired PRODH/POX functions, 
including PRODH/POX-mediated ROS generation, apoptosis, and PRODH/POX-inhibited 
HIF-1 signaling [62]. In contrast, the inhibitory antagomir of miR-23b* increased the expression 
of PRODH/POX protein in renal cancer cells. As a result, ROS production, the percentage of 
cells undergoing apoptosis increased, and HIF-1 signaling decreased. 
The clinical relevance of these in vitro ndings was substantiated by the data obtained in 
human renal carcinoma tissues in vivo [62]. There were statistical significant differences in 
both miR-23b* and PRODH/POX protein expression between carcinoma tissues and 
corresponding normal tissues, but not PRODH/POX mRNA levels. A negative correlation 
between miR-23b* and PRODH/POX protein was found.   
In summary, PRODH/POX is subject to the negative regulation of miR-23b*, which is a 
novel mechanism for cells to regulate PRODH/POX protein level and functions. The 
increased miR-23b* might contribute to renal oncogenesis and progression by 
downregulating tumor suppressor PRODH/POX. This provides a possible strategic opening 
to inhibit tumor growth by decreasing the levels of miR-23b* or by blocking its function.   
5. Regulation of miR-23b* in cancer    
5.1. MiR-23b* regulation by oncogenic protein MYC    
Recently, the oncogenic transcription factor MYC has been reported to transcriptionally 
suppress miR-23b to stimulate mitochondrial glutaminase expression and glutamine 
metabolism in lymphoma cells [5]. MiR-23b and miR-23b* are sibling miRNAs processed 
from the same transcript. Thus, this finding attracted our attention and compelled us to seek 
the potential effect of MYC on miR-23b* and related PRODH/POX expression and proline 
metabolism. As described above, MYC is a critical regulator of miRNAs expression at both 
transcriptional and post-transcriptional levels. Furthermore, proline and glutamine 
metabolism are closely related: not only their interconversions, but also both can be 
anaplerotic in the TCA cycle as an important energy source, as mentioned above. These facts 
strengthened our hypothesis that MYC may regulate the expression of miR-23b*, thereby 
PRODH/POX, and link proline and glutamine metabolism.   
Using human Burkitt lymphoma model P493 cells that bear a tetracycline-repressible MYC 
construct, we found that MYC upregulated the expression of miR-23b* [30]. In PC3 prostate 
cancer cells which overexpress MYC, the same result was obtained, i.e., MYC knockdown by 
siRNA resulted in the decrease of miR-23b* expression. These results are distinct from the 
previous report which showed MYC directly bound to the transcriptional unit 
encompassing miR-23b, and regulated its expression at the transcriptional level [5]. Re-
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In general, miRNAs can be dysregulated by transcription factors and, therefore, genetic or 
epigenetic alterations that result in the dysregulation of transcription factors can cause 
miRNA dysregulation. Importantly, miRNAs can also be directly regulated by genetic or 
epigenetic alterations. 
3.3.4. MiRNAs regulated by genetic and epigenetic changes 
MiRNAs are frequently located in fragile regions of the chromosomes, such as common 
chromosomal-breakpoints that are associated with the development of cancer [175, 176]. 
These fragile regions are often missing, amplified or mutated in cancer cells, resulting in the 
genetic alterations of miRNAs. The genetic alterations can affect the production of the 
primary miRNA transcript, their processing to mature miRNAs and/or interactions with 
mRNA targets. The dysregulation of miR-15 and miR-16 in most B cell chronic lymphocytic 
leukemias, one of the first observations between miRNAs and cancer development, is the 
result from chromosome 13q14 deletion [120]. Interestingly, somatic translocations in 
miRNA target sites can also occur, representing a drastic means of altering miRNA function 
[177, 178]. 
In addition to the structural genetic alterations, dysregulation of miRNAs in cancer can 
occur through epigenetic changes, such as methylation of the CpG islands of their 
promoters, the modification of histone [179-181]. As the example, miR-127 is silenced by 
promoter methylation, which leads to the overexpression of BCL6, an oncogene involved in 
the development of diffuse large B cell lymphoma [179]. The expression of miR-127 could be 
restored by using hypomethylating agents such as azacytidine. MiRNA-200 family could 
serve as another example. The miR-200 family can be shifted to hypermethylated or 
unmethylated 5'-CpG island status corresponding to the epithelial-mesenchymal transition 
(EMT) and mesenchymal-epithelial transition (MET) phenotypes, respectively, which 
contributes to the evolving and adapting phenotypes of human tumors [181].  
4. miR-23b* targets PRODH/POX 
Although numerous targets of miRNAs have been identified, miRNA regulators of critical 
cancer proteins and pathways remain largely unknown. As described above, PRODH/POX 
is frequently reduced in a variety of human cancers, including renal cancer, and 
PRODH/POX protein but not mRNA level is markedly down-regulated in renal cancers [46, 
62]. The fact that miRNAs are critical post-transcriptional regulators, and miRNAs function 
as oncogenes to inhibit the expression of tumor suppressors raises attractive possibility that 
some specific miRNAs may regulate PRODH/POX and proline catabolism. Target-
prediction algorithms have been used to identify the protein targets of miRNAs or miRNAs 
regulators of known protein, followed by experimental validation to eliminate false 
positives [141]. The bioinformatic analysis according to target-prediction algorithms 
predicted that 91 potential miRNAs could target PRODH/POX mRNA 3’UTR [62]. In 
miRNA microarrays, 10 miRNAs showed an increased expression in renal cancer cells 
relative to normal cells. However, only miR-23b* was shown to significantly inhibit 
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PRODH/POX protein expression, but not mRNA level. This is consistent with many previous 
reports, that is, in mammals, miRNAs more often inhibit protein translation of the target 
mRNA, other than inducing its degradation [113]. Subsequently, miR-23b* directly binding to 
PRODH/POX mRNA 3’UTR was experimentally confirmed through luciferase assays by co-
transfecting the mimic miR-23b* and the luciferase reporter containing 3’UTR of PRODH/POX 
mRNA. Functional analysis showed that this miRNA impaired PRODH/POX functions, 
including PRODH/POX-mediated ROS generation, apoptosis, and PRODH/POX-inhibited 
HIF-1 signaling [62]. In contrast, the inhibitory antagomir of miR-23b* increased the expression 
of PRODH/POX protein in renal cancer cells. As a result, ROS production, the percentage of 
cells undergoing apoptosis increased, and HIF-1 signaling decreased. 
The clinical relevance of these in vitro ndings was substantiated by the data obtained in 
human renal carcinoma tissues in vivo [62]. There were statistical significant differences in 
both miR-23b* and PRODH/POX protein expression between carcinoma tissues and 
corresponding normal tissues, but not PRODH/POX mRNA levels. A negative correlation 
between miR-23b* and PRODH/POX protein was found.   
In summary, PRODH/POX is subject to the negative regulation of miR-23b*, which is a 
novel mechanism for cells to regulate PRODH/POX protein level and functions. The 
increased miR-23b* might contribute to renal oncogenesis and progression by 
downregulating tumor suppressor PRODH/POX. This provides a possible strategic opening 
to inhibit tumor growth by decreasing the levels of miR-23b* or by blocking its function.   
5. Regulation of miR-23b* in cancer    
5.1. MiR-23b* regulation by oncogenic protein MYC    
Recently, the oncogenic transcription factor MYC has been reported to transcriptionally 
suppress miR-23b to stimulate mitochondrial glutaminase expression and glutamine 
metabolism in lymphoma cells [5]. MiR-23b and miR-23b* are sibling miRNAs processed 
from the same transcript. Thus, this finding attracted our attention and compelled us to seek 
the potential effect of MYC on miR-23b* and related PRODH/POX expression and proline 
metabolism. As described above, MYC is a critical regulator of miRNAs expression at both 
transcriptional and post-transcriptional levels. Furthermore, proline and glutamine 
metabolism are closely related: not only their interconversions, but also both can be 
anaplerotic in the TCA cycle as an important energy source, as mentioned above. These facts 
strengthened our hypothesis that MYC may regulate the expression of miR-23b*, thereby 
PRODH/POX, and link proline and glutamine metabolism.   
Using human Burkitt lymphoma model P493 cells that bear a tetracycline-repressible MYC 
construct, we found that MYC upregulated the expression of miR-23b* [30]. In PC3 prostate 
cancer cells which overexpress MYC, the same result was obtained, i.e., MYC knockdown by 
siRNA resulted in the decrease of miR-23b* expression. These results are distinct from the 
previous report which showed MYC directly bound to the transcriptional unit 
encompassing miR-23b, and regulated its expression at the transcriptional level [5]. Re-
 
Oncogene and Cancer – From Bench to Clinic 374 
examination of the expression of miR-23b*, miR-23b, and their primary transcript (pri-
miR23b) showed that pri-miR23b increased about 50% with MYC suppression by 
tetracycline and then decreased on MYC re-induction in P493 cells [30]. Similarly, in PC3 
prostate cancer cells, with MYC knockdown by siRNA, miR-23b* decreased 68%, while miR-
23b and Pri-miR-23b increased 51% and 70%, respectively [30]. Thus, the level of miR-23b* is 
higher than miR-23b in cells without MYC knockdown. These results support previous work 
that MYC suppresses miR-23b expression at the transcriptional level. Considering the fact that 
MYC enhances the expression of miR-23b*, the sibling of miR-23b, we hypothesized that 
differential effects of MYC on the sibling miRNAs may be due to their differential stabilization 
and/or degradation mediated by MYC. As a consequence, even if MYC suppressed the 
expression of miR-23b primary transcript, its effects on miR-23b* stabilization and/or 
degradation could account for net higher levels of miR-23b* as observed in this report.  
The mechanisms responsible for stabilized miRNA expression have been largely elusive. As 
mentioned above, Ago proteins, the key players in miRNA processing and function, recently 
have been shown to regulate miRNA stability [93-96]. Ago2 differentially regulates miRNAs 
expression [93, 96]. Not surprisingly, MYC significantly upregulated the expression of Ago2 
[30]. Knockdown of Ago2 in P493 MYC-overexpressed cells, the expression of miR-23b* and 
miR-23b were differentially decreased (76% vs. 42%, respectively), but not Pri-23b. Although 
the differential effects on miR-23b* and miR-23b resulted from Ago2 regulation by MYC do 
not completely account for the observed differential effects of MYC, they do support our 
hypothesis that MYC may regulate miRNA levels by differential effects on the stabilization 
of miRNAs, which can serve as a model for the effects on sibling miRNAs.    
Since a large number of RISC components are involved in the miRNA processing [86]. It is 
likely that MYC with its multitude of target genes may affect many proteins like Ago2 and 
differentially affect miR-23b* and miR-23b expression. In fact, several reports have described 
the regulation of MYC on other RISCs or accessory RISCs, such as the upregulation of XPO5 
and DEAD box protein 5 (DDX5) [86, 182, 183], and the aforementioned Lin28A and Lin28B 
regulation by MYC which affects the expression of mature let-7 miRNAs at multiple levels 
including their processing and modification [151, 156-159], but further studies are needed to 
elucidate how they affect the final expression of mature miRNAs and their interaction.  
5.2. miR-23b* regulation by other factors 
As mentioned above, PRODH/POX is encoded by a p53-induced gene [31]. Maxwell SA et al. 
reported that reduced expression of PRODH/POX mRNA in renal cancer was due to a p53 
mutation [184]. On the other hand, p53 is a critical regulator of miRNAs. Thus, the 
possibility exists that wild-type p53 may regulate the expression of PRODH/POX by both 
direct and indirect (miR-23b*-dependent) mechanism. Interestingly, the experiment showed 
that ectopic expression of p53 in p53-mutant renal cancer cell line TK10 increased the 
expression of miR-23b* [62]. This suggests that the upregulation of miR-23b* by p53 may 
counteract the direct induction of p53 on PRODH/POX gene expression in clear cell renal 
cell carcinoma. This interaction might also account for discrepancies between PRODH/POX 
mRNA and protein expression. 
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In addition, current evidence suggests that miR-23b* could be regulated by factors other 
than p53 and MYC. For example, as discussed above, several reports have shown the link 
between upregulation of miR-23b and hypoxia [167, 185, 186]. As miR-23b and miR-23b* 
share the same precursor, miR-23b* could also be regulated by HIF. In renal cell carcinoma, 
the constitutive expression of HIF due to VHL deciency may link this regulation of miR-
23b* with VHL. The fact that HIF-1 negatively regulates mitochondrial biogenesis by 
inhibiting MYC activity in VHL-decient renal carcinoma cells [187] further increases the 
possibility that miR-23b* could be regulated by VHL, HIF, thereby affecting the expression 
of PRODH/POX. These regulatory interactions are of great interest and worth to be pursued. 
6. Regulation of proline metabolism by MYC 
6.1. MYC suppresses PRODH/POX primarily through miR-23b* 
In view of the above findings, it is not surprising that MYC suppresses the expression of 
PRODH/POX through upregulating miR-23b*. First, PRODH/POX protein increased in a 
time-dependent fashion with diminished MYC expression and then decreased on MYC 
recovery in P493 cells. PRODH/POX mRNA expression also showed a significant increase 
with suppressed MYC expression, but the increase was far less than that of protein levels, 
raising the likelihood that miRNA mediates the effect of MYC on PRODH/POX at the post-
transcriptional level. MYC knockdown in PC3 prostate cancer cells by siRNA resulted in the 
inhibition of PRODH/POX expression with a pattern similar to the P493 cells. Secondly, the 
inhibition of miR-23b* by its antagomirs in the P493 cells with MYC overexpression 
increased PRODH/POX protein level [30]. By contrast, the transfection of mimic miR-23b* 
into the P493 cells under MYC inhibition by tetracycline resulted in a marked decrease of 
PRODH/POX protein expression. However, the decrease of PRODH/POX still was not 
comparable with that without tetracycline treatment, indicating that MYC could suppress 
PRODH/POX expression through pathways other than miRNA, such as the regulation at the 
transcriptional level, which also is supported by the decrease of PRODH/POX mRNA by 
MYC. Thirdly, the luciferase assays in PC cells showed that knockdown of MYC increased 
the luciferase activity of the luciferase reporter containing POX 3’UTR with the binding site 
of miR-23b*, indicating the decrease of miR-23b* by siMYC. Without MYC knockdown, the 
luciferase activity of this reporter was much lower than that of the original reporter without 
POX 3’UTR, due to high levels of miR-23b* binding to PRODH/POX mRNA 3’UTR, thereby 
suppressing luciferase expression. 
By transfecting the PRODH promoter/luciferase reporter construct containing PRODH 
promoter region in PC3 prostate cancer cells, knockdown of MYC resulted in the increase of 
PRODH promoter activity, which confirmed that MYC regulates PRODH/POX at the 
transcriptional level [41]. Analysis of PRODH promoter nucleotide sequence revealed one 
canonical MYC binding site 5’-CACGTG-3’ (E-box) and one noncanonical binding site (5’-
ACGGTG-3’) at -2808 to -2813bp and -637 to -642bp of the PRODH promoter region, 
respectively. However, ChIP assay showed none of these PRODH promoter regions had 
significant PCR amplification, suggesting that MYC does not directly interact with the 
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examination of the expression of miR-23b*, miR-23b, and their primary transcript (pri-
miR23b) showed that pri-miR23b increased about 50% with MYC suppression by 
tetracycline and then decreased on MYC re-induction in P493 cells [30]. Similarly, in PC3 
prostate cancer cells, with MYC knockdown by siRNA, miR-23b* decreased 68%, while miR-
23b and Pri-miR-23b increased 51% and 70%, respectively [30]. Thus, the level of miR-23b* is 
higher than miR-23b in cells without MYC knockdown. These results support previous work 
that MYC suppresses miR-23b expression at the transcriptional level. Considering the fact that 
MYC enhances the expression of miR-23b*, the sibling of miR-23b, we hypothesized that 
differential effects of MYC on the sibling miRNAs may be due to their differential stabilization 
and/or degradation mediated by MYC. As a consequence, even if MYC suppressed the 
expression of miR-23b primary transcript, its effects on miR-23b* stabilization and/or 
degradation could account for net higher levels of miR-23b* as observed in this report.  
The mechanisms responsible for stabilized miRNA expression have been largely elusive. As 
mentioned above, Ago proteins, the key players in miRNA processing and function, recently 
have been shown to regulate miRNA stability [93-96]. Ago2 differentially regulates miRNAs 
expression [93, 96]. Not surprisingly, MYC significantly upregulated the expression of Ago2 
[30]. Knockdown of Ago2 in P493 MYC-overexpressed cells, the expression of miR-23b* and 
miR-23b were differentially decreased (76% vs. 42%, respectively), but not Pri-23b. Although 
the differential effects on miR-23b* and miR-23b resulted from Ago2 regulation by MYC do 
not completely account for the observed differential effects of MYC, they do support our 
hypothesis that MYC may regulate miRNA levels by differential effects on the stabilization 
of miRNAs, which can serve as a model for the effects on sibling miRNAs.    
Since a large number of RISC components are involved in the miRNA processing [86]. It is 
likely that MYC with its multitude of target genes may affect many proteins like Ago2 and 
differentially affect miR-23b* and miR-23b expression. In fact, several reports have described 
the regulation of MYC on other RISCs or accessory RISCs, such as the upregulation of XPO5 
and DEAD box protein 5 (DDX5) [86, 182, 183], and the aforementioned Lin28A and Lin28B 
regulation by MYC which affects the expression of mature let-7 miRNAs at multiple levels 
including their processing and modification [151, 156-159], but further studies are needed to 
elucidate how they affect the final expression of mature miRNAs and their interaction.  
5.2. miR-23b* regulation by other factors 
As mentioned above, PRODH/POX is encoded by a p53-induced gene [31]. Maxwell SA et al. 
reported that reduced expression of PRODH/POX mRNA in renal cancer was due to a p53 
mutation [184]. On the other hand, p53 is a critical regulator of miRNAs. Thus, the 
possibility exists that wild-type p53 may regulate the expression of PRODH/POX by both 
direct and indirect (miR-23b*-dependent) mechanism. Interestingly, the experiment showed 
that ectopic expression of p53 in p53-mutant renal cancer cell line TK10 increased the 
expression of miR-23b* [62]. This suggests that the upregulation of miR-23b* by p53 may 
counteract the direct induction of p53 on PRODH/POX gene expression in clear cell renal 
cell carcinoma. This interaction might also account for discrepancies between PRODH/POX 
mRNA and protein expression. 
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In addition, current evidence suggests that miR-23b* could be regulated by factors other 
than p53 and MYC. For example, as discussed above, several reports have shown the link 
between upregulation of miR-23b and hypoxia [167, 185, 186]. As miR-23b and miR-23b* 
share the same precursor, miR-23b* could also be regulated by HIF. In renal cell carcinoma, 
the constitutive expression of HIF due to VHL deciency may link this regulation of miR-
23b* with VHL. The fact that HIF-1 negatively regulates mitochondrial biogenesis by 
inhibiting MYC activity in VHL-decient renal carcinoma cells [187] further increases the 
possibility that miR-23b* could be regulated by VHL, HIF, thereby affecting the expression 
of PRODH/POX. These regulatory interactions are of great interest and worth to be pursued. 
6. Regulation of proline metabolism by MYC 
6.1. MYC suppresses PRODH/POX primarily through miR-23b* 
In view of the above findings, it is not surprising that MYC suppresses the expression of 
PRODH/POX through upregulating miR-23b*. First, PRODH/POX protein increased in a 
time-dependent fashion with diminished MYC expression and then decreased on MYC 
recovery in P493 cells. PRODH/POX mRNA expression also showed a significant increase 
with suppressed MYC expression, but the increase was far less than that of protein levels, 
raising the likelihood that miRNA mediates the effect of MYC on PRODH/POX at the post-
transcriptional level. MYC knockdown in PC3 prostate cancer cells by siRNA resulted in the 
inhibition of PRODH/POX expression with a pattern similar to the P493 cells. Secondly, the 
inhibition of miR-23b* by its antagomirs in the P493 cells with MYC overexpression 
increased PRODH/POX protein level [30]. By contrast, the transfection of mimic miR-23b* 
into the P493 cells under MYC inhibition by tetracycline resulted in a marked decrease of 
PRODH/POX protein expression. However, the decrease of PRODH/POX still was not 
comparable with that without tetracycline treatment, indicating that MYC could suppress 
PRODH/POX expression through pathways other than miRNA, such as the regulation at the 
transcriptional level, which also is supported by the decrease of PRODH/POX mRNA by 
MYC. Thirdly, the luciferase assays in PC cells showed that knockdown of MYC increased 
the luciferase activity of the luciferase reporter containing POX 3’UTR with the binding site 
of miR-23b*, indicating the decrease of miR-23b* by siMYC. Without MYC knockdown, the 
luciferase activity of this reporter was much lower than that of the original reporter without 
POX 3’UTR, due to high levels of miR-23b* binding to PRODH/POX mRNA 3’UTR, thereby 
suppressing luciferase expression. 
By transfecting the PRODH promoter/luciferase reporter construct containing PRODH 
promoter region in PC3 prostate cancer cells, knockdown of MYC resulted in the increase of 
PRODH promoter activity, which confirmed that MYC regulates PRODH/POX at the 
transcriptional level [41]. Analysis of PRODH promoter nucleotide sequence revealed one 
canonical MYC binding site 5’-CACGTG-3’ (E-box) and one noncanonical binding site (5’-
ACGGTG-3’) at -2808 to -2813bp and -637 to -642bp of the PRODH promoter region, 
respectively. However, ChIP assay showed none of these PRODH promoter regions had 
significant PCR amplification, suggesting that MYC does not directly interact with the 
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PRODH gene, and the decreased PRODH/POX mRNA expression may be mediated through 
other transcription factors regulated by MYC [30].  
6.2. Suppression of proline catabolism is essential for MYC-mediated cancer cell 
proliferation and survival 
In addition to PRODH/POX, MYC also inhibits the expression of another enzyme in proline 
catabolism, P5CDH [30], but the mechanism remains unclear. However, the suppression of 
proline catabolism reflected by PRODH/POX inhibition by MYC has been shown to be 
essential for MYC-induced proliferation and cell survival. First, knockdown of PRODH/POX 
in P493 cells with MYC suppressed by tetracycline consistently reduced the production of 
ROS at different time points [30], although the suppression of MYC itself by tetracycline also 
decreased the accumulation of ROS at late stage which implicates the different effects of 
various MYC regulated genes on ROS production at various stages [188-190]. 
Correspondingly, the apoptosis assay by flow cytometry showed that PRODH/POX 
knockdown decreased the percentage of apoptotic and dead cells occurring with MYC 
suppression. In contrast, PRODH/POX siRNA significantly rescued 30~40% of the 
diminished growth rates resulting from MYC suppression by tetracycline [30]. These results 
indicated that PRODH/POX suppression is critical for MYC-mediated cancer cell 
proliferation and survival. The same assays performed in PC3 prostate cancer cells 
confirmed these results [30].    
To summarize, oncogenic transcription factor MYC inhibits PRODH/POX expression and 
thereby inhibits its tumor suppressor function. When MYC is suppressed, the increase of 
PRODH/POX promotes proline catabolism to generate ROS, leading to the initiation of 
apoptosis and the decrease of cell proliferation and growth. MYC-induced suppression of 
PRODH/POX contributes to MYC-mediated changes of cell behavior including proliferation 
and metabolic reprogramming, which in turn may contribute to tumorigenesis and tumor 
progression. These findings further indicate the critical roles of proline catabolism catalyzed 
by PRODH/POX in human cancers.  
6.3. MYC increases the biosynthesis of proline from glutamine  
Since MYC plays an important role in glutamine metabolism which is closely related with 
proline metabolism due to the interconversion of proline and glutamate, we not only 
investigated the effect of MYC on proline catabolism catalyzed by PRODH/POX as shown 
above, but also examined proline biosynthesis, especially from glutamine. Western blots 
showed that MYC robustly increased the expression of GLS, P5CS and PYCR1 in the 
pathway from glutamine to proline biosynthesis [30]. PC3 prostate cancer cells displayed 
the same correlation between MYC and glutamine and proline metabolism. The 
measurement of the intracellular proline levels showed that MYC dramatically increased the 
intracellular levels of proline. Consistently, using [13C,15N]-Glutamine as a tracer, the direct 
production of proline from glutamine induced by MYC was confirmed by GC-MS and NMR 
analysis [30]. Thus, MYC not only suppresses proline catabolism and stimulates glutamine 
oxidation to glutamate, but also markedly enhances proline biosynthesis from glutamate. 
 
MiRNA and Proline Metabolism in Cancer 377 
Both normal and tumor cells depend on glucose and glutamine consumption as sources of 
metabolic energy, and as precursors for biosynthesis of macromolecules [6, 191]. MYC 
oncogene is considered a master regulator of tumor cell metabolism and proliferation. It not 
only promotes glucose uptake and induces aerobic glycolysis, but also enhances glutamine 
uptake and stimulates glutamine catabolism. Although glutamine catabolism is linked to 
biosynthesis of protein, nucleotides and lipids, redox homeostasis and energy metabolism, 
the report from Wise et al. suggests that little of the glutamine uptake stimulated by MYC is 
used for macromolecular synthesis [6]. MYC-induced glutamine catabolism is involved in 
reprogramming mitochondrial metabolism to sustain cellular viability and TCA cycle 
anapleurosis [6]. More recent findings reported by Le et al. [192] and Wang et al. [193] 
emphasized the metabolic reprogramming controlled by MYC in tumor cells and activated 
T cells. The latter showed that glutamine catabolism driven by MYC coupled with multiple 
biosynthetic pathways, especially ornithine and polyamine biosynthesis [193]. However, the 
importance of the biosynthesis of the ornithine and polyamine from glutamine is 
understood only in part. Similarly, the metabolic advantage afforded by the increased 
conversion of glutamine to proline and how biosynthetic pathway fits into the MYC-driven 
metabolic reprogramming also remain unclear. The connection between the conversion of 
P5C to proline, the last step of proline biosynthesis and pentose phosphate pathway through 
the oxidation-reduction reactions of NADPH and NADP+ [8, 14, 15] provides us a clue to 
understand the importance of proline biosynthesis induced by MYC in cancer, since proline 
synthesis from P5C could also oxidize NADH to NAD+ to maintain glucose metabolism, 
glycolysis. In fact, our unpublished data showed that the blockade of proline biosynthesis 
by knocking down P5CS or PYCR1 markedly decreased glycolysis, which supports our 
hypothesis.     
It’s noteworthy that glutamine may be not the only source of proline biosynthesis promoted 
by MYC, since the increase of PYCR1 is much greater than that of P5CS and GLS [30], and 
ornithine could also be converted to proline by ornithine aminotransferase and PYCR1 (see 
Figure 1). This possibility and its importance in MYC-induced metabolic reprogramming are 
also worth pursuing. 
7. Conclusion 
Proline, the unique proteinogenic secondary amino acid, is metabolized by its own family of 
enzymes. Early studies showed that proline metabolism is linked with TCA cycle, pentose 
phosphate pathway and urea cycle. During the conversion of proline to P5C, the central 
enzyme of proline metabolism, PRODH/POX, donates electron to ETC to generate ROS or 
ATP depending on context. As a tumor suppressor, PRODH/POX is induced by p53, PPARγ 
and its ligands, and contributes to the initiation of apoptosis and the inhibition of tumor 
growth through ROS generation (Figure 2). On the other hand, PRODH/POX is suppressed 
by miR-23b* and oncogene MYC. MYC not only suppresses proline catabolism, but 
increases proline biosynthesis from glutamine (Figure 3). Thus, these recent studies reveal a 
new link in human cancer between MYC, miRNA regulation, proline metabolism, glutamine 
metabolism, TCA cycle, and even glycolysis. These metabolic links emphasizes the 
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PRODH gene, and the decreased PRODH/POX mRNA expression may be mediated through 
other transcription factors regulated by MYC [30].  
6.2. Suppression of proline catabolism is essential for MYC-mediated cancer cell 
proliferation and survival 
In addition to PRODH/POX, MYC also inhibits the expression of another enzyme in proline 
catabolism, P5CDH [30], but the mechanism remains unclear. However, the suppression of 
proline catabolism reflected by PRODH/POX inhibition by MYC has been shown to be 
essential for MYC-induced proliferation and cell survival. First, knockdown of PRODH/POX 
in P493 cells with MYC suppressed by tetracycline consistently reduced the production of 
ROS at different time points [30], although the suppression of MYC itself by tetracycline also 
decreased the accumulation of ROS at late stage which implicates the different effects of 
various MYC regulated genes on ROS production at various stages [188-190]. 
Correspondingly, the apoptosis assay by flow cytometry showed that PRODH/POX 
knockdown decreased the percentage of apoptotic and dead cells occurring with MYC 
suppression. In contrast, PRODH/POX siRNA significantly rescued 30~40% of the 
diminished growth rates resulting from MYC suppression by tetracycline [30]. These results 
indicated that PRODH/POX suppression is critical for MYC-mediated cancer cell 
proliferation and survival. The same assays performed in PC3 prostate cancer cells 
confirmed these results [30].    
To summarize, oncogenic transcription factor MYC inhibits PRODH/POX expression and 
thereby inhibits its tumor suppressor function. When MYC is suppressed, the increase of 
PRODH/POX promotes proline catabolism to generate ROS, leading to the initiation of 
apoptosis and the decrease of cell proliferation and growth. MYC-induced suppression of 
PRODH/POX contributes to MYC-mediated changes of cell behavior including proliferation 
and metabolic reprogramming, which in turn may contribute to tumorigenesis and tumor 
progression. These findings further indicate the critical roles of proline catabolism catalyzed 
by PRODH/POX in human cancers.  
6.3. MYC increases the biosynthesis of proline from glutamine  
Since MYC plays an important role in glutamine metabolism which is closely related with 
proline metabolism due to the interconversion of proline and glutamate, we not only 
investigated the effect of MYC on proline catabolism catalyzed by PRODH/POX as shown 
above, but also examined proline biosynthesis, especially from glutamine. Western blots 
showed that MYC robustly increased the expression of GLS, P5CS and PYCR1 in the 
pathway from glutamine to proline biosynthesis [30]. PC3 prostate cancer cells displayed 
the same correlation between MYC and glutamine and proline metabolism. The 
measurement of the intracellular proline levels showed that MYC dramatically increased the 
intracellular levels of proline. Consistently, using [13C,15N]-Glutamine as a tracer, the direct 
production of proline from glutamine induced by MYC was confirmed by GC-MS and NMR 
analysis [30]. Thus, MYC not only suppresses proline catabolism and stimulates glutamine 
oxidation to glutamate, but also markedly enhances proline biosynthesis from glutamate. 
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Both normal and tumor cells depend on glucose and glutamine consumption as sources of 
metabolic energy, and as precursors for biosynthesis of macromolecules [6, 191]. MYC 
oncogene is considered a master regulator of tumor cell metabolism and proliferation. It not 
only promotes glucose uptake and induces aerobic glycolysis, but also enhances glutamine 
uptake and stimulates glutamine catabolism. Although glutamine catabolism is linked to 
biosynthesis of protein, nucleotides and lipids, redox homeostasis and energy metabolism, 
the report from Wise et al. suggests that little of the glutamine uptake stimulated by MYC is 
used for macromolecular synthesis [6]. MYC-induced glutamine catabolism is involved in 
reprogramming mitochondrial metabolism to sustain cellular viability and TCA cycle 
anapleurosis [6]. More recent findings reported by Le et al. [192] and Wang et al. [193] 
emphasized the metabolic reprogramming controlled by MYC in tumor cells and activated 
T cells. The latter showed that glutamine catabolism driven by MYC coupled with multiple 
biosynthetic pathways, especially ornithine and polyamine biosynthesis [193]. However, the 
importance of the biosynthesis of the ornithine and polyamine from glutamine is 
understood only in part. Similarly, the metabolic advantage afforded by the increased 
conversion of glutamine to proline and how biosynthetic pathway fits into the MYC-driven 
metabolic reprogramming also remain unclear. The connection between the conversion of 
P5C to proline, the last step of proline biosynthesis and pentose phosphate pathway through 
the oxidation-reduction reactions of NADPH and NADP+ [8, 14, 15] provides us a clue to 
understand the importance of proline biosynthesis induced by MYC in cancer, since proline 
synthesis from P5C could also oxidize NADH to NAD+ to maintain glucose metabolism, 
glycolysis. In fact, our unpublished data showed that the blockade of proline biosynthesis 
by knocking down P5CS or PYCR1 markedly decreased glycolysis, which supports our 
hypothesis.     
It’s noteworthy that glutamine may be not the only source of proline biosynthesis promoted 
by MYC, since the increase of PYCR1 is much greater than that of P5CS and GLS [30], and 
ornithine could also be converted to proline by ornithine aminotransferase and PYCR1 (see 
Figure 1). This possibility and its importance in MYC-induced metabolic reprogramming are 
also worth pursuing. 
7. Conclusion 
Proline, the unique proteinogenic secondary amino acid, is metabolized by its own family of 
enzymes. Early studies showed that proline metabolism is linked with TCA cycle, pentose 
phosphate pathway and urea cycle. During the conversion of proline to P5C, the central 
enzyme of proline metabolism, PRODH/POX, donates electron to ETC to generate ROS or 
ATP depending on context. As a tumor suppressor, PRODH/POX is induced by p53, PPARγ 
and its ligands, and contributes to the initiation of apoptosis and the inhibition of tumor 
growth through ROS generation (Figure 2). On the other hand, PRODH/POX is suppressed 
by miR-23b* and oncogene MYC. MYC not only suppresses proline catabolism, but 
increases proline biosynthesis from glutamine (Figure 3). Thus, these recent studies reveal a 
new link in human cancer between MYC, miRNA regulation, proline metabolism, glutamine 
metabolism, TCA cycle, and even glycolysis. These metabolic links emphasizes the 
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complexity of tumor metabolism. Further studies of proline metabolism in tumor 
microenvironment will provide a deeper understanding of tumor metabolism and novel 
therapeutic strategies in cancer.  
 
Figure 3. MYC regulation of proline and glutamine metabolism. MYC suppresses proline catabolism 
through its inhibition of the expression of PRODH/POX and P5CDH. MYC inhibits the expression of 
PRODH/POX at both transcriptional and post-transcriptional levels (upregulation of miR-23b*), which 
is essential for MYC-induced proliferation and cell survival. On the other hand, MYC stimulates 
glutamine catabolism through miR-23a/b-mediated glutaminase (GLS) upregulation. Furthermore, 
MYC not only suppresses proline catabolism, but also enhances proline biosynthesis from glutamine. 
Proline and glutamine metabolism are connected by MYC and miRNA regulation.  
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therapeutic strategies in cancer.  
 
Figure 3. MYC regulation of proline and glutamine metabolism. MYC suppresses proline catabolism 
through its inhibition of the expression of PRODH/POX and P5CDH. MYC inhibits the expression of 
PRODH/POX at both transcriptional and post-transcriptional levels (upregulation of miR-23b*), which 
is essential for MYC-induced proliferation and cell survival. On the other hand, MYC stimulates 
glutamine catabolism through miR-23a/b-mediated glutaminase (GLS) upregulation. Furthermore, 
MYC not only suppresses proline catabolism, but also enhances proline biosynthesis from glutamine. 
Proline and glutamine metabolism are connected by MYC and miRNA regulation.  
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1. Introduction 
In the last years new players have been revealed in cancer biology: microRNA (miRNAs or 
miRs) a class of small non coding RNAs (19-22 nts) able to regulate gene expression at post-
transcriptional level, binding through partial sequence homology mainly the 3’ UTR of 
target mRNAs, and causing block of translation and/or mRNA degradation.  
miRNAs are generated by an endogenous transcript, they represent approximately 1% of 
the genome of different species, and each of them has hundreds of different conserved or 
non conserved targets: it has been estimated that about 30% of the genes are regulated by at 
least one miRNA. miRNA genes, expressed in several organisms, including Homo Sapiens, 
are highly conserved across different species [1].  
This discovery resulted in a pattern shift in our understanding of gene regulation because 
miRNAs are now known to repress thousands of target genes and coordinate normal 
processes, including cellular proliferation, differentiation and apoptosis. They are highly 
specific for tissue and developmental stage, and play crucial functions in the regulation of 
important processes, such as development, and stress response. In the last few years, 
miRNAs have indeed taken their place in the complex circuitry of cell biology, revealing a 
key role as regulators of gene expression.  
In 2002, Croce and colleagues first demonstrated that a miRNA cluster was frequently 
deleted or downregulated in chronic lymphocytic leukemia. This discovery suggested that 
non-coding genes were contributing to the development of cancer, and paved the way for a 
closer investigation of miRNA loss or amplification in tumors.  
miRNAs expression profiling has indeed provided evidence of the association of these tiny 
molecules with tumor development, progression and response to therapy, suggesting their 
possible use as diagnostic, prognostic and predictive biomarkers. It has been demonstrated 
that miRNAs can act either as oncogenes or tumor suppressors, and more recently it has 
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been demonstrated that a miRNAs can exploit both functions according to the cellular 
context of their target genes. Another important issue concerns the role of miRNAs in 
regulating the interaction between cancer cells and the microenvironment with respect to 
neo-angiogenesis or tissue invasion and metastasis. 
Outgrowths of disseminated metastases remain the primary cause of mortality in cancer 
patients, but the molecular and cellular mechanisms regulating metastatic spread remain 
largely unknown. Metastatic processes involve multiple steps, including detachment from 
primary tumors, crossing the basement membrane barriers and extracellular matrix, 
intravasation into the circulation, survival within the vasculature, extravasation into distant 
tissues, and finally, establishment of secondary tumors [2] . These processes rely on 
coordinated spatio-temporal expression of various genes and finely regulated protein 
products, which govern the ability of tumor cells to successfully complete the intricate task, 
and the pivotal role of miRNAs in metastasis has emerged only recently.  
2. miRNAs biogenesis and mechanism of action 
miRNAs are generated by endonucleolytic cleavage of hairpin precursor transcripts by 
Dicer ribonuclease (RNase) III–like proteins and can direct the cleavage of target transcripts 
by Argonaute RNAse H–like proteins in a sequence-specific manner. miRNAs can also 
inhibit translation of target mRNAs. 
miRNAs are transcribed for the most part by RNA Polimerase II as long primary transcripts 
characterized by hairpin structures (pri-microRNAs), and part of them are transcribed as 
distinct transcriptional units. 50% of known miRNA genes are located nearby other 
microRNAs, supporting the hypothesis that clustered miRNAs, representing miRNA 
families which are commonly related in sequence and function, can be transcribed from 
their own promoters as polycistronic pri-microRNAs. 
According to their genomic localization, microRNAs can be classified in: 
a) exonic microRNAs located in non coding transcripts, b) intronic microRNAs located in 
non coding transcripts and  microRNA located in protein-coding trancripts, c) mixed 
miRNA genes that can be assigned to one of the above groups depending on the given 
splicing pattern. Exonic microRNAs are transcribed within the pri-miR (up to 1 kb long) 
containing both the 5’-cap and the 3’-poly-A tail. The miRNAs localized within introns of 
protein-encoding or -non-encoding genes have been denominated “miRtrons”. miRtrons are 
regulatory RNAs transcribed within the mRNA of the host gene generating a hairpin 
structure, recognized and cleaved by the spliceosome machinery without Drosha-mediated 
cleavage.  
The initial step in pri-miRNA processing (Figure 1) is performed in the nucleus by the 
enzymatic activity of an RNAse III-type protein called Drosha. Drosha is a highly conserved 
160 kDa protein containing two RNAse III domains and one double-strand RNA-binding 
domain. Drosha forms a huge complex, 500 kDa in D. melanogaster and 650 kDA in H. 
sapiens, known as Microprocessor complex, which generates a ~70-nucleotides precursor 
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miRNA (pre-miRNA) and contains the co-factor Di George syndrome critical region 8 
(DGCR8), also known as Pasha in D. melanogaster and C. elegans. 
 
Figure 1. An overview of microRNAs biogenesis and mechanism of action. 
The originated precursor molecules are then actively exported by a Ran-GTP and Exportin 
5-mediated mechanism to the cytoplasm, where the second step of pre-miRNA processing 
(dicing) is mediated by the RNAse III Dicer (~200 kDa), which acts in complex with the 
transactivating response RNA-binding protein (TRBP), or PACT (also known as PRKRA), 
and Argonaute (AGO1-4), generating a dsRNA of approximately 22 nucleotides, named 
miR:miR*. This dsRNA includes the mature miRNA guide, and the complementary 
passenger strand, the miRNA* (star miRNA) (many publications refer to the two strand pair 
as miR-3p/miR-5p, referring to the direction of the functional miRNA). Whereas one of the 
two strands is selected as guide strand according to thermodynamic properties, the 
complementary one is usually subjected to degradation. The so called miRNA* was initially 
thought to be the strand subjected to degradation, instead more recent evidence suggests 
that it does not simply represent a non-functional bioproduct of miRNA biogenesis, but it 
can be selected as a functional strand and play significant biological roles [3] .  
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(DGCR8), also known as Pasha in D. melanogaster and C. elegans. 
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and Argonaute (AGO1-4), generating a dsRNA of approximately 22 nucleotides, named 
miR:miR*. This dsRNA includes the mature miRNA guide, and the complementary 
passenger strand, the miRNA* (star miRNA) (many publications refer to the two strand pair 
as miR-3p/miR-5p, referring to the direction of the functional miRNA). Whereas one of the 
two strands is selected as guide strand according to thermodynamic properties, the 
complementary one is usually subjected to degradation. The so called miRNA* was initially 
thought to be the strand subjected to degradation, instead more recent evidence suggests 
that it does not simply represent a non-functional bioproduct of miRNA biogenesis, but it 
can be selected as a functional strand and play significant biological roles [3] .  
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More in details, guided by the sequence complementarity between the small RNA and the 
target mRNA, miRNA-RISC-mediated gene inhibition is commonly divided into three 
processes: (i) site-specific cleavage, (ii) enhanced mRNA degradation and (iii) translational 
inhibition. The first process, commonly defined as RNA interference (RNAi) and restricted 
to miRNAs with a perfect or near-perfect match to the target RNA, is a very rare event in 
mammals, where it is carried out exclusively by Ago2. By contrast, the other two processes 
are more commonly associated with mismatched miRNA/target sequences, which is the 
most likely scenario in mammals. The combination of these two processes is commonly 
defined as a non-cleavage repression, and can be carried out by any of the four mammalian 
Ago proteins [4] . However, the exact mechanism through which miRNAs can impair 
translation is still debated.  
Moreover, even though it is known that microRNAs mainly recognize complementary 
sequences in the 3’ untraslated regions (UTRs) of their target mRNAs, more recent studies 
have reported that they can also bind to the 5’UTR or the ORF [5-8] and, even more 
surprisingly, they can upregulate translation upon growth arrest conditions [9] .  
Finally, whereas the 5’ end of the microRNA (the so called “seed site”) has always been 
considered the most important for the binding to the mRNA, recently the target sites have 
been further divided into three main classes, according to grade and localization of the 
complementarity [10] : the dominant seed site targets (5′ seed-only), the 5′ dominant 
canonical seed site targets (5′ dominant) and the 3′ complementary seed site targets (3′ 
canonical).  
Considering the different rules regulating the interaction between a microRNA and its 
target mRNA, it is not surprising that each miRNA has the potential to target a large 
number of genes [11-14]. Conversely, an estimated 60% of the mRNAs have one or more 
evolutionarily conserved sequences that are predicted to interact with miRNAs. 
Bioinformatical analysis predicts that the 3′ UTR of a single gene is frequently targeted by 
several different miRNAs [11] . Many of these predictions have been validated 
experimentally, suggesting that miRNAs might cooperate to regulate gene expression (a list 
of computational tools for miRNA target prediction is reported in Table 1).  
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To complicate the already intricate scenario, it has been recently reported that miRNAs can 
bind to ribonucleoproteins in a seed sequence and a RISC-independent manner and then 
interfere with their RNA binding functions (decoy activity) [15] . Three studies have 
reported that miRNAs can also regulate gene expression at the transcriptional level by direct 
binding to the DNA [16-18].  
Overall, these data show the complexity and widespread regulation of gene expression by 
miRNAs that should be taken into consideration when developing miRNA-based therapies. 
3. Metastasis 
The most deleterious effect of cancer is metastases development, indeed tumor metastasis is 
the primary cause of death in cancer patients. The ability to metastasize is a hallmark of 
malignant tumors [19] . Metastases represent the end point of a multi-step process that 
consists of local invasion through surrounding extracellular matrix and stromal cells, 
intravasation into the blood vessels, survival in the circulation, extravasation, and 
colonization of distant tissues [20]. Each step in this process represents a physiological 
barrier that must be overcome by the tumor cell to successfully metastasize. Malignant cells 
overcome these barriers through the accumulation of genetic and epigenetic changes, 
including modifications in microRNA expression profiles. Despite great improvement in the 
knowledge of metastasis biology, the molecular mechanisms which underlie this intricate 
process are still not completely understood.  
Tumor cells can invade surrounding tissues as cohesive multicellular units or as individual 
cells, and individual cells can invade through the ‘amoeboid invasion’ or the ‘mesenchymal 
invasion’ programs [21] . Amoeboid movement depends mainly from Rho/ROCK 
expression, and is independent from adhesion and proteolytic degradation of ECM [22,23]. 
On the contrary, mesenchymal motility depends upon interaction of carcinoma cells with 
the extracellular matrix through integrin recruitment and upon pericellular ECM proteolysis 
of the moving cells. Cells that use this program to invade are characterized by an elongated 
and polarized morphology, achievable with an epithelial to mesenchymal transition (EMT). 
EMT, first described as typical of embryonic development, generates cells with 
mesenchymal features phenotypically similar to invading cells. The EMT transcriptional 
programme has been associated with activation of several key transcriptions factors, 
including Snail1 and Snail2 (Slug), Twist, ZEB-1-2, etc, which lead to the regulation of a 
series of proteins causing decrease of E-cadherin for disruption of adherent junctions, 
increase in N-cadherin and Met proto-oncogene to drive motility, as well as increase in 
MMPs and urokinase–type plasminogen activator/urokinase–type plasminogen receptor 
(uPA/uPAR) proteolytic systems to degrade 3D barriers [24,25].  
The overexpression of many of these EMT regulators have been shown to correlate with 
disease relapse and decreased survival in patients with breast, colorectal, and ovarian 
carcinomas, suggesting that the induction of EMT leads to more aggressive tumors and 
poorer clinical outcomes. 
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Once tumor cells have invaded local microenvironment, they should intravasate, survive in 
the circulation and extravasate at distant sites. To successfully perform these steps, they 
have to cross the pericyte and endothelial cell barriers that form the walls of microvessels. In 
order to overcome physical barriers which represent an obstacle to extravasation in tissues 
with low intrinsic microvessel permeability, primary tumors are capable of secreting factors 
that perturb these distant microenvironments and induce vascular hyperpermeability. The 
ability of the cancer cell to develop into a metastatic lesion at distant sites is the most 
limiting step in cancer metastasis formation. Indeed, the disseminated tumor cells may stay 
in a quiescent state for long time, probably due to incompatibilities with the foreign 
microenvironments that surround them [2]. Some have proposed that carcinoma cells can 
address the problem of an incompatible microenvironment at the metastatic site via the 
establishment of a “premetastatic niche” [26]. 
4. miRNAs and metastasis  
Remarkably, a regulatory role for miRNAs in metastasis has been recognized, and the term 
“metastamir” has been coined by Welch and colleagues to refer to those regulatory miRNAs 
not just involved in tumorigenesis, but specific in the promotion or suppression of various 
steps of metastasis [27]. To date, microRNAs have mostly been found to influence the initial 
stages of metastasis, affecting cell migration and invasion (Figure 2). Although a particular 
miRNA that specifically regulates cancer cell intravasation and extravasation has not yet 
been identified, it is still believed that these steps may also be regulated by miRNAs. 
 
 
Figure 2. microRNAs implicated in the regulation of EMT and cell migration.  
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Several miRNAs have been found to regulate the EMT process, and the most well-known 
among them is the miR-200 family, which includes miR-200a, miR-200b, miR-200c, miR-141 
and miR-429.  
miR-200 family is recognized as a master regulator of the epithelial phenotype by post 
transcriptionally suppression of the expression of the ZEB1 and ZEB2 EMT-inducing 
transcription factors in breast [28] and gastric cancer [29]. Acting in the opposite direction, 
ZEB1 and ZEB2, which promote not only tumor cell dissemination, but also the tumor-
initiating capacity, has been shown to transcriptionally repress miR-200 family members, 
thereby establishing a double negative feedback loop that causes the reinforcement of cells 
in either the mesenchymal or epithelial state [25]. This miR family, as others able to control 
epithelial–mesenchymal plasticity, is likely to also affect events at metastatic sites. Recently, 
the putative DNA methylation-associated inactivation of various miR-200 members has 
been described in cancer. miR-200 epigenetic silencing resulted to be not a static and fixed 
process, instead there can be a shift to hypermethylated or unmethylated 5'-CpG island 
status corresponding to the EMT and mesenchymal-epithelial-transition (MET) phenotypes, 
respectively. In fact, careful laser microdissection in human colon revealed that in normal 
colon mucosa crypts (epithelia) and stroma (mesenchyma) 5'-CpG island status are 
unmethylated and methylated at these loci, respectively, and that the colorectal tumors 
undergo selective miR-200 hypermethylation of their epithelial component. These findings 
indicate that the epigenetic silencing plasticity of the miR-200 family contributes to the 
evolving and adapting phenotypes of human tumors [30]. 
Unexpectedly, it was reported that overexpression of miR-200 enhances macroscopic 
metastases in mouse breast cancer models. These findings were surprising but provide yet 
another example of the opposing activities of some miRNAs [31]. miR-200 levels are 
indirectly downregulated by miR-103/107  that target Dicer, a key component of the miRNA 
processing machinery. Accordingly, miR-103/107 are associated with metastasis and poor 
outcome in human breast cancer [32]. 
The transcription factor ZEB1 can also repress the expression of stemness-inhibiting miR-203 
[33]. Recently, miR-203 was reported as a metastasis suppressor miRNA, targeting Slug [34] 
and Snail1 [35] and is often silenced in different malignancies including hepatocellular 
carcinoma, prostate cancer, oral cancer, breast cancer and hematopoietic malignancy. Snail1 
and Slug play a key role during the early step of EMT, activating expression of ZEB factors 
in a context-dependent manner. Functionally, ectopic expression of miR-203 in BT549 and 
MDA-MB-231 breast cancer cell lines caused cell cycle arrest and apoptosis and inhibited 
cell invasion and migration in vitro. Thus the miR-203 and miR-200 feedback loops control 
cell plasticity in epithelial homeostasis. Snail1 is also regulated by miR-30a in non-small cell 
lung cancer (NSCLC), where it is dowmodulated [36]. 
Opposite to miR-200 family, miR-221/222 family promotes a poorly differentiated 
mesenchymal-like phenotype in breast cancer, and is highly expressed in triple negative 
breast cancers that basally expressed EMT markers. Increasing miR-221 or miR-222 can 
affect various characteristics associated with EMT, including increased invasive capacity, 
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[37,38], and anoikis resistance [39]. Forced expression of miR-221/222 in luminal breast 
cancer cells causes a decrease in E-cadherin and an increase in the mesenchymal marker 
vimentin [40]. Luminal cells expressing miR-221/222 gained a more mesenchymal 
morphology and had increased migratory and invasive capacity [41]. Furthermore, miR-221 
and miR-222 can regulate angiogenesis, repressing the proliferative and angiogenic 
properties of c-Kit in endothelial cells [42]. In addition other miRNAs can manage EMT, 
such as the ZEB1- and ZEB2-suppressing miR-205 [28], which has also been shown to exert 
an oncosuppressive activity in breast cancer [43,44] prostate cancer [45] and melanoma [46]; 
and miR-27, which promotes EMT in gastric cancer cell directly targeting APC gene and 
activating the Wnt pathway [47].  
Recently, the inhibition of EMT by p53 has been described as a new mode of tumor 
suppression which presumably prevents metastasis. p53 activation down-regulates Snail via 
induction of the miR-34a/b/c genes, which directly target Snail transcription factor. Ectopic 
miR-34a expression caused down-regulation of Slug and ZEB1, as well as the stemness 
factors BMI1, CD44, CD133, OLFM4 and c-MYC, thus provoking MET. Conversely, the 
transcription factors Snail and ZEB1 repress miR-34a and miR-34b/c expression [48]. 
Recently it has been described that miR-34 suppress also c-MET in hepatocellular carcinoma 
[49] and in osteosarcoma cells [50]. 
EMT is characterized by cadherin switching (from E-cadherin to N-cadherin), that correlates 
with a profound change in cell phenotype and behavior. miR-9, identified as a new 
“metastomiR” and activated by MYC and MYCN, directly targets CDH1, the E-cadherin-
encoding messenger RNA, leading to increased cell motility and invasiveness, activation of β-
catenin signaling and upregulation of VEGF. Moreover, overexpression of miR-9 in non-
metastatic breast tumor cells enables these cells to form pulmonary micrometastases in mice, 
and in colorectal cancer cells it promotes cell motility [51]. Conversely, inhibition of miR-9 in 
highly malignant cells impairs metastasis formation [52].  
N-cadherin (CDH2) was proved to be a direct target of miR-145 by Gao P and coworkers 
[53]. miR-145, suppressing N-cadherin protein translation and indirectly downregulating 
also its downstream effector matrix metallopeptidase 9 (MMP9), suppresses metastases. It 
has been reported that miR-145 exerts its anti metastatic role by directly targeting also the 
metastatic gene mucin 1 [54] in breast cancer and VEGF in osteosarcoma cells [55]. Moreover, 
suppression of Mucin1 by miR-145 causes a reduction of β-catenin as well as the oncogenic 
Cadherin 11 [54]. Accordingly miR-145, acting as a metastasis suppressor, is stepwise 
downregulated in normal gastric mucosa, primary gastric cancers and their secondary 
metastases [53] , and in osteosarcoma in comparison to normal tissues [55].  
Several miRNAs such as miR-34a [56], miR-373 and miR-520c [57] and mir-328 [58] have 
been reported to regulate the cell-surface glycoprotein encoding gene CD44 (cell surface 
receptor for hyaluronan). Cell lines with high CD44+/CD24− cell numbers are 
basal/mesenchymal or myoepithelial types and are more invasive than other cell lines [59]. 
miR-520/373 has been also reported to directly target TGFBR2 and to induce the suppression 
of Smad-dependent expression of the metastasis-promoting genes parathyroid hormone-
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related protein, plasminogen activator inhibitor-1 and angiopoietin-like 4, thus impairing 
tumor cell invasion, in vitro and in vivo. Remarkably, decreased expression of miR-520c 
correlated with lymph node metastasis specifically in ER negative breast tumors [60]. 
Recently Han M and coworkers [61] demonstrated that miR-21 regulates epithelial-
mesenchymal transition phenotype and hypoxia-inducible factor-1α (HIF-1α) expression in 
sphere forming breast cancer stem cells (CSC). Indeed inhibition of miR-21 by antagomir led 
to reversal of EMT, down-expression of HIF-1α, as well as suppression of invasion and 
migration, which indicates a key role of miR-21 in regulating CSC-associated features.  
EMT is a profound change in cell phenotype that causes immotile epithelial cells to acquire 
traits such as motility, invasiveness, anoikis and the ability to adapt to environmental 
changes to continue to invade successfully. Mesenchymal motility program is characterised 
by elongated and polarized cell morphology and depends upon ECM proteolysis of the 
moving cells and from integrin interaction with the extracellular matrix. 
Urokinase, a serin protease, activating plasmin triggers a proteolysis cascade that, 
depending on the physiological environment, participates in extracellular matrix 
degradation. miR-193a/b overexpression in MDA-MB-231 and MDA-MB-435 breast 
carcinoma cells significantly reduced its direct target uPA protein amounts and inhibited 
cell invasion [62]. In an immunodeficient mouse model, miR-193b significantly inhibited the 
growth and dissemination of xenografted tumors [63]. The expression of miR-193b is 
downregulated in metastatic breast cancer, and this microRNA is in turn able to upregulate 
uPA expression and to contribute to the progression of breast cancer. Recently, miR-23b was 
reported to directly target uPA and c-MET and to decrease migration and proliferation of 
human hepatocellular carcinoma cells [64]. Plasminogen activation can be regulated also 
indirectly by mir-17/20 expression, which is usually downregulated in highly invasive 
breast cancer cell lines and node-positive breast cancer specimens [65]. microRNA17/20 
directly repressed IL-8 by targeting its 3' UTR, and inhibited cytokeratin 8 via the cell cycle 
control protein cyclin D1, a secreted plasminogen activator. Indeed cell-conditioned 
medium from microRNA17/20-overexpressing non invasive breast cancer cell MCF7 was 
sufficient to inhibit MDA-MB-231 cell migration and invasion [65]. The invasion-related 
urokinase receptor is also indirectly regulated by a miRNA. Indeed, oncogenic miR-21, 
elevated in different tumor types, included colorectal cancer [66] melanoma and breast 
cancer [67], post-transcriptionally regulates PDCD4, that can suppress invasion and 
intravasation, at least in part by inhibiting expression of uPAR gene via the transcription 
factors Sp1/Sp3. Thus, miR-21 is able to enhance cancer cell intravasation, extravasation and 
metastasis in addition to cell proliferation.  
The restoration in hepatocellular carcinoma cells of miR-122 that exerts some of its action via 
regulation of ADAM17 caused a dramatic reduction of in vitro migration, invasion, in vivo 
tumorigenesis, angiogenesis, and local invasion in the liver of nude mice [68]. Under the 
transcriptional control of HNF1A, HNF3A and HNF3B, miR-122 is specifically repressed in 
a subset of primary tumors that are characterized by poor prognosis [69]. 
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related protein, plasminogen activator inhibitor-1 and angiopoietin-like 4, thus impairing 
tumor cell invasion, in vitro and in vivo. Remarkably, decreased expression of miR-520c 
correlated with lymph node metastasis specifically in ER negative breast tumors [60]. 
Recently Han M and coworkers [61] demonstrated that miR-21 regulates epithelial-
mesenchymal transition phenotype and hypoxia-inducible factor-1α (HIF-1α) expression in 
sphere forming breast cancer stem cells (CSC). Indeed inhibition of miR-21 by antagomir led 
to reversal of EMT, down-expression of HIF-1α, as well as suppression of invasion and 
migration, which indicates a key role of miR-21 in regulating CSC-associated features.  
EMT is a profound change in cell phenotype that causes immotile epithelial cells to acquire 
traits such as motility, invasiveness, anoikis and the ability to adapt to environmental 
changes to continue to invade successfully. Mesenchymal motility program is characterised 
by elongated and polarized cell morphology and depends upon ECM proteolysis of the 
moving cells and from integrin interaction with the extracellular matrix. 
Urokinase, a serin protease, activating plasmin triggers a proteolysis cascade that, 
depending on the physiological environment, participates in extracellular matrix 
degradation. miR-193a/b overexpression in MDA-MB-231 and MDA-MB-435 breast 
carcinoma cells significantly reduced its direct target uPA protein amounts and inhibited 
cell invasion [62]. In an immunodeficient mouse model, miR-193b significantly inhibited the 
growth and dissemination of xenografted tumors [63]. The expression of miR-193b is 
downregulated in metastatic breast cancer, and this microRNA is in turn able to upregulate 
uPA expression and to contribute to the progression of breast cancer. Recently, miR-23b was 
reported to directly target uPA and c-MET and to decrease migration and proliferation of 
human hepatocellular carcinoma cells [64]. Plasminogen activation can be regulated also 
indirectly by mir-17/20 expression, which is usually downregulated in highly invasive 
breast cancer cell lines and node-positive breast cancer specimens [65]. microRNA17/20 
directly repressed IL-8 by targeting its 3' UTR, and inhibited cytokeratin 8 via the cell cycle 
control protein cyclin D1, a secreted plasminogen activator. Indeed cell-conditioned 
medium from microRNA17/20-overexpressing non invasive breast cancer cell MCF7 was 
sufficient to inhibit MDA-MB-231 cell migration and invasion [65]. The invasion-related 
urokinase receptor is also indirectly regulated by a miRNA. Indeed, oncogenic miR-21, 
elevated in different tumor types, included colorectal cancer [66] melanoma and breast 
cancer [67], post-transcriptionally regulates PDCD4, that can suppress invasion and 
intravasation, at least in part by inhibiting expression of uPAR gene via the transcription 
factors Sp1/Sp3. Thus, miR-21 is able to enhance cancer cell intravasation, extravasation and 
metastasis in addition to cell proliferation.  
The restoration in hepatocellular carcinoma cells of miR-122 that exerts some of its action via 
regulation of ADAM17 caused a dramatic reduction of in vitro migration, invasion, in vivo 
tumorigenesis, angiogenesis, and local invasion in the liver of nude mice [68]. Under the 
transcriptional control of HNF1A, HNF3A and HNF3B, miR-122 is specifically repressed in 
a subset of primary tumors that are characterized by poor prognosis [69]. 
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ADAM9 is directly target by miR-126, which expression is reduced in invasive ductal 
adenocarcinoma (IDA) and pancreatic cancer cell lines. Re-expression of miR-126 and 
siRNA-based knockdown of ADAM9 in pancreatic cancer cells resulted in reduced cellular 
migration, invasion, and induction of epithelial marker E-cadherin [70]. It also directly 
regulates the adaptor protein Crk that binds to several tyrosine-phosphorylated proteins, 
inhibiting cell growth by inducing cell cycle arrest in G0/G1 phase, migration and invasion 
in vitro as well as tumorigenicity and metastasis in vivo in gastric cancer [71].  
Matrix metalloproteinase-2 (MMP2), involved in matrix degradation and involved in 
angiogenesis, is directly regulated by miR-29b, whose down modulation promotes 
angiogenesis, invasion, and metastasis of hepatocellular carcinomas [72]. MMP2 was 
confirmed to be a miR-29b target apart from Mcl-1, COL1A1, and COL4A1 also in prostate 
cancer cells [73].  
miR-29c-targeted genes identified in nasopharyngeal carcinomas (NPC) encode extracellular 
matrix proteins, including multiple collagens and Laminin γ1, that are associated with 
tumor cell invasiveness in culture and increased metastasis in animal models and multiple 
human solid tumors as well as fibrillin SPARC [74]. Interestingly, introduction of miR-29c 
led to a reduced transcription of these genes in cultured cells, and the down-regulation of 
mir-29c level in NPC human cancer correlated with increase of target mRNAs, which could 
facilitate rapid matrix generation and renewal during tumor growth and the acquisition of 
tumor motility.  
It was demonstrated that miR-183 targets ezrin, an intermediate between the plasma 
membrane and the actin cytoskeleton involved, together with radixin, in epithelial cell 
morphogenesis and adhesion [75], and may play a central role in the regulation of migration 
and metastasis in breast cancer [76], osteosarcoma [77] and lung cancer [78]. miR-183 is 
markedly down-regulated in osteosarcoma cells and tissues compared with matching 
normal bone tissues and its expression levels significantly correlated with lung metastasis as 
well as with local recurrence of osteosarcoma [77]. 
miR-223 is overexpressed in metastatic gastric cancer cells and stimulates non metastatic 
gastric cancer cells to migrate and to invade. Mechanistically, miR-223, induced by the 
transcription factor Twist, post transcriptionally downregulates EPB41L3 expression, 
thought to be involved in tethering the F-actin cytoskeleton to membrane proteins. Another 
functional downstream target of miR-223 is FBXW7, shown to have important roles in 
regulating the stability of multiple oncoprotein substrates, including Cyclin E, c-MYC, 
Notch, c-Jun, and Mcl-1. Overexpression of miR-223 is associated with poor metastasis-free 
survival in primary gastric carcinomas [79], with lymph node metastasis in gastric cancer, 
and poorer prognosis in oesophageal squamous cell carcinoma patients [80]. 
Cells can move also through an “amoeboid invasion” program. This motility style is largely 
independent from cell-ECM contact and from proteolytic degradation of ECM from MMPs. 
Furthermore, cell-ECM attachments of amoeboid moving cells are not organized in large 
focal adhesions but are very diffuse, and much weaker cell-ECM attachments are required, 
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indeed, amoeboid movement cannot be blocked by inhibition of integrin function. The 
amoeboid invasion depends from Rho/ROCK expression, and their expression can be 
regulated also by miRNAs. 
miR-10b, the first miRNA described to be pro-metastatic by Ma and colleagues in 2007 [81], 
inhibits the translation of mRNA encoding HOXD10, increasing the expression of Rho C, 
and thus leading to tumor cell invasion and metastasis. Ectopic expression of this miRNA 
endowed non-aggressive human breast cancer cells with the capacity to become invasive, as 
well as seed distant micrometastases when implanted as xenografts in immunodeficient 
mice. miR-10b was down-regulated in most breast cancers in comparison with normal 
mammary tissues, whereas it was highly expressed in about 50% of breast metastatic 
tumors.  Induced by transcription factor Twist, miR-10b function as a metastasis driver in 
different types of cancer: i.e pancreatic [82], gastric [83] and colorectal [84] cancers.  
RhoA, another member of Ras homolog gene family, was described also as a target for miR-
155, a Smad4 regulated miR in breast cancer [85]. 
Mir-31 is able to inhibit multiple steps in the metastatic process: local invasion, one or more 
early post-intravasation events (intraluminal viability, extravasation efficiency and/or 
capacity to initially survive in the lung parenchyma), and metastatic colonization. MiR-31 
carries out its anti-metastatic function regulating three genes: Rho A, Integrin α5 and 
Radixin. Via suppression of Rho A, it is able to inhibit in vitro invasiveness [86,87]. Notably it 
also reduces Integrin α5, a key effector of the mesenchymal invasion program, causing 
concomitant inhibition of both single-cell invasion programs. Controlling expression of 
Radixin, miR-31 causes anoikis-mediated cell death. In agreement with these data, miR-31 
expression has been found to be attenuated in human breast [88-90], prostate [91], ovary [92], 
stomach [93,94] and bladder cancer [95]. Moreover miR-31 levels in primary human breast 
tumors were inversely associated with distant metastases [86]. Paradoxically, upregulation of 
miR-31 in human colorectal [96,97], liver [98] and head-and-neck tumors [99,100], as well as 
squamous cell carcinomas of the tongue [101] has also been observed [102] . 
ROCK1 and ROCK2, the downstream targets of Rho A and Rho C, are regulated by miR-
148a [103] and by miR-139 [104], respectively, which all behave as anti-metastatic miRNAs. 
Overexpression of miR-148a in gastric cancer cells [103] as well as in head and neck cancer 
cells  [105], and of miR-139 in hepatocellular carcinoma cells (HCC) [104], suppressed cell 
migration and invasion in vitro and lung metastasis formation in vivo. Accordingly, miR-
148a expression was suppressed in gastric cancer compared with their corresponding non 
tumor tissues, and the downregulated miR-148a was significantly associated with tumor 
node metastasis and miR-139 expression is reduced in metastatic HCC tumors compared 
with primary tumors. 
In addition, others miRNAs with prominent roles in breast cancer metastasis have been 
reported. 
The c-MYC regulated miR-17-92 cluster, which targets the connective tissue growth factor 
(CTGF) and the anti-angiogenic adhesive glycoprotein Thrombospondin 1 (TSP1) is shown 
to be elevated in metastatic breast cancer cells compared with nonmetastatic cells. miRNAs 
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human solid tumors as well as fibrillin SPARC [74]. Interestingly, introduction of miR-29c 
led to a reduced transcription of these genes in cultured cells, and the down-regulation of 
mir-29c level in NPC human cancer correlated with increase of target mRNAs, which could 
facilitate rapid matrix generation and renewal during tumor growth and the acquisition of 
tumor motility.  
It was demonstrated that miR-183 targets ezrin, an intermediate between the plasma 
membrane and the actin cytoskeleton involved, together with radixin, in epithelial cell 
morphogenesis and adhesion [75], and may play a central role in the regulation of migration 
and metastasis in breast cancer [76], osteosarcoma [77] and lung cancer [78]. miR-183 is 
markedly down-regulated in osteosarcoma cells and tissues compared with matching 
normal bone tissues and its expression levels significantly correlated with lung metastasis as 
well as with local recurrence of osteosarcoma [77]. 
miR-223 is overexpressed in metastatic gastric cancer cells and stimulates non metastatic 
gastric cancer cells to migrate and to invade. Mechanistically, miR-223, induced by the 
transcription factor Twist, post transcriptionally downregulates EPB41L3 expression, 
thought to be involved in tethering the F-actin cytoskeleton to membrane proteins. Another 
functional downstream target of miR-223 is FBXW7, shown to have important roles in 
regulating the stability of multiple oncoprotein substrates, including Cyclin E, c-MYC, 
Notch, c-Jun, and Mcl-1. Overexpression of miR-223 is associated with poor metastasis-free 
survival in primary gastric carcinomas [79], with lymph node metastasis in gastric cancer, 
and poorer prognosis in oesophageal squamous cell carcinoma patients [80]. 
Cells can move also through an “amoeboid invasion” program. This motility style is largely 
independent from cell-ECM contact and from proteolytic degradation of ECM from MMPs. 
Furthermore, cell-ECM attachments of amoeboid moving cells are not organized in large 
focal adhesions but are very diffuse, and much weaker cell-ECM attachments are required, 
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indeed, amoeboid movement cannot be blocked by inhibition of integrin function. The 
amoeboid invasion depends from Rho/ROCK expression, and their expression can be 
regulated also by miRNAs. 
miR-10b, the first miRNA described to be pro-metastatic by Ma and colleagues in 2007 [81], 
inhibits the translation of mRNA encoding HOXD10, increasing the expression of Rho C, 
and thus leading to tumor cell invasion and metastasis. Ectopic expression of this miRNA 
endowed non-aggressive human breast cancer cells with the capacity to become invasive, as 
well as seed distant micrometastases when implanted as xenografts in immunodeficient 
mice. miR-10b was down-regulated in most breast cancers in comparison with normal 
mammary tissues, whereas it was highly expressed in about 50% of breast metastatic 
tumors.  Induced by transcription factor Twist, miR-10b function as a metastasis driver in 
different types of cancer: i.e pancreatic [82], gastric [83] and colorectal [84] cancers.  
RhoA, another member of Ras homolog gene family, was described also as a target for miR-
155, a Smad4 regulated miR in breast cancer [85]. 
Mir-31 is able to inhibit multiple steps in the metastatic process: local invasion, one or more 
early post-intravasation events (intraluminal viability, extravasation efficiency and/or 
capacity to initially survive in the lung parenchyma), and metastatic colonization. MiR-31 
carries out its anti-metastatic function regulating three genes: Rho A, Integrin α5 and 
Radixin. Via suppression of Rho A, it is able to inhibit in vitro invasiveness [86,87]. Notably it 
also reduces Integrin α5, a key effector of the mesenchymal invasion program, causing 
concomitant inhibition of both single-cell invasion programs. Controlling expression of 
Radixin, miR-31 causes anoikis-mediated cell death. In agreement with these data, miR-31 
expression has been found to be attenuated in human breast [88-90], prostate [91], ovary [92], 
stomach [93,94] and bladder cancer [95]. Moreover miR-31 levels in primary human breast 
tumors were inversely associated with distant metastases [86]. Paradoxically, upregulation of 
miR-31 in human colorectal [96,97], liver [98] and head-and-neck tumors [99,100], as well as 
squamous cell carcinomas of the tongue [101] has also been observed [102] . 
ROCK1 and ROCK2, the downstream targets of Rho A and Rho C, are regulated by miR-
148a [103] and by miR-139 [104], respectively, which all behave as anti-metastatic miRNAs. 
Overexpression of miR-148a in gastric cancer cells [103] as well as in head and neck cancer 
cells  [105], and of miR-139 in hepatocellular carcinoma cells (HCC) [104], suppressed cell 
migration and invasion in vitro and lung metastasis formation in vivo. Accordingly, miR-
148a expression was suppressed in gastric cancer compared with their corresponding non 
tumor tissues, and the downregulated miR-148a was significantly associated with tumor 
node metastasis and miR-139 expression is reduced in metastatic HCC tumors compared 
with primary tumors. 
In addition, others miRNAs with prominent roles in breast cancer metastasis have been 
reported. 
The c-MYC regulated miR-17-92 cluster, which targets the connective tissue growth factor 
(CTGF) and the anti-angiogenic adhesive glycoprotein Thrombospondin 1 (TSP1) is shown 
to be elevated in metastatic breast cancer cells compared with nonmetastatic cells. miRNAs 
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belonging to this cluster, attenuating also the TGFβ signaling pathway, indirectly shut down 
clusterin and angiopoietin-like 4 expressions, thereby stimulating angiogenesis and tumor 
cell growth [106].  Accordingly, blockade of miR-17 is shown to decrease breast cancer cell 
invasion/migration in vitro and metastasis in vivo [107]. Furthermore miR-17 and miR-20a 
were found to be significantly associated with reduced progression free survival in 
gastrointestinal cancer patients [108] . 
The team led by Joan Massague [109] found that miR-335, miR-126, and miR-206 are 
metastasis-suppressors. Authors performed array-based miRNA profiling in MDA-MB-231 
breast cancer cell derivatives (LM2) highly breast cancer cell derivatives highly metastatic to 
bone and lung, and found a signature of six genes (miR-335, miR-126, miR-206, miR-122a, 
miR-199a*, and miR-489) whose expression was highly decreased in metastatic cells. 
Restoring the expression of miR-335, miR-126 or miR-206 in LM2 cells decreased the lung 
colonizing activity of these cells by more than fivefold. They found that miR-335 suppresses 
metastasis and migration by targeting the progenitor cell transcription factor SOX4 and TNC 
messenger RNAs. Consequently, loss of miR-335 leads to the activation of SRY-box containing 
SOX4 and TNC, which are responsible for the acquisition of metastatic properties. Notably, 
knockdown of SOX4 and TNC using RNA interference diminished in vitro invasive ability and 
in vivo metastatic potential, evidencing that both genes are key effectors of metastasis [110]. 
miR-126, has recently been described to suppress metastatic endothelial recruitment, 
metastatic angiogenesis and metastatic colonization through coordinate targeting of IGFBP2, 
PITPNC1 and MERTK, novel pro-angiogenic genes and biomarkers of human metastasis 
through the IGFBP2/IGF1/IGF1R and GAS6/MERTK signaling pathways [111]. In addition, 
low expression of miR-335 or miR-126 in primary tumors from patients was associated with 
poor distal metastasis-free survival. 
IGF1R was identified as a direct target of miR-493 that has been described as a metastasis 
inhibitor. Indeed, high levels of miR-493 and miR-493(*), but not pri-miR-493, in primary 
colon cancer were inversely related to the presence of liver metastasis, and attributed to an 
increase of miR-493 expression during carcinogenesis [112]. 
Raf kinase inhibitor protein (RKIP) represses breast tumour cell intravasation and bone 
metastasis through inhibition of MAPK leading to decreased transcription of LIN28 by Myc. 
Suppression of LIN28 enables enhanced let-7 processing in breast cancer cells. let-7 appears 
to play a major role in regulating stemness however elevated let-7 expression inhibits 
HMGA2, a chromatin remodelling protein that activates pro-invasive and pro-metastatic 
genes, including Snail. LIN28 depletion and let-7 expression suppress bone metastasis, and 
LIN28 restores bone metastasis in mice bearing RKIP-expressing breast tumour cells [113]. 
miR-146a is very similar to miR-146b, which is encoded by a different gene, but differs by 
only two bases and appears to function redundantly in many systems as mediators of 
inflammatory signaling, influencing differentiation, proliferation and apoptosis. They are 
pleiotropic regulators of tumorigenesis, as altered expression of both miR-146a/b have been 
linked with cancer risk, tumor histogenesis and invasive and metastatic capacity in diverse 
cancers [114]. In fact Hurst and coworkers [27], showed that breast cancer metastasis 
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suppressor 1 (BRMS1), a protein that regulates expression of multiple genes [115] leading to 
suppression of metastasis, significantly up-regulates miR-146a and miR-146b in metastatic 
breast cancer cells. Transduction of miR-146a or miR-146b into MDA-MB-231 inhibited 
invasion and migration in vitro, and suppressed experimental lung metastasis. Bhaumik et 
al. confirmed that expression of miR-146a/b in MDA-MB-231 cells, impaired invasion and 
migration capacity by suppressing NF-κB activity [116]. In Table 2 both suppressing and 
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PITPNC1 and MERTK, novel pro-angiogenic genes and biomarkers of human metastasis 
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suppressor 1 (BRMS1), a protein that regulates expression of multiple genes [115] leading to 
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5. miRNAs as prognostic biomarkers 
After early studies indicating the role of microRNA genes in the pathogenesis of human 
cancer, platforms to assess the global expression of microRNA genes in normal and diseased 
tissues have been developed. Gene expression profiling has already demonstrated its 
effectiveness at subtyping various cancers, however miRNA profiles are equally 
discriminatory and can even be more informative, as changes in their expression can provide 
insights into the myriad of gene permutations observed in various cancer subtypes: links have 
indeed been made between misregulated miRNAs and the target genes that are affected, thus 
unraveling some of the unique gene networks involved [117]. miRNA profiles may identify 
cancer-specific signatures distinguishing between normal and cancerous tissue [118-121], but 
they can also discriminate different subtypes of a particular cancer [119,122,123].  
To discover microRNAs regulating the critical transition from ductal carcinoma in situ to 
invasive ductal carcinoma, a key event in breast cancer progression, Volinia et al. [124] 
performed a microRNA profile on 80 biopsies from invasive ductal carcinoma, 8 from ductal 
carcinoma in situ, and 6 from normal breast selected from a recently published deep-
sequencing dataset [125]. They found that the microRNA profile established for the normal 
breast to ductal carcinoma in situ transition was largely maintained in the in situ to invasive 
ductal carcinoma transition. Nevertheless, a nine-microRNA signature that differentiated 
invasive from in situ carcinoma was identified. Specifically, let-7d, miR-210, and -221 were 
down-regulated in the in situ and up-regulated in the invasive transition, thus featuring an 
expression reversal along the cancer progression path. Additionally, they identified 
microRNAs for overall survival and time to metastasis. Five noncoding genes were 
associated with both prognostic signatures miR-210, -21, -106b*, -197, and let-7i, with miR-
210 the only one also involved in the invasive transition.  
Concerning the possibility to use miRNAs as prognostic markers to predict outcome, several 
groups have successfully addressed this issue [123,126-130] and in particular, concerning 
involvement of microRNAs in metastatic disease. For example several studies conducted on 
samples from patient with lung cancer assessed the involvement of metastamiRs: Landi et al 
[122] analyzed 107 male with early-stage squamous cell lung cancers (SQ) and found 5 
miRNAs (miR-25, -34c-5p, -191, let- 7e, miR-34a) whose high expression strongly predicted 
longer SQ survival [122]. In another study, based on miRNA expression profiling of lung 
adenocarcinoma and SQ, ten miRNAs (hsa-miR-450b-3p, hsa-miR-29c*, hsa-miR-145*, hsa-
miR-148a*, hsa-miR-1, hsa-miR-30d, hsa-miR-187, hsa-miR-218, hsa-miR-708* and hsa-miR-
375) associated with brain metastasis were identified including miR-145*, which inhibit cell 
invasion and metastasis. Two miRNA signatures that are highly predictive of recurrence 
free survival of 357 stage I NSCLC were also identified, one independent of cancer subtype, 
the other specific for adenocarcinoma or SQ subtype [131]. From a small cohort of 20 NSCLC 
patients, Donnem and co-workers [132] in addition to miR differentially expressed between 
NSCLC tumors and normal control, found 37 miRs up/down regulated in tumors derived 
from patients with short versus long disease specific survival (DSS) including upregulated 
miR-31, miR-183, let-7a, miR-193b and downregulated miR-205, miR-378, miR-708 and miR-
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29c. A further analysis comparing short versus long DSS patients tumors identified 
significantly altered angiogenesis-related miRs (miR-21, miR-106a, miR-126, miR-155, miR-
182, miR-210 and miR-424) [123], on the basis of a small number of cases, found that the 
reduced expression of miR-17-5p and -30c in malignant mesothelioma correlated with better 
survival in patients with the sarcomatoid subtype.  
Studies relative to tumors in other body districts have been carried out to determine the 
involvement of miRs in metastatic disease. Heinzelman et al, analysed miRNA expression of 
30 human clear cell renal carcinoma (ccRCC) including 10 non-metastatic tumors, 4 tumors 
with metastasis after 3 years or later and 4 tumors with primary metastasis. They detected a 
miRNA signature that distinguishes between metastatic and non-metastatic ccRCC, including 
miR-451, miR-221, miR-30a, miR-10b and miR-29a. Furthermore, the authors identified a 
group of 12 miRNAs, such as let-7 family, miR-30c, miR-26a, which are decreased in highly 
aggressive primary metastatic tumours. They found also correlations between expression 
levels of specific miRNAs with progression-free survival and overall survival [133].  
Veerla et al [95], by miRNA expression analysis of 34 cases of urothelial carcinomas 
identified 51 miRNAs that discriminated the 3 pathological subtypes Ta, T1 and T2-T3. A 
score based on the expression levels of the 51 miRNAs, identified muscle invasive tumors 
with high precision and sensitivity. miRNAs showing high expression in muscle invasive 
tumors included miR-222 and miR-125b and in Ta tumors miR-10a. Moreover authors 
identified 2 miRNAs, miR-452 and miR-452*, associated with metastases in the lymph nodes 
and with a strong prognostic impact on death as endpoint. 
353 gastric samples from two independent subsets of patients from Japan were analysed by 
Ueda et al [119], with the aim to assess the relation between microRNA expression and 
prognosis of gastric cancer. They found a progression-related signature including miR-125b, 
miR-199a, and miR-100 as the most important microRNAs involved. Moreover they found 
that low expression of let-7g and miR-433 and high expression of miR-214 were associated 
with unfavourable outcome in overall survival independent of clinical covariates, including 
depth of invasion, lymph-node metastasis, and stage. 
6. Conclusion 
Although miRs that have been demonstrated to be implicated in the metastatic process 
might represent a possible therapeutic tool, there have been so far few reported successes in 
the development of miRNAs for use in therapy. There are two main strategies to target 
miRNAs expression in cancer. Direct strategies involve the use of oligonucleotides or virus-
based constructs to either block the expression of an oncogenic miRNA or to reintroduce a 
tumor suppressor miRNA lost in cancer. The indirect strategy involves the use of drugs to 
modulate miRNAs expression by targeting their transcription and their processing. Indeed, 
even though a number of reports have described the possibility to reintroduce or inhibit 
microRNAs (reviewed by Iorio and Croce, [134]), there are still many issues that need to be 
addressed for an effective translation in clinics, as the development of efficient methods of a 
specific drug delivery, and the accurate prevision of putative unwanted off target effects.  
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5. miRNAs as prognostic biomarkers 
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29c. A further analysis comparing short versus long DSS patients tumors identified 
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involvement of miRs in metastatic disease. Heinzelman et al, analysed miRNA expression of 
30 human clear cell renal carcinoma (ccRCC) including 10 non-metastatic tumors, 4 tumors 
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Veerla et al [95], by miRNA expression analysis of 34 cases of urothelial carcinomas 
identified 51 miRNAs that discriminated the 3 pathological subtypes Ta, T1 and T2-T3. A 
score based on the expression levels of the 51 miRNAs, identified muscle invasive tumors 
with high precision and sensitivity. miRNAs showing high expression in muscle invasive 
tumors included miR-222 and miR-125b and in Ta tumors miR-10a. Moreover authors 
identified 2 miRNAs, miR-452 and miR-452*, associated with metastases in the lymph nodes 
and with a strong prognostic impact on death as endpoint. 
353 gastric samples from two independent subsets of patients from Japan were analysed by 
Ueda et al [119], with the aim to assess the relation between microRNA expression and 
prognosis of gastric cancer. They found a progression-related signature including miR-125b, 
miR-199a, and miR-100 as the most important microRNAs involved. Moreover they found 
that low expression of let-7g and miR-433 and high expression of miR-214 were associated 
with unfavourable outcome in overall survival independent of clinical covariates, including 
depth of invasion, lymph-node metastasis, and stage. 
6. Conclusion 
Although miRs that have been demonstrated to be implicated in the metastatic process 
might represent a possible therapeutic tool, there have been so far few reported successes in 
the development of miRNAs for use in therapy. There are two main strategies to target 
miRNAs expression in cancer. Direct strategies involve the use of oligonucleotides or virus-
based constructs to either block the expression of an oncogenic miRNA or to reintroduce a 
tumor suppressor miRNA lost in cancer. The indirect strategy involves the use of drugs to 
modulate miRNAs expression by targeting their transcription and their processing. Indeed, 
even though a number of reports have described the possibility to reintroduce or inhibit 
microRNAs (reviewed by Iorio and Croce, [134]), there are still many issues that need to be 
addressed for an effective translation in clinics, as the development of efficient methods of a 
specific drug delivery, and the accurate prevision of putative unwanted off target effects.  
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Nevertheless, the results obtained up to date seem quite promising and encouraging, and 
even though we still have to improve the knowledge in microRNA field to even think of 
future therapeutic applications, we might be not so far from there. 
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1. Introduction 
Large-scale analysis of total genome transcripts (transcriptome) in organisms including 
human and mouse has revealed that many RNAs are transcribed from genomic regions that 
encode no proteins (referred to as ncRNA) (1-5). Among such ncRNAs, microRNAs 
(miRNAs), small molecule RNAs 18-28 bases long, have been extensively studied over the 
past decade, and a gene regulatory system called “RNA silencing” has been revealed. In 
humans, more than 400 miRNAs are known to regulate at least one-third of protein-
encoding genes (6-10). Most miRNAs are generated by processing of long miRNA 
precursors (pri-miRNAs) (6, 9). Pri-miRNAs are transcribed by RNA polymerase II and 5’ 
cap structures and poly A tails are added, similarly to protein-encoding mRNAs. Pri-
miRNAs are further processed in the nucleus into pre-miRNAs with an approximately 70 
base hairpin structure and are then exported to the cytoplasm. pre-miRNAs are finally 
processed into mature miRNAs by the enzyme, Dicer. It is noteworthy that miRNAs are 
sometimes encoded in the introns of other genes. A mature miRNA is incorporated into the 
RNA-induced silencing complex to act on its target mRNA. Broadly speaking, miRNAs can 
act on mRNAs in two ways. If there is limited homology between an miRNA and a target 
mRNA, the miRNA suppresses translation of the mRNA. However, if the miRNA has 
complete or nearly complete homology with a target mRNA, the mRNA is rapidly 
degraded. In animal cells, the former scenario usually occurs (7, 10-12). Many miRNAs have 
been reported to be associated with tumors, including AML and glioma; however, it is still 
unclear how predominant miRNAs are in tumorigenesis.  
Relatively large ncRNAs of over several hundred bases, which are longer than pri-miRNAs 
whose length is usually 200-300 bases, are called long-chain non-coding RNAs (lncRNAs). 
Despite their somewhat unclear definition and their largely undetermined functions (13), 
the public databases for lncRNAs, for example, lncRNAdb (http://www.lncrnadb.org/) (14) 
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or NONCODE (http://www.noncode.org) (15), contain several hundred mammalian 
lncRNAs, including more than 100 from human (16). The RNAs included are heterologous; 
some localize in the nucleus to form certain structures, others interact with chromatin 
modifying enzymes such as p300, while others function in the cytoplasm (Fig. 1). 
Both miRNAs and lncRNAs are physiologically important in many biological processes, 
including development and cell differentiation. Their association with disease, especially 
cancers, is of great interest (5). Association of miRNAs with various tumors, including 
different types of leukemia (Table 1) and glioma (Table 2), has been demonstrated. They 
sometimes act as tumor-promoting factors and sometimes as tumor suppressors. Expression 
of many lncRNAs, including NDM29 (neuroblastoma) (17, 18) and MALAT-1 (lung cancer) 
(19) are correlated with tumor progression, while MEG3 (pituitary tumor) (20, 21), HOTAIR 
(breast carcinoma) (22), H19 (Wilms’ tumor) (23), AK023948 (papillary thyroid tumor) (24) 
and LOC285194 (osteosarcoma) (25) are putative tumor suppressors (Table 3). These 
lncRNAs seem to control cancer cell growth by regulating other genes (NDM29, HOTAIR, 
H19) or by adjusting the mRNA splicing mechanism (MALAT-1) (Fig. 1) (14). 
 
Figure 1. Classification of ncRNAs. (a) Pri-miRNAs are synthesized and processed in the nucleus, then 
exported to the cytoplasm. They are incorporated in the RISC complex to degrade or inhibit 
transcription of target mRNAs. However, some synthesized lncRNAs associate with chromatin (b) to 
silence certain genes. Some lncRNAs are incorporated in intranuclear bodies (c) or make complexes 
with specific proteins (d). Some are exported to the cytoplasm to work in the RNA-protein complex (e). 
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Name Loci Name Loci
Oncogenic or Increased Expression in AML Tumor Suppressive or Decreased Expression in AML 
let-7b 22q13.31 let-7 9q22.32 
let-7e 19q13.41 let-7b 22q13.31 
miR-10a 17q21.32 miR-9* 1q22 
miR-10b 2q31.1 miR-15a 13q14.2 
miR-27a 19p13.13 miR-15b 3q25.33 
miR-30d 8q24.22 miR-16 13q14.2 
miR-126 9q34.3 miR-19a 13q31.3 
miR-129-5p 7q32.1 miR-20a 13q31.3 
miR-130b 22 miR-26a 3p22.2 
miR-142-5p 17q22 miR-29a 7q32.3 
miR-155 21q21.3 miR-29b 7q32.3 
miR-181a 1q31.3/9q33.3 miR-29c 1q32.2 
miR-181b 1q31.3/9q33.3 miR-30a-3p 6q13 
miR-181c 19p13.13 miR-34b 11q23.1 
miR-181d 19p13.13 miR-34c 11q23.1 
miR-195 17p13.1 miR-124 8p23.1 
miR-221 Xp11.3 miR-128-1 2q21.3 
miR-223 Xq12 miR-145 5q32 
miR-221/222 Xp11.3 miR-147 9q33.2 
miR-324-5p 17p13.1 miR-148a 7p15.2 
miR-326 11q13.4 miR-151 8q24.3 
miR-328 16q22.1 miR-181a 1q31.3/9q33.3 
miR-331 12q22 miR-181b 1q31.3/9q33.3 
miR-340 5q35.3 miR-182 7q32.2 
miR-374 Xq13.2 miR-184 15q25.1 
miR-424 Xq26.3 miR-194 1q41 
  miR-196a 17q21.32 
  miR-196a 17q21.32 
  miR-199a 19p13.2 
  miR-204 9q21.12 
  miR-219-5p 6q21.32 
  miR-220a Xq25 
  miR-302b* 4q25 
  miR-302d 4q25 
  miR-320 8q21.3 
  miR-320 8q21.3 
  miR-325 Xq21.1 
    
 
Data are chosen from references 54, 55, 62, 63, 65, 66. Data confined to cytogenetically normal AML where possible. 
Note some miRNA appeared both oncogenic and tumor-suppressive. 
Table 1. Examples of miRNAs associated with AML that change expression level 
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Name Genetic Locus Name Genetic Locus 
Oncogenic or Increased Expression in Glioma Tumor Suppressive or Decreased Expression in Glioma 
miR-9* 1q22 let-7 family 9q22.32 
miR-10a* 17q21.32 miR-7 9q21.32 
miR-10b 2q31.1 miR-15b 3q25.33 
miR-17/92 cluster 13q31.3 miR-17 13q31.3 
miR-21 17q23.1 miR-26b 2q35 
miR-25 7q22.1 miR-29b 7q32.3 
miR-26a 3p22.2 miR-34a 1p36.22 
miR-93 7q22.1 miR-101 1p31.3 
miR-125b 11q24.1 miR-106a Xq26.2 
miR-182 7q32.2 miR-124 8p23.1 
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miR-196b 7p15.2 miR-137 1p21.3 
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miR-296 20q13.32 miR-153 2q35 
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miR-455-3p 9q32 miR-184 15q25.1 
miR-486 8p11.21 miR-195 17p13.1 
  miR-199b-5p 9q34.11 
  miR-218 4p15.31 
  miR-326 11q13.4 
  miR-451 17q11.2 
    
 
Data are chosen from references 67 and 68. Data confined to cases of low grade gliomas but exclusion of data from 
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Tumor Function Refs 
Tumor promoting or Increased Expression 
AIRN  Airn 6q26 NA Wilms’ tumor NA (59) 
BC200 BCYRN1  Bc1 2p21 200 Breast cancer Regulation of protein 
biosynthesis 
(70) 
HIF1A-AS2 aHIF NA 14q23.2 2051 Multiple 
cancers 
Decoy of mRNA (71) 
HOTAIR Gm16258 Hotair 12q13.3 2364 Multiple  
cancers 
Epigenetic silencing of 
HOXD gene through 
histoneH3K27 methylation 
(72) 





IGF2AS PEG8 Igh2as 11p15.5 2091 Wilms' tumor NA (74) 
KRASP1  NA 6p12-p11 5178 Prostate cancer Decoy of miRNA (75) 





MALAT1 Neat2 Malat1 11q13.1 8708 Multiple cancer Control of RNA procession (19, 77) 





PCA3 DD3 NA 9q21-q22 3735 Prostate cancer NA (78) 
PCGEM1  NA 2q32 1603 Prostate cancer NA (79) 
PRNCR1  NA 8q24 >12756 Prostate cancer NA (80) 
SRA1  Sra1 5q31.3 1955 Breast cancer Activation of nuclear 
receptors 
(81) 
TERC  Terc 3q26 451 Multiple cancer Telomere template (82) 
UCA1 CUDR NA 19p13.12 1591 Bladder cancer Regulation of cell cycle (83) 
WT1-AS WIT1 NA 11p13 1333 Wilms' tumor 
AML 
Downregulation of WT1, 
tumor suppressor 
(84) 
XIST  Xist Xq13.2 19271 Multiple cancers Xinactivation (56, 85) 
Tumor Suppressing or Decreased Expression in Tumor 









Regulation of epigenetic 
transcriptional repression 
(58) 
BC040587  NA 3q13.31 NA Osteosarcoma NA (25) 
DLEU2  Dleu2 13q14.3 2768 Chronic 
lymphocytic 
leukemia 
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Tumor Function Refs 
GAS5  Gas5 1q25.1 651 Breast cancer Decoy of glucocorticoid 
receptor 
(87) 
H19  H19 11p15.5 2322 Wilms' tumor Epigenetic regulation 
through DNA methylation 
(88) 
KCNQ1OT1   LIT1, 
KvLQT1-AS, 
KvLQT1OT1 






through H3K27 methylation 
(57) 
LOC285194  NA 3q13.31 NA Osteosarcoma NA (25) 
MEG3 Gtl2 Meg3 14q32 1595 Glioma, pituitary 
adenoma and 
other tumor 
Regulation of p53 target 
proteins 
(89) 
NDM29 29A NA 11p15.3 131 Neuroblastoma Induction the appearance of 
neuronal-like properties 
(18) 
p53 mRNA   Tp53 17p13.1 19144 Multiple cancer RNA protein binding, MDM3 (90) 
PTENP1  NA 9p21 3932 Prostate cancer Decoy for PTEN-targeting 
miRNAs 
(75) 






TERRA  TelRNAs telomere 
repeats 
NA Many cancer cell 
lines 
Interaction with the TRF1 (92) 
vtRNA2-1  NA 5q31.1 100 AML, papillary 
thyroid cancer 
Regulation of RNA 
dependent protein kinase 
(pPKR) 
(93) 
ZNFX1-AS1 Zfas1 1500012 
F01Rik 
20q13.13 1020 Breast cancer NA (94) 
(a) no homologous RNA but binds to PSF, a transcriptional repressor. NA, not available. 
Table 3. Human lncRNAs associated with tumors described in public data bases. 
2. Genetic abnormality observed in acute myeloid leukemia (AML) 
AML, which comprises approximately 25% of hematopoietic malignancies, has 
heterogeneous clinical features and variable responses to contemporary therapy (26). 
Genetic alterations are often observed in AML cells and the clinical heterogeneity of the 
disease is considered to reflect the genetic diversity of these cells (27, 28). It is very 
important to study the genetic mutations in AML cells to fully understand the cause of the 
disease. However, genetic lesion(s) responsible for AML, such as the loss or gain of a certain 
gene, have not yet been fully elucidated. Indeed, the complex features of AML suggest that 
the genetic cause of this disease is multifactorial (29). Several protein-encoding genes have 
been identified that are useful for indicating the prognosis of the disease (30-32). These 
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include RUNX1 (AML1)-RUNX1T1 (ETO) and CBFB-MYH11, which are associated with 
specific chromosomal mutations, t(8;21)(q22;q22) and inv(16)(p13;q12)/t(16;16)(p13;q22), 
respectively. AML with these cytogenetic features (singly or together) represents about 15% 
of de novo AML. The patients with these diagnostic criteria are classified in the favorable 
clinical outcome group (standard-risk group). Several other chromosomal abnormalities 
have been recurrently observed, as described in the WHO classification. AML with balanced 
or unbalanced translocations involving the MLL gene located on chromosome 11 are also 
well documented and are mostly classified in the intermediate-risk group. Meanwhile, AML 
patients with a normal karyotype and no cytological abnormality include cases classified in 
the unfavorable (adverse-risk) or intermediate-risk group. Moreover, a genetic abnormality 
of the FL3 gene (internal tandem repeat) is found in many AML subtypes and, in 
combination with a wild-type NPM gene, contributes to poor prognosis (31). Recently, 
Paschka and colleagues have revealed that the genes encoding the metabolic enzymes, 
isocitrate dehydrogenase 1 and 2 (IDH1/2) are important for diagnosis and prognosis 
prediction of AML patients (33). These mutations of IDH1/2 change the activity of the 
enzymes to reduce α-ketoglutarate levels and to elevate 2-hydroxyglutarate levels. This 
results in changes to chromatin structure and destabilization of certain gene-regulatory 
proteins, including HIF-1 (34). While cytogenetically normal AML patients with an NPM 
mutation and a normal FL3 gene tend to show favorable outcomes, AML patients with the 
same genetic profile but also with IDH1/2 mutation showed adverse prognosis with poorer 
remission. IDH1/2 mutation was also found in several other tumors, including glioma (35). 
Therefore, a combination of genetic alterations resulting in mutation of specific genes as well 
as cytogenetically apparent chromosomal changes are important for AML malignancy. 
3. AML and CCDC26 
In HL-60 cells derived from AML, a small part of chromosome 8 is excised and amplified as 
an extrachromosomal element, or double minute chromosome (dmin). Dmin is a cytogenetic 
abnormality infrequently observed in AML. The dmin of HL-60 cells consists of several 
repeats of an amplification unit (referred as amplicon) of about 2 million base pairs. The 
amplicon, which is derived from several areas of an approximately 4.6 million base pair 
region of chromosome 8q24, contains an intact MYC oncogene. Besides MYC, several other 
genes, including CCDC26 and tribbles homolog 1 (TRIB1), are also encoded on the amplicon 
(Fig. 2). All are actively transcribed in HL-60 cells. The drug-induced differentiation of HL-
60 cells suppressed the expression of all these genes, indicating that they might be related to 
the cancerous nature of the cells. Some types of cancer cell respond to the anticancer drug 
hydroxyurea by excluding unstable extrachromosomal elements, which then lose their 
proliferative nature. In HL-60 cells, the original MYC genetic locus remained intact after 
dmin was excluded, but was no longer transcribed (36). These observations suggest that the 
expression of genes from dmin, with its altered DNA structure, and from the intact 
chromosome are different, and can be interpreted as being due to aberrant gene expression 
from dmin (including the MYC oncogene). Interestingly, in HL-60 cells, the CCDC26 gene on 
dmin is rearranged as a result of chromosomal rejoining and is amplified in an incomplete 
form to produce abnormal transcripts (37). 
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gene, have not yet been fully elucidated. Indeed, the complex features of AML suggest that 
the genetic cause of this disease is multifactorial (29). Several protein-encoding genes have 
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include RUNX1 (AML1)-RUNX1T1 (ETO) and CBFB-MYH11, which are associated with 
specific chromosomal mutations, t(8;21)(q22;q22) and inv(16)(p13;q12)/t(16;16)(p13;q22), 
respectively. AML with these cytogenetic features (singly or together) represents about 15% 
of de novo AML. The patients with these diagnostic criteria are classified in the favorable 
clinical outcome group (standard-risk group). Several other chromosomal abnormalities 
have been recurrently observed, as described in the WHO classification. AML with balanced 
or unbalanced translocations involving the MLL gene located on chromosome 11 are also 
well documented and are mostly classified in the intermediate-risk group. Meanwhile, AML 
patients with a normal karyotype and no cytological abnormality include cases classified in 
the unfavorable (adverse-risk) or intermediate-risk group. Moreover, a genetic abnormality 
of the FL3 gene (internal tandem repeat) is found in many AML subtypes and, in 
combination with a wild-type NPM gene, contributes to poor prognosis (31). Recently, 
Paschka and colleagues have revealed that the genes encoding the metabolic enzymes, 
isocitrate dehydrogenase 1 and 2 (IDH1/2) are important for diagnosis and prognosis 
prediction of AML patients (33). These mutations of IDH1/2 change the activity of the 
enzymes to reduce α-ketoglutarate levels and to elevate 2-hydroxyglutarate levels. This 
results in changes to chromatin structure and destabilization of certain gene-regulatory 
proteins, including HIF-1 (34). While cytogenetically normal AML patients with an NPM 
mutation and a normal FL3 gene tend to show favorable outcomes, AML patients with the 
same genetic profile but also with IDH1/2 mutation showed adverse prognosis with poorer 
remission. IDH1/2 mutation was also found in several other tumors, including glioma (35). 
Therefore, a combination of genetic alterations resulting in mutation of specific genes as well 
as cytogenetically apparent chromosomal changes are important for AML malignancy. 
3. AML and CCDC26 
In HL-60 cells derived from AML, a small part of chromosome 8 is excised and amplified as 
an extrachromosomal element, or double minute chromosome (dmin). Dmin is a cytogenetic 
abnormality infrequently observed in AML. The dmin of HL-60 cells consists of several 
repeats of an amplification unit (referred as amplicon) of about 2 million base pairs. The 
amplicon, which is derived from several areas of an approximately 4.6 million base pair 
region of chromosome 8q24, contains an intact MYC oncogene. Besides MYC, several other 
genes, including CCDC26 and tribbles homolog 1 (TRIB1), are also encoded on the amplicon 
(Fig. 2). All are actively transcribed in HL-60 cells. The drug-induced differentiation of HL-
60 cells suppressed the expression of all these genes, indicating that they might be related to 
the cancerous nature of the cells. Some types of cancer cell respond to the anticancer drug 
hydroxyurea by excluding unstable extrachromosomal elements, which then lose their 
proliferative nature. In HL-60 cells, the original MYC genetic locus remained intact after 
dmin was excluded, but was no longer transcribed (36). These observations suggest that the 
expression of genes from dmin, with its altered DNA structure, and from the intact 
chromosome are different, and can be interpreted as being due to aberrant gene expression 
from dmin (including the MYC oncogene). Interestingly, in HL-60 cells, the CCDC26 gene on 
dmin is rearranged as a result of chromosomal rejoining and is amplified in an incomplete 
form to produce abnormal transcripts (37). 
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Figure 2. Depiction of the generation of the discontinuous amplicon unit of dmin in HL-60 cells. Several 
replication initiation bubbles collapse and “corrupted” bubbles reunite to form an amplicon unit. 
Excision of an initial large amplicon (possibly as an episome) might precede replication. The arrows 
numbered 1 through 6 indicate regions reunited in the amplicon. Note that the lengths of the various 
regions are not to scale. Once the amplicon unit has formed, its multimerization results in a dmin. 
A common change occurs at the CCDC26 locus in cytologically dmin-positive AML patients. 
This chromosomal change occurs at a position consistent with the amplified region observed 
in HL-60 cells (38, 39). Furthermore, destruction of the internal structure of the CCDC26 
gene seems to underlie the common mechanism behind the generation of dmin-positive 
AML cells. 
A comprehensive genome-wide study of a group of childhood AML patients revealed that 
CCDC26 was one of the genes with the highest increase in copy number in AML cells. 
Radtke and colleagues investigated chromosome number alteration (CNA) in pediatric 
AML using a comprehensive single nucleotide polymorphism (SNP) array analysis. They 
found the most common CNA, in 14% (15 in 111) of pediatric AML patients, to be in 
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chromosome band 8q24 with a low-burden copy number increase (2.83-3.77 copies) (40). 
These included cases of trisomy 8, which frequently occurs in AML (41). The minimum 
altered region common in all 15 of these patients was located in a 20-megabase region of 
8q24, which contains CCDC26. 
Originally, CCDC26 was reported as a gene associated with differentiation and apoptosis of 
PLB985 cells (an HL-60 subclone) following induction by treatment with retinoic acid 
(CCDC26 is also known as RAM, retinoic acid modifying). In cells that have become 
resistant to differentiation and apoptosis after infection of retrovirus, the viral genome was 
seen to be inserted in the intron of CCDC26. Retinoic acid promotes differentiation and 
apoptosis of not only many leukemia cells but also of neuroblastoma and glioblastoma cells 
through transcriptional regulation of many other genes. CCDC26 may have a role with 
retinoic acid in differentiation and growth arrest of these cells (42). 
4. Glioma and CCDC26 
Primary brain tumor (PBT) is a disease with an incidence of 12 in 100,000 per year. Glioma 
accounts for a major part of PBT, and contains cases with different grades of malignancy, 
namely (I) benign glioma, (II) diffuse astrocytoma, (III) anaplastic astrocytoma and (IV) 
glioblastoma (43). Although many genetic abnormalities have been reported in gliomas, a 
single critical lesion responsible for tumorigenesis has not been found. Among these 
abnormalities, mutations occur in genes for DNA repair enzymes, including PRKDC, XRCC, 
PARP1, MGMT, ERCC1, ERCC2, epidermal growth factor and the inflammatory cytokine, 
IL-13. Furthermore, over-expression or amplification of the epidermal growth factor 
receptor gene and deletion of p16INK are correlated with poor survival (43). A genome wide 
association study using SNPs revealed the association of several genes with glioma, 
including telomerase regulating gene TERT, RTEL1, tumor suppressor gene CDKN2A/2B, 
pleckstrin homology-like domain family B member 1 (a protein with unknown function) 
and CCDC26 (44). The CCDC26 gene locus was strongly linked with this glioma by several 
SNPs, including rs4295627, rs16904140, rs6470745, rs891835, and rs10464870 (see Fig. 3a). A 
different SNP in the intergenic region bordering CCDC26, rs987525, was linked to cleft 
palate (45). Notably, cleft palate is also a risk factor of PBT. CCDC26 is, therefore, a potential 
common factor of both conditions. CCDC26 is just one of the risk factors for glioma and 
other genetic risk factors increase glioma incidence cumulatively. Therefore, there might be 
a synergistic effect with other genetic risk factors (46). CCDC26 is not necessarily a risk 
factor of high grade (III-IV) glioma (47). Interestingly, in concordance with the situation for 
AML, the CCDC26 genotype is associated with IDH1/2 mutation in low grade glioma. 
Considering the synergy of CCDC26 with IDH1/2, CCDC26 may have linkage to a 
subpopulation of gliomas with relatively lower grade (46, 48). 
The Gene Expression Omnibus database (GEO; http://www.ncbi.nlm.nih.gov/geo/) (49) 
contains data showing altered CCDC26 expression between normal and tumorigenic cells. 
Expression of CCDC26 is higher in myeloid leukemia cell lines, namely KG-1, THP-1 and 
U937, compared with normal monocytes (GEO dataset accession ID; GDS2251), and is 
higher in sporadic basal-like cancer compared with normal cells (GD2250). On the other 
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chromosome band 8q24 with a low-burden copy number increase (2.83-3.77 copies) (40). 
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8q24, which contains CCDC26. 
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(CCDC26 is also known as RAM, retinoic acid modifying). In cells that have become 
resistant to differentiation and apoptosis after infection of retrovirus, the viral genome was 
seen to be inserted in the intron of CCDC26. Retinoic acid promotes differentiation and 
apoptosis of not only many leukemia cells but also of neuroblastoma and glioblastoma cells 
through transcriptional regulation of many other genes. CCDC26 may have a role with 
retinoic acid in differentiation and growth arrest of these cells (42). 
4. Glioma and CCDC26 
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accounts for a major part of PBT, and contains cases with different grades of malignancy, 
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glioblastoma (43). Although many genetic abnormalities have been reported in gliomas, a 
single critical lesion responsible for tumorigenesis has not been found. Among these 
abnormalities, mutations occur in genes for DNA repair enzymes, including PRKDC, XRCC, 
PARP1, MGMT, ERCC1, ERCC2, epidermal growth factor and the inflammatory cytokine, 
IL-13. Furthermore, over-expression or amplification of the epidermal growth factor 
receptor gene and deletion of p16INK are correlated with poor survival (43). A genome wide 
association study using SNPs revealed the association of several genes with glioma, 
including telomerase regulating gene TERT, RTEL1, tumor suppressor gene CDKN2A/2B, 
pleckstrin homology-like domain family B member 1 (a protein with unknown function) 
and CCDC26 (44). The CCDC26 gene locus was strongly linked with this glioma by several 
SNPs, including rs4295627, rs16904140, rs6470745, rs891835, and rs10464870 (see Fig. 3a). A 
different SNP in the intergenic region bordering CCDC26, rs987525, was linked to cleft 
palate (45). Notably, cleft palate is also a risk factor of PBT. CCDC26 is, therefore, a potential 
common factor of both conditions. CCDC26 is just one of the risk factors for glioma and 
other genetic risk factors increase glioma incidence cumulatively. Therefore, there might be 
a synergistic effect with other genetic risk factors (46). CCDC26 is not necessarily a risk 
factor of high grade (III-IV) glioma (47). Interestingly, in concordance with the situation for 
AML, the CCDC26 genotype is associated with IDH1/2 mutation in low grade glioma. 
Considering the synergy of CCDC26 with IDH1/2, CCDC26 may have linkage to a 
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Figure 3. (A) Summary of genetic locus 8q24.31. The scale indicates the region 8q24.31 (130.35 Mb to 
130.71 Mb; numbering is based on human genome assembly 37.1). Marks on the scale indicate the 
locations of five SNPs that are linked to glioma (open circles; rs4295627, rs16904140, rs6470745, rs891835 
and rs10464870, left to right), three miRNAs registered in the public database (filled circles; mir-3669, 
mir-3673 and mir-3686, left to right) and a retrovirus insertion site (filled square) within the introns of 
CCDC26. Below the scale, which covers a 350-kb region, major variants of CCDC26 mRNA (long and 
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short) are shown. The long transcript consists of four (1-2-3-4) exons, and the short transcripts consist of 
three (1a-3-4) or four (1a-2a-3-4) exons. All variants share exon 3 and 4, in which the hypothetical open 
reading frame is encoded. Locations of the amplified region in HL-60 cells and the commonly amplified 
region (MAR) in childhood AML are shown with filled rectangles. The hypothetical open reading frame 
encoded in exons 3 and 4 is not included in the region amplified in HL-60 cells. The pattern of histone 
H3K27 acetylation, activity of transcription in leukemia cell lines, and bar plots for conserved synteny 
between human and each organism (m: mouse, d: dog, e: elephant and o: opossum) obtained from the 
UCSC Genome Browser (95) are shown. Actively transcribed regions that are not the major exons of 
CCDC26 mRNA are indicated by grey rectangles. (B) Optimal alignment of the CCDC26 exon 3-4 
encoded ORF and the region of conserved synteny on mouse chromosome 15. A possible ORF (94 
amino acids) in the mouse sequence is totally mismatched with that of human by frameshift changes. 
hand, CCDC26 expression is decreased in hyperplastic enlarged lobular units considered as 
the earliest precursors of breast cancer compared with normal units (GDS2739). Increased 
CCDC26 expression is associated with malignancy progression in some cancerous cells. 
CCDC26 expression was increased in CD133 positive neurosphere-like glioma cell lines 
compared with CD133 negative adherent glioma cell lines (GDS2728), and was increased in 
alveolar macrophages of cigarette smokers comparison with macrophages of non-smokers 
(GDS3496). Increased expression of CCDC26 might mean this gene is tumorigenic or 
oncogenic. However, the relationship of altered CCDC26 expression to malignancy is still 
ambiguous. 
5. Overview of the CCDC26 genetic locus 
As described in the previous section, all SNPs associated with glioma, and a retrovirus 
insertion site where virus insertion makes AML cells resistant to retinoic acid (42) are 
located in the intron of CCDC26 (Fig. 3a). Exon 4, which encodes the majority of a 
hypothetical open reading frame (ORF), is not amplified in pediatric AML or in AML-
derived HL-60 cells. The exonic sequence of CCDC26 is not well conserved in other species, 
including mouse, and an ORF has no homology with known proteins. These data strongly 
suggest that CCDC26 does not function as a protein-encoding RNA; rather it functions as a 
ncRNA. Highly conserved regions in the intron sequence of CCDC26 suggest the existence 
of another intronic ncRNA. As mentioned above, the CCDC26 locus is rearranged in the 
genome of HL-60 cells. It is plausible that the ncRNA encoded by this locus is important for 
the growth of these cells. 
A short putative ORF encoding a protein or with a length of 109 amino acids is present in 
the CCDC26 exons; there is no other ORF of more than 50 amino acids. This actual protein, 
however, has not been observed. Moreover, orthologous proteins are not found in any other 
organism. For example, a loosely homologous sequence of human exon 4, found in the 
mouse chromosome 15 region of conserved synteny, with an ORF of 94 amino acids is 
actively transcribed in mouse leukemia cells (T. Hirano unpublished observation). However, 
this ORF is completely different from the human sequence and even contains frame shift 
alterations (Fig. 3b). This indicates that the putative protein encoded by CCDC26 has no 
conserved function among species. Although this ORF may be coincidental due to the 
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Figure 3. (A) Summary of genetic locus 8q24.31. The scale indicates the region 8q24.31 (130.35 Mb to 
130.71 Mb; numbering is based on human genome assembly 37.1). Marks on the scale indicate the 
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and rs10464870, left to right), three miRNAs registered in the public database (filled circles; mir-3669, 
mir-3673 and mir-3686, left to right) and a retrovirus insertion site (filled square) within the introns of 
CCDC26. Below the scale, which covers a 350-kb region, major variants of CCDC26 mRNA (long and 
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absence of stop codons, an interesting possibility is that this unique protein has newly 
emerged during human evolution. mRNA stability is influenced by whether an ORF is 
encoded because nonsense mediated RNA decay, a mechanism associated with quality 
control of mRNA, rapidly degrades mRNAs that are not useful as templates for protein 
synthesis. Absence of an ORF in an mRNA promotes degradation by this mechanism, 
however, the existence of a CCDC26 protein will prolong the lifetime of CCDC26 mRNA and 
may maintain the function (if any) of the RNA itself. 
Because of the considerable length of the CCDC26 intron (330 kbp versus 1200 bp exons), it 
is very difficult to ignore the possibility that there is another transcript(s) within this intron 
with important function. Possible encoded ncRNAs within the CCDC26 exon-intron region 
are summarized in Fig. 4 and include, mRNA (a), intronic encoded ncRNA (b), intronic 
lariat RNA (c-d) and miRNA independently transcribed or processed from the precursor of 
the CCDC26 mRNA (e). Actually there are several regions in the CCDC26 intron where 
nucleosomal histones undergo high levels of methylation and acetylation, meaning that 
these locations may be actively transcribed (Fig.3a). Furthermore, most of these regions are 
 
Figure 4. A possible function of CCDC26. The 330-kb precursor RNA transcribed from the gene is 
processed into mature mRNA. It then forms a complex with proteins to perform its biological function, 
for example, silencing a certain genetic locus (a). Alternatively, the ncRNA independently encoded in 
the intronic region (b) or the processed intron lariat (c-d) could have biological functions. The intronic 
microRNA could be transcribed directly from the genome using its own promoter or processed from 
the precursor of the CCDC26 mRNA(e). Note that lengths of nucleic acid chains are not to scale. Length 
of the precursor RNA is approximately 330 kb; CCDC26 mRNA is 1.3 kb; the spliced lariat is more than 
100 kb; intronic microRNA is 18-23 bases. 
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highly conserved among mammals, suggesting that function is encoded. Also, expressed 
sequence tags other than known spliced CCDC26 mRNAs have been reported in the intron. 
There are three miRNAs (miR-3669, 3673 and 3686) in the intron of CCDC26 that are 
registered in the miRNA database (miRBase; http://www.mirbase.org/)(50). Although their 
functions are unknown, they may act as oncogenic or tumor suppressive ncRNAs.  
6. Hypothetical function of CCDC26 as a non-coding RNA 
Although many ncRNAs are registered in databases, only a few have clearly demonstrated 
functions and detailed mechanisms of action. CCDC26 might be a new ncRNA that is 
associated with cancer, including AML. Interestingly, expression of an miRNA, miR-21, is 
observed in many malignant cells, including AML cells (51). Also phorbol ester-induced 
differentiation of HL-60 cells into macrophage-like cells is accompanied by up-regulation of 
miR-21 (52). There are several reports suggesting that miRNAs act as oncogenic or tumor 
suppressive miRNAs in AML, as reviewed in (53, 54). Recently, Marcucci and colleagues used 
305 different probes to search for miRNA expression in favorable and adverse-risk groups of 
normal karyotype AML (monocytic leukemia). They then used these data to link expression 
profiles with the cohort analysis of the patients. They identified a certain pattern of miRNA 
expression in the adverse-risk group and linked the expression level of eight types of miRNA 
to AML prognosis (55). It is possible that an unknown miRNA in the CCDC26 locus affects 
cancer malignancy through the regulation of other genes. But all miRNAs described so far in 
the CCDC26 locus (mir-3669, mir-3673 and mir-3686) show no expression in leukemia cells and 
no conservation among mammals in contrast to other oncogenic miRNAs; for example miR21 
and let7, are actively transcribed and strongly conserved. 
Within the CCDC26 intronic region, there are some long regions (>10 kb) that are actively 
transcribed in leukemia cells (Fig. 3a). They seem to be too long for pri-miRNAs but could 
encode lncRNAs. Indeed, active transcription occurs in the CCDC26 region in cells derived 
from AML (T. Hirano unpublished observation), meaning that these transcripts might 
function as a tumor promoting or oncogenic lncRNAs. In contrast, if the original function of 
CCDC26, or of lncRNAs associated with CCDC26, was lost by chromosomal abnormality 
(for example in dmin of HL-60 cells), then they might function naturally as tumor 
suppressors. Some lncRNAs including XIST (56), KCNQ1OT1 (57), ANRIL (58) and AIRN 
(59) are known to suppress (in cis) the expression of neighboring gene. It is well known that 
genes located in extrachromosomal elements such as dmin are actively transcribed, but the 
mechanism behind this phenomenon is not well understood (60, 61). Differences between 
dmin and an intact chromosome are caused by differences in chromatin structure, which is 
indicated by differences in DNase I hypersensitivity (36). Similarly to other gene silencing 
lncRNAs, an ncRNA encoded by the CCDC26 locus might suppress the expression of other 
nearby genes. The hypothesis that neighboring genes, including the MYC oncogene, are 
activated when the normal CCDC26 locus structure is destroyed by a chromosomal 
abnormality could explain the high transcriptional activity of genes in extrachromosomal 
elements (Fig.5). Further evidence is needed to determine whether CCDC26 mRNA and/or 
its transcripts encoded in its intron are oncogenic or tumor suppressive. 
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highly conserved among mammals, suggesting that function is encoded. Also, expressed 
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There are three miRNAs (miR-3669, 3673 and 3686) in the intron of CCDC26 that are 
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functions are unknown, they may act as oncogenic or tumor suppressive ncRNAs.  
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305 different probes to search for miRNA expression in favorable and adverse-risk groups of 
normal karyotype AML (monocytic leukemia). They then used these data to link expression 
profiles with the cohort analysis of the patients. They identified a certain pattern of miRNA 
expression in the adverse-risk group and linked the expression level of eight types of miRNA 
to AML prognosis (55). It is possible that an unknown miRNA in the CCDC26 locus affects 
cancer malignancy through the regulation of other genes. But all miRNAs described so far in 
the CCDC26 locus (mir-3669, mir-3673 and mir-3686) show no expression in leukemia cells and 
no conservation among mammals in contrast to other oncogenic miRNAs; for example miR21 
and let7, are actively transcribed and strongly conserved. 
Within the CCDC26 intronic region, there are some long regions (>10 kb) that are actively 
transcribed in leukemia cells (Fig. 3a). They seem to be too long for pri-miRNAs but could 
encode lncRNAs. Indeed, active transcription occurs in the CCDC26 region in cells derived 
from AML (T. Hirano unpublished observation), meaning that these transcripts might 
function as a tumor promoting or oncogenic lncRNAs. In contrast, if the original function of 
CCDC26, or of lncRNAs associated with CCDC26, was lost by chromosomal abnormality 
(for example in dmin of HL-60 cells), then they might function naturally as tumor 
suppressors. Some lncRNAs including XIST (56), KCNQ1OT1 (57), ANRIL (58) and AIRN 
(59) are known to suppress (in cis) the expression of neighboring gene. It is well known that 
genes located in extrachromosomal elements such as dmin are actively transcribed, but the 
mechanism behind this phenomenon is not well understood (60, 61). Differences between 
dmin and an intact chromosome are caused by differences in chromatin structure, which is 
indicated by differences in DNase I hypersensitivity (36). Similarly to other gene silencing 
lncRNAs, an ncRNA encoded by the CCDC26 locus might suppress the expression of other 
nearby genes. The hypothesis that neighboring genes, including the MYC oncogene, are 
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elements (Fig.5). Further evidence is needed to determine whether CCDC26 mRNA and/or 
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Figure 5. Hypothetical mechanism by which an oncogene (for example MYC) is inactivated in an intact 
chromosome (a) by CCDC26 regulation. This suppression does not function on extrachromosomal 
chromatin (b). 
7. Future perspectives 
The size of the CCDC26 locus, spanning over 330,000 base pairs, makes it difficult to study. 
If the ORF of the gene is not functional then it is unclear which part(s) of the locus are 
functional. Therefore, to study this gene, it is first necessary to determine all transcripts 
produced by the CCDC26 locus and then to analyze their function. Comprehensive analysis 
of transcriptome of the relevant region using tiling microarray analysis is needed. Although 
lncRNA orthologs are frequently not found between species, homology analysis of this 
region between human and mouse could be helpful to identify functional sequences. Once 
transcripts are identified, we will be able to perform in situ hybridization to determine 
subcellular localization. Knock-down of transcripts will be useful to investigate their 
functions. Proteins interacting with the RNA transcripts will be identifiable by pull-down 
assays and mass spectrometry analysis. Finally, gene targeting should be used to investigate 
the effects of disruption of the region encoding the transcript. It will be of special interest if 
transcription of neighboring genes is activated or inactivated (in particular MYC), 
suggesting a regulatory function of the ncRNA encoded in the CCDC26 locus. If an ortholog 
of the gene is found in mice, making a knock-out mouse of the ncRNA or a transgenic 
mouse with forced expression of the ncRNA will help to demonstrate its relationship to 
disease. 
8. Conclusion 
As a conclusion, the CCDC26 locus is considered to encode an lncRNA involved in 
tumorigenesis. CCDC26 itself might be an lncRNA or its intron might contain a functional 
miRNA or lncRNA. The study of this gene will bring new knowledge to gene regulation and 
to cancer treatment strategies targeting lncRNAs. Further in vitro and in vivo study is needed 
to prove the relationship between transcripts from the locus and disease, such as leukemia 
and glioma. 
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1. Introduction 
MYCN is a member of the MYC family of oncogenes, which also includes c-MYC and MYCL. 
Despite knowing about the existence of MYCN for nearly thirty years, the majority of 
functional studies involving MYC family members have focused on c-MYC due to the 
limited expression profile of MYCN in human cancers, and also in part due to the existence 
of highly conserved functional domains between c-MYC and MYCN [1]. MYCN is normally 
expressed during embryonal development and orchestrates cell proliferation and 
differentiation in the developing peripheral neural crest [2]. However, the deregulated 
expression of MYCN has been shown to contribute to tumorigenesis and neuronal 
transformation [3]. Thus, MYCN represents a highly desirable therapeutic target. Previous 
studies have shown that downregulating MYCN expression, via antisense oligonucleotides, 
resulted in lower tumour incidence and decreased tumour mass in a murine neuroblastoma 
tumour model [4]. However, to date, no molecularly targeted therapies have been 
developed that are able to mimic this response in the clinic, and further studies are required 
to help elucidate the mechanisms that drive MYCN tumour formation and progression. 
2. The MYC family and the discovery of MYCN 
The eventual discovery of MYC oncogenes arose from early pioneering work on the Rous 
sarcoma virus (RSV), a transforming retrovirus able to cause sarcomas in infected chicken 
cells. Using the information provided by RSV, hybridisation studies were performed on a 
specific group of avian tumours involving a retrovirus responsible for inducing myeloid 
leukaemia. This led to the identification of a sequence that was named v-gag-myc, or v-myc 
for myelocytomatosis (the leukaemia that is induced following the transduction of avian 
cells with this virus) and supported the idea that viral integration into a host genome could 
activate a nearby host oncogene [5, 6]. As it transpired, the human homologue of v-myc, 
termed c-MYC (cellular-MYC) was the first cellular oncogene whose overexpression was 
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shown to be activated through retroviral insertional mutagenesis [7]. Deregulated 
expression of c-MYC has since been implicated in a range of cancers, and allowed the 
discovery of other important MYC family members including MYCN and MYCL. 
Neuroblastoma is the most common extracranial solid tumour of early childhood and 
accounts for approximately 15% of all cancer related deaths in children. Aggressive drug 
refractory neuroblastoma cells have been frequently observed to contain genomic 
aberrations referred to as double-minute chromatin bodies and homogeneously staining 
regions. Both of these types of aberrations were found to contain multiple copies or 
amplification of specific genes, and in particular, the critical gene within these regions was 
later identified to be the c-MYC-related oncogene, MYCN, so-called because of its 
identification in neuroblastoma cells [8]. Amplification of the MYCN oncogene has also been 
demonstrated in retinoblastoma, glioblastoma, medulloblastoma, astrocytoma and small cell 
lung cancer cells [9]. In addition, another member of the MYC-oncogene family, MYCL, was 
identified in small cell lung cancer (SCLC), and demonstrated homology to a small region of 
both c-MYC and MYCN. Gene mapping studies assigned MYCL to human chromosome 
region 1p32, a location that is distinct from that of either c-MYC or MYCN (regions 8q24 and 
2p24 respectively) but is also associated with cytogenetic abnormalities in certain human 
tumours such as thyroid cancer and lung cancer [10, 11]. MYCL was found to be amplified 
in some SCLC cells [12]. In mammals, a fourth member of the MYC family, s-Myc has been 
identified, however only c-MYC, MYCN and MYCL have been implicated in the 
tumorigenesis of specific human cancers [13].  
All three tumour-associated MYC genes have the same characteristic three-exon structure 
with the major polypeptide open reading frame residing in the second and third exons. The 
first exon is not conserved between the genes, but rather possesses regulatory functions, 
whereas the two coding exons produce highly homologous sections of amino acids 
interspersed with areas of diminished conservation, leading to the suggestion that 
individual MYC polypeptides have discrete, independent, functional domains [14]. In 
tumour biology, many cancers have been shown to exhibit increased levels of MYC protein 
in tumour tissue relative to the surrounding normal tissues, and this has been shown to 
contribute to the aggressiveness of the tumour [15]. Importantly, the MYC family of proteins 
share functionally similar roles, acting as transcription factors to drive cellular proliferation 
and vasculogenesis, promote metastasis and genomic instability, as well as inhibit cell 
differentiation and reduce cell adhesion [13, 16]. However, recent findings have also raised 
the possibility of transcriptionally-independent functions of the MYC proteins [17]. 
3. The functional activity of MYCN 
MYC proteins are well established as nuclear phosphoproteins that act as regulators of 
transcription, and can both activate and repress the expression of its target genes  [16]. MYCN 
encodes a 60kDa protein that has affinity for and binds to DNA, and is phosphorylated by 
casein kinase II [18, 19]. Phosphorylation is important for the transforming abilities of MYC 
family members and also for the regulation of MYC protein stability and activity [20]. The 
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affinity of MYCN protein for DNA relies on the presence of certain motifs, comprising a basic 
DNA binding region, an α-helical protein-protein interaction domain or helix-loop-helix 
(HLH), and a leucine zipper motif (Zip) encompassing the bHLH-Zip domain at the carboxy 
or C-terminus of the protein [9]. The mechanism that mediates the DNA-binding capacity of 
MYC proteins was confirmed via the identification of MAX, also a bHLH-Zip protein [21]. 
MYCN and MAX (Figure 1) interact to form a complex that binds to DNA in a sequence 
specific manner [22]. MYCN binds to MAX protein via its bHLH-LZ region. Several other 
proteins have also been shown to interact with the C-terminus of MYCN, including YY-1, AP-
2, TFII-I and BRCA1 [23], or with the central region of MYCN such as NMi [24], all of which 
are associated with MYCN’s function as a transcriptional regulator. 
 
Figure 1. Domains of the MYCN and MAX proteins. The N-terminus of MYCN has three elements, 
known as MYC homology boxes I-III, which are highly conserved in MYC proteins. The C-terminus 
contains the basic-region/helix-loop-helix/leucine-zipper that is responsible for interaction with the 
MAX protein. 
The amino or N-terminus of MYCN acts as a transactivation domain that contains two 
highly conserved regions called Myc Homology Boxes I and II (MBI and MBII) [1]. This 
region has been shown to bind to nuclear cofactors, including TRRAP, p107, BIN1, MM-1, 
AMY-1, PAM, α-Tubulin, TIP48 and TIP49, to assist the targeting of protein to specific gene 
promoters [23, 25]. Another protein YAF2, has been demonstrated to bind to the central 
region of MYCN to further stimulate transcription upon MYCN-MAX transactivation [26]. 
All of these interacting proteins are a part of a transcription factor complex by which target 
genes are activated. Myc Homology Box III (MBIII) is conserved only within c-MYC and 
MYCN, but not MYCL, and is necessary for cellular transformation [27]. A fourth Myc 
Homology Box (MBIV) is also necessary for MYC transforming activity [28]. 
Recent studies have provided evidence of a function of MYCN that is independent from its 
role as a classical transcription factor. MYCN was shown to remodel large domains of 
euchromatin, regions of lightly packaged chromatin that contain active, functioning genes, 
by regulating histone acetylation [29, 30]. Two possibilities have been suggested for this role. 
The first is that MYCN maintains the activity of euchromatin, whilst the second is that 
MYCN maintains euchromatin at remote sites to act as an enhancer and regulator of genes 
at a distance. Novel functions of other MYC proteins have been identified through 
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a transcription factor [28, 31]. c-MYC was found to increase the translation of specific 
mRNAs by promoting the methylation of the 5’ mRNA guanine “cap”, including mRNAs 
encoding cyclin T1 and CDK9 [31]. A role for c-MYC has also been described in the initiation 
of DNA replication by binding to various components of the pre-replicative complex and 
localising to early sites of DNA replication [32]. These observations suggest that c-MYC may 
play a role in controlling initiation of the S phase of the cell cycle and contribute to 
replicative stress and genomic instability, to further accelerate tumorigenesis [17]. Even 
though the evidence has yet to be provided, given the high level of homology between c-
MYC and MYCN, the described transcription-independent roles of c-MYC suggest similar 
roles will be identified for MYCN in contributing to tumour cell biology. 
4. MYCN as a transcriptional activator  
As indicated above, MYCN heterodimerises with MAX and binds with high affinity to a 
CACA/GTG E-box sequence found upstream of promoter target sequences [13]. The MYCN-
MAX heterodimer activates transcription via several mechanisms. TRRAP (or 
TRansactivation/tRansformation Associated Protein) binds to the N-terminal region of 
MYCN and is essential for MYCN transformation. Through TRRAP, MYCN recruits histone 
acetylation (HAT) complexes to chromatin, including the 1.8 megaDalton SAGA complex 
(SPT/ADA/GCN5/Acetyltransferase) [33]. Histone acetylation is associated with gene 
activation by chromatin modification influencing histone-DNA and histone-histone contact 
[34]. TRRAP is involved with another HAT complex, TIP60, an H2A/H4 acetylase [35]. 
Interestingly, in vivo acetylation of histone H4 is highly associated with MYC target gene 
activation [36]. Two other proteins, TIP48 and TIP49 that are found in the TIP60 complex 
also bind to the N-terminus of MYCN [25].  Both proteins are highly conserved hexameric 
ATPases that are involved in chromatin remodelling involving the movement or 
displacement of nucleosomes, as opposed to chromatin modification [37]. 
The MYC family represents a particularly unusual set of transcription factors in that they 
can bind to and regulate approximately 10-15% of the entire genome [14]. Some MYCN 
target genes have been shown to be activated independently of TRRAP and HAT 
complexes. Investigation into HAT independent activation has revealed the involvement of 
RNA polymerase II at the promoter regions of target genes. c-MYC protein binding has been 
shown to stimulate the clearance of RNA polymerase II from the promoter region to allow 
for efficient transcription elongation by the RNA pol II kinases, TFIIH and positive 
transcription elongation factor b (PTEFb) [38]. c-MYC also regulates RNA pol II promoter 
clearance by controlling the expression of RNA pol II kinases via mRNA cap methylation, 
polysome loading, and the rate of translation [31]. 
5. MYCN as a transcriptional repressor 
Most studies have focused on the role of MYC proteins as transcriptional activators. 
However, cells transformed by constitutive expression of c-MYC are characterised by the 
loss of expression of numerous genes such as those involved in cell adhesion and cell cycle 
regulation, and even loss of c-MYC itself [39-41]. An early indicator of the transcriptional 
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repressor role of MYC proteins was the involvement of c-MYC in a negative feedback loop, 
where the introduction of ectopic c-MYC or MYCN was able to downregulate endogenous 
expression of c-MYC in mouse fibroblast cells [42].  Structure and function analyses found 
that the regions of c-MYC that are required for transformation are also required for negative 
autoregulation [43] and led to the idea that the repression of target genes by MYC proteins 
could also contribute to transformation.  
The understanding of transcriptional repression by MYC proteins was greatly advanced via 
the identification of repressed target genes such as transglutaminase-2 (TG2) and interleukin-6 
(IL-6) [44]. Genomic studies have now revealed that MYC proteins repress as many targets 
as they activate, emphasising the role of gene repression by these oncoproteins during 
cellular transformation [14]. One recent example is the identification of TG2 repression by 
MYCN in neuroblastoma, which occurs via the interaction between MYCN with Specificity 
Protein I (SP1) [45]. TG2 is a multifunctional enzyme that catalyses the transamidation and 
multimerisation of proteins, but also promotes programmed cell death and induces neuritic 
differentiation in neuroblastoma cells [46]. Hence downregulation of TG2 by MYCN would 
allow neuroblastoma cells to overcome apoptosis and continue to proliferate. Similarly, 
MYCN has been shown to interact with SP1 to downregulate the expression of MRP3 (also 
known as ABCC3), the gene encoding an intermembrane transporter which is involved in 
the transport of organic anions, prostaglandins, leukotrienes and selected 
chemotherapeutics [47-49]. Another important gene that is downregulated by MYCN is IL-6, 
which has been shown to play an important anti-angiogenic role by inhibiting vascular 
endothelial cell proliferation [50]. The transcriptional repression by MYCN is also supported 
by the interaction between MYC proteins and another transcription factor MIZ-1 (Myc-
interacting zinc finger protein-1) [51]. MIZ-1 is a POZ/BTB (poxvirus and zinc finger/bric-a-
brac, tramtrack and broad complex) domain protein that transactivates genes involved in 
cell cycle regulation as well as tumour suppressor genes via the recruitment of the p300 
histone acetyltransferase [52]. Interestingly, high-level MIZ-1 expression is associated with a 
favourable disease outcome of neuroblastoma [53]. MIZ-1 interacts with the carboxy-
terminal HLH region of c-MYC and MYCN, where the binding of the MYC-MAX 
heterodimer to MIZ-1 disrupts the interaction between MIZ-1 and p300, causing the 
transcriptional repression of tumour suppressor genes [54]. MYC has also been shown to 
recruit a DNA methyltransferase, DNMT3a to the MYC-MIZ-1 complex, suggesting that 
repression can be mediated by the methylation of target gene promoters [55].  
6. Mechanisms of regulating MYCN expression 
Due to the gross transforming ability of deregulated expression of MYC proteins, the 
expression of these protooncogenes is tightly regulated in normal cells at both the 
transcriptional and protein level. For example, MYC mRNA transcripts and proteins have 
very short half-lives and are expressed at constant levels as cells enter the cell cycle [56, 57]. 
Furthermore, anti-proliferative signals trigger rapid down-regulation in expression, and the 
phosphorylation patterns of MYC proteins are known to influence their stability. In addition 
to these mechanisms, expression of MYCN is particularly tightly regulated with regards to 
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activation [36]. Two other proteins, TIP48 and TIP49 that are found in the TIP60 complex 
also bind to the N-terminus of MYCN [25].  Both proteins are highly conserved hexameric 
ATPases that are involved in chromatin remodelling involving the movement or 
displacement of nucleosomes, as opposed to chromatin modification [37]. 
The MYC family represents a particularly unusual set of transcription factors in that they 
can bind to and regulate approximately 10-15% of the entire genome [14]. Some MYCN 
target genes have been shown to be activated independently of TRRAP and HAT 
complexes. Investigation into HAT independent activation has revealed the involvement of 
RNA polymerase II at the promoter regions of target genes. c-MYC protein binding has been 
shown to stimulate the clearance of RNA polymerase II from the promoter region to allow 
for efficient transcription elongation by the RNA pol II kinases, TFIIH and positive 
transcription elongation factor b (PTEFb) [38]. c-MYC also regulates RNA pol II promoter 
clearance by controlling the expression of RNA pol II kinases via mRNA cap methylation, 
polysome loading, and the rate of translation [31]. 
5. MYCN as a transcriptional repressor 
Most studies have focused on the role of MYC proteins as transcriptional activators. 
However, cells transformed by constitutive expression of c-MYC are characterised by the 
loss of expression of numerous genes such as those involved in cell adhesion and cell cycle 
regulation, and even loss of c-MYC itself [39-41]. An early indicator of the transcriptional 
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repressor role of MYC proteins was the involvement of c-MYC in a negative feedback loop, 
where the introduction of ectopic c-MYC or MYCN was able to downregulate endogenous 
expression of c-MYC in mouse fibroblast cells [42].  Structure and function analyses found 
that the regions of c-MYC that are required for transformation are also required for negative 
autoregulation [43] and led to the idea that the repression of target genes by MYC proteins 
could also contribute to transformation.  
The understanding of transcriptional repression by MYC proteins was greatly advanced via 
the identification of repressed target genes such as transglutaminase-2 (TG2) and interleukin-6 
(IL-6) [44]. Genomic studies have now revealed that MYC proteins repress as many targets 
as they activate, emphasising the role of gene repression by these oncoproteins during 
cellular transformation [14]. One recent example is the identification of TG2 repression by 
MYCN in neuroblastoma, which occurs via the interaction between MYCN with Specificity 
Protein I (SP1) [45]. TG2 is a multifunctional enzyme that catalyses the transamidation and 
multimerisation of proteins, but also promotes programmed cell death and induces neuritic 
differentiation in neuroblastoma cells [46]. Hence downregulation of TG2 by MYCN would 
allow neuroblastoma cells to overcome apoptosis and continue to proliferate. Similarly, 
MYCN has been shown to interact with SP1 to downregulate the expression of MRP3 (also 
known as ABCC3), the gene encoding an intermembrane transporter which is involved in 
the transport of organic anions, prostaglandins, leukotrienes and selected 
chemotherapeutics [47-49]. Another important gene that is downregulated by MYCN is IL-6, 
which has been shown to play an important anti-angiogenic role by inhibiting vascular 
endothelial cell proliferation [50]. The transcriptional repression by MYCN is also supported 
by the interaction between MYC proteins and another transcription factor MIZ-1 (Myc-
interacting zinc finger protein-1) [51]. MIZ-1 is a POZ/BTB (poxvirus and zinc finger/bric-a-
brac, tramtrack and broad complex) domain protein that transactivates genes involved in 
cell cycle regulation as well as tumour suppressor genes via the recruitment of the p300 
histone acetyltransferase [52]. Interestingly, high-level MIZ-1 expression is associated with a 
favourable disease outcome of neuroblastoma [53]. MIZ-1 interacts with the carboxy-
terminal HLH region of c-MYC and MYCN, where the binding of the MYC-MAX 
heterodimer to MIZ-1 disrupts the interaction between MIZ-1 and p300, causing the 
transcriptional repression of tumour suppressor genes [54]. MYC has also been shown to 
recruit a DNA methyltransferase, DNMT3a to the MYC-MIZ-1 complex, suggesting that 
repression can be mediated by the methylation of target gene promoters [55].  
6. Mechanisms of regulating MYCN expression 
Due to the gross transforming ability of deregulated expression of MYC proteins, the 
expression of these protooncogenes is tightly regulated in normal cells at both the 
transcriptional and protein level. For example, MYC mRNA transcripts and proteins have 
very short half-lives and are expressed at constant levels as cells enter the cell cycle [56, 57]. 
Furthermore, anti-proliferative signals trigger rapid down-regulation in expression, and the 
phosphorylation patterns of MYC proteins are known to influence their stability. In addition 
to these mechanisms, expression of MYCN is particularly tightly regulated with regards to 
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timing and tissue specificity. Thus, MYCN is normally expressed during embryonal 
development of the peripheral nervous system in neural crest cells [2]. Neural crest cells 
migrate during mid-gestation to populate the entire peripheral nervous system, including 
autonomic and peripheral ganglia and the adrenal gland. These migrating progenitor cells 
represent a highly proliferative population, and during normal development exit the cell-
cycle and undergo differentiation following the colonisation to the ganglia and spinal cord 
area. This event is orchestrated by extracellular signalling molecules such as mitogens and 
cytokines and coincides with decreased expression of MYCN [56, 58]. Without this strict 
control, dysregulated MYCN expression impairs the ability of progenitor cells to undergo 
differentiation. Studies which sustained MYCN expression in murine neural crest cells 
under the control of a tyrosine hydroxylase promoter, demonstrated the capacity to cause 
neuroblastoma in transgenic mice [3]. Despite this transforming ability, MYCN is vital for 
normal embryonic development, and murine embryos lacking MYCN exhibit profound 
hypoplasia, particularly in the central and peripheral nervous system, disorganized 
architecture of the brain, defective heart development and defects in the lung, genitourinary 
system, stomach, intestines and limb buds [59]. 
In order to understand how extracellular stimuli controlled MYC expression in cells, gene 
mapping studies in association with MYC transcription studies were undertaken, and these 
identified response elements within the MYC transcript as well as their regulators. In 
neuronal cells, MYCN has been shown to be regulated in its promoter region as well as in an 
enhancer region upstream of the coding region. The elongation transcription factor, E2F 
binds to the promoter region of MYCN in response to different mitogenic signals [60]. The 
promoter region also contains positive transcription factor binding sites for SP1, SP3 and 
TGFβ [61]. However, the presence of a retinoic acid response element (RARE) within this 
region allows for negative regulation of MYCN by retinoic acid [62]. 
A key finding was made in 1986 which identified c-MYC as the first eukaryotic gene to be 
negatively regulated by transcriptional elongation control, where a block in the elongation 
of mRNA during transcription occurred during cellular differentiation [63]. This finding 
was later confirmed in MYCN studies where transcription elongation pausing sites were 
identified in exon 1 and intron 1 of human MYCN [64, 65]. Furthermore, there is in vivo 
evidence that the downregulation of MYCN during mouse embryogenesis is partly 
regulated by the control of transcriptional elongation [66]. 
Transcription alone cannot account for the large difference in mRNA levels following the 
introduction of proliferative or anti-proliferative stimuli. The rapid turnover of mRNA was 
also associated with the discovery of two distinct mechanisms of MYC mRNA decay. The 
first involves a translation-independent mechanism involving poly(A) tail shortening of the 
untranslated region of the transcript, while the second represents a translation-dependent 
mechanism that is regulated by a region of mRNA which corresponds to the C-terminus of 
the protein, called the coding region determinant [67-69]. This region is bound to a 75kDa 
protein that protects the region of mRNA from endonuclease attack, in response to growth 
signals that induce c-MYC stabilisation. In the case of MYCN, RNA stability factors have 
also been identified which bind to the untranslated region of MYCN mRNA. In addition, an 
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internal ribosomal entry segment (IRES) in the transcript acts to enhance neuronal specific 
translation [70, 71].  
7. Regulation of MYCN protein expression 
The regulation of MYCN protein levels has also been investigated and phosphopeptide 
analysis has revealed that specific serine and threonine residues of MYCN are 
phosphorylated in vivo. Two residues in particular, Threonine 58 (Thr58) and Serine 62 
(Ser62) have been demonstrated as important determinants of transformation and MYCN 
protein stability and activity [20]. Proliferative stimuli activate phosphorylation of Ser62 by 
cyclin B and Cdk1 during prophase to increase MYCN protein stability [72]. Phospho-ser62 
via a feedback mechanism, then serves as a platform for the phosphorylation of Thr58 by 
glycogen synthase kinase 3 (GSK3), allowing the tumour suppressor FBW7 to bind and 
recruit a ubiquitylation complex, directing MYCN protein for degradation. Mitotic 
degradation of MYCN in the absence of growth factor-dependent signals allows cell cycle 
exit and the commencement of differentiation [73]. Another kinase, Aurora A, has recently 
been identified and shown to inhibit degradation of ubiquitinated MYCN by supporting the 
synthesis of non-degradable ubiquitin chains [74]. 
8. MYCN downstream target genes 
The first transcriptional target for a MYC protein was discovered ten years after the 
identification of human c-MYC. The development of a conditionally expressed c-MYC 
construct, via the fusion of human c-MYC to the hormone-binding domain of the oestrogen 
receptor, led to the identification of a downstream target involved in cell cycle progression, 
α-prothymosin [75]. This approach was then used to identify additional targets including 
ornithine decarboxylase 1 (ODC1), the rate-limiting enzyme involved in polyamine 
synthesis [76]. A different method of identifying MYC targets utilised MYC-null models to 
determine whether the regulation of expression of genes was dependent on the presence of 
a MYC oncogene. Such examples of labour-intensive techniques were invaluable in 
determining single bona fide MYC targets, however recent advances in technology have 
allowed for large-scale analyses of MYC-regulated genes [77, 78].  
Expression microarrays and chromatin immunoprecipitation assays (ChIP) have helped 
researchers identify MYC-regulated targets as well as link MYC-target expression to 
functional cellular pathways which are associated with transformation [79, 80].  MYC and 
MYCN-regulated targets have since been linked to a number of transforming activities 
involving the cell cycle (eg. cyclin D2, CDK4, p21), cell proliferation (e.g. MDM2), growth, 
metabolism (e.g. ribosomal proteins, proteins involved in nucleotide biosynthesis such as 
thymidylate synthase and ODC1), cell adhesion and migration (e.g. integrins) and 
angiogenesis (e.g. thrombospondin) [81-86]. Indeed, the activation and repression of MYC 
target genes is a well-coordinated event. Time course studies using microarray have 
identified differences between early and delayed gene expression responses, following MYC 
activation in a MYC-inducible cell system [87]. Early-response MYC target genes are 
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timing and tissue specificity. Thus, MYCN is normally expressed during embryonal 
development of the peripheral nervous system in neural crest cells [2]. Neural crest cells 
migrate during mid-gestation to populate the entire peripheral nervous system, including 
autonomic and peripheral ganglia and the adrenal gland. These migrating progenitor cells 
represent a highly proliferative population, and during normal development exit the cell-
cycle and undergo differentiation following the colonisation to the ganglia and spinal cord 
area. This event is orchestrated by extracellular signalling molecules such as mitogens and 
cytokines and coincides with decreased expression of MYCN [56, 58]. Without this strict 
control, dysregulated MYCN expression impairs the ability of progenitor cells to undergo 
differentiation. Studies which sustained MYCN expression in murine neural crest cells 
under the control of a tyrosine hydroxylase promoter, demonstrated the capacity to cause 
neuroblastoma in transgenic mice [3]. Despite this transforming ability, MYCN is vital for 
normal embryonic development, and murine embryos lacking MYCN exhibit profound 
hypoplasia, particularly in the central and peripheral nervous system, disorganized 
architecture of the brain, defective heart development and defects in the lung, genitourinary 
system, stomach, intestines and limb buds [59]. 
In order to understand how extracellular stimuli controlled MYC expression in cells, gene 
mapping studies in association with MYC transcription studies were undertaken, and these 
identified response elements within the MYC transcript as well as their regulators. In 
neuronal cells, MYCN has been shown to be regulated in its promoter region as well as in an 
enhancer region upstream of the coding region. The elongation transcription factor, E2F 
binds to the promoter region of MYCN in response to different mitogenic signals [60]. The 
promoter region also contains positive transcription factor binding sites for SP1, SP3 and 
TGFβ [61]. However, the presence of a retinoic acid response element (RARE) within this 
region allows for negative regulation of MYCN by retinoic acid [62]. 
A key finding was made in 1986 which identified c-MYC as the first eukaryotic gene to be 
negatively regulated by transcriptional elongation control, where a block in the elongation 
of mRNA during transcription occurred during cellular differentiation [63]. This finding 
was later confirmed in MYCN studies where transcription elongation pausing sites were 
identified in exon 1 and intron 1 of human MYCN [64, 65]. Furthermore, there is in vivo 
evidence that the downregulation of MYCN during mouse embryogenesis is partly 
regulated by the control of transcriptional elongation [66]. 
Transcription alone cannot account for the large difference in mRNA levels following the 
introduction of proliferative or anti-proliferative stimuli. The rapid turnover of mRNA was 
also associated with the discovery of two distinct mechanisms of MYC mRNA decay. The 
first involves a translation-independent mechanism involving poly(A) tail shortening of the 
untranslated region of the transcript, while the second represents a translation-dependent 
mechanism that is regulated by a region of mRNA which corresponds to the C-terminus of 
the protein, called the coding region determinant [67-69]. This region is bound to a 75kDa 
protein that protects the region of mRNA from endonuclease attack, in response to growth 
signals that induce c-MYC stabilisation. In the case of MYCN, RNA stability factors have 
also been identified which bind to the untranslated region of MYCN mRNA. In addition, an 
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internal ribosomal entry segment (IRES) in the transcript acts to enhance neuronal specific 
translation [70, 71].  
7. Regulation of MYCN protein expression 
The regulation of MYCN protein levels has also been investigated and phosphopeptide 
analysis has revealed that specific serine and threonine residues of MYCN are 
phosphorylated in vivo. Two residues in particular, Threonine 58 (Thr58) and Serine 62 
(Ser62) have been demonstrated as important determinants of transformation and MYCN 
protein stability and activity [20]. Proliferative stimuli activate phosphorylation of Ser62 by 
cyclin B and Cdk1 during prophase to increase MYCN protein stability [72]. Phospho-ser62 
via a feedback mechanism, then serves as a platform for the phosphorylation of Thr58 by 
glycogen synthase kinase 3 (GSK3), allowing the tumour suppressor FBW7 to bind and 
recruit a ubiquitylation complex, directing MYCN protein for degradation. Mitotic 
degradation of MYCN in the absence of growth factor-dependent signals allows cell cycle 
exit and the commencement of differentiation [73]. Another kinase, Aurora A, has recently 
been identified and shown to inhibit degradation of ubiquitinated MYCN by supporting the 
synthesis of non-degradable ubiquitin chains [74]. 
8. MYCN downstream target genes 
The first transcriptional target for a MYC protein was discovered ten years after the 
identification of human c-MYC. The development of a conditionally expressed c-MYC 
construct, via the fusion of human c-MYC to the hormone-binding domain of the oestrogen 
receptor, led to the identification of a downstream target involved in cell cycle progression, 
α-prothymosin [75]. This approach was then used to identify additional targets including 
ornithine decarboxylase 1 (ODC1), the rate-limiting enzyme involved in polyamine 
synthesis [76]. A different method of identifying MYC targets utilised MYC-null models to 
determine whether the regulation of expression of genes was dependent on the presence of 
a MYC oncogene. Such examples of labour-intensive techniques were invaluable in 
determining single bona fide MYC targets, however recent advances in technology have 
allowed for large-scale analyses of MYC-regulated genes [77, 78].  
Expression microarrays and chromatin immunoprecipitation assays (ChIP) have helped 
researchers identify MYC-regulated targets as well as link MYC-target expression to 
functional cellular pathways which are associated with transformation [79, 80].  MYC and 
MYCN-regulated targets have since been linked to a number of transforming activities 
involving the cell cycle (eg. cyclin D2, CDK4, p21), cell proliferation (e.g. MDM2), growth, 
metabolism (e.g. ribosomal proteins, proteins involved in nucleotide biosynthesis such as 
thymidylate synthase and ODC1), cell adhesion and migration (e.g. integrins) and 
angiogenesis (e.g. thrombospondin) [81-86]. Indeed, the activation and repression of MYC 
target genes is a well-coordinated event. Time course studies using microarray have 
identified differences between early and delayed gene expression responses, following MYC 
activation in a MYC-inducible cell system [87]. Early-response MYC target genes are 
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primarily involved in MAPK signalling, RNA metabolism and transcription factors, which 
suggests a program that prepares cells for entry into the S phase. On the other hand, 
delayed-response MYC target genes are involved in ribosomal biogenesis, nucleotide 
metabolism and energy metabolism, suggesting subsequent maintenance of cells during the 
S phase. Finally, late steady-state MYC-mediated transcription involved genes that regulate 
the cell cycle, nucleotide metabolism and DNA replication. Most genes that were activated 
in the early response were then repressed during this late steady-state phase. Furthermore, 
sustained MYC activation led to the silencing of differentiation-related genes and 
upregulation of genes that are involved cell proliferation. 
During tumorigenesis, MYCN promotes cell cycle progression by the activation of cyclins 
(such as cyclin D1 and D2) as well as cyclin-dependent kinase 4 (CDK4), and represses the 
expression of mediators of cell cycle arrest such as p21 [73]. One important MYCN-
regulated metabolic pathway involves the synthesis of polyamines, which are organic 
cations that enhance transcription, translation and replication [88]. MYCN expression is 
strongly correlated with ODC1 expression in neuroblastoma, and the high levels of ODC1 
expression that are driven by MYCN-amplification and over-expression are strongly 
associated with poor clinical outcome of this disease [89].  
Another gene whose expression is strongly correlated with MYCN expression in 
neuroblastoma is that encoding the multidrug resistance-associated protein, MRP1, a 
glycoprotein that belongs to the superfamily of ATP-binding cassette (ABC) transmembrane 
transporters [90-92]. MRP1, also known as ABCC1, is able to confer resistance to a broad 
range of structurally unrelated chemotherapeutic drugs [93]. MRP1 has since been shown to 
be a downstream transcriptional target of MYCN in neuroblastoma, whose expression is 
highly predictive of outcome in this disease [91, 94, 95]. The expression of another gene that 
is also a member of the ABC family of transporters, MRP4 (or ABCC4), has also been 
demonstrated to be positively correlated to MYCN expression in neuroblastoma and like 
MRP1, its over-expression is a prognostic indicator of neuroblastoma outcome [95, 96]. In 
fact, it has recently been shown that MYCN can coordinate the transcription of a large set of 
ABC genes, and the expression profiles of these genes correlate with MYCN function [48]. 
9. MYCN tumorigenesis 
The evidence for a clinical role of MYCN in the tumorigenesis of neuroblastoma was first 
recognised when the amplification of the MYCN oncogene was identified in 24 out of 63 
primary untreated neuroblastoma tumour samples and appeared to correlate with more 
advanced stage of disease [97]. MYCN-amplification was subsequently associated with 
rapid disease progression as well as poor patient outcome in this disease [98]. Importantly, 
the progression-free survival of neuroblastoma patients was then shown to be dose-
dependent on MYCN where higher copy number resulted in lower survival. This association 
was independent of patient age and disease stage. MYCN-amplification was later confirmed 
in numerous studies to be a powerful prognostic marker for predicting neuroblastoma 
patient outcome, independent of other clinical variables [99-102]. Determination of MYCN 
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amplification status is now routinely determined in primary neuroblastomas and is one of 
the most powerful prognostic markers yet identified for this disease. 
The MYCN oncogene is normally located on the distal short arm of chromosome 2 (2p24). 
This region was found to be amplified across a panel of neuroblastoma cell lines [8], and 
although the exact mechanism by which this occurs is unknown, the process of 
amplification usually results in 50 to 400 copies of the gene per cell, leading to the 
production of abnormally high levels of MYCN RNA and protein, presumably conferring a 
selective advantage to the tumour cell [103].  
The potent transforming ability of MYCN has been demonstrated by several studies, while 
MYCN transfection studies have demonstrated that the oncoprotein plays a crucial role in 
neuroblastoma progression [104, 105]. Conditional overexpression of MYCN in 
neuroblastoma cell lines was shown to dramatically increase the growth rates and metastatic 
ability of these tumour cells, increase DNA synthesis, and inhibit exit from the cell cycle and 
neuronal differentiation [106, 107]. Furthermore, targeted expression of the MYCN oncogene 
in neuroectodermal cells of transgenic mice resulted in the development of neuroblastoma 
[3]. In these animals, human MYCN (hMYCN) oncogene expression was targeted to neural 
crest cells via an upstream rat tyrosine hydroxylase promoter. Tyrosine hydroxylase is the 
first and rate-limiting step in catecholamine synthesis. In contrast, reduction in the MYCN 
RNA levels via introduction of MYCN antisense oligonucleotides in vitro as well as in vivo 
led to reduced rates of growth and of tumorigenicity [4, 108, 109].  
Whilst MYCN-amplification has been shown to be associated with a highly malignant 
neuroblastoma phenotype, the precise role of this oncogene in non-amplified tumours 
remains controversial. Approximately 40% of those neuroblastomas that lack MYCN-
amplification are nevertheless still clinically aggressive, and the clinical significance of 
MYCN expression in the absence of MYCN-amplification, remains elusive with evidence 
both for and against an association with adverse outcome [110, 111]. One study that 
analysed both MYCN mRNA and protein levels in a cohort of non-amplified tumours, 
found no prognostic significance attributable to expression of this oncogene [110]. Rather, 
since the survival rates for older children with or without high MYCN expression were 
poor, the results suggested that additional factors contribute to tumour aggressiveness in 
this subgroup. Furthermore, in a more recent study involving 91 neuroblastoma patients, 
high MYCN expression was found to be associated with a favourable outcome in 
neuroblastomas lacking MYCN-amplification [111]. Interestingly, in this study, the forced 
expression of MYCN significantly suppressed growth of non-amplified neuroblastoma cells 
by inducing apoptosis. It is possible that the prognostic value of MYCN gene expression in 
neuroblastoma may be an artefact of the different biology of neuroblastoma in infants 
compared to older children, and further well-controlled, large cohort studies will be needed 
in order to clarify the precise role of MYCN in non-amplified neuroblastoma. 
Although the majority of the literature investigating MYCN in cancer comes from studies on 
neuroblastoma, this oncogene has also been shown to play a role in the tumorigenesis of 
other cancers, both adult and paediatric. For example, MYCN amplification and/or over-
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primarily involved in MAPK signalling, RNA metabolism and transcription factors, which 
suggests a program that prepares cells for entry into the S phase. On the other hand, 
delayed-response MYC target genes are involved in ribosomal biogenesis, nucleotide 
metabolism and energy metabolism, suggesting subsequent maintenance of cells during the 
S phase. Finally, late steady-state MYC-mediated transcription involved genes that regulate 
the cell cycle, nucleotide metabolism and DNA replication. Most genes that were activated 
in the early response were then repressed during this late steady-state phase. Furthermore, 
sustained MYC activation led to the silencing of differentiation-related genes and 
upregulation of genes that are involved cell proliferation. 
During tumorigenesis, MYCN promotes cell cycle progression by the activation of cyclins 
(such as cyclin D1 and D2) as well as cyclin-dependent kinase 4 (CDK4), and represses the 
expression of mediators of cell cycle arrest such as p21 [73]. One important MYCN-
regulated metabolic pathway involves the synthesis of polyamines, which are organic 
cations that enhance transcription, translation and replication [88]. MYCN expression is 
strongly correlated with ODC1 expression in neuroblastoma, and the high levels of ODC1 
expression that are driven by MYCN-amplification and over-expression are strongly 
associated with poor clinical outcome of this disease [89].  
Another gene whose expression is strongly correlated with MYCN expression in 
neuroblastoma is that encoding the multidrug resistance-associated protein, MRP1, a 
glycoprotein that belongs to the superfamily of ATP-binding cassette (ABC) transmembrane 
transporters [90-92]. MRP1, also known as ABCC1, is able to confer resistance to a broad 
range of structurally unrelated chemotherapeutic drugs [93]. MRP1 has since been shown to 
be a downstream transcriptional target of MYCN in neuroblastoma, whose expression is 
highly predictive of outcome in this disease [91, 94, 95]. The expression of another gene that 
is also a member of the ABC family of transporters, MRP4 (or ABCC4), has also been 
demonstrated to be positively correlated to MYCN expression in neuroblastoma and like 
MRP1, its over-expression is a prognostic indicator of neuroblastoma outcome [95, 96]. In 
fact, it has recently been shown that MYCN can coordinate the transcription of a large set of 
ABC genes, and the expression profiles of these genes correlate with MYCN function [48]. 
9. MYCN tumorigenesis 
The evidence for a clinical role of MYCN in the tumorigenesis of neuroblastoma was first 
recognised when the amplification of the MYCN oncogene was identified in 24 out of 63 
primary untreated neuroblastoma tumour samples and appeared to correlate with more 
advanced stage of disease [97]. MYCN-amplification was subsequently associated with 
rapid disease progression as well as poor patient outcome in this disease [98]. Importantly, 
the progression-free survival of neuroblastoma patients was then shown to be dose-
dependent on MYCN where higher copy number resulted in lower survival. This association 
was independent of patient age and disease stage. MYCN-amplification was later confirmed 
in numerous studies to be a powerful prognostic marker for predicting neuroblastoma 
patient outcome, independent of other clinical variables [99-102]. Determination of MYCN 
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amplification status is now routinely determined in primary neuroblastomas and is one of 
the most powerful prognostic markers yet identified for this disease. 
The MYCN oncogene is normally located on the distal short arm of chromosome 2 (2p24). 
This region was found to be amplified across a panel of neuroblastoma cell lines [8], and 
although the exact mechanism by which this occurs is unknown, the process of 
amplification usually results in 50 to 400 copies of the gene per cell, leading to the 
production of abnormally high levels of MYCN RNA and protein, presumably conferring a 
selective advantage to the tumour cell [103].  
The potent transforming ability of MYCN has been demonstrated by several studies, while 
MYCN transfection studies have demonstrated that the oncoprotein plays a crucial role in 
neuroblastoma progression [104, 105]. Conditional overexpression of MYCN in 
neuroblastoma cell lines was shown to dramatically increase the growth rates and metastatic 
ability of these tumour cells, increase DNA synthesis, and inhibit exit from the cell cycle and 
neuronal differentiation [106, 107]. Furthermore, targeted expression of the MYCN oncogene 
in neuroectodermal cells of transgenic mice resulted in the development of neuroblastoma 
[3]. In these animals, human MYCN (hMYCN) oncogene expression was targeted to neural 
crest cells via an upstream rat tyrosine hydroxylase promoter. Tyrosine hydroxylase is the 
first and rate-limiting step in catecholamine synthesis. In contrast, reduction in the MYCN 
RNA levels via introduction of MYCN antisense oligonucleotides in vitro as well as in vivo 
led to reduced rates of growth and of tumorigenicity [4, 108, 109].  
Whilst MYCN-amplification has been shown to be associated with a highly malignant 
neuroblastoma phenotype, the precise role of this oncogene in non-amplified tumours 
remains controversial. Approximately 40% of those neuroblastomas that lack MYCN-
amplification are nevertheless still clinically aggressive, and the clinical significance of 
MYCN expression in the absence of MYCN-amplification, remains elusive with evidence 
both for and against an association with adverse outcome [110, 111]. One study that 
analysed both MYCN mRNA and protein levels in a cohort of non-amplified tumours, 
found no prognostic significance attributable to expression of this oncogene [110]. Rather, 
since the survival rates for older children with or without high MYCN expression were 
poor, the results suggested that additional factors contribute to tumour aggressiveness in 
this subgroup. Furthermore, in a more recent study involving 91 neuroblastoma patients, 
high MYCN expression was found to be associated with a favourable outcome in 
neuroblastomas lacking MYCN-amplification [111]. Interestingly, in this study, the forced 
expression of MYCN significantly suppressed growth of non-amplified neuroblastoma cells 
by inducing apoptosis. It is possible that the prognostic value of MYCN gene expression in 
neuroblastoma may be an artefact of the different biology of neuroblastoma in infants 
compared to older children, and further well-controlled, large cohort studies will be needed 
in order to clarify the precise role of MYCN in non-amplified neuroblastoma. 
Although the majority of the literature investigating MYCN in cancer comes from studies on 
neuroblastoma, this oncogene has also been shown to play a role in the tumorigenesis of 
other cancers, both adult and paediatric. For example, MYCN amplification and/or over-
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expression has been observed in high grade C5 serous ovarian tumours, small cell lung 
cancer, rhabdomyosarcoma and neuroendocrine prostate cancer  [112-115], while gain of 2p 
(and MYCN) plays a role in chronic lymphocytic leukaemia [116]. In childhood 
medulloblastoma, MYCN, c-MYC, and to a lesser extent MYCL, appear to be involved in the 
biology of this disease [117]. MYCN amplification occurs in up to 10% of medulloblastoma 
patients and is associated with poor clinical outcome, and like neuroblastoma, the risk of 
death increases with increasing copy number [117]. Furthermore, MYCN expression was 
found to be high in foetal cerebella, with the levels decreasing to almost absent in adult 
cerebella, suggesting that MYCN is essential to normal foetal development [118]. 
Interestingly, in this study, MYCN expression was absent from the medulloblastoma cell 
lines tested, which differed from the expression pattern observed in the primary tumours 
[118]. Finally, as with neuroblastoma, the association of MYCN mRNA levels with clinical 
outcome remains unclear [119] and it has been postulated that mRNA levels of both c-MYC 
and MYCN may only be clinically relevant in subgroups of medulloblastoma [117]. 
The most compelling evidence for a role of MYCN in the biology of medulloblastoma comes 
from two mouse models of this disease. Firstly, targeted expression of MYCN to the 
cerebellum in transgenic mice has demonstrated the importance of MYCN in contributing to 
the initiation and progression of medulloblastoma and also in the metastatic spread of 
disease to the spinal and paraspinal tissues via cerebral spinal fluid. Furthermore, the 
MYCN downstream targets Odc1, MDM2 and Fb1 were upregulated and correlated with 
MYCN mRNA levels [118].  The second model used targeted Smoothened (SmoA1) to the 
cerebella of transgenic mice, which were then crossed with mice harbouring conditional 
knock-out of MYCN, to demonstrate that MYCN was essential for medulloblastoma 
tumorigenesis [120]. These two models thus serve to demonstrate the importance of MYCN 
in the initiation and progression of this disease. 
10. Molecular targeting of MYCN for therapeutic benefit 
Molecular targeted therapy involves targeting malignant cell growth by directly inhibiting 
the function of specific molecules within a cell, namely those that are responsible for driving 
cancer progression. Such agents aim to block or exploit various aspects of cancer biology, 
such as genetic instability, proliferative signal transduction, aberrant cell cycle control, 
deregulated survival, angiogenesis and metastasis [121]. Numerous methods of molecular 
targeted therapy have been investigated, including antisense oligonucleotides (ASOs) that 
hybridise to and inhibit the mRNA of a specific gene; peptide nucleic acids (PNAs), which 
are DNA analogues that specifically hybridise to DNA and/or RNA in a complementary 
manner to inhibit transcription/translation of a target gene; and small interfering RNA 
(siRNA), which silences gene expression by inducing the sequence specific degradation of 
complementary mRNA or by inhibiting translation [122]. However, such technologies 
although useful in the laboratory, have had limited success in the clinic due to problems 
associated with their delivery.  
Immunotherapy has also generated interest, and utilises the body’s immune system to target 
and remove cancer cells by the recognition of certain molecular markers, or block specific 
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cell receptor pathways. Another approach to molecular targeting, involves the development 
of synthetic small molecule inhibitors which potentially have the ability to interfere with a 
molecular target at multiple levels [122]. These small molecules may diffuse into cells to act 
directly on intracellular targets, such as inhibiting the expression of a target gene at the 
transcriptional or translational level, or inhibiting the function of a protein by directly 
binding to the protein and inducing conformational changes that prevent its interaction with 
other factors [123]. Synthetic small molecules are generally defined by a molecular weight 
cut-off of <500Da. They are favoured by the pharmaceutical industry because of their 
attractive pharmacokinetic properties, especially tumour cell penetration, and their relative 
ease of development and pharmaceutical production [123]. At present, strategies to develop 
novel small molecule inhibitors as viable therapies are aimed at using these technologies in 
combination with other cytotoxic drugs, with the hope of reducing drug dosages, and thus 
overcoming drug resistance associated with intensive chemotherapy, and reducing drug-
related toxicity and side effects.  
A number of molecular mechanisms have been identified as possible targets for the 
treatment of neuroblastoma. However, the prominent deregulated expression and 
amplification of MYCN suggests that this oncogene represents an ideal target for therapeutic 
inhibition [124]. In addition, normal MYCN expression is restricted to the early stages of 
embryonic development and is virtually undetectable in normal post-natal tissues, therefore 
weighing in its favour as a target for inhibition. Inhibition of MYCN expression by antisense 
treatment against MYCN mRNA or by retinoic acid has been demonstrated to decrease 
proliferation and induce neuronal differentiation in neuroblastoma cells [125-127]. 
Furthermore, the introduction of MYCN antisense oligonucleotides in the human MYCN 
(hMYCN) trangenic mouse model led to reduced rates of tumour growth in these animals [4, 
108, 109].  
Inhibition of MYCN protein through its protein-protein interactions and protein-DNA 
interactions was previously seen as too difficult to target by small molecules [128]. 
However, it has been reported that small-molecule antagonists of MYC/MAX dimerisation 
interfered with c-MYC-induced oncogenic transformation of chicken embryo fibroblasts in 
vitro [129]. In addition, a number of endogenous MYCN/MAX antagonists such as 
MAX/MAX have been found to compete for binding to E-box sequences and repress 
transcription [130], causing cell cycle arrest, terminal differentiation or apoptosis. More 
recently, inhibition of c-MYC transcription via a Bromodomain and Extra Terminal Domain 
(BET) inhibitor, JQ1, has been described [131]. This inhibitor has been shown to disrupt c-
MYC mRNA synthesis by preventing the recruitment of coactivator proteins required for c-
MYC transcriptional initiation and mRNA elongation [131]. Furthermore, this molecule was 
able to decrease the tumour burden in an orthotopic mouse model of multiple myeloma. 
Treatment of several MYCN-amplified neuroblastoma cell lines with JQ1, resulted in a 
decrease in MYCN expression, although this effect was far less dramatic that that observed 
in a c-MYC driven cell line [132]. Despite promising evidence for targeting MYCN as a 
therapeutic strategy, no MYC or MYCN inhibitors have yet entered clinical trial, and further 
studies are required to develop effective MYCN inhibitors. 
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directly on intracellular targets, such as inhibiting the expression of a target gene at the 
transcriptional or translational level, or inhibiting the function of a protein by directly 
binding to the protein and inducing conformational changes that prevent its interaction with 
other factors [123]. Synthetic small molecules are generally defined by a molecular weight 
cut-off of <500Da. They are favoured by the pharmaceutical industry because of their 
attractive pharmacokinetic properties, especially tumour cell penetration, and their relative 
ease of development and pharmaceutical production [123]. At present, strategies to develop 
novel small molecule inhibitors as viable therapies are aimed at using these technologies in 
combination with other cytotoxic drugs, with the hope of reducing drug dosages, and thus 
overcoming drug resistance associated with intensive chemotherapy, and reducing drug-
related toxicity and side effects.  
A number of molecular mechanisms have been identified as possible targets for the 
treatment of neuroblastoma. However, the prominent deregulated expression and 
amplification of MYCN suggests that this oncogene represents an ideal target for therapeutic 
inhibition [124]. In addition, normal MYCN expression is restricted to the early stages of 
embryonic development and is virtually undetectable in normal post-natal tissues, therefore 
weighing in its favour as a target for inhibition. Inhibition of MYCN expression by antisense 
treatment against MYCN mRNA or by retinoic acid has been demonstrated to decrease 
proliferation and induce neuronal differentiation in neuroblastoma cells [125-127]. 
Furthermore, the introduction of MYCN antisense oligonucleotides in the human MYCN 
(hMYCN) trangenic mouse model led to reduced rates of tumour growth in these animals [4, 
108, 109].  
Inhibition of MYCN protein through its protein-protein interactions and protein-DNA 
interactions was previously seen as too difficult to target by small molecules [128]. 
However, it has been reported that small-molecule antagonists of MYC/MAX dimerisation 
interfered with c-MYC-induced oncogenic transformation of chicken embryo fibroblasts in 
vitro [129]. In addition, a number of endogenous MYCN/MAX antagonists such as 
MAX/MAX have been found to compete for binding to E-box sequences and repress 
transcription [130], causing cell cycle arrest, terminal differentiation or apoptosis. More 
recently, inhibition of c-MYC transcription via a Bromodomain and Extra Terminal Domain 
(BET) inhibitor, JQ1, has been described [131]. This inhibitor has been shown to disrupt c-
MYC mRNA synthesis by preventing the recruitment of coactivator proteins required for c-
MYC transcriptional initiation and mRNA elongation [131]. Furthermore, this molecule was 
able to decrease the tumour burden in an orthotopic mouse model of multiple myeloma. 
Treatment of several MYCN-amplified neuroblastoma cell lines with JQ1, resulted in a 
decrease in MYCN expression, although this effect was far less dramatic that that observed 
in a c-MYC driven cell line [132]. Despite promising evidence for targeting MYCN as a 
therapeutic strategy, no MYC or MYCN inhibitors have yet entered clinical trial, and further 
studies are required to develop effective MYCN inhibitors. 
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11. Future perspectives 
The validity for targeting MYCN for therapeutic benefit relies on the gross transforming 
ability of this transcription factor. MYCN represents a particularly attractive target due to its 
lack of expression in adult and normal paediatric tissues. Although MYCN, and MYC 
proteins in general are commonly viewed as “undruggable” due to the nature of these 
proteins, MYCN offers potential advantages at a number of levels for therapeutic inhibition, 
either upstream, or downstream along the MYCN transcriptional pathway. If clinically 
useful MYCN inhibitors can be successfully developed, they are likely to find application in 
combination therapies involving conventional chemotherapeutic drugs and be used as an 
improved approach to target aggressive cancers that are driven by this oncoprotein. 
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1. Introduction 
The signal transducers and activators of transcription, STAT proteins, were originally 
discovered in interferon (IFN)-regulated gene transcription in the early 1990’s. Since then, a 
number of cytokines have been recognized to activate various STAT proteins. STATs 
constitute a family of seven transcription factors, STAT1α/β, STAT2, STAT3α/β, STAT4, 
STAT5A, STAT5B and STAT6, that transduce signals from a variety of extracellular stimuli 
initiated by different cytokine families that aside from interferons (interferon α, β and γ) 
include gp130 cytokines, i.e., IL-6, IL-12, IL-23 and γC cytokines that include IL-2, IL-15 and 
IL-21 [1 ].  
Although structurally similar, the seven STAT family members possess diverse biological 
roles and are engaged in numerous processes from embryonic development, organogenesis, 
cell differentiation to regulation of immune processes. Awareness of their important role in 
regulation of cell proliferation, differentiation and survival has spurred interest in 
investigation of their activity in malignant transformation [2]. Evidence has now 
accumulated that confirms their role in pathogenesis of leukemias and numerous solid 
tumors [3] (Table1). 
Aside from cytokine receptors, STATs are also activated by receptors for growth factors 
(family of tyrosine kinase receptors) that include receptors for epidermal growth factor - 
EGFR, platelet-derived growth factor - PDGF, hepatocyte growth factor - HGF and colony-
stimulating factor 1- CSF-1 receptors that possess an intrinsic tyrosine kinase activity [4]. 
These receptors may activate STAT proteins either directly or indirectly by means of JAK 
kinase proteins. Also, free intracellular enzymes, i.e., non-receptor tyrosine kinases that 
include oncogenes src and bcr-abl activate various STATs [5].  
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Different biological processes regulated by STAT proteins
Embryonic development    
Organogenesis and function    
Cells proliferation     
Cell differentiation, growth and apoptosis 
Innate and adoptive immunity    
Inflammation     
Angiogenesis     
Wound healing     
Malignant transformation       
Table 1. Role of STATs in the organism 
Interaction of cytokines and their specific receptors directly activates free intracellular non-
receptor enzymes, Janus kinases, and subsequently, latent STAT transcription factors that 
through the JAK/STAT signaling pathway lead to the expression of numerous genes that 
regulate important cellular processes. It is of importance that numerous cytokines, growth 
factors in different cell types activate STAT1, STAT3 and STAT5 and mediate broadly 
diverse biologic processes that control cell homeostasis. On the other hand, STATs such as 
STAT4 and STAT6 have a more specific role and they are engaged in T helper cell 
differentiation and maintenance of equilibrium between Th1 and Th2 immune response [6]. 
Defects in STAT molecules can lead to serious defects in development and to fetal death 
indicating the importance of JAK/STAT pathway in normal cell development. Defects in the 
JAK/STAT signaling pathway are often encountered in primary malignant tumors, as well 
as in peripheral blood lymphocytes [7,8,9] and STAT3 has been the first to be identified as a 
potential oncogene [2] (Fig.1). 
Given the critical roles of STAT proteins such as activation of pro-inflammatory and anti-
proliferative processes by STAT1 and control of cell-cycle progression and apoptosis by 
STAT3 and STAT5 it has been established in many studies that their dysregulation can 
contribute to oncogenesis [10] by increasing proliferation and slowing-down apoptosis. In 
this sense, studies show that STAT3 is activated in a majority of breast and prostate cancers, 
and that STAT3 inhibition using RNA interference or a dominant negative genotype leads to 
reduced cell proliferation, survival, and induces wound healing. Further, blocking STAT3 
interaction with EGFR using peptide aptamers has been shown to reduce tumor growth. On 
the other hand, STAT1 has been primarily defined as a tumor suppressor gene and its 
inactivation was associated with malignant transformation. Initially STAT proteins were 
extensively studied in leukemias, but later their role in the development of different solid 
tumors has been shown. 
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Figure 1. Mechanisms of STAT signaling upon activation of different tyrosine kinase (TK) signaling 
pathways that can induce activation of STAT proteins. In the case of growth factors like EGF that bind 
to receptor tyrosine kinases (RTKs), the receptor can directly phosphorylate STATs and/or indirectly 
induce STAT phosphorylation. Also, cytokines, like IL-6, that bind to cytokine receptors lacking intrinsic 
TK activity undergo ligand-induced dimerization of the receptor that results in phosphorylation of 
receptor-associated JAK kinases. JAKs in turn phosphorylate the receptor cytoplasmic tails on tyrosine, 
providing “docking sites” for recruitment of monomeric STATs. JAKs then phosphorylate the recruited 
STAT proteins on tyrosine, inducing dimerization, nuclear translocation, and DNA-binding activity. Other 
non-receptor bound free intracellular enzymes named non-receptor TKs such as SRC family kinases are 
also involved and can directly induce STAT activation. Once in the nucleus, activated STAT proteins bind 
to specific DNA sequences in the promoters of genes and induce their expression. In the context of 
oncogenesis, constitutive activation of TK-STAT signaling pathways induces elevated expression of genes 
involved in controlling cellular processes such as cell proliferation and survival. 
Aside from their role in the development of tumors STAT1,3 and 5 can be considered as 
molecular markers for early detection of certain types of tumors, as well as prognostic 
factors for determining tumor aggressiveness and predictors of response to various types of 
therapy. Novel data also indicate functional interplay between several activated STATs and 
association of STAT5 with certain well differentiated tumors with favorable prognosis 
[11].Based on numerous new data it appears that dysregulation of STAT signaling pathway 
may serve as a basis for designing novel targeted molecular therapeutic strategies that hold 
great potential for the treatment of solid tumors and leukemias. 
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1.1. Structural and functional characteristics of STATs 
STATs share structurally and functionally conserved domains that include the amino-
terminal domain (NH2), the coiled-coiled domain (CCD), the DNA binding domain (DBD), 
the linker domain and the SH2/tyrosine activation domain [12]. In contrast, the carboxyl-
terminal transcriptional activation domain (TAD) is quite divergent and contributes to STAT 
specificity (Table 2). 
Functionally, the amino-terminal domain of STAT molecules is the oligomerization domain 
that interacts with other proteins and mediates oligomerization of STAT dimers to form 
tetramers [13]. The DNA binding domain defines the DNA-binding specificity to tandem 
GAS elements and each STAT component of the dimer recognizes bases in the most 
proximal half of GAS and mediates distinct signals for specific ligands. 
SH2 domain, located near the C-terminal domain, plays an important role in signaling 
through its capacity to bind to specific phosphotyrosine motifs and to mediate specific 
interactions. Consistent with this, it is the most highly conserved STAT domain. The ability 
of this SH2 domain to recognize specific phosphotyrosine motifs plays an essential role in 
three STAT signaling events that include recruitment to the phosphorylated cytokine 
receptor through recognition of specific receptor phosphotyrosine motifs, association with 




   Oligomerization domain
Interacts with other proteins and mediates oligomerization of 
STAT dimers to form tetramers 
DNA binding domain Defines the DNA-binding specificity and mediates distinct 
signals for specific ligands 
SH2 domain Mediates specific interactions between STAT and receptors, 
STAT and JAK and STAT homo or hetero dimerization 
COOH-terminal domain 
   Transcription activation  
domain (TAD) 
TAD regulates  the transcriptional activity of STATs and 
provides  specificity 
   Tyrosine residue Phosphorylation site in the COOH-terminal domain that 
regulates the DNA-binding activity of all STATs. On 
phosphorylation mediates STAT dimerization 
   Serine residue A second phosphorylation site in the C-terminal domain 
Table 2. STAT structure 
Close to the SH2 domain the critical tyrosine residue is located that is required for SH-
phosphotyrosine interaction and thus STAT activation. This tyrosine residue is then rapidly 
phosphorylated by the active JAK determining STAT dimerization by binding to the SH2 
domain of the reciprocal STAT molecule.  
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A conserved serine residue in the C-terminal domain of STAT1,3, and 5 is a second 
phosphorylation site that enhances DNA binding affinity and transcriptional activity [15]. It 
has been determined that the transcriptional activity of several STATs can be modulated 
through serine phosphorylation. Serine phosphorylation appears to enhance the 
transcription of some, but not all target genes. It has been suggested that serine 
phosphorylation may alter the affinity for other transcriptional regulators like 
minichromosome maintenance complex component 5 (MCM5) and BRCA1 [12].  
C-terminal domain also encodes transcriptional activation domain (TAD) that contributes to 
STAT specificity and is thought to be involved in communication with transcriptional 
complexes, to regulate the transcriptional activity of STATs and provide functional 
specificity. Altered serine phosphorylation site associated with the c-terminal 
transactivation domain truncation of STAT1 and STAT3 reduces their transcriptional 
capacity by 20% [16]. Moreover, a c-TAD truncation leads to the α and β isoforms of STAT 
proteins that are biologically significant and appear to affect the cell’s fate [13].  
1.2. Mechanism and regulation of STAT protein function 
When ligands bind to their receptors they initiate a cascade of intracellular phosphorylation 
events. However, members of the hematopoietin receptor family possess no catalytic kinase 
activity. Rather, they rely on members of the JAK family of tyrosine kinases to provide this 
activity. JAKs are constitutively associated with a proline-rich domain of these receptors 
[17]. Upon ligand stimulation, receptors undergo the conformational changes that bring 
JAKs into proximity of each other, enabling activation by trans-phosphorylation [18]. Once 
activated, JAKs mediate the described signal transduction. Several studies have also 
suggested that JAKs associate with the receptor tyrosine kinases [12]. The phosphorylated 
JAKs, in turn, mediate phosphorylation at the specific receptor tyrosine residues, which then 
serve as docking sites for STATs and other signaling molecules. Once recruited to the 
receptor, STATs also become phosphorylated by JAKs, on a single tyrosine residue. The 
position of these tyrosines in STAT molecule is specific for each member of STAT family of 
proteins, such as Tyr 701 for STAT1, Tyr690 for STAT2, Tyr 705 for STAT3, Tyr 693 for 
STAT4, Tyr 694 for STAT5, and Tyr 641 for STAT6. Their phosphorylation mediates STAT 
dimerization which occurs by binding of the SH2 domain of one molecule with the domain 
containing the phosphotyrosine of another STAT molecule [19], so the resulting dimers are 
thus stabilized by bivalent bonds. STAT2 is the only STAT representative that does not act 
as a homodimer, forming instead a complex with STAT1 and p48. As a response to several 
cytokines, the heterodimers STAT1-2, STAT1-3 STAT5A-5B are formed, while no 
heterodimers with STAT 4 and STAT6 have been identified [20] (Table 3). 
Activated STATs dissociate from the receptor, dimerize, translocate to the nucleus and bind 
to members of the GAS (gamma activated site) family of enhancers. There are several more 
recent developments regarding STAT signaling, structural studies, nuclear as well as 
mitochondrial translocation, gene targeting and newly identified regulatory molecules. 
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Classical activation of STATs occurs after cytokine binding to cell-surface receptors that 
initiates a cascade of intracellular phosphorylation events. The phosphorylation of STATs is 
essential not only for dimerization, but also for the concomitant translocation of the dimers 
into the nucleus. Binding of STAT1 and STAT5B to importin-α5, a part of the 
nucleocytoplasmic transport machinery, has been described [21].  
Considering that a second phosphorylation site is serine residue in the c-terminal domain, 
STATs, in addition to tyrosine phosphorylation can be serine phosphorylated by various 
serine kinases [22] that regulate and increase STAT1,3 and 5 transcriptional activity. It is of 
interest that one of the kinases responsible for the phosphorylation of this serine in STAT1 
and STAT3, belongs to the MAP kinases family (ERKs, JNK and p38) which emphasizes the 
important ‘‘cross-talk’’ occurring between the two transductional pathways [23]. 
Furthermore, there is also evidence of the activity of ERK-independent serine kinases [24], 
such as the role of protein kinase C (PKC) in serine phosphorylation of STATs [25] and 
mTOR of the PKI2 pathway. The relative contribution of each of these serine kinases to 
STAT signaling in vivo would depend on cell-type specific expression of kinases [22]. 
Therefore, STATs can be phosphorylated in great many serine/threonine residues, which 
may modulate DNA binding and/or their transcriptional activity [26]. 
One can envision a negative feedback mechanism in which serine phosphorylation of STATs 
promotes the induction of physiologic inhibitors of STAT signaling, such as those of the 
suppressor of cytokine signaling (SOCS) family that inhibit at the level of JAKs [27]. 
Assumingly dual functional role is thus implied for STAT serine phosphorylation events, 
whereby the same serine kinases can apparently both enhance and repress STAT signaling, 
the indirect negative effect being due to preferential association of STAT proteins with the 
serine kinases, precluding interaction with tyrosine kinases [2, 25]. 
In addition to classical, canonical activation by tyrosine phosphorylation, the noncanonical 
STAT activation includes, besides serine phosphorylation, other, phosphorylation-
independent modifications that regulate their activity. In this sense, it has been shown that 
following stimulation of cells with IL-1 plus IL-6 unphosphorylated STAT3 affects gene 
expression in the nucleus through binding to NF-κB that mediates its nuclear import [28]. 
Furthermore, the classical IL-6 mediated activation of STAT3 induces tyrosine-
phosphorylation of STAT3 and activates many genes, including the STAT3 gene itself that 
results in STAT3 synthesis that in its unphosphorylated form can induce not only the 
synthesis of IL-6 but also the expression of other genes such as RANTES, IL-8, Met, and 
MRAS. 
Aside from this, the noncanonical STAT activation includes acetylation of lysine 685 in the 
SH2 STAT domain [29] that occurs in IL-6-induced acute phase reactions [30]. Novel 
findings indicate that acetylation of STAT3 is an important regulatory modification that 
influences protein–protein interaction and its transcriptional activity. Moreover, in 
oncogenesis new data regarding transmembrane glycoprotein CD44 [31], a marker of tumor 
metastatic phenotype, translocates into the nucleus in association with acetylated STAT3 
and by regulating transcription of cyclin D enhances cell proliferation [32] (Fig. 2).  
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Also, many more posttranslational STAT modifications such as isgylation [33], sumoylation 
[34] and ubiquitination [35] are being explored in STAT-dependent tumor formation and 
metastasis. These noncanonical pathways include the many roles of nontyrosine 
phosphorylated STATs, which alter their stability, dimerization, nuclear localization, 
transcriptional activation function, and association with histone acetyltransferases (HAT), 
and histone deacetylases (HDAC) [36] (Fig. 2). 
 
 
Figure 2. Different signaling pathways initiated by phosphorylation of STAT3 on tyrosine or serine 
residues. STAT3 is constitutively imported into and exported from the nucleus independent of its 
phosphorylation status. Oncogenic Ras can stimulate the autocrine production of IL-6, and the resulting 
phosphorylation of STAT3 Tyr705 promotes dimerization and the ability to bind specific DNA target 
sequences. STAT3 can also be phosphorylated on Ser727 and can mediate nuclear import of the NF-κB 
transcription factor. Serine phosphorylated STAT3 stimulates the electron transport chain in 
mitochondria and augments transformation by oncogenic Ras. 
The duration of STATs activation is a temporary process, thus within hours the activating 
signals decay and the STATs are exported back to the cytoplasm. Negative nuclear 
regulators of STATs are nuclear tyrosine phosphatases that induce STAT dephosphorylation 
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in the nucleus important for its export back to the cytoplasm. There is evidence that a 
specific nuclear tyrosine phosphatase (TC45), is a phosphatase relevant for STAT1 and 
STAT3 [37]. In addition, it has been reported that cells lacking this enzyme retain tyrosine 
phosphorylated STAT1 for much longer than normal cells, and overexpression of TC45 
leads to dephosphorylation of STAT5 [38]. However, TC45 has also been implicated in 
regulating cytoplasmic dephosphorylation of JAK1 and JAK3 [39]. 
Recently, the negative activity on STAT protein of a group of nuclear proteins termed 
“proteins that inhibit activated STATs” (PIAS) has been discovered. Studies in cultured 
mammalian cells indicated that PIAS1 and PIAS3 interact only with tyrosine-
phosphorylated STAT1 and STAT3, respectively [40]. PIAS prevents their binding to DNA, 
especially of STAT1, or it speeds-up their degradation in the proteasome. 
Besides nuclear, other phosphatases in the cytoplasm also represent negative STAT 
regulators, they include phosphatases such as SH2-containing phosphatase-1 (SH1), SH2, 
and protein-tyrosine-phosphatase-1B (PTP1B) implicated as cytoplasmic regulators of JAKs 
or STATs’ phosphorylation [38]. 
The activity of STAT proteins is also regulated by the inhibitors of the suppressors of the 
cytokine signal (SOCS) family, responsible for modulating the JAK-STAT pathway by 
acting on the JAK kinases. These cytokine-induced SOCS proteins are recruited to active 
receptor complexes to cause inhibition, and can also cause protein turnover of the 
receptor through a process of proteolytic degradation ubiquitine-proteasome mediated 
[41]. As SOCS belong to the family of target STAT genes they constitute with them a 
classical negative feedback mechanism [12] that can negatively regulate their own 
phosphorylation state [42]. Several members of this family have been identified, 
SOCS1,2,3,4,5,6 and 7. These regulatory proteins have an indirect negative effect on 
STATs by inhibiting their activating enzymes, especially Janus kinases (JAK1, JAK2, JAK3 
and Tyk2), as well as, upstream receptors for growth factors [43]. Considering  
their negative regulatory role, SOCS proteins represent an important intracellular 
mechanism for limiting the potentially adverse effects of  cytokines in immune reactions 
[44]. 
Aside from these mechanisms, mutations that augment the function of their activators or 
decreases the function of their inhibitors may lead to STAT hyperactivity and their 
engagement in malignant transformation. 
Moreover, due to alternate splicing of STAT gene the short forms of STATs, i.e., inactive 
STATβ form, can potentially act as dominant-negative protein and by competitive inhibition 
occupy DNA as non-functional protein without transcriptional capability or by binding to 
wild-type STATs form [45] competitive inhibition, prevent binding of the STATα isoform 
and transcription of target genes. Aside from that, the truncated STATγ isoform of this 
molecule that is created by proteolysis, also competitively inhibits transcription mediated by 
the active α form (Table 3). 
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Positive regulation of STATs Effects
Canonical regulation of STATs   
 STAT1 - Tyr 701 STAT4 - Tyr 693 
    Phosphorylation of tyrosine STAT2 - Tyr690 STAT5 - Tyr 694 
 STAT3 - Tyr 705 STAT6 - Tyr 641 
Noncannonical regulation of  STATs   
 STAT3 - Ser727  
    Phosphorylation of serine STAT4 - Ser721  
 STAT5 - Ser725/730  
    Unphosphorylated STAT 
IL-6 gene dependant expression 
IL-6 mediated acute phase reactions 
    NFκB Nuclear import of CD44 
    Acetylation   
    Isgylation   
    Sumoylation   
Genetic regulation   
    Mutations     
    Hypermorphic allele of STAT3 Increased transcription  
 Epigenetic regulation   
    Histone acetyl transferase (HAT)   
   
Negative regulation of STATs   
Negative cytoplasmic regulators   
    Tyrosine phosphatase (SHP1,2)   Dephosphorylation  
Protein-tyrosine-phosphatase-1B   
    Suppressors of cytokine signals  
     (SOCS1-7)   
  Inhibit JAK  
  degrade receptors 
 
    Proteases     STAT inactive forms (β and )  
Negative nuclear regulators   
    Nuclear tyrosine phosphatase Dephosphorylation  
    Proteins that inhibit activated STATs 
    (PIAS1-3) 
Inhibits STAT1-3 DNA binding 
Proteasome degradation 
 
    DNA methyltransferase (DNMT) Decreased transcription  
    Ubiquitination Degradation  
Table 3. Regulation of STAT activity 
2. STAT proteins in carcinogenesis 
Aside from their essential role in mediating the effect of cytokines, it has been shown that 
STATs can have a significant role in tumor development and they are being considered as 
potential oncogenes. In normal cells, the activation of STAT proteins is transient, ranging from 
between a few minutes to a few hours. However, in a large group of different tumors constitutive 
activation of STAT family, especially STAT3 and STAT5 members, as well as the loss of 
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STAT1 signaling, has been detected [3, 46]. Novel results indicate that STAT proteins 
regulate numerous pathways that participate in oncogenesis, such as cell cycle progression, 
apoptosis, angiogenesis, tumor invasiveness, metastasis, and immune response evasion. 
Based on this STAT proteins have become significant target molecules in novel therapeutic 
approaches in oncology as blocking of these molecules, directly or indirectly, may arrest the 
malignant process [47]. 
Gough et al. [48] provide evidence that STAT3 has joined a set of transcription factors that in 
mitochondria exhibit noncanonical roles independent of classical STAT3-mediated 
transcription in the nucleus. In this sense, mitochondria have become important in cancer 
research because they regulate proapoptotic and antiapoptotic factors.  
It is also of importance that according to their general principle of action STAT proteins may 
be divided into two groups that differ greatly. The group that comprises STAT2, STAT4 and 
STAT6 is activated by a limited number of cytokines and it is engaged in T cell 
development and the effect of interferons, while the other group that is comprised of 
STAT1, STAT3 and STAT5 is activated in numerous tissues and cell types by great many 
cytokines, different hormones and growth factors and aside from mediating immune 
reactions, regulates many important general processes such as cell proliferation, 
differentiation and survival in embryogenesis, as well as breast development [49]. In that 
sense, this second group of STAT proteins is of importance in malignant transformation. 
Aside from that, earlier results indicated that active STAT1 protein has tumor-suppressor 
characteristics as it down-regulates cell proliferation and induces apoptosis, so that its 
decreased activity is associated with numerous neoplasias. On the other hand, it has been 
shown for STAT3 and STAT5 that they are proto-oncogenes that activate oncogenes, c-
myc, cyklin D and antiapoptotic Bcl-xL protein, facilitate passage through G1/S check-point 
and in that sense, aside from down-regulating apoptosis, enhance cell proliferation and 
transformation [12].  
It has been shown that STAT3 is frequently activated in hematological and epithelial 
malignancies. Constitutive activation of STAT3 leads to proliferation of tumor cells and 
prevents apoptosis, down-regulates the production of numerous proinflamatory cytokines 
and chemokines and leads to secretion of factors that prevent dendritic cell (DC) maturation 
that suppresses adaptive antitumor immunity establishment. Aside from the disturbance of 
the JAK/STAT signaling pathway in primary tumors, a similar finding is frequently found in 
peripheral blood lymphocytes of patients with malignancies [3]. 
2.1. Constitutively activated STATs affect tumor microenvironment 
It is known that invasive tumors need to modulate gene expression in a manner that impairs 
the activity of innate and adaptive immunity in immune surveillance [50, 51]. STAT3 
positive tumors achieve this by preventing the production of proinflamatory cytokines, i.e., 
“danger signals”. Activation of the transcription factor STAT3 in the tumor and adjacent 
immune cells, including tumor associated macrophages (TAMs),T regulatory cells (Treg 
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cells), DCs, Th1 cells, Th2 cells, B regulatory cells (Bregs), myeloid derived suppressor cells 
(MDSCs), Th17 cells, as well as, normal epithelial cells, lead to production of cytokines IL-
1β, IL-6, IL-10, IL-17, as well as VEGF creating a feedback loop that promotes tumor growth,  
angiogenesis, evasion of immune surveillance and metastasis [52]. 
It has been shown that especially tumor produced IL-6 through JAKs/STAT3 signaling has 
an important role in modulating the tumor-associated immune microenvironment. IL-6 has 
pleiotropic functions by activating numerous cell types expressing membrane-bound gp130 
IL-6 receptor, i.e., classical IL-6 signaling, as well as, by soluble form of the IL-6 receptor 
(sIL-6 receptor) that after binding IL-6 and interaction with gp130 in the form of IL-6 trans-
signaling modulates a broad spectrum of target cells including epithelial cells, neutrophils, 
macrophages, and T cells [53]. Upregulated STAT3 in TAM has been shown to enhance the 
expression of IL-23 that leads to the expansion of Tregs, while conversely, transcriptionally 
repressing IL-12 that supports proinflamatory cytokines and antitumor immune reactions 
within the tumor milieu [54]. Also, tumor-evoked Bregs express activated STAT3 and 
induce TGFβ conversion of Tregs from resting T cells [55] (Fig.3). Therefore, the production  
 
Figure 3. Interaction between tumor cells and tumor microenvironment mediated by cytokines.  Tumor 
cells and different immune cells including TAMs, Treg cells, DC, Th17 cells, and non-tumor (normal 
epithelial) cells undergo STAT3 activation under the effect of various cytokines, and in turn produce 
more cytokines forming a feedback loop. STAT3 also regulates cell proliferation, cell cycle progression, 
apoptosis, angiogenesis together with immune evasion. Inhibition of STAT signaling could eliminate 
tumor cells while exerting minimal effect on the normal cells. Preclinical models have validated STAT3 
as a target for cancer therapy, although only indirect JAK inhibitors have advanced to clinical trials 
(Cytokines that induce STAT3 activation are written in bold letters). 
 
Oncogene and Cancer – From Bench to Clinic 464 
STAT1 signaling, has been detected [3, 46]. Novel results indicate that STAT proteins 
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and release of various survival factors, including IL-6 as a major activator of  STAT3, also 
serve to block apoptosis in cells during the inflammatory process, keeping them alive in 
very toxic environments. Unfortunately, at the same time these same pathways serve to 
maintain cells progressing towards neoplastic growth, protecting them from cellular 
apoptotic deletion and chemotherapeutic drugs. 
It is of importance that activation of STAT3 within tumors is heterogeneous and it has been 
found that pSTAT3 are highest on the leading edge of tumors and that this is associated 
with stromal, immune, and endothelial cells. This follows from IL-6 from cancer-associated 
fibroblasts or myeloid cells that in a feedback loop induces autocrine production of IL-6 and 
pSTAT3 expression in tumor cells, thus also leading to heterogeneous levels of pSTAT3 [56]. 
Therefore tumor STAT3 activity can mediate tumor immune evasion and induce tolerance 
rather than immunity by blocking both the production and sensing of inflammatory signals 
by components of the innate and adaptive immune systems that have been recently defined 
as “extrinsic tumor suppressors” [57]. 
Regarding tumor microenvironment, in physiological conditions the activation of STAT3 is 
of paramount importance during tissue remodeling in the process of „wound healing“ [58]. 
As tumor growth also includes tissue damage, the dysregulation of STAT3 in the context of 
tumor microenvironment has a detrimental effect that instead of wound healing leads to 
further tissue destruction, together with evasion of immune response. 
2.2. STATs support oncogene-dependent cellular transformation 
Oncogenes can only transform cells that have been immortalized by carcinogens or other 
oncogenes exemplifying the paradigm of multistep carcinogenesis. In this sense, mammal 
cells transformed by oncogenic src show constitutively active STAT3 and negative-dominant 
forms of STAT3 block the transforming ability of src, demonstrating a close correlation 
between STAT3 activation and the oncogenic transformation by this oncogene [59]. 
Moreover, recent studies have shown that constitutive activation of STAT3 in human breast 
cancer cells correlates with EGFR family kinase signaling and also with aberrant JAK and 
Src activity [60]. In addition to Src, many other transforming tyrosine kinases, such as Eyk, 
Ros and Lck, constitutively activate STAT3 in the context of oncogenesis. Another example 
of tumorigenic stimuli known to activate STAT proteins is Abl that may constitutively 
activate STAT3 and STAT5, whereas the fusion protein, Bcr-Abl, may activate them in the 
absence of constitutive JAK activation, showing that the presence of the JAK kinases is not 
always essential for STAT activation [2] (Table 4). 
In addition to its previously characterized nuclear roles, transformation specific function for 
mitochondrial STAT3 has now been shown. Although previous data implicated a Ras-
STAT3 axis in transformation, those cases were in the context of activated tyrosine kinases, 
such as NPM-ALK [61], RET [62], or autocrine cytokine signaling requiring STAT3 function 
in the nucleus. However, it has now been shown that for cellular transformation and 
anchorage-independent growth induced by activated H-, N- or K-Ras, STAT3 
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phosporylated on Serine727 and expressed exclusively in mitochondria was required. In 
contrast, recent findings also show that mitochondrially restricted STAT3 did not support 
src-driven anchorage-independent growth, consistent with former data that src requires 
nuclear functions of STAT3 [63]. 
 













Myeloid v-Src STAT1, STAT3, STAT5 
T cell Lck  STAT3, STAT5 
Mammary/Lung epithelial v-Src STAT3 
Gallbladder adenocarcinoma v-Src STAT3 
Pre-B lymphocytes v-Abl STAT1, STAT5 
Erythroleukemia/blast cells/ 
basophils/mast cells
Bcr-Abl STAT1, STAT5 
Primary bone marrow Bcr-Abl STAT5 
Table 4. STAT activation by oncogenes 
Mitochondrial STAT3 contributes to Ras-dependent cellular transformation by augmenting 
electron transport chain activity, particularly that of complexes II and V, accompanied by 
energy production to favor cytoplasmatic glycolysis that represents a hallmark of cancer 
formulated in the 1950’s by Warburg [64]. Additional analyses are required to understand 
the connections between glycolysis and oxidative phosphorylation affected by STAT3 in the 
presence or absence of oncogenic Ras. 
STAT3 apparently enters mitochondria associated with GRIM-19 that was identified as a 
subunit of the mitochondrial complex I and Ser727 appears to be needed for their interaction 
[65]. 
Therefore, the “metabolic shift” important for tumor growth mediated by mitochondrial 
STAT3 may reflect exploitation of a normal function and in this sense mitochondrial STAT3 
function could provide a new target for therapeutic approaches to cancer [65]. 
2.3. Anti-oncogenic and oncogenic characteristics of STAT1  
STAT1 has been considered to be an anti-oncogene, i.e., tumor-suppressor protein that 
blocks proliferation and induces apoptosis [66]. Moreover, it has been shown that its 
dysfunction leads to the loss of immune surveillance [67]. Loss of STAT1 supports 
angiogenesis and metastasis of tumors. 
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and release of various survival factors, including IL-6 as a major activator of  STAT3, also 
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mitochondrial STAT3 has now been shown. Although previous data implicated a Ras-
STAT3 axis in transformation, those cases were in the context of activated tyrosine kinases, 
such as NPM-ALK [61], RET [62], or autocrine cytokine signaling requiring STAT3 function 
in the nucleus. However, it has now been shown that for cellular transformation and 
anchorage-independent growth induced by activated H-, N- or K-Ras, STAT3 
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phosporylated on Serine727 and expressed exclusively in mitochondria was required. In 
contrast, recent findings also show that mitochondrially restricted STAT3 did not support 
src-driven anchorage-independent growth, consistent with former data that src requires 
nuclear functions of STAT3 [63]. 
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function could provide a new target for therapeutic approaches to cancer [65]. 
2.3. Anti-oncogenic and oncogenic characteristics of STAT1  
STAT1 has been considered to be an anti-oncogene, i.e., tumor-suppressor protein that 
blocks proliferation and induces apoptosis [66]. Moreover, it has been shown that its 
dysfunction leads to the loss of immune surveillance [67]. Loss of STAT1 supports 
angiogenesis and metastasis of tumors. 
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It has been established that STAT1, the first STAT to be discovered, is required for signaling 
by the IFNs which in addition to their role in innate immunity, serve as potent inhibitors of 
proliferation and promoters of apoptosis. The involvement of STAT1 in growth arrest and 
apoptosis in many cell types may be explained by its capacity to induce caspase and p21 
expression [68] and reduce c-myc expression. Although, normally, high p21 expression is 
associated with cell growth arrest, p21 increase has also been observed in some human 
neoplasias. This contradiction has been explained by Bowman et al. (2000) [2] with the fact 
that p21 is also responsible for the correct association of the cyclin D1/CDK cyclin complex, 
and thus its increase may be necessary for cell-cycle progression. Interestingly, in mammary 
cells p21 upregulation by STAT1 appears to involve BRCA1, which is often lost in familial 
and other forms of breast cancer. Effective STAT1-BRCA1 binding is mediated by serine 
phosphorylation of STAT1. More recently besides its role as tumor suppressor, new 
evidence has shown that STAT1 can be activated in some malignancies such as breast, lung, 
head and neck cancer and brain tumors [46]. In this sense, STAT1 tyrosine 701 
phosphorylation increase was demonstrated in human breast tumor cells with elevated 
levels of HER-2/Neu as well as in cell lines transfected with HER-2/Neu gene [70]. However, 
it is of interest that breast cancer patients with higher levels of phosphorylated and DNA-
bound STAT1 show better prognosis and live longer. 
Besides increased STAT activation, high expression of the unphosphorylated form of STAT1 
was also found in cancer cells. Moreover, it has been also shown that recurrent tumors 
express higher levels of unphosphorylated STAT1 compared to the original tumors [72], as 
well as cancer cells resistant to ionizing radiation and anticancer agents [73]. Recently, 
functions of some STAT1-induced genes in cancer cells have been investigated, and some 
have been shown to have pro-metastatic, pro-proliferative, or antiapoptotic properties [74]. 
In this sense it has been found in melanoma cells that high levels of STAT1 expression 
inhibits caspase 3/7 activation in response to doxorubicin which contributes to patients' 
resistance to this chemotherapeutic agent [75]. It has also been shown by Khodarev et al. 
(2007) [76] that ectopically increased expression of STAT1 can induce a radiation-resistant 
phenotype. 
Both type I and type II IFNs increase STAT1 expression in many cell types, including normal 
fibroblasts and mammary epithelial cells, and the newly synthesized STAT1 protein persists 
for many days after IFN stimulation in unphosphorylated form [77]. Certain types of human 
tumors are unresponsive to IFNs due to defects in the STAT1 activation pathway. 
Contrary to these findings, recent data states that the expression level of STAT1 does not 
influence the response to IFN adjuvant therapy in cancer [72] and that the overexpression of 
STAT1 in recurrent tumors might be caused by IFN treatment. In these tumor cells the 
found increase in STAT1 level does not result in enhanced anticancer effects of STAT1 as 
many IFN-induced pro-apoptotic and antiproliferative proteins as APO2L/TRAIL and IRF1 
[78] are not upregulated in resistant cells. This strongly indicates that IFN signaling is not 
responsible for STAT1 upregulation in cancer cells. It has also been found that high level of 
unphosphorylated STAT1 in tumors protects cancer cells from DNA damage [79]. 
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These observations suggest that increased levels of unphsphorylated STAT1 might 
participate in oncogenesis as well as resistance to cell death by inducing target genes that 
increase proliferation, decrease cell death, or increase repair of DNA damage. Increased 
DNA damage in cancer is due to oncogene-induced damage, chromosome instability, and 
other causes that are intrinsic to tumorigenesis. Therefore, evolving cancer cells must learn 
to resist the consequences of DNA damage, avoiding normal cellular responses such as cell 
cycle arrest or apoptosis, thus relying on support mechanisms that are characteristic for the 
tumor “stress phenotype”. A working hypothesis that is now being formulated is that the 
increase in STAT1 expression in cancers is due to processes intrinsic to tumorogenesis [77]. 
2.4. Oncogenic characteristics of STAT3 and STAT5 
Although STAT3 was originally identified as an acute phase response factor that is activated 
after stimulation by interleukin-6 (IL-6) [65], the biological functions of STAT3 are diverse, 
in part stemming from the activation of STAT3 by a wide range of cytokines, growth factors, 
as well as oncogenes. Among its many effects, it is now known to promote oncogenesis, 
while a hypermorphic allele of STAT3 can function as an oncogene [10]. 
It is established that the basic role of STAT3 in tumors is the prevention of apoptosis that is 
achieved by increased expression of antiapoptotic molecule, Bcl-2, or by affecting cell cycle 
progression by increased expression of c-myc and cyclin D1 engaged in the transition 
through G1/S check point. This is a characteristic of tumor cell lines with deleted STAT3 
gene (STAT3 -,-) where the lack of STAT3 activity leads to the appearance of apoptosis due 
to an increase in the level of caspases, and a decrease in the level of Bcl-2, while down-
regulated proliferation follows from decreased level of cycline D i c-myc oncogenes. 
In contrast to normal cells, in which STAT tyrosine phosphorylation occurs transiently, it has 
been determined that STATs 1, 3, and 5 are persistently tyrosine phosphorylated in most 
malignancies (particularly STAT3) [2, 46]. The mechanisms by which STAT3 is persistently or 
constitutively tyrosine phosphorylated in cancers include increased production of cytokines 
and cytokine receptors, which is initiated by tumor cells in an autocrine, and by tumor 
microenvironment in a paracrine manner, by a decrease in the expression of the SOCS proteins 
through gene promoter methylation, as well as loss of tyrosine phosphatase activity [11]. 
Most of the described oncogenic functions of STAT3 depend on the phosphorylation status 
of Tyr705, however, another role of STAT3 is independent of tyrosine phosphorylation, as 
unphosphorylated STAT3 can also affect gene expression in the nucleus, one mechanism is 
through binding to NF-κB and mediating its nuclear import [80]. 
STAT3 has been directly linked to human cancer as it is required for cell transformation by 
the src oncogene [81], as well as in promoting cellular transformation by the H-ras oncogene. 
This function, which is dependent on the noncanonical serine phosphorylation of STAT3, 
takes place in mitochondria. 
Unlike another member of STAT family, STAT1, that is imported in the nucleus only in 
phosphorylated form, STAT3 dynamically shuttles in and out of the nucleus independent of 
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phosphorylation of STAT1. More recently besides its role as tumor suppressor, new 
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head and neck cancer and brain tumors [46]. In this sense, STAT1 tyrosine 701 
phosphorylation increase was demonstrated in human breast tumor cells with elevated 
levels of HER-2/Neu as well as in cell lines transfected with HER-2/Neu gene [70]. However, 
it is of interest that breast cancer patients with higher levels of phosphorylated and DNA-
bound STAT1 show better prognosis and live longer. 
Besides increased STAT activation, high expression of the unphosphorylated form of STAT1 
was also found in cancer cells. Moreover, it has been also shown that recurrent tumors 
express higher levels of unphosphorylated STAT1 compared to the original tumors [72], as 
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functions of some STAT1-induced genes in cancer cells have been investigated, and some 
have been shown to have pro-metastatic, pro-proliferative, or antiapoptotic properties [74]. 
In this sense it has been found in melanoma cells that high levels of STAT1 expression 
inhibits caspase 3/7 activation in response to doxorubicin which contributes to patients' 
resistance to this chemotherapeutic agent [75]. It has also been shown by Khodarev et al. 
(2007) [76] that ectopically increased expression of STAT1 can induce a radiation-resistant 
phenotype. 
Both type I and type II IFNs increase STAT1 expression in many cell types, including normal 
fibroblasts and mammary epithelial cells, and the newly synthesized STAT1 protein persists 
for many days after IFN stimulation in unphosphorylated form [77]. Certain types of human 
tumors are unresponsive to IFNs due to defects in the STAT1 activation pathway. 
Contrary to these findings, recent data states that the expression level of STAT1 does not 
influence the response to IFN adjuvant therapy in cancer [72] and that the overexpression of 
STAT1 in recurrent tumors might be caused by IFN treatment. In these tumor cells the 
found increase in STAT1 level does not result in enhanced anticancer effects of STAT1 as 
many IFN-induced pro-apoptotic and antiproliferative proteins as APO2L/TRAIL and IRF1 
[78] are not upregulated in resistant cells. This strongly indicates that IFN signaling is not 
responsible for STAT1 upregulation in cancer cells. It has also been found that high level of 
unphosphorylated STAT1 in tumors protects cancer cells from DNA damage [79]. 
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These observations suggest that increased levels of unphsphorylated STAT1 might 
participate in oncogenesis as well as resistance to cell death by inducing target genes that 
increase proliferation, decrease cell death, or increase repair of DNA damage. Increased 
DNA damage in cancer is due to oncogene-induced damage, chromosome instability, and 
other causes that are intrinsic to tumorigenesis. Therefore, evolving cancer cells must learn 
to resist the consequences of DNA damage, avoiding normal cellular responses such as cell 
cycle arrest or apoptosis, thus relying on support mechanisms that are characteristic for the 
tumor “stress phenotype”. A working hypothesis that is now being formulated is that the 
increase in STAT1 expression in cancers is due to processes intrinsic to tumorogenesis [77]. 
2.4. Oncogenic characteristics of STAT3 and STAT5 
Although STAT3 was originally identified as an acute phase response factor that is activated 
after stimulation by interleukin-6 (IL-6) [65], the biological functions of STAT3 are diverse, 
in part stemming from the activation of STAT3 by a wide range of cytokines, growth factors, 
as well as oncogenes. Among its many effects, it is now known to promote oncogenesis, 
while a hypermorphic allele of STAT3 can function as an oncogene [10]. 
It is established that the basic role of STAT3 in tumors is the prevention of apoptosis that is 
achieved by increased expression of antiapoptotic molecule, Bcl-2, or by affecting cell cycle 
progression by increased expression of c-myc and cyclin D1 engaged in the transition 
through G1/S check point. This is a characteristic of tumor cell lines with deleted STAT3 
gene (STAT3 -,-) where the lack of STAT3 activity leads to the appearance of apoptosis due 
to an increase in the level of caspases, and a decrease in the level of Bcl-2, while down-
regulated proliferation follows from decreased level of cycline D i c-myc oncogenes. 
In contrast to normal cells, in which STAT tyrosine phosphorylation occurs transiently, it has 
been determined that STATs 1, 3, and 5 are persistently tyrosine phosphorylated in most 
malignancies (particularly STAT3) [2, 46]. The mechanisms by which STAT3 is persistently or 
constitutively tyrosine phosphorylated in cancers include increased production of cytokines 
and cytokine receptors, which is initiated by tumor cells in an autocrine, and by tumor 
microenvironment in a paracrine manner, by a decrease in the expression of the SOCS proteins 
through gene promoter methylation, as well as loss of tyrosine phosphatase activity [11]. 
Most of the described oncogenic functions of STAT3 depend on the phosphorylation status 
of Tyr705, however, another role of STAT3 is independent of tyrosine phosphorylation, as 
unphosphorylated STAT3 can also affect gene expression in the nucleus, one mechanism is 
through binding to NF-κB and mediating its nuclear import [80]. 
STAT3 has been directly linked to human cancer as it is required for cell transformation by 
the src oncogene [81], as well as in promoting cellular transformation by the H-ras oncogene. 
This function, which is dependent on the noncanonical serine phosphorylation of STAT3, 
takes place in mitochondria. 
Unlike another member of STAT family, STAT1, that is imported in the nucleus only in 
phosphorylated form, STAT3 dynamically shuttles in and out of the nucleus independent of 
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its tyrosine phosphorylation status [82, 83]. Nuclear import requires binding of STAT3 to an 
importin-α−importin-β dimer. On the other hand, mitochondrial import could be mediated 
in several ways, including by association with the cytosolic chaperones, heat shock proteins 
(Hsp70, Hsp90) [84] or associated with GRIM-19, a subunit of mitochondrial complex I of 
the electron transport chain [85] engaged in cell death processes in mitochondria that when 
overexpressed inhibits the activity of STAT3 by direct binding [86]. 
In light of this finding and the fact that STAT3 function has been linked to cancer, Gough et 
al. (2009) [48] evaluated the contribution of STAT3 to Ras oncogenic transformation. Ras 
protooncogenes become constitutively active oncogenes with the acquisition of specific 
point mutations [87], which stabilize Ras binding to guanosine 5´-triphosphate (GTP), thus 
allowing Ras in its GTP-bound state to stimulate numerous downstream effectors. However, 
Ras oncogenes can only transform cells that have been immortalized by carcinogens or other 
oncogenes, in the classical multistep carcinogenesis. Some of the signaling molecules 
activated in response to Ras can impact the STAT3 transcription factor. For example, 
mitogen-activated protein kinases (MAPKs) can phosphorylate STAT3 on Ser727 and 
downstream activation of the NF-κB transcription factor induces autocrine IL-6 production 
canonical tyrosine phosphorylation of STAT3 [88]. 
Cancer cells tend to have reduced oxidative phosphorylation in mitochondria, and have 
increased glycolysis in the cytoplasm leading to lactate production [89]. STAT3, inspite of its 
role in cellular transformation and cancer, promotes oxidative phosphorylation in 
mitochondria. New findings show that Ser727 phosphorylation of STAT3 contributed to 
oxidative phosphorylation  in mitohondria. The effect of STAT3 on oxidative 
phosphorylation in mitochondria was investigated by comparing enzyme activity in 
STAT3+/+ to STAT3−/− cells [48]. Wegrzyn et al. (2009) [90] showed that STAT3+/+ cells had 
comparatively greater activity of electron transport complex I and complex II but no 
difference in the activities of complex III or complex VI. Comparing Ras-transformed 
STAT3+/+ and STAT3−/− cells revealed that, the presence of STAT3 increased activities of 
electron transport complex II and V. Analogous to cells that lack oncogenic Ras [90], STAT3 
appears to stoke the powerhouse, i.e., mitochondria.   
Unexpectedly, STAT3-expressing cells also had decreased mitochondrial membrane 
potential and increased lactate dehydrogenase production, indicating a shift to cytoplasmic 
glycolysis. Additional analyses are required to understand the complex connections 
between glycolysis and oxidative phosphorylation affected by STAT3 in the presence or 
absence of oncogenic Ras. 
Originally, STAT5 was originally identified as a specific transcription factor that mediates 
the effects of prolactin [91]. STAT5A and STAT5B forms are 96% conserved at the protein 
level but they differ in their C terminal domain as STAT5A has 20 and STAT5B 8 unique 
amino acids in the C-terminus [92]. However, STAT5A transmits predominantly the signals 
initiated by the prolactin receptor, while STAT5B mediates the biological effects of growth 
hormone. 
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The most important role of STAT5A and STAT5B is in lymphoid, myeloid and erythroid cell 
development and function as they are activated by multiple cytokines, including IL-2, IL-3, 
IL-5, IL-7, IL-9, IL-15, GM-CSF and erythropoietin [93]. STAT5B serine 193 is a novel 
cytokine induced phospho-regulatory site that is constitutively activated in primary 
hematopoietic malignancies [94]. Following cytokine stimulation, human STAT5A and 
STAT5B are phosphorylated by JAK1, JAK2 or Tyk on the conserved tyrosine residues 694 
and 699, respectively, which allows for their dissociation from the receptor complex, 
formation of hetero- or homo-dimers, and nuclear translocation to bind specific elements in 
the promoter of target genes and activate transcription [95]. While tyrosine phosphorylation 
is a part of activation signal, the serine 726 on STAT5A and 731 on STAT5B phosphorylation 
may abrogate the transcriptional activity of STAT5A/B [96]. 
In addition to the physiological role of STAT5 in hematopoietic cell development, 
dysregulation of the STAT5 signaling pathway plays a role in oncogenesis and 
leukemogenesis [97]. Specifically, STAT5 has been shown to be constitutively activated in 
several forms of lymphoid, myeloid and erythroid leukemia [98-100]. Persistent activation of 
STAT5 was found to be a result of deregulated cytokine signaling [101] or the presence of 
oncogenic tyrosine kinases. STAT5 proteins can activate many oncogenic tyrosine kinases, 
including Bcr-Abl, mutated forms of Flt-3 and Kit, and the JAK2 V617F mutant [102-104]. In 
acute promyelocytic leukemia (APL) beside the most common PML-RARα chromosomal 
translocation, RARα gene can be fused with STAT5B forming a fusion protein that blocks 
myeloid differentiation [105]. 
The most probable molecular mechanism by which STAT5 promotes tumorogenesis is 
upregulation of cyclin D and c-myc expression which promotes progression from the G1 to 
the S-phase of the cell cycle [2]. Aside from stimulating proliferation, STAT5 inhibits 
apoptosis by inducing the expression of anti-apoptotic Bcl-xl protein and promotes survival 
of tumor cells [106].  
In addition to several types of leukemia and hematopoietic disorders [8], active STAT5A/B is 
also frequently detected in solid tumors, such as prostate cancer, breast cancer, uterine 
cancer, squamous cell carcinoma of the head and neck [107]. 
STAT5A/B controls viability and growth of prostate and breast cancer. The expression of 
nuclear, active STAT5A/B is often associated with high grade prostate cancer, predicts early 
disease recurrence and promotes metastatic dissemination. In prostate cancer, active 
STAT5A/B signaling pathway increases transcriptional activity of androgen receptors. 
Androgen receptor, in turn, increases transcriptional activity of STAT5A/B. STAT5A/B 
potentially contributes to castration resistant growth of prostate cancer [108]. The molecular 
mechanisms underlying constitutive activation of STAT5 in primary and recurrent human 
prostate cancers are currently unclear, and may involve the autocrine prolactine–JAK2 
pathway [109], Src kinases, or Rho GTPases.  
In breast cancer, the role of STAT5A/B is more complex. In rodent model systems STAT5A/B 
may promote malignant transformation and enhance growth of breast tumors [110], while in 
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comparatively greater activity of electron transport complex I and complex II but no 
difference in the activities of complex III or complex VI. Comparing Ras-transformed 
STAT3+/+ and STAT3−/− cells revealed that, the presence of STAT3 increased activities of 
electron transport complex II and V. Analogous to cells that lack oncogenic Ras [90], STAT3 
appears to stoke the powerhouse, i.e., mitochondria.   
Unexpectedly, STAT3-expressing cells also had decreased mitochondrial membrane 
potential and increased lactate dehydrogenase production, indicating a shift to cytoplasmic 
glycolysis. Additional analyses are required to understand the complex connections 
between glycolysis and oxidative phosphorylation affected by STAT3 in the presence or 
absence of oncogenic Ras. 
Originally, STAT5 was originally identified as a specific transcription factor that mediates 
the effects of prolactin [91]. STAT5A and STAT5B forms are 96% conserved at the protein 
level but they differ in their C terminal domain as STAT5A has 20 and STAT5B 8 unique 
amino acids in the C-terminus [92]. However, STAT5A transmits predominantly the signals 
initiated by the prolactin receptor, while STAT5B mediates the biological effects of growth 
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and 699, respectively, which allows for their dissociation from the receptor complex, 
formation of hetero- or homo-dimers, and nuclear translocation to bind specific elements in 
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is a part of activation signal, the serine 726 on STAT5A and 731 on STAT5B phosphorylation 
may abrogate the transcriptional activity of STAT5A/B [96]. 
In addition to the physiological role of STAT5 in hematopoietic cell development, 
dysregulation of the STAT5 signaling pathway plays a role in oncogenesis and 
leukemogenesis [97]. Specifically, STAT5 has been shown to be constitutively activated in 
several forms of lymphoid, myeloid and erythroid leukemia [98-100]. Persistent activation of 
STAT5 was found to be a result of deregulated cytokine signaling [101] or the presence of 
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acute promyelocytic leukemia (APL) beside the most common PML-RARα chromosomal 
translocation, RARα gene can be fused with STAT5B forming a fusion protein that blocks 
myeloid differentiation [105]. 
The most probable molecular mechanism by which STAT5 promotes tumorogenesis is 
upregulation of cyclin D and c-myc expression which promotes progression from the G1 to 
the S-phase of the cell cycle [2]. Aside from stimulating proliferation, STAT5 inhibits 
apoptosis by inducing the expression of anti-apoptotic Bcl-xl protein and promotes survival 
of tumor cells [106].  
In addition to several types of leukemia and hematopoietic disorders [8], active STAT5A/B is 
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cancer, squamous cell carcinoma of the head and neck [107]. 
STAT5A/B controls viability and growth of prostate and breast cancer. The expression of 
nuclear, active STAT5A/B is often associated with high grade prostate cancer, predicts early 
disease recurrence and promotes metastatic dissemination. In prostate cancer, active 
STAT5A/B signaling pathway increases transcriptional activity of androgen receptors. 
Androgen receptor, in turn, increases transcriptional activity of STAT5A/B. STAT5A/B 
potentially contributes to castration resistant growth of prostate cancer [108]. The molecular 
mechanisms underlying constitutive activation of STAT5 in primary and recurrent human 
prostate cancers are currently unclear, and may involve the autocrine prolactine–JAK2 
pathway [109], Src kinases, or Rho GTPases.  
In breast cancer, the role of STAT5A/B is more complex. In rodent model systems STAT5A/B 
may promote malignant transformation and enhance growth of breast tumors [110], while in 
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contrast, STAT5A/B activation in established human breast cancer positively correlates with 
tumor differentiation [111], prevents metastatic dissemination, and predicts favorable 
clinical outcome [112] of node-negative breast cancer. In addition, active STAT5A/B, 
induced by Akt-1, positively correlated with mammary epithelial cell differentiation and 
possibly a better response to endocrine therapy [113]. Collectively, these studies suggest a 
dual role for STAT5A/B in the mammary gland as an initiator of tumor formation, as well as 
a promoter of differentiations of established tumors.  
2.5. STAT dysfunction associated with different malignancies 
In addition to individual roles of each STAT, they may be coactivated in cancers. In this 
sense, STATs 1, 3, and 5 are simultaneously tyrosine phosphorylated in a number of human 
cancers including breast, lung, and head and neck tumors (Table5). The presence of pSTAT5 
in addition to pSTAT3 in head and neck tumors can enhance tumor growth and invasion 
and may contribute to resistance to EGFR inhibitors and chemotherapy [114]. 
The functional interplay between activated STAT3 and STAT5 has also been described in 
breast cancers. Considering that STAT3 is included in breast development in association 
with EGFR, it has been shown on breast cancer cell lines and primary tumors that EGFR 
mutations, as well as the activity of src proto-oncogene, lead to hyperactivity and STAT3 
oncogenic properties [115]. JAK/STAT3 signaling pathway is required for growth of 
CD44+CD23- breast cancer stem cells in tumors [116]. It has been shown that STAT1 
blocking by EGFR in this tumor, unlike inhibition of STAT3, does not show any influence on 
cell proliferation [117].  
Activated STAT3 and IL-6 are preferentially found in triple-negative breast cancers or in 
high-grade tumors and are associated with poor response to chemotherapy [118]. In human 
tumors, however, the presence of pSTAT5 is found predominantly in well-differentiated 
estrogen receptor (ER)–positive tumors and is associated with favorable prognosis. 
Furthermore, the presence of pSTAT5 is a predictive factor for endocrine therapy response 
and strong prognostic molecular marker in ER-positive breast cancer. Tumors expressing 
both activated STAT3 and STAT5 were more likely to be ER positive and human EGFR2 
negative and of a lower stage.  
Aside from the detected STAT dysregulation in tumors, more recent data report STAT status 
in peripheral blood lymphocytes (PBL). Results of an investigation of STATs in PBL of 
patients with breast cancer indicates constitutive, as well as stage-dependent, decrease in 
STAT1, STAT3, STAT5 expression and impaired induction of these proteins by Th1 
cytokines [119]. The commonly found dysfunction of NK cells in breast cancer patients [120-
122] is probably the consequence of cytokine dysbalance due to the prevalence of 
immunosuppressive cytokines such as IL-10 and TGFβ [123], as well as tumor-produced 
inhibitory factors [124]. This finding is in concordance with the only previous study 
published for breast cancer patients [125] and also with several other investigations showing 
STAT dysregulation in PBL of melanoma and renal cell carcinoma patients [126,127]. 
Moreover, we showed that breast cancer patients’ T and NK cell subsets have lower pSTAT1 
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level that could be a biomarker of decreased NK cell cytotoxicity and IFNγ production 
associated with progression of this disease [120, 128,129]. 
Constitutively active STAT3 present in breast cancer and many human solid tumors, is 
associated with immunosuppression of the host immune response. STAT3 expression 
promotes the production of IL-1β, IL-6, IL-10, TGFβ and VEGF by tumor cells [130] leading 
to STAT3 activation in immune cells and in turn production of more cytokines forming a 
feedback loop. These cytokines also inhibit dendritic cell maturation, exerting a pro-tumor 
response. In this sense, evaluation of STATs in PBL is of importance in predicting the 
possibility of immunomodulatory and antitumor effect of immunotherapy with cytokines in 
patients with malignancies. 
Constitutive activation of STATs has been detected in human head and neck squamous 
carcinoma cells [131]. In these cells, activation of STATs is dependent on TGFα induced 
activation of EGFR and studies utilizing antisense oligonucleotides have demonstrated that 
STAT3 mediates oncogenic growth of these cells. Activation of STATs in non-small cell lung 
carcinoma (NSCLC) increased production of TGFα by activating EGFR tyrosine kinase [132] 
induces downstream STAT3 activation and engages it in the pathogenesis of this 
malignancy. EGFR constitutive activation of STATs has also been detected in prostate, renal 
cell, lung, ovarian, and pancreatic cancers, as well as melanomas.  
In addition, activation of src also occurs with elevated frequency during progression of 
human breast, ovarian and prostate cancer, and EGFR and Src have been shown to 
cooperate in human breast cancer [133]. Aside from that, it is of importance that in prostate 
cancer cell lines the role of BRCA1 gene has been shown in forming of hyperactive STAT3 
[134]. When castration resistant disease develops in androgen receptor (AR) positive 
prostate cancer, these tumors often express higher levels of AR, possibly through activated 
STAT3, which can transcriptionally regulate AR. Thus, combining antiandrogens with anti- 
STAT3 drugs should be considered, rather than with chemotherapy in hormone-refractory 
metastatic prostate cancer [11]. Also, in B16 mouse melanoma cell line hyperactive STAT3 
has also been detected [135] (Table 5). 
STAT hyperactivity has been demonstrated in lymphomas and leukemias. In acute myeloid 
leukemia (AML), characterized by the presence of immature myeloid cells in the bone 
marrow, STAT3 and STAT5 hyperactivity has been found. This may follow from an 
overproduction of hematopoietic cytokines by tumor cells [136]. An increased level of 
STAT3β isoform in leuekimic blasts in the bone marrow has been found in patients with this 
leukemia that have an overall shorter time of survival [137]. It is presumed that STAT5 in 
AML is activated by mutations in the flt-3 gene. It has also been shown that hyperactive 
STAT3 induces increased production of VEGF in bone marrow of acute and chronic 
leukemia. This is in accord with the common finding of increased blood vessel density in 
bone marrow in these malignancies [138]. Constitutive activation of STATs 1 and 5 has been 
additionally detected in acute myelogenous leukemia (AML) and chronic myelogenous 
leukemia (CML) cells possessing the activated Bcr-Abl tyrosine kinase [139]. Moreover, T 
cell leukemia that arise in HIV infections, as well as Hodgkin’s disease, express active 
STAT3. 
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Tumor type Activated STAT proteins  
Solid tumors   
Breast cancer STAT1,STAT3, STAT5  
Head and neck cancer STAT1,STAT3, STAT5  
Melanoma STAT3  
Lung cancer STAT3,STAT5  
Ovarian cancer STAT3  
Pancreatic cancer STAT3  
Prostate cancer STAT3,STAT5  
   
Hematological malignancies   
Acute myelogenous leukemia  STAT1,STAT3  
HTLV-1 dependent leukemia STAT3,STAT5  
Multiple myeloma STAT1,STAT3, STAT5  
Acute lymphoblastic leukemia  STAT5  
LGL leukemia STAT3  
Chronic myelogenous leukemia  STAT5  
   
Lymphomas   
Cutaneous T cell lymphoma  STAT3  
EBV-related and Burkitt's lymphoma  STAT3  
B-cell non-Hodgkin's lymphoma STAT3  
Anaplastic LGL lymphoma STAT3  
Table 5. Activated STAT proteins found in various solid and hematologic tumors 
The constitutive activation of STAT3 is more striking than STAT5 in ALK+ anaplastic large 
T-cell lymphoma (ALCL). In Sezary Syndrome, a leukaemic form of cutaneous T cell 
lymphoma (CTCL), the JAK3-STAT3 pathway is constitutively activated, while STAT5 
activation is inducible [140]. In APL, aside from characteristic RARα - PML chimeric fusion 
protein, the novel translocation resulting in STAT5B - RARα is considered to be responsible 
for the lack of response to ATRA-mediated prodifferentiation therapy [141]. Moreover, 
inadequate activity of STAT4 leads to T helper 2 (Th2) cytokine (IL-4, IL-5 and IL-10) 
production and prevents adequate antitumor immune response.  
3. STATs as therapeutic targets  
As malignant tumors are now treated, aside from standard chemo and radiation therapy, by 
novel therapeutic approaches based on tumor molecular profile, therapy of different tumors 
now includes agents for specific targeted therapy designed to neutralize pathogenic 
mutations, a goal that is complex and in development. For this reason, novel therapy has 
extended to transcription factors, such as STATs, and agents have been designed that 
directly or indirectly block oncogenic STAT3 and STAT5 activity. 
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Following extensive cell-based screening systems for these agents in different normal, gene 
modified and malignant cell lines, as well as studies in experimental animals, it has been 
established that oncogenic STATs may be inhibited in a direct manner. One of the means is 
by decreasing STAT gene expression by antisense oligonucleotides (DNA and RNA) or by 
blocking STAT3 and STAT5 activity by small inhibitory molecules and peptide analogues. 
These STAT inhibitory agents have been most commonly designed to target the domains 
responsible for STAT dimerization , i.e., the  N-terminus domain and the Src homology 
(SH2) domain, as well as the DNA-binding domain that makes physical contact with the 
STAT-responsive elements in the promoters of target genes [142] (Figure 4). 
 
Figure 4. Available approaches and strategies to target STAT signaling pathways. These approaches 
target directly or indirectly STAT signaling in tumors and include interfering with STAT3 and/or 
STAT5 expression, phosphorylation, degradation, inhibition of receptor and non-receptor tyrosine 
kinases, direct interaction with STAT proteins intended to disrupt dimerization, and finally approaches 
to inhibit DNA-binding activity and gene transcription. These strategies should lead to a decrease in 
STAT signaling activity and even lower their level to normal values.  
On the other hand, hyperactive STAT molecules can also be inhibited indirectly by 
inhibiting up-stream, either receptor or non-receptor tyrosine kinases that drive tyrosine 
phosphorylation and activate STATs leading to their hyperactive state [143]. In this sense, 
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aside from JAK enzyme inhibitors, in use are also inhibitors of src oncogene and  inhibitors 
of EGFR enzymatic activity, including tyrosine kinase inhibitor gefitinib, and imatinib, an 
inhibitor of bcr-abl oncogene characteristic for CML, as well as passive immunotherapy with 
antibody for IL-6 or its receptor [47].  
JAK enzyme inhibitors, such as tyrphostine AG490, have been shown in clinical trials to be 
effective in the therapy of multiple myeloma and other hematological malignancies and 
solid tumors with aberrant activation of the JAK-STAT signaling pathway [144]. Other 
agents of this type, including ruxolitinib, by showing promising results in phase III clinical 
trials for myelofibrosis provide a basis for their study in solid tumors such as prostate 
cancer. In addition to improved outcome, many JAK inhibitors have been found to be 
tolerable with no adverse impact on the quality of life of patients possibly due to 
redundancies in signaling downstream of cytokine receptors, with STATs being only a part 
of the signaling network. 
Considering both the crosstalk between STAT and other signaling pathways and activation 
of other pathways by STAT inhibiting agents, such as activation of Erk MAPK kinases 
during pimozide STAT5 inhibitor therapy, therapeutic modalities may include STAT 
inhibitors in combination with MEK inhibitors, an approach defined as complementary 
signaling pathway inhibition [145]. Although STAT inhibitors may decrease expression of 
pro-survival genes, this may not be sufficient to induce apoptosis, but may merely lower the 
threshold for apoptosis. In this sense, a STAT inhibitor may reduce resistance to cytotoxic 
agents or ionizing radiation and may best be used in combination with standard therapies. 
Other indirect methods for inhibition include modulation of the activity of STAT molecule 
by using their natural negative regulators. Thus, the activity of these signaling molecules is 
suppressed by increased protease activity, especially for hyperactive STAT5, induction of 
nuclear and cytoplasmatic STAT inhibitory proteins, SOCS and PIAS, respectively, or up-
regulation of tyrosine-phosphatases that dephosphorylate them [146]. Application of statins, as 
trichostatin A, leads to inhibition of enzyme histone deacetylase (HDAC) that by decreasing 
STAT transcriptional activity promotes apoptosis of malignant cells, whereas direct binding of 
statins to STATs leads to their covalent modification and enhanced degradation [147].  
In this sense, different approaches in the context of modern targeted therapy of 
malignancies by decreasing expression, phosphorylation, dimerization or DNA binding of 
STATs can decrease the activity of these important signaling molecules or down-regulate 
them to almost normal level. Considering that inhibition of STAT3 and STAT5 leads to 
growth arrest and selective apoptosis of tumor cells, sparing benign cells, this approach may 
be of importance not only in the therapy, but also in chemoprevention of tumors. These 
aspects of molecular targeted therapy of cancer patients need to be validated in additional, 
properly designed clinical trials. 
4. Conclusion 
As STAT proteins are involved in regulating fundamental biological processes, including 
apoptosis and cell proliferation that are known to be dysregulated in tumors, it is not 
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surprising to frequently find defects in STAT signaling pathways in malignancies. In the 
past few years advances have been made in understanding molecular mechanisms that are 
responsible for STAT protein dysregualtion in different malignant diseases. The critical role 
of constitutively active STAT3 and STAT5 in tumorogenesis has now been definitely 
established. Aside from that, STAT1, 3 and 5 can be considered as molecular markers for 
early detection of certain tumors, as well as prognostic parameters for evaluation of  tumor 
aggressiveness and response to various types of therapies. 
Obtained data that associate these molecules with tumor development support the use of 
STATs as molecular targets in the therapy and chemoprevention of malignancies. Inhibition 
of oncogenic STATs represents a comprehensive approach in tumor therapy that leads to 
decreased cell proliferation, survival, angiogenesis and evasion of immune response. 
Blocking of constitutively active STATs in tumors allows the destruction of tumor cells with 
minimal effect on normal cells. It is of importance that this type of molecular therapy that 
inhibits hyperactive STATs can potentiate response to chemo or radiation therapy and may 
have great potential in the therapy of solid tumors and leukemia. The efficacy of STAT 
inhibitors in oncological therapy remains still to be evaluated in numerous undergoing and 
future clinical trials. 
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